<SEC-DOCUMENT>0001628280-26-033429.txt : 20260511
<SEC-HEADER>0001628280-26-033429.hdr.sgml : 20260511
<ACCEPTANCE-DATETIME>20260511160345
ACCESSION NUMBER:		0001628280-26-033429
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260511
DATE AS OF CHANGE:		20260511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bicara Therapeutics Inc.
		CENTRAL INDEX KEY:			0002023658
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42271
		FILM NUMBER:		26963064

	BUSINESS ADDRESS:	
		STREET 1:		116 HUNTINGTON AVENUE SUITE 703
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-468-4219

	MAIL ADDRESS:	
		STREET 1:		116 HUNTINGTON AVENUE SUITE 703
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bcax-20260331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cf6c2-c28f-747f-9e58-111c1e1d135b,g:94c43f23-f2a3-4ea7-b3a9-326e15be7355,d:586fa6c821a64d49b022e7b4061b879d-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:bcax="http://www.bicara.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bcax-20260331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0002023658</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-30">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-131" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-552">275</ix:nonNumeric><ix:nonNumeric contextRef="c-133" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-553">335</ix:nonNumeric><ix:nonNumeric contextRef="c-135" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-554">464</ix:nonNumeric><ix:nonNumeric contextRef="c-137" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-555">459</ix:nonNumeric><ix:nonNumeric contextRef="c-139" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-556">457</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bcax-20260331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>bcax:segment</xbrli:measure></xbrli:unit><xbrli:unit id="debtsecurity"><xbrli:measure>bcax:debtSecurity</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-16</xbrli:startDate><xbrli:endDate>2024-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-16</xbrli:startDate><xbrli:endDate>2024-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:February2026OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-01</xbrli:startDate><xbrli:endDate>2026-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-01</xbrli:startDate><xbrli:endDate>2026-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:February2026OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcax:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:February2026OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcax:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:February2026OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-01</xbrli:startDate><xbrli:endDate>2026-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-02</xbrli:startDate><xbrli:endDate>2025-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-03</xbrli:startDate><xbrli:endDate>2025-06-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-03</xbrli:startDate><xbrli:endDate>2025-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcax:IncentiveStockOptionsAndNonQualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2026InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementRefundableDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalServicesAgreementInvestigatorGrantPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalServicesAgreementInvestigatorGrantPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementDepositsForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementIncrementalReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcax:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcax:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:ClaireMazumdanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:ClaireMazumdanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:RyanCohlheppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:RyanCohlheppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:IvanHyepMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:IvanHyepMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:LaraMeisnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:LaraMeisnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:DavidRabenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002023658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:DavidRabenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i586fa6c821a64d49b022e7b4061b879d_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:11.65pt;padding-left:28.3pt;text-align:justify;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2026</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ____________ to _______________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-42271</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">BICARA THERAPEUTICS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;padding-left:28.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.121%"><tr><td style="width:1.0%"/><td style="width:40.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">83-2903745</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">116 Huntington Ave</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 703</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">02116</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">617</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">468-4219</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="margin-top:6pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Title of each class</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Trading Symbol(s)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.0001</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">BCAX</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Market</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.759%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%">o</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%">o</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:0.02pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-23">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="background-color:#ffffff;color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of May 5</span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, 2026, th</span><span style="background-color:#ffffff;color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e registrant ha</span><span style="color:#181717;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-26">65,703,866</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Page</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_10">PART I</a>:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_10">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_13">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_16">March 31</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_16">, 202</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_16">6</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_16"> and December 31, 202</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_16">5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_16">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_19">Condensed Consolidated Statements of Comprehensive Loss for the Three</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_19"> </a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_19">Months Ended </a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_19">March 31</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_19">, 202</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_19">6</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_19"> and 202</a>5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_19">9</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_22">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three </a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_22">Months Ended </a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_22">March 31</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_22">, 202</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_22">6</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_22"> and </a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_22">2025</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_22">11</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_28">Three</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_28"> Months Ended </a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_28">March 31, 2026</a><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_28"> and 202</a>5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_28">12</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_31">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_31">13</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_82">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_82">25</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_115">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_115">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_115">34</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_118">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_118">34</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_121">PART II</a>:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_121">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_121">35</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_124">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_124">35</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Item 1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline">Risk Factors</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_712">36</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_130">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_130">Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_130">86</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_133">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_133">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_133">86</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_136">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_136">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_136">86</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_139">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_139">86</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i586fa6c821a64d49b022e7b4061b879d_142">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_142">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_142">88</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_145">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i586fa6c821a64d49b022e7b4061b879d_145">90</a></span></div></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to numerous risks and uncertainties, including those further described below in the section titled &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business. In particular, the following considerations, among others, may offset our competitive strengths or have a negative effect on our business strategy, which could materially adversely affect our business, financial conditions, results of operations, future growth prospects, or cause a decline in the price of our common stock:</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">If we are unable to raise capital when needed, or on acceptable terms, we may be unable to complete the development and commercialization of ficerafusp alfa or any future product candidates.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our business is highly dependent on the success of ficerafusp alfa. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize ficerafusp alfa, or if we experience delays in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our business is dependent on our ability to advance ficerafusp alfa and future product candidates through clinical trials, obtain marketing approval and ultimately commercialize them.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize ficerafusp alfa and any future product candidates.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Ficerafusp alfa or any future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract research organizations to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We currently and in the future may depend on other third-party collaborators for the discovery, development and commercialization of ficerafusp alfa and any of our future product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The commercial success of ficerafusp alfa or any future product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our ability to compete may decline if we do not adequately protect our proprietary rights.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Unfavorable global economic and geopolitical conditions could adversely affect our business, financial condition, stock price and results of operations.</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:168%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our ability to develop product candidates, leverage our potential and our future growth depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel. If we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Additionally, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The summary risk factors described above should be read together with the text of the full risk factors in the section titled &#8220;Risk Factors&#8221; and the other information set forth in this Quarterly Report, including our condensed consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange Commission, or SEC. The risks summarized above or described in full elsewhere in this Quarterly Report are not the only risks that we face. Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:168%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This Quarterly Report on Form 10-Q contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing, progress, results and cost of our development activities for ficerafusp alfa, including the FORTIFI-HN01 Phase 2/3 pivotal trial, the expansion cohorts of our Phase 1/1b trial, and our alternate dose study, as well as our research and development programs and any current and future preclinical and clinical studies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the ability and the potential to secure pembrolizumab for our clinical trials and successfully manufacture our drug substances and ficerafusp alfa for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our expectations for the potential safety, efficacy and therapeutic effects of ficerafusp alfa, and the ability of our clinical trials to demonstrate such results;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our expectations for the development of ficerafusp alfa with a loading and every-three-week maintenance dosing regimen;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the timing, scope and likelihood of regulatory filings and approvals, including potential accelerated approval, for ficerafusp alfa and future product candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to initiate, recruit and enroll patients in and conduct and successfully complete our clinical trials at the pace that we project;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to maintain and further develop the specific shipping, storage, handling and administration of ficerafusp alfa at the clinical sites;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and ficerafusp alfa;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to obtain funding to continue development and commercialization of ficerafusp alfa;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of ficerafusp alfa;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to commercialize ficerafusp alfa, if approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the potential pricing and reimbursement of ficerafusp alfa, if approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the implementation of our business model, and strategic plans for our business, ficerafusp alfa and technology;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering ficerafusp alfa and other product candidate we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">estimates of our future expenses, revenues and capital requirements, our needs for additional financing and ability to raise capital, including under our &#8220;at-the-market&#8221; offering program;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">future agreements with third parties in connection with the development and commercialization of ficerafusp alfa and any other approved product;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the size and growth potential of the markets for ficerafusp alfa and our ability to serve those markets;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:168%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the rate and degree of market acceptance of ficerafusp alfa;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">regulatory developments in the U.S., Canada, European Union and other foreign countries;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the success of competing therapies that are or may become available and ficerafusp alfa&#8217;s differentiation from competitors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our ability to attract and retain key personnel;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">the impact of laws and regulations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">developments relating to our competitors and our industry; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, forward-looking statements can be identified by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report and the documents that we reference in this Quarterly Report and have filed with the SEC, as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report represent our views as of the date of this Quarterly Report. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Quarterly Report, their estimates, in particular as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report.</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:168%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">NOTE REGARDING TRADEMARKS</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Bicara Therapeutics Inc. is the owner of the Bicara trademark, as well as certain other registered trademarks, trademark applications and unregistered trademarks and service marks, including design versions of some of these trademarks. The symbols &#8482; and &#174; are not used in connection with the presentation of these trademarks in this report and their absence does not indicate a lack of trademark rights. Certain other trademarks used in this report are the property of third-party trademark owners and may be presented with or without trademark references. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">All brand names or trademarks appearing in this report are the property of their respective owners. Unless the context requires otherwise, references in this report to &#8220;Bicara,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Bicara Therapeutics Inc. and its subsidiary. </span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.15pt;padding-right:14.15pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:168%">7</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:133%">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i586fa6c821a64d49b022e7b4061b879d_13"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:133%">Item 1. Financial Statements (Unaudited)</span></div><div><span><br/></span></div><div id="i586fa6c821a64d49b022e7b4061b879d_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands, except shares and per share data)</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:66.991%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">March 31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">December 31, 2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Assets</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Cash and cash equivalents</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">323,462</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">96,685</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Prepaid expenses and other assets </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">5,162</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">7,252</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Marketable securities</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">216,291</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">318,116</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Total current assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">544,915</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">422,053</ix:nonFraction></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-40">346</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-41">330</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Right of use asset &#8211; operating lease</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-42">1,428</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-43">1,701</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Other assets </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">6,910</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">6,910</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Total assets</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-46">553,599</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-47">430,994</ix:nonFraction></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Liabilities  and stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Accounts payable </span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">6,188</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">5,515</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Accounts payable &#8211; related party</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">1,252</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">2,278</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Accrued expenses and other current liabilities </span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">29,948</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">18,898</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Accrued expenses and other current liabilities &#8211; related party </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-54">812</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">1,141</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Operating lease liability &#8211; current portion</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">1,140</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">1,117</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Total current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">39,340</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">28,949</ix:nonFraction></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Operating lease liability &#8211; net of current portion</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-60">301</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-61">593</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-62">39,641</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-63">29,542</ix:nonFraction></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Commitments and Contingencies (Note 7) </span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-64"></ix:nonFraction></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-65"></ix:nonFraction></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Stockholders' equity:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Preferred stock $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-66"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-67">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-69">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-71"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-73">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-74">&#8212;</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-75">&#8212;</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-76"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-77">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-78">500,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-79">500,000,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-81">65,547,037</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-83">56,600,724</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025, respectively</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-84">8</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-85">7</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-86">929,370</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-87">760,168</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Accumulated other comprehensive (loss) income</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-88">243</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-89">243</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Accumulated deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-90">415,177</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-91">358,966</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Total stockholders' equity</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-92">513,958</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-93">401,452</ix:nonFraction></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">553,599</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-95">430,994</ix:nonFraction></span></div></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">8</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands except shares and per share data)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Operating expenses</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Research and development - related party</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-96">1,982</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-97">6,575</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Research and development</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-98">45,518</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-99">27,758</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-100">12,742</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-101">7,455</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-102">60,242</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-103">41,788</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-104">60,242</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">41,788</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Other income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Interest income</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-106">4,083</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-107">5,014</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Total other income</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">4,083</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">5,014</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net loss before income taxes</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-110">56,159</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-111">36,774</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Income tax expense </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-112">52</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-113">72</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net loss</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-114">56,211</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-115">36,846</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net Loss per share, basic and diluted</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-116"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-117">0.93</ix:nonFraction></ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-118"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-119">0.68</ix:nonFraction></ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Weighted-average number common shares outstanding, basic and diluted</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-120"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-121">60,717,041</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-122"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-123">54,456,515</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Other comprehensive loss:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Unrealized loss on marketable securities, net of tax</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-124">486</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-125">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Total other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-126">486</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-127">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Total comprehensive loss</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-128">56,697</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-129">36,846</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">9</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands except shares)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.753%"><tr><td style="width:1.0%"/><td style="width:40.306%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Common Equity</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional Paid in Capital</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">December 31, 2024</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-130">54,440,013</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-131">7</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-132">712,884</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-133">221,016</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-134">491,875</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-135">88,962</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-136">477</ix:nonFraction></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-137">477</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-138">3,451</ix:nonFraction></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-139">3,451</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net loss</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-140">36,846</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">36,846</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">March 31, 2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-142">54,528,975</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-143">7</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-144">716,812</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-145">257,862</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-146">458,957</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">10</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands except shares)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:24.241%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.932%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt;text-align:center"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Common Equity</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional Paid in Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Accumulated</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></div></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Other Comprehensive Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">December 31, 2025</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-147">56,600,724</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-148">7</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-149">760,168</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-150">243</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-151">358,966</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-152">401,452</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock, and accompanying pre-funded warrants, net of issuance cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-153">8,581,250</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-154">1</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-155">161,762</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-156">161,763</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-157">365,063</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-158">1,582</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-159">1,582</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Stock-based compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-160">5,858</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-161">5,858</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Unrealized loss  on marketable securities, net of tax</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-162">486</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-163">486</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#8211;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">56,211</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">56,211</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">March 31, 2026</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-166">65,547,037</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-167">8</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">929,370</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-169">243</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">415,177</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">513,958</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">11</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:28.3pt;text-indent:-0.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">BICARA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Operating activities:</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-172">56,211</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-173">36,846</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Adjustments to reconcile net loss to cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-174">5,858</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-175">3,451</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Depreciation</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-176">44</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-177">19</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Non-cash lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-178">273</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-179">138</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net amortization of premiums and discounts on marketable securities</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-180">338</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="f-181">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Changes in operating assets and liabilities:</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Prepaid expenses and other assets</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-182">2,089</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-183">4,116</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Accounts payable and accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-184">11,725</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-185">2,116</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Accounts payable and accrued expenses &#8211; related party</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-186">1,354</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-187">3,279</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-188">270</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-189">147</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-190">37,508</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-191">28,106</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Investing activities:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from maturities and sales of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-192">101,000</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:fixed-zero" scale="3" id="f-193">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Purchase of property and equipment</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-194">60</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-195">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net cash provided by investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-196">100,940</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-197">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Financing activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-198">161,763</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-199">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from exercise of options</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-200">1,582</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-201">460</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-202">163,345</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-203">460</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Net (decrease)/increase in cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-204">226,777</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-205">27,646</ix:nonFraction>)</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-206">96,685</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-207">489,711</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Cash and cash equivalents at end of period</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-208">323,462</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-209">462,065</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Supplemental disclosure of cash flow information:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Cash paid for tax</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-210">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-211">72</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Non-cash investing and financing activities:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Offering costs included in accounts payable and accrued expenses</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="f-212">190</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="f-213">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">Vesting of early exercise stock options</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcax:VestingOfEarlyExerciseStockOptions" format="ixt:fixed-zero" scale="3" id="f-214">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bcax:VestingOfEarlyExerciseStockOptions" scale="3" id="f-215">17</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">12</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_31"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="i586fa6c821a64d49b022e7b4061b879d_34"></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-216" continuedAt="f-216-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Description of Business, Organization, and Liquidity</span></ix:nonNumeric></div><ix:continuation id="f-216-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Bicara Therapeutics Inc. (&#8220;Bicara&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in December 2018 and is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The Company is committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program ficerafusp alfa is a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to a human transforming growth factor beta ligand trap.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has operated in the preclinical and clinical stages and has devoted substantially all of its time and efforts to performing research and development activities, raising capital, and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, risks associated with the successful research, development and manufacturing of product candidates, competition from other companies, dependence on key personnel, protection of intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if our product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically has funded its operations from the issuance of common stock in connection with its initial public offering (&#8220;IPO&#8221;), issuance of common stock in connection with its at-the-market offering program (the &#8220;ATM Program&#8221;), issuance of equity securities in a public offering in February 2026, redeemable convertible preferred stock and through debt financing.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2024, the Company closed its IPO, through which it issued <ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-217">20,125,000</ix:nonFraction> shares of common stock with par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-38" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-218">0.0001</ix:nonFraction> per share and a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-38" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-219">18.00</ix:nonFraction> per share. The Company raised net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="f-220">332.4</ix:nonFraction>&#160;million from the issuance of common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In December 2025, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-221">1,604,000</ix:nonFraction> shares of common stock with par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-41" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-222">0.0001</ix:nonFraction> per share through the ATM Program and raised net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-223">29.5</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In February 2026, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-224">8,581,250</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-225">1,406,250</ix:nonFraction> shares pursuant to the exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-226">16.00</ix:nonFraction> per share. Further, in lieu of common stock to certain investors, the Company sold pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-227">2,200,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-228">15.9999</ix:nonFraction> per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-229">0.0001</ix:nonFraction> per share exercise price for each pre-funded warrant. As a result of the offering, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-230">161.8</ix:nonFraction>&#160;million in net proceeds.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. As of March&#160;31, 2026, the Company had cash, cash equivalents and marketable securities of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="f-231">539.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and an accumulated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">deficit </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-232">415.2</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that its cash, cash equivalents and marketable securities as of March&#160;31, 2026 of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="f-233">539.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">13</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-234" continuedAt="f-234-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Summary of Significant Accounting Policies</span></ix:nonNumeric></div><ix:continuation id="f-234-1" continuedAt="f-234-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-235" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-236" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements include the financial position, results of operations and cash flows of Bicara. The Company&#8217;s unaudited condensed consolidated financial statements are denominated in U.S. dollars. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of March&#160;31, 2026, condensed consolidated statements of comprehensive loss, condensed consolidated statement of stockholders' equity for the three months ended March 31, 2026 and 2025, and condensed consolidated cash flows for the three months ended March&#160;31, 2026 and 2025 and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s condensed consolidated financial position, results of operations and cash flows for the periods presented. The condensed consolidated results of operations for the three months ended March&#160;31, 2026 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December&#160;31, 2025 included herein was derived from the audited consolidated financial statements as of that date. As permitted under U.S. GAAP, certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s most recent Annual Report on Form 10-K for the year ended December 31, 2025 (the "Form 10-K").</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Bicara is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. The Company may take advantage of these exemptions until it is no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Bicara has elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, its financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that Bicara is no longer an emerging growth company. Bicara would cease to be an emerging growth company if it has more than $1.235 billion in total annual gross revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and it has been a public company for at least 12 months and has filed one annual report on Form 10-K), or it issues more than $1.0 billion of non-convertible debt securities over a three-year period.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-237" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, and the fair values of pre-IPO common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-234-2" continuedAt="f-234-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-238" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of obligations of, and issues guaranteed by the U.S. Treasury, U.S. Agencies and U.S. Government Sponsored Enterprises.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities are classified as available-for-sale and are carried at fair value. The Company classifies all available-for-sale securities as current assets. Marketable securities are classified as current assets because they are available to fund current operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any unrealized holding gains or losses on debt securities, including their tax effect, are reported as components of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statement of comprehensive loss. Realized gains and losses, included in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statement of comprehensive loss, are determined using the specific identification method for determining the cost of securities sold.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Declines in fair value below amortized cost related to credit losses (i.e., impairment due to credit losses) are included in the condensed consolidated statement of comprehensive loss, with a corresponding allowance established. If the estimate of expected credit losses decreases in subsequent periods, the Company will reverse the credit losses through current period earnings and adjust the allowance accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-239" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in accordance with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 730&#8221;). Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes salaries and benefits, stock-based compensation expense and the cost of services provided by outside contractors.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes advance payments for goods or services that will be used or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed. The Company also records expenses and accruals for estimated costs of research and development activities, including third party contract services for clinical research and contract manufacturing. The Company bases its estimates on the best information available at the time. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or as accrued research and development expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to the Company&#8217;s vendors. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-240" continuedAt="f-240-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-240-1">General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation expense, related to the Company's executive, finance and other support functions. Other general and administrative expenses include professional fees for legal, auditing, tax, consulting services, investor relations, IT and office expenses, rent and insurance.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-241" continuedAt="f-241-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based employee and nonemployee compensation awards in accordance with provisions of ASC 718,&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 718&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. We use the Black-Scholes option-pricing model to determine the fair value of options. The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends. In applying these assumptions, we consider the following factors: </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company&#8217;s common stock is listed on the Nasdaq Global Market and its value is determined by the market price on the Nasdaq Global Market as of the date of the grant.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-234-3" continuedAt="f-234-4"><ix:continuation id="f-241-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term:&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The expected life is applied to the stock option grant group as a whole as we do not expect substantially different exercise or post-vesting termination behavior among our employee population.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends due to absence of an active market for the Company&#8217;s common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We have not paid and do not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was&#160;zero.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For awards that vest based solely on achievement of a service condition, the Company recognizes expense on a straight-line basis over the period during which the award holder provides such services. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with forfeited awards. In accordance with ASU 2018-07, the Company accounts for share-based compensation for awards granted to non-employees in a similar fashion to the way it accounts for share-based compensation awards to employees.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="bcax:WarrantsPolicyPolicyTextBlock" id="f-242" continuedAt="f-242-1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-242-1">Management assesses warrants to determine whether they should be classified as equity or liability. If the classification is determined to be equity, proceeds received for the warrants are recorded as an increase to additional paid-in capital in the condensed consolidated balance sheets. If classified as a liability, the Company records the warrant as a liability on its consolidated balance sheet and remeasures this liability to fair value at each reporting date and recognizes changes in the fair value of the warrant in earnings.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-243" continuedAt="f-243-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><ix:continuation id="f-243-1" continuedAt="f-243-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is determined by dividing the net loss applicable to common shareholders by the weighted average common shares outstanding during the period. The pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-244">2,200,000</ix:nonFraction> shares of common stock issued in February 2026 and outstanding as of March 31, 2026 (see Note 9) were included in computing the weighted average common shares outstanding used in calculating basic and diluted loss per share. Outstanding common stock options are e</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-243-2">xcluded from the calculation of diluted net loss per share when their effect would be anti-dilutive.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-245" continuedAt="f-245-1" escape="true">For the three months ended March 31, 2026 and 2025, the following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:</ix:nonNumeric></span></div><ix:continuation id="f-245-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-246">11,874,116</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-247">8,271,217</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in the table above reflect the common stock equivalents of the noted instruments.</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-248" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-249">one</ix:nonFraction> operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-250" continuedAt="f-250-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews new accounting standards as they are issued by the FASB or other standard-setting bodies. The Company did not identify any new standards during the quarter ended March 31, 2026 that it believes will have a material impact on the Company&#8217;s financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-250-1"><ix:continuation id="f-234-4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2024-03&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses (DISE)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This new guidance requires all public entities to incorporate disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective prospectively for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption and retrospective application are permitted. We are currently evaluating the impact that ASU 2024-03 will have on our condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviewed additional recent accounting pronouncements and concluded they are either not applicable or that the Company does not expect adoption to have a material effect on the unaudited condensed consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div id="i586fa6c821a64d49b022e7b4061b879d_43"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-251" continuedAt="f-251-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Fair Value Measurements</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="f-252" escape="true"><ix:continuation id="f-251-1" continuedAt="f-251-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets that have been measured at fair value as of March&#160;31, 2026 and December&#160;31, 2025 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-254">216,291</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-255">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-256">216,291</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-257">320,694</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-258">&#8212;</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-260">320,694</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-261">320,694</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-262">216,291</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-263">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-264">536,985</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-265">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-266">318,116</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-267">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-268">318,116</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-269">93,595</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-270">&#8212;</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-271">&#8212;</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-272">93,595</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-273">93,595</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-274">318,116</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-275">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-276">411,711</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:continuation id="f-251-2">As of March 31, 2026 and December 31, 2025, the Company&#8217;s cash equivalents consisted of money market funds. During the three months ended March 31, 2026 and the year ended December 31, 2025, there were no transfers between Level 1, Level 2 and Level 3.</ix:continuation>  </span></div><div id="i586fa6c821a64d49b022e7b4061b879d_46"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentTextBlock" id="f-277" continuedAt="f-277-1" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-278" continuedAt="f-278-1" escape="true"><ix:continuation id="f-277-1" continuedAt="f-277-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The fair value of available-for-sale marketable securities by type of security was as follows (in thousands):</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-277-2" continuedAt="f-277-3"><ix:continuation id="f-278-1"><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">March 31, 2026</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Marketable Securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-279">163,516</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-280">2</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-281">74</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-282">163,444</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-283">163,516</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-284">2</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-285">74</ix:nonFraction>)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-286">163,444</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-287">53,018</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-288">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-289">171</ix:nonFraction>)</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-290">52,847</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one to two years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-291">53,018</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-292">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-293">171</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-294">52,847</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-295">216,534</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-296">2</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-297">245</ix:nonFraction>)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-298">216,291</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2025</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:center"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:center"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:center"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Marketable Securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-299">233,672</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-300">146</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-301">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-302">233,818</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-303">233,672</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-304">146</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-306">233,818</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-307">84,201</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-308">97</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-310">84,298</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one to two years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-311">84,201</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-312">97</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-314">84,298</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-315">317,873</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-316">243</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-317">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-318">318,116</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-319" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The following table summarizes the Company's available-for-sale securities in an unrealized loss position, aggregated by type and length of time in a continuous unrealized position (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">March 31, 2026</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Less than 12 Months</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">12 Months or Longer</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Marketable Securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-320">156,241</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-321">245</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="0" id="f-322">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="0" id="f-323">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-324">156,241</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-325">245</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-326">156,241</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-327">245</ix:nonFraction>)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-329">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-330">156,241</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-331">245</ix:nonFraction>)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:10pt;text-align:justify"><ix:continuation id="f-277-3" continuedAt="f-277-4"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">As summarized in the tables immediately above, the Company held </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="debtsecurity" contextRef="c-3" decimals="INF" name="bcax:DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition" format="ixt-sec:numwordsen" scale="0" id="f-332">eleven</ix:nonFraction></span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:continuation id="f-277-4"> debt securities that were in an unrealized loss position as of March 31, 2026. The unrealized losses at March 31, 2026 were attributable to changes in interest rates and do not represent credit losses. The Company does not intend to sell these securities, and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis. The Company held <ix:nonFraction unitRef="debtsecurity" contextRef="c-4" decimals="INF" name="bcax:DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition" format="ixt:fixed-zero" scale="0" id="f-333">no</ix:nonFraction> debt securities that were in an unrealized loss position as of December 31, 2025.</ix:continuation> </span></div><div id="i586fa6c821a64d49b022e7b4061b879d_76"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-334" continuedAt="f-334-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-334-1" continuedAt="f-334-2"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On August 16, 2023, the Company entered into a <ix:nonNumeric contextRef="c-81" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-335">2.5</ix:nonNumeric> years lease for <ix:nonFraction unitRef="sqft" contextRef="c-81" decimals="0" name="bcax:LesseeOperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-336">4,617</ix:nonFraction> square feet of office space in Boston, Massachusetts (the &#8220;Lease Agreement&#8221;). In October 2024, the Company amended its Lease Agreement to lease an additional <ix:nonFraction unitRef="sqft" contextRef="c-82" decimals="0" name="bcax:LesseeOperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-337">4,744</ix:nonFraction> square feet of office space in order to expand the Company&#8217;s headquarters to <ix:nonFraction unitRef="sqft" contextRef="c-3" decimals="0" name="bcax:LesseeOperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-338">9,361</ix:nonFraction> square feet of office space. The lease required a security deposit totaling $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:SecurityDepositLiability" scale="6" id="f-339">0.1</ix:nonFraction> million, which the Company has met with cash on deposit.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-334-2"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2025, the Company entered into a Sublease Agreement (the &#8220;Sublease&#8221;) with J.W. Childs Associates, L.P., as sublandlord, effective on June 4, 2025. Under the Sublease, the Company leased approximately <ix:nonFraction unitRef="sqft" contextRef="c-83" decimals="0" name="bcax:LesseeOperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-340">9,682</ix:nonFraction> square feet of additional office space as part of its corporate headquarters, through June 30, 2027. The base rent of the Sublease is approximately $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-341">0.5</ix:nonFraction>&#160;million per year. The Sublease required an immaterial security deposit, which the Company has satisfied with cash on deposit.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2025, the Company entered into a second amendment to the Lease Agreement (the Lease Agreement, together with all amendments, the &#8220;Amended Lease&#8221;) to extend the term for the <ix:nonFraction unitRef="sqft" contextRef="c-85" decimals="0" name="bcax:LesseeOperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-342">9,361</ix:nonFraction> square feet of office space leased under the Amended Lease through June 30, 2027. The modification of the Lease Agreement required the Company to remeasure the value of the asset and liability in accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The base rent under the Amended Lease continues to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-343">0.6</ix:nonFraction>&#160;million per year. The remeasurement did not have a material impact on the Company's right-of-use-assets.</span></div></ix:continuation><div id="i586fa6c821a64d49b022e7b4061b879d_49"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-344" continuedAt="f-344-1" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-345" escape="true"><ix:continuation id="f-344-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands): </span></div><div style="margin-top:10pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"/><td style="width:67.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcax:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-346">13,516</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcax:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-347">13,085</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcax:AccruedManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-348">12,615</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcax:AccruedManufacturingExpensesCurrent" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus and payroll related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-350">1,913</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-351">5,041</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-352">1,666</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-353">591</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-354">238</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-355">181</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-356">29,948</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-357">18,898</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div id="i586fa6c821a64d49b022e7b4061b879d_67"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7.  <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-358" continuedAt="f-358-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-358-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2024, a complaint was filed in federal district court in the District of Massachusetts by Y-Trap, Inc. ("Y-Trap"), naming as defendants the Company and Biocon Ltd ("Biocon"), captioned Y-Trap, Inc. v. Biocon Ltd and Bicara Therapeutics Inc., No. 24-cv-12678 (D. Mass.). On January 31, 2025, Y-Trap filed its operative amended complaint. The operative complaint alleges a claim against defendants for correction of inventorship of a number of patents, including patents alleged to be licensed to the Company relating to ficerafusp alfa. The complaint also alleges claims against defendants for unfair trade practices pursuant to Chapter 93A of the Massachusetts General Laws, unjust enrichment, and civil conspiracy. The operative complaint seeks, among other things, damages (including compensatory, enhanced, and punitive damages), an order correcting the inventorship of the patents at issue, costs and attorney&#8217;s fees, and other equitable and injunctive relief. On February 28, 2025, Biocon and Bicara moved to dismiss all of Y-Trap&#8217;s claims. On September 30, 2025, the court denied Bicara's motion. On October 30, 2025, Bicara answered the operative complaint. The Company will continue to vigorously defend against this litigation.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have contingency reserves established for any litigation liabilities as of March&#160;31, 2026 and December&#160;31, 2025.</span></div></ix:continuation><div id="i586fa6c821a64d49b022e7b4061b879d_52"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-359" continuedAt="f-359-1" escape="true">Stockholder's Equity</ix:nonNumeric></span></div><ix:continuation id="f-359-1" continuedAt="f-359-2"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The Company has <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-360">10,000,000</ix:nonFraction> shares of preferred stock authorized for issuance, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-361">0.0001</ix:nonFraction> per share. As of March 31, 2026 and December 31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-362"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-363"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-364"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-365">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock were issued or outstanding.</span></div></ix:continuation><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-359-2"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Common Stock</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The Company has <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-366">500,000,000</ix:nonFraction> shares of Common Stock authorized for issuance, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-367">0.0001</ix:nonFraction> per share. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">March&#160;31, 2026 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">December&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-368"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-369">65,547,037</ix:nonFraction></ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-370"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-371">56,600,724</ix:nonFraction></ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> shares were issued and</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> outstanding, respectively. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">February 2026 Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">In February 2026, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-372">8,581,250</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-373">1,406,250</ix:nonFraction> shares pursuant to the exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-374">16.00</ix:nonFraction> per share, and pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-375">2,200,000</ix:nonFraction> shares of common stock (the "pre-funded warrants", at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-376">15.9999</ix:nonFraction> per pre-funded warrant, which represents the per share public offering price of each share of common stock in the offering, less the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="bcax:ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference" scale="0" id="f-377">0.0001</ix:nonFraction> per share exercise price for each pre-funded warrant.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Pre-funded Warrants</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain requirements, the pre-funded warrants, sold in the Company's February 2026 offering, can be exercised by the holder at anytime. As of March 31, 2026, there have not been any exercises of the pre-funded warrants.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants meet the criteria to be classified as an equity instrument under ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and funds received were recorded as an increase in additional paid-in capital in the condensed consolidated balance sheets. Funds received upon exercise of warrants will be recorded as common stock in the condensed consolidated balance sheets as the exercise price represents the par value of the underlying common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">At-The-Market Program</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On October 3, 2025, the Company filed a shelf registration statement on Form S-3 (the &#8220;Registration Statement&#8221;), with the SEC covering the offering of up to $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration" scale="6" id="f-378">400.0</ix:nonFraction>&#160;million of common stock, preferred stock, debt securities, warrants and/units. The Registration Statement was declared effective by the SEC on November 26, 2025. Concurrent with the filing of the Registration Statement, the Company entered into a sales agreement, dated October 3, 2025, by and between the Company and TD Securities (USA) LLC, acting as sales agent, to establish the ATM Program, pursuant to which the Company may offer and sell shares of its common stock from time to time. In connection with the ATM Program, the Company filed a prospectus with the Registration Statement for the offer and sale of up to $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration" scale="6" id="f-379">150.0</ix:nonFraction>&#160;million of shares of common stock from time to time through the sales agent. The Company will pay the agent a commission rate up to <ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="bcax:SaleOfStockCommissionFeePercentage" scale="-2" id="f-380">3</ix:nonFraction>% of the gross proceeds of any shares sold and has agreed to provide the sales agent with customary indemnification and contributions against certain liabilities. As of March 31, 2026, the Company had remaining available capacity for share issuances of up to $<ix:nonFraction unitRef="shares" contextRef="c-90" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="f-381">120.0</ix:nonFraction>&#160;million under the ATM Program. During the quarter ended March 31, 2026, there were no sales under the ATM Program.</span></div></ix:continuation><div id="i586fa6c821a64d49b022e7b4061b879d_55"></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-382" continuedAt="f-382-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-382-1" continuedAt="f-382-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Stock Option and Grant Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, in connection with the Company&#8217;s IPO, the board of directors adopted, and the Company&#8217;s shareholders approved the 2024 Stock Option and Grant Plan (the &#8220;2024 Plan&#8221;) under which the Company may grant equity-based incentive awards to the Company&#8217;s employees, officers, directors, consultants and other key persons of the Company and its affiliates upon whose judgment, initiative, and efforts the Company largely depends for the successful conduct of its business. Following the effectiveness of the 2024 Plan, no shares remained available for future issuance under the 2019 Stock Option and Grant Plan (as amended, the &#8220;2019 Plan&#8221;). Any other options or awards outstanding under the 2019 Plan remain outstanding and effective.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Plan, initially allowed the Company to grant awards up to <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-383">2,453,616</ix:nonFraction> shares of Common Stock, plus shares of common stock subject to awards outstanding under the 2019 Plan that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated (other than by exercise). Each year starting on January 1, 2025 and on each January 1 thereafter, the number of shares of stock reserved and available for issuance under the 2024 Plan shall automatically be cumulatively increased by <ix:nonFraction unitRef="number" contextRef="c-92" decimals="INF" name="bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" scale="-2" id="f-384">5</ix:nonFraction>% of the outstanding shares on the immediately preceding December 31 or such lesser number of shares as approved by the Company. Through March&#160;31, 2026, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-385">5,239,109</ix:nonFraction> of options under the 2024 Plan. The terms of equity award agreements, including vesting requirements, were </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-382-2" continuedAt="f-382-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">determined by the board of directors and are subject to the provisions of the 2024 Plan. Equity awards granted to employees and non-employees generally vest over a <ix:nonNumeric contextRef="c-92" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-386">four-year</ix:nonNumeric> period but may be granted with different vesting terms. Certain options provide for early vesting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees and non-employees expire no more than <ix:nonNumeric contextRef="c-92" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-387">10</ix:nonNumeric> years from the date of grant and are generally service based. The 2024 Plan allows for awards to contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vested period. No awards with performance-based vesting criteria have been granted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2026 Inducement Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In January 2026, the Company&#8217;s board of directors adopted the Bicara Therapeutics Inc. 2026 Inducement Plan (the &#8220;Inducement Plan&#8221;) and reserved <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-388">1,000,000</ix:nonFraction> shares of common stock for future issuance under the Inducement Plan. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Inducement Plan has not been approved by the stockholders of the Company and provides for the grant of non-qualified stock options, stock appreciation rights, RSAs, RSUs, unrestricted stock awards and dividend equivalent rights to newly hired employees as a material inducement to accept employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-389" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense for non-employees and employees in its statements of comprehensive loss as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-390">2,225</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-391">1,141</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-392">3,633</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-393">2,310</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-394">5,858</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-395">3,451</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Stock Options</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation, measured at the grant date based on the fair value of the award, is typically recognized ratably over the requisite service period, using the straight-line method of expense attribution. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-396" continuedAt="f-396-1" escape="true">When utilizing the Black-Scholes option-pricing model to determine the grant date fair value of stock options granted to employees or non-employees, we used the following weighted average assumptions:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-396-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.689%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-397">3.7</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-100" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-398">3.9</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-399">4.0</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-102" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-400">4.4</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Expected life (in years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-401">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-13" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-402">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-403">94.1</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-100" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-404">94.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-405">90.6</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-102" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-406">90.8</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Expected dividend rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="-2" id="f-407">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="-2" id="f-408">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Fair value of common stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="INF" name="bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" scale="0" id="f-409">12.60</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="INF" name="bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" scale="0" id="f-410">13.77</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="INF" name="bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" scale="0" id="f-411">12.30</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-102" decimals="INF" name="bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" scale="0" id="f-412">12.70</ix:nonFraction></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-382-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-413" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">A summary of options award activity for non-employees and employees of the Company is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average &#8211;<br/>Remaining<br/>Contractual<br/>Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Intrinsic </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-414">9,850,977</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-415">9.03</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-416">2,389,555</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-417">16.79</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-418">366,416</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-419">4.34</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-420">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-421">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2026</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-422">11,874,116</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-423">10.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-424">8.56</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-425">108,757</ix:nonFraction></span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2026</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-426">3,349,637</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-427">7.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-428">7.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-429">42,004</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and expected to vest as of March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-430">11,874,116</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-431">10.74</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-432">8.56</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The aggregate intrinsic values is calculated as the difference between the exercise price of the underlying options and the fair value of the Company&#8217;s common stock on March 31, 2026 for the options that were in the money.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of options granted during the three months ended March 31, 2026 and 2025, was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-433">13.15</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-434">9.60</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised for the three months ended March 31, 2026 and 2025 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-435">5.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-436">0.6</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-437">8,524,479</ix:nonFraction> unvested stock options outstanding as of March&#160;31, 2026. As of March&#160;31, 2026, total unrecognized compensation costs of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-438">72.5</ix:nonFraction> million related to unvested stock options are expected to be recognized as expense over a weighted average period of <ix:nonNumeric contextRef="c-103" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-439">3.1</ix:nonNumeric> years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">2024 Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 5, 2024, the Company&#8217;s board of directors adopted, and its stockholders approved, the 2024 Employee Stock Purchase Plan (the "ESPP"), which became effective September 5, 2024. The ESPP initially reserves and authorizes the issuance of up to <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-440">507,383</ix:nonFraction> shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034, by the least of (i) <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" format="ixt:num-dot-decimal" scale="0" id="f-441">1,014,766</ix:nonFraction> shares of common stock, (ii) <ix:nonFraction unitRef="number" contextRef="c-105" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-442">1</ix:nonFraction>% of the sum of (A) the number of shares of our common stock issued and outstanding on the immediately preceding December 31, and (B) the number of shares of common stock issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire such common stock for a nominal exercise price on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend, or other change in our capitalization. There has been no activity on this plan to date, and no stock-based compensation expense was recognized during the three months ended March 31, 2026.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">22</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_58"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-443" continuedAt="f-443-1" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-444" escape="true"><ix:continuation id="f-443-1">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.</ix:continuation></ix:nonNumeric> </span></div><div id="i586fa6c821a64d49b022e7b4061b879d_61"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-445" continuedAt="f-445-1" escape="true">Significant Agreements &#8211; Related Parties</ix:nonNumeric></span></div><ix:continuation id="f-445-1" continuedAt="f-445-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a master services agreement on December 15, 2020 (the &#8220;Master Services Agreement&#8221;) with Biocon. Pursuant to the terms of the master service agreement, Biocon provided services related to research and development, clinical trials, regulatory interactions and manufacturing. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-446">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-447">0.0</ix:nonFraction> million expenses under the Master Services Agreement during the three months ended March&#160;31, 2026 and 2025, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;23, 2019, the Company entered into a contract manufacturing agreement with a wholly-owned subsidiary of Biocon, Biocon Biologics Limited (&#8220;BBL&#8221;) formerly Biocon Biologics India Limited, which was amended on November 6, 2024 to extend the term of the contract manufacturing agreement until July 23, 2026. Additionally, the Company entered into a material transfer agreement on August 17, 2023, a quality agreement on October 12, 2023, a service agreement on October 18, 2023, and a manufacturing service agreement on December 15, 2023 (collectively, the &#8220;BBL Agreements&#8221;). Pursuant to the terms of the BBL Agreements, BBL manufactures and supplies specified quantities of products to Bicara to be utilized in research and development and manufacturing as per purchase orders executed from time to time between the two parties. For the three months ended March&#160;31, 2026 and 2025, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-448">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-449">0.0</ix:nonFraction> million of research and development expenses, respectively, under the BBL Agreements. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, the Company owed $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-450">0.1</ix:nonFraction>&#160;million and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-451">0.0</ix:nonFraction> million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company additionally entered into a contract manufacturing agreement with a wholly-owned subsidiary of Biocon, Syngene International Limited (&#8220;Syngene&#8221;), on July 17, 2019, which was amended and restated on April 1, 2020 with the amended and restated manufacturing service agreement, as amended (the &#8220;Syngene Manufacturing Services Agreement&#8221;), and a master contract services agreement on July 24, 2020, as amended (the &#8220;Syngene Master Contract Services Agreement&#8221; and together with the Syngene Manufacturing Services Agreement, the &#8220;Syngene Agreements&#8221;). Pursuant to the terms of the Syngene Agreements, Syngene manufactures and supplies specified quantities of products to Bicara to be used in research and development as per purchase orders executed from time to time between the two parties and performs additional contract research services under the master contract services agreement. The Syngene Manufacturing Services Agreement expires on the later of October 31, 2027 or the completion of services under all work orders under the agreement. The Syngene Master Contract Services Agreement expires on the later of November 1, 2031 or the completion of all services under the statements of work under the agreement. On December 16, 2024, the Company entered into an additional master contract services agreement with Syngene, whereby Syngene agreed to provide the Company with dedicated research laboratories and personnel (&#8220;Dedicated Center Agreement&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Dedicated Center Agreement expires on the later of December 16, 2028 or the completion of all services under all statements of work under the agreement.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><ix:continuation id="f-445-2" continuedAt="f-445-3"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-452">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-453">6.4</ix:nonFraction> million of manufacturing and research and development expenses, respectively, under the Syngene Agreements. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, and December&#160;31, 2025, the Company owed Syngene $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-454">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-455">3.4</ix:nonFraction> million, respectively, relating to these incurred costs, of which $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-456">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-457">2.3</ix:nonFraction> million, respectively,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">were classified in accounts payable-related party and $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-458">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-459">1.1</ix:nonFraction> million, respectively,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-445-3">were classified as accrued expenses-related party on the balance sheets.</ix:continuation> </span></div><div id="i586fa6c821a64d49b022e7b4061b879d_64"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsDisclosureTextBlock" id="f-460" continuedAt="f-460-1" escape="true">Significant Agreements</ix:nonNumeric></span></div><ix:continuation id="f-460-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQVIA</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 15, 2019, the Company entered into a master clinical contract services agreement with IQVIA RDS Inc (&#8220;IQVIA&#8221;), which was amended in December 2023 to include global clinical trials. Pursuant to the terms of the agreement, as amended, IQVIA will provide the Company with certain global clinical-development related services and laboratory services under separately executed statements of work (&#8220;SOWs&#8221;). In June 2021, the Company entered into an SOW with IQVIA for lab and clinical development services, to be invoiced on a monthly basis based on work performed by IQVIA. Under this SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-461">1.8</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-462">1.0</ix:nonFraction>&#160;million was a refundable deposit and $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-463">0.8</ix:nonFraction>&#160;million for investigator grant payment in advance. In December 2022, Bicara entered into an authorized to proceed agreement (&#8220;ATP&#8221;) with IQVIA. Under the ATP, Bicara agreed to provide IQVIA with an additional refundable deposit of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-464">0.9</ix:nonFraction>&#160;million, which was paid in March 2023. Both the initial deposit and the ATP deposit will be held on account and reconciled against final invoices. As of March 31, 2026 and December 31, 2025, the refundable deposit balance was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="bcax:OtherCommitmentLiabilityRefundableDepositAmount" scale="6" id="f-465"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="bcax:OtherCommitmentLiabilityRefundableDepositAmount" scale="6" id="f-466">1.9</ix:nonFraction></ix:nonFraction>&#160;million, which is included within other assets on the balance sheets. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2024, the Company entered into a second SOW for lab and clinical development services with IQVIA, which was incorporated into the master clinical contract services agreement and part of the Company&#8217;s FORTIFI-HN01 Phase 2/3 clinical trial. Services will be invoiced on a monthly basis based on work performed by IQVIA. Under this SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-467">12.8</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-468">7.3</ix:nonFraction>&#160;million was for investigator grant payments, $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-469">4.5</ix:nonFraction>&#160;million was a deposit for services and $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="f-470">1.0</ix:nonFraction>&#160;million was a deposit for pass through costs. The deposits will be held on account with an incremental return starting the month after <ix:nonFraction unitRef="number" contextRef="c-124" decimals="2" name="bcax:OtherCommitmentPercentage" scale="-2" id="f-471">75</ix:nonFraction>% of the budgeted costs has been paid by the Company. IQVIA is eligible to receive potential additional payments and it is subject to potential penalties based on certain milestone targets. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025 the Company incurred </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-472">9.9</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-473">14.2</ix:nonFraction> million in expenses, respectively and paid </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="bcax:PaymentsForOtherCommitments" scale="6" id="f-474">7.7</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="bcax:PaymentsForOtherCommitments" scale="6" id="f-475">12.3</ix:nonFraction> million, respectively, to IQVIA. As of March&#160;31, 2026 and December&#160;31, 2025, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-476">1.1</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-477">0.4</ix:nonFraction> million classified in accounts payable, respectively, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-478">9.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-479">8.6</ix:nonFraction> million classified in accrued expenses and other current liabilities on the balance sheets.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Collaboration and Supply Agreement with MSD</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2022, we entered into a Clinical Trial Collaboration and Supply Agreement (the "MSD Agreement") with MSD International GmbH ("MSDIG"), and MSD International Business GmbH ("MSDIB" and collectively with MSDIG, "MSD"). Pursuant to the MSD Agreement, we provide ficerafusp alfa and MSD provides pembrolizumab to be used in combination in a clinical trial sponsored by us. The clinical trial is a First-in-Human, Phase 1/1b, Open-label, Multicenter Study intended to characterize the safety, tolerability and recommended dose of single agent ficerafusp alfa and combination ficerafusp alfa plus pembrolizumab. To facilitate such collaboration activities and information exchange and pursuant to the MSD Agreement, we and MSD created a joint development committee with an equal number of representatives from each party.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the MSD Agreement, all clinical data resulting from the portion of the clinical trial involving the combination of ficerafusp alfa and pembrolizumab is jointly owned by both us and MSD. We own all clinical data resulting from the part of the clinical trial involving ficerafusp alfa alone or in combination with other treatments that are not pembrolizumab, and MSD owns all clinical data resulting from the part of the clinical trial involving pembrolizumab alone or in combination with other treatments that are not ficerafusp alfa. There are no accounting considerations for this agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">24</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:DefinedContributionPlanTextBlock" id="f-480" continuedAt="f-480-1" escape="true">Defined Contribution Plan</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-align:justify"><ix:continuation id="f-480-1" continuedAt="f-480-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently maintains a tax-qualified 401(k) retirement savings plan for our employees. All eligible employees are able to participate in the plan beginning one month after their first day of employment. Under our defined contribution plan, employees may elect to defer a percentage of their compensation per year, subject to a maximum limit prescribed by tax law, and the Company match a portion of their eligible contributions. The Company provided matching discretionary contributions under the 401(k) plan of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-481">0.2</ix:nonFraction>&#160;million</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-480-2"> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-482">0.1</ix:nonFraction>&#160;million for the three months ended March 31, 2026 and March 31, 2025, respectively.</ix:continuation> </span></div><div id="i586fa6c821a64d49b022e7b4061b879d_70"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">14. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-483" continuedAt="f-483-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-483-1"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-484">one</ix:nonFraction> reportable segment relating to research and development of its product. The segment does not currently generate revenues as it is currently conducting clinical trials and has not commercialized.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Operating Decision Maker (the &#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and expenses by function and the CODM makes decisions using this information on a global basis. The CODM monitors performance at the consolidated level such that the measure of segment loss is consolidated net loss and the measure of reportable segment assets is reported on the balance sheet as total assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-485" escape="true"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended March 31, </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Manufacturing and process development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="bcax:ManufacturingAndProcessDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-486">23,208</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="bcax:ManufacturingAndProcessDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-487">18,655</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Clinical operations and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="bcax:ClinicalOperationsAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-488">14,570</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="bcax:ClinicalOperationsAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-489">10,026</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Research and development personnel cost and other (including stock-based compensation)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="bcax:ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense" format="ixt:num-dot-decimal" scale="3" id="f-490">9,121</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="bcax:ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense" format="ixt:num-dot-decimal" scale="3" id="f-491">5,096</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Research</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="f-492">601</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="f-493">556</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total research and development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-494">47,500</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-495">34,333</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">General and administrative personnel costs (including stock-based compensation)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="bcax:GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-496">7,963</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="bcax:GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-497">4,832</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Professional fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-498">3,560</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-499">1,504</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Facility costs, IT, office expense and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="bcax:FacilityITOfficeAndOtherExpense" format="ixt:num-dot-decimal" scale="3" id="f-500">1,219</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="bcax:FacilityITOfficeAndOtherExpense" format="ixt:num-dot-decimal" scale="3" id="f-501">1,119</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total general and administrative expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-502">12,742</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-503">7,455</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-504">60,242</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-505">41,788</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Operating loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-506">60,242</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-507">41,788</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Interest income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-508">4,083</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-509">5,014</ix:nonFraction>&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total other income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-510">4,083</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-511">5,014</ix:nonFraction>&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Net income before losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-512">56,159</ix:nonFraction>)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-513">36,774</ix:nonFraction>)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Income tax expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="bcax:IncomeTaxExpenseBenefitIncludingAdjustments" scale="3" id="f-514">52</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="bcax:IncomeTaxExpenseBenefitIncludingAdjustments" scale="3" id="f-515">72</ix:nonFraction>)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Segment and consolidated net loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-516">56,211</ix:nonFraction>)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-517">36,846</ix:nonFraction>)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included within facility costs, IT, office expense and other are depreciation expense, which is disclosed on the Statement of Cash Flows</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">25</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_85"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">following</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">discussion</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and analysis</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of our financial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">condition and results of operations should be read in conjunction with our unaudited financial statements and related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">notes appearing elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">analysis</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, includes forward-looking statements that involve risks and uncertainties and should be read together with the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q for a discussion of important factors that could cause our actual results to differ materially from those described in or implied by these forward-looking statements contained in the following discussion and analysis. Please also see the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_88"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This dual-targeting approach both enhances drug exposure within the tumor microenvironment, or TME, and limits systemic toxicity. This approach was deployed in the development of our lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor-, or EGFR, directed monoclonal antibody bound to a human transforming growth factor beta, or TGF-&#946;, ligand trap.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-&#946; signaling within the TME. Ficerafusp alfa directs the TGF-&#946; inhibitor into the immediate TME through the binding of EGFR on tumor cells, which we believe will drive the tumor penetration of immune cells that lead to deep and durable responses and an increase in overall survival.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We believe ficerafusp alfa has the potential to provide meaningful clinical benefit in solid tumors that are challenged by inadequate tumor penetration and where there is a strong biologic rationale for the dual inhibition of both EGFR and TGF-&#946;, such as head and neck cancers and other squamous cell carcinomas which typically overexpress EGFR and TGF-&#946; pathways. We are focusing our efforts and resources on the continued development of ficerafusp alfa in those tumor types for which there is strong biologic rationale and remaining unmet need for enhanced tumor penetration.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Pipeline</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our current development plan for ficerafusp alfa is summarized in the following pipeline chart:</span></div><div style="text-align:justify"><span><br/></span></div><div><img src="bcax-20260331_g1.jpg" alt="Pipeline Chart Final May2026.jpg" style="height:297px;margin-bottom:5pt;vertical-align:text-bottom;width:709px" id="i-1"/></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Highlights, Recent Progress and Key Upcoming Milestones </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt;text-decoration:underline">FORTIFI-HN01 Phase 2/3 pivotal trial</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">: We are currently conducting a global, randomized, double-blind, Phase 2/3 FORTIFI-HN01 pivotal trial evaluating 1500mg dosed once weekly, or QW, of ficerafusp alfa in combination with pembrolizumab in first-line, or 1L, recurrent/metastatic, or R/M, human papillomavirus infection, or HPV, -negative head and neck squamous cell carcinoma, or HNSCC, whose tumors express programmed death-ligand 1 with combined positive score, or CPS, of &#8805;1. In January 2026, we announced that 1500mg QW of ficerafusp alfa was selected as the optimal dose to bring forward in the Phase 3 portion of the FORTIFI-HN01 trial. In February 2026, the transition to the Phase 3 portion of the FORTIFI-HN01 trial was completed. The dose determination was informed by the open-label data sets from our Phase 1/1b trial, as well as data from the treatment arms of the Phase 2 portion of the FORTIFI-HN01 trial. The FORTIFI-HN01 will enroll approximately 650 patients, which we believe is sufficiently designed to achieve results to support potential approval by the U.S. Food and Drug Association, or the FDA. We enrolled the first patients in the FORTIFI-HN01 trial in February 2025. We expect to achieve substantial enrollment by the end of 2026 to enable an interim analysis in mid-2027 to support potential accelerated approval and U.S. launch in 2028.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt;text-decoration:underline">Alternate dose study to evaluate loading and every-three-week maintenance regimen</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">: In February 2026, we presented positive data from the Phase 1b expansion cohort evaluating 2000mg of ficerafusp alfa every-other-week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC at the 2026 Multidisciplinary Head and Neck Cancers Symposium and our plans to develop an alternate dosing regimen to potentially expand optionality for patients and providers. Based on recent discussions with the FDA, we plan to initiate a randomized clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg QW followed by maintenance dosing of 2250mg every three weeks. We expect to initiate the study in the third quarter of 2026 to have results in time for potential U.S. accelerated approval. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt;text-decoration:underline">Phase 1b expansion cohorts</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.46pt">1500mg QW, 750mg QW and 2000mg Q2W plus pembrolizumab in 1L R/M HPV-negative HNSCC</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">: In May 2026, our peer-reviewed manuscript was published in the Journal of Clinical Oncology detailing results from the Phase 1b expansion cohort evaluating 1500mg of ficerafusp alfa QW in combination with pembrolizumab in 1L HPV-negative R/M HNSCC, most recently presented in an oral session at the 2025 American Society of Clinical Oncology, or ASCO, Annual Meeting. As of the March 20, 2025 data snapshot, the data demonstrated deep and durable responses with prolonged survival, evidenced by a median overall survival of 21.3 months, in patients with 1L HPV-negative R/M HNSCC. Additionally, the results suggest that ficerafusp alfa facilitated tumor penetration of immune cells by modulating EGFR/TGF-&#946; in the tumor microenvironment. These findings support the potential of ficerafusp alfa as a well-tolerated, chemotherapy-free treatment option across the spectrum of disease burden, including patients with bulky or symptomatic disease, where rapid, meaningful responses would be particularly beneficial. At the upcoming 2026 ASCO Annual Meeting, we plan to present three-year follow-up data from the 1500mg QW cohort, which will allow us to characterize the long-term clinical benefit from this dose as compared to standard of care, and we will also share longer-term endpoints from the 750mg QW and 2000mg every-other-week, or Q2W, datasets.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.46pt">1500mg QW plus pembrolizumab in 1L R/M HPV-negative HNSCC with CPS&lt;1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">: We are continuing to enroll a Phase 1b expansion cohort evaluating 1500mg QW of ficerafusp alfa in combination with pembrolizumab in patients with 1L HPV-negative R/M HNSCC with a CPS&lt;1.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.46pt">1500mg QW plus pembrolizumab in 1L R/M HPV-positive smokers HNSCC</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">: We are continuing to enroll an additional Phase 1b expansion cohort evaluating 1500mg QW of ficerafusp alfa in combination with pembrolizumab in patients with HPV-positive R/M HNSCC and a history of heavy smoking.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.46pt">1500mg QW plus pembrolizumab in other solid tumors</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">: We are continuing to enroll Phase 1b expansion cohorts evaluating 1500mg QW of ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with third-line metastatic colorectal cancer with microsatellite stable RAS/BRAF wild-type. We expect to present data from these cohorts in the second half of 2026.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt;text-decoration:underline">Chief Medical Officer transition and appointment of Chief Commercial Officer</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">: On May 8, 2026, Bill Schelman, M.D., Ph.D., previously our Executive Vice President, Clinical Development, succeeded David Raben, M.D. to serve as our Chief Medical Officer, and Dr. Raben has transitioned to serve as a Senior Executive Advisor to the Company. In addition, we have appointed Chris Sarchi as Chief Commercial Officer to lead our commercial organization in preparation for launch readiness.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in December 2018, we have not generated any revenue from product sales or other sources and have incurred significant operating losses and negative cash flows from our operations. Our primary uses of cash to date have been conducting research and development, advancing development of ficerafusp alfa, raising capital, building infrastructure, developing intellectual property, hiring personnel and providing general and administrative support for these operations. To date, we have funded our operations primarily through sale of common stock in connection with our initial public offering, or IPO, ATM Program (as defined below), our February 2026 Offering (as defined below), exercise of stock options, private placements of our redeemable convertible preferred stock, and through debt financing. </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2026, we had raised aggregate net proceeds of </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$882.9 million an</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d had cash, cash equivalents and marketable securities of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$539.8 million</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The February 2026 Offering closed on February 26, 2026 and resulted in net proceeds to us of approximate</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ly $161.8 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses in each year since our inception. Our net losses were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$56.2 million</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$36.8 million</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, we had an accumulated deficit of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$415.2 million</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. We expect our expenses and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> operating losses will increase substantially as we:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our current</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">utilize</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">third</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">parties</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">manufacture</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">raw</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">materials</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">should</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we decide</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">do</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">so, build</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and maintain</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a commercial-scale</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">current</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">good manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">practice,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or cGMP, manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">facility;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and commercial,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and operational</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">personnel;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add quality</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">control,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">quality</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">assurance,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">legal,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">compliance,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">groups</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to support</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our operations;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expand,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">enforce,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">defend</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">protect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">intellectual</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">property</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">portfolio</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">intellectual property</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">obtained</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">license</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agreements)</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and provide</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of third-party</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to our patent</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">portfolio;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approvals</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp alfa or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we successfully</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">complete</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ultimately</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">establish</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">marketing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">distribution</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">infrastructure</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">commercialize</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa or any future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which we may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">obtain</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">marketing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approval;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">payments</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">due</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">under</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">potential</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">license</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agreements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">potential</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">milestones,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">royalties</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">other payments</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">due under</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in-license</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or collaboration</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agreements; and </span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">incur additional costs associated with being a public company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">losses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fluctuate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">significantly</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">quarter-to-quarter</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and year-to-year,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">depending</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">on the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">timing of our planned</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%">, </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing and research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">upon our current</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operating</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">plans,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we believe</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">existing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cash,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">equivalents and marketable securities,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sufficient</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fund</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operations and capital expenditure requirements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> into</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> the first half of 2029. Without</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">funding,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">believe</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have sufficient</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">funds</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to meet</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our obligations</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">within</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">next twelve</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">months</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">date</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">issuance</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> condensed </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">statements.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">do not expect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to generate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any revenue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">unless</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and until</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we successfully complete</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and obtain</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approval</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates, which will not be for at least the next several years, if ever. If we obtain regulatory approval for ficerafusp alfa or any of our future product candidates,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, until such time as we can generate significant revenue from sales of our product candidate, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. See the section titled &#8220;Liquidity and Capital Resources&#8221; below. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidate that we would otherwise prefer to develop and market ourselves.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">27</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">of Operations</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">currently</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">products</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approved</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sale,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">generated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">date.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the future,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">generate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">collaboration</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">license</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agreements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">enter</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with respect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to our product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidate,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as well</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any approved</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which approval</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we do not expect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to occur for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">least</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">next</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">several</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">years,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ever.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to generate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">depend on the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">successful development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">eventual</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">commercialization</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">pursue.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fail</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">complete</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of or to obtain</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approval</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or any future product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our ability</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to generate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">revenues,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and our results</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of operations</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and financial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">position would be adversely</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">affected.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_94"></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development&#8212;Related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Party)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">party</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development)</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have primarily consisted</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">external</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">internal</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">bifunctional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">antibody</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">therapies</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to treat</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">solid</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tumors,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of our product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidate.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">include:</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">including expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">incurred</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">under</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">third parties,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as sponsored</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agreements,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">consultants</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and our scientific</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">advisors;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cost</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to obtain</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">licenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to intellectual</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">property;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">salaries,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">bonuses,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">benefits,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stock-based</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">compensation</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for employees</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">engaged</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">functions;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">laboratory</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">supplies,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">materials</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and reagents;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of developing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and validating</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">process</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">use in our future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Most</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have been related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alf</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. We</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">use</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and infrastructure resources</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">across</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">breadth</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">directed</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">toward</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">identifying and developing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">all</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">periods</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">they</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">incurred.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">certain research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recognized</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">based</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">an evaluation</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">progress</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to completion</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of specific</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tasks</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">using</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">information</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">data</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">provided</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">us</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">by</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our vendors,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">parties</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and third-party</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">service providers.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">plan</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">substantially</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">foreseeable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as we continue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">determine</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to pursue. Due</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">inherently</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">unpredictable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">nature</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">pre-clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cannot</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">determine</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with certainty</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">timing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">initiation,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">duration</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and pre-clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">studies</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of product candidates.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">timelines</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.135em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">uncertain</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">can vary</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">significantly</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we pursue,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">programs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">inherently</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">unpredictable nature</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">anticipate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">make</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">determinations</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as to which programs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to pursue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and how</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">much</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">funding</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to direct</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to each</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">current</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">program on an ongoing basis</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in response</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">results, regulatory</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">developments,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and ongoing assessments</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as to each</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">program&#8217;s</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">commercial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">potential.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">central</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">business</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">model.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">later stages</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">generally</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have higher</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">than</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">those</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in earlier</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stages,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">primarily</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">due to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">increased</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">size</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">duration</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">later-stage</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a result,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we expect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">substantially</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">over the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">next</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">several</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">years</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as we expect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to (i)</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">advance ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">late-stage</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials, (ii)</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">develop ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa for other potential</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">indications</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and (iii)</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expand our manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">efforts.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">vary</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">significantly</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">based</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">various</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">factors</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">timely</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and successful completion</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">positive</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">receipt</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of marketing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approvals</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from applicable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">authorities,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">establishment</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of arrangements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with third</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">parties,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">intellectual</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">property</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">updates, and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">continued</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">acceptable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">safety,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tolerability</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and efficacy</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">profile</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of any product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">develop following</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approval.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">changes</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">outcome</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of any of these</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">variables</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with respect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of our therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in preclinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">mean</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a significant</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">change</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and timing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">these</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.16em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">example,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.165em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the FDA</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.155em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">another regulatory</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">authority</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">delay</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">planned</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">start</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.13em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">require</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">us</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">conduct</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">testing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">beyond</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">those</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">currently</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expect,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or if</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we experience</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">delays</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in enrollment</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in any of our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">planned</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">be required</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to expend significant</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">resources</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and time</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to complete</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidate.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">never</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">obtain</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approval</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any of our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">even if</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we do, drug commercialization</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">takes</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">several</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">years</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and millions</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of dollars in development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Administrative</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">administrative</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.125em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses consist</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">primarily of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">personnel-related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.12em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">salaries, bonuses, benefits, and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stock-based compensation charges</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">those</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">individuals in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">executive, legal,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">finance, human</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">resources,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">facility</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operations,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">administrative</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">functions.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">include</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">legal fees relating</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to intellectual</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">property, litigation</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and corporate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">matters,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">professional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fees for auditing, accounting, tax and consulting</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">services,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">office</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">information</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">technology</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">insurance</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs, and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">facilities,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">depreciation</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">general</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which include</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">rent</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and maintenance</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of facilities</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and utilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">anticipate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">general</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.23em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">administrative expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">foreseeable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.24em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.23500000000000001em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to support</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our increased</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">anticipate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">increased</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to audit, accounting,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">legal,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">regulatory,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tax-related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">services</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with maintaining</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">compliance</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with our Nasdaq and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exchange</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commission,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SEC, requirements,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">director</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">officer</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">insurance</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">premiums,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and investor</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">relations</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with operating</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as a public</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expenses) Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> I</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ncome</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">income</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">consists</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">primarily</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">interest</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">income</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">earned</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cash,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">equivalents and marketable securities.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">provision</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">income</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">taxes</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">not material</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2026 and 2025.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">inception,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recorded</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">state</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">income</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tax</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">benefits</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">losses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we have</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">incurred</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">each</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">year</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">earned</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tax</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">credits,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">due</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our uncertainty</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of realizing a benefit</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">those</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">items.</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Loss</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2026, the Company held marketable securities in U.S. Treasury Bills. The unrealized loss  on these instruments was recorded in Other Comprehensive Loss.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">29</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparison of the three months ended March 31, 2026 and 2025</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March 31, 2026 and 2025 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Operating Expenses:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Research and development&#8212;related party</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,982&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">6,575&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(4,593)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Research and development</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">45,518&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">27,758&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">17,760&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">12,742&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">7,455&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,287&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total operating expenses</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">60,242&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">41,788&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">18,454&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Loss from operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(60,242)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(41,788)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(18,454)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Other income</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Interest income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,083&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,014&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(931)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total other income</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,083&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,014&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(931)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Net loss before income taxes </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(56,159)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(36,774)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(19,385)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Income tax expense</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(52)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(72)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">20&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Net loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(56,211)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(36,846)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(19,365)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development&#8212;Related</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Party)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $13.2 million from $34.3&#160;million for the three months ended March 31, 2025 to $47.5&#160;million for the three months ended March 31, 2026. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the three months ended March 31, 2026 and 2025 (in thousands):</span></div><div style="margin-top:10pt;padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:54.336%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 3pt"><div style="margin-bottom:10pt;padding-left:2pt"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing and process development</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">23,208&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">18,655&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,553&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical operations and development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">14,570&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">10,026&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,544&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development personnel cost and other (including stock-based compensation)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">9,121&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,096&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,025&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-5.76pt;vertical-align:top"><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-5.76pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">601&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">556&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">45&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">47,500&#160;</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">34,333&#160;</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">13,167&#160;</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses for the three months ended March 31, 2026, compared to the three months ended March 31, 2025 was primarily due to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $4.6 million in increased manufacturing cost, driven by additional batch manufacturing of drug substance in connection with our Phase 2/3 FORTIFI-HN01 pivotal trial and Phase 1/1b clinical trial;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$4.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in increased clinical operation and development cost, driven by costs associated with our Phase 2/3 FORTIFI-HN01 pivotal trial and continued patient enrollment in our ongoing Phase 1/1b trials; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$4.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in increased personnel related costs, including stock-based compensation, driven by higher number and value of stock options granted and an increase in the size of our workforce to support clinical development, manufacturing and research and increased professional service expenses as we continue to build out our clinical operations and development functions.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Administrative</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">administrative</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.025em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">increased</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">by </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$5.3 million</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$7.5 million</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March 31, 2025</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$12.7 million</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> three</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March 31, 2026. The following</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">table</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">summarizes</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our general</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">three months</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March 31</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, 2026 and 2025 (in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">thousands):</span></div><div style="margin-top:10pt;padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:54.336%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.45pt;padding-right:8.45pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Change</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:9pt;padding-right:-1pt;text-indent:-7.2pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(including stock-based</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">compensation)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">7,963&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,832&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">3,131&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #231f20;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">3,560&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,504&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2,056&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> insurance, </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">IT, office</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expense</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and other</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,219&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,119&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">100&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:22pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">general</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and administrative</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">12,742&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">7,455&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,287&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:2pt double #231f20;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The increase in general and administrative expenses for the three months ended March 31, 2026, compared to the three months ended March 31, 2025 was primarily due to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$3.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in increased personnel related costs, including stock-based compensation, driven by an increase in the size of our workforce and by a higher number and value of stock options granted; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$2.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in increased professional service expenses associated with higher legal, accounting and other expenses as we continue to build out our general and administrative functions to support advancing of our clinical trials.</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended March 31, 2026 and 2025 was $4.1 million and $5.0 million, respectively. The decrease was primarily due to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> a lower average balance in cash, cash equivalents and marketable securities.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_100"></div><div style="margin-top:12pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">and Capital</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Resources</span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">inception</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2018, we have not generated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any revenue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any sources</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and have incurred</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operating</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">losses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and negative</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">flows</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operations.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to incur</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">significant expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operating</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">losses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">foreseeable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as we advance</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">elect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to pursue.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> Further we expect to incur additional costs associated with operating as a public company. </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our inception</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in December</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2018 through</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2026</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">received</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">aggregate net</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">proceeds</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$882.9</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fr</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">om</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sale</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of our common stock in the IPO, ATM Program and the February 2026 Offering, the exercise of stock options, and sale of redeemable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">convertible</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">preferred</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in private</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">placements and debt</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">financing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;At-the-Market&#8221; Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On October 3, 2025, we filed a Registration Statement on Form S-3 with the SEC covering the offering of up to $400.0 million of common stock, preferred stock, debt securities, warrants and/or units. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Registration Statement was declared effective by the SEC on November 26, 2025. </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Concurrent with the filing of the Registration Statement, we entered into a sales agreement, dated October 3, 2025, by and between the Company and TD Securities (USA) LLC, acting as sales agent, to establish an at-the-market offering program pursuant to which we may offer and sell shares of our common stock from time to time, or the ATM Program. In connection with the ATM Program, we filed a prospectus with the Registration Statement for the offer and sale of up to $150.0 million of shares of common stock from time to time through the sales agent. As market conditions permit, we may offer and sell securities under the Registration Statement, including through the ATM Program, in order to fund our operations or provide additional liquidity.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> During the quarter ended March 31, 2026, there were no sales of our common stock through the ATM Program. As of March 31, 2026, a total of 1,604,000 shares of our common stock had been sold through the ATM Program, resulting in net proceeds to us of $29.5 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">February 2026 Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In February 2026, we issued and sold 8,581,250 shares of its common stock, including 1,406,250 shares pursuant to the exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $16.00 per share, and in lieu of common stock to certain investors, we sold pre-funded warrants to purchase 2,200,000 shares of common stock at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant, or the February 2026 Offering. The February 2026 Offering closed on February 26, 2026 and resulted in net proceeds to us of approximately $161.8 million.</span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:-0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Requirements</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2026,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">had</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cash, cash</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">equivalents</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> and marketable securities </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$539.8 million</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Based upon our current operating</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">plans,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">believe that our existing cash, cash equivalents and marketable securities will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sufficient</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fund</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operations and capital expenditure requirements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> into</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> the first half of 2029.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">However,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">forecast</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">period</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of time</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">resources</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">adequate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">support</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a forward-looking statement</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">involves</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">risks</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">uncertainties,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and actual</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">vary</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">materially.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">process of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">testing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costly,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">timing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">progress</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.03em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">these</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.035em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials is</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">uncertain.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">need to raise</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">substantial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future.</span></div><div style="margin-top:12pt;padding-right:-1pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">requirements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">depend on many</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">factors,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">including</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">but not limited</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to:</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.4pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">type,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">number,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">scope,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">progress,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expansions,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">results,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">timing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp alfa</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.3pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.25em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">timing of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.245em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates and commercial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">thereof;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.3pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the costs, timing,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">outcome</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of regulatory review</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of ficerafusp alfa</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and any</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:-1pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">terms</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and timing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of establishing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and maintaining</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">licenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">similar</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">arrangements;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.35pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">legal</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">obtaining,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">maintaining,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">enforcing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.195em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">patents</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">intellectual</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.2em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">property rights</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(including</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">intellectual</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">property</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">obtained</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">license</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agreements);</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.3pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">efforts</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.065em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">enhance</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operational</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">systems</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">hire</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.055em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">satisfy</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">obligations</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.06em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.05em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a public</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">company;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:-1pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with hiring</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">personnel</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and consultants</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as our clinical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">increase;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.3pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and timing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of establishing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or securing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and marketing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">capabilities</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ficerafusp</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">alfa</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or any future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approved;</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:3.35pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ability</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">achieve</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sufficient</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">market</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">acceptance,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">coverage</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">adequate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.07em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">third-party</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">payors</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and adequate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">market</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">share</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and revenue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any approved</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">products;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="margin-top:6pt;padding-left:49.5pt;padding-right:-1pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">costs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">associated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with any products</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or technologies</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in-license</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or acquire.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">such time,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ever,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as we can generate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">substantial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to support</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our cost</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">structure,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we expect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to finance</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our cash</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">needs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">offerings,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">debt</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">financings,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sources,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">potentially including collaborations, licenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and other similar arrangements.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">However, we may be unable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to raise additional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">funds</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">enter</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">when</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">needed</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">favorable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">terms</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">all.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">extent that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we raise</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sale</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of equity</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or convertible</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">debt securities,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the ownership interest</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stockholders</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">diluted,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">terms</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of these</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">securities</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">include</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">liquidation</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or other preferences</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">adversely</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">affect</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">rights</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of our common</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stockholders.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Debt financing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and equity</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">financing,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">if available,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">involve</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agreements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">include</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">covenants</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">limiting</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.22em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">restricting</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.225em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ability</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.215em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.20500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">take</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.21em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">specific actions,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">incurring</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">additional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">debt,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">making</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expenditures,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or declaring</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">dividends.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we raise</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">funds through</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">collaborations,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.19em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">similar</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.185em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">third</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">parties,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17500000000000002em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.17em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">relinquish</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.18em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">valuable rights</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">technologies,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">streams,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">programs</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">current</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or grant</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">licenses</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">terms</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">not</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">be</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">favorable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">us</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and/or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">reduce</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">value</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of our common</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stock.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our failure</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">raise</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">enter</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">into</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">arrangements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">when</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">needed</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have a negative</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">impact</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">on our financial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">condition</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ability</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">pursue</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our business</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">plans</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and strategies.</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we are</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">unable</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to raise additional</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">funds</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">through</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">equity</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">debt</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">financings</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">when needed,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">be required</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to delay,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">limit,</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">reduce</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or terminate</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">commercialization</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.02em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">efforts</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or grant</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">rights</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to develop</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and market</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our current</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">even</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">would</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">otherwise</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">prefer</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">develop</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and market</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">such product candidates</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ourselves.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">32</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparison</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of the Three Months Ended March 31, 2026 and 2025</span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">following</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">table</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sets</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">forth</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">summary</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cash</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">flow</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.105em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activity</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.115em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.11em;line-height:120%"> three</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March 31, 2026 and 2025 (in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">thousands):</span></div><div style="margin-top:10pt;padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:66.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(37,508)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(28,106)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">100,940&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">by financing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">activities</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">163,345&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">460&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:22pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net decrease</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in cash</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and cash</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">226,777&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(27,646)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Activities</span></div><div style="margin-top:10pt;padding-right:3.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2026, net cash used in operating activities was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$37.5 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> resulting from our net loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$56.2 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by net increases in our operating assets and liabilities o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">f $12.2 million and by non-cash charges of $6.5 million, consisting of stock-based compensation expense, depreciation and non-cash lease e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">xpense. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, net cash used in operating activities was $28.1 million resulting from our net loss of 36.8 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">net decrease</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in our operating assets and liabilities of $5.1 million, partially offset by non-cash charges of $3.6 million. Non-cash charges consisted of stock-based compensation expense, depreciation and non-cash lease charges.</span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $100.9 million for the three months ended March 31, 2026 and immaterial for March 31, 2025. The increase in cash provided by investing ac</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tivities is due to proceeds from maturity of marketable securities in 2026, which were purchased in the third quarter of 2025.</span></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:10pt;padding-right:3.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$163.3 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2026, consisting primarily of proceeds from the offering of common stock and pre-funded warrants in February 2026 and proceeds from the exercise of stock options.</span></div><div style="margin-top:10pt;padding-right:3.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $0.5 million for the three months ended March 31, 2025, consisting primarily of proceeds from the exercise of common stock options.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_106"></div><div style="margin-top:10pt;padding-right:-1pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Polices</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">and Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which we have prepared in accordance with GAAP. The preparation of our financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, costs and expenses, and related disclosures. During the three months ended March 31, 2026, there were no material changes to our critical accounting policies and significant judgments described under Management&#8217;s Discussion and Analysis of Critical Accounting Policies and Significant Judgments which are included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_109"></div><div style="margin-top:10pt;padding-right:163.6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emerging</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Growth Company and Smaller</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Reporting Company Status</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012, or JOBS, permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an emerging growth company. We may choose to early adopt any new or revised accounting </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">standards whenever such early adoption is permitted for private companies. There are other exemptions and reduced reporting requirements provided by the JOBS Act that we are currently evaluating. For example, as an &#8220;emerging growth company,&#8221; we are exempt from Sections 14A(a) and (b) of the Securities Exchange Act of 1934, as amended, which would otherwise require us to (1) submit certain executive compensation matters to shareholder advisory votes, such as &#8220;say-on-pay,&#8221; &#8220;say-on-frequency,&#8221; and &#8220;golden parachutes;&#8221; and (2) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of our chief executive officer&#8217;s compensation to our median employee compensation. We also intend to rely on an exemption from the rule requiring us to provide an auditor&#8217;s attestation report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. We will continue to remain an &#8220;emerging growth company&#8221; until the earliest of the following: (1) the last day of the fiscal year following the fifth anniversary of the date of the completion of our IPO; (2) the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.235 billion; (3) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until for so long as either (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_112"></div><div style="margin-top:10pt;padding-right:303.5pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">description</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recently</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">issued</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">accounting</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">pronouncements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">potentially</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">impact</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our financial position</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">disclosed</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Note</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">titled</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.085em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.08em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Policie</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;letter-spacing:0.01em;line-height:120%">s</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.075em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.01em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">statements</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.015em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">included</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">elsewhere</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in this</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:0.005em;line-height:120%"> Quarterly Report on Form 10-Q</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_115"></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is not applicable as we are electing scaled disclosure requirements available to Smaller Reporting Companies with respect to this Item.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_118"></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Item 4. Controls and Procedures</span></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of March 31, 2026. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2026.</span></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">34</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:3.65pt;padding-right:3.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_124"></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to various litigation, claims and other proceedings that arise from time to time in the ordinary course of business. On October 22, 2024, a complaint was filed in federal district court in the District of Massachusetts by Y-Trap, Inc., or Y-Trap, naming as defendants us and Biocon Ltd, or Biocon, captioned Y-Trap, Inc. v. Biocon Ltd and Bicara Therapeutics Inc., No. 24-cv-12678 (D. Mass.). On January 31, 2025, Y-Trap filed its operative amended complaint. The operative complaint alleges a claim against the defendants for correction of inventorship of a number of patents, including patents alleged to be licensed to us relating to ficerafusp alfa. The complaint also alleges claims against defendants for unfair trade practices pursuant to Chapter 93A of the Massachusetts General Laws, unjust enrichment, and civil conspiracy. The operative complaint seeks, among other things, damages (including compensatory, enhanced, and punitive damages), an order correcting the inventorship of the patents at issue, costs and attorney&#8217;s fees, and other equitable and injunctive relief. On February 28, 2025, we and Biocon moved to dismiss all of Y-Trap&#8217;s claims. On September 30, 2025, the court denied our motion. On October 30, 2025, we answered the operative complaint. We will continue to vigorously defend against this litigation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">35</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_712"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-right:2.3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Investing in our common stock involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as the other information in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; before deciding whether to invest in our common stock. The risks described below are not the only ones facing us. The following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the trading price of our common stock could decline, and you may lose all or part of your investment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">This Quarterly Report on Form 10-Q also contains forward-looking statements and estimates that involve risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. Our actual results could differ materially from those anticipated in our forward-looking statements as a result of specific factors, including the risks and uncertainties described below. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in December 2018, and our operations to date have been limited to pre-commercial activities. We have not yet demonstrated an ability to generate revenue, obtain regulatory approval, manufacture any product on a commercial scale or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Our limited operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have no products approved for commercial sale and have not generated any revenue from product sales to date. We will continue to incur significant research and development and other expenses related to clinical development and ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. Our net losses totale</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">d $56.2 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">nd </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$36.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> f</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">or the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, we have not yet generated revenues. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, ficerafusp alfa. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">advance ficerafusp alfa through clinical development; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">seek regulatory approvals for ficerafusp alfa and any future our product candidates that successfully complete clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">hire additional clinical, quality control, medical, scientific and other technical personnel to support the clinical development of ficerafusp alfa and any future product candidate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">experience an increase in headcount as we expand our market development and pre-commercial planning activities; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">undertake any pre-commercial or commercial activities to establish sales, marketing and distribution capabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">advance any future product candidates into clinical development; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">seek to identify, acquire and develop additional product candidates, including through business development efforts to invest in or in-license other technologies or product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">make any payments due under our license agreements and any potential milestones, royalties or other payments due under any future in-license or collaboration agreements; and   </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">make milestone, royalty, interest or other payments due under any future financing or other arrangements with third parties. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Biopharmaceutical product development entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">approval, secure market access and reimbursement and become commercially viable, and therefore any investment in us is highly speculative. Accordingly, before making an investment in us, you should consider our prospects, factoring in the costs, uncertainties, delays and difficulties frequently encountered by companies in clinical development, especially clinical-stage biopharmaceutical companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they would otherwise be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or the FDA, Health Canada, the European Medicines Agency, or the EMA, or other comparable regulatory authorities to perform clinical trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our product candidate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unable to raise capital when needed, or on acceptable terms, we may be unable to complete the development and commercialization of ficerafusp alfa or any future product candidates. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek regulatory and marketing approval for, ficerafusp alfa. Even if ficerafusp alfa or any future product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. To date, we have funded our operations principally through our initial public offering, or our IPO, our ATM Program (as defined below), the February 2026 Offering (as defined below), and private financings and may in the future fund operations through additional sales of our securities, including under our ATM Program. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the clinical development of ficerafusp alfa, continue to develop and deploy our bifunctional approach, commence additional preclinical studies and clinical trials, and continue to identify and develop additional product candidates either through internal development or through acquisitions or in-licensing product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2026, we had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$539.8 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of cash, cash equivalents and marketable securities. Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2029. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We may also raise additional financing on an opportunistic basis in the future. For example, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop ficerafusp alfa. Our future capital requirements will depend on many factors, including but not limited to: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the scope, timing, progress, costs and results of clinical trials for ficerafusp alfa or the discovery and preclinical development of any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the number of clinical trials required for regulatory approval of ficerafusp alfa or future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of ficerafusp alfa or any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs associated with acquiring or licensing additional product candidates, technologies or assets, including the timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the cost of manufacturing clinical and commercial supplies of ficerafusp alfa or any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the effectiveness of our approach at identifying target patient populations and utilizing our approach to enrich our patient population in our clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">expenses to attract, hire and retain skilled personnel;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs of operating as a public company;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the effect of macroeconomic trends including inflation and rising interest rates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">addressing any potential supply chain interruptions or delays;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the extent to which we acquire or invest in business, products and technologies.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Because of the numerous risks and uncertainties associated with research and development of product candidates, we may not be able to accurately predict the timing or amount of our working capital requirements. In addition, if we obtain regulatory approval for ficerafusp alfa, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution which make it difficult to predict when or if we will be able to achieve or maintain profitability. Furthermore, we expect to continue to incur increased costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to support our continuing operations. Our ability to raise additional funds will depend on financial, economic, political and market conditions and other factors, over which we may have no or limited control. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, future commercialization efforts or other operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to ficerafusp alfa. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations with our existing cash, cash equivalents and marketable securities, the net proceeds from our IPO, sales of our common stock under our ATM Program, marketable securities, equity financings, or any future equity or debt financings and upfront and milestone and royalties payments, if any, received under any future licenses or collaborations. In the future, if we raise additional capital through the sale of equity or convertible debt securities or issue any equity or convertible debt securities in connection with a collaboration agreement or other contractual arrangement, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to decline. In October 2025, we filed a Registration Statement pursuant to which we may issue up to $400.0 million in shares of our common stock, preferred stock, debt securities, warrants and/or units. Concurrent with the filing of the Registration Statement, we entered into a common stock sales agreement, dated October 3, 2025, by and between the Company and TD Securities (USA) LLC, acting as the sales agent, to establish an at-the-market offering program pursuant to which we may offer and sell shares of our common stock from time to time, or the ATM Program. In connection with the ATM Program, we filed a prospectus with the Registration Statement for the offer and sale of up to $150.0 million of shares of common stock from time to time through the sales agents, or the ATM Prospectus. As of March 31, 2026, we have sold 1,604,000 shares of common stock under our ATM Program for aggregate net proceeds to us of $29.5 million. In February 2026, we entered into an underwriting agreement with Morgan Stanley &amp; Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters named therein, pursuant to which we issued and sold an aggregate of 8,581,250 shares of our common stock at a price to the public of $16.00 per share, which included full exercise of the underwriters&#8217; option to purchase 1,406,250 additional shares, and pre-funded warrants to purchase up to 2,200,000 shares of common stock to the underwriters at a public offering price of $15.9999 per pre-funded warrant, or the February 2026 Offering. The February 2026 Offering resulted in net proceeds to us of approximately $161.8 million. </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As market conditions permit, we may offer and sell securities under the Registration Statement, including through the ATM Program or additional equity financings, which may cause dilution to our stockholders or impact the market price of our common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or acquiring, selling or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties in the future, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results and prospects. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We maintain the majority of our cash, cash equivalents and marketable securities in accounts with major U.S. and multi-national financial institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions and changes in financial regulations and policies can impact the viability of these institutions. In the event of failure of any of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">the financial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. In addition, changes in regulations governing financial institutions are beyond our control and difficult to predict; consequently, the impact of such changes on our business and results of operations is difficult to predict and may have an adverse effect on us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Risks Related to Our Business Operations and Industry </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our business is highly dependent on the success of ficerafusp alfa. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize ficerafusp alfa, or if we experience delays in doing so, our business will be materially harmed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">To date, as an organization, we have not completed the development of any product candidates, and ficerafusp alfa remains in clinical development. Our future success and ability to generate revenue from ficerafusp alfa is dependent on our ability to successfully develop and commercialize ficerafusp alfa or any of our future product candidates. If any of our product candidates encounters safety or efficacy problems, development delays or regulatory issues or other problems, our development plans and business would be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may not have the financial resources to continue development of ficerafusp alfa if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, ficerafusp alfa, including:     </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our inability to demonstrate to the satisfaction of the FDA, Health Canada, the EMA or other comparable regulatory authorities that ficerafusp alfa is safe and effective;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial or a suspension, termination, or hold, of a clinical trial once commenced; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">conditions imposed by the FDA, Health Canada, the EMA or other comparable regulatory authorities regarding the scope or design of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays or failures in reaching agreement on acceptable terms with clinical trial sites or contract research organizations, or CROs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">poor effectiveness of ficerafusp alfa during clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">better than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive results from our clinical trials;     </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">higher than anticipated clinical trial or manufacturing costs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unfavorable FDA, Health Canada, the EMA or other comparable regulatory authority inspection and review of our clinical trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">failure of our CROs, clinical trial sites, or investigators to comply with regulatory requirements or the clinical trial protocol or otherwise meet their contractual obligations in a timely manner, or at all;   </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays and changes in regulatory requirements, policies and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our therapies in particular; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">varying interpretations of data by the FDA, Health Canada, the EMA and other comparable regulatory authorities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The biotechnology industry is intensely competitive and subject to rapid and significant technological change. ficerafusp alfa or any future product candidates may face competition from major pharmaceutical companies, specialty pharmaceutical companies, universities and other research institutions and from products and therapies that currently exist or are being developed, some of which products and therapies we may not currently know about. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products, and they may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA, Health Canada, the EMA or other regulatory approval or discovering, developing and commercializing products in our field before we do, which could result in our competitors establishing a strong market position before we are able to enter the market. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our competitors may obtain FDA, Health Canada, the EMA or other regulatory approval of their product candidates more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">commercialize ficerafusp alfa. Our competitors may also develop drugs or discovery platforms that are more effective, more convenient, more widely used or less costly than ficerafusp alfa or, in the case of drugs, have a better safety profile than ficerafusp alfa. These competitors may also be more successful than us in manufacturing and marketing their products and have significantly greater financial resources and expertise in research and development. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. In addition, numerous compounds are in clinical development for cancer treatment. Many of these companies are well-capitalized and have significant clinical experience. More specifically, we expect to compete with commercially available therapies for the treatment of head and neck squamous cell carcinoma, or HNSCC, including pembrolizumab (marketed as Keytruda by Merck &amp; Co); the combination of pembrolizumab, platinum chemotherapy and 5-fluorouracil; and the combination of cetuximab (marketed as Erbitux by Eli Lilly &amp; Company in the U.S. and by Merck KGaA outside of the U.S.), platinum chemotherapy and 5-fluorouracil. In addition, there are numerous companies that are developing new treatments for HNSCC, including but not limited to Akeso, Inc., AstraZeneca PLC, AVEO Pharmaceuticals, Inc., BioAtla Inc., BioNTech SE, Corbus Pharmaceuticals Holdings Inc., GSK plc, InhibRx Biosciences, Inc., Johnson &amp; Johnson, Merus N.V. (a Genmab A/S company), PDS Biotechnology Corp, Pyxis Oncology, Inc., and Rakuten Medical, Inc.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Smaller and other early-stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, ficerafusp alfa and any future product candidates. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render ficerafusp alfa obsolete, less competitive or uneconomical. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors may also obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize ficerafusp alfa. Even if ficerafusp alfa achieves marketing approval, it may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. If we do not compete successfully, we may not generate or derive sufficient revenue from any product candidate for which we obtain marketing approval and may not become or remain profitable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Due to the significant resources required for the development of our pipeline, and depending on our ability to access capital, we must prioritize the development of certain product candidates over others. Moreover, we may fail to expend our limited resources on product candidates or indications that may have been more profitable or for which there is a greater likelihood of success. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our initial focus is the development of ficerafusp alfa in HNSCC and, more generally, we seek to bring transformative bifunctional therapies to patients with solid tumors. We are currently conducting our Phase 2/3 FORTIFI-HN01 pivotal trial of ficerafusp alfa in combination with pembrolizumab in first-line, or 1L, recurrent/metastatic, or R/M, human papillomavirus, or HPV, -negative HNSCC, as well as evaluating ficerafusp alfa in multiple Phase 1b expansion cohorts and planning to initiate an alternate dosing study to evaluate ficerafusp alfa with a loading and every-three-week maintenance regimen.</span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Due to the significant resources required for the development of our product candidates, we must decide which product candidates and indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates, therapeutic areas or indications may not lead to the development of viable commercial products and may divert resources away from better opportunities. If we make incorrect determinations regarding the viability or market potential of any of our product candidates or misread trends in the pharmaceutical industry, in particular for disorders of the brain and nervous system, our business, financial condition and results of operations could be materially and adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may seek to grow our business through acquisitions or investments in new or complementary businesses, products or technologies, through the licensing of products or technologies from third parties or other strategic alliances. The failure to manage acquisitions, investments, licenses or other strategic alliances, or the failure to integrate them with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">our existing business, could have a material adverse effect on our operating results, dilute our stockholders&#8217; ownership, increase our debt or cause us to incur significant expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our success depends on our ability to continually enhance and broaden our product offerings in response to changing clinician and patients&#8217; needs, competitive technologies and market pressures. Accordingly, from time to time we may consider opportunities to acquire, make investments in or license other technologies, products and businesses that may enhance our capabilities, complement our existing products and technologies or expand the breadth of our markets or customer base. Potential and completed acquisitions, strategic investments, licenses and other alliances involve numerous risks, including: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">difficulty assimilating or integrating acquired or licensed technologies, products, employees or business operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">issues maintaining uniform standards, procedures, controls and policies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unanticipated costs associated with acquisitions or strategic alliances, including the assumption of unknown or contingent liabilities and the incurrence of debt or future write-offs of intangible assets or goodwill; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">diversion of management&#8217;s attention from our core business and disruption of ongoing operations; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">adverse effects on existing business relationships with suppliers, sales agents, health care facilities, surgeons and other health care providers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">risks associated with entering new markets in which we have limited or no experience;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential losses related to investments in other companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential loss of key employees of acquired businesses; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">increased legal and accounting compliance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We do not know if we will be able to identify acquisitions or strategic relationships we deem suitable, whether we will be able to successfully complete any such transactions on favorable terms, if at all, or whether we will be able to successfully integrate any acquired business, product or technology into our business or retain any key personnel, suppliers, sales agent, health care facilities, physicians or other health care providers. Our ability to successfully grow through strategic transactions depends upon our ability to identify, negotiate, complete and integrate suitable target businesses, technologies or products and to obtain any necessary financing. These efforts could be expensive and time-consuming and may disrupt our ongoing business and prevent management from focusing on our operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">To finance any acquisitions, investments or strategic alliances, we may choose to issue shares of our common stock as consideration, which could dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may be unable to consummate any acquisitions, investments or strategic alliances using our common stock as consideration. Additional funds may not be available on terms that are favorable to us, or at all. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Our employees, independent contractors, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are exposed to the risk of employee fraud or other illegal activity by our current and any future employees, independent contractors, consultants, contract manufacturing organizations, or CMOs, and vendors. Misconduct by these parties could include intentional, reckless, and/or negligent conduct that fails to comply with FDA, Health Canada, the EMA or other regulations, provide true, complete and accurate information to the FDA, Health Canada, the EMA and other comparable regulatory authorities, comply with manufacturing standards we may establish, comply with healthcare fraud and abuse laws and regulations, report financial information or data accurately, or disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the U.S., our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We, our collaborators and our service providers are subject to a variety of privacy and data security laws, regulations and contractual obligations, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with them could expose us to significant fines and other penalties and otherwise harm our business and operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The legislative and regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of personal information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, several jurisdictions, including those in which we operate or collect personal information, have established their own data security and privacy frameworks with which we must comply. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the U.S., numerous federal and state laws and regulations, including federal health information privacy laws, state information security and data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information, could apply to our operations or the operations of our collaborators and service providers. In particular, regulations promulgated pursuant to the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and impose requirements regarding the privacy and security of individually identifiable health information, including mandatory contractual terms, for covered entities, or certain healthcare providers, health plans and healthcare clearinghouses, and their business associates that provide services to the covered entity that involve individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information. While pharmaceutical and biotechnology companies are typically not directly regulated by HIPAA, our business may be indirectly impacted by HIPAA in our interactions with providers, payors, and others that have HIPAA compliance obligations. If we are unable to properly protect the privacy and security of protected health information, we could be found to have violated these privacy and security laws and/or breached certain contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face significant civil and criminal penalties. U.S. Department of Health &amp; Human Services, or HHS, enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">At the state level, numerous states have enacted comprehensive data privacy and security laws, rules and regulations while other states have enacted laws focused on more narrow aspects of privacy. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance. Additionally, some states have passed laws focused specifically on health privacy. In the state of Washington, for example, the My Health My Data Act, which has a private right of action that further increases the relevant compliance risk, requires regulated entities to obtain consent to collect health-related information and grants consumers certain rights, including to request deletion of their information. Connecticut and Nevada have also passed similar laws regulating consumer health data. In addition, other states have proposed and/or passed legislation that regulates the privacy and/or security of certain specific types of information. For example, a small number of states, including Illinois and Texas, have passed laws that regulate biometric data specifically. Although many of the existing state privacy laws exempt clinical trial information and health information governed by HIPAA, future privacy and data protection laws may be broader in scope. These various privacy and security laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Regulators and legislators in the U.S. are increasingly scrutinizing and restricting certain personal data transfers and transactions involving foreign countries. For example, the Department of Justice&#8217;s January 8, 2025, rule on &#8220;Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons,&#8221; prohibits data brokerage transactions involving certain sensitive personal data categories, including health data, genetic data, and biospecimens, to countries of concern, including China. The regulations also restrict certain investment agreements, employment agreements and vendor agreements involving such data and countries of concern, absent specified cybersecurity controls. Actual or alleged violations of these regulations may be punishable by criminal and/or civil sanctions and may result in exclusion from participation in federal and state programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If we conduct clinical trials in the European Economic Area, or the EEA, and/or the United Kingdom, or the U.K., we will be subject to additional, more stringent privacy laws in other jurisdictions, such as the General Data Protection Regulation, or the EU GDPR, as well as other national data protection legislation in force in relevant EU Member States, with respect to the EEA, and the U.K. General Data Protection Regulation, or the U.K. GDPR, with respect to the U.K. We refer to the U.K. GDPR together with the EU GDPR as the &#8220;GDPR.&#8221; The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including strict requirements relating to processing of sensitive data (such as health data), ensuring there is a legal basis or condition to justify the processing of personal data, where required strict requirements relating to obtaining consent of individuals, disclosures about how personal information is to be used, limitations on retention of information, implementing safeguards to protect the security and confidentiality of personal data, where required providing notification of data breaches, maintaining records of processing activities, documenting data protection impact assessments where there is high risk processing and taking certain measures when engaging third-party processors. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA or the U.K., including the United States (see below), and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million (&#163;17.5 million GBP) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Non-compliance could also result in the imposition of orders to stop data processing activities, which could have a material adverse effect on our business, financial position and results of operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">When subject to GDPR, we will be required to put in place mechanisms to ensure compliance, including as implemented by national laws of EU Member States which may partially deviate from the EU GDPR and impose different and more restrictive obligations from country to country. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European and U.K. activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The U.K. GDPR and the U.K. Data Protection Act 2018 set out the U.K.&#8217;s data protection regime, which is independent from but, currently, aligned to the EU&#8217;s data protection regime. The European Commission has adopted an adequacy decision in respect of transfers of personal data to the U.K. In December 2025, the European Commission adopted a decision to extend the validity of the U.K. adequacy decision for six years until December 2031, determining that the U.K. continues to offer a level of data protection that is &#8220;essentially equivalent&#8221; to the EU standards. This follows the U.K.&#8217;s adoption of the Data (Use and Access) Act 2025, or the DUAA, on June 19, 2025. Like the EU GDPR, the U.K. GDPR restricts personal data transfers outside the U.K. to countries not regarded by the U.K. as providing adequate protection. The U.K. Government has confirmed that personal data transfers from the U.K. to the EEA remain free flowing. The respective provisions and enforcement of the EU GDPR and U.K. GDPR may further diverge in the future and create additional regulatory challenges and uncertainties. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we will be required to implement adequate safeguards to enable the transfer of personal data outside of the EEA or the U.K., in particular to the U.S., in compliance with the GDPR. In some cases, we may rely upon the European Commission&#8217;s approved standard contractual clauses to legitimize transfers of personal data out of the EEA from controllers or processors established outside the EEA (and not subject to the GDPR). The U.K. is not subject to the European Commission&#8217;s standard contractual clauses but has published its own transfer mechanism, the International Data Transfer Addendum/Agreement, which enables transfers from the U.K. Changes with respect to any of these matters may lead to additional costs and increase our overall risk exposure. The EU and U.S. have adopted its adequacy decision for the EU U.S. Data Privacy Framework, or the Framework, which entered into force on July 11, 2023. This Framework provides that the protection of personal data transferred between the EU and certified companies in the U.S. is comparable to that offered in the EU. Moreover, the U.K. Government adopted the Data Protection (Adequacy) Regulations 2023, also referred to as the &#8220;UK-U.S. Data Bridge&#8221;, which, since October 12, 2023 allows companies to transfer personal data from the U.K. to the U.S. on the basis of the Framework. This provides a further avenue to ensuring transfers to the U.S. are carried out in line with GDPR. However, the long-term validity of the Framework remains uncertain and it has already been challenged before European courts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies, utilize management&#8217;s time and/or divert resources from other initiatives and projects. Any failure or perceived failure by us to comply with any applicable federal, state or foreign laws and regulations relating to data privacy and security could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, injunctions, penalties or judgments. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, the NIS 2 Directive, or NIS 2, is replacing the cybersecurity legal framework under the current NIS framework in the EU, aiming to ensure a high level of cybersecurity in the region. NIS 2 brings new medium and large organizations providing services in the EU within scope of the legal framework. It extends to additional sectors and expands the list of in-scope healthcare organizations, including to certain providers engaged in research and development of medicinal products. The new regime imposes direct obligations on management in respect of an in-scope organization</span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">s compliance with NIS 2, requires covered organizations to put in place certain cyber risk management measures, strengthens incident reporting requirements and provides supervisory authorities with a greater oversight. The majority of obligations will come into force when national legislation implementing NIS 2 becomes effective in the relevant EU Member State. EU Member States had until October 17, 2024 to transpose NIS 2 into national legislation, although some countries have still not completed the transposition. As such, the cybersecurity regulatory landscape in the EU is currently fragmented and uncertain. To the extent we are subject to NIS 2, we will require additional investment of our resources in compliance </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">programs. Under NIS 2 companies may be subject to administrative fines of up to the higher amount of &#8364;10 million or 2% of worldwide turnover.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unable to protect the confidentiality of our proprietary information, the value of ficerafusp alfa could be adversely affected. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets and/or confidential know-how, unpatented know-how and/or other proprietary information. We may rely on other proprietary rights, including protection of trade secrets, confidential know-how, unpatented know-how and/or other proprietary information to protect ficerafusp alfa, especially where patent protection is believed to be of limited value. However, trade secrets and/or confidential know-how are difficult to maintain as confidential. To maintain the confidentiality of this type of information, it is our policy to enter into confidentiality agreements with our employees, consultants, advisors, collaborators, contractors (including CROs), and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual(s) or made known to the individual by us during the course of the individual&#8217;s relationship or work with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms, intentionally or unintentionally. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants, contractors or others use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us or a current or future licensor is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. The disclosure of our trade secrets could impair our competitive position and may materially harm our business, financial condition and results of operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements and theft of trade secret claims may vary from jurisdiction to jurisdiction. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. As such, adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. Such persons may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, such persons could limit our use of our trade secrets and/or confidential know-how. Under certain circumstances and to guarantee our freedom to operate, we may also decide to publish some know-how to prevent others from obtaining patent rights covering such know-how.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">The use of new and evolving technologies, such as artificial intelligence, or AI, in our operations may result in spending material resources and presents risks and challenges that can impact our business including by posing security and other risks to our confidential information, proprietary information and personal information, and as a result we may be exposed to reputational harm and liability. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may use and integrate AI into our operations both in our own development and implementation of AI and through the adoption of commercially available tools. Use of this technology could pose cybersecurity, data privacy, IT, intellectual property, regulatory, legal, operational, competitive, reputational and other risks and challenges that could affect our business. Specifically, risks related to accuracy, bias, artificial intelligence hallucinations, discrimination, harmful content, misinformation, fraud, scams, targeted attacks (including model poisoning or data poisoning), surveillance, data leakage, inequality, environmental harms, and other harms may flow from our development, use, or deployment of AI technologies. The use of certain AI technology can give rise to intellectual property risks, including by disclosing or otherwise compromising our confidential or proprietary intellectual property and intellectual property infringement, or by undermining our ability to assert or defend ownership rights in intellectual property created with the assistance of AI tools. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, we have seen increasing government and supranational regulation related to AI use and ethics, which may significantly increase the burden and cost of research, development and compliance in this area. For example, the EU began implementing the Artificial Intelligence Act, or the AI Act, on August 1, 2024, with a significant part of the law scheduled to come into effect in August 2026. As currently enacted, the AI Act, which may be amended as part of the EU&#8217;s Digital Omnibus, imposes significant obligations on providers and deployers of high risk AI systems, and encourages </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">providers and deployers of AI systems to account for EU ethical principles in their development and use of these systems. The scope of requirements depends on judicial interpretations and forthcoming legislative amendments, and non-compliance can lead to significant fines. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the U.S., the AI regulatory environment is complex and uncertain. Over the past year, states have advanced, and in some cases passed, dozens of laws focusing on AI governance and regulation, including on deployment of AI in healthcare settings. At the federal level, the Trump Administration has endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on &#8220;Ensuring a National Policy Framework for Artificial Intelligence.&#8221; So far, these efforts have not been successful at curtailing state action on AI regulation, contributing to a complicated legislative patchwork, which may be litigated in state and federal courts. If we deploy AI systems that are governed by these laws or regulations, we may be required to adopt higher standards of data quality, transparency, and human oversight, and adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our vendors may in turn incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. In addition, the use of generative AI models in our internal or third-party systems may create new attack surfaces or methods for adversaries, which could impact us and our vendors. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to the Discovery and Development of ficerafusp alfa or Future Product Candidates </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our business is dependent on our ability to advance ficerafusp alfa and future product candidates through clinical trials, obtain marketing approval and ultimately commercialize them. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual regulatory approval and commercialization of ficerafusp alfa or any future product candidates we develop, which may never occur. Our current product candidate, ficerafusp alfa, remains in clinical development. Ficerafusp alfa and any future product candidates we develop will require additional preclinical or clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the U.S., Canada and other jurisdictions, demonstration of effectiveness to pricing and reimbursement authorities, sufficient manufacturing supply for both preclinical and clinical development and commercial production, building of a commercial organization and substantial investment and significant marketing efforts before we generate any revenues from product sales. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The clinical and commercial success of ficerafusp alfa and any future product candidates will depend on several factors, including the following:  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">timely and successful completion of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary clinical trials and any additional preclinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our plans to successfully submit new Investigational New Drug, or IND, applications with the FDA for ficerafusp alfa and any future product candidates; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">successful enrollment in, and completion of clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">successful data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended patient populations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to establish agreements with third-party manufacturers on a timely and cost-efficient manner;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">whether we are required by the FDA, Health Canada, the EMA or comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned or anticipated to support approval of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">acceptance of our proposed indications and the primary endpoint assessments evaluated in the clinical trials of our product candidates by the FDA and comparable foreign regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">receipt and maintenance of timely marketing approvals from applicable regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">successfully launching commercial sales of our product candidates, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">entry into collaborations to further the development of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">acceptance of the benefits and uses of our product candidates, if approved, by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintaining a continued acceptable safety, tolerability and efficacy profile of any product candidates following approval;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our compliance with any post-approval requirements imposed on our products, such as post-marketing studies, a Risk Evaluation and Mitigation Strategy, or REMS, or additional requirements that might limit the promotion, advertising, distribution or sales of our products or make the products cost prohibitive;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">competing effectively with other therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">enforcing and defending intellectual property rights and claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">These factors, many of which are beyond our control, could cause us to fall behind our competitors, experience significant delays or an inability to obtain regulatory approvals or commercialize ficerafusp alfa or future product candidates, and could otherwise materially harm our business. Successful completion of preclinical studies and clinical trials does not mean that ficerafusp alfa or any future product candidates we develop will receive regulatory approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product candidates we develop, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of ficerafusp alfa or any future product candidate, we may not be able to continue our business operations or achieve profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize ficerafusp alfa and any future product candidates. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">To obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe, pure and potent in humans and have a favorable risk-benefit profile. Clinical trials are expensive and can take many years to complete, with a highly uncertain outcome. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. We may experience delays in completing our clinical trials or preclinical studies and initiating or completing additional clinical trials. We cannot be certain the ongoing and planned preclinical studies or clinical trials for ficerafusp alfa or any other future product candidates will begin on time, not require redesign, enroll an adequate number of subjects on time or be completed on schedule, if at all. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">results from preclinical studies or clinical trials may not be predictive of results from later clinical trials of any product candidate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or other regulatory authorities, Institutional Review Boards, or IRBs, or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements on us, before permitting us to initiate a clinical trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, as the terms of these agreements can be subject to extensive negotiation and vary significantly among different CROs and trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">clinical trials of any product candidate may fail to show safety, purity or potency, or may produce negative or inconclusive results, which may cause us to decide, or regulators to require us, to conduct additional nonclinical studies or clinical trials or which may cause us to decide to abandon product candidate development programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the number of patients required for clinical trials may be larger than we anticipate, or we may have difficulty in recruiting and enrolling patients to participate in clinical trials, including as a result of the size and nature of the patient population, the proximity of patients to clinical trial sites, eligibility criteria for the clinical trial, the nature of the clinical trial protocol, the availability of approved effective treatments for the relevant disease and competition from other clinical trial programs for similar indications and clinical trial subjects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or may fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our CROs and other third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any of our product candidates could cause undesirable side effects that could result in significant negative consequences, including the inability to enter clinical development or receive regulatory approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the cost of preclinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may face hurdles in addressing subject safety concerns that arise during the course of a trial, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate trials, or reports may arise from nonclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the supply, quality or timeliness of delivery of materials for product candidates we develop or other materials necessary to conduct clinical trials may be insufficient or inadequate; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may need to change the manufacturing site and potentially the CMO for our product candidates from those that are able to produce clinical supply for our clinical trials to those with the capacity and ability to perform commercial manufacturing and/or the production of clinical material for our later stage clinical trials. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We could encounter delays if a clinical trial is suspended or terminated by us, or by the IRBs of the institutions in which such trials are being conducted, ethics committees or the Data and Safety Monitoring Board, or the DSMB, for such trial or by the FDA, Health Canada, competent authorities in the EU, the Medicines and Healthcare Products Regulatory Agency, or the MHRA, or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, Health Canada, competent authorities in the EU, the MHRA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our product candidates. The FDA, Health Canada, the EMA or other regulatory authorities may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Further, the FDA, Health Canada, the EMA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials. For example, we are conducting and may in the future conduct additional &#8220;open-label&#8221; clinical trials. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical trials often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. For example, in our ongoing Phase 1/1b trial, objective response rate as determined using RECIST 1.1 criteria is assessed by the trial investigators who may be aware of the trial treatment, patient history or other information that could impact their choices in applying the rules and conventions of RECIST 1.1. The published literature demonstrates a consistent decrease in response rate when investigator assessed response rates are verified by independent radiology review.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or other compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing ficerafusp alfa or any future product candidates. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down the development and approval process for our product candidates and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates. Any such events would impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or result in the development of our product candidates stopping early.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are currently conducting, and may in the future conduct, clinical trials for ficerafusp alfa or any future product candidates outside the U.S., and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are currently conducting, and may in the future conduct, clinical trials for ficerafusp alfa or any future product candidates outside the U.S., and the FDA and comparable foreign regulatory authorities may not accept data from such trials. We are currently conducting clinical trials in the U.S. and Canada, and we expect to continue to conduct trials internationally in the future. The acceptance of data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA, Health Canada, the EMA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice, (ii) the trials were performed by clinical investigators of recognized competence and pursuant to good clinical practice, or GCP, regulations, and (iii) the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, Health Canada, the EMA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA, Health Canada, the EMA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in ficerafusp alfa or any future product candidates that we may develop being delayed or not receiving approval for commercialization in the applicable jurisdiction. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results in any of our clinical trials may not be indicative of results obtained when the trial is completed or in later stage trials.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The results of preclinical studies may not be predictive of the results of clinical trials. Preclinical studies and early-stage clinical trials are primarily designed to (i) test safety, (ii) study pharmacokinetics and pharmacodynamics and (iii) understand the side effects of product candidates at various doses and schedules, and the results of any early-stage clinical trials may not be predictive of the results of later-stage, large-scale efficacy clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs and biological products proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials. For example, ficerafusp alfa or any future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show desired pharmacological properties or produce the necessary safety and efficacy results despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit, validation and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Interim data and results from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit, validation and verification procedures that may result in the final data being materially different from the interim and preliminary data we previously published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, third parties, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could delay or prevent regulatory approval of, or limit commercial prospects for, the particular product candidate. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine to disclose. If regulatory authorities disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Ficerafusp alfa or any future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, pure and potent for use in each target indication, and failures can occur at any stage of testing. As with most biological products, use of ficerafusp alfa or any future product candidates could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. There have been serious adverse side effects reported in response to product therapeutics and bispecifics in oncology. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">EGFR-targeted drugs have been observed to cause side effects, predominantly related to skin toxicity and rash, and TGF-&#946; inhibitors have been shown to have side effects primarily related to bleeding. While we have observed these side effects during our studies, the severity of these has been minimal but additional or more severe treatment-related side effects may emerge at a later time in our trials. In addition to any potential side effects caused by the product or product candidate, the administration process or related procedures also can cause adverse side effects. If unacceptable adverse events occur, our clinical trials or any future marketing authorization could be suspended or terminated. Additionally, we may be required to repeat or conduct additional clinical trials or nonclinical studies for our product candidates beyond those that we currently contemplate. There can be no assurance that ficerafusp alfa or any future product candidates will not demonstrate unacceptable toxicities in later testing that may render it unsafe or intolerable. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our trials are conducted or the DSMB could suspend or terminate our clinical trials or the FDA, Health Canada, the EMA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Although ficerafusp alfa and future product candidates have undergone and will undergo safety testing to the extent possible and, where applicable, under such conditions discussed with regulatory authorities, not all adverse effects of drugs can be predicted or anticipated. Antibody therapeutics and bispecifics and their method of action of harnessing the body&#8217;s immune system are powerful and could lead to serious side effects that we only discover in clinical trials or during commercial marketing. Unforeseen side effects could arise either during clinical development or after our product candidates have been approved by regulatory authorities and the approved product has been marketed, resulting in the exposure of additional patients. So far, we have not demonstrated that ficerafusp alfa is safe in humans, and we cannot predict if ongoing or future clinical trials will do so. If ficerafusp alfa or any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, we will not be able to generate revenue and our business will be harmed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we intend to pursue our product candidates in combination with other therapies and may develop future product candidates in combination with other therapies, which exposes us to additional risks relating to undesirable side effects or other properties. For example, the other therapies may lead to toxicities that are improperly attributed to our product candidates or the combination of our product candidates with other therapies may result in toxicities that the product candidate or other therapy does not produce when used alone. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Even if we successfully advance our product candidates through clinical trials, such trials will likely only include a limited number of subjects and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">to the product candidate. Further, any clinical trial may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Even if we successfully develop a product candidate and it receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of treatment outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">regulatory authorities may limit, suspend, or withdraw their approval of the product or may refuse to approve supplemental applications for such product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be required to recall a product or change the way such product is administered to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our reputation may suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues, which would materially harm our business. In addition, if one or more of our product candidates or our antibody therapeutic development approach generally prove to be unsafe, our entire technology platform and pipeline could be affected, which would also materially harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs and delayed timelines.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The design and implementation of clinical trials is a complex process. We may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. A clinical trial that is not well designed may delay or even prevent initiation of the trial, can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the trial results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third-party payors. Additionally, a trial that is not well-designed could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could lead to a shortfall in funding. We also expect to continue to rely on third parties to conduct our clinical trials. Consequently, we may be unable to successfully and efficiently execute and complete clinical trials that are required for Biologics License Application, or BLA, submission and FDA approval of ficerafusp alfa or any future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we or our collaborators encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise be adversely affected.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The successful and timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the trial until the trial&#8217;s conclusion, including any follow-up period. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the patient eligibility criteria defined in the protocol;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the nature and size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the number and location of participating and available clinical sites or patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays in, inability, or failure to add new clinical trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the design of the trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the availability of competing commercially available therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain and maintain patient informed consents for participation in our clinical trials; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current and potential future product candidates. It is also likely that we may compete with competitors developing product candidates in the same therapeutic areas for clinical trial sites. This competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such sites. Moreover, because our current and potential future product candidates may represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in our ongoing or any future clinical trial. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Delays of difficulties in patient enrollment may result in increased costs or may affect the timing, outcome or completion of clinical trials, which would adversely affect our ability to advance the development of the product candidates we develop. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Preclinical development is uncertain. Any preclinical programs we pursue may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The risk of failure for product candidates still in the discovery or preclinical stage is high. In addition, any one or more of our product candidates that have not yet entered the clinic may never advance into clinical development. In order to obtain FDA approval to market a new biologic we must demonstrate proof of safety, purity and potency, including efficacy, in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned clinical trials in humans. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of ficerafusp alfa or any future product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA, Health Canada, the EMA, the MHRA or other regulatory authorities allowing clinical trials to begin. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time of such testing may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">an inability to generate sufficient preclinical or other </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">or </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> data to support the initiation of clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">delays in reaching a consensus with regulatory agencies on trial design; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or foreign regulatory authorities not permitting the reliance on preclinical or other data from published scientific literature.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have engaged a third party and may engage additional third parties to develop companion diagnostics for our product candidates. At least in some cases, the FDA and similar regulatory authorities outside the United States may request or require the development and regulatory approval of a companion diagnostic as a condition to approving one or more of our product candidates. Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate clearance or approval prior to their commercialization. We do not have experience or capabilities in developing or commercializing diagnostics and are relying, and in the future plan to continue to rely, in large part on third parties to perform these functions. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In most cases, we will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third-party contractors to successfully develop and commercialize these companion diagnostics. Our contractors:</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">may not perform their obligations as expected;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">may encounter production difficulties that could constrain the supply of the companion diagnostic;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">may not commit sufficient resources to the marketing and distribution of such product; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">may terminate their relationship with us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We and our third-party collaborators may encounter difficulties in developing and obtaining approval for these companion diagnostics. Any delay or failure by us or third- party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval of our related product candidates. Further, if any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third-party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate.</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Dependence On and Work with Third Parties </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates, and our business could be substantially harmed. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct monitor and manage data for our preclinical studies and clinical trials. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the competent authorities of the member states of the EEA, the MHRA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, Health Canada, the EMA, the MHRA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with the product candidate produced under FDA&#8217;s current good manufacturing practice, or cGMP, regulations or similar foreign regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Further, these principal investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers may require us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We currently and in the future may depend on other third-party collaborators for the discovery, development and commercialization of ficerafusp alfa and any of our future product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into collaborations with MSD International GmbH, or MSDIG, and MSD International Business GmbH, or MSDIB, and collectively with MSDIG, MSD and Biocon Ltd, or Biocon. In the future, we may form or seek other strategic alliances, joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we develop. Our current and potential future collaborations involving our product candidates may pose various risks to us, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation or that could jeopardize or invalidate our intellectual property or proprietary information, exposing us to potential litigation or other intellectual property proceedings;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">collaboration agreements may restrict our right to independently pursue new product candidates; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the mutual termination of the Contract Transfer and License Agreement with Biocon could delay the commercialization of ficerafusp alfa.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For future collaborations, if we enter into such collaboration agreements and strategic partnerships or license our intellectual property, products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or net income that justifies such transaction. Any of the factors set forth above, among others, could delay the development and commercialization of our product candidates, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We currently have established collaborations and may seek to establish future collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The advancement of our product candidates and development programs and the potential commercialization of ficerafusp alfa and any of our future product candidates will require substantial additional cash to fund expenses. We currently collaborate with pharmaceutical and biotechnology companies with respect to development and potential commercialization of ficerafusp alfa, and we may also do so with any future product candidates. These relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for other collaborations will depend, among other things, upon our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval by the FDA, Health Canada, the EMA or comparable regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Further, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Such exclusivity could limit our ability to enter into strategic collaborations with future collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any marketing or sales activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We currently rely on third-party suppliers and other third parties for production of our product candidates and our dependence on these third parties may impair the advancement of our research and development programs and the development of our product candidates. Moreover, we intend to rely on third parties to produce commercial supplies of any approved product candidate and our commercialization of any of our product candidates could be stopped, delayed or made less profitable if those third parties fail to obtain approval of the FDA, Health Canada, the EMA or comparable foreign regulatory authorities following inspection of their facilities and procedures to manufacture our product candidates, fail to provide us with sufficient quantities of a product candidate or fail to do so at acceptable timing, quality levels or prices or fail to otherwise complete their duties in compliance with their obligations to us or other parties.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We rely on and expect to continue to rely on third-party CMOs for the supply of cGMP-grade clinical trial materials and commercial quantities of our product candidates and products, if approved. Reliance on third-party providers may expose us to more risk than if we were to manufacture product candidates ourselves. The facilities used by our CMOs to manufacture our product candidates must be approved by the FDA foreign regulatory authorities pursuant to inspections that will be conducted after we submit our BLA, to the FDA, or similar applications to foreign regulatory authorities. We have limited control over the manufacturing process of, and beyond contractual terms, we are completely dependent on our CMOs for compliance with cGMP, and applicable product tracking and tracing requirements, or similar foreign requirements for the manufacture of our product candidates. If our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, Health Canada, the EMA or comparable foreign regulatory authorities, or are unable to do so in a timely manner, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities or may result in delay of our ability to obtain marketing authorization, if any, of our product candidates. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, Health Canada, the EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates or that obtained approvals could be revoked, which would adversely affect our business and reputation. Furthermore, third-party providers may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement because of their own financial difficulties or business priorities, at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed. In addition, the fact that we are dependent on our collaborators, our CMOs and other third parties for the manufacture, filling, storage and distribution of our product candidates means that we are subject </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">to the risk that the products may have manufacturing defects that we have limited ability to prevent or control. The sale of products containing such defects could adversely affect our business, financial condition and results of operations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We rely on our CMOs to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials, and will rely on our existing and future collaborators to purchase from third-party suppliers the materials necessary to develop and produce our product candidates for future clinical trials and, upon approval, our products for commercialization. There are a limited number of suppliers for raw materials that we use to manufacture our product candidates and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, ultimately for commercial sale. Apart from contractual measures, we do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers or manufacturers paid by our collaborators. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of an product candidate to complete the clinical trial or have secured resupply capacity, any significant delay in the supply of an product candidate, or the raw material components thereof, for a planned or an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the manufacturing of our product candidates is expensive and time-consuming, and generally requires more complex processes than those associated with small-molecule drugs. If we are successful in obtaining regulatory approval for any of our product candidates, we might have limited quantities of such product candidates available to us in connection with a potential commercial launch, and these supplies may be further limited by our ongoing clinical development activities. If our manufacturers, collaborators or we are unable to purchase or produce sufficient quantities of raw materials or of our product candidates after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates could be delayed or there could be a shortage in supply, which in either case, would impair our ability to generate revenues from the sale of our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We rely on our manufacturers and other subcontractors to comply with and respect the proprietary rights of others in conducting their contractual obligations for us. If our manufacturers or other subcontractors fail to acquire the proper licenses or otherwise infringe third party proprietary rights in the course of completing their contractual obligations to us, we may have to find alternative manufacturers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The operations of our suppliers, many of which are located outside of the United States, are subject to additional risks that are beyond our control and that could harm our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We currently rely on and engage third-party manufacturers to provide all of the drug substance and the final drug product formulation of all of our product candidates that are being used in our clinical trials and preclinical studies. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we primarily rely on WuXi Biologics (Hong Kong) Limited for the production of product necessary to complete our ongoing clinical trials. If an additional manufacturer became necessary in the future, we may incur added costs and delays in identifying and qualifying another manufacturer. We currently do not have any long-term supply agreements in place, though we intend to enter into such agreements as well as evaluate additional product manufacturing sources in the future. As a result of our dependence on ex-U.S. suppliers, we are subject to risks associated with doing business abroad, including:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">geopolitical tensions, political unrest, terrorism, labor disputes and economic instability resulting in the disruption of trade from foreign countries in which our products are manufactured, particularly China;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the imposition of new laws and regulations, including those relating to labor conditions, safety standards, information and data transfer, imports, duties, taxes, and other charges on imports, as well as trade restrictions and restrictions on currency exchange or the transfer of funds, particularly new or increased tariffs imposed on imports from countries where our suppliers operate, including China; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">greater challenges and increased costs with enforcing and periodically auditing or reviewing our suppliers&#8217; and manufacturers&#8217; compliance with cGMPs or status acceptable to the FDA, Health Canada, the EMA or comparable foreign regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reduced protection for intellectual property rights, including trade secret protection, in some countries, particularly China;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">disruptions in operations due to global, regional, or local epidemics, pandemics, public health crises or other emergencies or natural disasters;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">disruptions or delays in shipments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in local economic conditions in countries where our manufacturers or suppliers are located.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On December 18, 2025, the Fiscal Year 2026 National Defense Authorization Act (P.L. 119-60) was signed into law, Section 851 of which (commonly known as the BIOSECURE Act) restricts U.S. federal executive agencies, and federal contractors, grant recipients, and loan recipients, from procuring or using biotechnology equipment or services from entities designated as &#8220;biotechnology companies of concern&#8221; (BCCs) in performance of U.S. federal contracts, grants, or loans. BCCs include entities on the Department of Defense&#8217;s Section 1260H list of Chinese military companies operating in the United States (to the extent such entities are involved in the manufacturing, distribution, provision, or procurement of biotechnology equipment or services) and entities identified through a forthcoming Office of Management and Budget, or OMB, -led interagency designation process. The BIOSECURE Act&#8217;s prohibitions are subject to a multi-year implementation timeline, with the initial OMB list due by December 2026, followed by implementing guidance and Federal Acquisition Regulation rulemaking &#8212; and the substantive prohibitions are not expected to take effect until 2027 at the earliest, subject to a five-year grandfather period for certain pre-existing contractual arrangements. We do anticipate continued scrutiny on the biopharmaceutical industry's relationships with Chinese biotechnology companies, which could adversely impact our Chinese biotech business partners&#8217; operations or financial position, and, in turn, could impair their ability to supply us with product in the future. We may also face additional manufacturing and supply-chain risks due to (i) evolving regulatory and legal requirements in China, (ii) the deterioration of the geo-political relationship between China and the U.S., including but not limited to potential sanctions imposed by the U.S. government on Chinese biotech partners, or other companies in China on whom we might rely, or (iii) similar developments affecting any of the other countries in which our products or product candidates are or are expected to be manufactured or marketed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">These and other factors beyond our control could interrupt our suppliers&#8217; production, influence the ability of our suppliers to export our clinical supplies cost-effectively or at all and inhibit our supplier&#8217;s ability to procure certain materials, any of which could delay our clinical trials or otherwise harm our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates or increase the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product candidates, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of our product candidates. The transition to larger scale production could prove difficult. In addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates while maintaining the same quality then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may need to maintain licenses for drug substances from third parties to develop and commercialize some of our product candidates, which could increase our development costs and delay our ability to commercialize those product candidates. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Should we decide to use any cell line and raw materials in any of our product candidates that are proprietary to one or more third parties, we would need to maintain licenses to those drug substances from those third parties. If we are unable to gain or continue to access rights to these drug substances prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop alternate product candidates from these programs by either accessing or developing alternate drug substances, resulting in increased development costs and delays in commercialization of these product candidates. If we are unable to gain or maintain continued access rights to the desired drug substances on commercially reasonable terms or develop suitable alternate drug substances, we may not be able to commercialize product candidates from these programs. </span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Risks Related to Government Regulation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval (or maintain approval) may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. For example, the Oncology Center of Excellence within the FDA has </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">advanced Project Optimus, which is an initiative to reform the dose optimization and dose selection paradigm in oncology drug development to emphasize selection of an optimal dose, which is a dose or doses that maximizes not only the efficacy of a drug but the safety and tolerability as well. This shift from the prior approach, which generally determined the maximum tolerated dose, has required and will require us to continue to spend additional time and resources to further explore a product candidate&#8217;s dose-response relationship to facilitate optimum dose selection in a target population. Other recent Oncology Center of Excellence initiatives have included Project FrontRunner, a new initiative with a goal of developing a framework for identifying candidate drugs for initial clinical development in the earlier advanced setting rather than for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options, and Project Confirm, which is an initiative to promote the transparency of outcomes related to accelerated approvals for oncology indications and provide a framework to foster discussion, research and innovation in approval and post-marketing processes, with the goal to enhance the balance. We are considering these and other policy changes as they relate to our programs. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have not obtained regulatory approval for any product candidate. Neither we nor any future collaborator is permitted to market any biological product in the U.S. until we or the future collaborator receives regulatory approval of a BLA, from the FDA. It is possible that ficerafusp alfa or any future product candidates will not obtain regulatory approval from the FDA, Health Canada, the European Commission or comparable foreign regulatory authorities. Ficerafusp alfa and any future product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, Health Canada, the EMA or comparable foreign regulatory authorities that a product candidate has an acceptable risk-benefit profile in the proposed indication;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, Health Canada, the EMA or comparable foreign regulatory authorities that the facility in which a product candidate is manufactured meets standards designed to assure that the product candidate continues to be safe, pure, and potent;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, Health Canada, the EMA or comparable foreign regulatory authorities for approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA, Health Canada, the EMA or regulatory submissions to comparable regulatory authorities to obtain regulatory approval in such jurisdiction; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the FDA, Health Canada, the EMA or comparable foreign regulatory authorities may find deficiencies with or fail to approve our manufacturing processes or facility or the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies.           </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, results of operations and prospects. The FDA and other comparable foreign authorities have substantial discretion in the approval process and in determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, Health Canada, the EMA or any other regulatory authority.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, even if we were to obtain approval, the FDA may approve any of our product candidates for fewer or more limited indications, or a more limited patient population, than we request, may grant approval contingent on the performance of costly clinical trials or other post-marketing requirements, or may approve a product candidate with a label that does not include the labeling claims we believe are necessary or desirable for the successful commercialization of such product candidates. Even if we obtain regulatory approval for our product candidates, we will be required to submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process and the FDA or comparable foreign regulatory authority may refuse to approve such applications or supplements.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the FDA, Health Canada, the EMA or comparable foreign regulatory authorities may change their policies, promulgate additional regulations, revise existing regulations or take other actions that may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy personnel, and substantial leadership, personnel and policy changes or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">otherwise, could prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Without the appropriation of adequate funding to federal agencies, our business operations related to our product development activities for the U.S. market could be impacted. A prolonged government shutdown could significantly impact the ability of the FDA to timely review and process our regulatory submissions, the National Institutes of Health, or NIH, to conduct research or provide grants, or other agencies to slow their work, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Disruptions at the FDA and other agencies, including substantial leadership, personnel, and policy changes, may also slow the time necessary for biological products or modifications to approved biological products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. Changes and cuts in FDA staffing have been reported by some within the pharmaceutical industry as creating instances of delays in the FDA&#8217;s responsiveness or in its ability to review IND submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">There is substantial uncertainty as to whether and how the current administration will continue to seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates and any products for which we obtain approval. This uncertainty could present new challenges and/or opportunities as we navigate development and approval of our product candidates. Additionally, the current administration could continue to issue or promulgate executive orders, regulations, policies or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Clinical trials must be conducted in accordance with GCP requirements, which are regulations and guidelines enforced by the FDA, Health Canada, the EMA and comparable foreign regulatory authorities. Clinical trials are subject to oversight by the FDA, other foreign governmental agencies and IRBs or ethical committees at the trial sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates manufactured in accordance with applicable cGMP. Clinical trials may be suspended by the FDA, other foreign regulatory authorities, us, or by an IRB or ethics committee with respect to a particular clinical trial site, for various reasons, including:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or trial protocols;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">deficiencies in the clinical trial operations or trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unforeseen adverse side effects or the emergence of undue risks to trial subjects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">deficiencies in the trial design necessary to demonstrate efficacy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">ficerafusp alfa may not appear to offer benefits over current therapies; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the quality or stability of ficerafusp alfa may fall below acceptable standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We intend to develop our product candidates in part in combination with other therapies and may develop our future product candidates in combination with other therapies, which exposes us to additional regulatory risks. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We intend to develop our product candidates in part in combination with other therapies, including ficerafusp alfa in combination with pembrolizumab, and may develop ficerafusp alfa and any future product candidates in combination with one or more currently approved cancer therapies. These combinations have not been previously tested in the clinic and may, among other things, fail to demonstrate synergistic activity, may fail to achieve superior outcomes relative to the use of single agents or other combination therapies, or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combination therapy. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we did not develop or obtain regulatory approval for, and we do not manufacture or sell, any of these approved therapeutics. The other therapies we are using in combination may be removed from the market, or we may not be able to secure adequate quantities of such materials for which we have no guaranteed supply contract, and thus be unavailable for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">testing or commercial use with any of our approved products. The other therapies we may use in combination with our product candidates may also be supplanted in the market by newer, safer or more efficacious products or combinations of products. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA, Health Canada, the European Commission or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially. Combination therapies are commonly used for the treatment of cancer diseases, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may also evaluate ficerafusp alfa or any future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA, Health Canada, the EMA or comparable foreign regulatory authorities. We will not be able to market and sell any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If the FDA, Health Canada, the European Commission or comparable foreign regulatory authorities do not approve these other biological products or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the biological products we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval of or market any such product candidate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Even if we receive marketing approval of ficerafusp alfa, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. If we fail to comply or experience unanticipated problems with our products, we may be subject to administrative and judicial enforcement, including monetary penalties, for non-compliance and our approved products, if any, could be deemed misbranded or adulterated and prohibited from continued distribution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Any marketing approvals that we may receive for ficerafusp alfa or any future product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or the conditions of approval or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require implementation of a REMS as a condition of approval of any product candidate, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, Health Canada, the EMA or a comparable foreign regulatory authority approves a product candidate, the manufacturing processes, labeling, packaging, distribution, tracking and tracing event and deviation reporting, storage, advertising, promotion, import and export and record keeping for the product candidate will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP, for any clinical trials that we may conduct post-approval. Later discovery of previously unknown problems with any approved candidate, including adverse events of unanticipated severity or frequency, or with our or our third-party manufacturers&#8217; manufacturing processes or facilities, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">suspension of, or imposition of restrictions on, the marketing or manufacturing of the product, withdrawal of the product from the market, or product recalls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Warning letters or untitled letters, or holds on clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications we file, or suspension or revocation of approved biologics licenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">product seizure or detention, monetary penalties, refusal to permit the import or export of the product, or placement on Import Alert; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">permanent injunctions and consent decrees including the imposition of civil or criminal penalties.      </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Given the nature of biological products manufacturing, there is a risk of contamination. Any contamination could materially adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials and other components required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product or product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially and adversely affect our development and commercialization timelines and our business, financial condition, results of operations and prospects and could adversely affect our ability to meet our supply obligations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, the FDA strictly regulates the promotional claims that may be made about drug and biological products. In particular, an approved product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling, or off-label uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. The FDA has issued guidance on the factors that it will consider in determining whether a firm&#8217;s product communication is consistent with the FDA-required labeling for that product, and those factors contain complexity and potential for overlap and misinterpretation. A company that is found to have improperly promoted off-label uses of their products may be subject to significant civil, criminal and administrative penalties. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The FDA and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay marketing approval of a product. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">While we intend to seek designations for our potential product candidates with the FDA and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process, there can be no assurance that we will successfully obtain such designations. In addition, even if one or more of our potential product candidates are granted such designations, we may not be able to realize the intended benefits of such designations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The FDA and comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities and priority review. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">However, there can be no assurance that we will successfully obtain such designations for any potential product candidates. In addition, while such designations could expedite the development or approval process, they generally do not change the standards for approval. Even if we obtain such designations for one or more of our potential product candidates, there can be no assurance that we will realize their intended benefits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For example, we have received a breakthrough therapy designation for ficerafusp alfa in combination with pembrolizumab for the 1L treatment of patients with R/M HNSCC whose tumors express programmed death-ligand 1 with CPS &#8805;1, excluding HPV-positive oropharyngeal squamous cell carcinoma, and we may seek breakthrough therapy designation for </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">ficerafusp alfa</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> for additional uses or for some of our potential product candidates in the future. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our potential product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our potential product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we may seek fast-track designation for some of our potential product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy nonclinical or clinical data demonstrates the potential to address unmet medical needs for this condition, the therapy sponsor may apply for fast-track designation. The FDA has </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a fast-track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw fast-track designation if it believes that the designation is no longer supported by data from our clinical development program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for the product candidates that we may develop. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may not be able to obtain or maintain orphan drug designations for our product candidates, and we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Regulatory authorities in some jurisdictions, including the United States and European Union, may designate drugs for relatively small patient populations as orphan drugs. For example, the FDA may designate a product as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the U.S., or a patient population of greater than 200,000 individuals in the U.S. but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. We may not be able to obtain orphan drug designation for any indications for our product candidates, and we may not be able to maintain such designations if granted. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same biologic for the same approved use or indication within such rare disease or condition for seven years. Even if we are able to obtain orphan drug designation or orphan drug exclusivity, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same approved use or condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same approved use or condition if, among other things, the FDA concludes that the later drug is clinically superior, if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. Even if we receive orphan drug designation or orphan drug exclusivity for any of our product candidates, there is no guarantee that we will enjoy the benefits of such designations or exclusivity periods. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">While we may seek accelerated approval for some of our product candidates, we may not be able to obtain it as the sufficiency of our clinical trial results for accelerated approval are subject to the FDA&#8217;s discretion. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We plan to seek approval for ficerafusp alfa under the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and generally provides a meaningful advantage over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. For more information, see the section titled &#8220;Business&#8212;Government Regulation&#8212;Accelerated Approval&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, or Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. There can be no assurance that the FDA would allow any of the product candidates we may develop to proceed on an accelerated approval pathway, and even if the FDA did allow such pathway, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Risks Related to Commercialization</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The commercial success of ficerafusp alfa or any future product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Ficerafusp alfa and any future product candidates may not be commercially successful. Even if ficerafusp alfa or any future product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors, or the medical community. The commercial success of ficerafusp alfa or any future product candidates will depend significantly on the broad adoption and use of the resulting product by these individuals and organizations for approved indications. The degree of market acceptance of our products will depend on a number of factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">demonstration of clinical efficacy and safety, including as compared to any more established products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the indications for which ficerafusp alfa or any future product candidates are approved, if any;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">acceptance of a new drug for the relevant indication by healthcare providers and their patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any restrictions on the use of our products, and the prevalence and severity of any adverse effects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential product liability claims;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing of market introduction of our products as well as availability, safety and efficacy of competitive drugs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the effectiveness of our or any current or future collaborators&#8217; sales and marketing strategies; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unfavorable publicity relating to the product.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If ficerafusp alfa or any future product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The market opportunities for ficerafusp alfa or any future product candidate we develop, if approved, may prove to be smaller than we believe.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Any revenue we are able to generate in the future from product sales will be dependent, in part, upon the size of the market in the U.S. and any other jurisdiction for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, even if approved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The number of patients who have the types of cancer we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for ficerafusp alfa or any future product candidates may be limited, if and when approved. Even if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Further, cancer therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. The number of patients who receive second- and third-line treatment is significantly smaller than the number of patients who receive first-line treatment, and the prognosis of patients who receive second- or third-line treatment is often poorer than that of patients who receive first-line treatment. There is no guarantee that any product candidate we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">If approved, our product candidates that are regulated as biological products, or biologics, may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, established an abbreviated pathway for the approval of biosimilar and interchangeable biologics with an FDA-licensed reference biologic product. Under the BPCIA, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">a reference biological product is granted 12 years of non-patent data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as their BLA does not rely on the reference product or sponsor&#8217;s data and is not submitted as a biosimilar application. Certain changes and supplements to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest, or other related entity do not qualify for the 12-year exclusivity period. The law is complex and any new policies or processes adopted by the FDA could have a material adverse effect on the future commercial prospects for our biological products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We believe that any of the product candidates we develop that is approved in the U.S. as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidate to be a reference product for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing. The approval of a biosimilar of our product candidates could have a material adverse impact on our business due to increased competition and pricing pressure. It is also possible that payors will give reimbursement preference to biosimilars over reference biological products, even absent a determination of interchangeability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Laws and regulations outside the United States differ, including the length and extent of patent and exclusivity protection and pathways for competition to enter the market. Other countries may have significantly shorter or longer periods of exclusivity. In addition, other countries may have different standards in determining similarity to a reference product. Any market entry of competing products to our product candidates in these other regions could adversely affect our business in those regions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">To the extent that we do not receive any anticipated periods of regulatory exclusivity for our product candidates it could adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Obtaining and maintaining marketing approval of ficerafusp alfa and any future product candidates in one jurisdiction does not mean that we will be successful in obtaining and maintaining marketing approval of ficerafusp alfa and any future product candidates in other jurisdictions. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Obtaining and maintaining marketing approval of ficerafusp alfa and any future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical studies or clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may enter into agreements with third parties to sell, distribute and/or market ficerafusp alfa, or any future product candidates, if we obtain regulatory approval, which may adversely affect our ability to generate revenues.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Given the development stage of ficerafusp alfa, we have no experience in sales, marketing and distribution of biotech products. However, if ficerafusp alfa, or any future product candidates that we may develop, obtains marketing approval, we might intend to develop sales and marketing capacity, either alone or with partners, or rely upon the sales and marketing capabilities of our partners. Outsourcing sales, distribution and marketing may subject us to a variety of risks, including:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our inability to exercise direct control over sales, distribution and marketing activities and personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential failure or inability of contracted sales personnel to successfully market our products to physicians; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential disputes with third parties concerning distribution, sales and marketing expenses, calculation of royalties, and sales and marketing strategies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to partner with a third party that has adequate sales, marketing, and distribution capabilities, we may have difficulty commercializing ficerafusp alfa or any other product candidates which would adversely affect our business, financial condition, and ability to generate product revenues. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Off-label use or misuse of ficerafusp alfa may harm our reputation in the marketplace or result in injuries that lead to costly product liability suits.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If ficerafusp alfa is approved by the FDA, we may only promote or market ficerafusp alfa in a manner consistent with its FDA-approved labeling. We will train our marketing and sales force against promoting ficerafusp alfa for uses outside of the approved indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician from using ficerafusp alfa off-label, when in the physician&#8217;s independent professional medical judgment, he or she deems it appropriate. Furthermore, the use of ficerafusp alfa for indications other than those approved by the FDA may not effectively treat such conditions. Any such off-label use of ficerafusp alfa could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use ficerafusp alfa for these uses for which they are not approved, which could lead to product liability suits that might require significant financial and management resources and that could harm our reputation. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are subject to export and import controls, economic sanctions and anti-corruption laws and regulations of the United States and other jurisdictions. We can face criminal liability and other serious consequences for violations of these laws and regulations, which can harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control. Export controls and trade sanctions laws and regulations may restrict or prohibit altogether the provision, sale, or supply of our products to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions or an embargo. We are also subject to anti-corruption and anti-bribery laws, including the U.S. Foreign Corrupt Practices Act of 1977, or FCPA, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, and other state and national anti-bribery laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violation of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we or any third-party manufacturer we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and waste. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Although we maintain general liability insurance as well as workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Further, with respect to the operations of our current and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of ficerafusp alfa or products. In addition, our supply chain may be adversely impacted if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance with environmental, health and safety laws and regulations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Intellectual Property </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our ability to compete may decline if we do not adequately protect our proprietary rights. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial success depends, in part, on obtaining and maintaining patents and other forms of intellectual property rights for ficerafusp alfa, including ficerafusp alfa and any future product candidates, methods used to produce, purify, and manufacture those product candidates, and methods of utilizing the product candidates, including methods for treating patients, among other aspects of ficerafusp alfa or on licensing-in such rights. Failure to protect or to obtain, maintain, or extend adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market ficerafusp alfa. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our strategy depends in part on our ability to identify and seek patent protection for our discoveries. The patent prosecution process is time-consuming and expensive, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our current or future licensors, licensees, or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The standards which the United States Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change in the future. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, the issuance, scope, validity, enforceability, and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; current and future patent rights are highly uncertain. We cannot predict whether additional patents protecting ficerafusp alfa will issue in the U.S. or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications may not result in patents being issued which protect ficerafusp alfa or other technology, in whole or in part, or which effectively prevent others from commercializing competitive products and technology. The patent examination process may require us or our current or future licensors, licensees or collaborators to narrow the scope of the claims of our or our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, or have issued and even if such patents cover a product candidate, and/or other technologies, third parties may initiate opposition, interference, re-examination, post-grant review, inter partes review, litigation, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability, scope, inventorship, or ownership of such patents, which may result in the patent claims being narrowed, invalidated, held unenforceable, or unavailable to us. Our and our current and future licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issue from such application(s), and then only to the extent the issued claims cover the technology in the relevant jurisdiction.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries. As such, we cannot be certain that we or our licensors were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the U.S. and in foreign countries cannot be predicted with certainty and, as a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, changes in, or different interpretations of, patent laws in the U.S. and other countries may permit others to use our discoveries or to develop and commercialize ficerafusp alfa without providing any notice or compensation to us or may limit the scope of patent protection that we or our licensors are able to obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws and those countries may lack adequate rules and procedures for defending our intellectual property rights. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Filing, prosecuting and defending patents on ficerafusp alfa in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. could be less extensive than those in the U.S., assuming that rights are obtained in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. As such, we will not file for patent protection in all national and regional jurisdictions in the world where such protection may be available. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Accordingly, competitors may use our and our existing or future licensors&#8217;, licensees&#8217; or collaborators&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our existing or future licensors, licensees or collaborators have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with ficerafusp alfa or other technologies, and our and our existing or future licensors&#8217;, licensees&#8217; or collaborators&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Patent protection must be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, and the requirements for patentability differ, in varying degrees, from country to country, and the laws of some foreign countries do not protect intellectual property rights, including trade secrets, to the same extent as federal and state laws of the United States. As a result, many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. Such issues may make it difficult for us to stop the infringement, misappropriation or other violation of our intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, proceedings to enforce our patent rights and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful, while the damages and other remedies we may be ordered to pay such third parties may be significant. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Issued patents covering ficerafusp alfa and related technology could be found invalid or unenforceable if challenged in court or before a patent office. We are currently, and may in the future become, involved in lawsuits involving our intellectual property, including patents, to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Issued patents may be challenged, narrowed, invalidated, circumvented, or otherwise encumbered by a third party. We may from time to time need to resort or become a party to litigation (or other adversarial proceeding) to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties in the U.S. and in other jurisdictions. For example, in October 2024, a complaint was filed in federal court, which among other things, alleges a claim for correction of inventorship of a number of patents, including patents alleged to be licensed to us relating to ficerafusp alfa. For more information on this pending litigation, see the section titled &#8220;Legal Proceedings.&#8221; As enforcement of intellectual property rights is difficult, unpredictable and expensive, we may fail in enforcing our rights&#8212;in which case our competitors may be permitted to use our product without being enjoined, required to pay us any license fees, or compensate us for lost profits or reasonable royalty. In addition, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize technology covered by our patents we seek to enforce, such as those covering ficerafusp alfa and related methods, among other technologies, and then compete directly with us, without payment to us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If we were to initiate legal proceedings against a third party to enforce a patent covering ficerafusp alfa or other technology, the defendant could counterclaim that our patent is invalid and/or unenforceable, which is commonplace in patent litigation in the U.S. and other foreign jurisdictions. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements for patentability, for example, lack of utility, novelty, obviousness, non-enablement or lack of written description or as constituting unpatentable subject matter. Grounds for an unenforceability assertion could be an allegation that someone substantively involved in prosecution of the patent withheld but-for material information from the USPTO or engaged in affirmatively egregious misconduct, during prosecution, with a specific intent to deceive the USPTO. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we could lose at least part, and perhaps all, of the patent protection on ficerafusp alfa or other technology. Such a loss of patent protection could have a material adverse impact on our business. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Patents and other intellectual property rights also will not protect ficerafusp alfa if competitors design around our protected technology without infringing our patents or other intellectual property rights. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Even if such litigation (or other adversarial proceedings or disputes) is resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, this could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings and the legal costs associated with them, could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unsuccessful in defending against any claims by competitors or others that we are infringing upon their intellectual property rights, our business could be materially harmed. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial success will depend, in part, on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or other proprietary rights that could limit our ability to make, use, sell, offer for sale or import a product candidate, a future approved product, or impair our competitive position. We are aware of third party issued patents and/or pending patent applications, including in the U.S., that could be alleged as covering ficerafusp alfa, irrespective of the merits of any such allegation, for example in August 2024, we received a letter alleging ficerafusp alfa infringes certain third party patents. For example, in October 2024, a complaint was filed in federal court, which among other things, alleges a claim for correction of inventorship of a number of patents, including patents alleged to be licensed to us relating to ficerafusp alfa. Although we believe that these patents are not infringed, and/or are invalid and/or unenforceable, if a court should find that they cover a product candidate and we are unable to invalidate such patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We believe that if such patents or patent applications were asserted against us, we would have counterclaims and defenses against such claims, including non-infringement, the affirmative defense of safe harbor designed to protect activity undertaken to obtain federal regulatory approval of a drug, including under 35 U.S.C. &#167; 271(e) and similar foreign exceptions to infringement, and defenses concerning patent invalidity and/or unenforceability. However, if such counterclaims and defenses were not successful and such patents were successfully asserted against us such that they are found to be valid and enforceable, and infringed, unless we obtain a license to such patents, which may not be available on commercially reasonable terms or at all, we could be prevented from continuing to develop or commercialize ficerafusp alfa. We could also be required to pay substantial damages. We cannot assure you that we will ultimately prevail if any of this third-party intellectual property is asserted against us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the biotechnology industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties&#8217; patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, opposition or other proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">These lawsuits (or other proceedings) would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, if the breadth or strength of protection provided by our or our present or future licensors&#8217;, collaborators&#8217; or partners&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize ficerafusp alfa or any future product candidates. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Third party intellectual property right holders, including our competitors, may actively bring infringement claims against us. We may not be able to successfully settle, license on commercially acceptable terms or otherwise resolve such potential infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing any approved products. If we fail in any such dispute, in addition to being forced to potentially pay damages, we or our licensees may be temporarily or permanently prohibited from commercializing our product candidates that are held to be infringing or be forced to redesign our product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The biotechnology industry has produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing ficerafusp alfa to market and be precluded from manufacturing or selling ficerafusp alfa.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our products. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">It is also possible that in our evaluation of third-party intellectual property, we failed to identify relevant patents or applications. We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the U.S. and abroad that is relevant to or necessary for the commercialization of ficerafusp alfa in any jurisdiction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market ficerafusp alfa. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For example, U.S. applications filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Furthermore, we operate in a highly competitive field, and given our limited resources, it is unreasonable to monitor all patent applications purporting to claim broad coverage in the areas in which we are active. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover ficerafusp alfa or related technology. We cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are currently party to intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various obligations on us. For example, we have entered into patent and know-how license agreements that grant us the right to use certain technologies related to our clinical product candidate and related methods. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be unsuccessful in licensing or acquiring third-party intellectual property that may be required to develop and commercialize ficerafusp alfa. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have rights, through patents that we have in-licensed or own, to the intellectual property to develop ficerafusp alfa. Because our programs may involve additional product candidates, that may require the use of intellectual property or proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use such intellectual property and proprietary rights. We may be unable to acquire or in-license any third-party intellectual property or proprietary rights or to do so on commercially reasonable terms. For example, we sometimes collaborate with public or private academic institutions to accelerate our research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the strategic collaboration. Regardless of such option, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us, and the institution may license such intellectual property rights to third parties, potentially blocking our ability to pursue our development and commercialization plans. The same situation may occur with a present or future development partner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The licensing and acquisition of third-party intellectual property and proprietary rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property and proprietary rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size and greater capital resources and development and commercialization capabilities. In </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">addition, companies that perceive us to be a competitor may be unwilling to assign or license intellectual property and proprietary rights to us.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to successfully acquire or in-license rights to required third-party intellectual property and proprietary rights or maintain our intellectual property and proprietary rights, we may have to cease development of the relevant the relevant program, product or product candidate, which could have a material adverse effect on our business. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution and post grant or issuance. We employ reputable law firms and other professionals to help us comply. Additionally, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or patent applications. We rely on our outside counsel or our agents to pay these fees when due. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If such an event were to occur, it could have a material adverse effect on our business. In addition, we may be responsible for the payment of patent fees for patent rights that we license from third parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights. If we or our existing or future licensors fail to maintain the patents and patent applications covering ficerafusp alfa, our competitors might be able to enter the market, which would have an adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering ficerafusp alfa, our business may be materially harmed.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Patents typically have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date, not including potential patent term extensions or adjustments that may be available in the U.S., and under comparable laws applicable outside the U.S., where certain conditions are met. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering ficerafusp alfa are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including biosimilar medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours, causing our revenue from applicable products to be reduced, possibly materially, and potentially harming our ability to recover our investment in such product or obtain a reasonable return on that investment. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Depending upon the timing, duration, and conditions of FDA marketing approval of ficerafusp alfa, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at other biotechnology or pharmaceutical companies, universities, and/or research institutions and the like, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">patents and applications we have filed to protect inventions of these employees, even those related to ficerafusp alfa, are rightfully owned by their former or concurrent employer. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize ficerafusp alfa. Such a license may not be available on commercially reasonable terms or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arising from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Healthcare, Insurance and Legal Matters</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of ficerafusp alfa. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We face an inherent risk of product liability exposure related to the testing of ficerafusp alfa in human trials and may face greater risk if we commercialize any products that we develop. Product liability claims may be brought against us by subjects enrolled in our trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against such claims, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">decreased demand for any product candidate we may develop;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">withdrawal of trial participants;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">termination of clinical trial sites or entire trial programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">significant time and costs to defend the related litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">substantial monetary awards to trial subjects or patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">diversion of management and scientific resources from our business operations; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the inability to commercialize any product candidates that we may develop.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">While we currently hold trial liability insurance coverage consistent with industry standards, the amount of coverage may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain marketing approval for ficerafusp alfa, but we may be unable to obtain commercially reasonable product liability insurance. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The successful commercialization of ficerafusp alfa or any future product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs including but not limited to Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as ficerafusp alfa or any future product candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third-party payors will have an effect on our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">ability to successfully commercialize those products. Accordingly, we will need to successfully implement a coverage and reimbursement strategy for any approved product candidate. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. For more information, see the section titled &#8220;Business&#8212;Government Regulation&#8212;Pharmaceutical Coverage, Pricing and Reimbursement&#8221; in our Annual Report. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If we participate in the Medicaid Drug Rebate Program or other governmental pricing programs, in certain circumstances, our products would be subject to ceiling prices set by such programs, which could reduce the revenue we may generate from any such products. Participation in such programs would also expose us to the risk of significant civil monetary penalties, sanctions and fines should we be found to be in violation of any applicable obligations thereunder. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and offer to reimburse patients only for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the U.S., third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for ficerafusp alfa or any future product candidates. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Obtaining and maintaining reimbursement status is time-consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, and, in some cases, at short notice, and we believe that changes in these rules and regulations are likely. For products administered under the supervision of a physician (including products administered in the clinical setting), obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the administration of the product, or the treatment or procedure in which the product is used, may not be available, which may impact physician utilization.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of ficerafusp alfa or any future product candidates, if approved in these jurisdictions. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, increasing efforts by governmental and other third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, and prescription drugs, surgical procedures and other treatments in particular, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare and Medicaid beneficiaries, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. In addition, the U.S. Supreme Court&#8217;s June 2024 decision to overturn established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our product candidate may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are subject to various U.S. federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our reputation, subject us to significant fines and liability or otherwise adversely affect our business.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, and plan to market, sell and distribute any products for which we obtain regulatory approval. For more information, see the section titled &#8220;Business&#8212;Government Regulation&#8212;Other U.S. Healthcare Laws&#8221; in our Annual Report.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly and time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be noncompliant with applicable laws or regulations, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs. We plan to implement a corporate compliance program designed to identify, prevent and mitigate risk through the implementation of policies and procedures, training, and auditing and monitoring. We expect to devote resources to implement, maintain, administer and expand the compliance program as necessary. We cannot be certain, however, that our compliance program will ensure compliance with the various complex laws and regulations to which we are subject now or in the future. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Current and future healthcare reform legislation or regulation may increase the difficulty and cost for us to obtain coverage for and commercialize ficerafusp alfa, if approved, or any future product candidates and may adversely affect the prices we may set. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the U.S. and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and biologics and affect our ability to profitably sell ficerafusp alfa or any future product candidates for which we obtain regulatory approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, the Inflation Reduction Act of 2022, or the IRA, includes several provisions that will impact our business to varying degrees, including provisions that allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, among others. Negotiated maximum fair prices for the first ten Medicare Part D drugs took effect January 1, 2026, and Medicare Part B drugs become subject to negotiated prices beginning January 1, 2028. Our lead candidate ficerafusp alfa is being developed in indications that may rely heavily on Medicare reimbursement. Accordingly, these price-negotiation provisions may have a negative impact on our future revenue and profits. The IRA exempts orphan drugs from price negotiation if they have received only one orphan designation and are approved solely for that rare disease. However, the One Big Beautiful Bill Act of 2025, or the OBBBA, revised this exemption, effective for the initial price applicability year 2028 and subsequent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">years, in two ways: first, all orphan drugs designated for one or more rare diseases or conditions and approved only for such designated indications are exempt from the negotiation program (expanding the prior single-orphan-indication exclusion); and second, for orphan-designated products that later lose exclusion status upon approval of a non-orphan indication, the negotiation eligibility period begins on the date of such first non-orphan indication, the negotiation eligibility period begins on the date of such first non-orphan approval rather than on the products&#8217; original approval date. While the OBBBA amendments may broaden the exemption for certain products, its effect on our future pipeline remains uncertain. Further, the IRA also imposed rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. For more information, see the section titled &#8220;Business&#8212;Government Regulation&#8212;Current and Future U.S. Healthcare Reform Legislation&#8221; in our Annual Report.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In 2025, the Trump Administration issued executive actions and supported regulatory initiatives focused on implementing most-favored-nation, or MFN, pricing concepts, expanding direct-to-consumer sales models, and directing CMS to propose reimbursement models that would incorporate international reference pricing benchmarks into Medicare and Medicaid payment structures. These initiatives, if implemented, could adversely affect the prices we could obtain for ficerafusp alfa, if approved, and for any future product candidates, and could increase our compliance costs and commercial complexity.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for ficerafusp alfa and any future product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We expect that these existing laws and other federal and state healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our potential products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize ficerafusp alfa or any future product candidates, if approved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Failure to comply with laws and regulations related to the protection of research subjects could result in fines, penalties, and litigation, and have a material adverse effect upon our business.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may be subject to regulation under international, federal, state, and local laws and regulations relating to the protection of research subjects. Federally funded human-subject research in the U.S., including the collection of identifiable human biospecimens, is governed by 45 CFR Part 46, also known as the Health and Human Services Policy for Protection of Human Research Subjects or the &#8220;Common Rule.&#8221; Use of biospecimens in certain other research is subject to FDA regulations for the Protection of Human Subjects and Institutional Review Boards at 21 CFR Parts 50 and 56. Research funded by the NIH, may be subject to grant or contract requirements, as well as NIH Certificates of Confidentiality. When collecting specimens for research in the U.S., our company and its collection sites are responsible for ensuring that specimens are collected in accordance with these regulations. In addition, other countries have their own regulations around the ethical collection of human specimens for research. While we believe that we are in compliance with these laws, we may not be aware of all such laws or may fail to properly audit and identify gaps in compliance. Similarly, we may find errors in our product candidates and processes and may fail to properly match the compliance requirements of our researchers to the compliance requirements of our suppliers. Failure of our company or our suppliers to comply with international, federal, state, and local laws and regulations could subject us to denial of the right to conduct business, fines, criminal penalties, and/or other enforcement actions which could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Manufacturing of Our Product Candidates </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in methods of product candidate manufacturing may result in additional costs or delay. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes. In addition, we may need a different CMO for manufacturing ficerafusp alfa or any future product candidates for commercial supply needs. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause ficerafusp alfa or any future product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">approval. This could delay completion of clinical trials, increase clinical trial costs, delay approval of ficerafusp alfa and jeopardize our ability to commence sales and generate revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are subject to various manufacturing risks, any of which could substantially increase our costs and limit supply of ficerafusp alfa.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The process of manufacturing product therapeutics and bispecifics, including ficerafusp alfa, is complex, time-consuming, highly regulated and subject to several risks, including:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">product loss during the manufacturing process, including loss caused by contamination, equipment failure or improper installation or operation of equipment, or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination; the manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor and raw material shortages, natural disasters, power failures and numerous other factors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.          </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">                  </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Scaling up a biopharmaceutical manufacturing process is a difficult and uncertain task and involves additional risks, including cost overruns, process scale-up, process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of sufficient quantity of raw materials. Even if we obtain regulatory approval for any of our product candidates, manufacturers may not be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may also make changes to our manufacturing processes at various points during development, for a number of reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause ficerafusp alfa to perform differently and affect the results of our ongoing or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Employee Matters and Managing Growth </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our ability to develop product candidates, leverage our potential and our future growth depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel. If we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Additionally, we will need to grow the size of our organization, and we may experience difficulties in managing this growth. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of our objectives. The loss of services of any of these individuals could delay or prevent the successful development of ficerafusp alfa, completion of our planned clinical trials or the commercialization of ficerafusp alfa. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our success also depends upon the continued contributions of our key management and scientific personnel, many of whom have been instrumental for us and have substantial experience with developing therapies, identifying potential product candidates and building the technologies related to the clinical development of our product candidates. Given the specialized nature of dual-action biologics and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our product candidates in our pipeline, we will require personnel with medical, scientific, or technical qualifications specific to each program. The loss of key personnel, in particular our scientists, would delay our research and development activities. Despite our efforts to retain valuable employees, members of our team may terminate their employment with us on short notice. The competition for qualified personnel in the biotechnology and biopharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions, and other organizations. If we hire employees from competitors or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, it may harm our ability to recruit and retain highly skilled employees. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which would have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As our development plans and strategies develop, and as we continue operating as a public company, we expect to need additional managerial, operational, marketing, sales, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">managing our internal development efforts effectively, including the clinical and FDA review process for ficerafusp alfa and any other future product candidates we develop, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our future financial performance and our ability to advance development of and, if approved, commercialize ficerafusp alfa and any future product candidates we develop, will depend, in part, on our ability to effectively manage any future growth, and our management may have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We currently rely, and for the foreseeable future will continue to rely, in substantial part, on certain independent organizations, advisors and consultants to provide certain services. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of ficerafusp alfa or any future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize ficerafusp alfa or any future product candidates we develop and, accordingly, may not achieve our research, development and commercialization goals. </span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Risks Related to Ownership of Our Common Stock </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The price of our stock may be volatile, and you could lose all or part of your investment. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this section and elsewhere in this Quarterly Report on Form 10-Q, these factors include:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the commencement, enrollment, completion or results of our current or future preclinical and clinical trials for ficerafusp alfa;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any delay in identifying and advancing a clinical candidate for our other programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any delay in our regulatory filings for ficerafusp alfa and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">adverse regulatory decisions, including failure to receive regulatory approval or potential accelerated approval of ficerafusp alfa or the failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in laws or regulations applicable to ficerafusp alfa, including but not limited to clinical trial requirements for approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">adverse developments concerning our manufacturers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our inability to establish collaborations, if needed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our failure to commercialize ficerafusp alfa, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unanticipated serious safety concerns related to ficerafusp alfa or any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">introduction of new products or services offered by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">actual or anticipated variations in operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our cash position;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">publication of research reports about us or our industry, or ficerafusp alfa in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in the structure of the healthcare payment systems;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in accounting practices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">ineffectiveness of our internal controls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">general geopolitical and economic conditions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">other events or factors, many of which are beyond our control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our quarterly and annual operating results may fluctuate significantly, due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing and cost of, and level of investment in, research, development and, if approved, commercialization activities relating to ficerafusp alfa or any future product candidates, which may change from time to time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing and status of enrollment for clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the cost of manufacturing ficerafusp alfa, as well as building out our supply chain, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing and success or failure of preclinical studies and clinical trials for ficerafusp alfa or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing and success or failure of preclinical studies and clinical trials for ficerafusp alfa or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing of receipt of approvals for ficerafusp alfa from regulatory authorities in the U.S. and internationally;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">exchange rate fluctuations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">coverage and reimbursement policies with respect to ficerafusp alfa, if approved, and potential future drugs that compete with our products; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the level of demand for ficerafusp alfa, if approved, may vary significantly over time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our future revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our executive officers, directors, principal stockholders and their respective affiliates own a significant percentage of our common stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Based on the beneficial ownership of our common stock as of March 31, 2026, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially own a significant percentage of our common stock. These stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. In addition, certain of our principal stockholders, including Biocon, RA Capital and TPG LSA, are affiliated with members of our board of directors. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Future sales or issuances of our common stock in the public market could cause our common stock price to fall. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our common stock price could decline as a result of sales of a large number of shares of common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate. For example, in February 2026, we completed our February 2026 Offering of 8,581,250 shares of our common stock and pre-funded warrants to purchase 2,200,000 shares of our common stock. In the future, we may issue additional shares of common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We expect to issue additional capital stock in the future, including potentially through our ATM Program, that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. In addition, as of the date of this Quarterly Report on Form 10-Q, we had outstanding pre-funded warrants to purchase 2,200,000 shares of our common stock with an exercise price of $0.0001 per share. The pre-funded warrants may be exercised at any time after the date of issuance solely by cashless exercise, at the holder&#8217;s election, until all of the pre-funded warrants are exercised in full, according to a formula set forth in the pre-funded warrants. Accordingly, we will not receive additional proceeds from the exercise of the pre-funded warrants and issuance of the underlying shares. If some or all of these pre-funded warrants are exercised, our stockholders could experience substantial dilution and such exercise may cause the market price of our stock to decline. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, as part of our business strategy, we may acquire or make investments in complementary companies, products or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We do not currently intend to pay dividends on our common stock and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation of the value of our common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our fifth amended and restated certificate of incorporation, or our certificate of incorporation, and third amended and restated bylaws, or our bylaws, contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">establish a classified board of directors such that only one of three classes of directors is elected each year;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from our board of directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">require the approval of not less than two-thirds of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation or bylaws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws (including the interpretation, validity or enforceability thereof), or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act of 1933, or the Securities Act, Securities Exchange Act of 1934, as amended, or the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the U.S. shall be the sole and exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, or the Federal Forum Provision. In addition, our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Delaware Forum Provision and the Federal Forum Provision in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the U.S. may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may not be able to satisfy listing requirements of Nasdaq or maintain a listing of our common stock on Nasdaq. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We must meet certain financial and liquidity criteria to maintain the listing of our common stock on Nasdaq. If we fail to meet any of Nasdaq&#8217;s listing standards, our common stock may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair our stockholders&#8217; ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Other General Risks </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Unfavorable global economic and geopolitical conditions could adversely affect our business, financial condition, stock price and results of operations. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our business could be adversely affected by unstable economic and political conditions within the United States and foreign jurisdictions, including as a result of an economic downturn and geopolitical events, such as changes in U.S. federal policy that affect the geopolitical landscape. Changes to policy implemented by the U.S. Congress, the current administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. In early 2025, the United States imposed tariffs on imports on its trading partners, including Canada, Mexico, the EU and China. Historically, tariffs have led to increased trade and political tensions, between not only the U.S. and China, but also between the U.S. and other countries in the international community. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Additionally, in September 2025, the current administration also announced a 100% tariff on brand-name or patented drugs unless pharmaceutical companies expand their manufacturing operations in the U.S. Although the pharmaceutical tariff is currently on hold, this could have a material adverse effect on our supply chain and business prospects as well as the larger biopharmaceutical industry. On February 20, 2026, the United States Supreme Court invalidated the reciprocal tariffs; however, President Trump has stated that he intends to use other authorities to maintain historically elevated tariffs. Historically, increased tariffs have led to more trade and political tensions and the status of these agreements between the United States and the various countries, in light of the U.S. Supreme Court&#8217;s February 20, 2026 decision, is not yet clear. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a material adverse effect on our financial condition or results of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The global credit and financial markets have also experienced extreme volatility and disruptions (including as a result of actual or perceived changes in interest rates, inflation and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability, global supply chain disruptions, and increases in unemployment rates. The financial markets and the global economy may also be adversely affected by military conflict, including the ongoing conflict between Russia and Ukraine, the conflicts in the Middle East, or other geopolitical events. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand for our drug candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. For example, there has been proposed U.S. legislation that may restrict the ability of U.S. biopharmaceutical companies to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We continue to assess the legislation as it develops to determine whether it could have an effect on our contractual relationships. Furthermore, any disruptions to our supply chain as a result of unfavorable global economic conditions, including due to geopolitical conflicts or public health crises, could negatively impact the timely execution of our ongoing and future clinical trials. In addition, current inflationary trends in the global economy may impact salaries and wages, costs of goods and transportation expenses, among other things, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures may create market and economic instability. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We, or the third parties upon whom we depend, may be adversely affected by natural disasters, public health crises or other business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Natural disasters or public health crises could severely disrupt our operations, and have a material adverse impact on our business, results of operations, financial condition, and prospects. If a natural disaster, power outage, public health crisis or other event occurred that prevented us from conducting our clinical trials, releasing clinical trial results or delaying our ability to obtain regulatory approval for ficerafusp alfa, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer cybersecurity incidents or breaches, which could adversely affect our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Despite the implementation of security measures, our information technology systems and data and those of our current or future CROs or other contractors and consultants are vulnerable to compromise or damage from computer hacking, computer viruses, social engineering (e.g., phishing attacks) and malware (e.g., ransomware malicious software), fraudulent activity, employee and vendor misconduct, human error, telecommunication and electrical failures, natural disasters, or other cybersecurity attacks or accidents. Future acquisitions could expose us to additional cybersecurity risks and vulnerabilities from any newly acquired information technology infrastructure. Cybersecurity attacks are constantly increasing in frequency and sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, &#8220;hacktivists,&#8221; nation states, and others. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Attempts to disrupt or gain unauthorized access to our and our third-party vendors&#8217; information systems from malicious third parties or insider threats may incorporate widely varying and frequently changing tactics, which may be enhanced or facilitated by evolving technologies, including artificial intelligence. As a result of a continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. Further, as a company with an increasingly global presence, our systems are subject to frequent attacks, which are becoming more commonplace in the industry, including attempted hacking, phishing attempts, such as cyber-related threats involving spoofed or manipulated electronic communications, which increasingly represent considerable risk. Due to the nature of some of the attacks described herein, there is a risk that an attack may remain undetected for a period of time. Even if identified, we may be unable to adequately investigate or remediate cybersecurity incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. While we continue to make investments to improve the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or cybersecurity incidents or breaches. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Like other companies in our industry, we and our service providers have experienced threats and cybersecurity incidents relating to our information technology systems and infrastructure. Any significant cybersecurity incident could adversely affect our business, by leading to, for example, the loss of trade secrets or other intellectual property, demands for ransom or other forms of blackmail, or the unauthorized disclosure of personal or other sensitive information of our employees, clinical trial patients, customers, and others. If we were to experience a significant cybersecurity incident, it could seriously harm our development programs and our business operations. We could be subject to cybersecurity incident or breach notification requirements, regulatory actions taken by governmental authorities, litigation under laws that protect the privacy of personal information, or other forms of legal proceedings, which could result in significant liabilities or penalties, result in substantial costs and require attention from management. Further, a significant cybersecurity incident or breach may disrupt our business or damage our reputation, which could have a material adverse effect on our business, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">prospects, operating results, share price and shareholder value, and financial condition. We could also incur substantial remediation costs, including the costs of investigating the incident, repairing or replacing damaged systems, restoring normal business operations, implementing increased cybersecurity protections, and paying increased insurance premiums. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If a cybersecurity breach or other incident were to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of clinical trial data or personal data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media, and other parties pursuant to privacy and security laws. Likewise, we rely on our third-party research institution collaborators for research and development of ficerafusp alfa and other third parties for the manufacture of ficerafusp alfa and to conduct clinical trials, and similar events relating to their information technology systems could also seriously harm our business. Any security compromise affecting us, our collaborators or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures, and lead to regulatory scrutiny. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">To the extent that any disruption or significant cybersecurity incident or breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary or personal information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of ficerafusp alfa could be delayed, result in substantial costs and require attention from management. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations. Further, although we maintain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any significant cybersecurity incident or breach.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are eligible to be treated as an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and our election of reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in this Quarterly Report on Form 10-Q and our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements. We could be an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have more than $1.235 billion in total annual gross revenue. (ii) the date we qualify as a &#8220;large accelerated filer,&#8221; which occurs when the market value of our common stock that is held by non-affiliates exceeds $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period; and (iv) the last day of the fiscal year ending after the fifth anniversary of our IPO. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements of Section 404;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">providing only two years of audited financial statements in addition to any required unaudited interim financial statements and a correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this Quarterly Report on Form 10-Q;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reduced disclosure obligations regarding executive compensation; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In this Quarterly Report on Form 10-Q and our periodic reports and proxy statements, we have not included and do not expect to include all of the executive compensation-related information that would be required if we were not an emerging growth company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Even after we no longer qualify as an emerging growth company, we could still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in this Quarterly Report on Form 10-Q and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the JOBS Act provides that an emerging growth company can also take advantage of an extended transition period for complying with new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We will continue to incur increased costs as a result of operating as a public company, and our management need to devote substantial time to related compliance initiatives and corporate governance practices. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to continue to require that we incur substantial legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. We cannot accurately predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we fail to establish and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be reevaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. We have implemented the process of documenting, reviewing and improving our internal controls and procedures for compliance with Section 404 of the Sarbanes-Oxley Act, which requires annual management assessment of the effectiveness of our internal control over financial reporting beginning with this Quarterly Report on Form 10-Q. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company or a non-accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. We could be an emerging growth company for up to five years following our IPO. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2025, we had approx</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">imately $191.6 million of federal net operating losses, or NOLs. Federal NOLs generated in taxable years since inception, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of our taxable income. As of December 31, 2025, we had approximately $187.4 million of state NOLs. Of the state NOLs, some are of indefinite life, but most are of definite life with various expiration dates, beginning in 2039. As of December 31, 2025, we had approximately $7.5 million of federal research and development tax credit carryforwards. Federal tax credit carryforwards expire at various dates, beginning in 2040. As of December 31, 2025, we had approximately $1.0 million of state research and development tax credit carryforwards. The state tax credits, which have various carryforward rules, begin to expire in 2035. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by one or more &#8220;5-percent shareholders&#8221; over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. A corporation that experiences an ownership change will generally be subject to an annual limitation on the use of its pre-ownership change NOLs equal to the value of the corporation immediately before the ownership change, multiplied by the long-term tax-exempt rate (subject to certain adjustments). We may have experienced ownership changes in the past and may experience ownership changes as a result of our acquisitions of assets and/or subsequent shifts in our stock ownership (some of which are outside our control). There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs by federal or state taxing authorities or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities. As a result, our ability to use our pre-change NOLs and tax credits to offset future taxable income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in tax law could adversely affect our business and financial condition. </span></div><div style="text-align:justify;text-indent:24.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the U.S. Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application), including with respect to NOLs and research and development tax credits, could adversely affect us or holders of our common stock. For example, the OBBBA was signed into law on July 4, 2025 and made significant changes to U.S. federal tax law. Under Section 174 of the Code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development performed outside the U.S. will be capitalized and amortized, which may have an adverse effect on our cash flow. The OBBBA provides that for taxable years beginning after December 31, 2024, expenses that are incurred for research and development performed in the U.S. may, at the taxpayer&#8217;s election, be immediately deducted or capitalized and amortized. In addition, the OBBBA provides that for taxable years beginning after December 31, 2021 and before January 1, 2025, certain eligible taxpayers generally may elect to retroactively deduct expenses for research and development performed in the U.S. in such taxable years by filing amended tax returns for such taxable years, and all other taxpayers that are not eligible to make such an election and that amortized expenses for research and development performed in the U.S. in such taxable years generally may elect to accelerate and deduct the remaining unamortized amounts of such research and development expenses (i) in the first taxable year beginning after December 31, 2024, or (ii) ratably over the two-taxable year period beginning with the first taxable year beginning after December 31, 2024. In recent years, many changes to tax laws have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may become involved in securities class action litigation that could divert management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events, such as negative </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">results from clinical trials. These events may also result in or be concurrent with investigations by the SEC. We may be exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#8217;s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction.</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i586fa6c821a64d49b022e7b4061b879d_130"></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Recent Sales of Unregistered Securities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Use of Proceeds from Initial Public Offering</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2024, our Registration Statement on Form S-1 (No. 333-281722) relating to our IPO was declared effective by the SEC. There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on September 13, 2024. </span></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Issuer Repurchases of Equity Securities</span></div><div style="padding-right:2.3pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Not applicable.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_133"></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_136"></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i586fa6c821a64d49b022e7b4061b879d_139"></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:82%">(a)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:82%">(b)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chief Medical Officer Transition</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2026, or the Transition Date, David Raben, M.D. resigned from his role as our Chief Medical Officer and transitioned to serve as a Senior Executive Advisor to the Company, effective on the Transition Date. Dr. Raben&#8217;s resignation was not the result of any disagreement with the Company or our board of directors or any matter relating to our operations, policies or practices. On May 8, 2026, Bill Schelman, M.D., Ph.D., previously our Executive Vice President, Clinical Development, succeeded Dr. Raben to serve as our Chief Medical Officer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On the Transition Date, we entered into a separation agreement, or the Separation Agreement, with Dr. Raben, pursuant to which he is entitled to receive (i) his base salary for 12 months following the Transition Date and (ii) subject to copayment of premium amounts at the applicable active employees&#8217; rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount that we would have paid to provide health insurance to him had he remained employed until the earliest of (A) May 30, 2027, (B) his eligibility for group medical plan benefits under any other employer&#8217;s group medical plan, or (C) at the end of his COBRA health continuation period. The Separation Agreement also contains non-disparagement and cooperation covenants, a reaffirmation of Dr. Raben&#8217;s confidentiality obligations, and a general release of claims by Dr. Raben.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Dr. Raben entered into a consulting agreement, or the Consulting Agreement, with us, pursuant to which Dr. Raben now serves as a Senior Executive Advisor to the Company. The Consulting Agreement was effective as of the Transition Date and ends on December 31, 2026, unless terminated at an earlier date by Dr. Raben or by us. Dr. Raben will be compensated at a monthly rate of $8,000 for his services under the Consulting Agreement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or an amount pro-rated in any month wherein the consulting relationship with us has been terminated, and his existing equity grants will continue to vest pursuant to the terms of the underlying award agreements and the applicable equity plan so long as he has a service relationship with us under the Consulting Agreement. The Consulting Agreement also contains non-disclosure and non-competition covenants.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing summaries of the Separation Agreement and Consulting Agreement are not complete and are qualified in their entirety by the Separation Agreement and Consulting Agreement, copies of which we intend to file with the SEC as exhibits to our Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:82%">(c) </span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes for the three months ended March 31, 2026 each trading arrangement under which our directors or officers <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-518">adopted</ix:nonNumeric>, materially modified, or <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-519"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-520">terminated</ix:nonNumeric></ix:nonNumeric> any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.</span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-521" continuedAt="f-521-1" escape="true"><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"><tr><td style="width:1.0pt"/><td style="width:126.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:69.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/></tr><tr style="height:36pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Name (Title)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Action Taken (Date of Action)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Type of Trading Arrangements</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Nature of Trading Arrangements</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Duration of Trading Arrangement</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Aggregate Number of Securities</span></div></td></tr><tr style="height:132pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-131" name="ecd:TrdArrIndName" id="f-522">Claire Mazumdar</ix:nonNumeric>, Ph.D. (<ix:nonNumeric contextRef="c-131" name="ecd:TrdArrIndTitle" id="f-523">Chief Executive Officer and Director</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-131" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-524">Adoption</ix:nonNumeric> (<ix:nonNumeric contextRef="c-131" name="ecd:TrdArrAdoptionDate" id="f-525">March&#160;31, 2026</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Rule 10b5-1 trading arrangement</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Sale</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Until the earlier of a) <ix:nonNumeric contextRef="c-131" name="ecd:TrdArrExpirationDate" id="f-526">December&#160;31, 2026</ix:nonNumeric>; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Up to <ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-527">150,000</ix:nonFraction> shares of common stock</span></div></td></tr><tr style="height:132pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-133" name="ecd:TrdArrIndName" id="f-528">Ryan Cohlhepp</ix:nonNumeric>, Pharm.D. (<ix:nonNumeric contextRef="c-133" name="ecd:TrdArrIndTitle" id="f-529">President, Chief Operating Officer and Director</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-133" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-530">Adoption</ix:nonNumeric> (<ix:nonNumeric contextRef="c-133" name="ecd:TrdArrAdoptionDate" id="f-531">March&#160;31, 2026</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Rule 10b5-1 trading arrangement</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Sale</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Until the earlier of a) <ix:nonNumeric contextRef="c-133" name="ecd:TrdArrExpirationDate" id="f-532">March&#160;1, 2027</ix:nonNumeric>; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Up to <ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-533">180,000</ix:nonFraction> shares of common stock</span></div></td></tr><tr style="height:120pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-135" name="ecd:TrdArrIndName" id="f-534">Ivan Hyep</ix:nonNumeric> (<ix:nonNumeric contextRef="c-135" name="ecd:TrdArrIndTitle" id="f-535">Chief Financial Officer and Treasurer</ix:nonNumeric> )</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-135" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-536">Adoption</ix:nonNumeric> (<ix:nonNumeric contextRef="c-135" name="ecd:TrdArrAdoptionDate" id="f-537">March&#160;31, 2026</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Rule 10b5-1 trading arrangement</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Sale</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Until the earlier of a) <ix:nonNumeric contextRef="c-135" name="ecd:TrdArrExpirationDate" id="f-538">July&#160;8, 2027</ix:nonNumeric>; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Up to <ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-539">205,000</ix:nonFraction> shares of common stock</span></div></td></tr></table></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-521-1"><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"><tr><td style="width:1.0pt"/><td style="width:126.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:69.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/></tr><tr style="height:120pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-137" name="ecd:TrdArrIndName" id="f-540">Lara Meisner</ix:nonNumeric> (<ix:nonNumeric contextRef="c-137" name="ecd:TrdArrIndTitle" id="f-541">Chief Legal Officer, Compliance Officer and Corporate Secretary</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-137" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-542">Adoption</ix:nonNumeric> (<ix:nonNumeric contextRef="c-137" name="ecd:TrdArrAdoptionDate" id="f-543">March&#160;31, 2026</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Rule 10b5-1 trading arrangement</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Sale</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Until the earlier of a) <ix:nonNumeric contextRef="c-137" name="ecd:TrdArrExpirationDate" id="f-544">July&#160;3, 2027</ix:nonNumeric>; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Up to <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-545">173,789</ix:nonFraction> shares of common stock</span></div></td></tr><tr style="height:120pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-139" name="ecd:TrdArrIndName" id="f-546">David Raben</ix:nonNumeric>, M.D. (former <ix:nonNumeric contextRef="c-139" name="ecd:TrdArrIndTitle" id="f-547">Chief Medical Officer</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-139" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-548">Adoption</ix:nonNumeric> (<ix:nonNumeric contextRef="c-139" name="ecd:TrdArrAdoptionDate" id="f-549">March&#160;31, 2026</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Rule 10b5-1 trading arrangement</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Sale</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Until the earlier of a) <ix:nonNumeric contextRef="c-139" name="ecd:TrdArrExpirationDate" id="f-550">July&#160;1, 2027</ix:nonNumeric>; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Up to <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-551">104,000</ix:nonFraction> shares of common stock</span></div></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i586fa6c821a64d49b022e7b4061b879d_142"></div><div style="-sec-extract:summary;margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-bottom:10pt;padding-right:2.3pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-right:2.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Description</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524219617/d844648dex31.htm">Fifth Amended and Restated Certificate of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524219617/d844648dex31.htm">Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 8-K (File No. 001-42271) filed on September 16, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524219617/d844648dex32.htm">Third Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Form 8-K (File No. 001-42271) filed on September 16, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524214674/d821336dex41.htm">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-281722) filed on September 6, 2024).</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524205393/d821336dex42.htm">Amended and Restated Investors&#8217; Rights Agreement among the Registrant and certain of its stockholders, dated December 6, 2023. (incorporated by reference to Exhibit 4.2 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-281722) filed on August 22, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2023658/000119312526076560/d938194dex41.htm">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42271) filed on February 26, 2026).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.1#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0002023658/000162828026022010/a1012bicara-2026inducement.htm">2026 Inducement Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.12 of the Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0002023658/000162828026022010/a1012bicara-2026inducement.htm">'</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0002023658/000162828026022010/a1012bicara-2026inducement.htm">s Annual Report on Form 10-K (File No. 001-42271) filed on March 30, 2026).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit311q1-26.htm">31.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit311q1-26.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) promulgated under the Exchange Act.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit312q1-26.htm">31.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit312q1-26.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) promulgated under the Exchange Act.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit321q1-26.htm">32.1**</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit321q1-26.htm">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-right:2.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Filed herewith.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:133%">**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">89</span></div></div></div><div id="i586fa6c821a64d49b022e7b4061b879d_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:3.65pt;padding-right:3.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;padding-right:2.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:10pt;padding-right:2.3pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-right:2.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:23.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Bicara Therapeutics Inc.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Date: May 11, 2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">/s/ Claire Mazumdar</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Claire Mazumdar, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Chief Executive Officer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Date: May 11, 2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">/s/ Ivan Hyep</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Ivan Hyep</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Chief Financial Officer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(Principal Financial and Accounting Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">90</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311q1-26.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i57d35a714687429fb8828e32e64c09fd_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">I, Claire Mazumdar, Ph.D., certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">I have reviewed this Quarterly Report on Form 10-Q of Bicara Therapeutics Inc.&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58; May 11, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Claire Mazumdar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Claire Mazumdar, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312q1-26.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i9b0b66a9fd2d46b29d8f16b5e63aa0fe_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">I, Ivan Hyep, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">I have reviewed this Quarterly Report on Form 10-Q of Bicara Therapeutics Inc.&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58; May 11, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Ivan Hyep</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Ivan Hyep</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321q1-26.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ief4c9429491547fb92aaa9ec40904826_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Bicara Therapeutics Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58; May 11, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Claire Mazumdar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Claire Mazumdar, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58; May 11, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Ivan Hyep</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Ivan Hyep</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>bcax-20260331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cf6c2-c28f-747f-9e58-111c1e1d135b,g:94c43f23-f2a3-4ea7-b3a9-326e15be7355-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bcax="http://www.bicara.com/20260331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bicara.com/20260331">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcax-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcax-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcax-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcax-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.bicara.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessOrganizationandLiquidity" roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity">
        <link:definition>9952156 - Disclosure - Description of Business, Organization, and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.bicara.com/role/FairValueMeasurements">
        <link:definition>9952158 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.bicara.com/role/MarketableSecurities">
        <link:definition>9952159 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.bicara.com/role/Leases">
        <link:definition>9952160 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>9952161 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.bicara.com/role/CommitmentsandContingencies">
        <link:definition>9952162 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.bicara.com/role/StockholdersEquity">
        <link:definition>9952163 - Disclosure - Stockholder's Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.bicara.com/role/StockBasedCompensation">
        <link:definition>9952164 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.bicara.com/role/IncomeTaxes">
        <link:definition>9952165 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsRelatedParties" roleURI="http://www.bicara.com/role/SignificantAgreementsRelatedParties">
        <link:definition>9952166 - Disclosure - Significant Agreements &#8211; Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreements" roleURI="http://www.bicara.com/role/SignificantAgreements">
        <link:definition>9952167 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlan" roleURI="http://www.bicara.com/role/DefinedContributionPlan">
        <link:definition>9952168 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.bicara.com/role/SegmentReporting">
        <link:definition>9952169 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.bicara.com/role/FairValueMeasurementsTables">
        <link:definition>9955513 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.bicara.com/role/MarketableSecuritiesTables">
        <link:definition>9955514 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9955515 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.bicara.com/role/StockBasedCompensationTables">
        <link:definition>9955516 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.bicara.com/role/SegmentReportingTables">
        <link:definition>9955517 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessOrganizationandLiquidityDetails" roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails">
        <link:definition>9955518 - Disclosure - Description of Business, Organization, and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955519 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>9955520 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.bicara.com/role/FairValueMeasurementsDetails">
        <link:definition>9955521 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails" roleURI="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails">
        <link:definition>9955522 - Disclosure - Marketable Securities - Schedule of Available-For-Sale Investments by Type of Security (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails" roleURI="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails">
        <link:definition>9955523 - Disclosure - Marketable Securities - Schedule of Available-For-Sale Securities in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesNarrativeDetails" roleURI="http://www.bicara.com/role/MarketableSecuritiesNarrativeDetails">
        <link:definition>9955524 - Disclosure - Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.bicara.com/role/LeasesDetails">
        <link:definition>9955525 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9955526 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.bicara.com/role/StockholdersEquityDetails">
        <link:definition>9955527 - Disclosure - Stockholder's Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.bicara.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9955528 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails" roleURI="http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails">
        <link:definition>9955529 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized In Statements Of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails" roleURI="http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails">
        <link:definition>9955530 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockOptionsActivityDetails" roleURI="http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails">
        <link:definition>9955531 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsRelatedPartiesDetails" roleURI="http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails">
        <link:definition>9955532 - Disclosure - Significant Agreements &#8211; Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsDetails" roleURI="http://www.bicara.com/role/SignificantAgreementsDetails">
        <link:definition>9955533 - Disclosure - Significant Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlanDetails" roleURI="http://www.bicara.com/role/DefinedContributionPlanDetails">
        <link:definition>9955534 - Disclosure - Defined Contribution Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.bicara.com/role/SegmentReportingNarrativeDetails">
        <link:definition>9955535 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails" roleURI="http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails">
        <link:definition>9955536 - Disclosure - Segment Reporting - Schedule Segment Profit or Loss, Including Significant Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" abstract="false" name="OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_VestingOfEarlyExerciseStockOptions" abstract="false" name="VestingOfEarlyExerciseStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_WarrantsPolicyPolicyTextBlock" abstract="false" name="WarrantsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcax_ATMProgramMember" abstract="true" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_February2026OfferingMember" abstract="true" name="February2026OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_InvestmentCategorizationAxisAxis" abstract="true" name="InvestmentCategorizationAxisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bcax_InvestmentCategorizationAxisDomain" abstract="true" name="InvestmentCategorizationAxisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_InvestmentsWithMaturityOfOneYearOrLessMember" abstract="true" name="InvestmentsWithMaturityOfOneYearOrLessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_InvestmentsWithMaturityOfOneToTwoYearsMember" abstract="true" name="InvestmentsWithMaturityOfOneToTwoYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition" abstract="false" name="DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcax_LesseeOperatingLeaseArea" abstract="false" name="LesseeOperatingLeaseArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="bcax_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_AccruedManufacturingExpensesCurrent" abstract="false" name="AccruedManufacturingExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference" abstract="false" name="ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bcax_SaleOfStockCommissionFeePercentage" abstract="false" name="SaleOfStockCommissionFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcax_A2024StockOptionAndGrantPlanMember" abstract="true" name="A2024StockOptionAndGrantPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_A2026InducementPlanMember" abstract="true" name="A2026InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" abstract="true" name="IncentiveStockOptionsAndNonQualifiedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bcax_MasterServicesAgreementMember" abstract="true" name="MasterServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_BBLAgreementsMember" abstract="true" name="BBLAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_SyngeneAgreementsMember" abstract="true" name="SyngeneAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_IQVIARDSIncMember" abstract="true" name="IQVIARDSIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalContractServicesAgreementMember" abstract="true" name="MasterClinicalContractServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" abstract="true" name="MasterClinicalContractServicesAgreementRefundableDepositMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" abstract="true" name="MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" abstract="true" name="MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember" abstract="true" name="MasterClinicalContractServicesAgreementDepositsForServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember" abstract="true" name="MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember" abstract="true" name="MasterClinicalContractServicesAgreementIncrementalReturnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_OtherCommitmentLiabilityRefundableDepositAmount" abstract="false" name="OtherCommitmentLiabilityRefundableDepositAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_OtherCommitmentPercentage" abstract="false" name="OtherCommitmentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bcax_PaymentsForOtherCommitments" abstract="false" name="PaymentsForOtherCommitments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_ClinicalOperationsAndDevelopmentExpense" abstract="false" name="ClinicalOperationsAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_ManufacturingAndProcessDevelopmentExpense" abstract="false" name="ManufacturingAndProcessDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense" abstract="false" name="ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation" abstract="false" name="GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_FacilityITOfficeAndOtherExpense" abstract="false" name="FacilityITOfficeAndOtherExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_IncomeTaxExpenseBenefitIncludingAdjustments" abstract="false" name="IncomeTaxExpenseBenefitIncludingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcax_ClaireMazumdanMember" abstract="true" name="ClaireMazumdanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_RyanCohlheppMember" abstract="true" name="RyanCohlheppMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_IvanHyepMember" abstract="true" name="IvanHyepMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_LaraMeisnerMember" abstract="true" name="LaraMeisnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcax_DavidRabenMember" abstract="true" name="DavidRabenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>bcax-20260331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cf6c2-c28f-747f-9e58-111c1e1d135b,g:94c43f23-f2a3-4ea7-b3a9-326e15be7355-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cf6c2-c34a-7d76-ae33-cf3a04594f94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019cf6c2-c34a-7636-82a1-fd22b2fbbe18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cf6c2-c34a-7d76-ae33-cf3a04594f94" xlink:to="loc_us-gaap_Liabilities_019cf6c2-c34a-7636-82a1-fd22b2fbbe18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019cf6c2-c34a-7594-9c02-01fea12603f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cf6c2-c34a-7d76-ae33-cf3a04594f94" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019cf6c2-c34a-7594-9c02-01fea12603f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7f57-98a6-a114eded3cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cf6c2-c34a-7d76-ae33-cf3a04594f94" xlink:to="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7f57-98a6-a114eded3cdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019cf6c2-c34a-70e8-a2b2-e76339bf9c87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cf6c2-c34a-7ed9-ac3c-52788a20f54b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019cf6c2-c34a-70e8-a2b2-e76339bf9c87" xlink:to="loc_us-gaap_LiabilitiesCurrent_019cf6c2-c34a-7ed9-ac3c-52788a20f54b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cf6c2-c34a-779e-bbee-47bc2ec2c9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019cf6c2-c34a-70e8-a2b2-e76339bf9c87" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cf6c2-c34a-779e-bbee-47bc2ec2c9b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cf6c2-c34a-7121-8505-d7dd185187d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cf6c2-c34a-7544-89d7-9abe67878e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cf6c2-c34a-7121-8505-d7dd185187d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cf6c2-c34a-7544-89d7-9abe67878e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cf6c2-c34a-7188-9f6b-30fe5a79b89e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cf6c2-c34a-7121-8505-d7dd185187d2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cf6c2-c34a-7188-9f6b-30fe5a79b89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_019cf6c2-c34a-7c29-b366-8fe96f9273a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cf6c2-c34a-7121-8505-d7dd185187d2" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_019cf6c2-c34a-7c29-b366-8fe96f9273a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cf6c2-c34a-702f-9046-b41aca2c5dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cf6c2-c34a-717a-9bc2-4fed3fe3a598" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cf6c2-c34a-702f-9046-b41aca2c5dda" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cf6c2-c34a-717a-9bc2-4fed3fe3a598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-78d8-992d-9152f4a4cc56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cf6c2-c34a-702f-9046-b41aca2c5dda" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-78d8-992d-9152f4a4cc56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cf6c2-c34a-79a3-9cd0-bb5cad1c7a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cf6c2-c34a-702f-9046-b41aca2c5dda" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cf6c2-c34a-79a3-9cd0-bb5cad1c7a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019cf6c2-c34a-77b6-bfa1-effda71aacd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cf6c2-c34a-7fba-80b2-23681f7114ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cf6c2-c34a-77b6-bfa1-effda71aacd1" xlink:to="loc_us-gaap_AssetsCurrent_019cf6c2-c34a-7fba-80b2-23681f7114ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cf6c2-c34a-7a59-be04-321cf4a8c37d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cf6c2-c34a-77b6-bfa1-effda71aacd1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019cf6c2-c34a-7a59-be04-321cf4a8c37d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cf6c2-c34a-7a65-aad8-a38b0e9fa1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cf6c2-c34a-77b6-bfa1-effda71aacd1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cf6c2-c34a-7a65-aad8-a38b0e9fa1a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019cf6c2-c34a-7b47-abe5-b4123b3b570e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cf6c2-c34a-77b6-bfa1-effda71aacd1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019cf6c2-c34a-7b47-abe5-b4123b3b570e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7802-8028-c1221df4b925" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019cf6c2-c34a-7e57-b02b-521ffbbfc1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7802-8028-c1221df4b925" xlink:to="loc_us-gaap_PreferredStockValue_019cf6c2-c34a-7e57-b02b-521ffbbfc1c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019cf6c2-c34a-7942-972e-33c2331efd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7802-8028-c1221df4b925" xlink:to="loc_us-gaap_CommonStockValue_019cf6c2-c34a-7942-972e-33c2331efd1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019cf6c2-c34a-72e8-afcd-1ea18e8959a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7802-8028-c1221df4b925" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019cf6c2-c34a-72e8-afcd-1ea18e8959a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cf6c2-c34a-7956-9d51-f8e68b19e8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7802-8028-c1221df4b925" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cf6c2-c34a-7956-9d51-f8e68b19e8fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cf6c2-c34a-7c81-a132-01f2b9a20df7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7802-8028-c1221df4b925" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cf6c2-c34a-7c81-a132-01f2b9a20df7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c34a-7beb-a579-ba6a4a69d4da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cf6c2-c34a-7bd4-b2a5-12454af388e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c34a-7beb-a579-ba6a4a69d4da" xlink:to="loc_us-gaap_OperatingExpenses_019cf6c2-c34a-7bd4-b2a5-12454af388e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c34a-73a6-9797-cab78aae8af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c34a-781c-a859-ec3fd9cd06cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c34a-73a6-9797-cab78aae8af1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c34a-781c-a859-ec3fd9cd06cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c34a-7013-95b7-9ab5d03adb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c34a-73a6-9797-cab78aae8af1" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c34a-7013-95b7-9ab5d03adb1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cf6c2-c34a-7a2b-8002-54920e889e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c34a-77f2-bbfe-3d02b8ef5066" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019cf6c2-c34a-7a2b-8002-54920e889e91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c34a-77f2-bbfe-3d02b8ef5066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c34a-7371-9690-c9fa5d81fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019cf6c2-c34a-7a2b-8002-54920e889e91" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c34a-7371-9690-c9fa5d81fd07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cf6c2-c34a-7178-8d14-9b6ab71fe28f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-79ca-ad48-643971310eca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cf6c2-c34a-7178-8d14-9b6ab71fe28f" xlink:to="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-79ca-ad48-643971310eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7456-85fd-19b0874fecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cf6c2-c34a-7178-8d14-9b6ab71fe28f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7456-85fd-19b0874fecfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c34a-7933-b7be-bff03b24028e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019cf6c2-c34a-7b14-bf2e-a2d4ece07cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c34a-7933-b7be-bff03b24028e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019cf6c2-c34a-7b14-bf2e-a2d4ece07cb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7dce-a244-739f80c75bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7d9e-ae4a-38861b9509c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7dce-a244-739f80c75bdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7d9e-ae4a-38861b9509c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-71ae-9598-789a0f1158e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c34a-7424-b671-dd633c292740" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-71ae-9598-789a0f1158e5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c34a-7424-b671-dd633c292740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019cf6c2-c34a-70a6-b108-d21bda03a04d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-71ae-9598-789a0f1158e5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019cf6c2-c34a-70a6-b108-d21bda03a04d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cf6c2-c34a-7c54-b711-a806b77bad01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_019cf6c2-c34a-7fac-86a4-9805b3838493" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cf6c2-c34a-7c54-b711-a806b77bad01" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_019cf6c2-c34a-7fac-86a4-9805b3838493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cf6c2-c34a-71ae-b6ff-342dbd8bacdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cf6c2-c34a-7c54-b711-a806b77bad01" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cf6c2-c34a-71ae-b6ff-342dbd8bacdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cf6c2-c34a-7556-8073-f09125462f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cf6c2-c34a-763d-b7fe-4841f6ef75ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cf6c2-c34a-7556-8073-f09125462f5b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cf6c2-c34a-763d-b7fe-4841f6ef75ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-7359-ad8c-b3f2778f5143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cf6c2-c34a-7556-8073-f09125462f5b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-7359-ad8c-b3f2778f5143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cf6c2-c34a-70f0-ac37-fb7272db20a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cf6c2-c34a-7556-8073-f09125462f5b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cf6c2-c34a-70f0-ac37-fb7272db20a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cf6c2-c34a-7614-8b68-2ed1c1eaa8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cf6c2-c34a-7928-ab0f-a728056754d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cf6c2-c34a-7614-8b68-2ed1c1eaa8cd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cf6c2-c34a-7928-ab0f-a728056754d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019cf6c2-c34a-7671-a4da-a54ebd049843" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cf6c2-c34a-7614-8b68-2ed1c1eaa8cd" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019cf6c2-c34a-7671-a4da-a54ebd049843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-74ab-9323-4f83b3799a26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-75f7-9d04-a61edc09d613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-74ab-9323-4f83b3799a26" xlink:to="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-75f7-9d04-a61edc09d613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019cf6c2-c34a-7fae-9748-968a92ec81c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-74ab-9323-4f83b3799a26" xlink:to="loc_us-gaap_ShareBasedCompensation_019cf6c2-c34a-7fae-9748-968a92ec81c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019cf6c2-c34a-7ca2-a180-2427204464af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-74ab-9323-4f83b3799a26" xlink:to="loc_us-gaap_Depreciation_019cf6c2-c34a-7ca2-a180-2427204464af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cf6c2-c34a-75b7-ba1c-10512bdc57f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-74ab-9323-4f83b3799a26" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cf6c2-c34a-75b7-ba1c-10512bdc57f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cf6c2-c34a-7e26-8340-919ba888a648" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-74ab-9323-4f83b3799a26" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cf6c2-c34a-7e26-8340-919ba888a648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019cf6c2-c34a-70ad-b0f6-1afe91edfd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-74ab-9323-4f83b3799a26" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019cf6c2-c34a-70ad-b0f6-1afe91edfd2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019cf6c2-c34a-7b9b-aa0f-215c04d021b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-74ab-9323-4f83b3799a26" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019cf6c2-c34a-7b9b-aa0f-215c04d021b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cf6c2-c34a-72e9-bc2b-aaa87398ec61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-74ab-9323-4f83b3799a26" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cf6c2-c34a-72e9-bc2b-aaa87398ec61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019dfef4-0ecb-7b5c-a860-3a3e65f3a21c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019dfef4-0ecb-7f5c-a880-cccb7fbf77cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019dfef4-0ecb-7b5c-a860-3a3e65f3a21c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019dfef4-0ecb-7f5c-a880-cccb7fbf77cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cf6c2-c34a-76e8-9033-e34674824bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cf6c2-c34a-7935-83eb-b2445bd7deb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cf6c2-c34a-76e8-9033-e34674824bb2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cf6c2-c34a-7935-83eb-b2445bd7deb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cf6c2-c34a-7e55-9adc-dea70055db84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cf6c2-c34a-76e8-9033-e34674824bb2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cf6c2-c34a-7e55-9adc-dea70055db84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cf6c2-c34a-7946-81f8-bb6bc16e6974" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cf6c2-c34a-76e8-9033-e34674824bb2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cf6c2-c34a-7946-81f8-bb6bc16e6974" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019cf6c2-c34a-7319-8c1a-f5208cc45bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019cf6c2-c34a-7c7a-ad92-7bc93a60f3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019cf6c2-c34a-7319-8c1a-f5208cc45bb3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019cf6c2-c34a-7c7a-ad92-7bc93a60f3dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019cf6c2-c34a-77c9-9027-9454458b0852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019cf6c2-c34a-7319-8c1a-f5208cc45bb3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019cf6c2-c34a-77c9-9027-9454458b0852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019cf6c2-c34a-7c11-b513-47962f0afd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019cf6c2-c34a-7e97-beec-121c8bab33d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019cf6c2-c34a-7c11-b513-47962f0afd6c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019cf6c2-c34a-7e97-beec-121c8bab33d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019cf6c2-c34a-7c00-a7e2-83e1e3a376d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019cf6c2-c34a-7c11-b513-47962f0afd6c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019cf6c2-c34a-7c00-a7e2-83e1e3a376d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-746a-b27b-19b405c077d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_019cf6c2-c34a-774c-843b-788d30068013" xlink:href="bcax-20260331.xsd#bcax_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-746a-b27b-19b405c077d5" xlink:to="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_019cf6c2-c34a-774c-843b-788d30068013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedManufacturingExpensesCurrent_019cf6c2-c34a-7895-87c7-1e62ff4eb9f9" xlink:href="bcax-20260331.xsd#bcax_AccruedManufacturingExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-746a-b27b-19b405c077d5" xlink:to="loc_bcax_AccruedManufacturingExpensesCurrent_019cf6c2-c34a-7895-87c7-1e62ff4eb9f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cf6c2-c34a-7ba0-8863-af5cb50998d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-746a-b27b-19b405c077d5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cf6c2-c34a-7ba0-8863-af5cb50998d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_019cf6c2-c34a-7b8a-b052-749e543ee6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-746a-b27b-19b405c077d5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_019cf6c2-c34a-7b8a-b052-749e543ee6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019daa80-6dfe-7943-8682-bbec68130771" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-746a-b27b-19b405c077d5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019daa80-6dfe-7943-8682-bbec68130771" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3eb-7b6d-bd82-870f83e8c44e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ClinicalOperationsAndDevelopmentExpense_019cf6c2-c3eb-71e8-84c6-5b25dc898a22" xlink:href="bcax-20260331.xsd#bcax_ClinicalOperationsAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3eb-7b6d-bd82-870f83e8c44e" xlink:to="loc_bcax_ClinicalOperationsAndDevelopmentExpense_019cf6c2-c3eb-71e8-84c6-5b25dc898a22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cf6c2-c3eb-7703-b9de-f321d2690f82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3eb-7b6d-bd82-870f83e8c44e" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cf6c2-c3eb-7703-b9de-f321d2690f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense_019cf6c2-c3eb-7675-91a1-fc6a8607e08c" xlink:href="bcax-20260331.xsd#bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3eb-7b6d-bd82-870f83e8c44e" xlink:to="loc_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense_019cf6c2-c3eb-7675-91a1-fc6a8607e08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ManufacturingAndProcessDevelopmentExpense_019cf6c2-c3eb-7c89-be8d-f7c356302ac4" xlink:href="bcax-20260331.xsd#bcax_ManufacturingAndProcessDevelopmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3eb-7b6d-bd82-870f83e8c44e" xlink:to="loc_bcax_ManufacturingAndProcessDevelopmentExpense_019cf6c2-c3eb-7c89-be8d-f7c356302ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c3eb-7b5e-baec-666c209ce492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncomeTaxExpenseBenefitIncludingAdjustments_019cf6c2-c3eb-7174-947c-a49addbcdf81" xlink:href="bcax-20260331.xsd#bcax_IncomeTaxExpenseBenefitIncludingAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cf6c2-c3eb-7b5e-baec-666c209ce492" xlink:to="loc_bcax_IncomeTaxExpenseBenefitIncludingAdjustments_019cf6c2-c3eb-7174-947c-a49addbcdf81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c3eb-70ad-a52e-96e41a2539d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cf6c2-c3eb-7b5e-baec-666c209ce492" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c3eb-70ad-a52e-96e41a2539d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c3eb-7aca-ac9d-a8b1847a0ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation_019cf6c2-c3eb-73ff-bc7d-374ce6ea32c5" xlink:href="bcax-20260331.xsd#bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c3eb-7aca-ac9d-a8b1847a0ba5" xlink:to="loc_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation_019cf6c2-c3eb-73ff-bc7d-374ce6ea32c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FacilityITOfficeAndOtherExpense_019cf6c2-c3eb-73b4-86b9-1dba535fdd97" xlink:href="bcax-20260331.xsd#bcax_FacilityITOfficeAndOtherExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c3eb-7aca-ac9d-a8b1847a0ba5" xlink:to="loc_bcax_FacilityITOfficeAndOtherExpense_019cf6c2-c3eb-73b4-86b9-1dba535fdd97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_019cf6c2-c3eb-7081-9fad-a73e490d06cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c3eb-7aca-ac9d-a8b1847a0ba5" xlink:to="loc_us-gaap_ProfessionalFees_019cf6c2-c3eb-7081-9fad-a73e490d06cf" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>bcax-20260331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cf6c2-c28f-747f-9e58-111c1e1d135b,g:94c43f23-f2a3-4ea7-b3a9-326e15be7355-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cf6c2-c34a-791b-abe8-fa922e1eda8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cf6c2-c34a-7032-b1f1-d8b24865c977" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-791b-abe8-fa922e1eda8e" xlink:to="loc_us-gaap_StatementTable_019cf6c2-c34a-7032-b1f1-d8b24865c977" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-76f0-8db3-d0e8b599de79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-7032-b1f1-d8b24865c977" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-76f0-8db3-d0e8b599de79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-76f0-8db3-d0e8b599de79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-76f0-8db3-d0e8b599de79" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-76f0-8db3-d0e8b599de79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d6b-92bf-7a4424e582f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-76f0-8db3-d0e8b599de79" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d6b-92bf-7a4424e582f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-73bc-9a42-1018db068b29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d6b-92bf-7a4424e582f8" xlink:to="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-73bc-9a42-1018db068b29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7e18-80ea-9b97f236d7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d6b-92bf-7a4424e582f8" xlink:to="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7e18-80ea-9b97f236d7e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-791b-abe8-fa922e1eda8e" xlink:to="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cf6c2-c34a-78c0-bdf1-3c17f36502ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cf6c2-c34a-78c0-bdf1-3c17f36502ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cf6c2-c34a-7039-8fdc-94db0c5f66af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cf6c2-c34a-7039-8fdc-94db0c5f66af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_019cf6c2-c34a-7580-aeb9-2a373bfe9f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_019cf6c2-c34a-7580-aeb9-2a373bfe9f0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cf6c2-c34a-7ba8-90e5-91023f89dfab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:to="loc_us-gaap_AssetsCurrent_019cf6c2-c34a-7ba8-90e5-91023f89dfab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cf6c2-c34a-7d1f-bd75-ffe859112e64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019cf6c2-c34a-7d1f-bd75-ffe859112e64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cf6c2-c34a-7f6b-956a-99043945a33c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cf6c2-c34a-7f6b-956a-99043945a33c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019cf6c2-c34a-7a99-b38b-734b19f5c748" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019cf6c2-c34a-7a99-b38b-734b19f5c748" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019cf6c2-c34a-7980-a99b-557c61125769" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:to="loc_us-gaap_Assets_019cf6c2-c34a-7980-a99b-557c61125769" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-791b-abe8-fa922e1eda8e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cf6c2-c34a-7d90-a72e-5d4e4dfcff2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cf6c2-c34a-7d90-a72e-5d4e4dfcff2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-7538-a36d-6157d1b632a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-7538-a36d-6157d1b632a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cf6c2-c34a-7017-9437-75a6af114c46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cf6c2-c34a-7017-9437-75a6af114c46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cf6c2-c34a-7459-8595-56cb00d14ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:to="loc_us-gaap_LiabilitiesCurrent_019cf6c2-c34a-7459-8595-56cb00d14ed4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cf6c2-c34a-7236-8cc8-1cfbe12f892c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cf6c2-c34a-7236-8cc8-1cfbe12f892c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019cf6c2-c34a-7408-8d50-517ff0a2b925" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:to="loc_us-gaap_Liabilities_019cf6c2-c34a-7408-8d50-517ff0a2b925" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019cf6c2-c34a-7b6d-a18b-e6908c813177" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019cf6c2-c34a-7b6d-a18b-e6908c813177" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019cf6c2-c34a-7e03-931b-a3159e3a41ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_PreferredStockValue_019cf6c2-c34a-7e03-931b-a3159e3a41ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019cf6c2-c34a-7360-b078-6f114ad63af4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_CommonStockValue_019cf6c2-c34a-7360-b078-6f114ad63af4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019cf6c2-c34a-71c9-b376-ec3ee8f4e3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019cf6c2-c34a-71c9-b376-ec3ee8f4e3c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cf6c2-c34a-7477-94ee-8814d117688f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cf6c2-c34a-7477-94ee-8814d117688f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cf6c2-c34a-7791-833e-bd16e1bb93e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cf6c2-c34a-7791-833e-bd16e1bb93e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7047-ae6b-95a0b99bc55e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7047-ae6b-95a0b99bc55e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cf6c2-c34a-70d0-864d-c148973ca231" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-791b-abe8-fa922e1eda8e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cf6c2-c34a-70d0-864d-c148973ca231" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cf6c2-c34a-7261-bdce-1a7d6364c139" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_StatementTable_019cf6c2-c34a-7261-bdce-1a7d6364c139" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-7e80-ab80-b77ab1c51b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-7261-bdce-1a7d6364c139" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-7e80-ab80-b77ab1c51b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7e80-ab80-b77ab1c51b3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-7e80-ab80-b77ab1c51b3f" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7e80-ab80-b77ab1c51b3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-729f-8f17-79c2892aeaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-7e80-ab80-b77ab1c51b3f" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-729f-8f17-79c2892aeaeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7345-a757-b08b21211b94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-729f-8f17-79c2892aeaeb" xlink:to="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7345-a757-b08b21211b94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-79a7-bc6b-f5683e02a0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-729f-8f17-79c2892aeaeb" xlink:to="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-79a7-bc6b-f5683e02a0ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019cf6c2-c34a-767b-9745-495d3dcd8922" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019cf6c2-c34a-767b-9745-495d3dcd8922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c34a-7311-be57-0d479b9fa67e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cf6c2-c34a-767b-9745-495d3dcd8922" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c34a-7311-be57-0d479b9fa67e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c34a-753f-8d13-147510e2e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cf6c2-c34a-767b-9745-495d3dcd8922" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c34a-753f-8d13-147510e2e45a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cf6c2-c34a-7937-9706-40a8a15bea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cf6c2-c34a-767b-9745-495d3dcd8922" xlink:to="loc_us-gaap_OperatingExpenses_019cf6c2-c34a-7937-9706-40a8a15bea0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c34a-78ea-a435-83eee97bdd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c34a-78ea-a435-83eee97bdd1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019cf6c2-c34a-721a-920b-31502afd3848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019cf6c2-c34a-721a-920b-31502afd3848" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019cf6c2-c34a-7b07-bd26-87c340050d50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019cf6c2-c34a-721a-920b-31502afd3848" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019cf6c2-c34a-7b07-bd26-87c340050d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c34a-7852-b1f1-9fdce9405f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019cf6c2-c34a-721a-920b-31502afd3848" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c34a-7852-b1f1-9fdce9405f9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c34a-7d6d-be41-07c825a77e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c34a-7d6d-be41-07c825a77e0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019cf6c2-c34a-7c8e-8f74-e5ee2abcaf32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019cf6c2-c34a-7c8e-8f74-e5ee2abcaf32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-7005-b4c9-b1250e7a91ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-7005-b4c9-b1250e7a91ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019cf6c2-c34a-7762-a179-5dc953494fad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_EarningsPerShareBasic_019cf6c2-c34a-7762-a179-5dc953494fad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019cf6c2-c34a-7427-a771-7f9a09c258a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019cf6c2-c34a-7427-a771-7f9a09c258a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cf6c2-c34a-797e-a312-6517df1b8dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cf6c2-c34a-797e-a312-6517df1b8dae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cf6c2-c34a-7e88-8936-4eb43eeac668" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cf6c2-c34a-7e88-8936-4eb43eeac668" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c34a-7a57-a634-4988692baac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c34a-7a57-a634-4988692baac4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7ff6-ae0b-e6e3e3f60b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c34a-7a57-a634-4988692baac4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7ff6-ae0b-e6e3e3f60b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7bd5-abe0-cfcbcb24e952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c34a-7a57-a634-4988692baac4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7bd5-abe0-cfcbcb24e952" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cf6c2-c34a-70a7-9eed-3d4e9db89f71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c34a-7a57-a634-4988692baac4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cf6c2-c34a-70a7-9eed-3d4e9db89f71" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7ad0-a083-ce4c79b1f50e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cf6c2-c34a-736f-9b6f-6884988aff60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7ad0-a083-ce4c79b1f50e" xlink:to="loc_us-gaap_StatementTable_019cf6c2-c34a-736f-9b6f-6884988aff60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019cf6c2-c34a-70b1-bda7-c5edccaae929" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-736f-9b6f-6884988aff60" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019cf6c2-c34a-70b1-bda7-c5edccaae929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-70b1-bda7-c5edccaae929_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019cf6c2-c34a-70b1-bda7-c5edccaae929" xlink:to="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-70b1-bda7-c5edccaae929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019cf6c2-c34a-70b1-bda7-c5edccaae929" xlink:to="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cf6c2-c34a-7c4b-89e1-8f35682a40a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:to="loc_us-gaap_CommonStockMember_019cf6c2-c34a-7c4b-89e1-8f35682a40a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019cf6c2-c34a-7346-b8c3-b189b29970e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019cf6c2-c34a-7346-b8c3-b189b29970e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cf6c2-c34a-710e-868a-6b6ec3d326ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cf6c2-c34a-710e-868a-6b6ec3d326ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019cf6c2-c34a-76c4-b6a0-cd5c86a07198" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:to="loc_us-gaap_RetainedEarningsMember_019cf6c2-c34a-76c4-b6a0-cd5c86a07198" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7ad0-a083-ce4c79b1f50e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cf6c2-c34a-7ab5-886c-70d83eb832a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cf6c2-c34a-7ab5-886c-70d83eb832a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7f50-98bd-6ee6b4340583" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7f50-98bd-6ee6b4340583" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019cf6c2-c34a-7afc-8881-d7340e658342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019cf6c2-c34a-7afc-8881-d7340e658342" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019cf6c2-c34a-72f5-b043-61478c45177a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019cf6c2-c34a-72f5-b043-61478c45177a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cf6c2-c34a-7952-90b4-a3668d1b64cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cf6c2-c34a-7952-90b4-a3668d1b64cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019cf6c2-c34a-7f40-8551-987c3a96c242" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019cf6c2-c34a-7f40-8551-987c3a96c242" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cf6c2-c34a-7cff-85e7-89dbf284aea1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cf6c2-c34a-7cff-85e7-89dbf284aea1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019daa22-bcbb-7b45-86e8-2f5ccc5a4e12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019daa22-bcbb-7b45-86e8-2f5ccc5a4e12" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-7dcc-af00-4458d8aad831" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-7dcc-af00-4458d8aad831" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cf6c2-c34a-707e-92b5-46c43f846dff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-77da-b5e4-399d4e6de325" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cf6c2-c34a-752a-bc63-093e480776d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_StatementTable_019cf6c2-c34a-752a-bc63-093e480776d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-74d0-b968-bc7986c3b2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-752a-bc63-093e480776d9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-74d0-b968-bc7986c3b2c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-74d0-b968-bc7986c3b2c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-74d0-b968-bc7986c3b2c0" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-74d0-b968-bc7986c3b2c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7a29-9f64-63332a48cbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-74d0-b968-bc7986c3b2c0" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7a29-9f64-63332a48cbe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-78f6-8f28-6c4a6ca84466" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7a29-9f64-63332a48cbe7" xlink:to="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-78f6-8f28-6c4a6ca84466" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7e96-a029-1cdf29297151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7a29-9f64-63332a48cbe7" xlink:to="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7e96-a029-1cdf29297151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-79e8-8295-c40c11d6bd77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:to="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-79e8-8295-c40c11d6bd77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019cf6c2-c34a-7c6c-8108-aca7d47480f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:to="loc_us-gaap_ShareBasedCompensation_019cf6c2-c34a-7c6c-8108-aca7d47480f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019cf6c2-c34a-748e-a499-4dde9a374acb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:to="loc_us-gaap_Depreciation_019cf6c2-c34a-748e-a499-4dde9a374acb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cf6c2-c34a-796c-b1c1-1cc992df966f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cf6c2-c34a-796c-b1c1-1cc992df966f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cf6c2-c34a-7d12-9bb6-7957c577ea16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cf6c2-c34a-7d12-9bb6-7957c577ea16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c34a-72bb-816a-7f05512fb592" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c34a-72bb-816a-7f05512fb592" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cf6c2-c34a-781f-8386-01d3180e84eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c34a-72bb-816a-7f05512fb592" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cf6c2-c34a-781f-8386-01d3180e84eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019cf6c2-c34a-751d-9943-974b7201e565" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c34a-72bb-816a-7f05512fb592" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019cf6c2-c34a-751d-9943-974b7201e565" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019cf6c2-c34a-7daf-bc78-3c9d1d0b82ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c34a-72bb-816a-7f05512fb592" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019cf6c2-c34a-7daf-bc78-3c9d1d0b82ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-7f3e-b718-4983fe96e645" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-7f3e-b718-4983fe96e645" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c34a-73d6-bb0f-eced3d0b652c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c34a-73d6-bb0f-eced3d0b652c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_019daa27-f7b5-7058-bd88-07dc7b2f76f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c34a-73d6-bb0f-eced3d0b652c" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_019daa27-f7b5-7058-bd88-07dc7b2f76f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cf6c2-c34a-7088-900e-caf75515150f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c34a-73d6-bb0f-eced3d0b652c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cf6c2-c34a-7088-900e-caf75515150f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cf6c2-c34a-7aba-a556-bd7c586eb112" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c34a-73d6-bb0f-eced3d0b652c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cf6c2-c34a-7aba-a556-bd7c586eb112" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c34a-7b3a-938c-9ff773b03110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c34a-7b3a-938c-9ff773b03110" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cf6c2-c34a-7be5-a54d-2383b1cf1ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c34a-7b3a-938c-9ff773b03110" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cf6c2-c34a-7be5-a54d-2383b1cf1ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019cf6c2-c34a-7405-9bea-a24b973265f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c34a-7b3a-938c-9ff773b03110" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019cf6c2-c34a-7405-9bea-a24b973265f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cf6c2-c34a-7249-af66-0db9eade6a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c34a-7b3a-938c-9ff773b03110" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cf6c2-c34a-7249-af66-0db9eade6a32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cf6c2-c34a-7cc2-9d06-33377b8b92ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cf6c2-c34a-7cc2-9d06-33377b8b92ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cf6c2-c34a-7257-9de5-87e129aec912" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cf6c2-c34a-7257-9de5-87e129aec912" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cf6c2-c34a-77b6-8556-c08f7db6424e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cf6c2-c34a-7ee8-941d-f14af056ef40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cf6c2-c34a-7ee8-941d-f14af056ef40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_019cf6c2-c34a-7562-8e34-bf21ea865063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cf6c2-c34a-7ee8-941d-f14af056ef40" xlink:to="loc_us-gaap_IncomeTaxesPaid_019cf6c2-c34a-7562-8e34-bf21ea865063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019cf6c2-c34a-7eec-a951-0cdd2a1c00c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019cf6c2-c34a-7eec-a951-0cdd2a1c00c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_019cf6c2-c34a-7d39-bc8c-2be3b7ee10a4" xlink:href="bcax-20260331.xsd#bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019cf6c2-c34a-7eec-a951-0cdd2a1c00c3" xlink:to="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_019cf6c2-c34a-7d39-bc8c-2be3b7ee10a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_VestingOfEarlyExerciseStockOptions_019cf6c2-c34a-7534-8ce2-d72a252f8747" xlink:href="bcax-20260331.xsd#bcax_VestingOfEarlyExerciseStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019cf6c2-c34a-7eec-a951-0cdd2a1c00c3" xlink:to="loc_bcax_VestingOfEarlyExerciseStockOptions_019cf6c2-c34a-7534-8ce2-d72a252f8747" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#DescriptionofBusinessOrganizationandLiquidityDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa57-bd47-7c5b-98be-4cc7fa029000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa57-bd47-7c5b-98be-4cc7fa029000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7c5b-98be-4cc7fa029000_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa57-bd47-7c5b-98be-4cc7fa029000" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7c5b-98be-4cc7fa029000_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa57-bd47-7c5b-98be-4cc7fa029000" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_019daa57-bd47-7d2f-a4ca-e306f69d53de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:to="loc_us-gaap_IPOMember_019daa57-bd47-7d2f-a4ca-e306f69d53de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ATMProgramMember_019daa57-bd47-77f5-8259-d2fec8b6f7ca" xlink:href="bcax-20260331.xsd#bcax_ATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:to="loc_bcax_ATMProgramMember_019daa57-bd47-77f5-8259-d2fec8b6f7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_February2026OfferingMember_019daa57-bd47-78c4-90c0-e415d7d717b5" xlink:href="bcax-20260331.xsd#bcax_February2026OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:to="loc_bcax_February2026OfferingMember_019daa57-bd47-78c4-90c0-e415d7d717b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019daa57-bd47-798e-ac38-1c551517d08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019daa57-bd47-798e-ac38-1c551517d08e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019daa57-bd47-7c2c-9341-50293c4fe928" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019daa57-bd47-7c2c-9341-50293c4fe928" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019daa57-bd47-7c2c-9341-50293c4fe928_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019daa57-bd47-7c2c-9341-50293c4fe928" xlink:to="loc_us-gaap_ClassOfStockDomain_019daa57-bd47-7c2c-9341-50293c4fe928_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019daa57-bd47-72c9-a16a-d92353d02ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019daa57-bd47-7c2c-9341-50293c4fe928" xlink:to="loc_us-gaap_ClassOfStockDomain_019daa57-bd47-72c9-a16a-d92353d02ba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019daa57-bd47-79fd-aedf-9a5561ba7d01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019daa57-bd47-72c9-a16a-d92353d02ba7" xlink:to="loc_us-gaap_CommonStockMember_019daa57-bd47-79fd-aedf-9a5561ba7d01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa57-bd47-7848-bb09-456b666e9f29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa57-bd47-7848-bb09-456b666e9f29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa57-bd47-7848-bb09-456b666e9f29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa57-bd47-7848-bb09-456b666e9f29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa57-bd47-7848-bb09-456b666e9f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa57-bd47-7c81-9258-f4337e5c48e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa57-bd47-7848-bb09-456b666e9f29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa57-bd47-7c81-9258-f4337e5c48e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PreFundedWarrantsMember_019daa57-bd47-79e0-9164-ec0eb17edaeb" xlink:href="bcax-20260331.xsd#bcax_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa57-bd47-7c81-9258-f4337e5c48e8" xlink:to="loc_bcax_PreFundedWarrantsMember_019daa57-bd47-79e0-9164-ec0eb17edaeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019daa57-bd47-7e5b-8390-9b1f34c3fe9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019daa57-bd47-7e5b-8390-9b1f34c3fe9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019daa57-bd47-7195-b12a-38ae6f8fbc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019daa57-bd47-7195-b12a-38ae6f8fbc7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019daa57-bd47-7530-b69b-e82f9e04f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019daa57-bd47-7530-b69b-e82f9e04f88e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_019daa57-bd47-7146-8312-85a57a9ebd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_019daa57-bd47-7146-8312-85a57a9ebd1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019daa57-bd47-7f0b-8efa-fc575cafeade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019daa57-bd47-7f0b-8efa-fc575cafeade" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019daa57-bd47-7df3-9bea-4333e9fa1deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019daa57-bd47-7df3-9bea-4333e9fa1deb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019daa57-bd47-7cea-8c24-8011d4334e71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019daa57-bd47-7cea-8c24-8011d4334e71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_019daa57-bd47-7f9e-88b9-a2fbb218dc25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_InvestmentsAndCash_019daa57-bd47-7f9e-88b9-a2fbb218dc25" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019daa57-bd47-7b6c-9250-4457c4fe0c82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019daa57-bd47-7b6c-9250-4457c4fe0c82" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019daa6d-c3d0-7de6-a0d6-6192a0fc0b29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019daa6d-c3d0-7bd9-80f5-d9ba4a5e3a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019daa6d-c3d0-7de6-a0d6-6192a0fc0b29" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019daa6d-c3d0-7bd9-80f5-d9ba4a5e3a2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa6d-c3d0-76c0-b75c-f33eb50983d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019daa6d-c3d0-7bd9-80f5-d9ba4a5e3a2a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa6d-c3d0-76c0-b75c-f33eb50983d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa6d-c3d0-76c0-b75c-f33eb50983d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa6d-c3d0-76c0-b75c-f33eb50983d3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa6d-c3d0-76c0-b75c-f33eb50983d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa6d-c3d0-719c-8e92-2d6d7aee7611" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa6d-c3d0-76c0-b75c-f33eb50983d3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa6d-c3d0-719c-8e92-2d6d7aee7611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PreFundedWarrantsMember_019daa6d-c3d0-776f-b090-874732ec7272" xlink:href="bcax-20260331.xsd#bcax_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa6d-c3d0-719c-8e92-2d6d7aee7611" xlink:to="loc_bcax_PreFundedWarrantsMember_019daa6d-c3d0-776f-b090-874732ec7272" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa6d-c3d0-7f20-8313-e09754a2d342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019daa6d-c3d0-7bd9-80f5-d9ba4a5e3a2a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa6d-c3d0-7f20-8313-e09754a2d342" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa6d-c3d0-7f20-8313-e09754a2d342_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa6d-c3d0-7f20-8313-e09754a2d342" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa6d-c3d0-7f20-8313-e09754a2d342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa6d-c3d0-71ba-92fd-419b3c1df86b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa6d-c3d0-7f20-8313-e09754a2d342" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa6d-c3d0-71ba-92fd-419b3c1df86b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_February2026OfferingMember_019daa6d-c3d0-740d-80f4-9934da7170c7" xlink:href="bcax-20260331.xsd#bcax_February2026OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa6d-c3d0-71ba-92fd-419b3c1df86b" xlink:to="loc_bcax_February2026OfferingMember_019daa6d-c3d0-740d-80f4-9934da7170c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019daa6d-c3d0-79a1-b79a-1be2619adb86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019daa6d-c3d0-7de6-a0d6-6192a0fc0b29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019daa6d-c3d0-79a1-b79a-1be2619adb86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019daa6e-0d10-7caf-8d81-24856482b7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019daa6d-c3d0-7de6-a0d6-6192a0fc0b29" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019daa6e-0d10-7caf-8d81-24856482b7cb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cf6c2-c34a-7e45-9cbc-317ce1ca452f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cf6c2-c34a-7e15-bdd9-436c5b251726" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cf6c2-c34a-7e45-9cbc-317ce1ca452f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cf6c2-c34a-7e15-bdd9-436c5b251726" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cf6c2-c34a-7e4a-b147-f4dd53c0795b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cf6c2-c34a-7e15-bdd9-436c5b251726" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cf6c2-c34a-7e4a-b147-f4dd53c0795b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cf6c2-c34a-7e4a-b147-f4dd53c0795b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cf6c2-c34a-7e4a-b147-f4dd53c0795b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cf6c2-c34a-7e4a-b147-f4dd53c0795b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cf6c2-c34a-7fea-bedf-569e4c29d722" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cf6c2-c34a-7e4a-b147-f4dd53c0795b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cf6c2-c34a-7fea-bedf-569e4c29d722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_019cf6c2-c34a-7663-84fd-686565e3ee50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cf6c2-c34a-7fea-bedf-569e4c29d722" xlink:to="loc_us-gaap_StockCompensationPlanMember_019cf6c2-c34a-7663-84fd-686565e3ee50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cf6c2-c34a-7521-8d96-8d0e9c893dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cf6c2-c34a-7e45-9cbc-317ce1ca452f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cf6c2-c34a-7521-8d96-8d0e9c893dae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cf6c2-c34a-770e-8a39-90c33bb52b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cf6c2-c34a-7d35-ad7b-81cd40c52b49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cf6c2-c34a-770e-8a39-90c33bb52b2e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cf6c2-c34a-7d35-ad7b-81cd40c52b49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019cf6c2-c34a-786a-b650-36bf4139711c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cf6c2-c34a-7d35-ad7b-81cd40c52b49" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019cf6c2-c34a-786a-b650-36bf4139711c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c34a-786a-b650-36bf4139711c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019cf6c2-c34a-786a-b650-36bf4139711c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c34a-786a-b650-36bf4139711c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c34a-71e6-be68-9ccbdddcd417" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019cf6c2-c34a-786a-b650-36bf4139711c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c34a-71e6-be68-9ccbdddcd417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-75a3-965e-cd2ffc52319c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c34a-71e6-be68-9ccbdddcd417" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-75a3-965e-cd2ffc52319c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019cf6c2-c34a-7723-8916-2cbee7d951cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c34a-71e6-be68-9ccbdddcd417" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019cf6c2-c34a-7723-8916-2cbee7d951cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cf6c2-c34a-7c51-991d-137ee5abb4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cf6c2-c34a-7d35-ad7b-81cd40c52b49" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cf6c2-c34a-7c51-991d-137ee5abb4ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7c51-991d-137ee5abb4ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cf6c2-c34a-7c51-991d-137ee5abb4ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7c51-991d-137ee5abb4ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7de9-809f-39c7dc2db06f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cf6c2-c34a-7c51-991d-137ee5abb4ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7de9-809f-39c7dc2db06f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019cf6c2-c34a-79ee-9fea-08d2563b778f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7de9-809f-39c7dc2db06f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019cf6c2-c34a-79ee-9fea-08d2563b778f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019cf6c2-c34a-7fe5-9897-b8fd8ef4d324" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7de9-809f-39c7dc2db06f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019cf6c2-c34a-7fe5-9897-b8fd8ef4d324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019cf6c2-c34a-7a8e-8b80-ffa4397d4879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7de9-809f-39c7dc2db06f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019cf6c2-c34a-7a8e-8b80-ffa4397d4879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cf6c2-c34a-7a93-8baf-768b4df9862f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cf6c2-c34a-770e-8a39-90c33bb52b2e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cf6c2-c34a-7a93-8baf-768b4df9862f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019cf6c2-c34a-74ca-9d1c-3af0e24dc773" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cf6c2-c34a-770e-8a39-90c33bb52b2e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019cf6c2-c34a-74ca-9d1c-3af0e24dc773" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7061-84d8-777ad37360b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7061-84d8-777ad37360b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7c14-9732-a59190a85ded" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7061-84d8-777ad37360b7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7c14-9732-a59190a85ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-7c14-9732-a59190a85ded_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7c14-9732-a59190a85ded" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-7c14-9732-a59190a85ded_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-7ea0-b9bc-4d1b2aff3b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7c14-9732-a59190a85ded" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-7ea0-b9bc-4d1b2aff3b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-7a34-9b7f-b225fa04d810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-7ea0-b9bc-4d1b2aff3b0f" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-7a34-9b7f-b225fa04d810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentCategorizationAxisAxis_019cf6c2-c34a-74d7-bab2-672bfe5847fd" xlink:href="bcax-20260331.xsd#bcax_InvestmentCategorizationAxisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7061-84d8-777ad37360b7" xlink:to="loc_bcax_InvestmentCategorizationAxisAxis_019cf6c2-c34a-74d7-bab2-672bfe5847fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c34a-74d7-bab2-672bfe5847fd_default" xlink:href="bcax-20260331.xsd#bcax_InvestmentCategorizationAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bcax_InvestmentCategorizationAxisAxis_019cf6c2-c34a-74d7-bab2-672bfe5847fd" xlink:to="loc_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c34a-74d7-bab2-672bfe5847fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c34a-7e1c-b155-1169b22a403e" xlink:href="bcax-20260331.xsd#bcax_InvestmentCategorizationAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bcax_InvestmentCategorizationAxisAxis_019cf6c2-c34a-74d7-bab2-672bfe5847fd" xlink:to="loc_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c34a-7e1c-b155-1169b22a403e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentsWithMaturityOfOneYearOrLessMember_019cf6c2-c34a-7573-ae19-5ea1e9fb82c5" xlink:href="bcax-20260331.xsd#bcax_InvestmentsWithMaturityOfOneYearOrLessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c34a-7e1c-b155-1169b22a403e" xlink:to="loc_bcax_InvestmentsWithMaturityOfOneYearOrLessMember_019cf6c2-c34a-7573-ae19-5ea1e9fb82c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember_019cf6c2-c34a-77b2-a89b-ca188dc87108" xlink:href="bcax-20260331.xsd#bcax_InvestmentsWithMaturityOfOneToTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c34a-7e1c-b155-1169b22a403e" xlink:to="loc_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember_019cf6c2-c34a-77b2-a89b-ca188dc87108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cf6c2-c34a-753e-b316-315c4c4386f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cf6c2-c34a-753e-b316-315c4c4386f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cf6c2-c34a-7e44-966b-6661df977db6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cf6c2-c34a-7e44-966b-6661df977db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cf6c2-c34a-7cd7-91a4-d7b157d491c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cf6c2-c34a-7cd7-91a4-d7b157d491c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cf6c2-c34a-74b1-bca9-c75cc7266677" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cf6c2-c34a-74b1-bca9-c75cc7266677" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7653-94f7-5bbbda1c4359" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7653-94f7-5bbbda1c4359" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7aff-8f81-7c5e716e7f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7653-94f7-5bbbda1c4359" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7aff-8f81-7c5e716e7f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-7aff-8f81-7c5e716e7f2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7aff-8f81-7c5e716e7f2d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-7aff-8f81-7c5e716e7f2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-74b9-9a31-dc9b42c2eda1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7aff-8f81-7c5e716e7f2d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-74b9-9a31-dc9b42c2eda1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-7ac6-93fc-34b15895c87f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-74b9-9a31-dc9b42c2eda1" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-7ac6-93fc-34b15895c87f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019cf6c2-c34a-7936-8ca7-d3bfb78886e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019cf6c2-c34a-7936-8ca7-d3bfb78886e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019cf6c2-c34a-72b8-a2eb-2ab048858868" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019cf6c2-c34a-72b8-a2eb-2ab048858868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019cf6c2-c34a-7e1b-a9b9-56761110b639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019cf6c2-c34a-7e1b-a9b9-56761110b639" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019cf6c2-c34a-794a-9d86-48bc1fd1e79b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019cf6c2-c34a-794a-9d86-48bc1fd1e79b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019cf6c2-c34a-7bc3-8337-8dc9349d5268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019cf6c2-c34a-7bc3-8337-8dc9349d5268" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019cf6c2-c34a-7e11-bf28-bcf23924f49b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019cf6c2-c34a-7e11-bf28-bcf23924f49b" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34a-7ebb-a9d1-c98e5cbd6f68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34a-7ebb-a9d1-c98e5cbd6f68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-73a1-943e-1fd7e899c9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34a-7ebb-a9d1-c98e5cbd6f68" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-73a1-943e-1fd7e899c9c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-73a1-943e-1fd7e899c9c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-73a1-943e-1fd7e899c9c6" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-73a1-943e-1fd7e899c9c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d1c-ba1a-3ddecdb0afb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-73a1-943e-1fd7e899c9c6" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d1c-ba1a-3ddecdb0afb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-760c-ba83-f6cbb293775c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d1c-ba1a-3ddecdb0afb0" xlink:to="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-760c-ba83-f6cbb293775c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_019cf6c2-c34a-719c-a829-1410d4e6c67a" xlink:href="bcax-20260331.xsd#bcax_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_019cf6c2-c34a-719c-a829-1410d4e6c67a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedManufacturingExpensesCurrent_019daa80-4077-700e-a5ac-24f77df2c3e6" xlink:href="bcax-20260331.xsd#bcax_AccruedManufacturingExpensesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_bcax_AccruedManufacturingExpensesCurrent_019daa80-4077-700e-a5ac-24f77df2c3e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cf6c2-c34a-710a-a88b-c3a854390f49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cf6c2-c34a-710a-a88b-c3a854390f49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_019cf6c2-c34a-73be-9f3a-1a393c19824f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_019cf6c2-c34a-73be-9f3a-1a393c19824f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019cf6c2-c34a-78bd-97ab-486ad69ea375" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019cf6c2-c34a-78bd-97ab-486ad69ea375" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-7dea-af7c-4f0207add783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-7dea-af7c-4f0207add783" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019dd835-488c-78fc-b437-46ac3007a8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019dd835-488c-78fc-b437-46ac3007a8fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019dd835-488c-78fc-b437-46ac3007a8fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019dd835-488c-78fc-b437-46ac3007a8fb" xlink:to="loc_us-gaap_ClassOfStockDomain_019dd835-488c-78fc-b437-46ac3007a8fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019dd835-488c-721a-bf17-55480006fc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019dd835-488c-78fc-b437-46ac3007a8fb" xlink:to="loc_us-gaap_ClassOfStockDomain_019dd835-488c-721a-bf17-55480006fc1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019dd835-488c-7acd-82d3-fa41ddb33b28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019dd835-488c-721a-bf17-55480006fc1b" xlink:to="loc_us-gaap_CommonStockMember_019dd835-488c-7acd-82d3-fa41ddb33b28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019dd835-488c-77cd-b97c-1733d085e65e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019dd835-488c-77cd-b97c-1733d085e65e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-77cd-b97c-1733d085e65e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019dd835-488c-77cd-b97c-1733d085e65e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-77cd-b97c-1733d085e65e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-7031-b353-9596a232711a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019dd835-488c-77cd-b97c-1733d085e65e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-7031-b353-9596a232711a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_February2026OfferingMember_019dd835-488c-70dc-97d4-ac54122dd79d" xlink:href="bcax-20260331.xsd#bcax_February2026OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-7031-b353-9596a232711a" xlink:to="loc_bcax_February2026OfferingMember_019dd835-488c-70dc-97d4-ac54122dd79d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019dd835-488c-7e0e-a567-eb346f48cd07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-7031-b353-9596a232711a" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019dd835-488c-7e0e-a567-eb346f48cd07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ATMProgramMember_019dd835-6e08-7016-be7d-80fa5c6565e9" xlink:href="bcax-20260331.xsd#bcax_ATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-7031-b353-9596a232711a" xlink:to="loc_bcax_ATMProgramMember_019dd835-6e08-7016-be7d-80fa5c6565e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019de454-e903-7835-aa4d-1faf7ad7b503" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019de454-e903-7835-aa4d-1faf7ad7b503" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019de454-e903-7835-aa4d-1faf7ad7b503_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019de454-e903-7835-aa4d-1faf7ad7b503" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019de454-e903-7835-aa4d-1faf7ad7b503_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019de454-e903-7b0f-8d71-4bf8b5afb527" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019de454-e903-7835-aa4d-1faf7ad7b503" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019de454-e903-7b0f-8d71-4bf8b5afb527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PreFundedWarrantsMember_019de454-e903-7e7c-a8cc-435dd4404e63" xlink:href="bcax-20260331.xsd#bcax_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019de454-e903-7b0f-8d71-4bf8b5afb527" xlink:to="loc_bcax_PreFundedWarrantsMember_019de454-e903-7e7c-a8cc-435dd4404e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019dd835-488c-7b0a-8792-9d0effca486c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019dd835-488c-7b0a-8792-9d0effca486c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019dd835-488c-7853-b772-6db68e5f0b42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019dd835-488c-7853-b772-6db68e5f0b42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_019dd835-488c-7321-a461-a966905a4504" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_PreferredStockSharesIssued_019dd835-488c-7321-a461-a966905a4504" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019dd835-488c-7592-b69e-7820f5903673" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019dd835-488c-7592-b69e-7820f5903673" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019dd835-488c-7809-8d8d-69e2ed29d011" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019dd835-488c-7809-8d8d-69e2ed29d011" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019dd835-488c-7ece-b687-82556f591dab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019dd835-488c-7ece-b687-82556f591dab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019dd835-488c-7de3-9fff-d186c19af408" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_CommonStockSharesIssued_019dd835-488c-7de3-9fff-d186c19af408" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019dd835-488c-7d8f-9303-7706c0affd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019dd835-488c-7d8f-9303-7706c0affd2d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019dd835-488c-7203-be3e-42083796059c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019dd835-488c-7203-be3e-42083796059c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019dd835-488c-7185-acb0-e008b4ac1af0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019dd835-488c-7185-acb0-e008b4ac1af0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019de454-e903-7774-9c69-d06299d0042e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019de454-e903-7774-9c69-d06299d0042e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019de454-e903-73c4-9976-c6b81bef00bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019de454-e903-73c4-9976-c6b81bef00bf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference_019df4af-c5c5-71c1-929b-ccf5b75694e1" xlink:href="bcax-20260331.xsd#bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference_019df4af-c5c5-71c1-929b-ccf5b75694e1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_019dd835-6e08-7a9c-a844-426e975e7745" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_019dd835-6e08-7a9c-a844-426e975e7745" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SaleOfStockCommissionFeePercentage_019dd835-6e08-7f34-9fd2-28de2cf97dee" xlink:href="bcax-20260331.xsd#bcax_SaleOfStockCommissionFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_bcax_SaleOfStockCommissionFeePercentage_019dd835-6e08-7f34-9fd2-28de2cf97dee" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019dd835-6e08-73af-9547-e5e9955ea769" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019dd835-6e08-73af-9547-e5e9955ea769" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34a-7910-b93a-61d44d721c03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34a-7910-b93a-61d44d721c03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019daab6-47d9-7076-8da7-58533da63e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34a-7910-b93a-61d44d721c03" xlink:to="loc_us-gaap_PlanNameAxis_019daab6-47d9-7076-8da7-58533da63e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019daab6-47d9-7076-8da7-58533da63e4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019daab6-47d9-7076-8da7-58533da63e4e" xlink:to="loc_us-gaap_PlanNameDomain_019daab6-47d9-7076-8da7-58533da63e4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019daab6-47d9-7e99-8d30-b903eba047a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019daab6-47d9-7076-8da7-58533da63e4e" xlink:to="loc_us-gaap_PlanNameDomain_019daab6-47d9-7e99-8d30-b903eba047a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2024StockOptionAndGrantPlanMember_019daab6-47d9-705c-8d83-91c83a0d61e3" xlink:href="bcax-20260331.xsd#bcax_A2024StockOptionAndGrantPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019daab6-47d9-7e99-8d30-b903eba047a0" xlink:to="loc_bcax_A2024StockOptionAndGrantPlanMember_019daab6-47d9-705c-8d83-91c83a0d61e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2026InducementPlanMember_019daab6-77db-722e-9997-260ad2a50939" xlink:href="bcax-20260331.xsd#bcax_A2026InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019daab6-47d9-7e99-8d30-b903eba047a0" xlink:to="loc_bcax_A2026InducementPlanMember_019daab6-77db-722e-9997-260ad2a50939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019daab6-47d9-7379-8a08-cdbb7cdfe12f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34a-7910-b93a-61d44d721c03" xlink:to="loc_us-gaap_AwardTypeAxis_019daab6-47d9-7379-8a08-cdbb7cdfe12f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7379-8a08-cdbb7cdfe12f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019daab6-47d9-7379-8a08-cdbb7cdfe12f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7379-8a08-cdbb7cdfe12f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7bf9-8e6c-0793f8074b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019daab6-47d9-7379-8a08-cdbb7cdfe12f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7bf9-8e6c-0793f8074b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_019daab6-47d9-79fc-be9f-2bac0b22cdc1" xlink:href="bcax-20260331.xsd#bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7bf9-8e6c-0793f8074b4e" xlink:to="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_019daab6-47d9-79fc-be9f-2bac0b22cdc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019daab6-a14f-7113-90ff-1f41dab816c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7bf9-8e6c-0793f8074b4e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019daab6-a14f-7113-90ff-1f41dab816c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019daab6-e2f8-7cff-8da0-4fd6ffe708dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7bf9-8e6c-0793f8074b4e" xlink:to="loc_us-gaap_EmployeeStockMember_019daab6-e2f8-7cff-8da0-4fd6ffe708dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019daab6-47d9-7e52-83ef-f66779f24832" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019daab6-47d9-7e52-83ef-f66779f24832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_019daab6-47d9-799d-b678-7f25e41cf5b8" xlink:href="bcax-20260331.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_019daab6-47d9-799d-b678-7f25e41cf5b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_019daab6-47d9-7316-a920-a955823f93cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_019daab6-47d9-7316-a920-a955823f93cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019daab6-47d9-71c2-8a82-1fb64c59a58e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019daab6-47d9-71c2-8a82-1fb64c59a58e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019daab6-47d9-7604-a919-3b05db4e758c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019daab6-47d9-7604-a919-3b05db4e758c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019daab6-77db-7a7d-ae88-7847d4929eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019daab6-77db-7a7d-ae88-7847d4929eb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019daab6-a14f-762e-8724-62cbb3b1d38b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019daab6-a14f-762e-8724-62cbb3b1d38b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019daab6-a14f-7511-8f21-fc1f4191bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019daab6-a14f-7511-8f21-fc1f4191bc4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_019daab6-a14f-74cb-993c-a4bc9aa590ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_019daab6-a14f-74cb-993c-a4bc9aa590ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019daab6-a14f-791f-9a52-a1d782323e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019daab6-a14f-791f-9a52-a1d782323e2a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019daab6-a14f-7114-918f-64f716109ace" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019daab6-a14f-7114-918f-64f716109ace" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_019daab6-e2f8-7853-9ec7-52e614d50961" xlink:href="bcax-20260331.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_019daab6-e2f8-7853-9ec7-52e614d50961" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_019daab6-e2f8-76e7-bcbc-65187b419350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_019daab6-e2f8-76e7-bcbc-65187b419350" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-785f-a85f-bb67546f585a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-78de-bf50-4eaaf16da74b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-785f-a85f-bb67546f585a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-78de-bf50-4eaaf16da74b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019cf6c2-c34b-74e9-b861-29fc1ddf82a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-78de-bf50-4eaaf16da74b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019cf6c2-c34b-74e9-b861-29fc1ddf82a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cf6c2-c34b-74e9-b861-29fc1ddf82a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cf6c2-c34b-74e9-b861-29fc1ddf82a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cf6c2-c34b-74e9-b861-29fc1ddf82a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cf6c2-c34b-780d-a988-57e6ccfe7b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cf6c2-c34b-74e9-b861-29fc1ddf82a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cf6c2-c34b-780d-a988-57e6ccfe7b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cf6c2-c34b-72f0-b636-189058f3a677" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cf6c2-c34b-780d-a988-57e6ccfe7b6b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cf6c2-c34b-72f0-b636-189058f3a677" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cf6c2-c34b-7b02-ab73-afa5214d08e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cf6c2-c34b-780d-a988-57e6ccfe7b6b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cf6c2-c34b-7b02-ab73-afa5214d08e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cf6c2-c34b-794f-bfa6-383181a9fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-785f-a85f-bb67546f585a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cf6c2-c34b-794f-bfa6-383181a9fd07" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-71aa-8823-93985b3e476f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-71aa-8823-93985b3e476f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cf6c2-c34b-787c-ae58-9e8c36b776f8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-71aa-8823-93985b3e476f" xlink:to="loc_srt_RangeAxis_019cf6c2-c34b-787c-ae58-9e8c36b776f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cf6c2-c34b-787c-ae58-9e8c36b776f8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019cf6c2-c34b-787c-ae58-9e8c36b776f8" xlink:to="loc_srt_RangeMember_019cf6c2-c34b-787c-ae58-9e8c36b776f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cf6c2-c34b-78fc-b968-002c45b0e504" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019cf6c2-c34b-787c-ae58-9e8c36b776f8" xlink:to="loc_srt_RangeMember_019cf6c2-c34b-78fc-b968-002c45b0e504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019cf6c2-c34b-7d02-b14f-2f576c74df88" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019cf6c2-c34b-78fc-b968-002c45b0e504" xlink:to="loc_srt_MinimumMember_019cf6c2-c34b-7d02-b14f-2f576c74df88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019cf6c2-c34b-7700-889c-4053400cf3f4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019cf6c2-c34b-78fc-b968-002c45b0e504" xlink:to="loc_srt_MaximumMember_019cf6c2-c34b-7700-889c-4053400cf3f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019cf6c2-c34b-7963-b827-2b52c24ab835" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019cf6c2-c34b-7963-b827-2b52c24ab835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019cf6c2-c34b-783e-9741-2f9bf01d5405" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019cf6c2-c34b-783e-9741-2f9bf01d5405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019cf6c2-c34b-72fe-9d17-8568cd9b40cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019cf6c2-c34b-72fe-9d17-8568cd9b40cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_019cf6c2-c34b-745c-9d45-45a7deaeb425" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_019cf6c2-c34b-745c-9d45-45a7deaeb425" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice_019cf6c2-c34b-7c48-87c6-c420ceaf76a3" xlink:href="bcax-20260331.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice_019cf6c2-c34b-7c48-87c6-c420ceaf76a3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SignificantAgreementsRelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34b-76e7-afbe-39a79fddeb65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34b-76e7-afbe-39a79fddeb65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019dc397-7d79-7752-b9c5-dfc80136bede" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34b-76e7-afbe-39a79fddeb65" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019dc397-7d79-7752-b9c5-dfc80136bede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7752-b9c5-dfc80136bede_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019dc397-7d79-7752-b9c5-dfc80136bede" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7752-b9c5-dfc80136bede_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7fd1-97a5-f7c5fb7cade2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019dc397-7d79-7752-b9c5-dfc80136bede" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7fd1-97a5-f7c5fb7cade2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterServicesAgreementMember_019dc397-7d79-7770-8a8b-b1a4365b63dd" xlink:href="bcax-20260331.xsd#bcax_MasterServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7fd1-97a5-f7c5fb7cade2" xlink:to="loc_bcax_MasterServicesAgreementMember_019dc397-7d79-7770-8a8b-b1a4365b63dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BBLAgreementsMember_019dc397-7d79-7597-8109-15a6261e37bb" xlink:href="bcax-20260331.xsd#bcax_BBLAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7fd1-97a5-f7c5fb7cade2" xlink:to="loc_bcax_BBLAgreementsMember_019dc397-7d79-7597-8109-15a6261e37bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementsMember_019dc397-7d79-7432-a81d-cae1c9980540" xlink:href="bcax-20260331.xsd#bcax_SyngeneAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7fd1-97a5-f7c5fb7cade2" xlink:to="loc_bcax_SyngeneAgreementsMember_019dc397-7d79-7432-a81d-cae1c9980540" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019dc397-7d79-70cf-b7b7-dd56e5040c08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34b-76e7-afbe-39a79fddeb65" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019dc397-7d79-70cf-b7b7-dd56e5040c08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019dc397-7d79-70cf-b7b7-dd56e5040c08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019dc397-7d79-70cf-b7b7-dd56e5040c08" xlink:to="loc_us-gaap_RelatedPartyDomain_019dc397-7d79-70cf-b7b7-dd56e5040c08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019dc397-7d79-70f3-a550-0facdb89dd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019dc397-7d79-70cf-b7b7-dd56e5040c08" xlink:to="loc_us-gaap_RelatedPartyDomain_019dc397-7d79-70f3-a550-0facdb89dd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019dc397-7d79-7690-a93f-144618b2becf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019dc397-7d79-70f3-a550-0facdb89dd0d" xlink:to="loc_us-gaap_RelatedPartyMember_019dc397-7d79-7690-a93f-144618b2becf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019dc397-7d79-7cd5-8ddf-cfe111f91e51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019dc397-7d79-7cd5-8ddf-cfe111f91e51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019dc397-7d79-7390-8007-5742e6855725" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019dc397-7d79-7390-8007-5742e6855725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019dc397-7d79-7978-8586-bca5f81858e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:to="loc_us-gaap_LiabilitiesCurrent_019dc397-7d79-7978-8586-bca5f81858e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019dc397-7d79-72b0-b2ed-57393102a2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:to="loc_us-gaap_AccountsPayableCurrent_019dc397-7d79-72b0-b2ed-57393102a2f5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreementsDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SignificantAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/SignificantAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cf6c2-c3eb-713b-a253-422f4f01389e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cf6c2-c3eb-713b-a253-422f4f01389e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019daaaa-ffd0-7211-a250-41bb342b65e2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cf6c2-c3eb-713b-a253-422f4f01389e" xlink:to="loc_srt_CounterpartyNameAxis_019daaaa-ffd0-7211-a250-41bb342b65e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019daaaa-ffd0-7211-a250-41bb342b65e2_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019daaaa-ffd0-7211-a250-41bb342b65e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019daaaa-ffd0-7211-a250-41bb342b65e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019daaaa-ffd0-7c92-b600-650fb8d26359" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019daaaa-ffd0-7211-a250-41bb342b65e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019daaaa-ffd0-7c92-b600-650fb8d26359" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IQVIARDSIncMember_019daaaa-ffd0-7079-955e-84686a2f1f85" xlink:href="bcax-20260331.xsd#bcax_IQVIARDSIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019daaaa-ffd0-7c92-b600-650fb8d26359" xlink:to="loc_bcax_IQVIARDSIncMember_019daaaa-ffd0-7079-955e-84686a2f1f85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_019daaaa-ffd0-7166-8764-46bf81beac6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cf6c2-c3eb-713b-a253-422f4f01389e" xlink:to="loc_us-gaap_OtherCommitmentsAxis_019daaaa-ffd0-7166-8764-46bf81beac6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-7166-8764-46bf81beac6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_019daaaa-ffd0-7166-8764-46bf81beac6c" xlink:to="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-7166-8764-46bf81beac6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_019daaaa-ffd0-7166-8764-46bf81beac6c" xlink:to="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementMember_019daaaa-ffd0-74a1-9e3e-95ae329cfe51" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementMember_019daaaa-ffd0-74a1-9e3e-95ae329cfe51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_019daaaa-ffd0-7072-a371-d3d180053bbf" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementRefundableDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_019daaaa-ffd0-7072-a371-d3d180053bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_019daaaa-ffd0-7dcf-b678-47bb08416525" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_019daaaa-ffd0-7dcf-b678-47bb08416525" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_019daaaa-ffd0-7a39-9f4d-44aebc4c8363" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_019daaaa-ffd0-7a39-9f4d-44aebc4c8363" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember_019daaab-21ac-7248-8e99-cf65e9499d95" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember_019daaab-21ac-7248-8e99-cf65e9499d95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember_019daaab-21ac-7ece-abf8-759d32165d7f" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember_019daaab-21ac-7ece-abf8-759d32165d7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember_019daaab-21ac-738d-88a7-7a55c6fa3449" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember_019daaab-21ac-738d-88a7-7a55c6fa3449" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_019daaaa-ffd0-7edf-a5b2-0f82d0e55a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_us-gaap_OtherCommitment_019daaaa-ffd0-7edf-a5b2-0f82d0e55a2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount_019daaaa-ffd0-70d3-a215-ca00d699d2fe" xlink:href="bcax-20260331.xsd#bcax_OtherCommitmentLiabilityRefundableDepositAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount_019daaaa-ffd0-70d3-a215-ca00d699d2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OtherCommitmentPercentage_019daaab-21ac-7d2c-8b28-c23999f81225" xlink:href="bcax-20260331.xsd#bcax_OtherCommitmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_bcax_OtherCommitmentPercentage_019daaab-21ac-7d2c-8b28-c23999f81225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019daaab-21ac-75b4-ac68-309bd5721afc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_us-gaap_OperatingExpenses_019daaab-21ac-75b4-ac68-309bd5721afc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PaymentsForOtherCommitments_019daaab-21ac-7bde-9b4b-6a48d71302ea" xlink:href="bcax-20260331.xsd#bcax_PaymentsForOtherCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_bcax_PaymentsForOtherCommitments_019daaab-21ac-7bde-9b4b-6a48d71302ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019daaab-21ac-7dfc-936f-a3098266c224" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_us-gaap_AccountsPayableCurrent_019daaab-21ac-7dfc-936f-a3098266c224" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019daaab-21ac-7ecf-90db-ed7a315a53a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019daaab-21ac-7ecf-90db-ed7a315a53a7" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cf6c2-c3eb-7fb9-b04d-f827c01e8b34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cf6c2-c3eb-7fb9-b04d-f827c01e8b34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019cf6c2-c3eb-7680-8117-f045aaf34a58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cf6c2-c3eb-7fb9-b04d-f827c01e8b34" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019cf6c2-c3eb-7680-8117-f045aaf34a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cf6c2-c3eb-7680-8117-f045aaf34a58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cf6c2-c3eb-7680-8117-f045aaf34a58" xlink:to="loc_us-gaap_SegmentDomain_019cf6c2-c3eb-7680-8117-f045aaf34a58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cf6c2-c3eb-7942-a9db-68ffe8866045" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cf6c2-c3eb-7680-8117-f045aaf34a58" xlink:to="loc_us-gaap_SegmentDomain_019cf6c2-c3eb-7942-a9db-68ffe8866045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ReportableSegmentMember_019cf6c2-c3eb-76f5-bfa3-466e10ffdc5b" xlink:href="bcax-20260331.xsd#bcax_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019cf6c2-c3eb-7942-a9db-68ffe8866045" xlink:to="loc_bcax_ReportableSegmentMember_019cf6c2-c3eb-76f5-bfa3-466e10ffdc5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ClinicalOperationsAndDevelopmentExpense_019cf6c2-c3eb-7cb3-b771-6310ab1d2e30" xlink:href="bcax-20260331.xsd#bcax_ClinicalOperationsAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_ClinicalOperationsAndDevelopmentExpense_019cf6c2-c3eb-7cb3-b771-6310ab1d2e30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ManufacturingAndProcessDevelopmentExpense_019cf6c2-c3eb-7ed1-9de0-bb4ae967d55a" xlink:href="bcax-20260331.xsd#bcax_ManufacturingAndProcessDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_ManufacturingAndProcessDevelopmentExpense_019cf6c2-c3eb-7ed1-9de0-bb4ae967d55a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense_019cf6c2-c3eb-7155-8e1d-308c349766bc" xlink:href="bcax-20260331.xsd#bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense_019cf6c2-c3eb-7155-8e1d-308c349766bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cf6c2-c3eb-7c4a-968e-449776ce77a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cf6c2-c3eb-7c4a-968e-449776ce77a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3eb-78b1-957f-ac255555a1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3eb-78b1-957f-ac255555a1b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation_019cf6c2-c3eb-7290-b385-5e6685ad3d5f" xlink:href="bcax-20260331.xsd#bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation_019cf6c2-c3eb-7290-b385-5e6685ad3d5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_019cf6c2-c3eb-7705-8971-cd2c6898200f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_ProfessionalFees_019cf6c2-c3eb-7705-8971-cd2c6898200f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FacilityITOfficeAndOtherExpense_019cf6c2-c3eb-77d8-83b2-3dfe1082c76d" xlink:href="bcax-20260331.xsd#bcax_FacilityITOfficeAndOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_FacilityITOfficeAndOtherExpense_019cf6c2-c3eb-77d8-83b2-3dfe1082c76d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c3eb-785e-9f08-bf6f9cea45da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c3eb-785e-9f08-bf6f9cea45da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cf6c2-c3eb-740b-8017-95a99f7fa932" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_OperatingExpenses_019cf6c2-c3eb-740b-8017-95a99f7fa932" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c3eb-7190-9465-b01c3e3f5a69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c3eb-7190-9465-b01c3e3f5a69" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019cf6c2-c3eb-7d19-b493-6de5088399d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019cf6c2-c3eb-7d19-b493-6de5088399d9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c3eb-7735-9b6e-7fa786b0abb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c3eb-7735-9b6e-7fa786b0abb5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c3eb-7d07-8f68-5f41bb3d9c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c3eb-7d07-8f68-5f41bb3d9c4d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncomeTaxExpenseBenefitIncludingAdjustments_019cf6c2-c3eb-7851-bd1d-f61c3207d642" xlink:href="bcax-20260331.xsd#bcax_IncomeTaxExpenseBenefitIncludingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_IncomeTaxExpenseBenefitIncludingAdjustments_019cf6c2-c3eb-7851-bd1d-f61c3207d642" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c3eb-732b-86c7-036905566ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_NetIncomeLoss_019cf6c2-c3eb-732b-86c7-036905566ae7" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ClaireMazumdanMember_019df306-18aa-7b49-8f4a-609b0a68a263" xlink:href="bcax-20260331.xsd#bcax_ClaireMazumdanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcax_ClaireMazumdanMember_019df306-18aa-7b49-8f4a-609b0a68a263" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_RyanCohlheppMember_019df30b-06c6-7242-a3d7-7c04bd41cc10" xlink:href="bcax-20260331.xsd#bcax_RyanCohlheppMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcax_RyanCohlheppMember_019df30b-06c6-7242-a3d7-7c04bd41cc10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IvanHyepMember_019df30b-4775-7c4c-bcc2-a537570b29ed" xlink:href="bcax-20260331.xsd#bcax_IvanHyepMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcax_IvanHyepMember_019df30b-4775-7c4c-bcc2-a537570b29ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LaraMeisnerMember_019df30b-9101-774a-bd40-e3cb11ca1bfc" xlink:href="bcax-20260331.xsd#bcax_LaraMeisnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcax_LaraMeisnerMember_019df30b-9101-774a-bd40-e3cb11ca1bfc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_DavidRabenMember_019df30c-3cb9-7562-b538-2f782b9a6a69" xlink:href="bcax-20260331.xsd#bcax_DavidRabenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcax_DavidRabenMember_019df30c-3cb9-7562-b538-2f782b9a6a69" xlink:type="arc" order="6"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>bcax-20260331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cf6c2-c28f-747f-9e58-111c1e1d135b,g:94c43f23-f2a3-4ea7-b3a9-326e15be7355-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_RangeMember_019cf6c2-c3eb-7be4-ac26-7b3c2e1d8e13_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_PaymentsForOtherCommitments_019cf6c2-c47b-7280-bd3c-c086c3ca86f7_terseLabel_en-US" xlink:label="lab_bcax_PaymentsForOtherCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount paid</link:label>
    <link:label id="lab_bcax_PaymentsForOtherCommitments_label_en-US" xlink:label="lab_bcax_PaymentsForOtherCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Other Commitments</link:label>
    <link:label id="lab_bcax_PaymentsForOtherCommitments_documentation_en-US" xlink:label="lab_bcax_PaymentsForOtherCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Other Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PaymentsForOtherCommitments" xlink:href="bcax-20260331.xsd#bcax_PaymentsForOtherCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_PaymentsForOtherCommitments" xlink:to="lab_bcax_PaymentsForOtherCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019cf6c2-c3eb-79f3-bcb6-4807076c7a65_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-For-Sale Investments by Type of Security</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_019cf6c2-c3ec-7a24-9248-5a4ded02d5b9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019cf6c2-c3ec-724f-8d61-ec1075dcb977_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_019cf6c2-c3ec-787d-aee4-bd9e7d477a3d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ClaireMazumdanMember_label_en-US" xlink:label="lab_bcax_ClaireMazumdanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Claire Mazumdan [Member]</link:label>
    <link:label id="lab_bcax_ClaireMazumdanMember_documentation_en-US" xlink:label="lab_bcax_ClaireMazumdanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Claire Mazumdan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ClaireMazumdanMember" xlink:href="bcax-20260331.xsd#bcax_ClaireMazumdanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ClaireMazumdanMember" xlink:to="lab_bcax_ClaireMazumdanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_019cf6c2-c3eb-7150-8812-7fec2b735c48_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019cf6c2-c3eb-7ec3-a2c2-8e006ad59744_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements and Accounting Pronouncements Issued and Not Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_019cf6c2-c3eb-7feb-a756-5235f053b6cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Assets Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_019cf6c2-c3eb-7b20-b62a-fa53f828d578_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c3eb-7449-b7dd-4ef13f9e2f4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cf6c2-c3ec-76dc-9cf0-de75da652d2e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019cf6c2-c3ec-7043-8bbb-737144568b92_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per share, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019cf6c2-c47b-7472-80cc-aefbdc1253df_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Agreements &#8211; Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019cf6c2-c47b-7284-a28a-67d69c693793_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019cf6c2-c3eb-74e8-b7fb-9cf891ea345d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c3ec-7702-ad83-caf46e6a38e4_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury Bills</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c3eb-7d39-8957-efe2a98c8a20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019cf6c2-c3ec-7309-bc4c-873b77571bd2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_019cf6c2-c3eb-7b1a-b285-e0030d51b3a9_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_019cf6c2-c3ec-7c40-83d7-5c7c416e7aed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019cf6c2-c3eb-7e2c-b988-4a3ad4cde38c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_019cf6c2-c3ec-77fe-b2f1-9af560c7ad7c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_019cf6c2-c3eb-7e01-aa99-8c019fbb9949_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cf6c2-c3ec-753b-89e5-99413c61fd71_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019cf6c2-c3eb-7abe-a696-3e00bafa079d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019cf6c2-c3eb-7803-ba2b-d616904452b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019cf6c2-c3eb-755c-908b-cd00d15b17c9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019cf6c2-c3eb-7049-8dc3-64b31dba9e8d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_019cf6c2-c3eb-79b4-a8b0-950b5ff1c821_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition_019cf6c2-c3eb-7ddc-91d3-bab95a41f11a_terseLabel_en-US" xlink:label="lab_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities held in unrealized loss position</link:label>
    <link:label id="lab_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition_label_en-US" xlink:label="lab_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Number Of Securities In Unrealized Loss Position</link:label>
    <link:label id="lab_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition_documentation_en-US" xlink:label="lab_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Number Of Securities In Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition" xlink:href="bcax-20260331.xsd#bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition" xlink:to="lab_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019cf6c2-c3eb-76d8-88ad-bff91d28d018_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, and accompanying pre-funded warrants, net of offering cost (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_019cf6c2-c3ec-783d-a4dd-2c5b06412443_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019cf6c2-c3eb-71da-b58b-4abb4b8f7c94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019cf6c2-c3ec-7493-99a2-93d87b64439d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_VestingOfEarlyExerciseStockOptions_019cf6c2-c3eb-7b7d-9837-6cbdaeb221a2_terseLabel_en-US" xlink:label="lab_bcax_VestingOfEarlyExerciseStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of early exercise stock options</link:label>
    <link:label id="lab_bcax_VestingOfEarlyExerciseStockOptions_label_en-US" xlink:label="lab_bcax_VestingOfEarlyExerciseStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting of Early Exercise Stock Options</link:label>
    <link:label id="lab_bcax_VestingOfEarlyExerciseStockOptions_documentation_en-US" xlink:label="lab_bcax_VestingOfEarlyExerciseStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting of Early Exercise Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_VestingOfEarlyExerciseStockOptions" xlink:href="bcax-20260331.xsd#bcax_VestingOfEarlyExerciseStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_VestingOfEarlyExerciseStockOptions" xlink:to="lab_bcax_VestingOfEarlyExerciseStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cf6c2-c3eb-7364-b337-99757c760612_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019cf6c2-c3ec-7374-8a05-2bca6d833de4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c3eb-79c0-9ec5-fb28c9643b09_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cf6c2-c47b-7def-b3ff-243b7b862e0e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019cf6c2-c3eb-7647-9f5e-24c5565ad9dc_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019cf6c2-c3eb-7f9c-a78a-9eac81f4c7b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, Exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_019cf6c2-c3ec-799e-89ed-6d19fba1d2e0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019cf6c2-c3ec-74d7-9ec0-381ce50c4495_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c3eb-7afe-88a9-79ca795a634f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_019daa57-bd47-7d1e-9049-d2ac6cf93739_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_A2026InducementPlanMember_019daa9e-7838-70b9-937d-8159a47c4887_terseLabel_en-US" xlink:label="lab_bcax_A2026InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026 Inducement Plan</link:label>
    <link:label id="lab_bcax_A2026InducementPlanMember_label_en-US" xlink:label="lab_bcax_A2026InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026 Inducement Plan [Member]</link:label>
    <link:label id="lab_bcax_A2026InducementPlanMember_documentation_en-US" xlink:label="lab_bcax_A2026InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2026 Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2026InducementPlanMember" xlink:href="bcax-20260331.xsd#bcax_A2026InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_A2026InducementPlanMember" xlink:to="lab_bcax_A2026InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c3eb-7c98-80cc-ee992226db3e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c3eb-78b0-bbba-89ce5311cd14_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income before losses</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019cf6c2-c47b-7446-8e82-4ce2f323ce11_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_019cf6c2-c3eb-7ef7-9c35-76656be5825e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDepositLiability_019cf6c2-c3ec-7467-a3f3-814031793397_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDepositLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDepositLiability_label_en-US" xlink:label="lab_us-gaap_SecurityDepositLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDepositLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDepositLiability" xlink:to="lab_us-gaap_SecurityDepositLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019cf6c2-c3eb-7414-869a-35ad07a281fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense Recognized in Statements of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_019cf6c2-c3ec-7afa-9ecf-2fb1de683f18_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability &#8211; current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_019cf6c2-c3eb-79d1-81a0-880f88eda2b0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019cf6c2-c3eb-7d07-bba3-139565d768e8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_019cf6c2-c3eb-7452-a683-f3bb2c45799f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019cf6c2-c3eb-7193-b6d0-2f525abcc43e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019cf6c2-c3eb-7c59-8074-f97ad6e9ca44_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019cf6c2-c3eb-7bb4-b176-84169778944c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019cf6c2-c3eb-7e11-9a2e-d0faa4a76014_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_019cf6c2-c3eb-7eb8-ba83-9e8a22571374_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019cf6c2-c3eb-7432-bed8-64809980625e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c3eb-7602-9ccb-7e50899b2e4d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_LaraMeisnerMember_label_en-US" xlink:label="lab_bcax_LaraMeisnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lara Meisner [Member]</link:label>
    <link:label id="lab_bcax_LaraMeisnerMember_documentation_en-US" xlink:label="lab_bcax_LaraMeisnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lara Meisner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LaraMeisnerMember" xlink:href="bcax-20260331.xsd#bcax_LaraMeisnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_LaraMeisnerMember" xlink:to="lab_bcax_LaraMeisnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_019cf6c2-c3eb-73e0-a065-f86b5c0ca0ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019cf6c2-c3eb-7c16-adca-a5f72cca9ad5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019cf6c2-c3ec-730b-b5f5-f199c5d66bdc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember_019cf6c2-c3eb-7200-ba3f-550fc1db1833_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement Incremental Return</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember_label_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement Incremental Return [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement Incremental Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember" xlink:to="lab_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cf6c2-c3ec-7c5b-853d-781246ea53ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cf6c2-c3ec-7739-b33b-7d599caa1e20_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_019cf6c2-c3eb-7bb8-941b-e32f78804d4a_terseLabel_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registration payment arrangement, maximum potential consideration</link:label>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_label_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Registration Payment Arrangement, Maximum Potential Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:to="lab_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_019cf6c2-c3eb-7364-afa5-c390d574fd0c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_019cf6c2-c3ec-7e71-b3f2-662f55944f9d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019cf6c2-c3eb-71d1-9797-108c2196c475_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019cf6c2-c3eb-7a8b-81d9-8918f70c0719_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019cf6c2-c3eb-7a0e-93e8-53988f14e6d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_019cf6c2-c3eb-7674-866c-2e802cb3a8d0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_019cf6c2-c3eb-77dd-b194-91bfb86bf833_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_019cf6c2-c3eb-7113-aed5-d8a6b6ed6854_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_019cf6c2-c3eb-7fc5-8aaa-105795c59d11_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent_019cf6c2-c3ec-7bfa-9c25-7b09bc79cf29_terseLabel_en-US" xlink:label="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="bcax-20260331.xsd#bcax_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_bcax_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_019daa9d-5c8b-7087-ac7a-3af52bfea5a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c3eb-7993-9430-b324c5265aea_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019cf6c2-c3eb-78c8-9ab8-e99e19396f97_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019cf6c2-c3ec-7d85-a0d0-a314234727b2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cf6c2-c3ec-7396-9f08-b48fc5a4f191_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019cf6c2-c3eb-7dba-b71e-1aeb5ab98ba8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019cf6c2-c3eb-75c8-bff7-39ad7ad7e6f0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cf6c2-c3eb-7349-a7d8-b3bccce3dac0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cf6c2-c3eb-76f0-820a-495827304403_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019cf6c2-c3ec-7aa5-8a06-93957566b90f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019cf6c2-c3ec-7410-abd1-af427cf4a447_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12 Months or Longer, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_019cf6c2-c3ec-727b-b00f-3598065aa6f1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementMember_019cf6c2-c47b-7553-933f-0b95ad5b31a9_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementMember_label_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementMember" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalContractServicesAgreementMember" xlink:to="lab_bcax_MasterClinicalContractServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_019cf6c2-c3eb-7c2a-9a61-caad95efc067_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cf6c2-c3ec-7851-8e07-0b47ae89599f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_019cf6c2-c3eb-7e56-b76e-42a3c46f7779_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price, Exercisable and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c3ec-7165-a5f0-64fa99ae5532_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cf6c2-c3eb-7ddd-80d2-b0f2293c56ec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_019cf6c2-c3eb-7b00-928b-1a59333d2102_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019cf6c2-c3ec-7979-802d-701903ba8db6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_DavidRabenMember_label_en-US" xlink:label="lab_bcax_DavidRabenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">David Raben [Member]</link:label>
    <link:label id="lab_bcax_DavidRabenMember_documentation_en-US" xlink:label="lab_bcax_DavidRabenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">David Raben</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_DavidRabenMember" xlink:href="bcax-20260331.xsd#bcax_DavidRabenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_DavidRabenMember" xlink:to="lab_bcax_DavidRabenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTextBlock_019cf6c2-c3ec-7bd6-b7bc-ca9aa6c18357_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c3eb-7cb3-8b36-a22b9cc25c36_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c3eb-7c1b-bbfd-b791abfa7dc0_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c3eb-76c6-84b6-7493fad0d64b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c3eb-7cc5-a981-e0ef6ba9b828_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c3eb-7cd6-a27b-c1a4e747ad98_totalLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019cf6c2-c3ec-75f3-a249-1ad47e0cf085_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c3eb-7c37-9e81-b827d7c756cd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_019cf6c2-c47b-74a6-aebc-e4b468141cff_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_019cf6c2-c3eb-7fda-a9c7-1fcaa9f19442_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_019cf6c2-c3eb-72cf-a5ed-5ce9e28703ae_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_019cf6c2-c3eb-756d-999e-974a6ab1b30e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_019cf6c2-c3eb-79ec-9b5a-ffce2c6d9e01_terseLabel_en-US" xlink:label="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:label id="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_documentation_en-US" xlink:label="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="bcax-20260331.xsd#bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019cf6c2-c3ec-7d94-b9e4-690e9522ff72_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_019cf6c2-c3eb-7fe2-a3b1-0e1712291d5f_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_019cf6c2-c3eb-7427-a9fa-fe482c7f971c_terseLabel_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of increase in future issuance reserved share</link:label>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_label_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Share Authorization Increase, Percentage</link:label>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_documentation_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Share Authorization Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:href="bcax-20260331.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:to="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_019cf6c2-c3eb-7f3b-8482-ec4cb662a502_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business, Organization, and Liquidity</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_019cf6c2-c47b-7ca3-8840-f5c5eaedd537_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_019cf6c2-c3ec-793f-b487-c7e5da142b76_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_019cf6c2-c3eb-7eda-adda-331a62878fa0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cf6c2-c3ec-7320-b99d-5c507cbafb75_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019cf6c2-c3eb-7142-9113-71521dd53ae1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019cf6c2-c3eb-7efd-8798-4e936d497c83_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_IQVIARDSIncMember_019cf6c2-c3eb-7296-937d-45b99f32e52e_terseLabel_en-US" xlink:label="lab_bcax_IQVIARDSIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IQVIA RDS Inc</link:label>
    <link:label id="lab_bcax_IQVIARDSIncMember_label_en-US" xlink:label="lab_bcax_IQVIARDSIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IQVIA RDS Inc [Member]</link:label>
    <link:label id="lab_bcax_IQVIARDSIncMember_documentation_en-US" xlink:label="lab_bcax_IQVIARDSIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IQVIA RDS Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IQVIARDSIncMember" xlink:href="bcax-20260331.xsd#bcax_IQVIARDSIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_IQVIARDSIncMember" xlink:to="lab_bcax_IQVIARDSIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_019daa65-c085-7955-a599-536eef07e3b0_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cf6c2-c3eb-75bd-9ee1-8c036e4cf128_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_SyngeneAgreementsMember_019cf6c2-c3ec-7a7d-883d-43ea8e25d0a0_terseLabel_en-US" xlink:label="lab_bcax_SyngeneAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Syngene Agreements</link:label>
    <link:label id="lab_bcax_SyngeneAgreementsMember_label_en-US" xlink:label="lab_bcax_SyngeneAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Syngene Agreements [Member]</link:label>
    <link:label id="lab_bcax_SyngeneAgreementsMember_documentation_en-US" xlink:label="lab_bcax_SyngeneAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Syngene Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementsMember" xlink:href="bcax-20260331.xsd#bcax_SyngeneAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_SyngeneAgreementsMember" xlink:to="lab_bcax_SyngeneAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_019cf6c2-c3eb-7901-b6de-dd787b96f288_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019cf6c2-c3eb-74f3-9ff0-4d484728172a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019cf6c2-c3eb-72ed-b2cd-f6ae0c88af80_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_019daa31-cf0c-79ad-854e-809d6572e916_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c3eb-763e-bc50-5b4bccce18eb_terseLabel_en-US" xlink:label="lab_bcax_InvestmentCategorizationAxisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Categorization Axis [Domain]</link:label>
    <link:label id="lab_bcax_InvestmentCategorizationAxisDomain_label_en-US" xlink:label="lab_bcax_InvestmentCategorizationAxisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Categorization Axis [Domain]</link:label>
    <link:label id="lab_bcax_InvestmentCategorizationAxisDomain_documentation_en-US" xlink:label="lab_bcax_InvestmentCategorizationAxisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Categorization Axis [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentCategorizationAxisDomain" xlink:href="bcax-20260331.xsd#bcax_InvestmentCategorizationAxisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_InvestmentCategorizationAxisDomain" xlink:to="lab_bcax_InvestmentCategorizationAxisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_019cf6c2-c3eb-7444-8728-5b6e1bcb290d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution, plan cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_019cf6c2-c3eb-77cd-bcfe-029d27460baf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cf6c2-c3eb-7606-b8b3-f6d9f200218a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019cf6c2-c3eb-717a-b98c-9549092455a5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019cf6c2-c3eb-74a8-ada3-e90c763b1e8a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_019cf6c2-c3ec-707a-9e9d-60bd92b0f7a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset &#8211; operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019cf6c2-c3eb-7142-affb-15133e3531d8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_019cf6c2-c47b-71a9-a56e-73152a65c360_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_019cf6c2-c3eb-723f-91bd-308d811a63d7_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Services Agreement, Investigator Grant Payment</link:label>
    <link:label id="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_label_en-US" xlink:label="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Services Agreement, Investigator Grant Payment [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Services Agreement, Investigator Grant Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:to="lab_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019cf6c2-c3eb-7de8-bd4a-4e5b365720cb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized share-based compensation cost, period of recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cf6c2-c3eb-7626-8775-9990b51c8a30_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cf6c2-c3eb-7e3c-a533-31b58acfc5e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019cf6c2-c3eb-706f-a0bd-034e462b7d39_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_019cf6c2-c3eb-77f1-9401-5f62eb1b04a8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019cf6c2-c3ec-79fb-9730-6bdd27b80b95_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cf6c2-c3eb-7ebc-8d17-5276f5d1a24f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c3ec-7528-802f-18ca4f3271b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice_019cf6c2-c47b-7716-84c6-112287a3de65_terseLabel_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock (in usd per share)</link:label>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice_label_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions During Period, Exercise Price</link:label>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice_documentation_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions During Period, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" xlink:href="bcax-20260331.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" xlink:to="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cf6c2-c3eb-75b9-9ac7-02904cfacae8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_019cf6c2-c3eb-7034-a05b-37270956a9d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019cf6c2-c3eb-7b90-b077-93febcbaddbd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_SaleOfStockCommissionFeePercentage_019daa92-63a7-7dc7-9155-52ca63d46589_terseLabel_en-US" xlink:label="lab_bcax_SaleOfStockCommissionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, commission fee percentage</link:label>
    <link:label id="lab_bcax_SaleOfStockCommissionFeePercentage_label_en-US" xlink:label="lab_bcax_SaleOfStockCommissionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Commission Fee, Percentage</link:label>
    <link:label id="lab_bcax_SaleOfStockCommissionFeePercentage_documentation_en-US" xlink:label="lab_bcax_SaleOfStockCommissionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Commission Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SaleOfStockCommissionFeePercentage" xlink:href="bcax-20260331.xsd#bcax_SaleOfStockCommissionFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_SaleOfStockCommissionFeePercentage" xlink:to="lab_bcax_SaleOfStockCommissionFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019daa57-bd47-7f0e-bfd6-f06ab9076d8a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cf6c2-c3eb-7f7d-b2c1-166c0055d5d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_019cf6c2-c3eb-7b18-adf5-c854024638f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019daa57-bd47-76e5-91fd-eb092eeaddba_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cf6c2-c3ec-7326-ad0f-fa84e22fac6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019cf6c2-c3ec-7025-939c-5d95b3b2ba9c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_019cf6c2-c3ec-7cd4-bdde-ae5513362c82_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019cf6c2-c3ec-7416-9651-4f21cbb9d084_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember_019cf6c2-c3eb-7215-a22f-a084b1a9b247_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement Deposit For Pass Through Costs</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember_label_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement Deposit For Pass Through Costs [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement Deposit For Pass Through Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember" xlink:to="lab_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019cf6c2-c3eb-7a47-8c74-c41d78492e5d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019cf6c2-c3eb-7d22-82b6-36c7f7784b68_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_019cf6c2-c3ec-7b13-9133-2bc4be61fd4f_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_019daa57-bd47-70ea-b57b-efcafa248a01_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_019cf6c2-c3eb-7014-b6fe-a6531382db9f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_019cf6c2-c3eb-7a66-a0d7-b49bda317b84_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Refundable Deposit</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_label_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Refundable Deposit [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Refundable Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementRefundableDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:to="lab_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_019cf6c2-c3ec-724c-aa3c-93d1f5b49e00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_019cf6c2-c3eb-75db-a890-b718fbc40420_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019cf6c2-c3eb-7ab0-a10b-37e72e696712_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_019cf6c2-c3eb-784e-903d-48c88b316156_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3ec-72c6-92d3-3660b4b8f3ad_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3ec-7efc-8de0-c4b2b9f9a3f0_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cf6c2-c3eb-7064-becb-0cd65e8e2514_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_PreFundedWarrantsMember_019daa57-bd47-777a-b7f2-be8a46c17db7_terseLabel_en-US" xlink:label="lab_bcax_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_bcax_PreFundedWarrantsMember_label_en-US" xlink:label="lab_bcax_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_bcax_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_bcax_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PreFundedWarrantsMember" xlink:href="bcax-20260331.xsd#bcax_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_PreFundedWarrantsMember" xlink:to="lab_bcax_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_019cf6c2-c3ec-7936-a199-56358b604dd4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability &#8211; net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference_019df4af-c5c5-782b-937a-5a134c58840d_terseLabel_en-US" xlink:label="lab_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference in offering price from common stock (in usd per share)</link:label>
    <link:label id="lab_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference_label_en-US" xlink:label="lab_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Common Stock, Exercise Price of Warrants or Rights, Difference</link:label>
    <link:label id="lab_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference_documentation_en-US" xlink:label="lab_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Common Stock, Exercise Price of Warrants or Rights, Difference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference" xlink:href="bcax-20260331.xsd#bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference" xlink:to="lab_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019cf6c2-c3ec-7452-a52f-39fd6838e492_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019cf6c2-c3eb-79c6-afe8-8a70d939230b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_019cf6c2-c3eb-7821-885b-ad40da105b79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Exercisable and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c3eb-7df0-b09f-319c634e3f0c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_019cf6c2-c3eb-737b-9f83-2c6a44f096bb_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019cf6c2-c3ec-7c6b-b315-5f107bb62309_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_019dfef4-0ecb-71bc-85c9-2237ce163b19_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_019cf6c2-c3ec-7e94-b69b-57b437de6051_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_019daa6e-0d10-7c31-babb-5ca1432e5a62_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cf6c2-c3eb-7f69-aa45-0e88b8d1c868_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019cf6c2-c3eb-79e4-b746-c6dcfd030e93_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average &#8211; Remaining Contractual Life (years), Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c47b-7601-b921-7e5a413e5e3f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember_019cf6c2-c3eb-72e6-96fd-1006b8b636fe_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement Deposits For Services</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember_label_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement Deposits For Services [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement Deposits For Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember" xlink:to="lab_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_WarrantsPolicyPolicyTextBlock_019daa69-f5d3-7e6d-8afe-9087a536cbe6_terseLabel_en-US" xlink:label="lab_bcax_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_bcax_WarrantsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_bcax_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Policy [Policy Text Block]</link:label>
    <link:label id="lab_bcax_WarrantsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_bcax_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_WarrantsPolicyPolicyTextBlock" xlink:href="bcax-20260331.xsd#bcax_WarrantsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_WarrantsPolicyPolicyTextBlock" xlink:to="lab_bcax_WarrantsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019cf6c2-c3ec-79c0-af4c-6d951346c99a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_019cf6c2-c3ec-7cad-a7b8-33d66e9c1527_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cf6c2-c3eb-7bd8-9f6e-77c749d27377_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019cf6c2-c3eb-7f16-a5a4-f90b0148a84c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_019cf6c2-c3ec-7b77-b1ec-ca7c03c55d99_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_019cf6c2-c3ec-7d70-9488-5998476ef71f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial payment amount</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_019cf6c2-c3eb-7f63-8d4c-7345d54daa0a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_019cf6c2-c3eb-7860-b586-aab158f2eeb0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Agreements</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cf6c2-c3eb-7d60-b130-2bdf2e56e3b3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cf6c2-c3ec-7077-99cd-de640d8fe5bd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c3eb-7b7c-847d-e7545de6e4eb_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019cf6c2-c3eb-7f10-a476-690cf6662fd9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_019cf6c2-c3eb-744b-af79-5db8e133e555_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_019cf6c2-c3eb-7b5c-995b-35c396c060d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c3ec-747a-969d-710a42c9375e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019cf6c2-c3eb-7011-961f-5df3da4b20bd_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019daa57-bd47-71a7-9f53-ecd355019e95_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_019cf6c2-c3eb-7b5a-93f6-327de6ad781a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ClinicalOperationsAndDevelopmentExpense_019cf6c2-c3ec-71d8-906d-2ddd04887bd3_terseLabel_en-US" xlink:label="lab_bcax_ClinicalOperationsAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing and process development</link:label>
    <link:label id="lab_bcax_ClinicalOperationsAndDevelopmentExpense_label_en-US" xlink:label="lab_bcax_ClinicalOperationsAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Operations And Development Expense</link:label>
    <link:label id="lab_bcax_ClinicalOperationsAndDevelopmentExpense_documentation_en-US" xlink:label="lab_bcax_ClinicalOperationsAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Operations And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ClinicalOperationsAndDevelopmentExpense" xlink:href="bcax-20260331.xsd#bcax_ClinicalOperationsAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ClinicalOperationsAndDevelopmentExpense" xlink:to="lab_bcax_ClinicalOperationsAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_IncomeTaxExpenseBenefitIncludingAdjustments_019cf6c2-c3eb-703a-a2c9-7087220ebe97_negatedLabel_en-US" xlink:label="lab_bcax_IncomeTaxExpenseBenefitIncludingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_bcax_IncomeTaxExpenseBenefitIncludingAdjustments_label_en-US" xlink:label="lab_bcax_IncomeTaxExpenseBenefitIncludingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Including Adjustments</link:label>
    <link:label id="lab_bcax_IncomeTaxExpenseBenefitIncludingAdjustments_documentation_en-US" xlink:label="lab_bcax_IncomeTaxExpenseBenefitIncludingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Including Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncomeTaxExpenseBenefitIncludingAdjustments" xlink:href="bcax-20260331.xsd#bcax_IncomeTaxExpenseBenefitIncludingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_IncomeTaxExpenseBenefitIncludingAdjustments" xlink:to="lab_bcax_IncomeTaxExpenseBenefitIncludingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_019cf6c2-c47b-7e5b-bf15-7bd05b76fc95_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_019cf6c2-c3eb-735d-a881-a847ea56c74a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_019cf6c2-c3eb-794e-b016-c603b0a9d122_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value, 500,000,000 and 500,000,000 shares authorized; 65,547,037 and 56,600,724 shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_RyanCohlheppMember_label_en-US" xlink:label="lab_bcax_RyanCohlheppMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ryan Cohlhepp [Member]</link:label>
    <link:label id="lab_bcax_RyanCohlheppMember_documentation_en-US" xlink:label="lab_bcax_RyanCohlheppMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ryan Cohlhepp</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_RyanCohlheppMember" xlink:href="bcax-20260331.xsd#bcax_RyanCohlheppMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_RyanCohlheppMember" xlink:to="lab_bcax_RyanCohlheppMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019cf6c2-c3eb-7065-bcd8-453512ddaf1f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterServicesAgreementMember_019cf6c2-c3ec-7a2f-820d-3601edf31c67_terseLabel_en-US" xlink:label="lab_bcax_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Services Agreement</link:label>
    <link:label id="lab_bcax_MasterServicesAgreementMember_label_en-US" xlink:label="lab_bcax_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Services Agreement [Member]</link:label>
    <link:label id="lab_bcax_MasterServicesAgreementMember_documentation_en-US" xlink:label="lab_bcax_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterServicesAgreementMember" xlink:href="bcax-20260331.xsd#bcax_MasterServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterServicesAgreementMember" xlink:to="lab_bcax_MasterServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cf6c2-c3ec-777d-9a3b-10f1727a3cd9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount_019daaaa-ffd0-7557-bc5f-8609727617c0_terseLabel_en-US" xlink:label="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other commitment, liability, refundable deposit, amount</link:label>
    <link:label id="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount_label_en-US" xlink:label="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment, Liability, Refundable Deposit, Amount</link:label>
    <link:label id="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount_documentation_en-US" xlink:label="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Commitment, Liability, Refundable Deposit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:href="bcax-20260331.xsd#bcax_OtherCommitmentLiabilityRefundableDepositAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:to="lab_bcax_OtherCommitmentLiabilityRefundableDepositAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_019daa6a-db63-7d33-9ad3-fa1bd8e3c0c3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019cf6c2-c3ec-79b2-8deb-50d95e6b4e1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019cf6c2-c3eb-7913-b369-8e7b3671435d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_019cf6c2-c3ec-701b-8283-80e8b52418e3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019cf6c2-c3eb-7df8-9b59-0699ad8bf134_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019cf6c2-c3eb-77ef-9e6d-b00b0c9c1ca9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019cf6c2-c3eb-75d2-ba5e-91b5b5b9c0fe_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember_019cf6c2-c3eb-7e3c-9485-5cc16ef24518_terseLabel_en-US" xlink:label="lab_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities with original maturity of one to two years</link:label>
    <link:label id="lab_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember_label_en-US" xlink:label="lab_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments With Maturity Of One To Two Years [Member]</link:label>
    <link:label id="lab_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember_documentation_en-US" xlink:label="lab_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments With Maturity Of One To Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember" xlink:href="bcax-20260331.xsd#bcax_InvestmentsWithMaturityOfOneToTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember" xlink:to="lab_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_LesseeOperatingLeaseArea_019cf6c2-c3eb-7b1a-ad43-b1cb6a740ecc_terseLabel_en-US" xlink:label="lab_bcax_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of land (in square feet)</link:label>
    <link:label id="lab_bcax_LesseeOperatingLeaseArea_label_en-US" xlink:label="lab_bcax_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area</link:label>
    <link:label id="lab_bcax_LesseeOperatingLeaseArea_documentation_en-US" xlink:label="lab_bcax_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LesseeOperatingLeaseArea" xlink:href="bcax-20260331.xsd#bcax_LesseeOperatingLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_LesseeOperatingLeaseArea" xlink:to="lab_bcax_LesseeOperatingLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c3eb-7b0a-8a66-2069acc86912_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_019cf6c2-c3eb-73f5-9daf-630790af8cb6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_FacilityITOfficeAndOtherExpense_019cf6c2-c3eb-78d1-a10b-52ab15e6b790_terseLabel_en-US" xlink:label="lab_bcax_FacilityITOfficeAndOtherExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility costs, IT, office expense and other</link:label>
    <link:label id="lab_bcax_FacilityITOfficeAndOtherExpense_label_en-US" xlink:label="lab_bcax_FacilityITOfficeAndOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility, IT, Office And Other Expense</link:label>
    <link:label id="lab_bcax_FacilityITOfficeAndOtherExpense_documentation_en-US" xlink:label="lab_bcax_FacilityITOfficeAndOtherExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility, IT, Office And Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FacilityITOfficeAndOtherExpense" xlink:href="bcax-20260331.xsd#bcax_FacilityITOfficeAndOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_FacilityITOfficeAndOtherExpense" xlink:to="lab_bcax_FacilityITOfficeAndOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019cf6c2-c3eb-704c-94e2-83b2b89817f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average &#8211; Remaining Contractual Life (years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019cf6c2-c3eb-76c3-b0ae-19aec3ab9cd9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_019cf6c2-c47b-7baf-8d04-c1bce9adfd8c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019cf6c2-c3ec-7f98-ae14-34e981bef2db_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_019cf6c2-c3eb-740b-bdac-5008c3a6498c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_019cf6c2-c47b-7cb6-9175-c6d796a5543b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_019cf6c2-c3ec-7946-bc02-0ef21ec38997_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cf6c2-c3ec-77ef-9178-46b5306cb317_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019cf6c2-c3eb-7851-88d7-28cdf4233e62_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019cf6c2-c3eb-7adc-b1f0-09d0da4a445b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019cf6c2-c3eb-7569-8b30-44a739329983_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_A2024StockOptionAndGrantPlanMember_019cf6c2-c3eb-7161-bf2f-f2b010acb479_terseLabel_en-US" xlink:label="lab_bcax_A2024StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Stock Option And Grant Plan</link:label>
    <link:label id="lab_bcax_A2024StockOptionAndGrantPlanMember_label_en-US" xlink:label="lab_bcax_A2024StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Stock Option and Grant Plan [Member]</link:label>
    <link:label id="lab_bcax_A2024StockOptionAndGrantPlanMember_documentation_en-US" xlink:label="lab_bcax_A2024StockOptionAndGrantPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Stock Option and Grant Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2024StockOptionAndGrantPlanMember" xlink:href="bcax-20260331.xsd#bcax_A2024StockOptionAndGrantPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_A2024StockOptionAndGrantPlanMember" xlink:to="lab_bcax_A2024StockOptionAndGrantPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_019cf6c2-c3eb-7990-a125-eb95f472d2e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019daab6-a14f-79d8-bb61-71883e1f89d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_019daa0c-c310-7f7c-b0d4-cfa7b6735d50_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cf6c2-c3eb-7324-8ec5-bb2599331ea6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c3ec-7ed0-9dab-087c833ef3ae_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c3eb-770a-b239-c10337c9dc67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_019cf6c2-c3ec-7551-844d-077207c6581c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_019cf6c2-c3ec-7bf2-b359-7adf858a7e9f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_019cf6c2-c3ec-7045-ad93-e264aa790e1e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c3eb-790b-9144-86e26774e2f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019cf6c2-c3eb-77f0-8d3d-1ee28e2f47c2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per share, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019cf6c2-c3ec-7274-8002-35a3a621ff2e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019cf6c2-c3ec-7bf9-89d0-083ccb0b3d51_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c3eb-7699-ab84-f97a391716d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cf6c2-c3eb-7cbe-8e2b-10c9ed84e0a1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense_019cf6c2-c47b-76e2-acb3-0c6fcec817af_terseLabel_en-US" xlink:label="lab_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development personnel cost and other (including stock-based compensation)</link:label>
    <link:label id="lab_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense_label_en-US" xlink:label="lab_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Personnel Cost, Including Share-Based Payment Arrangement Expense</link:label>
    <link:label id="lab_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense_documentation_en-US" xlink:label="lab_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Personnel Cost, Including Share-Based Payment Arrangement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense" xlink:href="bcax-20260331.xsd#bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense" xlink:to="lab_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019cf6c2-c3eb-7746-8240-df2c26b5b487_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019cf6c2-c3eb-781d-b38f-c8b50028f6e2_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ATMProgramMember_019daa2c-47a2-76af-bba6-c6f21fc9ed6e_terseLabel_en-US" xlink:label="lab_bcax_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_bcax_ATMProgramMember_label_en-US" xlink:label="lab_bcax_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATM Program [Member]</link:label>
    <link:label id="lab_bcax_ATMProgramMember_documentation_en-US" xlink:label="lab_bcax_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ATMProgramMember" xlink:href="bcax-20260331.xsd#bcax_ATMProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ATMProgramMember" xlink:to="lab_bcax_ATMProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c3eb-7a7e-b834-edd19ad7b042_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019cf6c2-c3eb-710b-9573-ad4070e29d72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019cf6c2-c3eb-77c5-84b6-4cb606ad4300_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cf6c2-c3eb-74be-9c17-91483cadfbeb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019cf6c2-c3eb-73a5-9135-bcf3a90a5ca2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cf6c2-c3eb-72a9-98cf-447ff96939ad_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued bonus and payroll related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_AccruedManufacturingExpensesCurrent_019cf6c2-c3eb-7651-a0c6-f6c3eab63d45_terseLabel_en-US" xlink:label="lab_bcax_AccruedManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued manufacturing expenses</link:label>
    <link:label id="lab_bcax_AccruedManufacturingExpensesCurrent_label_en-US" xlink:label="lab_bcax_AccruedManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing Expenses, Current</link:label>
    <link:label id="lab_bcax_AccruedManufacturingExpensesCurrent_documentation_en-US" xlink:label="lab_bcax_AccruedManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedManufacturingExpensesCurrent" xlink:href="bcax-20260331.xsd#bcax_AccruedManufacturingExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_AccruedManufacturingExpensesCurrent" xlink:to="lab_bcax_AccruedManufacturingExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_019cf6c2-c3eb-7b55-992c-75e9ff9be8f2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research</link:label>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_019daa9d-5c8a-782d-95b1-2d478c8aa3ad_terseLabel_en-US" xlink:label="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options</link:label>
    <link:label id="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_label_en-US" xlink:label="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options [Member]</link:label>
    <link:label id="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_documentation_en-US" xlink:label="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:href="bcax-20260331.xsd#bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:to="lab_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019cf6c2-c3eb-753f-a48b-68babcfde8d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholder's Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019cf6c2-c3eb-7765-bfe1-2739ddf28294_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019cf6c2-c3eb-7645-a959-5faf43b2fb32_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019cf6c2-c3ec-7a56-94ec-e43a55f47786_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019cf6c2-c3eb-763c-b285-1d6492484e60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-For-Sale Securities in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_019cf6c2-c3eb-7593-983a-918958714441_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_019cf6c2-c3eb-74cb-a9e5-37720c0a950a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019cf6c2-c3eb-7b79-bfb9-848cd923256d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019cf6c2-c3ec-73e1-b4de-0bc601cb0b2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019cf6c2-c3ec-797e-a03a-c4e4a0381583_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3ec-7dcd-bf75-f5af613416db_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_019cf6c2-c3ec-7e0b-bc51-494fc9a9c9d2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_019cf6c2-c3eb-7731-8ecd-e9cefb4cc213_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_019cf6c2-c3ec-7ad3-b617-561f4c44c347_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average &#8211; Remaining Contractual Life (years), Exercisable and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019cf6c2-c3eb-70e0-8f47-4389971866dd_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_019daa7e-2287-79e7-afed-300fea8b3099_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_019cf6c2-c3eb-7ae1-8af6-627e34b16f87_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019cf6c2-c3eb-7bf5-9e60-8a08db3800b2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019cf6c2-c3eb-7181-8994-45e2e04cf3bb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019cf6c2-c3eb-75cf-bee5-311787ff2fd6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019cf6c2-c3eb-7292-ba68-4aa9dcefa1a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_IvanHyepMember_label_en-US" xlink:label="lab_bcax_IvanHyepMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ivan Hyep [Member]</link:label>
    <link:label id="lab_bcax_IvanHyepMember_documentation_en-US" xlink:label="lab_bcax_IvanHyepMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ivan Hyep</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IvanHyepMember" xlink:href="bcax-20260331.xsd#bcax_IvanHyepMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_IvanHyepMember" xlink:to="lab_bcax_IvanHyepMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_019cf6c2-c47b-76c8-b3cb-8d5780046746_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019cf6c2-c3eb-777d-a4aa-7ccf771ccf98_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12 Months or Longer, Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_019cf6c2-c3ec-7a90-950f-b6eeecdfaa27_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019cf6c2-c3eb-7221-bbd3-f543d8ed4c1b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019cf6c2-c3eb-76bd-8184-563ee73b800d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019cf6c2-c3eb-73cb-ab4b-e3e1996fff2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 Months, Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_InvestmentsWithMaturityOfOneYearOrLessMember_019cf6c2-c3eb-774e-8a71-11fbf16ceb20_terseLabel_en-US" xlink:label="lab_bcax_InvestmentsWithMaturityOfOneYearOrLessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities with original maturity of one year or less</link:label>
    <link:label id="lab_bcax_InvestmentsWithMaturityOfOneYearOrLessMember_label_en-US" xlink:label="lab_bcax_InvestmentsWithMaturityOfOneYearOrLessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments With Maturity Of One Year Or Less [Member]</link:label>
    <link:label id="lab_bcax_InvestmentsWithMaturityOfOneYearOrLessMember_documentation_en-US" xlink:label="lab_bcax_InvestmentsWithMaturityOfOneYearOrLessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments With Maturity Of One Year Or Less</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentsWithMaturityOfOneYearOrLessMember" xlink:href="bcax-20260331.xsd#bcax_InvestmentsWithMaturityOfOneYearOrLessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_InvestmentsWithMaturityOfOneYearOrLessMember" xlink:to="lab_bcax_InvestmentsWithMaturityOfOneYearOrLessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_019cf6c2-c3eb-766f-926f-8d9ec8dec0c7_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ReportableSegmentMember_019cf6c2-c3ec-798e-9241-31d152f8a71c_terseLabel_en-US" xlink:label="lab_bcax_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_bcax_ReportableSegmentMember_label_en-US" xlink:label="lab_bcax_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_bcax_ReportableSegmentMember_documentation_en-US" xlink:label="lab_bcax_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ReportableSegmentMember" xlink:href="bcax-20260331.xsd#bcax_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ReportableSegmentMember" xlink:to="lab_bcax_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019cf6c2-c3ec-7a0e-984e-13950b19fd65_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c3eb-719d-afdb-fe8107d61d6c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c3eb-71f8-8cfe-f77ee3433f8e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019cf6c2-c3ec-7bff-a205-8aec2c7ab4ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019cf6c2-c3eb-71f0-964a-4db95e2d0a19_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total, Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cf6c2-c3eb-7836-b77d-e279341680be_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019cf6c2-c3eb-78d4-8577-29bb5ce0a437_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_019cf6c2-c3ec-7293-aeaf-39c0ccce75db_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_019cf6c2-c3ec-7ce8-a783-be1cd86c247c_terseLabel_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Additional Refundable Deposit</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_label_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Additional Refundable Deposit [Member]</link:label>
    <link:label id="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_documentation_en-US" xlink:label="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Master Clinical Contract Services Agreement, Additional Refundable Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:to="lab_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019cf6c2-c3eb-72e9-bcd4-62bbf22ed192_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_019cf6c2-c3eb-7b7a-baad-5e9efdd87547_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cf6c2-c3eb-77b4-a06f-72ea27f159f1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019cf6c2-c3eb-736c-95c9-35188f0c7e78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_019cf6c2-c3eb-7185-8946-2c834f769dd2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_019cf6c2-c3eb-774e-9749-82d548f47170_terseLabel_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares allowable under the plan (in shares)</link:label>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_label_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:label id="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_documentation_en-US" xlink:label="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:href="bcax-20260331.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="lab_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cf6c2-c3eb-7a72-baa8-0b20cc93d899_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation_019cf6c2-c3eb-7d1b-8a38-1f448233808c_terseLabel_en-US" xlink:label="lab_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative personnel costs (including stock-based compensation)</link:label>
    <link:label id="lab_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation_label_en-US" xlink:label="lab_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Personnel Costs Including Stock-based Compensation</link:label>
    <link:label id="lab_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation_documentation_en-US" xlink:label="lab_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Personnel Costs Including Stock-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation" xlink:href="bcax-20260331.xsd#bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation" xlink:to="lab_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_019cf6c2-c3eb-754f-9afe-18c21ad6783b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019cf6c2-c3eb-7084-ace1-847124bc18d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_019cf6c2-c3eb-73d4-8bf4-790bc186d389_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, base rent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019cf6c2-c3eb-7431-b5d4-d96dc61ef40d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_019cf6c2-c3eb-7e7e-9166-d5c493fc7d5d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019cf6c2-c3eb-7c3c-91c9-a2e0759e5c21_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_InvestmentCategorizationAxisAxis_019cf6c2-c3ec-72cf-947c-3b2710018699_terseLabel_en-US" xlink:label="lab_bcax_InvestmentCategorizationAxisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Categorization Axis [Axis]</link:label>
    <link:label id="lab_bcax_InvestmentCategorizationAxisAxis_label_en-US" xlink:label="lab_bcax_InvestmentCategorizationAxisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Categorization Axis [Axis]</link:label>
    <link:label id="lab_bcax_InvestmentCategorizationAxisAxis_documentation_en-US" xlink:label="lab_bcax_InvestmentCategorizationAxisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Categorization Axis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentCategorizationAxisAxis" xlink:href="bcax-20260331.xsd#bcax_InvestmentCategorizationAxisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_InvestmentCategorizationAxisAxis" xlink:to="lab_bcax_InvestmentCategorizationAxisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cf6c2-c3eb-75ba-aac3-3cf2da6f5430_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cf6c2-c3eb-78d2-b681-bec193cc3960_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c3eb-7b34-bc78-dd452096620c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019cf6c2-c3eb-70f6-b8b4-3764e6fe5244_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_OtherCommitmentPercentage_019cf6c2-c3eb-7143-9cf3-7fa74cfb045e_terseLabel_en-US" xlink:label="lab_bcax_OtherCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other commitment percentage</link:label>
    <link:label id="lab_bcax_OtherCommitmentPercentage_label_en-US" xlink:label="lab_bcax_OtherCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment Percentage</link:label>
    <link:label id="lab_bcax_OtherCommitmentPercentage_documentation_en-US" xlink:label="lab_bcax_OtherCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Commitment Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OtherCommitmentPercentage" xlink:href="bcax-20260331.xsd#bcax_OtherCommitmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_OtherCommitmentPercentage" xlink:to="lab_bcax_OtherCommitmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019cf6c2-c3eb-7fab-9cc4-93b709bd2cd9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019cf6c2-c3ec-79a2-a4a2-8e50a919f64d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_019cf6c2-c3ec-7463-90c7-7ed431be40ce_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_ManufacturingAndProcessDevelopmentExpense_019cf6c2-c3eb-7bbc-a041-51b3de0ea204_terseLabel_en-US" xlink:label="lab_bcax_ManufacturingAndProcessDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical operations and development</link:label>
    <link:label id="lab_bcax_ManufacturingAndProcessDevelopmentExpense_label_en-US" xlink:label="lab_bcax_ManufacturingAndProcessDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing And Process Development Expense</link:label>
    <link:label id="lab_bcax_ManufacturingAndProcessDevelopmentExpense_documentation_en-US" xlink:label="lab_bcax_ManufacturingAndProcessDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing And Process Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ManufacturingAndProcessDevelopmentExpense" xlink:href="bcax-20260331.xsd#bcax_ManufacturingAndProcessDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_ManufacturingAndProcessDevelopmentExpense" xlink:to="lab_bcax_ManufacturingAndProcessDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019cf6c2-c3ec-7b85-b4fb-d813f14df105_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019cf6c2-c3ec-79f8-b590-bea8d858dc5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_February2026OfferingMember_019daa30-931c-7932-bf61-ceb12a6c40bd_terseLabel_en-US" xlink:label="lab_bcax_February2026OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">February 2026 Offering</link:label>
    <link:label id="lab_bcax_February2026OfferingMember_label_en-US" xlink:label="lab_bcax_February2026OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February 2026 Offering [Member]</link:label>
    <link:label id="lab_bcax_February2026OfferingMember_documentation_en-US" xlink:label="lab_bcax_February2026OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">February 2026 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_February2026OfferingMember" xlink:href="bcax-20260331.xsd#bcax_February2026OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_February2026OfferingMember" xlink:to="lab_bcax_February2026OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcax_BBLAgreementsMember_019cf6c2-c3ec-7d87-8ce8-1ee0cdc03d5c_terseLabel_en-US" xlink:label="lab_bcax_BBLAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BBL Agreements</link:label>
    <link:label id="lab_bcax_BBLAgreementsMember_label_en-US" xlink:label="lab_bcax_BBLAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BBL Agreements [Member]</link:label>
    <link:label id="lab_bcax_BBLAgreementsMember_documentation_en-US" xlink:label="lab_bcax_BBLAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BBL Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BBLAgreementsMember" xlink:href="bcax-20260331.xsd#bcax_BBLAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcax_BBLAgreementsMember" xlink:to="lab_bcax_BBLAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_019cf6c2-c3eb-7e05-a06b-fb49741a45c0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_019cf6c2-c3eb-7ca0-ae28-12ced2825bb3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_019cf6c2-c47b-746f-a1d9-d762a367c4de_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_019cf6c2-c3ec-763b-b0f2-c40e22a65760_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_019cf6c2-c3eb-760d-bc72-2db76bd343b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_019cf6c2-c3ec-7b8f-90ff-c0f8961c6883_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, and accompanying pre-funded warrants, net of issuance cost</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019cf6c2-c3eb-7d27-9147-6fef4451a81b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cf6c2-c3ec-7791-b5e7-0295254d945b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_019cf6c2-c3eb-7df2-a16e-a66af125801e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019cf6c2-c3ec-718f-a585-6bcd6bdcf36c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Equity</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cf6c2-c3eb-733d-bdc9-d3ac76e3d08e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019cf6c2-c3eb-78f6-b586-689ef4d1e260_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cf6c2-c3eb-70a5-8037-cd3b945b6ab4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease)/increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_019cf6c2-c3ec-7dae-bdd1-dbad265ec5f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>bcax-20260331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cf6c2-c28f-747f-9e58-111c1e1d135b,g:94c43f23-f2a3-4ea7-b3a9-326e15be7355-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bicara.com/role/CoverPage" xlink:type="simple" xlink:href="bcax-20260331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019cf6c2-c34a-7d75-8677-96711a15718c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_DocumentType_019cf6c2-c34a-7d75-8677-96711a15718c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019cf6c2-c34a-76eb-8d12-05138362346f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_DocumentQuarterlyReport_019cf6c2-c34a-76eb-8d12-05138362346f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019cf6c2-c34a-7c7f-b4ce-3da3e73f27cd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_DocumentPeriodEndDate_019cf6c2-c34a-7c7f-b4ce-3da3e73f27cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019cf6c2-c34a-7f2c-ac31-f5a3ac043642" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_DocumentTransitionReport_019cf6c2-c34a-7f2c-ac31-f5a3ac043642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019cf6c2-c34a-7db2-a292-bd513e09cb4f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityFileNumber_019cf6c2-c34a-7db2-a292-bd513e09cb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019cf6c2-c34a-797f-8d4a-307e7363b07a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityRegistrantName_019cf6c2-c34a-797f-8d4a-307e7363b07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019cf6c2-c34a-7280-8144-d2f987bac4d0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019cf6c2-c34a-7280-8144-d2f987bac4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019cf6c2-c34a-7090-9edb-9461024508cb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityTaxIdentificationNumber_019cf6c2-c34a-7090-9edb-9461024508cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019cf6c2-c34a-710d-a7ec-7432756ce24e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityAddressAddressLine1_019cf6c2-c34a-710d-a7ec-7432756ce24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_019cf6c2-c34a-7ba9-b4dd-a106671430da" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityAddressAddressLine2_019cf6c2-c34a-7ba9-b4dd-a106671430da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019cf6c2-c34a-7e1a-90ce-85b3c61d793e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityAddressCityOrTown_019cf6c2-c34a-7e1a-90ce-85b3c61d793e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019cf6c2-c34a-7e0c-86a4-51cee75fe6ca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityAddressStateOrProvince_019cf6c2-c34a-7e0c-86a4-51cee75fe6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019cf6c2-c34a-7196-b1e9-718df41fc67b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityAddressPostalZipCode_019cf6c2-c34a-7196-b1e9-718df41fc67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019cf6c2-c34a-7e6e-89de-b40211fa49b7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_CityAreaCode_019cf6c2-c34a-7e6e-89de-b40211fa49b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019cf6c2-c34a-75d0-9e6e-11d66201a5fc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_LocalPhoneNumber_019cf6c2-c34a-75d0-9e6e-11d66201a5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019cf6c2-c34a-7bd9-a018-aba5f9bcf12b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_Security12bTitle_019cf6c2-c34a-7bd9-a018-aba5f9bcf12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019cf6c2-c34a-7639-8ce5-b14c3b86c6b8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_TradingSymbol_019cf6c2-c34a-7639-8ce5-b14c3b86c6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019cf6c2-c34a-7e4b-beba-7a3c8b433108" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_SecurityExchangeName_019cf6c2-c34a-7e4b-beba-7a3c8b433108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019cf6c2-c34a-72ff-ae94-708eb8f6ae1c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityCurrentReportingStatus_019cf6c2-c34a-72ff-ae94-708eb8f6ae1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019cf6c2-c34a-742a-8ecb-5d8cc286f7e0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityInteractiveDataCurrent_019cf6c2-c34a-742a-8ecb-5d8cc286f7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019cf6c2-c34a-7772-bb8b-fb347a3c3009" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityFilerCategory_019cf6c2-c34a-7772-bb8b-fb347a3c3009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019cf6c2-c34a-7ee8-9078-31335b9a0560" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntitySmallBusiness_019cf6c2-c34a-7ee8-9078-31335b9a0560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019cf6c2-c34a-76e2-93a9-56ef74656e0d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityEmergingGrowthCompany_019cf6c2-c34a-76e2-93a9-56ef74656e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_019cf6c2-c34a-7868-ada3-7c3d19a6054d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityExTransitionPeriod_019cf6c2-c34a-7868-ada3-7c3d19a6054d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019cf6c2-c34a-79fe-acaf-92ccc96780a9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityShellCompany_019cf6c2-c34a-79fe-acaf-92ccc96780a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019cf6c2-c34a-7d9f-8a03-644a49bbc0ef" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019cf6c2-c34a-7d9f-8a03-644a49bbc0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019cf6c2-c34a-70cf-b5c6-80ab11b65782" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_EntityCentralIndexKey_019cf6c2-c34a-70cf-b5c6-80ab11b65782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019cf6c2-c34a-71c4-8b7d-11b151ba97e4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_CurrentFiscalYearEndDate_019cf6c2-c34a-71c4-8b7d-11b151ba97e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019cf6c2-c34a-782e-b176-6c1288367187" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_DocumentFiscalYearFocus_019cf6c2-c34a-782e-b176-6c1288367187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019cf6c2-c34a-7ed1-8db5-348d76588723" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019cf6c2-c34a-7ed1-8db5-348d76588723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019cf6c2-c34a-7b2d-9fef-eeaa4dc35e45" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cf6c2-c34a-74ac-bf87-77d6c38aad43" xlink:to="loc_dei_AmendmentFlag_019cf6c2-c34a-7b2d-9fef-eeaa4dc35e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7ab8-bf2b-5792dc424002" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cf6c2-c34a-7032-b1f1-d8b24865c977" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7ab8-bf2b-5792dc424002" xlink:to="loc_us-gaap_StatementTable_019cf6c2-c34a-7032-b1f1-d8b24865c977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-76f0-8db3-d0e8b599de79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-7032-b1f1-d8b24865c977" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-76f0-8db3-d0e8b599de79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d6b-92bf-7a4424e582f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-76f0-8db3-d0e8b599de79" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d6b-92bf-7a4424e582f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-73bc-9a42-1018db068b29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d6b-92bf-7a4424e582f8" xlink:to="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-73bc-9a42-1018db068b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7e18-80ea-9b97f236d7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d6b-92bf-7a4424e582f8" xlink:to="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7e18-80ea-9b97f236d7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cf6c2-c34a-791b-abe8-fa922e1eda8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-7032-b1f1-d8b24865c977" xlink:to="loc_us-gaap_StatementLineItems_019cf6c2-c34a-791b-abe8-fa922e1eda8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-791b-abe8-fa922e1eda8e" xlink:to="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cf6c2-c34a-78c0-bdf1-3c17f36502ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cf6c2-c34a-78c0-bdf1-3c17f36502ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cf6c2-c34a-7039-8fdc-94db0c5f66af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cf6c2-c34a-7039-8fdc-94db0c5f66af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_019cf6c2-c34a-7580-aeb9-2a373bfe9f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_019cf6c2-c34a-7580-aeb9-2a373bfe9f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cf6c2-c34a-7ba8-90e5-91023f89dfab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cf6c2-c34a-7182-a18c-f0f4186d595f" xlink:to="loc_us-gaap_AssetsCurrent_019cf6c2-c34a-7ba8-90e5-91023f89dfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cf6c2-c34a-7d1f-bd75-ffe859112e64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019cf6c2-c34a-7d1f-bd75-ffe859112e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cf6c2-c34a-7f6b-956a-99043945a33c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cf6c2-c34a-7f6b-956a-99043945a33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019cf6c2-c34a-7a99-b38b-734b19f5c748" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019cf6c2-c34a-7a99-b38b-734b19f5c748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019cf6c2-c34a-7980-a99b-557c61125769" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cf6c2-c34a-7021-a540-2215f68d3f45" xlink:to="loc_us-gaap_Assets_019cf6c2-c34a-7980-a99b-557c61125769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-791b-abe8-fa922e1eda8e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cf6c2-c34a-7d90-a72e-5d4e4dfcff2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cf6c2-c34a-7d90-a72e-5d4e4dfcff2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-7538-a36d-6157d1b632a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-7538-a36d-6157d1b632a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cf6c2-c34a-7017-9437-75a6af114c46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cf6c2-c34a-7017-9437-75a6af114c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cf6c2-c34a-7459-8595-56cb00d14ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cf6c2-c34a-72a3-9aef-75e518738f17" xlink:to="loc_us-gaap_LiabilitiesCurrent_019cf6c2-c34a-7459-8595-56cb00d14ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cf6c2-c34a-7236-8cc8-1cfbe12f892c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cf6c2-c34a-7236-8cc8-1cfbe12f892c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019cf6c2-c34a-7408-8d50-517ff0a2b925" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:to="loc_us-gaap_Liabilities_019cf6c2-c34a-7408-8d50-517ff0a2b925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019cf6c2-c34a-7b6d-a18b-e6908c813177" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019cf6c2-c34a-7b6d-a18b-e6908c813177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019cf6c2-c34a-71f9-b264-c34a399047f8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019cf6c2-c34a-7e03-931b-a3159e3a41ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_PreferredStockValue_019cf6c2-c34a-7e03-931b-a3159e3a41ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019cf6c2-c34a-7360-b078-6f114ad63af4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_CommonStockValue_019cf6c2-c34a-7360-b078-6f114ad63af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019cf6c2-c34a-71c9-b376-ec3ee8f4e3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019cf6c2-c34a-71c9-b376-ec3ee8f4e3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cf6c2-c34a-7477-94ee-8814d117688f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cf6c2-c34a-7477-94ee-8814d117688f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cf6c2-c34a-7791-833e-bd16e1bb93e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cf6c2-c34a-7791-833e-bd16e1bb93e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7047-ae6b-95a0b99bc55e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cf6c2-c34a-7a5f-880a-1330570ac3bc" xlink:to="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7047-ae6b-95a0b99bc55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cf6c2-c34a-70d0-864d-c148973ca231" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-791b-abe8-fa922e1eda8e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cf6c2-c34a-70d0-864d-c148973ca231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7732-a55d-794a5b2fd450" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019cf6c2-c34a-7a23-b571-a67f11618e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7732-a55d-794a5b2fd450" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019cf6c2-c34a-7a23-b571-a67f11618e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019cf6c2-c34a-7fbc-8649-3ce33ec5df25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7732-a55d-794a5b2fd450" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019cf6c2-c34a-7fbc-8649-3ce33ec5df25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_019cf6c2-c34a-7e85-9928-fab69e365c73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7732-a55d-794a5b2fd450" xlink:to="loc_us-gaap_PreferredStockSharesIssued_019cf6c2-c34a-7e85-9928-fab69e365c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019cf6c2-c34a-7cf9-b68c-f1d0e2e34de4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7732-a55d-794a5b2fd450" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019cf6c2-c34a-7cf9-b68c-f1d0e2e34de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cf6c2-c34a-716c-b5d8-11ab1c64938e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7732-a55d-794a5b2fd450" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cf6c2-c34a-716c-b5d8-11ab1c64938e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019cf6c2-c34a-7a92-a6f4-c826526b44d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7732-a55d-794a5b2fd450" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019cf6c2-c34a-7a92-a6f4-c826526b44d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019cf6c2-c34a-7b80-b01e-f40daf3f51ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7732-a55d-794a5b2fd450" xlink:to="loc_us-gaap_CommonStockSharesIssued_019cf6c2-c34a-7b80-b01e-f40daf3f51ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cf6c2-c34a-7704-974d-647f9ac6de56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cf6c2-c34a-7732-a55d-794a5b2fd450" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cf6c2-c34a-7704-974d-647f9ac6de56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019cf6c2-c34a-7d4a-8e2b-786c987bc11c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cf6c2-c34a-7261-bdce-1a7d6364c139" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cf6c2-c34a-7d4a-8e2b-786c987bc11c" xlink:to="loc_us-gaap_StatementTable_019cf6c2-c34a-7261-bdce-1a7d6364c139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-7e80-ab80-b77ab1c51b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-7261-bdce-1a7d6364c139" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-7e80-ab80-b77ab1c51b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-729f-8f17-79c2892aeaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-7e80-ab80-b77ab1c51b3f" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-729f-8f17-79c2892aeaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7345-a757-b08b21211b94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-729f-8f17-79c2892aeaeb" xlink:to="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7345-a757-b08b21211b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-79a7-bc6b-f5683e02a0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-729f-8f17-79c2892aeaeb" xlink:to="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-79a7-bc6b-f5683e02a0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-7261-bdce-1a7d6364c139" xlink:to="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019cf6c2-c34a-767b-9745-495d3dcd8922" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019cf6c2-c34a-767b-9745-495d3dcd8922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c34a-7311-be57-0d479b9fa67e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cf6c2-c34a-767b-9745-495d3dcd8922" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c34a-7311-be57-0d479b9fa67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c34a-753f-8d13-147510e2e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cf6c2-c34a-767b-9745-495d3dcd8922" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c34a-753f-8d13-147510e2e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cf6c2-c34a-7937-9706-40a8a15bea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cf6c2-c34a-767b-9745-495d3dcd8922" xlink:to="loc_us-gaap_OperatingExpenses_019cf6c2-c34a-7937-9706-40a8a15bea0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c34a-78ea-a435-83eee97bdd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c34a-78ea-a435-83eee97bdd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019cf6c2-c34a-721a-920b-31502afd3848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019cf6c2-c34a-721a-920b-31502afd3848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019cf6c2-c34a-7b07-bd26-87c340050d50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019cf6c2-c34a-721a-920b-31502afd3848" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019cf6c2-c34a-7b07-bd26-87c340050d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c34a-7852-b1f1-9fdce9405f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019cf6c2-c34a-721a-920b-31502afd3848" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c34a-7852-b1f1-9fdce9405f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c34a-7d6d-be41-07c825a77e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c34a-7d6d-be41-07c825a77e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019cf6c2-c34a-7c8e-8f74-e5ee2abcaf32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019cf6c2-c34a-7c8e-8f74-e5ee2abcaf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-7005-b4c9-b1250e7a91ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-7005-b4c9-b1250e7a91ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019cf6c2-c34a-7762-a179-5dc953494fad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_EarningsPerShareBasic_019cf6c2-c34a-7762-a179-5dc953494fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019cf6c2-c34a-7427-a771-7f9a09c258a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019cf6c2-c34a-7427-a771-7f9a09c258a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cf6c2-c34a-797e-a312-6517df1b8dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cf6c2-c34a-797e-a312-6517df1b8dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cf6c2-c34a-7e88-8936-4eb43eeac668" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cf6c2-c34a-7e88-8936-4eb43eeac668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c34a-7a57-a634-4988692baac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7b04-8df1-8da4c6190175" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c34a-7a57-a634-4988692baac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7ff6-ae0b-e6e3e3f60b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c34a-7a57-a634-4988692baac4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7ff6-ae0b-e6e3e3f60b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7bd5-abe0-cfcbcb24e952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c34a-7a57-a634-4988692baac4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cf6c2-c34a-7bd5-abe0-cfcbcb24e952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cf6c2-c34a-70a7-9eed-3d4e9db89f71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_019cf6c2-c34a-7a57-a634-4988692baac4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cf6c2-c34a-70a7-9eed-3d4e9db89f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019cf6c2-c34a-7305-8e8b-93afda1c6a09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cf6c2-c34a-736f-9b6f-6884988aff60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019cf6c2-c34a-7305-8e8b-93afda1c6a09" xlink:to="loc_us-gaap_StatementTable_019cf6c2-c34a-736f-9b6f-6884988aff60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019cf6c2-c34a-70b1-bda7-c5edccaae929" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-736f-9b6f-6884988aff60" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019cf6c2-c34a-70b1-bda7-c5edccaae929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019cf6c2-c34a-70b1-bda7-c5edccaae929" xlink:to="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cf6c2-c34a-7c4b-89e1-8f35682a40a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:to="loc_us-gaap_CommonStockMember_019cf6c2-c34a-7c4b-89e1-8f35682a40a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019cf6c2-c34a-7346-b8c3-b189b29970e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019cf6c2-c34a-7346-b8c3-b189b29970e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cf6c2-c34a-710e-868a-6b6ec3d326ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cf6c2-c34a-710e-868a-6b6ec3d326ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019cf6c2-c34a-76c4-b6a0-cd5c86a07198" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cf6c2-c34a-736a-85d3-8daccd8ed699" xlink:to="loc_us-gaap_RetainedEarningsMember_019cf6c2-c34a-76c4-b6a0-cd5c86a07198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7ad0-a083-ce4c79b1f50e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-736f-9b6f-6884988aff60" xlink:to="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7ad0-a083-ce4c79b1f50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7ad0-a083-ce4c79b1f50e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cf6c2-c34a-7ab5-886c-70d83eb832a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cf6c2-c34a-7ab5-886c-70d83eb832a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7f50-98bd-6ee6b4340583" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-7f50-98bd-6ee6b4340583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019cf6c2-c34a-7afc-8881-d7340e658342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019cf6c2-c34a-7afc-8881-d7340e658342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019cf6c2-c34a-72f5-b043-61478c45177a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019cf6c2-c34a-72f5-b043-61478c45177a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cf6c2-c34a-7952-90b4-a3668d1b64cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cf6c2-c34a-7952-90b4-a3668d1b64cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019cf6c2-c34a-7f40-8551-987c3a96c242" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019cf6c2-c34a-7f40-8551-987c3a96c242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cf6c2-c34a-7cff-85e7-89dbf284aea1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cf6c2-c34a-7cff-85e7-89dbf284aea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019daa22-bcbb-7b45-86e8-2f5ccc5a4e12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_019daa22-bcbb-7b45-86e8-2f5ccc5a4e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-7dcc-af00-4458d8aad831" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-7dcc-af00-4458d8aad831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cf6c2-c34a-707e-92b5-46c43f846dff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cf6c2-c34a-707e-92b5-46c43f846dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-77da-b5e4-399d4e6de325" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cf6c2-c34a-74ae-965e-6fc8c09b5d72" xlink:to="loc_us-gaap_StockholdersEquity_019cf6c2-c34a-77da-b5e4-399d4e6de325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="bcax-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019cf6c2-c34a-7b76-b542-27efdda6ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cf6c2-c34a-752a-bc63-093e480776d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cf6c2-c34a-7b76-b542-27efdda6ff29" xlink:to="loc_us-gaap_StatementTable_019cf6c2-c34a-752a-bc63-093e480776d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-74d0-b968-bc7986c3b2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-752a-bc63-093e480776d9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-74d0-b968-bc7986c3b2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7a29-9f64-63332a48cbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-74d0-b968-bc7986c3b2c0" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7a29-9f64-63332a48cbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-78f6-8f28-6c4a6ca84466" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7a29-9f64-63332a48cbe7" xlink:to="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-78f6-8f28-6c4a6ca84466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7e96-a029-1cdf29297151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7a29-9f64-63332a48cbe7" xlink:to="loc_us-gaap_RelatedPartyMember_019cf6c2-c34a-7e96-a029-1cdf29297151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cf6c2-c34a-752a-bc63-093e480776d9" xlink:to="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-79e8-8295-c40c11d6bd77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:to="loc_us-gaap_NetIncomeLoss_019cf6c2-c34a-79e8-8295-c40c11d6bd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019cf6c2-c34a-7c6c-8108-aca7d47480f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:to="loc_us-gaap_ShareBasedCompensation_019cf6c2-c34a-7c6c-8108-aca7d47480f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019cf6c2-c34a-748e-a499-4dde9a374acb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:to="loc_us-gaap_Depreciation_019cf6c2-c34a-748e-a499-4dde9a374acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cf6c2-c34a-796c-b1c1-1cc992df966f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cf6c2-c34a-796c-b1c1-1cc992df966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cf6c2-c34a-7d12-9bb6-7957c577ea16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7885-b042-c61fc76e1fbe" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cf6c2-c34a-7d12-9bb6-7957c577ea16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c34a-72bb-816a-7f05512fb592" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c34a-72bb-816a-7f05512fb592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cf6c2-c34a-781f-8386-01d3180e84eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c34a-72bb-816a-7f05512fb592" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cf6c2-c34a-781f-8386-01d3180e84eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019cf6c2-c34a-751d-9943-974b7201e565" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c34a-72bb-816a-7f05512fb592" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019cf6c2-c34a-751d-9943-974b7201e565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019cf6c2-c34a-7daf-bc78-3c9d1d0b82ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cf6c2-c34a-72bb-816a-7f05512fb592" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019cf6c2-c34a-7daf-bc78-3c9d1d0b82ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-7f3e-b718-4983fe96e645" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cf6c2-c34a-7a8d-aac2-8c6d1890b517" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cf6c2-c34a-7f3e-b718-4983fe96e645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c34a-73d6-bb0f-eced3d0b652c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c34a-73d6-bb0f-eced3d0b652c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_019daa27-f7b5-7058-bd88-07dc7b2f76f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c34a-73d6-bb0f-eced3d0b652c" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_019daa27-f7b5-7058-bd88-07dc7b2f76f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cf6c2-c34a-7088-900e-caf75515150f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c34a-73d6-bb0f-eced3d0b652c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cf6c2-c34a-7088-900e-caf75515150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cf6c2-c34a-7aba-a556-bd7c586eb112" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cf6c2-c34a-73d6-bb0f-eced3d0b652c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cf6c2-c34a-7aba-a556-bd7c586eb112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c34a-7b3a-938c-9ff773b03110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c34a-7b3a-938c-9ff773b03110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cf6c2-c34a-7be5-a54d-2383b1cf1ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c34a-7b3a-938c-9ff773b03110" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cf6c2-c34a-7be5-a54d-2383b1cf1ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019cf6c2-c34a-7405-9bea-a24b973265f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c34a-7b3a-938c-9ff773b03110" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019cf6c2-c34a-7405-9bea-a24b973265f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cf6c2-c34a-7249-af66-0db9eade6a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cf6c2-c34a-7b3a-938c-9ff773b03110" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cf6c2-c34a-7249-af66-0db9eade6a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cf6c2-c34a-7cc2-9d06-33377b8b92ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cf6c2-c34a-7cc2-9d06-33377b8b92ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cf6c2-c34a-7257-9de5-87e129aec912" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cf6c2-c34a-7257-9de5-87e129aec912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cf6c2-c34a-77b6-8556-c08f7db6424e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cf6c2-c34a-77b6-8556-c08f7db6424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cf6c2-c34a-7ee8-941d-f14af056ef40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cf6c2-c34a-7ee8-941d-f14af056ef40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_019cf6c2-c34a-7562-8e34-bf21ea865063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019cf6c2-c34a-7ee8-941d-f14af056ef40" xlink:to="loc_us-gaap_IncomeTaxesPaid_019cf6c2-c34a-7562-8e34-bf21ea865063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019cf6c2-c34a-7eec-a951-0cdd2a1c00c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cf6c2-c34a-7905-ad8f-cb0ebebe945e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019cf6c2-c34a-7eec-a951-0cdd2a1c00c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_019cf6c2-c34a-7d39-bc8c-2be3b7ee10a4" xlink:href="bcax-20260331.xsd#bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019cf6c2-c34a-7eec-a951-0cdd2a1c00c3" xlink:to="loc_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_019cf6c2-c34a-7d39-bc8c-2be3b7ee10a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_VestingOfEarlyExerciseStockOptions_019cf6c2-c34a-7534-8ce2-d72a252f8747" xlink:href="bcax-20260331.xsd#bcax_VestingOfEarlyExerciseStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019cf6c2-c34a-7eec-a951-0cdd2a1c00c3" xlink:to="loc_bcax_VestingOfEarlyExerciseStockOptions_019cf6c2-c34a-7534-8ce2-d72a252f8747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity" xlink:type="simple" xlink:href="bcax-20260331.xsd#DescriptionofBusinessOrganizationandLiquidity"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7d62-a382-5da0850ff9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_019cf6c2-c34a-7727-8b2a-11dc652bed65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7d62-a382-5da0850ff9a7" xlink:to="loc_us-gaap_NatureOfOperations_019cf6c2-c34a-7727-8b2a-11dc652bed65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="bcax-20260331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7909-84f7-8ac933ce5b92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_019cf6c2-c34a-78ac-871f-aabdb568dbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7909-84f7-8ac933ce5b92" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_019cf6c2-c34a-78ac-871f-aabdb568dbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="bcax-20260331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019cf6c2-c34a-73b3-9806-37fb70145bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_019cf6c2-c34a-7936-b2b2-f2dbaaaa79ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019cf6c2-c34a-73b3-9806-37fb70145bf5" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_019cf6c2-c34a-7936-b2b2-f2dbaaaa79ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/MarketableSecurities" xlink:type="simple" xlink:href="bcax-20260331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-74e7-a3ac-30be191067ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock_019cf6c2-c34a-73ed-ba0a-d8c15a042c75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-74e7-a3ac-30be191067ef" xlink:to="loc_us-gaap_InvestmentTextBlock_019cf6c2-c34a-73ed-ba0a-d8c15a042c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/Leases" xlink:type="simple" xlink:href="bcax-20260331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019cf6c2-c3eb-7762-8fba-cd2c532e9d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_019cf6c2-c3eb-715b-b2ce-7484974790f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019cf6c2-c3eb-7762-8fba-cd2c532e9d3a" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_019cf6c2-c3eb-715b-b2ce-7484974790f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="bcax-20260331.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019cf6c2-c34a-7df7-aa76-39d2574e99a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_019cf6c2-c34a-7470-9781-5e2b69556e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019cf6c2-c34a-7df7-aa76-39d2574e99a5" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_019cf6c2-c34a-7470-9781-5e2b69556e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="bcax-20260331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019cf6c2-c3eb-7d01-a1d6-c820a95b45d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019cf6c2-c3eb-7681-b2e5-d24f95432f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019cf6c2-c3eb-7d01-a1d6-c820a95b45d8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019cf6c2-c3eb-7681-b2e5-d24f95432f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockholdersEquity" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019cf6c2-c34a-73ca-8998-b505bc1436f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019cf6c2-c34a-738d-881b-71273e2cf6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019cf6c2-c34a-73ca-8998-b505bc1436f7" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019cf6c2-c34a-738d-881b-71273e2cf6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34a-7b95-973c-b509534b98ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019cf6c2-c34a-706f-8c68-34a3d37330e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34a-7b95-973c-b509534b98ec" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019cf6c2-c34a-706f-8c68-34a3d37330e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/IncomeTaxes" xlink:type="simple" xlink:href="bcax-20260331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019cf6c2-c34b-7576-ba19-c509b0241e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_019cf6c2-c34b-7959-9990-38bf0532014e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019cf6c2-c34b-7576-ba19-c509b0241e3b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_019cf6c2-c34b-7959-9990-38bf0532014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreementsRelatedParties" xlink:type="simple" xlink:href="bcax-20260331.xsd#SignificantAgreementsRelatedParties"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SignificantAgreementsRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019cf6c2-c34b-73bc-80fb-7a968f07c5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019cf6c2-c34b-7ec8-a7c0-583995e3778d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019cf6c2-c34b-73bc-80fb-7a968f07c5a8" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019cf6c2-c34b-7ec8-a7c0-583995e3778d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreements" xlink:type="simple" xlink:href="bcax-20260331.xsd#SignificantAgreements"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SignificantAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019cf6c2-c3eb-78fb-bf2e-78c9a851674b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_019cf6c2-c3eb-7e9a-a90e-a332ee2c71f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019cf6c2-c3eb-78fb-bf2e-78c9a851674b" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_019cf6c2-c3eb-7e9a-a90e-a332ee2c71f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/DefinedContributionPlan" xlink:type="simple" xlink:href="bcax-20260331.xsd#DefinedContributionPlan"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/DefinedContributionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_019cf6c2-c3eb-745d-969c-2d2e2e27c01e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_019cf6c2-c3eb-7c68-b940-4357bd66976f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_019cf6c2-c3eb-745d-969c-2d2e2e27c01e" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_019cf6c2-c3eb-7c68-b940-4357bd66976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SegmentReporting" xlink:type="simple" xlink:href="bcax-20260331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cf6c2-c3eb-7387-b295-819d68f5f366" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019cf6c2-c3eb-7189-9d11-13fb45cba580" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cf6c2-c3eb-7387-b295-819d68f5f366" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019cf6c2-c3eb-7189-9d11-13fb45cba580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="bcax-20260331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019cf6c2-c34a-756a-8177-d5682877d44c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019cf6c2-c34a-756a-8177-d5682877d44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_019cf6c2-c34a-725a-9f67-4b9e6b5f1bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_019cf6c2-c34a-725a-9f67-4b9e6b5f1bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_019cf6c2-c34a-7de1-977b-7fcd92d5b987" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_UseOfEstimates_019cf6c2-c34a-7de1-977b-7fcd92d5b987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_019daa65-c085-7344-af72-f12dfd3c116b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_019daa65-c085-7344-af72-f12dfd3c116b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_019cf6c2-c34a-72af-a3cd-2591177a8641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_019cf6c2-c34a-72af-a3cd-2591177a8641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_019cf6c2-c34a-7322-af80-b7875c739856" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_019cf6c2-c34a-7322-af80-b7875c739856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019cf6c2-c34a-7229-9c69-ea660c079cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019cf6c2-c34a-7229-9c69-ea660c079cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_WarrantsPolicyPolicyTextBlock_019daa69-f5d3-7bb3-875e-2d7b694eeca6" xlink:href="bcax-20260331.xsd#bcax_WarrantsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_bcax_WarrantsPolicyPolicyTextBlock_019daa69-f5d3-7bb3-875e-2d7b694eeca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_019cf6c2-c34a-7a18-9d67-dc4e599d2a33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_019cf6c2-c34a-7a18-9d67-dc4e599d2a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_019daa6a-db63-7b99-b356-6aadebaeee0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_019daa6a-db63-7b99-b356-6aadebaeee0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019cf6c2-c34a-7449-909a-b566c2ca5641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019cf6c2-c34a-7449-909a-b566c2ca5641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_019cf6c2-c34a-75f0-bd81-77c2d013a25e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7450-985e-2d813a7c768a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_019cf6c2-c34a-75f0-bd81-77c2d013a25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="bcax-20260331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-72c2-8ee8-eb1a6b08b7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019cf6c2-c34a-7afc-9228-de9de8511f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-72c2-8ee8-eb1a6b08b7ce" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019cf6c2-c34a-7afc-9228-de9de8511f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="bcax-20260331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019cf6c2-c34a-7d6d-98a6-9afd26395f17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_019cf6c2-c34a-7651-a712-e3fb3fbfb7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019cf6c2-c34a-7d6d-98a6-9afd26395f17" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_019cf6c2-c34a-7651-a712-e3fb3fbfb7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="bcax-20260331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-7468-a6a5-de9d51dfe8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019cf6c2-c34a-7d74-a538-74c5a7f2827b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-7468-a6a5-de9d51dfe8a8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019cf6c2-c34a-7d74-a538-74c5a7f2827b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019cf6c2-c34a-77f8-a978-f17147d728ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-7468-a6a5-de9d51dfe8a8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019cf6c2-c34a-77f8-a978-f17147d728ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="bcax-20260331.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019cf6c2-c34a-7734-8751-3d52beb29adb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019cf6c2-c34a-7a85-8707-20c72368f3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019cf6c2-c34a-7734-8751-3d52beb29adb" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019cf6c2-c34a-7a85-8707-20c72368f3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34a-7ca4-9b6a-ba89c1492bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019cf6c2-c34a-7201-9874-61e76a15e2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34a-7ca4-9b6a-ba89c1492bcd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019cf6c2-c34a-7201-9874-61e76a15e2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_019cf6c2-c34a-7851-ab12-612565fc813a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34a-7ca4-9b6a-ba89c1492bcd" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_019cf6c2-c34a-7851-ab12-612565fc813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019cf6c2-c34a-768c-a119-14bc144f0468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34a-7ca4-9b6a-ba89c1492bcd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019cf6c2-c34a-768c-a119-14bc144f0468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="bcax-20260331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cf6c2-c3eb-78a9-a618-77ddf171fd24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019cf6c2-c3eb-73c2-a4fb-b83fbdf8b821" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cf6c2-c3eb-78a9-a618-77ddf171fd24" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019cf6c2-c3eb-73c2-a4fb-b83fbdf8b821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#DescriptionofBusinessOrganizationandLiquidityDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7653-b924-17714ad716de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7653-b924-17714ad716de" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa57-bd47-7c5b-98be-4cc7fa029000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa57-bd47-7c5b-98be-4cc7fa029000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa57-bd47-7c5b-98be-4cc7fa029000" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_019daa57-bd47-7d2f-a4ca-e306f69d53de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:to="loc_us-gaap_IPOMember_019daa57-bd47-7d2f-a4ca-e306f69d53de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ATMProgramMember_019daa57-bd47-77f5-8259-d2fec8b6f7ca" xlink:href="bcax-20260331.xsd#bcax_ATMProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:to="loc_bcax_ATMProgramMember_019daa57-bd47-77f5-8259-d2fec8b6f7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_February2026OfferingMember_019daa57-bd47-78c4-90c0-e415d7d717b5" xlink:href="bcax-20260331.xsd#bcax_February2026OfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:to="loc_bcax_February2026OfferingMember_019daa57-bd47-78c4-90c0-e415d7d717b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019daa57-bd47-798e-ac38-1c551517d08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa57-bd47-7fc7-b0fb-e53ed504ca37" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019daa57-bd47-798e-ac38-1c551517d08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019daa57-bd47-7c2c-9341-50293c4fe928" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019daa57-bd47-7c2c-9341-50293c4fe928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019daa57-bd47-72c9-a16a-d92353d02ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019daa57-bd47-7c2c-9341-50293c4fe928" xlink:to="loc_us-gaap_ClassOfStockDomain_019daa57-bd47-72c9-a16a-d92353d02ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019daa57-bd47-79fd-aedf-9a5561ba7d01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019daa57-bd47-72c9-a16a-d92353d02ba7" xlink:to="loc_us-gaap_CommonStockMember_019daa57-bd47-79fd-aedf-9a5561ba7d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa57-bd47-7848-bb09-456b666e9f29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa57-bd47-7848-bb09-456b666e9f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa57-bd47-7c81-9258-f4337e5c48e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa57-bd47-7848-bb09-456b666e9f29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa57-bd47-7c81-9258-f4337e5c48e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PreFundedWarrantsMember_019daa57-bd47-79e0-9164-ec0eb17edaeb" xlink:href="bcax-20260331.xsd#bcax_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa57-bd47-7c81-9258-f4337e5c48e8" xlink:to="loc_bcax_PreFundedWarrantsMember_019daa57-bd47-79e0-9164-ec0eb17edaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_019cf6c2-c34a-7d48-ac7a-71e0d9b56c6a" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019daa57-bd47-7e5b-8390-9b1f34c3fe9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019daa57-bd47-7e5b-8390-9b1f34c3fe9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019daa57-bd47-7195-b12a-38ae6f8fbc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019daa57-bd47-7195-b12a-38ae6f8fbc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019daa57-bd47-7530-b69b-e82f9e04f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019daa57-bd47-7530-b69b-e82f9e04f88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_019daa57-bd47-7146-8312-85a57a9ebd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_019daa57-bd47-7146-8312-85a57a9ebd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019daa57-bd47-7f0b-8efa-fc575cafeade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019daa57-bd47-7f0b-8efa-fc575cafeade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019daa57-bd47-7df3-9bea-4333e9fa1deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019daa57-bd47-7df3-9bea-4333e9fa1deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019daa57-bd47-7cea-8c24-8011d4334e71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019daa57-bd47-7cea-8c24-8011d4334e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_019daa57-bd47-7f9e-88b9-a2fbb218dc25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_InvestmentsAndCash_019daa57-bd47-7f9e-88b9-a2fbb218dc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019daa57-bd47-7b6c-9250-4457c4fe0c82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_019daa57-bd47-79da-9f03-86eda8f9e3e9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019daa57-bd47-7b6c-9250-4457c4fe0c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7de0-9aa0-fd3b318b9b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019daa6d-c3d0-7bd9-80f5-d9ba4a5e3a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-7de0-9aa0-fd3b318b9b6b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019daa6d-c3d0-7bd9-80f5-d9ba4a5e3a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa6d-c3d0-76c0-b75c-f33eb50983d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019daa6d-c3d0-7bd9-80f5-d9ba4a5e3a2a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa6d-c3d0-76c0-b75c-f33eb50983d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa6d-c3d0-719c-8e92-2d6d7aee7611" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019daa6d-c3d0-76c0-b75c-f33eb50983d3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa6d-c3d0-719c-8e92-2d6d7aee7611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PreFundedWarrantsMember_019daa6d-c3d0-776f-b090-874732ec7272" xlink:href="bcax-20260331.xsd#bcax_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019daa6d-c3d0-719c-8e92-2d6d7aee7611" xlink:to="loc_bcax_PreFundedWarrantsMember_019daa6d-c3d0-776f-b090-874732ec7272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa6d-c3d0-7f20-8313-e09754a2d342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019daa6d-c3d0-7bd9-80f5-d9ba4a5e3a2a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa6d-c3d0-7f20-8313-e09754a2d342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa6d-c3d0-71ba-92fd-419b3c1df86b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019daa6d-c3d0-7f20-8313-e09754a2d342" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa6d-c3d0-71ba-92fd-419b3c1df86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_February2026OfferingMember_019daa6d-c3d0-740d-80f4-9934da7170c7" xlink:href="bcax-20260331.xsd#bcax_February2026OfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019daa6d-c3d0-71ba-92fd-419b3c1df86b" xlink:to="loc_bcax_February2026OfferingMember_019daa6d-c3d0-740d-80f4-9934da7170c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019daa6d-c3d0-7de6-a0d6-6192a0fc0b29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019daa6d-c3d0-7bd9-80f5-d9ba4a5e3a2a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019daa6d-c3d0-7de6-a0d6-6192a0fc0b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019daa6d-c3d0-79a1-b79a-1be2619adb86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019daa6d-c3d0-7de6-a0d6-6192a0fc0b29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019daa6d-c3d0-79a1-b79a-1be2619adb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019daa6e-0d10-7caf-8d81-24856482b7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019daa6d-c3d0-7de6-a0d6-6192a0fc0b29" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019daa6e-0d10-7caf-8d81-24856482b7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-75ff-bac8-368e9e0ddd83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cf6c2-c34a-7e15-bdd9-436c5b251726" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cf6c2-c34a-75ff-bac8-368e9e0ddd83" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cf6c2-c34a-7e15-bdd9-436c5b251726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cf6c2-c34a-7e4a-b147-f4dd53c0795b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cf6c2-c34a-7e15-bdd9-436c5b251726" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cf6c2-c34a-7e4a-b147-f4dd53c0795b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cf6c2-c34a-7fea-bedf-569e4c29d722" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cf6c2-c34a-7e4a-b147-f4dd53c0795b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cf6c2-c34a-7fea-bedf-569e4c29d722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_019cf6c2-c34a-7663-84fd-686565e3ee50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cf6c2-c34a-7fea-bedf-569e4c29d722" xlink:to="loc_us-gaap_StockCompensationPlanMember_019cf6c2-c34a-7663-84fd-686565e3ee50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cf6c2-c34a-7e45-9cbc-317ce1ca452f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cf6c2-c34a-7e15-bdd9-436c5b251726" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cf6c2-c34a-7e45-9cbc-317ce1ca452f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cf6c2-c34a-7521-8d96-8d0e9c893dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cf6c2-c34a-7e45-9cbc-317ce1ca452f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cf6c2-c34a-7521-8d96-8d0e9c893dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019cf6c2-c34a-7b2f-9213-0b2142f5808c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cf6c2-c34a-7d35-ad7b-81cd40c52b49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019cf6c2-c34a-7b2f-9213-0b2142f5808c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cf6c2-c34a-7d35-ad7b-81cd40c52b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019cf6c2-c34a-786a-b650-36bf4139711c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cf6c2-c34a-7d35-ad7b-81cd40c52b49" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019cf6c2-c34a-786a-b650-36bf4139711c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c34a-71e6-be68-9ccbdddcd417" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019cf6c2-c34a-786a-b650-36bf4139711c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c34a-71e6-be68-9ccbdddcd417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-75a3-965e-cd2ffc52319c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c34a-71e6-be68-9ccbdddcd417" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-75a3-965e-cd2ffc52319c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019cf6c2-c34a-7723-8916-2cbee7d951cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cf6c2-c34a-71e6-be68-9ccbdddcd417" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019cf6c2-c34a-7723-8916-2cbee7d951cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cf6c2-c34a-7c51-991d-137ee5abb4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cf6c2-c34a-7d35-ad7b-81cd40c52b49" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cf6c2-c34a-7c51-991d-137ee5abb4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7de9-809f-39c7dc2db06f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cf6c2-c34a-7c51-991d-137ee5abb4ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7de9-809f-39c7dc2db06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019cf6c2-c34a-79ee-9fea-08d2563b778f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7de9-809f-39c7dc2db06f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019cf6c2-c34a-79ee-9fea-08d2563b778f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019cf6c2-c34a-7fe5-9897-b8fd8ef4d324" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7de9-809f-39c7dc2db06f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019cf6c2-c34a-7fe5-9897-b8fd8ef4d324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019cf6c2-c34a-7a8e-8b80-ffa4397d4879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cf6c2-c34a-7de9-809f-39c7dc2db06f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019cf6c2-c34a-7a8e-8b80-ffa4397d4879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cf6c2-c34a-770e-8a39-90c33bb52b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cf6c2-c34a-7d35-ad7b-81cd40c52b49" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cf6c2-c34a-770e-8a39-90c33bb52b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cf6c2-c34a-7a93-8baf-768b4df9862f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cf6c2-c34a-770e-8a39-90c33bb52b2e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cf6c2-c34a-7a93-8baf-768b4df9862f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019cf6c2-c34a-74ca-9d1c-3af0e24dc773" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cf6c2-c34a-770e-8a39-90c33bb52b2e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019cf6c2-c34a-74ca-9d1c-3af0e24dc773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-751e-889e-f4cb230abc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7061-84d8-777ad37360b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-751e-889e-f4cb230abc9b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7061-84d8-777ad37360b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7c14-9732-a59190a85ded" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7061-84d8-777ad37360b7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7c14-9732-a59190a85ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-7ea0-b9bc-4d1b2aff3b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7c14-9732-a59190a85ded" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-7ea0-b9bc-4d1b2aff3b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-7a34-9b7f-b225fa04d810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-7ea0-b9bc-4d1b2aff3b0f" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-7a34-9b7f-b225fa04d810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentCategorizationAxisAxis_019cf6c2-c34a-74d7-bab2-672bfe5847fd" xlink:href="bcax-20260331.xsd#bcax_InvestmentCategorizationAxisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7061-84d8-777ad37360b7" xlink:to="loc_bcax_InvestmentCategorizationAxisAxis_019cf6c2-c34a-74d7-bab2-672bfe5847fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c34a-7e1c-b155-1169b22a403e" xlink:href="bcax-20260331.xsd#bcax_InvestmentCategorizationAxisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcax_InvestmentCategorizationAxisAxis_019cf6c2-c34a-74d7-bab2-672bfe5847fd" xlink:to="loc_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c34a-7e1c-b155-1169b22a403e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentsWithMaturityOfOneYearOrLessMember_019cf6c2-c34a-7573-ae19-5ea1e9fb82c5" xlink:href="bcax-20260331.xsd#bcax_InvestmentsWithMaturityOfOneYearOrLessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c34a-7e1c-b155-1169b22a403e" xlink:to="loc_bcax_InvestmentsWithMaturityOfOneYearOrLessMember_019cf6c2-c34a-7573-ae19-5ea1e9fb82c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember_019cf6c2-c34a-77b2-a89b-ca188dc87108" xlink:href="bcax-20260331.xsd#bcax_InvestmentsWithMaturityOfOneToTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcax_InvestmentCategorizationAxisDomain_019cf6c2-c34a-7e1c-b155-1169b22a403e" xlink:to="loc_bcax_InvestmentsWithMaturityOfOneToTwoYearsMember_019cf6c2-c34a-77b2-a89b-ca188dc87108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7061-84d8-777ad37360b7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cf6c2-c34a-753e-b316-315c4c4386f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cf6c2-c34a-753e-b316-315c4c4386f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cf6c2-c34a-7e44-966b-6661df977db6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cf6c2-c34a-7e44-966b-6661df977db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cf6c2-c34a-7cd7-91a4-d7b157d491c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cf6c2-c34a-7cd7-91a4-d7b157d491c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cf6c2-c34a-74b1-bca9-c75cc7266677" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-78cd-b556-c6571ca5c9c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cf6c2-c34a-74b1-bca9-c75cc7266677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-7bd2-8aee-197783b11954" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7653-94f7-5bbbda1c4359" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-7bd2-8aee-197783b11954" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7653-94f7-5bbbda1c4359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7aff-8f81-7c5e716e7f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7653-94f7-5bbbda1c4359" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7aff-8f81-7c5e716e7f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-74b9-9a31-dc9b42c2eda1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cf6c2-c34a-7aff-8f81-7c5e716e7f2d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-74b9-9a31-dc9b42c2eda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-7ac6-93fc-34b15895c87f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cf6c2-c34a-74b9-9a31-dc9b42c2eda1" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_019cf6c2-c34a-7ac6-93fc-34b15895c87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_019cf6c2-c34a-7653-94f7-5bbbda1c4359" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019cf6c2-c34a-7936-8ca7-d3bfb78886e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019cf6c2-c34a-7936-8ca7-d3bfb78886e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019cf6c2-c34a-72b8-a2eb-2ab048858868" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019cf6c2-c34a-72b8-a2eb-2ab048858868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019cf6c2-c34a-7e1b-a9b9-56761110b639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019cf6c2-c34a-7e1b-a9b9-56761110b639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019cf6c2-c34a-794a-9d86-48bc1fd1e79b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019cf6c2-c34a-794a-9d86-48bc1fd1e79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019cf6c2-c34a-7bc3-8337-8dc9349d5268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019cf6c2-c34a-7bc3-8337-8dc9349d5268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019cf6c2-c34a-7e11-bf28-bcf23924f49b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_019cf6c2-c34a-76b6-a7e6-aecddda3b85b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019cf6c2-c34a-7e11-bf28-bcf23924f49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-762e-82ba-89e1a3e3175a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition_019cf6c2-c34a-79cb-a479-71b5c70a68e1" xlink:href="bcax-20260331.xsd#bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019cf6c2-c34a-762e-82ba-89e1a3e3175a" xlink:to="loc_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition_019cf6c2-c34a-79cb-a479-71b5c70a68e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/LeasesDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019daa7e-2287-74b2-a1aa-a4ab589994a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_019daa7e-2287-7807-984b-c114063b2b77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019daa7e-2287-74b2-a1aa-a4ab589994a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_019daa7e-2287-7807-984b-c114063b2b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LesseeOperatingLeaseArea_019daa7e-2287-7bf7-ac53-cc486c31f1f5" xlink:href="bcax-20260331.xsd#bcax_LesseeOperatingLeaseArea"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019daa7e-2287-74b2-a1aa-a4ab589994a1" xlink:to="loc_bcax_LesseeOperatingLeaseArea_019daa7e-2287-7bf7-ac53-cc486c31f1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDepositLiability_019daa7e-2287-720f-97b2-b173e3904558" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDepositLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019daa7e-2287-74b2-a1aa-a4ab589994a1" xlink:to="loc_us-gaap_SecurityDepositLiability_019daa7e-2287-720f-97b2-b173e3904558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_019daa7e-2287-7af6-b943-fc2a4965c228" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019daa7e-2287-74b2-a1aa-a4ab589994a1" xlink:to="loc_us-gaap_OperatingLeaseExpense_019daa7e-2287-7af6-b943-fc2a4965c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019cf6c2-c34a-7c36-9e4f-51338ea21e49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34a-7ebb-a9d1-c98e5cbd6f68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019cf6c2-c34a-7c36-9e4f-51338ea21e49" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34a-7ebb-a9d1-c98e5cbd6f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-73a1-943e-1fd7e899c9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34a-7ebb-a9d1-c98e5cbd6f68" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-73a1-943e-1fd7e899c9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d1c-ba1a-3ddecdb0afb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cf6c2-c34a-73a1-943e-1fd7e899c9c6" xlink:to="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d1c-ba1a-3ddecdb0afb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-760c-ba83-f6cbb293775c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cf6c2-c34a-7d1c-ba1a-3ddecdb0afb0" xlink:to="loc_us-gaap_NonrelatedPartyMember_019cf6c2-c34a-760c-ba83-f6cbb293775c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34a-7ebb-a9d1-c98e5cbd6f68" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_019cf6c2-c34a-719c-a829-1410d4e6c67a" xlink:href="bcax-20260331.xsd#bcax_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_bcax_AccruedResearchAndDevelopmentExpenseCurrent_019cf6c2-c34a-719c-a829-1410d4e6c67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_AccruedManufacturingExpensesCurrent_019daa80-4077-700e-a5ac-24f77df2c3e6" xlink:href="bcax-20260331.xsd#bcax_AccruedManufacturingExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_bcax_AccruedManufacturingExpensesCurrent_019daa80-4077-700e-a5ac-24f77df2c3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cf6c2-c34a-710a-a88b-c3a854390f49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cf6c2-c34a-710a-a88b-c3a854390f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_019cf6c2-c34a-73be-9f3a-1a393c19824f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_019cf6c2-c34a-73be-9f3a-1a393c19824f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019cf6c2-c34a-78bd-97ab-486ad69ea375" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019cf6c2-c34a-78bd-97ab-486ad69ea375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-7dea-af7c-4f0207add783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cf6c2-c34a-7d3b-989d-f169f0733344" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019cf6c2-c34a-7dea-af7c-4f0207add783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019cf6c2-c34a-7a2c-94cc-18940105fe86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019cf6c2-c34a-7a2c-94cc-18940105fe86" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019dd835-488c-78fc-b437-46ac3007a8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019dd835-488c-78fc-b437-46ac3007a8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019dd835-488c-721a-bf17-55480006fc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019dd835-488c-78fc-b437-46ac3007a8fb" xlink:to="loc_us-gaap_ClassOfStockDomain_019dd835-488c-721a-bf17-55480006fc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019dd835-488c-7acd-82d3-fa41ddb33b28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019dd835-488c-721a-bf17-55480006fc1b" xlink:to="loc_us-gaap_CommonStockMember_019dd835-488c-7acd-82d3-fa41ddb33b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019dd835-488c-77cd-b97c-1733d085e65e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019dd835-488c-77cd-b97c-1733d085e65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-7031-b353-9596a232711a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019dd835-488c-77cd-b97c-1733d085e65e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-7031-b353-9596a232711a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_February2026OfferingMember_019dd835-488c-70dc-97d4-ac54122dd79d" xlink:href="bcax-20260331.xsd#bcax_February2026OfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-7031-b353-9596a232711a" xlink:to="loc_bcax_February2026OfferingMember_019dd835-488c-70dc-97d4-ac54122dd79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019dd835-488c-7e0e-a567-eb346f48cd07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-7031-b353-9596a232711a" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019dd835-488c-7e0e-a567-eb346f48cd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ATMProgramMember_019dd835-6e08-7016-be7d-80fa5c6565e9" xlink:href="bcax-20260331.xsd#bcax_ATMProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019dd835-488c-7031-b353-9596a232711a" xlink:to="loc_bcax_ATMProgramMember_019dd835-6e08-7016-be7d-80fa5c6565e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019de454-e903-7835-aa4d-1faf7ad7b503" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019de454-e903-7835-aa4d-1faf7ad7b503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019de454-e903-7b0f-8d71-4bf8b5afb527" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019de454-e903-7835-aa4d-1faf7ad7b503" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019de454-e903-7b0f-8d71-4bf8b5afb527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PreFundedWarrantsMember_019de454-e903-7e7c-a8cc-435dd4404e63" xlink:href="bcax-20260331.xsd#bcax_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019de454-e903-7b0f-8d71-4bf8b5afb527" xlink:to="loc_bcax_PreFundedWarrantsMember_019de454-e903-7e7c-a8cc-435dd4404e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cf6c2-c34a-76b5-bdb4-2e0c1162a695" xlink:to="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019dd835-488c-7b0a-8792-9d0effca486c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019dd835-488c-7b0a-8792-9d0effca486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019dd835-488c-7853-b772-6db68e5f0b42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019dd835-488c-7853-b772-6db68e5f0b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_019dd835-488c-7321-a461-a966905a4504" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_PreferredStockSharesIssued_019dd835-488c-7321-a461-a966905a4504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019dd835-488c-7592-b69e-7820f5903673" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019dd835-488c-7592-b69e-7820f5903673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019dd835-488c-7809-8d8d-69e2ed29d011" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019dd835-488c-7809-8d8d-69e2ed29d011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019dd835-488c-7ece-b687-82556f591dab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019dd835-488c-7ece-b687-82556f591dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019dd835-488c-7de3-9fff-d186c19af408" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_CommonStockSharesIssued_019dd835-488c-7de3-9fff-d186c19af408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019dd835-488c-7d8f-9303-7706c0affd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019dd835-488c-7d8f-9303-7706c0affd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019dd835-488c-7203-be3e-42083796059c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019dd835-488c-7203-be3e-42083796059c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019dd835-488c-7185-acb0-e008b4ac1af0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019dd835-488c-7185-acb0-e008b4ac1af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019de454-e903-7774-9c69-d06299d0042e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019de454-e903-7774-9c69-d06299d0042e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019de454-e903-73c4-9976-c6b81bef00bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019de454-e903-73c4-9976-c6b81bef00bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference_019df4af-c5c5-71c1-929b-ccf5b75694e1" xlink:href="bcax-20260331.xsd#bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference_019df4af-c5c5-71c1-929b-ccf5b75694e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_019dd835-6e08-7a9c-a844-426e975e7745" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_019dd835-6e08-7a9c-a844-426e975e7745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SaleOfStockCommissionFeePercentage_019dd835-6e08-7f34-9fd2-28de2cf97dee" xlink:href="bcax-20260331.xsd#bcax_SaleOfStockCommissionFeePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_bcax_SaleOfStockCommissionFeePercentage_019dd835-6e08-7f34-9fd2-28de2cf97dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019dd835-6e08-73af-9547-e5e9955ea769" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019dd835-488c-7e95-a1ce-ddb4d84c10cc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019dd835-6e08-73af-9547-e5e9955ea769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34a-7212-868d-cd4355365956" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34a-7910-b93a-61d44d721c03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34a-7212-868d-cd4355365956" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34a-7910-b93a-61d44d721c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019daab6-47d9-7076-8da7-58533da63e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34a-7910-b93a-61d44d721c03" xlink:to="loc_us-gaap_PlanNameAxis_019daab6-47d9-7076-8da7-58533da63e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019daab6-47d9-7e99-8d30-b903eba047a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019daab6-47d9-7076-8da7-58533da63e4e" xlink:to="loc_us-gaap_PlanNameDomain_019daab6-47d9-7e99-8d30-b903eba047a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2024StockOptionAndGrantPlanMember_019daab6-47d9-705c-8d83-91c83a0d61e3" xlink:href="bcax-20260331.xsd#bcax_A2024StockOptionAndGrantPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019daab6-47d9-7e99-8d30-b903eba047a0" xlink:to="loc_bcax_A2024StockOptionAndGrantPlanMember_019daab6-47d9-705c-8d83-91c83a0d61e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_A2026InducementPlanMember_019daab6-77db-722e-9997-260ad2a50939" xlink:href="bcax-20260331.xsd#bcax_A2026InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019daab6-47d9-7e99-8d30-b903eba047a0" xlink:to="loc_bcax_A2026InducementPlanMember_019daab6-77db-722e-9997-260ad2a50939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019daab6-47d9-7379-8a08-cdbb7cdfe12f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34a-7910-b93a-61d44d721c03" xlink:to="loc_us-gaap_AwardTypeAxis_019daab6-47d9-7379-8a08-cdbb7cdfe12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7bf9-8e6c-0793f8074b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019daab6-47d9-7379-8a08-cdbb7cdfe12f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7bf9-8e6c-0793f8074b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_019daab6-47d9-79fc-be9f-2bac0b22cdc1" xlink:href="bcax-20260331.xsd#bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7bf9-8e6c-0793f8074b4e" xlink:to="loc_bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_019daab6-47d9-79fc-be9f-2bac0b22cdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019daab6-a14f-7113-90ff-1f41dab816c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7bf9-8e6c-0793f8074b4e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019daab6-a14f-7113-90ff-1f41dab816c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019daab6-e2f8-7cff-8da0-4fd6ffe708dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019daab6-47d9-7bf9-8e6c-0793f8074b4e" xlink:to="loc_us-gaap_EmployeeStockMember_019daab6-e2f8-7cff-8da0-4fd6ffe708dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34a-7910-b93a-61d44d721c03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019daab6-47d9-7e52-83ef-f66779f24832" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019daab6-47d9-7e52-83ef-f66779f24832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_019daab6-47d9-799d-b678-7f25e41cf5b8" xlink:href="bcax-20260331.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage_019daab6-47d9-799d-b678-7f25e41cf5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_019daab6-47d9-7316-a920-a955823f93cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_019daab6-47d9-7316-a920-a955823f93cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019daab6-47d9-71c2-8a82-1fb64c59a58e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019daab6-47d9-71c2-8a82-1fb64c59a58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019daab6-47d9-7604-a919-3b05db4e758c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019daab6-47d9-7604-a919-3b05db4e758c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019daab6-77db-7a7d-ae88-7847d4929eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019daab6-77db-7a7d-ae88-7847d4929eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019daab6-a14f-762e-8724-62cbb3b1d38b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019daab6-a14f-762e-8724-62cbb3b1d38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019daab6-a14f-7511-8f21-fc1f4191bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019daab6-a14f-7511-8f21-fc1f4191bc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_019daab6-a14f-74cb-993c-a4bc9aa590ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_019daab6-a14f-74cb-993c-a4bc9aa590ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019daab6-a14f-791f-9a52-a1d782323e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019daab6-a14f-791f-9a52-a1d782323e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019daab6-a14f-7114-918f-64f716109ace" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019daab6-a14f-7114-918f-64f716109ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_019daab6-e2f8-7853-9ec7-52e614d50961" xlink:href="bcax-20260331.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_019daab6-e2f8-7853-9ec7-52e614d50961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_019daab6-e2f8-76e7-bcbc-65187b419350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019daab6-47d9-7f09-a812-97380ab765cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_019daab6-e2f8-76e7-bcbc-65187b419350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34b-7be9-9a0a-d86f4a743e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-78de-bf50-4eaaf16da74b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34b-7be9-9a0a-d86f4a743e1b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-78de-bf50-4eaaf16da74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019cf6c2-c34b-74e9-b861-29fc1ddf82a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-78de-bf50-4eaaf16da74b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019cf6c2-c34b-74e9-b861-29fc1ddf82a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cf6c2-c34b-780d-a988-57e6ccfe7b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cf6c2-c34b-74e9-b861-29fc1ddf82a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cf6c2-c34b-780d-a988-57e6ccfe7b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cf6c2-c34b-72f0-b636-189058f3a677" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cf6c2-c34b-780d-a988-57e6ccfe7b6b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cf6c2-c34b-72f0-b636-189058f3a677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cf6c2-c34b-7b02-ab73-afa5214d08e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cf6c2-c34b-780d-a988-57e6ccfe7b6b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cf6c2-c34b-7b02-ab73-afa5214d08e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-785f-a85f-bb67546f585a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-78de-bf50-4eaaf16da74b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-785f-a85f-bb67546f585a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cf6c2-c34b-794f-bfa6-383181a9fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-785f-a85f-bb67546f585a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cf6c2-c34b-794f-bfa6-383181a9fd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34b-79cf-9680-e85c1b438647" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-71aa-8823-93985b3e476f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34b-79cf-9680-e85c1b438647" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-71aa-8823-93985b3e476f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cf6c2-c34b-787c-ae58-9e8c36b776f8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-71aa-8823-93985b3e476f" xlink:to="loc_srt_RangeAxis_019cf6c2-c34b-787c-ae58-9e8c36b776f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cf6c2-c34b-78fc-b968-002c45b0e504" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019cf6c2-c34b-787c-ae58-9e8c36b776f8" xlink:to="loc_srt_RangeMember_019cf6c2-c34b-78fc-b968-002c45b0e504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019cf6c2-c34b-7d02-b14f-2f576c74df88" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019cf6c2-c34b-78fc-b968-002c45b0e504" xlink:to="loc_srt_MinimumMember_019cf6c2-c34b-7d02-b14f-2f576c74df88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019cf6c2-c34b-7700-889c-4053400cf3f4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019cf6c2-c34b-78fc-b968-002c45b0e504" xlink:to="loc_srt_MaximumMember_019cf6c2-c34b-7700-889c-4053400cf3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019cf6c2-c34b-71aa-8823-93985b3e476f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019cf6c2-c34b-7963-b827-2b52c24ab835" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019cf6c2-c34b-7963-b827-2b52c24ab835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019cf6c2-c34b-783e-9741-2f9bf01d5405" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019cf6c2-c34b-783e-9741-2f9bf01d5405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019cf6c2-c34b-72fe-9d17-8568cd9b40cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019cf6c2-c34b-72fe-9d17-8568cd9b40cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_019cf6c2-c34b-745c-9d45-45a7deaeb425" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_019cf6c2-c34b-745c-9d45-45a7deaeb425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice_019cf6c2-c34b-7c48-87c6-c420ceaf76a3" xlink:href="bcax-20260331.xsd#bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019cf6c2-c34b-70d2-b034-54aea2d4d4df" xlink:to="loc_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice_019cf6c2-c34b-7c48-87c6-c420ceaf76a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#StockBasedCompensationScheduleofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34b-7c97-a923-f7e26be3e771" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019cf6c2-c34b-7539-9588-3e9eb6edc1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34b-7c97-a923-f7e26be3e771" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019cf6c2-c34b-7539-9588-3e9eb6edc1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cf6c2-c34b-7de5-9d48-f9078ca168b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019cf6c2-c34b-7539-9588-3e9eb6edc1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cf6c2-c34b-7de5-9d48-f9078ca168b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019cf6c2-c34b-7d13-84b3-9d9ef33b9b42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019cf6c2-c34b-7539-9588-3e9eb6edc1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019cf6c2-c34b-7d13-84b3-9d9ef33b9b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cf6c2-c34b-7c36-8b3e-852aa3e54471" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019cf6c2-c34b-7539-9588-3e9eb6edc1c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019cf6c2-c34b-7c36-8b3e-852aa3e54471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019cf6c2-c34b-7fdd-8d93-a070651e791a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019cf6c2-c34b-7539-9588-3e9eb6edc1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019cf6c2-c34b-7fdd-8d93-a070651e791a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cf6c2-c34b-795d-9fb7-5ba46501df06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019cf6c2-c34b-7539-9588-3e9eb6edc1c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019cf6c2-c34b-795d-9fb7-5ba46501df06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019cf6c2-c34b-792a-b86b-62732f206dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34b-7c97-a923-f7e26be3e771" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019cf6c2-c34b-792a-b86b-62732f206dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cf6c2-c34b-7d83-87ca-13c27398d18d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019cf6c2-c34b-792a-b86b-62732f206dbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cf6c2-c34b-7d83-87ca-13c27398d18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019cf6c2-c34b-7947-961c-0d31086939b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019cf6c2-c34b-792a-b86b-62732f206dbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019cf6c2-c34b-7947-961c-0d31086939b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019cf6c2-c34b-77fd-9852-5f2ef0f5a425" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019cf6c2-c34b-792a-b86b-62732f206dbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019cf6c2-c34b-77fd-9852-5f2ef0f5a425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019cf6c2-c34b-7020-9bce-85220ed4c62e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019cf6c2-c34b-792a-b86b-62732f206dbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019cf6c2-c34b-7020-9bce-85220ed4c62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cf6c2-c34b-7209-8dca-02de5f7a5c80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019cf6c2-c34b-792a-b86b-62732f206dbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019cf6c2-c34b-7209-8dca-02de5f7a5c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cf6c2-c34b-7c97-a923-f7e26be3e771" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019cf6c2-c34b-7c5d-a695-20e7323fd376" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019cf6c2-c34b-7c5d-a695-20e7323fd376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019cf6c2-c34b-73ae-8559-2b2d9a0cf85a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019cf6c2-c34b-73ae-8559-2b2d9a0cf85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019cf6c2-c34b-705c-9af5-6ee1a5c7483b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019cf6c2-c34b-705c-9af5-6ee1a5c7483b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019cf6c2-c34b-777e-83bc-4b14e66af86e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019cf6c2-c34b-777e-83bc-4b14e66af86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019cf6c2-c34b-78ac-981b-4e54dd3408db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019cf6c2-c34b-78ac-981b-4e54dd3408db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019cf6c2-c34b-7992-aacb-f48e331f8a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019cf6c2-c34b-7992-aacb-f48e331f8a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_019cf6c2-c34b-749e-9ec8-b916e97ea891" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_019cf6c2-c34b-749e-9ec8-b916e97ea891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_019cf6c2-c34b-778e-9f21-74b8cdf58605" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_019cf6c2-c34b-778e-9f21-74b8cdf58605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_019cf6c2-c34b-7fd9-b74b-3015e572cae4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019cf6c2-c34b-7fe8-878b-c8f6891dcbaa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_019cf6c2-c34b-7fd9-b74b-3015e572cae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SignificantAgreementsRelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019cf6c2-c34b-7da7-8a4f-2e7d01e333bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34b-76e7-afbe-39a79fddeb65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019cf6c2-c34b-7da7-8a4f-2e7d01e333bd" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34b-76e7-afbe-39a79fddeb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019dc397-7d79-7752-b9c5-dfc80136bede" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34b-76e7-afbe-39a79fddeb65" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019dc397-7d79-7752-b9c5-dfc80136bede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7fd1-97a5-f7c5fb7cade2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019dc397-7d79-7752-b9c5-dfc80136bede" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7fd1-97a5-f7c5fb7cade2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterServicesAgreementMember_019dc397-7d79-7770-8a8b-b1a4365b63dd" xlink:href="bcax-20260331.xsd#bcax_MasterServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7fd1-97a5-f7c5fb7cade2" xlink:to="loc_bcax_MasterServicesAgreementMember_019dc397-7d79-7770-8a8b-b1a4365b63dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_BBLAgreementsMember_019dc397-7d79-7597-8109-15a6261e37bb" xlink:href="bcax-20260331.xsd#bcax_BBLAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7fd1-97a5-f7c5fb7cade2" xlink:to="loc_bcax_BBLAgreementsMember_019dc397-7d79-7597-8109-15a6261e37bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_SyngeneAgreementsMember_019dc397-7d79-7432-a81d-cae1c9980540" xlink:href="bcax-20260331.xsd#bcax_SyngeneAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019dc397-7d79-7fd1-97a5-f7c5fb7cade2" xlink:to="loc_bcax_SyngeneAgreementsMember_019dc397-7d79-7432-a81d-cae1c9980540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019dc397-7d79-70cf-b7b7-dd56e5040c08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34b-76e7-afbe-39a79fddeb65" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019dc397-7d79-70cf-b7b7-dd56e5040c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019dc397-7d79-70f3-a550-0facdb89dd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019dc397-7d79-70cf-b7b7-dd56e5040c08" xlink:to="loc_us-gaap_RelatedPartyDomain_019dc397-7d79-70f3-a550-0facdb89dd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019dc397-7d79-7690-a93f-144618b2becf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019dc397-7d79-70f3-a550-0facdb89dd0d" xlink:to="loc_us-gaap_RelatedPartyMember_019dc397-7d79-7690-a93f-144618b2becf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cf6c2-c34b-76e7-afbe-39a79fddeb65" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019dc397-7d79-7cd5-8ddf-cfe111f91e51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019dc397-7d79-7cd5-8ddf-cfe111f91e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019dc397-7d79-7390-8007-5742e6855725" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019dc397-7d79-7390-8007-5742e6855725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019dc397-7d79-7978-8586-bca5f81858e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:to="loc_us-gaap_LiabilitiesCurrent_019dc397-7d79-7978-8586-bca5f81858e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019dc397-7d79-72b0-b2ed-57393102a2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019dc397-7d79-7257-8188-c331d84383da" xlink:to="loc_us-gaap_AccountsPayableCurrent_019dc397-7d79-72b0-b2ed-57393102a2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SignificantAgreementsDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SignificantAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SignificantAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019cf6c2-c3eb-7313-bff7-1a0538144e69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cf6c2-c3eb-713b-a253-422f4f01389e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019cf6c2-c3eb-7313-bff7-1a0538144e69" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cf6c2-c3eb-713b-a253-422f4f01389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019daaaa-ffd0-7211-a250-41bb342b65e2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cf6c2-c3eb-713b-a253-422f4f01389e" xlink:to="loc_srt_CounterpartyNameAxis_019daaaa-ffd0-7211-a250-41bb342b65e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019daaaa-ffd0-7c92-b600-650fb8d26359" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019daaaa-ffd0-7211-a250-41bb342b65e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019daaaa-ffd0-7c92-b600-650fb8d26359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IQVIARDSIncMember_019daaaa-ffd0-7079-955e-84686a2f1f85" xlink:href="bcax-20260331.xsd#bcax_IQVIARDSIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019daaaa-ffd0-7c92-b600-650fb8d26359" xlink:to="loc_bcax_IQVIARDSIncMember_019daaaa-ffd0-7079-955e-84686a2f1f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_019daaaa-ffd0-7166-8764-46bf81beac6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cf6c2-c3eb-713b-a253-422f4f01389e" xlink:to="loc_us-gaap_OtherCommitmentsAxis_019daaaa-ffd0-7166-8764-46bf81beac6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_019daaaa-ffd0-7166-8764-46bf81beac6c" xlink:to="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementMember_019daaaa-ffd0-74a1-9e3e-95ae329cfe51" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementMember_019daaaa-ffd0-74a1-9e3e-95ae329cfe51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_019daaaa-ffd0-7072-a371-d3d180053bbf" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementRefundableDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementRefundableDepositMember_019daaaa-ffd0-7072-a371-d3d180053bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_019daaaa-ffd0-7dcf-b678-47bb08416525" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember_019daaaa-ffd0-7dcf-b678-47bb08416525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_019daaaa-ffd0-7a39-9f4d-44aebc4c8363" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember_019daaaa-ffd0-7a39-9f4d-44aebc4c8363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember_019daaab-21ac-7248-8e99-cf65e9499d95" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember_019daaab-21ac-7248-8e99-cf65e9499d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember_019daaab-21ac-7ece-abf8-759d32165d7f" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember_019daaab-21ac-7ece-abf8-759d32165d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember_019daaab-21ac-738d-88a7-7a55c6fa3449" xlink:href="bcax-20260331.xsd#bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019daaaa-ffd0-74e6-9814-376f4f71e6ca" xlink:to="loc_bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember_019daaab-21ac-738d-88a7-7a55c6fa3449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cf6c2-c3eb-713b-a253-422f4f01389e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_019daaaa-ffd0-7edf-a5b2-0f82d0e55a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_us-gaap_OtherCommitment_019daaaa-ffd0-7edf-a5b2-0f82d0e55a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount_019daaaa-ffd0-70d3-a215-ca00d699d2fe" xlink:href="bcax-20260331.xsd#bcax_OtherCommitmentLiabilityRefundableDepositAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_bcax_OtherCommitmentLiabilityRefundableDepositAmount_019daaaa-ffd0-70d3-a215-ca00d699d2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_OtherCommitmentPercentage_019daaab-21ac-7d2c-8b28-c23999f81225" xlink:href="bcax-20260331.xsd#bcax_OtherCommitmentPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_bcax_OtherCommitmentPercentage_019daaab-21ac-7d2c-8b28-c23999f81225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019daaab-21ac-75b4-ac68-309bd5721afc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_us-gaap_OperatingExpenses_019daaab-21ac-75b4-ac68-309bd5721afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_PaymentsForOtherCommitments_019daaab-21ac-7bde-9b4b-6a48d71302ea" xlink:href="bcax-20260331.xsd#bcax_PaymentsForOtherCommitments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_bcax_PaymentsForOtherCommitments_019daaab-21ac-7bde-9b4b-6a48d71302ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019daaab-21ac-7dfc-936f-a3098266c224" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_us-gaap_AccountsPayableCurrent_019daaab-21ac-7dfc-936f-a3098266c224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019daaab-21ac-7ecf-90db-ed7a315a53a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019daaaa-ffd0-7777-bca7-2638f70c76da" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019daaab-21ac-7ecf-90db-ed7a315a53a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/DefinedContributionPlanDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#DefinedContributionPlanDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/DefinedContributionPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_019cf6c2-c3eb-7f66-9570-ef0618d561e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_019cf6c2-c3eb-75b8-8bed-6dc814811d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_019cf6c2-c3eb-7f66-9570-ef0618d561e5" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_019cf6c2-c3eb-75b8-8bed-6dc814811d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cf6c2-c3eb-7417-80de-ea286b2e0870" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019cf6c2-c3eb-7d0e-ae48-e90ea78750b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cf6c2-c3eb-7417-80de-ea286b2e0870" xlink:to="loc_us-gaap_NumberOfReportableSegments_019cf6c2-c3eb-7d0e-ae48-e90ea78750b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails" xlink:type="simple" xlink:href="bcax-20260331.xsd#SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cf6c2-c3eb-70a3-b089-6c2d04218de5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cf6c2-c3eb-7fb9-b04d-f827c01e8b34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cf6c2-c3eb-70a3-b089-6c2d04218de5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cf6c2-c3eb-7fb9-b04d-f827c01e8b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019cf6c2-c3eb-7680-8117-f045aaf34a58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cf6c2-c3eb-7fb9-b04d-f827c01e8b34" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019cf6c2-c3eb-7680-8117-f045aaf34a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cf6c2-c3eb-7942-a9db-68ffe8866045" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cf6c2-c3eb-7680-8117-f045aaf34a58" xlink:to="loc_us-gaap_SegmentDomain_019cf6c2-c3eb-7942-a9db-68ffe8866045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ReportableSegmentMember_019cf6c2-c3eb-76f5-bfa3-466e10ffdc5b" xlink:href="bcax-20260331.xsd#bcax_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019cf6c2-c3eb-7942-a9db-68ffe8866045" xlink:to="loc_bcax_ReportableSegmentMember_019cf6c2-c3eb-76f5-bfa3-466e10ffdc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019cf6c2-c3eb-7fb9-b04d-f827c01e8b34" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ClinicalOperationsAndDevelopmentExpense_019cf6c2-c3eb-7cb3-b771-6310ab1d2e30" xlink:href="bcax-20260331.xsd#bcax_ClinicalOperationsAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_ClinicalOperationsAndDevelopmentExpense_019cf6c2-c3eb-7cb3-b771-6310ab1d2e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ManufacturingAndProcessDevelopmentExpense_019cf6c2-c3eb-7ed1-9de0-bb4ae967d55a" xlink:href="bcax-20260331.xsd#bcax_ManufacturingAndProcessDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_ManufacturingAndProcessDevelopmentExpense_019cf6c2-c3eb-7ed1-9de0-bb4ae967d55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense_019cf6c2-c3eb-7155-8e1d-308c349766bc" xlink:href="bcax-20260331.xsd#bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense_019cf6c2-c3eb-7155-8e1d-308c349766bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cf6c2-c3eb-7c4a-968e-449776ce77a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_019cf6c2-c3eb-7c4a-968e-449776ce77a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3eb-78b1-957f-ac255555a1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cf6c2-c3eb-78b1-957f-ac255555a1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation_019cf6c2-c3eb-7290-b385-5e6685ad3d5f" xlink:href="bcax-20260331.xsd#bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation_019cf6c2-c3eb-7290-b385-5e6685ad3d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_019cf6c2-c3eb-7705-8971-cd2c6898200f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_ProfessionalFees_019cf6c2-c3eb-7705-8971-cd2c6898200f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_FacilityITOfficeAndOtherExpense_019cf6c2-c3eb-77d8-83b2-3dfe1082c76d" xlink:href="bcax-20260331.xsd#bcax_FacilityITOfficeAndOtherExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_FacilityITOfficeAndOtherExpense_019cf6c2-c3eb-77d8-83b2-3dfe1082c76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c3eb-785e-9f08-bf6f9cea45da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cf6c2-c3eb-785e-9f08-bf6f9cea45da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cf6c2-c3eb-740b-8017-95a99f7fa932" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_OperatingExpenses_019cf6c2-c3eb-740b-8017-95a99f7fa932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c3eb-7190-9465-b01c3e3f5a69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cf6c2-c3eb-7190-9465-b01c3e3f5a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019cf6c2-c3eb-7d19-b493-6de5088399d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019cf6c2-c3eb-7d19-b493-6de5088399d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c3eb-7735-9b6e-7fa786b0abb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cf6c2-c3eb-7735-9b6e-7fa786b0abb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c3eb-7d07-8f68-5f41bb3d9c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cf6c2-c3eb-7d07-8f68-5f41bb3d9c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IncomeTaxExpenseBenefitIncludingAdjustments_019cf6c2-c3eb-7851-bd1d-f61c3207d642" xlink:href="bcax-20260331.xsd#bcax_IncomeTaxExpenseBenefitIncludingAdjustments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_bcax_IncomeTaxExpenseBenefitIncludingAdjustments_019cf6c2-c3eb-7851-bd1d-f61c3207d642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cf6c2-c3eb-732b-86c7-036905566ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019cf6c2-c3eb-7e30-ad99-ce758058b4e3" xlink:to="loc_us-gaap_NetIncomeLoss_019cf6c2-c3eb-732b-86c7-036905566ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_ClaireMazumdanMember" xlink:href="bcax-20260331.xsd#bcax_ClaireMazumdanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcax_ClaireMazumdanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_RyanCohlheppMember" xlink:href="bcax-20260331.xsd#bcax_RyanCohlheppMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcax_RyanCohlheppMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_IvanHyepMember" xlink:href="bcax-20260331.xsd#bcax_IvanHyepMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcax_IvanHyepMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_LaraMeisnerMember" xlink:href="bcax-20260331.xsd#bcax_LaraMeisnerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcax_LaraMeisnerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcax_DavidRabenMember" xlink:href="bcax-20260331.xsd#bcax_DavidRabenMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcax_DavidRabenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>bcax-20260331_g1.jpg
<TEXT>
begin 644 bcax-20260331_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ;[$*<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KW?]HW2K+3_AW\%9K6SM[:
M:Y\-*\\D,2HTK94Y8@?,>3R?4UX17T#^TQ_R33X&_P#8L+_-:\G%MK%X9><O
M_26=]!+V%;T7_I2/GZBBBO6. **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M8?VG=.M-,\7>&XK.UAM(CX<LF*01A%)^<9P._ _*O'J]I_:K_P"1S\-?]BW8
M_P#L]>77;^NT%Y3_ /;3NI+_ &:J_./ZGBU%%%>H<(4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 6M*19-4LT=0RM,@*D9!&X<5Z=^U19V]A\=_$L%K!';0*+
M7;'$@51FVB)P!QUKS+1_^0M9?]=T_P#0A7J?[6?_ "7[Q/\ 2U_])8J\JHW_
M &A37]R?_I4#NC_NDW_>C^4CR&BBBO5.$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .L^$D,=Q\5?!D4J++$^M6:NCC*L#.F00>HJU\;;:&S^+WC"&WB2"%-
M3G"QQJ%51O/0#I4'P>_Y*WX)_P"PW9?^CTJY\=O^2R>,_P#L*3_^AFO*;?\
M:*7]S_VY'=_S"7_O?H<)1117JG"%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'<? K_DMWP]_[&+3O_2F.OV+K\=/@5_R6[X>_P#8Q:=_Z4QU^Q=?D7&W^\4?
M\+_,^]X;_@U/5?D%%%%?FY]@?CI\=?\ DMWQ"_[&+4?_ $IDKAZ[CXZ_\EN^
M(7_8Q:C_ .E,E</7]-X3_=Z?^%?D?C%?^+/U?YA111748A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?0/[3'_ "33X&_]BPO\UKY^KZ!_:8_Y)I\#?^Q87^:UY&+_
M -[PWK+_ -(9WT/X%;T7_I2/GZBBBO7. **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O:?VJ_P#D<_#7_8MV/_L]>+5[3^U7_P CGX:_[%NQ_P#9Z\JO_OM#
MTG_[:=U+_=JOK']3Q:BBBO5.$**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +>
MC_\ (6LO^NZ?^A"O4_VL_P#DOWB?Z6O_ *2Q5Y9H_P#R%K+_ *[I_P"A"O4_
MVL_^2_>)_I:_^DL5>54_Y&-+_!/_ -*@=T/]TG_BC^4CR&BBBO5.$**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .O^#W_ "5OP3_V&[+_ -'I5SX[?\ED\9_]
MA2?_ -#-4_@]_P E;\$_]ANR_P#1Z5<^.W_)9/&?_84G_P#0S7DO_D8K_!_[
M<CN_YA/^WOT.$HHHKUCA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME%%%>L<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117O'[/\
M^R)XH^.$2ZM+*/#WA?<5&HW$9=[@CJ(8\C< >"Q(4<X)((KEQ.*HX.DZV(DH
MQ75_UKZ&M*C4KS5.DKMG@]%?ISX;_8*^$VB6@BO].U#Q!-G)GOK^2,_0"$QC
M'X$^]6]7_86^#VI6<D-OX?NM*E88%S::E<,Z>X$KNOY@U\>^,LN4N51FUWLK
M?G?\#Z%</8QJ[<5\W_D?EW17TW^T'^Q'KGPHTZZ\0^'+M_$?AN %YT=-MW:)
MW9P.'0=V7&.I4 $U\R5]7@L=A\PI>UPTN9?EY-=#Q,3A:V$GR5HV?Y^@4445
MWG(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 445[1^RC\%]$^.OQ&OM UZZU"TLX-,DO5?3I$20NLL
M2 $NCC&)#V].:Y\3B(86C*O4^&*NS6E2E6J1IPW;L>+T5]J_M!?L4^!_A1\(
M]>\4Z1JOB"XU"P$1BBO;B!HCNE1#N"PJ>C'H1S7Q57'E^98?,Z3JX=NR=M5;
M6R?ZG5B\%6P4E&MN]0HHHKU#@"BBB@ HK[)_9K_8U\%_&/X3:=XHUK5->M=0
MN9IXWCL+B!(@$D*C :%CT'/->7_M;_ 7P_\  3Q-H6G>'[S4KR"_LWN)6U*6
M-V#!]H"[$08QZ@UX-+.\)6QCP$6_:)M;::;Z_(]1Y;B(X;ZVTN3??N[?J>#4
M445[QY84444 %%%% !1110 4444 %%%% !1110 4444 %%%% '<? K_DMWP]
M_P"QBT[_ -*8Z_8NOQT^!7_);OA[_P!C%IW_ *4QU^Q=?D7&W^\4?\+_ #/O
M>&_X-3U7Y!1117YN?8'XZ?'7_DMWQ"_[&+4?_2F2N'KN/CK_ ,EN^(7_ &,6
MH_\ I3)7#U_3>$_W>G_A7Y'XQ7_BS]7^84445U&(4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR>%O@[X':1A9^&_#.DPY.U=D<2_0<LQ)]V8GN37C&C_M\?"O5O$2Z6\VK:?
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M@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOEO_ .!-?DD?9?[5G_)O'CG_ *\#_P"AK7YJ_#_X ?$+XHV9O/#/A:\U"R'
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MG[1^B_#_ ()^1U%?=7[=7[-^GQ:-/\2/#EI'9W,,@_MBU@3"3*S8%P .C!B
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M1:+K-TI-I<VDI>"X=069"K<H<#(Y8'!'!QG\XD1I'554LS' 4#))KZ5_8W^
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MCK3/#FCW>LWQUN\)BM(B^Q?.8;F/15R1\S$#WK]:(O\ 5)]!7BOCWXP_"_\
M9?:ZM[M6CU?5YY=3GL=-A$MW<O(Y+2R$D #)(7>PX&%X''R^08^K@:U3ZO2=
M2<E9)>M[OT_IH]O,\-#%8>,:D^6*:;?R:_4^$;S]C7XR6-G)<R>"IFC12Q6&
M]M97Q[(LI8GV S7D&IZ7>:+?SV.H6D]C>P-LEMKF,QR1MZ,K $'V-?KA\&?V
M@O"'QULKJ7PW<7"75H%-Q87T0CGB#9VL0"5(.#RK'WQ7CG[?WPGTW7_AH?&T
M%M'%K>BRQ)+<*N&FMG<)L8]]K,K#/3YL=:^SP/$^*^NQP>8TE%R:6ETTWM=-
MNZ?_  3YZODM">&=?!U'*R;Z.]M]DM?^&/SIKJ/ _P +_%OQ*NF@\,>'[_66
M1MKR6T1,49QD!Y#A5_X$15WX,?#>;XM?$S0?"T3M$E]/^_F3K'"H+2,/<*IQ
MGOBOUGLK'PQ\'/ ?E0);:#X:T:V+L<86-%&2S=V8]2>2Q/<FO:SW/EE/+2I0
MYJDMET2VOW=WLCRLKRQYA*4I.T8[^O;^O(_-(?L4_&<KN_X0PX_["=GG\O.K
MAO'OP3\=?#%!)XG\,7^EVV0OVID$EOD]!YJ$IGVSFOO-/^"A/PM?5S9F'7TM
M]^W^T&L4\C'][ D\S'_ ,^U?0MO/H_CKPS%-']GU?0]5M@Z[T#Q7$,BY&01R
M"#T-?-5.)<VP3C+&X9*+\FOQ;>OR/:AD^7XB\,/6;DO-/\++\S\4:NZ-H>H^
M(]1AT_2;"ZU._FR([6SA:65\#)PJ@D\5W?[17P]M?A=\9O$WAW3U9-.MYUEM
M5<Y*Q2(LBKGJ=N_;D\_+7Z'_ +*'P4TOX3?"_2KD6L9\0ZO;1W>H7C+^\RZA
MEB![*@(&.YR>]?69EGM' X&&+BN;VEN5;;J^OIU^X\'#994KXN6%;MRWN_1V
MT]>A\(V'[&OQDU&V2>+P5,B. 0)[ZUA?\5>4$?0BL?Q9^R_\4_!-DUYJO@O4
M%ME!+RV92[" #)+>2S[1QU.!7WA\0OVXOAM\//$=YHDQU;6;ZRE:"Y_LNU1D
MBD4D,I:1T!((Q\N1[UZ%\(?CKX1^-VF7%WX8OGEEM2HN;*YC\N>#=TW+R"#@
M\J2.",\5\G/B/.J--8FKADJ?>TEH]M;Z>MCWEE&72G[&-9\_:ZW^[\+GX^45
M]D_M^_ G3_#%U8^/]#M$LX=1N#;:G!"N$,Y!9)@!P"P5@WJ0#U)-> ?L]?!R
MX^.'Q+L?#RR/;Z>BFZU"YCQNBMU(W8S_ !,2JCT+9P0#7W.#S7#XO!?7K\L4
MG>_2V_\ P.Y\UB\#5PN(^K[MVMYWV_R.=\"_##Q7\3+UK7POH%[K,B$"1[>/
M]W%G.-\APJ9P<;B*]#N?V,/C+:V[3/X+D9%&2(]0M)&_!5E)/X"OTQT_3?"W
MP<\#>3;1VGAWPUI,!=C]U(U'5F/5F)ZDY+$]R:\D\+?MR_"[Q5XM308KO4;
MRR"&#4+^U$=K,Q.% 8,67.>KJH]<5\0^*,RQ<ISR_#7A'NFW^#2^6OS/H_[%
MPF'A'ZY6M)]FDOQ3^_0_,W7/#^I^&-2ET[6-.NM*OXL;[6]A:*1<],JP!JA7
MZZ?'SX#Z'\=?!\VGWT4=OK$*,VG:H$'F6\G8$]2C' 9>_7@@$?DQK6CW?A[6
M+[2[^$P7UE.]M/$>J2(Q5A^!!KZK),[IYQ3>G+..Z_5>7Y'C9GEDLODFG>#V
M?Z,I4445],>(?IO^PI\.+;P=\$[/6F@5=4\0NUW-*1\WE*Q6%<^FT%OJYIO[
M4_[6G_"A[VRT+1M,@U7Q'=0?:6-VS""VC+%5+!2"Y)5N 1@#.>E?"OA/]I3X
MF^"-,MM.T;QA?6MA;((X;:0)-'&HQA5$BL !CI7+^/?B'XA^)_B!M<\3:B=3
MU1HDA,YBCB^1?NC:BJOZ5^>_ZLU,3F<\9C9*5-MNUW?^ZMMDO/H?5T\XAA\"
ML/034TEKI:_5[]=>A]Z?LQ?MI7'QA\6IX4\3Z39Z;K%S&\EG=:<7$,Q4%FC*
M.S%3M!(.X@X/3C/K/[3G@:Q\>_ _Q99WD2O):6,NH6LA',4T*%U8'MG!4^S$
M=Z^+/V"/AAJ/B?XNP^*_)DCT;P^DC/<$862=XV18@>YPY8XZ8&?O#/V9^U5X
M[M? /P)\57,\@2XOK1]-M4R-SRS*4&/7 +,?937RV<X2A@\XI4LO5G[NBZ2O
M_E9GNY1B*F(P<YXS6.NKZQMKZ]3\EJ***_:S\W"BBB@ HHHH **** "BBB@
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MJNJG!W5M=5?1O;5?/J>EF&;4L=AHTW#W]'?L^MO+[OP*M=MX"^"?CKXG+O\
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M]8_FCV\E_P!_I_/_ -)9:_X*/?\ )'O#W_8>C_\ 2>>O#/\ @G?_ ,EUOO\
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MJS_P3<UR"?X>^*]'#C[3;:HMVR=]DD2J#^<+5Q0YO]59<O\ -K_X&CHK<O\
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M>%K_ .@5]U_LS^&X/"OP%\$6<$?E>9ID5W(.YDF'FN3^+FOA3]O;_DX?4/\
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M??:(Q^%?8?[*'@R\\"? +PIINH1F&]DA>\EB9=K)YTC2*K#L0K*#GN*^._\
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MR.*_WBIZO\PHHHK<Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *^@?VF/\ DFGP-_[%A?YK7S]7
MT#^TQ_R33X&_]BPO\UKR,7_O>&]9?^D,[Z'\"MZ+_P!*1\_4445ZYP!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?J#^PG_
M ,FX:'_U]7?_ *.:OH*OGW]A/_DW#0_^OJ[_ /1S5XQ_P4O_ ./[X>_]<[_^
M=O7X16P/]I9[4PG-R\TI:VOM=[77;N?IF'Q'U3*HU[7Y4M-MVE^I]T,P49)
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ML(HQ%MTFWE< 8S)(@D<_BS$_C7QQ_P %&O!FGZ+X]\->(+2)8;O6;66.["
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MC>OLC_@FO_R.7C3_ *\(/_1AKYWB+_D55_3]4>CEO^^4O5'NO[>7_)NFJ_\
M7[:?^C17YA5^GO[>7_)NFJ_]?MI_Z-%?F%7B<%_\B^?^-_\ I,3VN)/]ZA_A
M7_I4C[T_X)J?\BWXY_Z^[7_T"2NQ_P""A/B:ZT3X(VNGVSF--6U2*VN"#C,:
MH\F/^^D3\JX[_@FI_P BWXY_Z^[7_P! DKN?V_\ PC=^)/@:E]:1-*=&U&*]
MF5!DB(J\;'Z R*3[ FOF<:X+BA.IMS0_])C;\3TLMYWDCY-[5/\ TJ1^:5?I
M3_P3Z\3W6N_ V:QN6+KI&IS6L!)SB-E24#\&D;]*_-:OTG_X)\^&KO0_@=<7
MURC1IJVJ374 88S&J)'G\6C:OL.+N3^RWS;\RMZ_\-<\#(K_ %Z-NS^ZW^=C
MSW_@I7HZFW\":JJ_.K7=J[<<@B-E'Z-^M?#5?</_  4KUM"? ND*X,@^U7<B
M ]!^[521^#X^AKX>K?A;F_LFES?WK?\ @3-,_P"7Z\[;V5_N_P K!1117UA\
MZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7M/[5
M?_(Y^&O^Q;L?_9Z\6KVG]JO_ )'/PU_V+=C_ .SUY5?_ 'VAZ3_]M.ZE_NU7
MUC^IXM1117JG"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?4W_!.G_DN&K?\ 8 G_ /1]O7Z.U^<7_!.G_DN&K?\
M8 G_ /1]O7V?^TW_ ,F_^//^P5-_*OQ?BJG[7-XT[VNHK[VS]$R!\N"E+LW^
M2/3JS-:\3:/X<M'NM6U6RTNU09::\N$B1?J6(%?B?17KK@=7UQ'_ )+_ /;'
M"^)7TH_^3?\  /MK]K;]LG2O$/AZ^\$^!+EKV&\!AU'64!6,Q_Q10YY;=T+]
M,<#.<CXPT?\ Y"UE_P!=T_\ 0A52K>C_ /(6LO\ KNG_ *$*^]RS+:&5T?8T
M%YMO=OS/E,QQM7'-U*G9V71'[:Q?ZI/H*_(W]IO7KCQ%\?/'%U<N6:/4Y;5
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MUU\>/&'P%TSP[J7AO3-*OK"^FEM[N34H99/+D 5HPNR1,9'F=<_=[5\U1?\
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MU]VJOJKGU6"F\VP,_K:NTVD[>2=_O=M.Q^0=%%%?L9^?!1110 4444 %%%%
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MA\/\WUSW=N5W_#]3Y/\ ^"BWAB'2_BSHNL0HJ'5-, EP/OR1.5W'WVL@_P"
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M-QYMP_8D?PH#U<\#H,D@'\H?%?BC4/&OB74M=U:<W&HZA.UQ/)VW,<X'H!T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M72+N=@L8=SEH"3]TEOF7/4LPZD _%=%?95<FPU7+UEVT4M'U3[^M]_5GSO\
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M,?0L1DXKS6BBOTC#T*>&I1HTE:,59'R%:M/$5)5:F["BBBMS$**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O:?VJ_P#D<_#7_8MV
M/_L]>+5[3^U7_P CGX:_[%NQ_P#9Z\JO_OM#TG_[:=U+_=JOK']3Q:BBBO5.
M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^IO^"=/_)<-6_[ $_\ Z/MZ^S_VF_\ DW_QY_V"IOY5^3_ASQ7K?@^^
M>]T'6-0T2\>,Q-<:==/;R,A()4LA!(R <>P]*VM3^,/CW6]/N+#4?&_B._L;
MA#'-;76K7$D4BGJK*SD$>QKXC->'ZN88^&,C422MIKT=SZ7+\VA@\/*A*+;;
M?XHY"BBBOMSYH*MZ/_R%K+_KNG_H0JI2H[1NKHQ5E.0P."#ZTR)+FBT?M_%_
MJD^@K\>_CU_R6WQY_P!AN\_]'-48^.OQ) P/B%XJQ_V&KG_XNN.O]0NM5OKB
M]O;F:\O+AS+-<7$A>21R<EF8\DD\DFOB<AR"KE%:=6<U+F5M/4^HS+-H8ZA&
ME&+5FG^#7ZGTC_P3X_Y+Y)_V![G_ -#CK[3_ &K/^3>/'/\ UX'_ -#6ORG\
M/>*-9\(Z@;[0M6OM%OBAC^TZ?<O!)M.,KN0@X.!Q[5M:M\7O'>O:=/I^I^-?
M$6HV$Z[)K6[U6>6*1?1E9R"/K2S3(*N/S"&,C424>73T=Q9=FL,%AY491;;;
M?X)?H>E_L8_%C3_A3\8H9=8N!:Z1JULVG3W#G"0LS*T;L>PW* 3T 8D\"OTU
M\3>&=)\<>'+W1M8M(M2TF_B\N:!S\KJ>001R".""#D$ BOQ2KTSP1^TK\3?A
MUIB:=H/BZ\MK! %CMKA([I(@.@03*VP>RX%3GO#T\RK1Q6&FHU%IK>VFSNM4
MU_EL+*LU6!C*E5C>+=]-_P#@GW=X9_88^%/@[6VUF>WO]6CA;SDM=7NU>UAP
M<Y*JJ[@/1RPQUS7LW@;Q]H'Q%TJXU#PW?Q:EI]O=269GA^X73 ;:>XY&".",
M$9!!K\I/'O[0_P 1OB;8?8?$?BN]O;$_>M8E2WAD_P!](E56Z?Q XKG/#?Q'
M\6^#K.2TT#Q1K6AVLDGFO!INH36Z,^ -Q5& )P ,^PKRZO"V.QM/FQN)YJBV
MW:2Z[VW]%YW.^&=87#S_ -FHVB]]DWV/>/\ @H!X?N-#^/,>K*KQQ:GI\$\<
MRY&7CS&0#ZC8AX]17UW^S#^T9I7QM\(6MM<745OXOL852_L78*TI  \^,=T;
MJ<?=)P>Q/YC>)O'7B3QH;<^(?$.JZ\;?=Y)U.]DN/*W8W;=['&<#..N!678:
MA=:5>PWEE<S6=W P>*XMY"DD;#H58<@^XKW*_#ZQ>6TL'7E[]-:27^7:UK^A
MYJS9TL;+%4E[LK73]/\ /8_4_P"+/[(/P\^,&MR:SJ5M>Z5K$V//O=)G6)I\
M# WJZNA..^T$]S6M\'/V9? _P/N9KWP_:7-QJLT1A?4=0F\V8QD@E1@*J@D#
M.U03CFOSUT?]L#XPZ'91VMMXWNI(HQ@->6UO<R'ZO+&S'ZDU5\1_M7?%KQ59
M-:7_ (WOT@;[PL4BLV/MNA1#CVS7SO\ JYG3I?57B5[+:UY;>EOPO8];^U\N
M<_;NB^?O9;_?^-CZJ_;P^/\ I6F>$+GX=Z/>)=ZWJ#)_:/DMD6D"L&V,1T=R
M!\O4+DG&5S\F?LX_&63X'?$ZRUYXWN-+F0VFHP1GYG@8@DK_ +2D*P]<8XSF
MO,&8NQ9B68G)).2325]G@,EP^!P4L$_>4K\S[WT^7EV]3Y[&YC5Q>(5?X>7;
MRMK]Y^ST<OA?XO>""4:S\1^&M6AP<$/%*I['T8$>Q4CL17CNA_L(_"S0_%4>
MM+:ZG>1Q2"6+2[R[$EHC Y'&T.P!'1G(/?-?G7X'^*'BWX:W33^&/$%_HS.V
MYX[:4B*0XP"\9RK?\"!KT5_VT_C-)$8SXT<*1C*Z;9@_F(<U\=_JQF>#E*.7
MXFT)=VT_P35_/0]_^VL)B81^N4;R79)K\6ONU/T;^,7Q@T#X*^#KG6]9N(UD
M",MG8A@);N4#A$'7KC)QA1R:_([Q=XHO_&WBC5=?U.3S;_4;E[F9AG 9CG S
MT Z =@!2>)_%NM^--4;4=?U:\UB^88^T7L[2L!G.T%CP.> .!637T^1Y%#)X
M2E*7-4EN^B79?UJ>1F>:2Q]H15H+\7W84445]2>$?K-^RK\-8/AE\$_#UH(1
M'J&H0+J5\Y&&:650V#_NKM3_ (#7KM?CE'\<?B/#&L<?Q \4I&@"JJZU<@ #
MH -]._X7K\2O^BA>*O\ P=W/_P 77Y9BN$<7BZ\Z\ZRO)M[/J?:8;/:&&HPH
MQIOW5;I_6I^Q=<E\7?\ DE'C3_L"WO\ Z(>ORA_X7K\2O^BA>*O_  =W/_Q=
M17GQJ^(6H6D]K=>//$US:SHT4L,VL7#I(A&&5E+X(()!!K&GP7B(34O;+1]F
M=<>):,6G[-_>CC****_63X **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>#AE((KW<;P_''X"CAZLK5*:24EMHK:KL[+T?X^;1S9X?&5,13C[LW=I_?\
MFV?IQ\1OV)/AK\1]?N-9EAU+0[^ZD,URVCW"1I,YZL4='4$GD[0,G)/)KN/A
M!\!/!_P/LKJ+PS92I<7847-[=S&6:8+G:">  ,GA0!7YU6'[97QDTZV2"+QK
M,Z(  9[&UF?\6>(D_4FL3Q?^TU\4/'5BUEK'C/4)+1P5>&UV6JR C!5A"J;A
M['(KYV7#F<U::PU7$KV?:\GIZ6_"YZRS?+HS]M&B^?T6_P!_XV/H?]OCX_Z7
MX@MK?X>>'[M+[[/<BXU6Y@;=&KJ"$@!'#$$EFQT(4=<@>+_LF_':/X'?$8SZ
MD7/AW546UU#8,F+!RDP'?82<@<[6;&3@5XE17VN%R;#8; /+WK%[OJV^OEY=
MK(^=Q.8U<1B5B=FK6\K?UKZG[/:[H'ACXN^"VLM0AM/$/AS4X@ZE'WQR*>5=
M'4Y!'4,I!'8UY-X%_8C^&G@+Q=#XAMH=2U*YMI1-:VVI7*R06[@Y5E544L1V
MWEO7J,U^=?@/XQ>-?ABQ_P"$8\2W^DQ,2S6\<F^!F/\ $8FRA/'4C-=U<_MG
M_&6Z@:%_&DBHPP3'I]HC?@RQ CZ@U\6N&,TPO-2P6)2IR\VOP2:^9]#_ &U@
ML0HRQ5&\EY)_FU]Q^@W[07QYT;X%^"[B_NIXIM<N(V33--W?O)Y.@8CJ$4\L
MW3MU(!_)?4M1N=8U&ZO[R5KB[NI7GFE?J[L2S,?<DDU-KGB#4_$^I2ZCK&HW
M6JW\N-]U>S-+(V.F68DU0KZS),DIY/3DK\TY;O\ 1>7YGBYGF<LPDDE:*V7Z
MO^M HHHKZ4\0_0#]AK]H_3M5\,V?P[\07J6NL6&8]+EG;:MU#G(B!/\ &F<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'7_![_DK?@G_ +#=E_Z/2KGQV_Y+)XS_ .PI/_Z&:I_![_DK?@G_ +#=E_Z/
M2KGQV_Y+)XS_ .PI/_Z&:\E_\C%?X/\ VY'=_P PG_;WZ'"4445ZQPA1110
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M)+FTBME_6[/J7]BK]I>R^%.H7/A/Q/<&W\-ZE,)H+UN5L[@@*=_I&X R?X2
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M+VWO+.XEM+NWD66&X@<I)&ZG*LK#D$$ @CIBNQ/QT^))!!^(7BH@]O[:N?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OH']IC_DFGP-_[%A?YK7S]7T#^TQ_R33X&_P#8L+_-:\C%_P"]X;UE_P"D
M,[Z'\"MZ+_TI'S]1117KG %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7M/[
M5?\ R.?AK_L6['_V>O%J]I_:K_Y'/PU_V+=C_P"SUY5?_?:'I/\ ]M.ZE_NU
M7UC^IXM1117JG"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %O1_^0M9?]=T_
M]"%>I_M9_P#)?O$_TM?_ $EBKRS1_P#D+67_ %W3_P!"%>I_M9_\E^\3_2U_
M])8J\JI_R,:7^"?_ *5 [H?[I/\ Q1_*1Y#1117JG"%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '7_![_DK?@G_L-V7_ */2KGQV_P"2R>,_^PI/_P"AFJ?P
M>_Y*WX)_[#=E_P"CTJY\=O\ DLGC/_L*3_\ H9KR7_R,5_@_]N1W?\PG_;WZ
M'"4445ZQPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!W'P*_Y+=\/?\ L8M.
M_P#2F.OV+K\=/@5_R6[X>_\ 8Q:=_P"E,=?L77Y%QM_O%'_"_P S[WAO^#4]
M5^04445^;GV!^.GQU_Y+=\0O^QBU'_TIDKAZ[CXZ_P#);OB%_P!C%J/_ *4R
M5P]?TWA/]WI_X5^1^,5_XL_5_F%%%%=1B%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5] _M,?\DT^!O_8L+_-:^?J^@?VF/^2:? W_ +%A?YK7D8O_ 'O#>LO_ $AG
M?0_@5O1?^E(^?J***]<X HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]I_:K
M_P"1S\-?]BW8_P#L]>+5[3^U7_R.?AK_ +%NQ_\ 9Z\JO_OM#TG_ .VG=2_W
M:KZQ_4\6HHHKU3A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"WH__(6LO^NZ
M?^A"O4_VL_\ DOWB?Z6O_I+%7EFC_P#(6LO^NZ?^A"O4_P!K/_DOWB?Z6O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/AK_ -!OQ5_X%VW_ ,CU]4T4?V_FG_/^0?V7@O\ GTCY6_X=R?#7_H-^*O\
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M!=M_\CU]4T4?V_FG_/\ D']EX+_GTCY6_P"'<GPU_P"@WXJ_\"[;_P"1Z/\
MAW)\-?\ H-^*O_ NV_\ D>OJFBC^W\T_Y_R#^R\%_P ^D?*W_#N3X:_]!OQ5
M_P"!=M_\CT?\.Y/AK_T&_%7_ (%VW_R/7U311_;^:?\ /^0?V7@O^?2/E;_A
MW)\-?^@WXJ_\"[;_ .1Z/^'<GPU_Z#?BK_P+MO\ Y'KZIHH_M_-/^?\ (/[+
MP7_/I'RM_P .Y/AK_P!!OQ5_X%VW_P CT?\ #N3X:_\ 0;\5?^!=M_\ (]?5
M-%']OYI_S_D']EX+_GTCY6_X=R?#7_H-^*O_  +MO_D>C_AW)\-?^@WXJ_\
M NV_^1Z^J:*/[?S3_G_(/[+P7_/I'RM_P[D^&O\ T&_%7_@7;?\ R/1_P[D^
M&O\ T&_%7_@7;?\ R/7U311_;^:?\_Y!_9>"_P"?2/E;_AW)\-?^@WXJ_P#
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MXJ_\"[;_ .1Z^J:*/[?S3_G_ "#^R\%_SZ1\K?\ #N3X:_\ 0;\5?^!=M_\
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M?#7_ *#?BK_P+MO_ )'KZIHH_M_-/^?\@_LO!?\ /I'RM_P[D^&O_0;\5?\
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M^1Z^J:*/[?S3_G_(/[+P7_/I'RM_P[D^&O\ T&_%7_@7;?\ R/1_P[D^&O\
MT&_%7_@7;?\ R/7U311_;^:?\_Y!_9>"_P"?2/E;_AW)\-?^@WXJ_P# NV_^
M1Z/^'<GPU_Z#?BK_ ,"[;_Y'KZIHH_M_-/\ G_(/[+P7_/I'RM_P[D^&O_0;
M\5?^!=M_\CT?\.Y/AK_T&_%7_@7;?_(]?5-%']OYI_S_ )!_9>"_Y](^5O\
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M_P"!=M_\CT?\.Y/AK_T&_%7_ (%VW_R/7U316G]OYI_S_D1_9>"_Y](^5O\
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MMO\ Y'KZIHH_M_-/^?\ (/[+P7_/I'RM_P .Y/AK_P!!OQ5_X%VW_P CT?\
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MY/AK_P!!OQ5_X%VW_P CU]4T4?V_FG_/^0?V7@O^?2/E;_AW)\-?^@WXJ_\
M NV_^1Z/^'<GPU_Z#?BK_P "[;_Y'KZIHH_M_-/^?\@_LO!?\^D?*W_#N3X:
M_P#0;\5?^!=M_P#(]'_#N3X:_P#0;\5?^!=M_P#(]?5-%']OYI_S_D']EX+_
M )](^5O^'<GPU_Z#?BK_ ,"[;_Y'H_X=R?#7_H-^*O\ P+MO_D>OJFBC^W\T
M_P"?\@_LO!?\^D?*W_#N3X:_]!OQ5_X%VW_R/1_P[D^&O_0;\5?^!=M_\CU]
M4T4?V_FG_/\ D']EX+_GTCY6_P"'<GPU_P"@WXJ_\"[;_P"1ZV/%'[&O@KXL
M7EMJ6KZIKUM/8VR:9&ME<0*IBBSM+;H6.[YCD@@>PKZ1K'\,?\>=Q_U\/_2I
M>=9C*2J.L[K;Y[E++L(DXJFK/]#YN_X=R?#7_H-^*O\ P+MO_D>C_AW)\-?^
M@WXJ_P# NV_^1Z^J:*K^W\T_Y_R)_LO!?\^D?*W_  [D^&O_ $&_%7_@7;?_
M "/1_P .Y/AK_P!!OQ5_X%VW_P CU]4T4?V_FG_/^0?V7@O^?2/E;_AW)\-?
M^@WXJ_\  NV_^1Z/^'<GPU_Z#?BK_P "[;_Y'KZIHH_M_-/^?\@_LO!?\^D?
M*W_#N3X:_P#0;\5?^!=M_P#(]'_#N3X:_P#0;\5?^!=M_P#(]?5-%']OYI_S
M_D']EX+_ )](^5O^'<GPU_Z#?BK_ ,"[;_Y'H_X=R?#7_H-^*O\ P+MO_D>O
MJFBC^W\T_P"?\@_LO!?\^D?*W_#N3X:_]!OQ5_X%VW_R/1_P[D^&O_0;\5?^
M!=M_\CU]4T4?V_FG_/\ D']EX+_GTCY6_P"'<GPU_P"@WXJ_\"[;_P"1Z/\
MAW)\-?\ H-^*O_ NV_\ D>OJFBC^W\T_Y_R#^R\%_P ^D?*W_#N3X:_]!OQ5
M_P"!=M_\CT?\.Y/AK_T&_%7_ (%VW_R/7U311_;^:?\ /^0?V7@O^?2/E;_A
MW)\-?^@WXJ_\"[;_ .1Z/^'<GPU_Z#?BK_P+MO\ Y'KZIHH_M_-/^?\ (/[+
MP7_/I'RM_P .Y/AK_P!!OQ5_X%VW_P CT?\ #N3X:_\ 0;\5?^!=M_\ (]?5
M-%']OYI_S_D']EX+_GTCY6_X=R?#7_H-^*O_  +MO_D>C_AW)\-?^@WXJ_\
M NV_^1Z^J:*/[?S3_G_(/[+P7_/I'RM_P[D^&O\ T&_%7_@7;?\ R/1_P[D^
M&O\ T&_%7_@7;?\ R/7U311_;^:?\_Y!_9>"_P"?2/E;_AW)\-?^@WXJ_P#
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MXJ_\"[;_ .1Z^J:*/[?S3_G_ "#^R\%_SZ1\K?\ #N3X:_\ 0;\5?^!=M_\
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M?#7_ *#?BK_P+MO_ )'KZIHH_M_-/^?\@_LO!?\ /I'RM_P[D^&O_0;\5?\
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M%']OYI_S_D']EX+_ )](^5O^'<GPU_Z#?BK_ ,"[;_Y'H_X=R?#7_H-^*O\
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M^@WXJ_\  NV_^1Z^J:*/[?S3_G_(/[+P7_/I'RM_P[D^&O\ T&_%7_@7;?\
MR/1_P[D^&O\ T&_%7_@7;?\ R/7U311_;^:?\_Y!_9>"_P"?2/E;_AW)\-?^
M@WXJ_P# NV_^1Z/^'<GPU_Z#?BK_ ,"[;_Y'KZIHH_M_-/\ G_(/[+P7_/I'
MRM_P[D^&O_0;\5?^!=M_\CT?\.Y/AK_T&_%7_@7;?_(]?5-%']OYI_S_ )!_
M9>"_Y](^5O\ AW)\-?\ H-^*O_ NV_\ D>C_ (=R?#7_ *#?BK_P+MO_ )'K
MZIHH_M_-/^?\@_LO!?\ /I'RM_P[D^&O_0;\5?\ @7;?_(]'_#N3X:_]!OQ5
M_P"!=M_\CU]4T4?V_FG_ #_D']EX+_GTCY6_X=R?#7_H-^*O_ NV_P#D>C_A
MW)\-?^@WXJ_\"[;_ .1Z^J:*/[?S3_G_ "#^R\%_SZ1\K?\ #N3X:_\ 0;\5
M?^!=M_\ (]'_  [D^&O_ $&_%7_@7;?_ "/7U311_;^:?\_Y!_9>"_Y](^5O
M^'<GPU_Z#?BK_P "[;_Y'H_X=R?#7_H-^*O_  +MO_D>OJFBC^W\T_Y_R#^R
M\%_SZ1\K?\.Y/AK_ -!OQ5_X%VW_ ,CT?\.Y/AK_ -!OQ5_X%VW_ ,CU]4T4
M?V_FG_/^0?V7@O\ GTCY6_X=R?#7_H-^*O\ P+MO_D>C_AW)\-?^@WXJ_P#
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M<$''<4[7/V$? /CW6+SQ%J&K^)(;W4Y6NIH[:YMUC5F.2%#0$@?4FOI'5O\
MD%WG_7%__033-$_Y!%I_US7^53_;68\WM?;/FVOY%?V=A+<GLU;<^9/^'<GP
MU_Z#?BK_ ,"[;_Y'H_X=R?#7_H-^*O\ P+MO_D>OJFBJ_M_-/^?\B?[+P7_/
MI'RM_P .Y/AK_P!!OQ5_X%VW_P CT?\ #N3X:_\ 0;\5?^!=M_\ (]?5-%']
MOYI_S_D']EX+_GTCY6_X=R?#7_H-^*O_  +MO_D>C_AW)\-?^@WXJ_\  NV_
M^1Z^J:*/[?S3_G_(/[+P7_/I'RM_P[D^&O\ T&_%7_@7;?\ R/1_P[D^&O\
MT&_%7_@7;?\ R/7U311_;^:?\_Y!_9>"_P"?2/E;_AW)\-?^@WXJ_P# NV_^
M1Z/^'<GPU_Z#?BK_ ,"[;_Y'KZIHH_M_-/\ G_(/[+P7_/I'RM_P[D^&O_0;
M\5?^!=M_\CT?\.Y/AK_T&_%7_@7;?_(]?5-%']OYI_S_ )!_9>"_Y](^5O\
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MMO\ Y'KZIHH_M_-/^?\ (/[+P7_/I'RM_P .Y/AK_P!!OQ5_X%VW_P CT?\
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M%%%<)TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5C^&/^/.X_Z^'_I6Q6/X8_X\[C_KX?\
MI5+9BZFQ1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DW^J?_=-9OA?_
M ) =M_P+_P!"-:4W^J?_ '36;X7_ .0';?\  O\ T(U7V1=35HHHJ1A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!4U;_ )!=Y_UQ?_T$TS1/^01:?]<U_E3]
M6_Y!=Y_UQ?\ ]!-,T3_D$6G_ %S7^55]D74O4445(PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_#'_'G<?]?#
M_P!*V*Q_#'_'G<?]?#_TJELQ=38HHHJ1A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 R;_5/_ +IK-\+_ /(#MO\ @7_H1K2F_P!4_P#NFLWPO_R [;_@7_H1
MJOLBZFK1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4SCSS;1[/K_K-V/PK/\ VDO&^A^/?@0^HZ#J4.HVO]H0*QCR&0_-PRG!4^Q
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MBG5_[1T)W\NYC^R0QE%/'F H@/R]<=QFNN_;D_X^/"/^[<_SCKY8K]XX=RG
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MS&/56  ;Z,,GU%?8OA?Q1IOC+0;36-)N5NK"Z3='(."/4$=B#P1ZBOA#X_\
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MV<C#J1V]*]+L+^VU2SAN[*XBN[690\<\#AT=?4$<$5R'QA_X0S_A#F_X3O\
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MO["<9CGA;*GU'L1W!Y'>KQ>68W )/$TG%/JUI]XJ>(HUG:G)-FA117F_CO\
M:#\$?#Z[ELM0U0W6HQ</9V"&:1#Z,>%4^Q(-<V&PM?&3]GAX.4NR5S6<XTUS
M3=D>D45X /VU? Q;']F:^!_>^S0X_P#1U>@^ ?CGX-^)%PMKI&JA=0()%E=H
M8I3_ +H/#>ORDUZ&(R7,<+!U*U"2BNMMO6VQSPQ=";Y8S5SOJ***\4ZPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "L?PQ_QYW'_7P_]*V*Q_#'_'G<
M?]?#_P!*I;,74V****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,F_U3_[
MIK-\+_\ (#MO^!?^A&M*;_5/_NFLWPO_ ,@.V_X%_P"A&J^R+J:M%%%2,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** *FK?\ (+O/^N+_ /H)IFB?\@BT_P"N
M:_RI^K?\@N\_ZXO_ .@FF:)_R"+3_KFO\JK[(NI>HHHJ1A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M::'8Q&0,2(I/'I17GU*52C-TZL7&2Z-6?W'7"<:D5*#NGU1V5%%%9%A1110
M4444 ?%F@?LL^)_'7C'5+W54/A[17O9G\Z=<SRJ9"?DCZC/JV!SD9Z5>_:N\
M":-\._"W@C2-$M!;6R279=SS)*^(<N[=V/\ ]88  K[%KY:_;F_X]/!O^_=_
MRAK]/R?/<9FN<8:G6=H*]HK;X):ON_7Y6/#Q&#I4*%6I%7D[ZG'?L5_\E/U/
M_L%2?^C8J^UJ^*?V*_\ DI^I_P#8*D_]&Q5]K5Y?&G_(VE_AB+)_]W?K^B/E
MK]N;_CT\&_[]W_*&O./V0_\ DLUK_P!>=Q_Z"*]'_;F_X]/!O^_=_P H:\X_
M9#_Y+-:_]>=Q_P"@BOM,N_Y)&7^&I_Z5(X,9_P C&'K'\S[LHHHK\0/K HHH
MH *^-?VV_P#D?-!_[!O_ +5>OLJOC7]MO_D?-!_[!O\ [5>ON.#?^1Q#TE^1
MYF9?[I/Y?FCC/V=?BSI'PC\1ZIJ&L6U[<PW5H($6Q1'8-O#9.YUXP*]]_P"&
MUO __0*\0?\ @/!_\>KY?^%GPFU?XN:K>:?H]S96TUK#Y[M?.Z*5W!<#:C<Y
M-:7Q'^ 'B_X860OM4M8;K3MP5KVPD,D:$]-V0&7/J1CMFOTK,LKR3,,P<<5/
M]\[:<UNFA\YAJ^+HT6Z4?=7D>G?%K]KF#Q?X4OM#\/Z1<V8OHS#-=WKJ&6,_
M>554GDCC)/ [>G@G@OPC?^.O$^GZ)IL32W-W($R!D1K_ !.?0*,D_2F>$X=#
MN-=MH_$4]Y:Z2S8EFL45I$]\-V]>I]CTK] /A'\-_!O@G0XKSPG$EU%>QAO[
M4=Q++.G;Y^P_V0 ,CIFL,?B\'PCA71PE)\T]GJU?S;[=E^&Y=.-;-*G[R2LO
MZT7ZG:Z981:5IMI90Y\FVB2%,_W5  _05\M_MO\ B/,OAK04;HLE]*,^OR)_
M*2OJVO@#]IC7V\3_ !IUE(LNMFR6$2CGE!AA_P!]EJ^!X-P[Q.;*M+["<OF]
M/UN>]F,U1PDDM+V7]?),^D/V0?#?]B_"9+YTVRZI=R7&>Y1?W:_^@,?QKR3]
MMO\ Y'S0?^P;_P"U7KZM\#>'E\)^#=$T=0%^Q6<4+8[L%&X_B<G\:^4OVV_^
M1\T'_L&_^U7KNR#%?7>)98CI+G:]+.WX'-7I^RRWD\E]]U<X?X3>'/\ A)OA
MY\38%3?-;Z?!>1XZ@Q2,Y_\ '0P_&G?LQ>)_^$9^,>C;W*07^^PDYZ[Q\G_C
MX2O1?V*-.AU*?QM%."T<MK! Z]BKF4-_*OGZ^@NO!/C&>%28[W2;XJI/!#Q2
M<'\UK]"4HX[$YAELNJC_ .302_"R/":<*%*O'=-_YK]3Z[_;-\3?V7\.K'2$
M8B75+P;@#UCC&X_^/%*^??A!X<^V>#/B3K;IE+'1C;HQ[/(P/_H,9_.MK]JO
MQY%XU\8:,+1PUI;Z7#,H#9 >91(?_'2@_"N^^%'AS^R/V3?&.HNFV75(+N8-
MW*(OEK^JN?QKP,)%Y1D-&$E:=6<?QDG_ .DH].I)8O,(I;17Z7_-GS%H7_(;
MT[_KXC_]"%?J17Y;Z%_R&]._Z^(__0A7ZD5YGB!\>&])?^VADF]3Y?J%%%%?
MDA]0?"/[7/\ R6B]_P"O2W_] JC\#?CS_P *7M]8B_L/^V/[0:)L_:_(\O8'
M_P!ALYW>W2KW[7/_ "6B]_Z]+?\ ] JC\#?@-_PNBWUB7^W/['_L]HEQ]D\_
MS-X?_;7&-OOUK^B*/U'_ %>H_P!H_P +DA??RM\.N]MCXJO[7Z^_8_%?3[O/
M3:YZC_PW1_U)/_E6_P#M%<?\6?VIO^%H>"+OP]_PC']F?:'C?[3_ &AYNW8X
M;&WRESG&.M=A_P ,+_\ 4[?^4G_[?7'_ !9_99_X5?X(N_$/_"3_ -I_9WC3
M[-_9_E;M[A<[O-;&,YZ5X>!_U2^M4OJO\3F7+_%WOIOIOWT.N?\ :G)+FVL[
M_#M;7\#RGX9_\E'\*?\ 86M/_1R5^EES<16=O+/,XCAB0N[MT50,DG\*_-/X
M9_\ )1_"G_86M/\ T<E?>GQXU*32O@_XKN(G*/\ 8FB##_;(0_\ H5</&M'Z
MQC\)17VM/ODD5DS4?:M^7ZGQ'\9?BI?_ !5\7W%_-(Z:9"S1V-H3\L4>>#C^
M\W4G\.@%>B?#W]C_ %OQAX<@U;4]7BT$7,8EM[8VQFD*D94O\R[,C!QR>><=
M*\'TZ6"'4+62Z1I+9)5:5%ZL@(W ?AFOLQ?VU? R*%72=?  P +:#C_R-7TV
M=/,<NP]'"Y)2T6[23LE:RUTUUNSAPSHXFM*KBY?U_DCY6^(OP[UGX4^*&TK5
M %F4":WNH"=DJ9X=#P>HQZ@BOL;]F+XL7/Q*\%RVVJ2^=K.DLL,TIZS1D'RY
M#[_*P/NN>]?/G[1WQJ\-_%^WT0Z/8ZC;7=B\HDDOHHTW(P7@%7;/*]ZT?V+M
M4>U^)NH663Y=WIKDCMN1T(/Y%OSK@SG#ULRR#V^.I\M:"O\ <[/Y-:V_R-:,
MX8;&I4)7A*R^_P#R9Z7^V!XA\0KHEAX?T:PU"2QNU,]_=6T#M&5!PL1<#'4%
MB,]E]:\#^#OP$UGXNW-XT=PFDZ;9L(YKN>,L=YYV*F1DXY.2,9'K7W'X[^(6
MA_#?13J>NW@MH"=D<:C=),W]U%[G]!W(KYR\3_MO7#2.GAWPW&B _)/J<Q8L
M/>-,8_[[-?/Y!C<U>7?5<LPR3O\ Q&U:]]79JS=M.MNQZ..I8=UE4Q%33^7^
MO,YGXE_LCZEX#\+7NN66O0ZQ!91^;/"]L;=P@ZE?F8''7DC@&O,_@[XLNO!G
MQ)T#4+:9XE-W'!.JGB2%V"NI'?@Y^H![5L>-OVB?'/CNRN+&^U5;;3K@%9+.
MRA6)&4]5)Y8CV+&N)\*_\C1H_P#U^0_^ABOT/!8?'O U*6;2C.33V71K9Z)?
M<CP,3/#\ZEA4U;^M#],=?UJW\-Z'J&JW;;;6R@>XD/\ LJI)_'BOS;\?>.=3
M^(GBB\UO5)2\T[?NX\_+#'_"BCL /SY/4U]Q?M-WKV7P2\2&/AI%BB)ST#2H
M#^F1^-?$/PQTN'6_B-X8L+A0T%QJ5O'(IZ%3(N1^(KXG@C#TJ.$KYA-7DFU\
MDDW;UO\ @>UG-27N4EL]?7HOU/7? /['>N>*M!AU/5]7B\/_ &A!)#;&V,\N
MT\@N-RA<C!QDGUP>*\[^*?PJ\1?!W4/[-U"82Z??#=%<VS-Y-P%/0@]&7(X/
M3/!.:_1;I7AG[8NF0WGPD6Z=09K2_A>-NXW;E(_7]*X<HXLQV+S.%+$6=.;M
M:RTOM9[Z.V]S6MEE&GAY./Q)-W[V1\N? +_DLGA+_K]7^1K]%Z_.CX!?\ED\
M)?\ 7ZO\C7Z+UAQ[_OU'_!^K)R;X)^H5#>W(LK.>X,<DPBC:3RXE+.V!G"@=
M2>PJ:BOS-6OJ?1'YN_$:\\4^,O&EWJ>MZ=?P7U[-LAM[B!T**3A(E##H.@%>
MS:)^Q#J=YI44^I^)X-.OG4,UK#9F=4)'W2_F+SZX&/3->G_$K]JWPOX$OY]-
ML()?$.IP,4D2W<1P1L.JF0@\C_94_7->)^(?VS?&>IK)'IEGINC1G[KK$9I5
M_%SM/_?-?MU/%<08_#THY?06'@ENVG==+)JZ7R=^Y\I4I8.C5E+$3YV^G_#'
MF'Q0^&NH_"KQ5)HFHRPW#^6LT4\&=LD;9P<'D'(((]N_6OJG]C;Q7=ZY\/K_
M $N[E>?^RKH) SG)6)UR$^@(;'UQ7R!XJ\7ZSXWU5M2US4)=1O2H3S9<#"C)
M"@   <G@#'-?4/[#O_($\5_]?$'_ *"]=O%%*H\A;Q5I5(\MVMKW2;7WLYL%
M*'UZ/L;J+O\ D_U*_P"W-_QZ>#?]^[_E#7S=X1;7M2N9/#N@F9IM:9+>2"$X
M,P!R%)[+GD]N.>E?2/[<W_'IX-_W[O\ E#7G_P"QU8QW?Q@\UP"UKIT\R9'<
ME$_DYK/),0L)PPL0XI\BFTGM=2;7XV-,?%SQR@G:]E]^ATO_  Q#K(T,SGQ+
M9G5@F19BW;R2WIYN[/X[*^<]1L+G1M2N;*ZC:"[M96BEC/5'4X(_ BOU,K\Z
M/CW"(/C)XM48YOF;CW /]:YN$\^QN:XBK1Q<E*RNM$K:VMITUZZFN8X&CAZ,
M9TUK>WX/_(^T_@!XNN?&WPGT+4;V1IKU4:WFD;J[1L4W$]R0 2?4UX/^V'\5
M+JXUM/!5A.8K&W1)K_8<>;(W*H?91@X]3["O4/V0?^2-V_\ U^S_ ,Q7R9\;
MKM[WXO>+Y)"2PU*:,9/96*C]%%>5D6749<18EN/NTG)I=GS:?=K;Y'17KSAE
MT&GJ[+Y:_P"1:^$?P6UOXOZC/%I[1V=A:X^TWTX)1">B@#EF/)Q^9'%=[\1?
MV2->\":)+K6D:NFNQV:^=-'';F"=%')9!N;=CKU!]J]V_9.TN'3_ (+:7-&H
M$EY///*<=6\PH/\ QU%KV!T61&1U#*PP5(R"*Y\TXNQ^'S.=.C;V<)-<MEK9
MV=WOKY6#!Y;0JX=3J;R_#^O,_*^>>2ZGDFF=I99&+N[G)9B<DD^M?H5^SI_R
M13PK_P!>[?\ HQZ^!O%FGII/BG6;&(8CMKV:%0/17('\J^^?V=/^2*>%?^O=
MO_1CU[O',E/+:,H[.2_])9R97%PQDXO=)_FCTBBBBOQ ^N/E#]N3_CX\(_[M
MS_..O#_AO\-[CXC6/B9+$,^I:;8B]MXE_P"6N' 9/J5)Q[@#O7N'[<G_ !\>
M$?\ =N?YQUC?L1_\CQX@_P"P</\ T:M?NF6XJI@>%HXFE\44W_Y._P SY3&0
MC4S%0EL^7\D>$>%?$U_X+\1V&LZ=(8;VRE$B9Z''53[$9!'H37Z,>$?&EA\0
M? UOKNG-^XNK=BT9.6B< AD/N#D?KWKY&_:K^$G_  A'BS^W].AV:+J[EF5!
MA8+CJR^P;EA_P(=J9^R_\6CX-UVY\.:A-MT?5P5C+GY8;G&%/L&X4^^WTK//
M<)2XARVGF>$7OQ5_.WVH^J>WSMN+!SEEV,]C4^%M?\!_Y_\  /#YO]=)_O&O
MTV\!_P#(C^'?^P=;_P#HI:_,F;_72?[QK]+?"UU]@^&VD7/_ #QTF&3GVA!_
MI7-QXG*CADN[_)%9.KXB:_K<^0?VH_B[=^,_&-UX>L[ADT'293"8T/$\Z\.[
M>N#D#Z$]ZI?!_P#9EUGXJ:3_ &Q-?QZ'I#L5AFDA,LDQ!P2J97Y0>,D]0< U
MX_=7+WEU-<2L6DE<NS'N2<FOK7P-^UKX(\)>#=$T8Z5KF^QLXH)##;PE"ZJ
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M_BCPOJ?@O7KO2-6MGM+ZV?:R,.#Z,I[J>H(ZUZ/X+_:E\=^#K>.V:]AUNTC
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M0ZOJNLQ:))=1B:"V:W,\A4C(,GS+M)ZXY////%>'>&+--1\2Z3:2#*3W<,3
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MMZ_U\K;&E\7?@7K?PDU"SBN9(]3LKTD6UU;*1N88RK+U5N1QR#Z]:^@OV/\
MQ!XB_L>_\/:SI^H1V%LHGL+NY@=8U4G#1!B,=2& ]VKB/"W[;&N6DB1^(-#L
M]1AX!ELF:"7W)!W*3[#;7TI\./BKX>^*>EO>:'=,SQ8$]I.NR: GIN7)X/J"
M1[\&OB>(,5FJR[ZMF6&3_P"GB=U>^CLEIVUM<]+"4\++$*I0G;^Z_P"M3KZ*
M**_)3Z8\S_:2U1M*^"OB:1"0\L26X(]'D53^A-? &D68U'5;*T)P)YTBSZ;F
M _K7WM^U!8-?_!+Q"%&XP^3-CV65,_IFO@O1+M;#6;"Z?[L-Q'(?H&!_I7[E
MP.DLLJN'Q<[_ /28V/D\[^.':WZ_\,?J);6T=G;100J$BB0(BCH% P!4M-CD
M65%="&1@"".XIU?ASNWJ?5JUE;8HZCH>FZP]N]_I]K>O;L6A:YA60QD]2N0<
M'Z5= "@ # '  K$\4^.-!\$I9OKNIP:7'=R^3"]P2%9L9P3C &.YP*U+#4;3
M5;2.ZLKJ&\MI!E)K>0.C#V8<&MI0JJG&<D^7H];>=NA-X\UNIYS^T)\47^%O
M@&6ZLRO]KWK_ &6SR,[&():3'?:!^9%?#'ACPUK7Q-\6PZ;8[[[5;Z1G>6=R
M?=I'8]AR2?YFO>/VX-2D?Q'X9L-Y\J*TEGV]LLX7/_CE>??L[_%/0OA+XEU+
M5-:L[VZ,]I]GA-E&CLN7#-G<ZX!VCI7[9P[AIY?D3Q>%I\U::;]=;)>BW^\^
M6S*I[7%*A.5HJWXZM_=H=MXD_8LUS2O#TE[INNV^KZC$A=[ 6QBW8&2L;[CN
M/ID+FO'OAO\ $+5OA9XMM]6L&=3&WEW5JQ(6>//S(P_EZ'!KZI_X;6\#_P#0
M*\0?^ \'_P >KY(\?:S8>(_&NMZKI<,MMI][=R7$,4RA74,V<$ D#DGH37?D
M=3-<;&KALZI7BUHVDK]UI^'4Y\9#"TXQGA9:I]_Q/TJT;5K?7M(LM2LWWVMY
M EQ$WJK*&'Z&OSS^//\ R6+Q;_U_O_2OL/\ 9>U1]4^">@&0DO;^=;Y/HLK;
M?TP*^//CS_R6+Q;_ -?[_P!*^8X0P_U3.,5A_P"1-?=)(]#,*CK8&G4>[:_)
MGUI^R1_R173O^OFX_P#1AKQ3]MG_ )*3HW_8)3_T=+7M?[)'_)%=._Z^;C_T
M8:\4_;9_Y*3HW_8)3_T=+6.4?\E76]:GZE5/^17\E^:.E_8:_P"9Q_[=?_:M
M?5=?*G[#7_,X_P#;K_[5KZKKYGBW_D=5_P#MW_TF)U93_NJ]7^85XM^UUJ<F
MG_!J[BC8J+R[@MVQW7)?'_CE>TUX=^V)9M=?!\R*NX6^H02L?0$.F?S<?G7G
M9"HO-<,I?SK\]#T,1=4*EOY7^3/C[X;:3'KOQ"\-:?, 8;G4;>)P>ZF1<C\J
M_3*OS1^%NH1Z5\2O"UW*0L4.IVS.QZ >8N37Z75]MQ\Y?6*">W*_OOK^AX.2
MV_>?+]0JA>Z#IFHWD%W=Z=:75W;@B&>:!7>,'KM8C(Z#I5^L#Q+X^\.^#KRQ
MMM<U>UTN6^W>1]J?8K;<;LL>%^\.I%?F-&-6<^6BFY:[7OY[>6Y]))Q2;EL;
M]>'_ +5WB3Q!IO@B#2= L;^9M29EN[FS@=Q% H&5+*/EW$@?0-ZU[7:W4-[;
MQSV\T=Q!(-R2Q,&5AZ@C@UE>+O&&D>!=#GU?6[Q+*RBX+-RSL>BJ!RS'T%=V
M6U7AL93J>R]HT](]WT_$BHN>FTI6NM^Q\"_";X*ZU\6-<N;&V9=-MK-0UU=W
M*'$>20JA>I8X/''0\UZ7XU_8SU/PWX>O=3TWQ'#JSVD+3O;2VAMRRJ,G:=[
MG Z'%=!XJ_;=59)(O#?AS>@/R7.IRXS]8T_^+KRCQ=^TWX^\7VT]K)J<6FV4
MZE)+?3H1&"I&"-QR^,?[5?M,9\38W$1JQC&C3T]UM2OWNTF]?E^I\FHY?1BX
MS;F_+3];?F<%X.\3WG@SQ/INLV$S0W%I,LF5.-RY^93Z@C((]#7Z=QR"6-77
M[K $5^5=?J?9?\><'_7-?Y5\]Q_3BI8:HEJ^9?)<MOS9ODLGSSCTT/RVO/\
MC[G_ -]OYUU_A_P)XU^,%_=WNF:=<ZS,F%FN&=(T7  5=[E5X &%!Z8XKD+S
M_C[G_P!]OYU^@G[-^BP:)\&?#:PH%:YA-U*PZLSL3D_A@?0"OM.(LWEDV$C7
MI04IM\JOLM+O:SZ=SAPV'^M8F5-NRU;^_P#X)Y?^R3\)]7\):]XBU77],GTV
M\A1;*!+A,;@QWNRGH1P@R,CDUYU^U-\7;OQ?XQNO#EG<,FA:5+Y31H>)YUX=
MV]0#E1]">]?;=Y/]EM)YL9\M&?'K@9K\MKVZ>^O)[F1BTDTC2,3U))R:^3X9
MF\\S.MFF)BN:"BDNB;TNON?WGI8Z"P.%5&F_B;U_KU1ZW\'_ -FG6_BMIAU:
M2]BT31RQ2*XEB,LDQ!P2B9&5!R,DCGIGG$7QE_9RUCX1V$6I_;XM8TAY!$US
M'&8GB<]-Z$G /8@GWQQG[0^%>FQ:3\-?"]K$H1$TVW) _O&,%C^))-;VJ:18
MZY9/9ZC96^H6CD%H+J)9(V(.1E6!!P>:\>IQGCJ>82D[.BFURV6U[;[W^=O(
MVI971GAU?XFKW\SXX_9&^*=SH/BY/"=Y.SZ5JF?LZ.<B&X R-OH& ((]=OO7
MLG[8/_)'9/\ K_@_]FKU_3= TS1E"Z?IMI8@<8MH%C_]! KR#]L'_DCLG_7_
M  ?^S5PPS&CFO$&'Q5&ER7E&^M[N^^R.F&'GAL)4IRE?1_+0^7?V=_\ DM7A
M3_KY/_HMJ^X?B_\ \DL\6_\ 8+N/_19KX>_9W_Y+5X4_Z^3_ .BVK[A^+_\
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M?]K3C*^R25UWO9)?F?/8N6$:2P\6N_\ 39^F/P\\0/XK\":!K$IS->V,,TI
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MQ7_P\MTW_H0KO_P9K_\ &J/^'ENF_P#0A7?_ (,U_P#C5/\ U9S;_GS^,?\
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MG_#QOXE?] 3PK_X"7/\ \D52X2S1_97WH3S[!=W]Q^C5%?G+_P /&_B5_P!
M3PK_ . ES_\ )%'_  \;^)7_ $!/"O\ X"7/_P D4_\ 5'-.T?O#^WL%W?W'
MZ-45^<O_  \;^)7_ $!/"O\ X"7/_P D4?\ #QOXE?\ 0$\*_P#@)<__ "11
M_JCFG:/WA_;V"[O[C]&J*_.7_ANWXR?] ?2O_!7-_P#'*/\ ANWXR?\ 0'TK
M_P %<W_QRC_5+,>\?_ O^ ']O83^]]Q^C5%?G+_PW;\9/^@/I7_@KF_^.4?\
M-V_&3_H#Z5_X*YO_ (Y1_JEF/>/_ (%_P _M["?WON/T:HK\Y?\ ANWXR?\
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MMS#](2^[_@GZ-45^<O\ PTE^TO\ ] W5?_"9'_QJC_AI+]I?_H&ZK_X3(_\
MC5'^JN+_ .?M/_P)_P"0?VY0_DG]W_!/T:HK\Y?^&DOVE_\ H&ZK_P"$R/\
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M #[^*_\ P41__&J/^$Q_:R_Y]_%?_@HC_P#C5'^K%3_H)I?^!?\  #^VH?\
M/F?W?\$_1JBOSE_X3']K+_GW\5_^"B/_ .-4?\)C^UE_S[^*_P#P41__ !JC
M_5BI_P!!-+_P+_@!_;4/^?,_N_X)^C5%?G+_ &G^UEJO[W9XK3;\N/LT<'O]
MW:N>O7'\J/\ C++_ *FO_P AT?ZM-;XJE_X$']LKI0G]Q^C5%?G+_P 99?\
M4U_^0Z/^,LO^IK_\AT?ZM?\ 472_\"#^V/\ IQ/[C]&J*_.7_C++_J:__(='
M]C?M9:M_RT\5Q^7_ -/D=OG/_ EST]\?C1_JVEOBZ7_@0?VPWM0G]Q^C5%?G
M+_PAW[67_/QXK_\ !O'_ /':/^$._:R_Y^/%?_@WC_\ CM'^KE/_ *#*7_@0
M?VO/_H'G]Q^C5%?G+_PAW[67_/QXK_\ !O'_ /':/^$._:R_Y^/%?_@WC_\
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M?^2L/KV8/_F&_P#)D?</_"=^&O\ H8=*_P# V+_XJC_A._#7_0PZ5_X&Q?\
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MNOCK_AVGJ?\ T/EI_P""QO\ XY1_P[3U/_H?+3_P6-_\<H_L[(_^@U_^ /\
MR#ZWF?\ T#+_ ,"1]A3_ !?\!VT323>-O#L4:]7?5H% _$O53_A>OPU_Z*%X
M5_\ !W;?_%U\E1_\$TM0,BA_'ULJ9&XKI;$@=\#S1G\ZN?\ #LW_ *J1_P"4
M+_[IH_L_(5OC7_X _P#(/K6:/;#K_P "7^9]4_\ "]?AK_T4+PK_ .#NV_\
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M /!8O_QVCZGP_P#]!4O_  %__(A]8S7_ )\1^]?YGT;_ ,-'_"[_ *'[P_\
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MW@C_ *&?Q!^<'_QNC_AV]X(_Z&?Q!^<'_P ;H^K\.?\ /^I]R_\ D0]KF_\
MS[A]_P#P3U7_ (; ^#W_ $.]I_X#3_\ QNFR?MA_!Z-&<^-K8A02=MK<$_@!
M'DUY9_P[>\$?]#/X@_.#_P"-TZ/_ ()O^!A(I?Q+XA9,C<%: $CO@^6<?E1]
M7X<_Y_U/N7_R(>US?_GW#[_^">AR?MK_  8:-@/&7)!'_(+O?_C-4=!_;/\
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MNGX/_P#0?N__  6S_P#Q%'_#=/P?_P"@_=_^"V?_ .(K#_X=Z_"[_GX\0?\
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MW_/OX@_\ H__ ([6Y_PPM\'_ /H 7?\ X,I__BZ/^&%O@_\ ] "[_P#!E/\
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M4*)X&TY@3G]X9'/YLQ-'UGAU?\N*GW__ &P>QS=_\O8_=_P#Q/\ X>3^&O\
MH3=5_P# F*C_ (>3^&O^A-U7_P "8J]Q_P"&6/A-_P!"+I7_ 'PW^-'_  RQ
M\)O^A%TK_OAO\:/K7#W_ $#3_P# O_M@]AFW_/Z/W?\  /#O^'D_AK_H3=5_
M\"8J/^'D_AK_ *$W5?\ P)BKW'_AECX3?]"+I7_?#?XT?\,L?";_ *$72O\
MOAO\:/K7#W_0-/\ \"_^V#V&;?\ /Z/W?\ \'NO^"E6B)M^S^"-0EZ[O-OD3
M'IC"G-0?\/+=-_Z$*[_\&:__ !JOH:U_9D^%5INV> ]%;=C/FVPD_+=G'X5/
M_P ,X?"[_H0?#_\ X 1_X4?7.'E_S"S_ / G_P#)!]7S;_G_ !^[_@'SE_P\
MMTW_ *$*[_\ !FO_ ,:H_P"'ENF_]"%=_P#@S7_XU7T;_P ,X?"[_H0?#_\
MX 1_X4?\,X?"[_H0?#__ ( 1_P"%'USA_P#Z!9?^!/\ ^2#ZOFO_ #_C]R_R
M/G+_ (>6Z;_T(5W_ .#-?_C5,G_X*76*Q,8? %Q))V5]550?Q$)_E7TA_P ,
MX?"[_H0?#_\ X 1_X5)!^SO\,+>59$\ >'2PZ!]-B<?D5(-'UWA__H$E_P"!
M/_Y(/J^:_P#/]?<O\CY@_P"'F7_5-_\ RN__ '-1_P /,O\ JF__ )7?_N:O
MJG_A17PU_P"B>^%?_!);?_$4?\**^&O_ $3WPK_X)+;_ .(H^O9!_P! <O\
MP.7^8?5LU_Z"%_X"O\CY6_X>9?\ 5-__ "N__<U'_#S+_JF__E=_^YJ^J?\
MA17PU_Z)[X5_\$EM_P#$4?\ "BOAK_T3WPK_ ."2V_\ B*/KV0?] <O_  .7
M^8?5LU_Z"%_X"O\ (^5O^'F7_5-__*[_ /<U4Y/^"ENH&1BG@&V5,G:&U1B0
M.V3Y0S^5?6O_  HKX:_]$]\*_P#@DMO_ (BKL?PC\"Q(J)X+\/(B@!572H
M/0?)1_:&0K;!/_P-_P"8?5<T>^(7_@*_R/CO_AY9J?\ T(=I_P"#-O\ XW1_
MP\LU/_H0[3_P9M_\;K[%_P"%3^"/^A-\/_\ @K@_^(H_X5/X(_Z$WP__ ."N
M#_XBC^T<C_Z G_X&_P#,/JF9_P#02O\ P%'QU_P\LU/_ *$.T_\ !FW_ ,;H
M_P"'EFI_]"':?^#-O_C=?8O_  J?P1_T)OA__P %<'_Q%'_"I_!'_0F^'_\
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M _.7_A!_VLKG]U]I\5#S/DS_ &U&F,\?>\T8^N>*/^%.?M9?]!#Q5_X5\?\
M\DU^C5%'^M%9?#AZ2_[=?^8?V)3>]6?W_P# /SE_X4Y^UE_T$/%7_A7Q_P#R
M31_PIS]K+_H(>*O_  KX_P#Y)K]&J*/]:<1_SXI?^ O_ .2#^Q*7_/V?WK_(
M_.7_ (4Y^UE_T$/%7_A7Q_\ R31_PIS]K+_H(>*O_"OC_P#DFOT:HH_UIQ'_
M #XI?^ O_P"2#^Q*7_/V?WK_ "/SE_X9S_:;N/WLNI:QYC_,WF>)P6R>3D^<
M<G\:/^&;?VE_^@EJO_A3#_X[7Z-44?ZU8O\ Y]4__ 7_ )A_8=#_ )^3^_\
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M^AE%3_K9FG\Z_P# 4']A8+^5_>S\\_\ AV]XW_Z&;P_^<_\ \;H_X=O>-_\
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MA\M/_!8W_P <H_X=IZG_ -#Y:?\ @L;_ ..5]X44?ZTYM_S]_P#)8_Y!_8F
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M_P"9\<_\.V/#7_0Y:K_X#14?\.V/#7_0Y:K_ . T5?8U%'^L>:_\_P!_<O\
M(/[(P/\ S[7WO_,^0+7_ ()M^$4W?:/%FM2]-OE1PICUSE3FI_\ AV]X(_Z&
M?Q!^<'_QNOKBBI?$6:O_ )?O\/\ (?\ 9.!7_+I?B?(__#M[P1_T,_B#\X/_
M (W1_P .WO!'_0S^(/S@_P#C=?7%%'^L.:?\_P!_A_D/^R<%_P ^E^)\C_\
M#M[P1_T,_B#\X/\ XW3H_P#@F_X&$BE_$OB%DR-P5H 2.^#Y9Q^5?6U%'^L.
M:?\ /]_A_D']DX+_ )]+\3Y6_P"'<GPU_P"@WXJ_\"[;_P"1Z/\ AW)\-?\
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M89!'[WT-?/?[0G[/>I>"]<O-;T.REO/#=RYF(@4LUF2<E6 YV>C= .#[^?\
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M[0FB2Z%\9/%$4BE1/=&[0^JR@/G_ ,>/Y5]2_L@_\D;@_P"OV?\ F*J?M.?
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MA^%>1Q['VE'#5H:QO+7U2:_)FV4+DKSA+>WY,_-2\_X^Y_\ ?;^=?H_\&_\
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MX(WBO-)2U^;;^1M3PTL-@*BGN]3S/]CO_DL _P"P?/\ S2ON6OAK]CO_ )+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 9-_JG_W36;X7_P"0';?\"_\ 0C6E-_JG_P!TUF^%
M_P#D!VW_  +_ -"-5]D74U:***D84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 5-6_P"07>?]<7_]!-,T3_D$6G_7-?Y4_5O^07>?]<7_ /033-$_Y!%I_P!<
MU_E5?9%U+U%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$N+ZQGMHVE)"!GC9020"<9/8&NVC7FZM/VDGRIK=Z+4E1BG=+4_,"OU/LO\
MCS@_ZYK_ "KXP_X8I\<?]!7P_P#^!$__ ,9K[2MXS#;Q(<$JH4X]A7Z#QIF6
M$S!8?ZK44^7FO;I?EM^1\[E>'JT9R=2-M!9H8[B)XI466-P59'&0P[@CO7/V
M_P -O"-I=BZ@\+:+#<J=PFCT^%7!]=P7-='17YM"K4IIJ$FK]F?1.,9;JX44
M45D4%9>M>%]&\2*BZOI%AJJI]T7MLDP7Z;@<5J45<)RIOF@[/R$TFK,R]%\*
MZ+X:#C2-'L-*#_>%E:I#N^NT#-:E%%$YRJ/FF[OS!)15D@HHHJ!A1110 444
M4 %%%% !4-Y96^H6[V]U!%<P.,-%,@=6'N#P:FHIIM.Z YB+X7^#8)A-'X2T
M*.4'(D7380P/UVUTL<:Q(J(H1%&%51@ >@IU%:U*U2K_ !)-^KN2HQC\*L%%
M%%8E&#JO@+PSKMT;G4_#NDZC<GK-=V,4KG\64FM73]-M-)M$M;&UALK9/NPV
M\8C1?HH&!5FBM95:DXJ$I-I=+Z$\L4^:VH4445D4%<_J/P\\*ZQ<-<7_ (9T
M>^G8Y:6YL(I&)]R5)KH**TIU:E)WIR:?D[":4E9HR-&\(:%X<<OI.B:=I;$8
M+6=I'"3_ -\@5KT44ISE4?--W?F"BHJR04445 PHHHH **** "BBB@ J"]L+
M;4K9K>\MXKJW?[T4Z!U/U!XJ>BFFT[H#F(OA?X-@F$L?A+0HY0<ATTV$,#]=
MM=*B+&BHBA548"@8 %.HK6I6J5?XDF_5W)C",?A5@HHHK$H**** "BBB@ HH
MHH **** "BBB@ HHHH Y_4OA[X6UF[:ZU#PUH]]<L<M-<V$4CD^[,I-;%AIU
MII5JEM96L-G;)]V&WC"(OT X%6**VE6J3BH2DVETN2HQ3NEJ%%%%8E!1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !6/X8_X\[C_ *^'_I6Q6/X8_P"/.X_Z^'_I
M5+9BZFQ1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DW^J?_ '36;X7_
M .0';?\  O\ T(UI3?ZI_P#=-9OA?_D!VW_ O_0C5?9%U-6BBBI&%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %35O^07>?\ 7%__ $$TS1/^01:?]<U_E3]6
M_P"07>?]<7_]!-,T3_D$6G_7-?Y57V1=2]1114C"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\,?\ 'G<?]?#_
M -*V*Q_#'_'G<?\ 7P_]*I;,74V****D84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ,F_P!4_P#NFLWPO_R [;_@7_H1K2F_U3_[IK-\+_\ (#MO^!?^A&J^
MR+J:M%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FK?\@N\_ZXO_ .@F
MF:)_R"+3_KFO\J?JW_(+O/\ KB__ *":9HG_ ""+3_KFO\JK[(NI>HHHJ1A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5C^&/^/.X_Z^'_I6Q6/X8_X\[C_KX?\ I5+9BZFQ1114C"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@!DW^J?_=-9OA?_ ) =M_P+_P!"-:4W^J?_ '36
M;X7_ .0';?\  O\ T(U7V1=35HHHJ1A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!4U;_ )!=Y_UQ?_T$TS1/^01:?]<U_E4][ US97$*D!I(V0$],D8ING6[
M6EC!"Y!:- I*]*KH+J6:***D84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >*_M(?M9>$?V7O^$=_X2K3M;U#^W/M'V;^QX(9-GD^5OW^9+'C/G+C&>AS
MCC/BO_#V/X1_]"[XU_\  &T_^2J\X_X+ ?\ -)?^XO\ ^V5?G)7[%D'#&79C
MEM+%5T^:5[V=MI-?DCY?&YA7H5Y4X-65NGDC]8O^'L?PC_Z%WQK_ . -I_\
M)5'_  ]C^$?_ $+OC7_P!M/_ )*K\G:*^@_U+RG^67_@1Q?VKB>Z^X_6+_A[
M'\(_^A=\:_\ @#:?_)5'_#V/X1_]"[XU_P# &T_^2J_)VE'6C_4O*?Y9?^!!
M_:N)[K[C]8O^'L/PC_Z%WQK_ . -I_\ )5'_  ]A^$?_ $+OC7_P!M/_ )*K
M\GZ*/]2\I_EE_P"!!_:N)[K[C]8/^'L'PC/_ #+OC7_P!M/_ )*I?^'L'PD_
MZ%WQK_X VG_R57Y0#I2T?ZEY3_++_P "#^U<3W7W'ZO?\/7_ (2'_F7?&G_@
M#:?_ "52_P##U[X2?]"[XT_\ ;3_ .2J_* =:=1_J7E/\LO_  (/[5Q/=?<?
MJ[_P]>^$G_0N^-/_  !M/_DJE_X>N_"3_H7?&G_@#:?_ "57Y0T\=*/]2\I_
MEE_X$']JXGNON/U;_P"'KGPD_P"A=\:?^ -I_P#)5 _X*N?"4_\ ,N^-/_ &
MT_\ DJORDI5ZT?ZEY3_++_P(/[5Q/=?<?JW_ ,/6_A+_ -"[XT_\ K3_ .2J
M/^'K?PE_Z%WQI_X!6G_R57Y344?ZEY3_ "R_\"#^U<3W7W'ZM?\ #UGX2_\
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M+7_Y(K\V:*/]2\I_EE_X$']JXGNON/TG_P"'DOPS_P"@'XL_\!+;_P"2*/\
MAY+\,_\ H!^+/_ 2V_\ DBOS;HH_U+RG^67_ ($']JXGNON/TD_X>2?#,_\
M,#\6?^ EM_\ )%+_ ,/(_AG_ - /Q9_X"6W_ ,D5^;@Z4M'^I>4_RR_\"#^U
M<3W7W'Z1#_@I'\,S_P P/Q7_ . EM_\ )%+_ ,/(OAI_T _%?_@);?\ R17Y
MNKUI:/\ 4O*?Y9?^!!_:N)[K[C](?^'D7PT_Z ?BO_P$MO\ Y(I?^'D'PT_Z
M ?BO_P !+;_Y(K\W:>.E'^I>4_RR_P# @_M7$]U]Q^C_ /P\@^&G_0#\5_\
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M/\LO_ @_M7$]U]Q^C'_#QCX;?] 3Q5_X"6W_ ,D4?\/%_AM_T!/%7_@);?\
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M  \*^'7_ $!?%'_@+;?_ "10/^"A/PZ/_,%\4?\ @+;?_)%?GM2K1_J7E/\
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MI>4_RR_\"#^U<3W7W'WU_P -]?#[_H#^)?\ P%M__C]'_#?/P^/_ #!_$O\
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M\LO_  (/[5Q/=?<?=?\ PW5X"_Z!'B/_ ,!K?_X_1_PW5X"_Z!'B/_P&M_\
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M_J7E/\LO_ @_M7$]U]Q]Q_\ #<G@3_H$^(O_  &@_P#CU _;C\"'_F$^(O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&>)M0"LCHP(92"001@@UT3@WCX8>#LI)_?>*_5F4))8:=66K3_#WO\D?<?\
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M27^S9;:+^S?MGV3S/-F2+/F>6^,;\_=.<8XZUYU^PY^V]_PV=8^+KC_A"_\
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MTKQ+X<U&'5M#U2W6YM+R G;+&PX//(/8@@$$$$ BOP*^$_\ RD9T3_LHY_\
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M[J6'(S6/^SK_ ,%%?@[^TKXEC\-Z!?ZEH7B28,;;2O$-LEO+=!1D^4R/)&Q
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M[J&QL;6-II[FYD$<<4:C+,S' 4  DD\"G)."O(46I.T=RS17Q;\0_P#@KE\
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MZTE*O6@!U%%% #J*** '+2TBTM !3Z93Z "E7I24J]* %I1UI*4=: '4444
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MKNTDFT=E#.P&>< 9JXJ,J7M$^MEY]_NT^\F3<:BIVZ7?Z?>>GT453U?6=/\
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M_)L/BC_L;;C_ -)+2C![8GY?G K$?\N?G_[<?H#1114#/YZ/^"@D,MS^V_\
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M[.7@SQ7;:[I[:5%H=K]MNVN$2.UDCA43+*2<1E&# AB,8K\*?VZ?B9HOQ?\
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M+_@LEX!LDL+9+-[>U+6ZPJ(S_H<W5<8K]2K#3+/2XFBLK2"TB8[BD$80$^N
M.O%?F%\8/^4T'P__ .O>U_\ 2.>OU&J,/_NJ_P =3_TH=;_>'_AA^3"BBBK
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M^OA/_2NYJC^V;J=OX=_X*O\ P3U'4'^S60BT<&9^%&;RX3.?3)&36>"VR_\
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M_P""H?P%^"G[-GASP/X4^'>A6^E>*KZYEO\ 4&:]FNKK[*J;$+F1VV*SEL
M F,\<5KB7*,U*3M+F6W>_3R7Y(PP]G"T%>+3W[6W?F_S/T._:HU*?6?V!/'&
MH73[[J[\&>?*WJ[0*S'\R:^3?^"2/[(G@[7_ (<W'Q;\7:+9>(M5N[Z2TT>#
M4(EGALXHB \HC8%?,:3< Q!*A!C&XU]4?M)\_P#!/#Q9_P!B,G_I.E>:?\$?
MOB+I?B?]E9/#$%TC:OX:U.YBNK7<-Z1S.9HY,==K;G /JC>E=%E'%XEQZ)?+
MWV<L6Y87#WZO7_P%?J;?_!1?]D3P1\4/@#XL\5V/A^PTKQIX:L)=5MM4L;9(
MI9XX5+R02E0-ZE V-WW3@C'(-W_@EE\9]2^,'[*>FQZS<27FJ>&;R30GN96W
M/+$BH\))[D1R*F>^S->B_MU?$O1_A?\ LI_$>^U:ZB@;4='N=(LH7;#7%S<1
M-$B*.I/S%CCHJL>@->(?\$=O M_X5_93N=6OHVB3Q#KEQ?VJL,9A1(X WXM$
M_P"&*RP^]>/2T7_V]?\ .W3YG57MRT9/XKR7RM^5_P C[IK\U/\ @M[_ ,DO
M^&?_ &&;G_T0*_2NOS4_X+>_\DO^&?\ V&;G_P!$"N+%?PU_BC_Z4C>A\;])
M?^DL^C_VD_\ E'AXL_[$9/\ TG2OE;_@D5^R]X,\6_#;4?BAXMT2T\2ZNNI2
M:;I$>J1"XAL88@CL\<;@J':21OFQD;>,;FS]4_M)_P#*/#Q9_P!B,G_I.E<1
M_P $B?\ DS32O^PQ?_\ HP5Z;TQF)?5)?^EO]+H\R'^ZX9=&_P#VQ,YW_@K!
M\ ?!&H_LS:QXZ@\/:=IWBK0;FT:'4[.V2&:6*29(6BD90"ZXDR >A48QSGV;
M_@G7XIN_%_[&'PQOKZY:[N(K&6R\U\YVP7$L* YZX6-1GVKG_P#@J3_R9#X_
M_P!^P_\ 2V"G_P#!+C_DQSX=?74/_2^XK.@OW59?WH_^DL[*Z_@SZ^\OEN?5
ME?#?_!6K_DB?A#_L85_])IJ^Y*^&_P#@K5_R1/PA_P!C"O\ Z335[_#W_(VP
M_P#B1RXG^!4_PO\ (^*/V=OAO^T#XV\/ZK<?!^[U^WTF&Z$=Z-(\1)IJ&;8"
M-R-/'N.W'.#Z9KUG_A07[;__ $%/&O\ X7<7_P F5[E_P21_Y)5XX_[#2?\
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MAOXJU>VTK1?B#X6UC5+DE8+*PUJVGFE(!)"HCEFX!/ Z UV]?$7P&_X)I_\
M"DOBWX=\;_\ "QO[:_LB5Y?L/]A^1YNZ)X\>9]I;;C?G[IZ5]NUS9G0P-"K&
M. K.I&VK::L[[:I="\/.O-/VT.7YW"BBBO'.L**** /SD_X+ ?\ -)?^XO\
M^V5?G)7Z-_\ !8#_ )I+_P!Q?_VRK\Y*_H[A'_D2T/\ M[_TN1\+F?\ O<_E
M^2"BBBOKSS I1UI*4=: '4444 .'2EI!TI:  =:=31UIU !3QTIE/'2@ I5Z
MTE*O6@!U%%% #ATHH'2B@!RTM(M+0 4^F4^@ I5I*5: %I1UI*4=: '4444
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MMD[[([95!/N<9)[DFO4OV5O^41.H_P#8J^)?_1E[7&_\%O?^27_#/_L,W/\
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MY@\57_A?P3<6L>I^)/L&-]W%!)MBBYX)+3$C=E1C<58JHK]9?$O_ "C4N_\
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MH4374!(#+OB%_N7(((R.A!KT5^[Q$.D5:ZWNK+_A[^?I;CTJ4IIN[=]>SO\
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M'VY\!/&VF?$3X*>"/$>DW,-S87^CVTBO"055A&H=#Z%6#*1U!4@]*\C^'?\
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M9!^'%E>^!_%^N:K\.-;U"*WU/1]7E1WBO51VAFS&B(P*B1<[ R],L&X^J_\
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M_P#)I7Q?_P"Q7U#_ -$-7#!<F54ZL=[/\(Q?ZZ]SM?O8^<7M?\V_Z78^*/\
M@B=\4]<UK0OB#X$U"]FN]&T<VNH:=%*Y86IE,BRHF3PI*(VT< [CU8UXW_P4
MU^./B[X\?M0P_!+P]=RQZ#I=]:Z5!IT<I2.^U&;9F27'7:TBHH.=NUB.6-=G
M_P $//\ D=?BO_V#[#_T9-7B/[0-Q_PI;_@J'=ZYKP^SZ?:^,['6I)I@=OV6
M22*4N/4!6/XK[5WS2K8K#QJ;26OJFDOP_*_0XX2=.A7E#=;>C5W^/YV/K)O^
M".6G>!_ D6M^#/B3XBL_BUI< N[/4$:*&Q:Z0;@J(J"6,$_*&\QL9R0?NU\9
M_P#!-*2ZF_;V\!27VXWKSZDT^\8/F&QN=V1ZYS7[PZ[XJTGPYX7OO$6HW]O;
M:)9VCWLU\\@\I857<7W=,8YS7X5_\$[=7B\0?\%#_".J0Q^5#?7^K7*1_P!U
M7L[I@/P!HPTI?7.7IRR?IH_S_P#;2JL8_5)2_IZ/[[?J?O51116104444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %</\<O ]_\3?@S
MXX\(Z7+;P:EKFBW>G6TMVS+"DDL3(I<JK$*"PR0"<=C7<45$XJ<7%[,N$G"2
MFMT?FY^PE_P3;^)G[,'Q]MO''BG7/"=_I,6G7-H8='N[F2??( %($EO&N..?
MF_"OTCHHK9R<DD^G_#_J8QBHMM=?\K?H%<%\;?@CX2_:$^'NH>#?&>G"_P!*
MNOF1T(6:UE .V:%\'8ZY.#T()!!!(/>T5E**DK,UC)Q=T?C/\1?^"1WQL^%/
MBIM;^$OB2V\0PV\F^PN+74#I6JP@YZEBL8(!QN649Y^49Q6%=_\ !/O]LSXU
MW-MIOCZ_U!["%M\4_B_Q@M_!"W3*K'-.P.">BU^VM%-*RL]?43=W=:'R-^Q1
M_P $\?"W[)F_Q!?7P\5^/[B$POJK1>7!9QM]Z.W0DD9Z&0G<P' 4$@^T?M/_
M  NU7XU_ 'QOX'T.XL[75M<L#:VTVH.Z0(Y93EV168#CLIKU&BBLO;Q<)[-6
M^0J7[J2E'>]_F?GI_P $^/\ @GG\1OV3_C-J_B[Q=K7A?4=-N]#FTR.+1;JY
MEF$KSP2 D26\8VXB;G.<D<>GZ%T45I*;DHI]%;\6_P!25%1;:Z_\,?FS^VU_
MP2KUOXX_%^;QQ\,=3\.Z%_:Z&76+'69IX$-T#_KHO*ADSO'+ X^8$\[CCZG_
M &)_A3\4/@?\&;3P-\3-4T+6Y-'?R=(O=%NIYB+3&5BE\V&/!0Y"D9^7 XV\
M^_T5%/\ =0=..S_K\-EY:%5/WDE.6Z_K^O/4:XW(P'4C%?E-^S__ ,$HOBW\
M*?VA/!WCO5O$7@NXTC1M9CU&XALKZ[:X:-7R0BM:JI;V+ >]?JW11#]W556.
MZ_34)^_2E1>TM_N:_4*^%_\ @HS^PMX]_:\\3>"M1\':OX<TV#1;.YM[A=<N
M;B)G:1T92GE02 C"G.2*^Z**B4%)IOIK^#7ZE*32:74\+_8I^!>O?LX?LZ^'
M? 7B6[TZ^UC3I;J26?2I9)+=A+</(NUI$1CPXSE1SGK7POX)_P""47Q;\-_M
M*Z)\0KGQ%X+DT6Q\5PZ[)!%?79N3 MV)BH4VH7?M&,%@,]\<U^KE%;<[]O'$
M_:CM^'^2,^5>SE2Z/_@_YL****@H^.O^"C7['7C/]KW0/!-CX.U/0M-ET2ZN
M9KAM<N)HE=9$0+L\J&3)^0YSCM77?L ?LT>)_P!E3X)7G@[Q9?Z1J.IS:Q/J
M"RZ+-++"(WCB4 F2.,[LQG^''3FOI>BBG^Z4U'[6_P"'^2"?[SDYOL[?C_FP
MHHHH _*32O\ @E%\6[']I>U^(DGB+P6=%B\6KKS0+?7?VGR!>>?M"_9=N_;Q
MC=C/?'-?JW111#W*4:*VCM]R7Z!+WINH]W_P?\SXZ_X*-?L=>,_VO= \$V/@
M[4]"TV71+JYFN&URXFB5UD1 NSRH9,GY#G..U==^P!^S1XG_ &5/@E>>#O%E
M_I&HZG-K$^H++HLTLL(C>.)0"9(XSNS&?X<=.:^EZ**?[I34?M;_ (?Y()_O
M.3F^SM^/^;/S _:__P""7_Q3_: _:0\4_$#P]K_@^ST;57MFA@U.\NH[A1';
MQ1MN5+9U'*'&&/&*_3NWC,-O$AP2JA3CV%244XOEIJDME_P/\AS]^?M'N?$'
M_!0O_@GM>?M8:CH'BCP5>Z/HOC.R4V=]+J\DL4%Y:<E,M''(?,1B0/EY5R"?
ME45I_P#!./\ 8R\:_L@Z=XYM_&.J:!J3Z[+:26QT.XGE""(2AM_FPQXSY@QC
M/0]*^S**5/\ =*2CM+_-/\T*I^]Y7+H>$?M;_L@^$/VNO T.C:_))I6M6#-)
MI6NVL8>:S=AA@5.-\;87<F1G:""" :_.*Y_X(E_%--?,-OXZ\'RZ)YF!>2M=
M)<[,_>\@0E<^WF?C7[*45,8J+NNI3DY*S/G7]C?]BGPI^Q]X5O;;3+N77_$V
MJ;/[3UVXB$32A?NQQ1@GRXP23C)))R2< #Z*HHK64G-W9G&*BK(^5/\ @HA^
MRIXM_:V^%OASPUX0U'1=-OM.UE=1EDUN>:*)HQ!+'A3%%(2V9!P0!C/-6O\
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MY!YP:^ZO@/\  ;PA^SC\.K'P;X,L6M-,MR999YF#W%W,<;IIGP-SG [
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M73^:U"OBK]JW_@FOI/QL\>#XD?#_ ,4W'PV^(PD6>6]M@Y@NIE&%ERC*\,O
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M%L$"@QPNS@2 , R@< ]0*\&^&O[$7[:GP>\)6OACP9\7_ OAW0[9G=+2S:0
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M3^(O$7BZ_P!&U+5;NU2RL#I$LLBPQ%MTQ8R1I@DK$!@'@'UK[&HKWX9YC:>
M>6QE^[?EKJ[M7]3CJ82E5K*O)>\K?AM_7D%%%%> =@4444 %%%% !1110!^<
MG_!8#_FDO_<7_P#;*OSDK]&_^"P'_-)?^XO_ .V5?G)7]'<(_P#(EH?]O?\
MI<CX7,_][G\OR04445]>>8%*.M)2CK0 ZBBB@!PZ4M(.E+0 #K3J:.M.H *>
M.E,IXZ4 %*O6DI5ZT .HHHH <.E% Z44 .6EI%I: "GTRGT %*M)2K0 M*.M
M)2CK0 ZBBB@!R]*6D7I2T  ZTZFCK3J "G#I3:<.E "THZTE*.M #J*** '#
MI10.E% "KUIU-7K3J "G#I3:<.E "TJTE*M "THZTE*.M #J*** '#I2T@Z4
MM "KUI:1>M+0 4\=*93QTH *5>M)2KUH =1110 ZBBB@!RTM(M+0 4^F4^@
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MI2T  ZT^F#K3Z "E7I24J]* %I1UI*4=: '4444 .'2EI!TI:  =:=31UIU
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MD2*A ')/ ZU^0G_!*7X,?\+4_:JTS5[NW,ND>$+=M9F)7*&<'9;J??>V\?\
M7(U]:_M0_P#!//\ :%^/'Q2\4SV?Q;LQ\-=5U#[9:Z!JVNZB\=JIP=HM?*:(
M;6R0 P'TKZF_8Q_8[T#]C[P!>:/8W[:]K^J3+<:IK+P"$SE00D:)D[8T!; )
M))9CWP(PON3>(EHVE9=;ZZ^JO^"^5XGWH*A'57=WY:?G;\3Z N+>*[@D@FC6
M6&52CQN,JRD8(([@BOS,^+G_  1[U"P\<S>+/@?\0O\ A#Y_.,]KIVH--";%
MCG(ANX<R!1G !0D#JQK]-Z*GE7-SK<KF?*XO8_*&;_@E/^T%\5]1LX/BW\<X
M-6T>V8O&SZGJ&M2Q$]=D=RL2J2.,AOP-?HU\!O@3X7_9S^&.F^!_",$L>F6>
MYWGN6#3W4S<O-*P !9CZ       "O1**N_NN"V>_F9N*;4GT/S:_9-_X)L?$
MWX$?M56/Q,U_7?"=YH,$M^[6^FW=T]T1/'(J85[=%X+C/S>N,UZG^VE_P31\
M-_M3>(_^$QT77#X.\:M$L5U<-;?:+6_5%VIYB!E*N %7>"?E !4X!'VE14.*
M<(0_D5E_7S-.9\\ZG66Y^3DW_!,W]K'4-)_X1F]^/%I-X1:,6SZ>_B;5I(?(
MQC9]F,/ED8XVYQ7UY^Q3^P+X7_8_MM0U-=4D\4^--2B^SW.L2P"".*'<&\F&
M/+%5)"EB6)8J.@XKZGHK53<;M;OKU,W%2LGLN@5ROQ1^&7A[XR> =9\&^*K%
M=1T+5H#!<0DX8<Y5T/\ "ZL RMV(!KJJ*RE%27*]BTW%W1^5%_\ \$F/C/\
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M;R9TR"R@DE6!RI8\,#BOJNBKJ?O5%2^SM^+_ %?RT)A^[;:Z[_U\C\>/!?\
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MVK6.@Z9=:EJ=[;Z=I]K&TUQ=W<JQ10H!EF=V("@#J2<4TFW9 6Z*Y+PQ\7O
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M2H( _P!IU)S7PA^Q1^Q\W[4>LZOXJ\7ZC>Q>%;&YV3R12?Z3J-TV'9/,;.
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M8VJL;6BFK)-I>]H]=>CTT/%EF*EB(4J.J>[_ ,O\_P"G^EE%%%?GI[04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!^<G_!8#_FDO\ W%__ &RK\Y*_
M1O\ X+ ?\TE_[B__ +95^<E?T=PC_P B6A_V]_Z7(^%S/_>Y_+\D%%%%?7GF
M!2CK24HZT .HHHH <.E+2#I2T  ZTZFCK3J "GCI3*>.E !2KUI*5>M #J**
M* '#I10.E% #EI:1:6@ I],I] !2K24JT +2CK24HZT .HHHH <O2EI%Z4M
M .M.IHZTZ@ IPZ4VG#I0 M*.M)2CK0 ZBBB@!PZ44#I10 J]:=35ZTZ@ IPZ
M4VG#I0 M*M)2K0 M*.M)2CK0 ZBBB@!PZ4M(.E+0 J]:6D7K2T %/'2F4\=*
M "E7K24J]: '4444 .HHHH <M+2+2T %/IE/H *5>E)2KTH 6E'6DI1UH =1
M110 Y>E+2+TI:  =:=31UIU !3ATIM.'2@!:5>M)2KUH =1110 X=**!THH
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M)W'_ "T([J#T]3]*^PJ_'N,.(>9O+<++3[;_ /;?\_N[GT^68*UJ]1>G^?\
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MW'[*T5^%GBOXF?MI?L6:KI&L^-_$'BJVM;Z7;$GB'54URQN2O)B8F654) /
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MKU9I5PV+QCC'$645VZ_U^!X;_P % ?V8]2_:"^'.GZAX:B6X\5>'7DFMK4D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@!U%%% #ATI:0=*6@!5ZTM(O6EH *>.E,IXZ4 %*O6DI5ZT .HHHH =1110
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MO"5'-KF6W>S3_+3^G9;44EBJ7*M':_K=?@]3\_?V0?VE_P!I_P"(6NZY\/?
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MPZAE93R"!@G]X/''BN'P)X+U[Q)<VEU?VVCV,]_+:V**T\J1(798U8J"Q"D
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M;1M0\/7&I^$I;F72=5@:"YM)"GS1.C $%3D9P,C!'!K\H_\ @G_XB^-L^O\
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M^"H/[1?@?PI\.M(.AZ?8V\EO:R>(;F&WF;S&5IYG4.PPH1<1H78A21UP+O\
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M>?$#]FG]I3X[> -6\??$>XU*\OM)MU?2O#DD"M>76YT#^7:P +%A22?EWL4
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MI*5>M #J*** '#I10.E% #EI:1:6@ I],I] !2K24JT +2CK24HZT .HHHH
M<O2EI%Z4M  .M.IHZTZ@ IPZ4VG#I0 M*.M)2CK0 ZBBB@!PZ44#I10 J]:=
M35ZTZ@ IPZ4VG#I0 M*M)2K0 M*.M)2CK0 ZBBB@!PZ4M(.E+0 J]:6D7K2T
M %/'2F4\=* "E7K24J]: '4444 .HHHH <M+2+2T %/IE/H *5>E)2KTH 6E
M'6DI1UH =1110 Y>E+2+TI:  =:=31UIU !3ATIM.'2@!:5>M)2KUH =1110
M X=**!THH 5>M.IJ]:=0 4^F4^@ I5I*5: %HHHH ?1110 X=*6D'2EH 5>M
M+2+UI: "GCI3*>.E !2K24JT .HHHH =1110 Y:6D6EH !UI],'6GT %*O2D
MI5Z4 +2CK24HZT .HHHH <.E+2#I2T  ZTZFCK3J "GCI3*>.E !2KUI*5>M
M #J*** '#I10.E% #EI:1:6@ I],I] !2K24JT +2CK24HZT .HHHH <O2EI
M%Z4M "KUI:1>M+0 4^F4^@ I5I*5: '4444 .HHHH <O2EI%Z4M  .M/I@ZT
M^@ I5Z4E*O2@!:4=:2E'6@!U%%% #ATI:0=*6@ '6G4T=:=0 4\=*93QTH *
M5>M)2KUH =1110 ZBBB@!RTM(M+0 4^F4^@ I5Z4E*O2@!:4=:2E'6@!U%%%
M #EZ4M(O2EH !UIU-'6G4 %/IE/H *5:2E6@!U ZT4#K0 ZBBB@!R]*6D7I2
MT  ZT^F#K3Z "G#I3:<.E !2CK24HZT .K1\/>'[_P 4ZU::5ID#7-[=2"..
M->Y/<^@'K5".-YI$CC1GD<A551DDGH *^Z?V:O@6GPWT8:UJ\"GQ'?1C*L,F
MUC/.P>C'O^5?.YYG-+)L*ZLM9O2*[O\ R74[L'A98JIRK9;L[+X-?">P^$WA
M.+3X=L^HS 27MWC!DDQT'HHZ 5WU%%?S9B,15Q=65>M*\I.[9]Y"$:<5""LD
M%%%%<Y84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU2KUK]Y/^&;_ (2?]$M\%_\ A/6G_P ;H_X9O^$O_1+O!?\ X3UI_P#&Z/\
M7[#?\^)?>@_L:I_.C\':*_>/_AF_X2_]$N\%_P#A/6G_ ,;H_P"&;_A+_P!$
MN\%_^$]:?_&Z/]?L-_SXE]Z#^QJG\Z/P>'2BOWA_X9P^$O\ T2[P7_X3]I_\
M;H_X9P^$O_1+O!?_ (3]I_\ &Z/]?L-_SXE]Z#^QJG\Z/P@6EK]WO^&</A+_
M -$N\&?^$_:?_&Z/^&<?A-_T2_P9_P"$_:?_ !NC_7[#?\^)?>@_L:I_.C\(
M:?7[M_\ #./PF_Z)?X,_\)^T_P#C=+_PSC\)O^B7^#/_  G[3_XW1_K]AO\
MGQ+[T']C5/YT?A'2K7[M_P##./PF_P"B7^#/_"?M/_C='_#.7PF_Z)?X,_\
M"?M/_C='^OV&_P"?$OO0?V-4_G1^$M*.M?NS_P ,Y?"?_HE_@S_PG[3_ .-T
M?\,Y?"?_ *)?X,_\)^T_^-T?Z_8;_GQ+[T']C5/YT?A117[K_P##.?PG_P"B
M8>#/_"?M/_C='_#.?PG_ .B8>#/_  G[3_XW1_K]AO\ GQ+[T']C5/YT?A4O
M2EK]U?\ AG/X3_\ 1,/!O_A/VG_QNC_AG3X3_P#1,/!O_A/VG_QNC_7[#?\
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M&?OA=_T3;PC_ ."*U_\ C='^OV&_Y\2^]!_8U3^='XGTHZU^U_\ PS_\+O\
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M8U3^='XW4J]:_:7_ (4#\,/^B<>$O_!':_\ QNC_ (4%\,/^B<>$O_!':_\
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M2V_^(H_U^PW_ #XE]Z#^QJG\Z/QT6EK]BO\ A1/PU_Z)[X5_\$EM_P#$4?\
M"BOAK_T3WPK_ ."2V_\ B*/]?L-_SXE]Z#^QJG\Z/QU'6GU^P_\ PHKX:_\
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M?^%O_!+;?_$4?Z_8;_GQ+[T']C5/YT?D-17Z]?\ "C_AQ_T3_P +?^":V_\
MB*/^%'_#C_HG_A;_ ,$UM_\ $4?Z_8;_ )\2^]!_8U3^='Y#CI17Z\?\*/\
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M\._^A"\,?^">W_\ B*/]?L-_SXE]Z#^QJG\Z/R5I]?K/_P *3^'?_0A>&/\
MP3V__P 11_PI3X>?]"'X8_\ !/;_ /Q%'^OV&_Y\2^]!_8U3^='Y,4JU^LW_
M  I3X>?]"'X8_P#!/;__ !%+_P *5^'G_0A^&?\ P3V__P 11_K]AO\ GQ+[
MT']C5/YT?DU17ZR_\*5^'G_0A^&?_!/;_P#Q%'_"E?AY_P!"'X9_\$]O_P#$
M4?Z_8;_GQ+[T']C5/YT?DY17ZQ_\*6^'O_0A^&?_  3V_P#\11_PI;X>_P#0
MA^&?_!/;_P#Q%'^OV&_Y\2^]!_8U3^='Y/+TI:_6#_A2WP]_Z$3PS_X)[?\
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M_P"(H_X4UX _Z$;PW_X*+?\ ^(H_U^PW_/B7WH/[&J?SH_*VE7K7ZH_\*:\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6/X8_X\[C_KX?^E;%8_AC_CSN/^OA_P"E
M4MF+J;%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &3?ZI_]TUF^%_\
MD!VW_ O_ $(UI3?ZI_\ =-9OA?\ Y =M_P "_P#0C5?9%U-6BBBI&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %?4)6@L+F1#M=(F93Z$ XINES/<Z=;2R-N
MD= 6.,9-)JW_ ""[S_KB_P#Z":9HG_((M/\ KFO\JKH+J7J***D84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_
MAC_CSN/^OA_Z5L5C^&/^/.X_Z^'_ *52V8NIL4445(PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 9-_JG_W36;X7_P"0';?\"_\ 0C6E-_JG_P!TUF^%_P#D
M!VW_  +_ -"-5]D74U:***D84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-6
M_P"07>?]<7_]!-,T3_D$6G_7-?Y4_5O^07>?]<7_ /033-$_Y!%I_P!<U_E5
M?9%U+U%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "L?PQ_QYW'_7P_\ 2MBL?PQ_QYW'_7P_]*I;,74V****
MD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 -==R,!U(Q531K)].TV&WD*LZ9
MR4/'))_K5VBG?H 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""]@:YL
MKB%2 TD;(">F2,4W3K=K2Q@A<@M&@4E>E6:*=^@!1112 **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /BO_@I!^T1\0?@)_PKS_A!/$']A?VM_:/VS_0K
M>X\WROLOE_ZZ-]N/,?[N,YYS@5\5_P##Q#]H+_H?_P#RC:?_ /(]?1O_  6
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MLL_Z!J?_ (!'_(/K6(_Y^/[V?1O_  \+_: _Z'[_ ,HVG_\ QBG?\/"OC_\
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MTZC^QLL_Z!J?_@$?\@^M8C_GX_O9]"C]OSX\X_Y'K_RCV'_QBG#]OOX\$_\
M(]?^4BP_^,5\]#I3EZT?V-EG_0-3_P# (_Y!]:Q'_/Q_>SZ$_P"&^OCQ_P!#
MU_Y2+#_XQ3O^&^?CO_T/7_E(L/\ XQ7SW3J/[&RS_H&I_P#@$?\ (/K6(_Y^
M/[V?08_;X^.^/^1Z_P#*18?_ !BG#]O?X[$_\CS_ .4BP_\ C%?/@Z4Y>M']
MC99_T#4__ (_Y!]:Q'_/Q_>SZ"_X;V^.W_0\_P#E(L/_ (Q3A^WK\=O^AY_\
MI%A_\8KY]IPZ4?V-EG_0-3_\ C_D'UK$?\_'][/H$?MZ_'4_\SS_ .4BQ_\
MC%*/V]/CKG_D>?\ RD6/_P 8KY_6E'6C^QLL_P"@:G_X!'_(/K6(_P"?C^]G
MT#_PWG\=/^AX_P#*18__ !BE'[>7QTQ_R/'_ )2+'_XQ7@%.'2C^QLL_Z!J?
M_@$?\@^M8C_GX_O9[^/V\?CF3_R/'_E(L?\ XQ2_\-X?'/\ Z'C_ ,I-C_\
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M)L?_ (S3A^W/\;B?^1V_\I-C_P#&:\%'2G+UH_L;+/\ H&I_^ 1_R#ZUB/\
MGX_O9[S_ ,-S?&[_ *'7_P I5C_\9IP_;E^-W_0Z_P#E*L?_ (S7@M/'2C^Q
MLL_Z!J?_ (!'_(/K6(_Y^/[V>\#]N3XVG_F=?_*59?\ QFE'[<?QMS_R.O\
MY2K+_P",UX.M.'6C^QLL_P"@:G_X!'_(/K6(_P"?C^]GO'_#<7QL_P"AT_\
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MZ?\ #;7QI_Z'/_REV7_QFE'[;/QH/_,Y?^4NR_\ C->&4Y>E']C99_T#4_\
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M&_\ \IEG_P#&:\47K2T?V-EG_0-3_P# (_Y!]:Q'_/Q_>SVS_ALKXP_]#?\
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MH_R-Z'\6'JOS/S3_ &(O^":/@C]J#X#V?CK7O%/B#2=0GOKFU-MIWD>4%C8
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MN+_X)]_$3Q'\5_V3O!OBOQ;JLVM^(-2EOY+J^G"AI"+Z=5&% 50%4 *
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M[PQK]SXW\507.JZ7:WTL47V;8CRQ*Y"YB)P"QQFNG_X+9?\ )OG@?_L:%_\
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M]Q^[W+[JA=_^ 4Z]9RHQQ%O>DMO[R]UKU<E^)5*DHUI4%LGI_A>J?HD_P/R
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MP/H00:^2O'W['<#?\$ZG^#]K:I)K>E:$M[!Y7635(_\ 2'(/^W+YB?1ZR?\
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M*Z<;_5+C[+:!@ADV,_)Z#"@FI]'U>TU_38-0L)?/M)UW1R;2NX9QT(!'3O2
MN45C>)O&&D>#K:&XUB[^QPROY:-Y;OEL9QA0>U:5C>PZE907=L_F6\\:R1O@
MC<I&0<'D<>M ;$]%<CJWQ:\(Z)=-;76MPB93AEA1YL'T)12 ?:M'P[XYT'Q6
M2NE:I!=R 9,0)63'KM8 X]\4+78'IN;M%%% !16$WC?1$\2_\(^U[C5\;OLY
MB?IMW?>QMZ<]:R;SXQ^#;&[:VEUR(RJ=I,<<DBY_WE4K^M '9T54TS5;/6;-
M+NPNHKNV?[LL+AE/MQW]JL2RI!$\LKK'&@+,[G 4#J2:'IN&X^BN*NOC/X,L
M[AH9-<B9U."8HI)%_P"^E4@_G73:-KVG>(K,76F7L-[!G!>%LX/H1U!]C1OJ
M!?HK&\3>,-(\'6T-QK%W]CAE?RT;RW?+8SC"@]JIZW\2/#7AP0_VAJT,#2H)
M$C"L[[2,@E5!(R#W% ['2T5A^&_&VA^+E<Z1J,5X4&60 JZCU*L <>^*S=6^
M+7A'1+U[2[UJ%9T.&6)'E"GT)12 :-A;G75R/B/XF:7X8\4:?H-U!=R7E]Y?
MEO"BF,;W*#<2P/4=@:Z#1M<L/$-BEYIMW%>6S<"2)L@'T/H?8UXI\7?^2U>$
M_I:_^E#4?;C%]6)OW)271'O-%<CJWQ9\):'>O:7>M1+<(<,L4;RA3Z$HI -;
MVBZ_IWB.S%UIE[#>P="T39VGT(Z@^QH6JNA[:,T**P_$WC71O!XMO[7O/LGV
MDE8OW3ON(QG[JG'4=:S]6^*OA30]1:QO=8BBNE.&18W<*?0E5(!]B: .LHJO
M%J%M-8K>I<1M:-'YHGW#84QG=GIC%<E=_&;P997#0R:Y$SJ<$Q122+_WTJD'
M\Z.M@\SM:YOQQX[L/ &G07NH0W,T4TOE*+959@<$\[F''%:6A^(],\2VOVC2
M[Z&]B'#&)LE3Z,.H/L:\R_:6_P"11TW_ *_1_P"@-4S;BON*BE)GI:^(;9_#
M0UP)+]D-K]LV8'F;-F[&,XSCW_&LSP+\0=.^(-I=7&G0W4*6[B-Q=(JDDC/&
MUC3?#_V3_A6>G_VA_P >']E)]HZ_ZORAN^[STSTYJI\,?^$/^P7O_"'_ /'M
MYH\__7??QQ_K>>GI6C5I27;_ #,XN\8L[2BN&E^-O@J&5XWUK:Z$JP^RS\$?
M\ IG_"\O!'_0;_\ )2?_ .(J=RCO**P?"_CC1/&8N#H][]L%OM\W]TZ;<YQ]
MY1GH>E)H'CO0O%&H75CIE]]INK8$RQ^3(FW!P>64 \^E'D!OT4R658(GD<[4
M12S'T ZUB>%_'&B>,Q<'1[W[8+?;YO[ITVYSC[RC/0]* VU-ZBL"+QWH4WB"
MXT1;\?VG;J7EA:-U" #))<C;P#ZUE7'QE\&6UT;=]=B,@.TE(I'3/^\%*_CF
M@#M**SIO$>EP:0-5DU"V732NX71D'ED>Q[_2N>L?C!X.U*\2UAUR'S6.T>;'
M)&I/^\R@?K1UL'2YV5%'6L7Q#XRT3PJJG5=2@LV896-VR[#U"C)(]\4 ;5%<
M3:_&CP7>3K%'KD:LQP#+#+&OXLR@#\Z[.&:.YA26*198G 970@JP/0@CK0!R
M>C?$W2]<\87GAR"WO$OK4R!Y)$01'8<'!#$]_2NOKP#P'<16OQX\2332)##&
M;IGDD8*J@.,DD]!7I7_"YO!GVK[/_;L7F9VY\J39_P!];=N/?-"UC%]6@?Q2
M\F=K145K=0WUO'/;31W$$@W)+$P96'J".#4M %35M2BT;2KR_G5VAM87F=8P
M"Q502<9(YXK%\#>/M/\ B!87%WIT-S#'!)Y3"Z55). >-K'CFM;7OL7]B:A_
M:7_(.^SR?:?O?ZO:=WW>>F>G-<Y\,_\ A$?[,N_^$0_X\_._??Z[[^T?\]>>
MF.G%"W=^P/9'945@6GCO0K[6[W28=04W]DK/<1O&Z",*0&)8@+QD=ZR9_C/X
M,M[EH'UR(N#@E(I'3_OH*1^M ':T56T[4K35[2.ZLKF*[MI/NRPN&4_B*LT
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!^<G_!8#_FDO\ W%__ &RK\Y*_1O\ X+ ?\TE_[B__ +95^<E?
MT=PC_P B6A_V]_Z7(^%S/_>Y_+\D%.6FTY:^O/,%'6GTP=:?0 X=*5>M(.E*
MO6@!U/IE/H 5>E.'6FKTIPZT .IPZ4VG#I0 Y>M+2+UI: 'TY>E-IR]* %'6
MG4T=:=0 \=*5:0=*5: '#K3J:.M.H <.E.7K31TIR]: '4ZFTZ@!PZ4Y>M-'
M2G+UH =3ATIM.'2@!RTHZTBTHZT /IPZ4VG#I0 J]:=35ZTZ@!]*O2DI5Z4
M.'6G4T=:=0 X=*<M-'2G+0 X=:=31UIU #ATIR]::.E.7K0 M/'2F4\=* %6
MG#K35IPZT .IPZ4VG#I0 Y:<.M-6G#K0 ZG#I3:<.E #EZTZFKUIU #J<O2F
MTY>E #AUIU-'6G4 .'2G+31TIRT +3Z93Z %7I3AUIJ]*<.M #J<.E-IPZ4
M.6G#K35IPZT .IPZ4VG#I0 Y>M+2+UI: 'TY>E-IR]* '+UI:1>M+0 ^E6DI
M5H <.M.IHZTZ@!PZ4Y>M-'2G+UH =3J;3J '+TIPZTU>E.'6@!U.'2FTX=*
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M?[M410B+G!;(VZ0TJ*47HM;];]-/Z7J935Z;C):O2W3SU_IGV[11169H8'Q
M_P"1#\2?]@VY_P#135\(?\$4/^3=_&?_ &-#_P#I+;U][^,+"?5/"6MV5JGF
MW-S8SPQ)D#<[1L%&3P.2.M?)G_!+S]G[Q]^SK\&?$VA?$+0?^$?U6\UYKV"W
M^V6]SOA-O"@;=#(ZCYD88)SQTHH:5*S?6$4O_ @JZPII=)/_ -)%_P""M?\
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M'/'8&NBT/XXV7[.7_!.[P3\0+VT.H#2O!>D^19AMGVB>2WACB0M@X!=UR<'
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M^DO(\%HUPB$Q*RRSRJ5+[1A50\\$&K%O^R7^TC^QG\8/%GB/]G>UT+QKX/\
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M7QK_ &@_CQX8^+'[2E]H^F6OAETGTCP=H;ATCE5PZ[BK.JKO5'8^9(S[0I(
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M,PAONY/6OM^NJLU.;FMG=_CU.6A%PIJF]XI+\.A^=W_!;+_DWSP/_P!C0O\
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MDURT^6;<ZBV>B_5_HMMGY'3.\4HP>KW?;R7ZOY=S]"?A/\)O"_P1\!Z9X/\
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MLV?"NSER)(/"VF1MD8.1:QCI5T()X.<;_;6W>\VU]^GF%6I;%0E;[/7M:/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^TBY_99[/3)8UFB>-P&1U*L#T(-8GC?Q4/!GAZ?5#9RWWE,H\F+@X)Y).#@
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MB?\ T-JQ?VA/^2<R_P#7S%_,UL?!UU?X:Z$5(($3 X]0[4H[2]5^02WCZ/\
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MMKEK_:FI7\8G9KAR0BL,J ,^F.353]I90GA;1E&<"[P,_P"X:]-\' +X1T0
M8'V&#@?]<UI1VEZ_H.5WR7[?J?.OC_PJ?!_Q.ATWP]-)8+?HB1!'.8Q*2C+G
MKCK^=>RV/P0\(VFEBSDTP7,A7#W,DC>8Q_O @\?0<5Y[\5_^2X>&_P#>M/\
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MBC+M_FR:>KDNY<^'/BV/7_ %CJEQ* T$)2Y<GHT8PQ/U S^-?.NGPS_%3XH
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M^UOYI_/>7=;1HRX.,=7!SQZ5#\3OCG%XOT.32-*LIK:VG(,TUR0'90<A0H)
MY YS6U\&?AGX:\6>#?MVJZ;]JNOM,D?F>?*GRC&!A6 [UZ'9?!OP;83++%H4
M+,IR!-))*OY.Q!JY*[][R(B[;'G'[-_A"YCN[SQ#<1&.W:(V]N6&/,)(+,/8
M8 S[GTK3^-WPFO/$5V->T:+[1=[ ES:@X9P.C+ZG'!'L,5[+'&D,:QQJJ(H"
MJJC  ] *\FU/]H?3]/U]M-.D7*K%<?9YIIY%3R\-M9MHSG')QD4I>\TE\AQ]
MU-L\-TCQ7XD\"W+P6=[=Z9(C?/;2 [0?>-AC/U%>E>%OVD[V"2.'7[&.ZAX!
MN;0;)![E3P?PVU[GJFB:7XBME2_LK;4(2,KYT:N #W!/3ZBOGGXY_#O1O!;Z
M?=:3NMA=LZM:%RP& /F7/('/\J.9K<+)['T7I6JVNMZ=!?6,RW%K.N^.1>A'
M]#[56U_POI7BBT^SZK8PWL?;S%^9?]UAROX&O+O@#K+Z=\.=9N;A7DM;&>25
M57J0(PS ?Y[UR6L_%_Q?\0;MM.\.VDUE$_'EV0+S$>K2?PCW&/K3DO>Y5J*+
MTNRC\5OAGH?@N0R:=KT?FDY&F3DM,/H5'3_> ^IK7^!'CO7;SQ5;Z+=:A+=Z
M<\4C".?YRI5<C#'D#CIG%3^%OV<;^^=;GQ'??958[FM[<B24^NYSP#]-U>R>
M&/ NA^#X@NEZ?%!)C#3D;I6^KGG\.GM3C[N["7O;%G5O"VDZ[>6MUJ-A#>S6
MP81&==RKG&?E/!Z#J*\=_:>4*GAL   >> !V_P!77N]>$_M0=/#G_;Q_[3K&
M6\?7_,TCN=9^SY_R3B#_ *^9?YUZ57FO[/G_ "3B#_KYE_G7I5=%3?Y+\C*.
MP4445F4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^'OVX_P!F_P"(OQA_:3^ GBKPAX=_M?0?#&H1SZO=_;K:#[,@
MNX)"=DDBL_R(QP@;IZXK[AHHHC[E-4UM=O\ \"W"7O3YWO9+[@HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5D>,+"?5/"6MV5JGFW-S8SPQ)D#<[1L%&3P.2.M:]%9U
M(*I!P>S5BX2<)*2Z'Y:_\$S?V+/C+^SY^T)?^)O'_@[^P-$ET&XLDNO[4LKG
M,S2PLJ[89G;D(W.,<=:_4JBBNB4W)13Z*WXM_J8J*BVUU_X8****S+"BBB@
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MZYI2=VFPBK)V.<TCX/\ Q!GC&ERRRZ;I3GYU>_#0X[GRT8Y_*N(\8:##X?\
M%U[I-J[2QVTJPAWZLP R?Q.:Z_3]7^*FC:='IEK:ZU':Q+Y:+_9Q<J/0.4)
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M.>\,^"=/\->$TT%%,]LT;).S?*9BP^<G'3/3V&*U=*T>QT.T6UT^TALK=?\
MEG @4?4XZGWJY13;N[B2MH%%%%(85Y-\>/ VM^,QHO\ 8UE]L^S^=YO[U$V[
MMF/O,,]#TKUFBI:O8:=CA_@[X<U'PKX*BL-4M_LMVLTCF/>K\$\<J2*[BBBM
M&[NY*5@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?G)_P6 _YI+_W%_\ VRK\Y*_1O_@L!_S27_N+_P#ME7YR
M5_1W"/\ R):'_;W_ *7(^%S/_>Y_+\D%.6FTY:^O/,%'6GTP=:?0 X=*5>M(
M.E*O6@!U/IE/H 5>E.'6FKTIPZT .IPZ4VG#I0 Y>M+2+UI: 'TY>E-IR]*
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MP4I\:_'WX+^$[#XB?";QE-IWAFS MM<TI=*LKK[/EOW=TK2PN^TDA&&<#Y"
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ME5<!IYB.?+4D#:""Q. 0 6'Q)I7Q^_X*"_$CP>_Q+\.:<\/@V2)KR*"STG3
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M+X*ZC\3)[*"?Q+KM_-9P7KH#);V<)"F-"?N[I Y;&,X3/05]V?$GX=Z%\6/
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MF\L O(> D: D99V*J!ZL*_(G7_\ @IM^T_\ 'KQ7=VWPCT&;2K6WS*FF>&=
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MU]>W4BCYI'6X>!2Q]DA4?A7YX^/4C^"/_!5LG1%2RMX/'%G*(XAA5CNVB:5
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MUK\VOVQOVA_V@]/_ &V-#^#WPA\:VOA^/6-,MY+:VO=/LY(1.RS,[-++;R.
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MFY9%5BA8K(LBO'A2N?E'4W&-Y<GVK-V]-_N(<DHJ>ZTU]=OO/N.BOC;]L/\
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MS[>I^BE%?G!XF_:%_:Q_8HO=)UKXXQ>'_BC\.;NZ2WOM9\/0I%/8EN  4B@
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ME^2"G+3:<M?7GF"CK3Z8.M/H <.E*O6D'2E7K0 ZGTRGT *O2G#K35Z4X=:
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M535?^P++_P"CX*^UJ^*?V*?^2J:K_P!@67_T?!7VM7\^\:?\C:7^&)]KE/\
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M3XU:'X6\,_%KQ=I7@C59-;\)V>I30Z;?R+@RPAB%.<G<!T#?Q !L#.!^]/\
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M^RVF@V45N#T",TCL1_P)F_*OVO\ "EA9Z7X6T>RT]$CT^WLH8;=$&%$:H H
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MSMIYL6'B\/.4:F_O6\[I_E?TLC[G_P"".W_)H)_[&*]_]!AK[BKX=_X([?\
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MV-W<Z%+^[EU6TLVO-'U. -E//4?ZIADX#%'7+;2022?$S_@H!^T9^U[X:G\
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M3GWC_@FI^R9X]\??'>3X[_$O3;ZPL[6>;4;235H##-JM_-N)F5" ?+7>S[L
M%BH7.&QUQ:K8R.*7PI7?KH[+[FEZKS,)IT\-.C)>\WI^/^?YGZQ^(O$.F>$M
M!U#6M9OH-,TG3X'N;J\N7"1PQ*,LS$]  *_'K]H;]HCXE?\ !2[XJI\*?A!I
MUU;_  _MIQ([2EH4NE5L?;+U\?)$IY2/DYP<,^U5[_\ X+/_ +0NIVFH>'/@
M]I-W);:=/:KK.LB-L?:,R,MO$V#RJF-W(/!)0_PU\)_!3]L'XM?LZZ%>Z/\
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M:#9(SS8\L12':@+;'15;>JML=-S BLN9*<5/2+Z]GTOY7W->5N+<=6NG?O\
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  -N_P#Y%H_UCRG_ *"(A]1Q/\C/C%>E.'6OLT?\$I?BT/\ F8O!?_@;=_\
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MY3_T$1#ZCB?Y&?'@Z4Y>M?88_P""6WQ5 _Y&#P=_X&W?_P C4H_X);_%4?\
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M^$O_  ,NO_D>C_6/*?\ H(B'U'$_R,^3EIPZU]8#_@FM\31_S'?"?_@9=?\
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M7_AW#\2O^@YX4_\  NY_^1Z/]8\I_P"@B(?4<3_(SY6IR]*^J/\ AW%\2O\
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M\";C_P",4?ZQY3_T$1#ZCB?Y&?.@ZTZOHK_AA7Q[_P!!?PY_X$W'_P 8I?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **:[;48CJ!FJFC7KZCIL-Q(%5WSD(.."1_2
MG;J!=HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14%[.UM97$R@%HXV
M< ],@9ING7#7=C!,X :1 Q"]*=NH%FBBBD 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %8_AC_CSN/\ KX?^E;%8
M_AC_ (\[C_KX?^E4MF+J;%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&3?ZI_\ =-9OA?\ Y =M_P "_P#0C6E-_JG_ -TUF^%_^0';?\"_]"-5]D74
MU:***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 5-6_Y!=Y_P!<7_\ 033-
M$_Y!%I_US7^5/U;_ )!=Y_UQ?_T$TS1/^01:?]<U_E5?9%U+U%%%2,**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
ML?PQ_P >=Q_U\/\ TK8K'\,?\>=Q_P!?#_TJELQ=38HHHJ1A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 R;_ %3_ .Z:S?"__(#MO^!?^A&M.0%HV ZD$51T
M&UELM*@AF79(N[*Y!Q\Q/:JZ"ZFA1114C"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "53A_P52^+!_P"9>\&_^ 5W_P#)5'^I>;?RQ_\  @_M7#=W]Q^J%%?E@/\
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M_P %*/B:?^8%X3_\!+K_ .2*4?\ !2;XF'_F!^$__ 2Y_P#DBC_4O-OY8_\
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M\!;C_P"/TX?\% ?B&?\ F#>&?_ 6X_\ C]'^I>;?RQ_\"#^U<-W?W'Z 45\
MC]O_ .(1_P"8-X9_\!;C_P"/TX?M^_$(C_D#>&?_  %N/_C]'^I>;?RQ_P#
M@_M7#=W]Q]^45\"#]OSX@D?\@?PS_P" MQ_\?IW_  WU\0?^@/X:_P# 6X_^
M/T?ZEYM_+'_P(/[5PW=_<??-%?!'_#?'Q _Z _AK_P !;C_X_3O^&]OB!_T!
M_#7_ ("W'_Q^C_4O-OY8_P#@0?VKAN[^X^]:*^#!^WIX_)_Y _AO_P !KC_X
M_2C]O+Q^3_R!_#?_ (#7'_Q^C_4O-OY8_P#@0?VKAN[^X^\J*^#Q^WCX_/\
MS"/#?_@-<?\ Q^G#]N_Q\?\ F$>&_P#P&N/_ (_1_J7FW\L?_ @_M7#=W]Q]
MW45\)C]NWQ\?^81X<_\  :X_^/TX?MU^/3_S"/#G_@-<?_'Z/]2\V_EC_P"!
M!_:N&[O[C[JHKX7'[=/CTC_D$>'/_ :X_P#C]*/VZ/'A'_()\.?^ T__ ,?H
M_P!2\V_EC_X$']JX;N_N/N>BOAK_ (;F\>?] GP[_P" T_\ \?IW_#<GCO\
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MZ.^EVOT.ZAB(8F//3VV-BBBBO'.H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC8 'YXV.3]:]QU;_ ((PZ!H5C)?> OBKXFT+Q/"-]I=W2QF,..0"81&ZY/\
M$"<=<'I6TTZ?Q>3^_4RA)5/A\U]SL?I%17Y]_P#!,K]IGQ[XI\5^.?@C\4[^
M?5_%?A R/;ZC=R^;<,D4P@GADD/,FQRA5SDD,<G@5R_P;_Y3-?%7_L#O_P"D
MUC34;U(Q3TE%R3\E_5OEU$Y.,).2LXR46O-_U?\ R/TLHHHJ"PHHHH ****
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MX4$+P"02,U]OT+WH1J+9W_!M?H#]V;@]U;\4G^3"BBB@ HHHH **_-+]E/\
MY2U_'W_L&WO_ *465?I;1#WZ-*M_/'FMVU:M^ Y>[4G3_E=@HHHH$%%%>#_M
MR?&'Q%\!_P!F'QCXT\*26\&OV*V\=M-=0B5(C+/'$7"G@L Y(SD9 R".*B<U
M"/,RX0=22BNI[Q17C/[&WB[6?'W[+_PY\1>(=0FU76]3TM;F[O9R"\LC.Q).
M.!]!P!P.*]FK:<'3DX/IH8TYJI!3757"BOS5_P""W:[OAA\,AZZS<C_R *U_
M^"0OC+4O#FC_ !+^"OB(^5K/A'53=0PEL_NI"8Y0GJHDC#9_Z;#UK.B_;.HM
MN7\=(M_<I?@75_=*$NDOPU:7XK\3]$Z**_!+_@I+XYU#XT_M$^./%%H?.\*>
M$[ZV\'VTV3CS52=W"]CF2*Y)/IL]:B4[24;;_@M%^;2^9I&-XN3>WXOM]R;^
M1^]M%>4?$/\ Y-7\2?\ 8FW'_I$U?*O_  16_P"38?%'_8VW'_I):5T<G[VM
M2_D2?K>7+\NY@I7I4ZO\[:]-$S] :**_,7XE_P#*:?P+_P!@^+_TWW%9)WJ0
MI_S.WX-_H:/2G.?\JO\ BE^I^G5%?G=_P6R_Y-\\#_\ 8T+_ .DEQ5K_ ()5
M?M47OBSPQ=?!+QPTUIXS\)1E=.2^!2:XLE.#$0W.^$X7']PK_=8TZ7[WG2WC
M^*LF_NO]UV34?L^1O:7X:V7W_P"1^@]%,E_U3_0U^8__  10_P!3\:?^O^P_
M]N:=-<\IQ_E5_P 4OU*E[M/G\TOO3?Z'Z=T5\<_M^_MIZK^S[#H/@'X>6<>K
M_%;Q45CL(B@E^Q1N_EI+Y?1Y'?*HI^7*L3D#:WE/A[_@EEXH^,VGQ:[^T+\8
M?%&N^([H>>^EZ7<JT-@S<E%DE#H<<<1QHHQ@9 !J(WFG)+1.U_/JEWMU[#E:
M#46]7K;R\^U^G<_1RBORJ^,O[,'Q>_X)WZ,OQ*^"WQ*UGQ!X)TN57U3PUJY\
MQ(H20-\D2D1RH3PS*B.@.0>K+^@7[,WQ\TG]I;X,Z#X]TF$V8OD:.[L6;<UI
M<H=LL1/< C(/&5*G SBM%:47*+VW75?\#S(E>+2EUV_KOY'J=%?E9/KGQ:_X
M*9_'SQWX9\.^/;SX<_!_PE.;23^S]^Z[!=T0R*CIYSR>6[89MB*!P3][LKW_
M ((V:?X;MO[2\ ?&'Q/X>\61#?%?S(NQGQZPF-TR?X@S8ST-9Q;<%4:T:NN]
MN]OZ9<DE-TT]4[/M?U/TAHKX&_X)Y_M0?$/5?B3XQ^ 7QBN&U'QMX561[759
MFW37$<3JDD<C\>8?GC=)#\S*Q+$X!K[YK1I6C*+NI*Z?D9IN[C)6:=GZA17%
M?&KXGV7P6^$WBOQSJ$1N+;0M/EO3 K;3,ZCY(P>Q9BJY]Z_.#X _LK>,?^"C
M'ARZ^+'QQ^(OB&W\.:I=S#1?#NASK%%$B.4+HLBO'&@960 (6;:69LGG.+<I
M.,>BN_GM\W8MVC%2EU=E^;/U4HK\GOC3\,_'?_!*S7_"OCKX<>.-8\3?"V^O
MUL-1\,ZY,'4,5+[2% CRZI(5E5$92H!W D'[]^/?[2.D?!K]FS5/BQ'&+VV&
MFPW6F6\F5^TS3A1;HW< LZENX ;THE**I.JMD[/O?HOGT[@HR=14WNU=>:V?
MW=3V2BOR]^!W[!FL_ML^ [3XM?'OXC>*KC4/$6Z]TG2M*N(XX[*W9CL8"6.1
M45AAE2-5 7&223C6^#'B[X@?L(?M;Z'\#_&WBZ\\9?"_Q@BKX=U+4W9I+.1B
M4B52Q.SYU$31@[?G1P%R16J@^=4IZ2>R\][7[_J9N2Y'4AK%=?+:_H?I917R
M5_P4A_:GUK]FCX.V$/A$A/&OBF[.G:;.4#FU4+F695.0SC<BJ"",R G.,'QG
MPG_P2,L?B#X;LM?^,?Q/\9ZY\0KN%9KFXM+Z-X[9R,^7OGCD>3:>-VY0<< 5
ME%N7,TM$[?.U[+Y;FLDH\J>[U^5[7^\_1NBOS4_9R^(?Q*_9 _;%M/V<_'GB
MJZ\=>#/$$ E\/ZG?,SS6^Y7,14L695)B>-H\E0P#+@9W>W?\%#/VH?$WP5\.
M^%O OPW03?$WQU=_8-,8*'>UCW*AE53QO9W1%+<#YC_#3DURQE3][FT7>][6
M]5U\M24O>E&>G*KOM;>_I^NA]>T5^=FF_P#!('3/%F@Q:S\1/BQXRUCXFS1>
M9/K%O=I);PSD9  F1I9 IXSYB%L9PN<#MOV"]3^.WP_^(7C?X1?%>R\0>(O#
MNB%Y-!\;:E9S&&X574>6MRX/F*Z.KJ"S%=KKDX &D8IR<&];-^6F^O\ 5^A+
M=HJ:6E[>>NVG]6ZGV[1114%!117X4_M7?\I3[W_L;M$_] M*(>_6A1_FZ_-+
M]13]RE*KV_R;_0_=:BBB@84444 %%%% !1110 4444 %%%<A\8/'C_"WX4^,
M/&,=DNHR:#I-SJ2VC2>6)C%$SA"V#MSMQG!J924(N3V148N<E&.[.OHK\\/^
M";?[87Q&_:N^-'Q#N?&=_;QZ78Z5 ]AHNG0^5:VA:;#$ DL[$ ?,[,>N, XK
M]#ZT<6HQD^JO^+7Z&2DI2E%=';\$_P!0HHHJ2PHHHH **** "BBB@ HHHH *
M*_/3_@L3\<_%_P +?AQX(\.^%=9O-!3Q+=71O[O3YC#.\4"Q8B#KAE5C-DX(
MSMP>"0?'OV"?^"<FI^)M*^&OQSG^)4NG":]359-!M;!RT\,5PP\M[D3K]_9R
M/+(PQ'-%']ZVWI%-*_\ P/O^X*O[J,>LI)M+T=C];**** "BBOPN_P""MW_)
MZ=__ -@G3_\ T THN]:G2_GE;TT;_0N,>:,I=E?\4OU/W1HKY*_X*>?\F*>.
M/IIW_I9!7AG_  1#_P"23_$G_L-P?^B*JFN=U%_+^.W^9BY6A2G_ #_AI<_2
MBBBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 445\#_\%./VW_'/[,4_AWPIX$M[&RU'7K*6ZDUR
MZC\^6V57V 11GY-V>=SAAVV]ZSG-0LGN]%]U_P D7&#E?R/OBBO-_P!FO7M0
M\4_L\?#+6=7O)=0U74/#6G7=W=SMNDFE>V1G=CW)8D_C7I%=%6FZ4Y4WNFU]
MQC"2G%274****S+"BBOBG_@KW_R9OJ'_ &&K#_T)JQJU/914K7U2^]I?J:4X
M<[MY-_<KGVM17YX_\$4/^3=_&?\ V-#_ /I+;U^AU==2'LY6OT3^])_J80ES
MJ_F_P=@HHHK(L***^'/^"FG[:OC/]E72_"NC>![.PCU7Q+%=.VL7J><UFL7E
MK^[B/RER90=S[E&W&TYR(E-1MYEQBY7\C[CHKR/]DCQ3JWC?]F?X:^(-=OY=
M3UG4]$M[J[O)SEYI77+,?J3VXKURMIQ<).#Z&,)*<5)=0HHHJ"PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1NBJ!DFC8">BN;\,_$3P]XQNY;72-0^USQ)YCIY,B87(&<LH'4BNDH ****
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M\=_\C&'^!?\ I4SZ_)_X#]7^2-BBBBOS8]X**** "BBB@ KQC]M'_DTKXO\
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MY\SIM=#N3S86R'4C .164DZOL87YHRDX]GIKR_DO1[FL6J;JS>CC%.W3M?\
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M $)J^C_V;=3LM8_9Z^&=YI[*UE+X:TXQ;1@ ?9HQC';&,8K/#13AB)/^>/\
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MK<[5DHR2796;?S;/KKX.Z-'X=^$G@G2H8_*BLM$LK=4X^4) BXXX[=J^ _\
M@L.K:)XF^ /B:U/EWUAK%R(W7ALA[61<'M@I^M?='[.GBNU\<? /X=Z[9NLD
M%]H%E)E3D*WDJ&7ZA@P/N*^%O^"KI_X3_P".'[.OPXL6\_4+W4WFEMTY*I-/
M;Q(Q Y ^27G_ &3Z5WUK_7X+K[1?F[_A<X</98.3EM[-W_\  ;+\;'Z&>*/
M/A?X@0V0\3>&M(\1):MYUNNK6,5T('./F3S%.T\#D8Z5HZ_K^F^%=$OM8UB^
MM],TJQA:XNKRZD$<4,:C+.S'@  5G^.O'6@?##P?J?B?Q-J<&C:#I<!FN;RX
M;"HHX '<L3@!1DDD  DU^9NH:[\4?^"L?CJ;2-&%W\/_ -GC1[P?:KQAB;46
M4@@-VDFZ,(QE(L@L6;;NY/>G+V=+??R2[O\ J[V.E)1BIU-MO-OLOZT)O@E?
MWO[>7_!19OB]IEC-;_#7P#&L%E>3Q%?M!C63R%Y_C>21YL=515!P2,Y/[<7Q
MNL?A9_P4O\$^)=7TZZUZR\)Z C6NE6OWY[MX[IH$''&Z62') . ,X)&*_3/X
M3_";PO\ !'P'IG@_P?I<>DZ)IZ;8XDY>1C]Z21NKNQY+'DU^<'[9WA^P\,_\
M%3/@GXA\01*N@:L=,(FD4;#/'</&,Y_NL823V!%4DE5P]&F].9J_6[4KR];Z
MKT1+;=*O6FM7';R35D>DZG:_\%!?'&F+XRTO5O!/@J%X_M$/@<11/=%>JQN\
MT$@#L,9S.F,\[#P/4OV'/VUKS]H^3Q%X+\<:)'X4^*?A=BNI:;&K)'.BOL:1
M$8ED97PKH2<94@D-A?K.OS-^'JI<?\%I/&CZ"%-G%I;G43;_ '0WV"!7W>_G
M%,_[552:=7V5M'&3\TXJZU_!W%-/V3J7U3CZ.[2:MWUNO1GT/^V'\ ?CA\7_
M !UX$U/X5?$?_A"=&TD/_:]G_;E]8?;,RHP^2WC99/E5A\Y'7'0FOJNBBIC[
ML.1;7;^\;5YN?6R7W!7X4_M7?\I3[W_L;M$_] M*_=:OPI_:N_Y2GWO_ &-V
MB?\ H%I2H_[[2^?YQ"M_NE7^NDC]1OV\?VK1^R;\%9-<T^"&\\5:M/\ V?HU
MO/S&LI4LTSCNL:C..Y*CC.:_.;X"_L7?&'_@H;H5S\2/B'\4+W3=%N+B5-/N
M=2B?4'N'5L2&&W$D:0Q!@5&TCE2 N!FO8/\ @N)I%])I'PEU14=M-AGU&VD<
M$[5E=8&0'W*QOC_=-?6G_!.'7M,U[]C#X:-IDB,MI926=PB=8YTF<2!AV)/S
M?1@>]*A%3C4JRU::279?UK\UV1=:3@Z5..BDFV^^NW]=GZGYP:EXT^./_!*[
MXWZ7H&H^))_%_@6Z07$-A+-(UCJ%IOVOY:.3]FG7OL/!*Y+J>?T7_;&\9:7\
M1/V O'GBC19_M.DZQX:2^M9>[1R&-ER.QP>1V-?'G_!</7=-FU?X3Z/'+&VK
MV\.H74T8QO2&1H%C)[@%HY,?[IKV.YT>_P!"_P"".+6FI(\=U_PAHFVN3D1R
M3>9'U_V'7CM6%:3JY=6E/5QNK^5I?Y?F:0BJ>-HJ&BDDVNS37YWOZ6/A']@;
MP)\7OCJWBGX7_#WQDW@#PO=F'4_$>MVP<3A%S'%$I1E9MQ9OD#(&"MN;  -7
M]H_X'?$?_@G#\8="NO#OQ N[B34X#>V6NZ<KV;3E' DBGA+N& )7*LSJP89[
M@?3G_!#:)#<_&*0K\X325#>Q-WG^0JE_P7'_ .1C^$/_ %Z:G_Z';5V8ENC5
MI.+U=KOO[K:^Y)+Y'/12G&K&2T6R]6F_O;9^@OA+]H*RNOV5-+^,>NPBVMCX
M837[V"#LP@WNB9]6!5<^HK\BO ^E_&/_ (*J_''5K;5?%;Z1X>LD^VSHYDDT
M_28"VV*.&W# /(>F206VL6;BON77-/O-3_X(]0PV(9IU\"6TS!1D^6FQY/\
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MZQ<17D<EWJ-PFH066\8:UC2)DC 0$QKO7^'.,YJE_P %H?\ DZ30/^Q6MO\
MTIN:_7GX)::FC_!GP%81A0EMH%A"-HP/EMT''Y5S85)474ZQD[?-RO\ DCIQ
M<FZT:?1Q5_DH_P"9^./_  5FN7\-?ME:=<6N9'T_0=->+SV+[BCR%=Q)RW09
M.<GUKTCXH?L%_&KX\_!*_P#C9\1?BJU]XG.E2>(+?PG/;.T%O!Y?FB%)/,"0
M-Y8^XL6-W!;JU>:?\%@P&_;# /0^'['_ -"EK]AO&D2P? /78T&U$\,SJH]
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M'Q%I_B"VGTX>4)?]($4/EX0\,=V.#UKZ%^(W_!*GXT>+? EQ\1/$'Q4?Q/\
M$]+;[<^AW:2R,''SF&.\,IPX'"@1JFX  @?-7AG[4.LV/AW_ (*=ZOJNIR+%
MIUCXQTVYN9'QM6)#;LY.>P )K]X)[R"WLY+J25%MDC,K2EOE" 9)SZ8K*BK9
M?2FG9VW[6C'\^OHC2H_]LG'IV[ZO\NGJ?F1_P2>_;2\5>/?$=[\(?'NK7&N7
M$5F]YHFI7\ADN@(R/-MI';YG 4[E+<@(PSC:!^GU?A1_P3BC?Q-_P4.TC4]'
M4_V<EQJ]\^S(5;=H)U7/MF2,<^HK]UZ[)2=2E2JR5G*-WZW9ARJG5J4HNZ3T
M_K\?F>%?MI?M)1_LL_ ;5_&,4$5YK<DB:?I%K-_JY+N0':7QR515=R!C(3&1
MG-?F/\ OV-_BO_P49TG4_B9X^^*-UIVGF[DM[&YO[9[]II%YD$4 EC2&)2=H
MVG&00%XS7TY_P6PTZ\N/V?\ P5=Q*S6=MXD G(SA2UM,$)_)A^-?*W[)/[*G
M[3'Q=^"^G^(/A9\:X_"?A1KJXA31D\5:I9&VE5SOW0P1-&I8D/P>0P)ZUR45
MSSJRDK\NB\M(Z_C^1T56XQIQB[7U?GOI^'YG3?!_XX_%/_@GE^U1:_"/XA>)
MIO$G@*>>"V=;B=YH(;:8@0W=MO.Z';GYXQ\ORN,$A6K[%_X*8?L=I^TA\*_^
M$G\.6:R?$#PQ"\UH(U^?4+7EI+7CJW5T_P!K(&-Y-?(?C'_@DG^TO\1-835O
M%?Q-\+>)]52)85OM9U_4[N=8U)*H'DM6;:"S$#..3ZU^ML^KVO@7P.=2\1ZA
M!:6FDZ?YVH7\KXB18X\R2$D#C@GI6E5*>'7M)>]%[^71_+KW3MMH13;A7_=K
MW9+;SZKY].UK[GXT_LB_\%*;_P#9Z_9W\8^!=8BFU'6-.@9_!SR(72.61MKP
M2^B1EC*,]0'7(^45M_\ !+O]E*]^/?Q3O?C1X[274-"T>_:XMVO1N.JZH6WF
M1B?O+&6#D]W*CG#"OC[]HGQGH_Q<^-WCWQCX0\/'1?#=[?R7D=K"C$11LZIY
MTG9#([!B.@:3:.U?M'_P3)^./A3XK_LS:#H>A65KHFK>$H4TS4])M^ K\E;@
M \D3?,Y)S\^\9.,G>A)S3Q4E[]E\O/U6B[WL^AC6BH/ZO%^XV_GY?/7RW2W1
M\U?\%R?^0=\'?^NNJ_RM*\S_ &<OV//B_P#MT?!71M1\2_$Z;P?\.](MTTGP
M]I*VKW,-PMN"C2&!98U'S!@9&+.Q## 55KTS_@N3_P @[X._]==5_E:5]6?\
M$S]<T_6_V*OAR+"1'-G#<VEPJXRDRW,NX$#N<@_1@>]<^'@I4:C>MI?YZ_+;
MYG3B).,J"6EXO7_MYZ?/?Y'YK_"WXQ_%+_@FM^TS_P *]\5ZS-J7@V&ZBCU'
M33,\MG+9RD%;NV5O]6X4[OE R5*MG''Z(?\ !1C]L"\_9>^#=A)X6DA;QCXH
MD>VTJX=0Z6L2J&EN=IX8J&0*#QN<$@@$'\^?^"Q6IVFK_M=6EG9%9KNS\.V=
MM<K&<L)6DFD52/79(A^C"N[_ ."P^@ZIIFD? 1[U7,<.AW%G(Q)(%PJVV\'/
M<\?7%9N<JN&AS/7FY;]UK_\ (V_[>]!J$:6(?*M''FMYZ?YW^7J9'P3_ .";
M?Q,_:_\ A];?%GQK\5+C3-4UD-<:8-4MY=1N)X@2%DDD,R>4K$94*&^7!P.E
M=G^PQ^U-\2_@9^TW/^SU\6M:N-=L9+Y](MI[^Y:X>QO%'[GRIG^9H)1M 4]-
MZ$!?F!Y?X%?L:_M9^/\ X/\ A+Q#X'^/L>D>$]0L(YM.TZ+QCJ]N+6+&/*\N
M*$HA0@J54D @BNA\'_\ !*G]H.T^-?AKX@>)_'_A37M1L-9LM3O+^ZUC4+J]
MG$,L;??DM<LVU !N;L!D"NZ%J>(4'I#9K]?5:_,XY-SH<U[SW3_KIM\CZ*_X
M*@_MG:W^S9X-T;PKX*N!9>,O$J22?VD &;3[1"%9T!R/,=CM4D<!7/7!KY3^
M%7_!+'XD?M(?#33OB=XP^*DFG^)-<MAJ%A:ZI;S:C/+$R[H7GN6F#1EA@X"N
M0"#URHI?\%K-*O;?]HCP?J$JM]@N?#20P.?N[X[F<NH]QYB'_@0K]7_@#K-E
MXB^!?P]U+3BAL;GP_821",Y55-NGR_AT_"N2A!3HU*K^+FM?M\2T^[\SJKR<
M*T*2^'EOZOW7K]_X'PE_P3J@_:I^&?Q'G\'_ !!\->(-4^&N^:UDO]<N%_XE
MTL8(26V:9Q))"Q4+M0%2&#+CG/QO_P %)/V8_P#AG7XVO??\))_PD'_":3WV
MO>7]@^S?8_,N6/E9\Q_,QN^]\O3I7[,Z#^UG\'_$GCR]\%6/Q"T4^*K._?2Y
M-*N)C;S-=*Q0Q1B0+YIW CY-P)Z5^;/_  6\_P"2K?#7_L"W'_H^LJTVY49=
M[J_=<K?Z+Y>15.*BJL>VMNSNE^K_ .'/>O\ @F[^Q#%\!+;2/C7/XY&JP^)O
M"$<CZ0VE?9Q9K<""Y),_GMOV"/;]Q<YSQTKY:\6_%OXK?\%/OVE+GX?^$O$4
M_ACX?1^=)%9K*Z6\5A&P!NKE$(,\C$IA#P"X4;1N:OTE^%5A=:O^P%X7LM/R
MU]<_#B"&W"'!,C::%4 CODBOQ:_8P^$WQ.^,/Q3U#0OA1X[C\ >*4TN6X>\?
M5KO36GMUDC#Q"2V1F;YBC%2,?+GM7=62ECIT6KQIIV7SEOWM;UU?D<]-\N%C
M43M*;5W\H_G?\/4]_P#CK^S!\7O^"9<6A?$#P)\4+G5=#N+U+6Z:UMWLT$^U
MF1+BU,DD<L;!6&23SV!P:_3'X,?M7Z+\2OV3HOC1?Q"RMK+2KB\U>TA.?)GM
ME;ST3/8E"5SV9:^"_%__  3-_:[^(6C-I'BGXW:7XETEG65K#6/%FKW<!=?N
ML8Y+8KD=CCBO8O#W[*WCO]FS_@FW\;/ OB74M*U;59H;_5+8Z%-+-$EOY$)=
M"9(HVW?NI21@C!'/8<\YRCAJSD]4KQ[]-/S?R1K&$95Z7*MW:7XZ_DOFSXR\
M)VOQC_X*I_'G4K&_\3/I.@6JM>RPRN[Z=H]MOVHD4"D"20Y !.&?:26 ''2?
MMI?LT_%W]D#X+6OA>X^(DOQ ^$FLWL*>7<6[0G3KV/=)&$B:23RE8!^4?:V#
MN4':3Z7_ ,$/-;L8/%?Q7TB1T74KFRT^ZA4M\S11O,LF!W ,L>?J*^C?^"P.
MLZ=I_P"R#/9W<B"\U#6[**R0GYF=2SL0/9%?\Z6)BL/2@J>SY;^=Y)?AWWNK
MW"A)UJLW/I>WE[M_Z\M#C_\ @BA_R;OXS_[&A_\ TEMZ_0ZOSQ_X(H?\F[^,
M_P#L:'_]);>OT.KMQ/QKTC_Z2CFH_"_5_FSY#_X*-ZQ\>D^&VG:+\$-!U:Y-
M\TKZSK.B2(+RVA4#9#"H82[G))+1C("8!&ZOBY/^"0_C_6OA$_Q U[XC"T\<
M/IK:K+H-_82.Z2;#((I;MIMRR8X;]V<-D9.,U]&?\%+?V_O$_P"S7K.D^ ?A
M]':VWB>_L?[0N]8NX!-]CA9F2-8HV^0N2C$EPP  ^4DY'CLW[&O[5WQV\!77
MBCXJ_&Z;1-"N],;4)=$6^GE)3RRX22UA\JW7(]&.,\CM7E[4JE2/3[3Z6OLN
MVFUNG6]SO?\ $ITY?<NNV_W_ (K:PW_@D!^T[XX\2?$K6/AAXE\07WB#06TF
M34-.&I3-/)9R1/&I2-VRPC9'/RYP"@P!DY\+_P""H?[,G_"B/C/_ ,)3_P )
M)_;G_"P-0U/6/LGV#[/]@_?(WE[_ #'\W_78W83[O3GC5_X(Z?\ )WLG_8N7
MO_H<->O?\%Q_^1C^$/\ UZ:G_P"AVU=6*^*A/JTT_P#R;_)?<<^'?NUH=$T_
MR_S?WGIG_!,G]AC_ (5E_P (G\<O^$V_M+_A(?#A_P")#_9/E?9_/V-_K_/;
M=MV8_P!6,Y[5^C5>'?L.D']D+X1X.?\ BG;3I_N5[C717TJ."V3:7I=F%#6F
MIO=I-^MD%%%%<YN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5S/Q)\0S^%_!6IZA:@FZ2,)$0,X9B%!_#.?PKI
MJ*35U8:=G<\+^#GPITSQ#HI\0:_$VHSW4CF.*5VV@!B"S8/S$D'K5KXO?"+1
M=.\,W.M:-;_V==6>)'2)CLD7(!X)X(SD$5[57B?QS\?K?QCPAHV;R]N)%6Y\
MD;L<Y$8QU8G&?3&/H3=[*/R".FLCKOA3XSDUKX<)J>I2%Y+(21SS'DN$&=Q]
M]I'XUYK\._#O_"Y/%NJZ_P"(-\]E P5+8,0I)SM3(YVJ!VZDCWKN9?#3^ _@
M=J5@[9NOL<CSLG3>_4?09Q^%5OV;H!'X&NY !F2^?)[\(E7HZDGV7X]2-H+S
M9'\3/@OHDGAJ[O\ 1K,:??V<9F A8[9549*D$]< X([UM?!'QC-XM\'*MW(9
M;VQ?[/([')=<95C[XX_"NYU)%ETZZ1AE6B8$'N,&O"_V;[AH+;Q5@_+&D3CZ
MXD_PJ%*W-Z7+:NHM=[%80/\ &OXL74%U,_\ 8>G;]L:''[M6"\>A=N2>N/H*
M]!\2_ WPSJNC2P6%@FG7JH?(N(F;ANP;).X'OGFN+_9DB$EUXBN#R^(5R>O)
M<G^0KWFFXVBHBYKS;/'OV>O%=S>6-_X>OG9IM..Z'<<D1YP5_P" G^?M6)\2
MKNZ^(_Q1LO"%O.T6GVS@2[.F[;N=SZD+P/?/K3/A8?LOQS\1PQC$9:[7'L)0
M?Z4?#,?;OCQX@G/)C:Z8;NH_>!?Y&A/G<&^JO]PG[BFEWM]YZ'<?!'PA-I9L
MUTL0MMPMRDC>:#_>R3R?8\>U</\ !C5;OPCXWU7P5>RF6%7<P$] Z\Y'H&7G
M\*]TKY_U<_9OVE;9H_E+RQ9QWS" :<7^\2[Z!)>X_+4]RO-=TW3KN"UN]0M+
M6ZGQY4$TZH\F3@;5)R>>.*CU+Q+I&C2B*_U6RL9",A+FX2,D?0D5X=^T1=3V
M/C?0+BU.VYAMUDB.,X82$C]:ZC2OV?=*NK 3Z]>7M[J]P-\\PFQM<\G&0<_4
MYS4J[5QO1V/5;6[@OH$GMIH[B%^5DB<,K?0CBLZ;Q?H5O=&VEUK3H[D':87N
MXPX/IC.:^;_#^F:]IOC74O VEZI);V]U.T$TJ]HUR2X&>"5'..O2O1==_9XT
M"W\.W364]XM_#$TB32R!@[ 9PRX P?:ANRYN@TKRY>I[""" 0<@TR>>.VA>6
M:1(HD&6=V"JH]237DO[.&OW6I^&[^PN)&E2QE40ESDJC _+] 5/YUS'B";4/
MC3\2IM"@NWMM#L&;=MY7"'#/CNQ)P,] ?K525I**)3]WF9[C8^*M%U2Y%O9:
MQ87<YZ1072.WY YJ6'7M,N=1DT^'4;26_CSOM4G4RKCKE0<BO--4_9TT,Z>?
M[*NKRTU&,;HIY)0P+CIN  Q]1C%<5\%)+Z3XMWO]ILSZ@L$R3L_WBZE5.??B
MB-G+E]0>BN?1]-=UC4LQ"JHR2>@%.KFOB5>R:?X!UZ>(XD%HZ@CMN&W^M1)V
M39<5=I'B^KZGJ_QV\:2:3I]PUKH-L2V3G:$!QYC#^)CV';VY->DZ9\!/!]A;
M+'/8RZA*!S-/.X)_!2!^E<]^S-8QQ^'-6O !YLMT(B<=E0$?^AFO9:T<5!**
M,[\SN>)>//@%:VMG)J7A9YK6[MQY@M#(6#8Y^1C\P;ZDY]JWO@C\2)_&.FSZ
M=J<GF:I9 'S#P9H^FX^X/!^HKT^OG3P:HT+]H6[M+?Y(9+BXCV+TVE6<#\"!
M^53'XN7HQR^'F[&G\9[N_P#%WC_2?",$KV]F6CWG!VL[\ECZ[5Z#ZUW]E\%?
M!]I8+:MI"7!VX:::1C(Q]<@C'X8KN:HZUK=EX=TR>_U"=;>UA7+.W\@.Y/84
MM(QLRM6SP%+*3X._&&RLK">1M+OS&#&YSF-V*X/J58$@^WUJ[\?+5_#WCK0?
M$4(V[@I)'=XF!_D0/PJ#PA!>?%[XJMXBEA:#2K"177=T 3_5IGU)^8_C[5W/
M[06B?VIX">Z509+"9)L]]I^5O_0@?PH;<8QD]T_P"RE*45LU^)Z3;SI=01S1
MG='(H=3Z@C(KP/XFVK_$3XO6_A^%OW=I;E"0> VPN3_Z"/PKT[X6Z\FH_#;2
MKV:08M[<QRL?X?+RO/X*#7 ? >%_$7B[Q-XGG7+2.40GL78L<?0!1^-5*/[R
MW17?^1,9-0OU=E_F7?V;=89]&U71I3B2SG$JJ>H##!'X%?UKK_C)K/\ 8OP[
MU:0-MDG06R8]7.#_ ..[J\Z\/G_A!_V@;VQXCM=3+!1V_>#>N/\ @0Q5_P#:
M2U)YH-"T2'+2W$QF*#OCY5_5C^53*\XQ\[+_ #_ J/N2?EJ;_P"S]H?]E> D
MNF7$M_,TQ/?:/E7_ -!)_&O3*H:!I2:'H=AI\8 2U@2+CO@ $_C5^M)N\M"(
M[:E'4]<TW1%C;4=0M;!9"0ANIEC#$=<;B,TW4O$&EZ,$.H:E9V(D&4^TSK'N
M^FXC->1?M.G&FZ ?^FTO_H*U)X3^#$?BZQ77O%MW=76H7ZB588WV+&A'R@\9
MZ8X& .E9J[OY%/2WF>P6&I6FJP">RNH;R$G'F02!U_,'%>>_M"_\DYE_Z^8O
MYFO._%.@7WP(\4V&JZ-=RS:5<MM:*4\L!]Z-\8!X.0<?RKO?CM>1ZC\+$NX3
MNAGE@E0^JMR/YTI6<;KN5'25GV9T'PA8+\--"9B ! 22>WS-71Z7KVF:WYG]
MG:C:7_EXW_99UDV9Z9VDXZ&N6^%W_)*-)_Z]7_\ 0FK@_P!F/IXB_P!Z'_V>
MM9:U)+M_F9K2$6>X7%Q%:P233R)##&I=Y)&"JJCDDD] *K:9K6GZW$\NG7]M
M?QH=K/:S+(%/H2I/-9_CS_D2/$'_ %X3_P#HMJ\Y_9F_Y%C5O^OP?^@"HCJY
M+LK_ (E/1)]SUG4-4L])@\Z^NX+.'./,N)%C7/U)JKI_BC1M7F\JQU>QO9?[
MEO<I(WY FOG_ ,/6%M\7/B+JO_"2ZE)!Y186]HL@0L Q 1<] !U &3U]:ZOQ
ME^SU91Z6USX9:Y34XB&2"28%9.>S'&T]\Y[4E\*D^HVM7%=#VFBN=\ Q:W;^
M%;.'Q"N-3B!1V\P.7 /RDD=\8S]*Z*J:LR4[HI:GK6GZ)$DFHW]M81N=JO=3
M+&&/H"Q&33+_ ,0:7I444M[J5G9Q2C,;W$Z(KCV)/->5_M,_\BSI'_7X?_0#
M53P3\'D\::;#K_BNZN;B>[C4P6T;[!'%C"YXSTQ@#&!ZYJ5K?R*>EO,]ET_5
M;+5X?.L;R"]ASCS+>59%S]035JOG+QIX4O/@?KUAK>@7DSZ?,^QHYCGD<F-\
M8#*1G'<8]LUZGX\^(R:!\/(]=LL&>^CC%H'Y 9USD^N!D_44-KEYA)/FY3J]
M3U[3-%V_VAJ-I8;ON_:9UCS]-Q%.TW6M/UE&?3[^VOD7JUM,L@'UVDUXIX ^
M#*>,]-3Q#XHO;NYGOOWJ1+)@E>S.Q!//8#&!C\(/B#\+W^&,$?B?PM?W-O\
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M^NVGAG1[G4[YV2UMUW.44L>2   /<BOF[XE?&&_\>QRZ?IUO)9Z.GSNG624
M]7(X Z<?F3Q7T7X@T&V\6Z!-IMZ9%MKE5W^4P#<$-P2#Z5Q7CWP?H_A'X5Z_
M!I-A%:*T*[W&6=_G7[S')/YUG+2[?0J+YK6ZGGG[,_\ R-NJ?]>)_P#1B5]'
M5\X_LS_\C;JG_7B?_1B5]'5M+9?UU,UNPHHHJ"@HHHH **** "BBB@ HHHH
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M3=1U"[0/;0#A(P9+BVDP!T5@^WH#@"NH^ G[#_Q+\:_'ZT^.?[1^NV&J>);
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M'F)][&<\9P:I_P#!57]E/XI_M):U\.+CX<^%_P#A(HM(M[Y+UO[0M;7RFD:
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M\3?VDK+X;1_#GPU_PD3Z1)J#7P^WVMKY(E%OY?\ KY4W9\M_NYQCG&17T?\
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M2&WW6U/SJ_;2_P""7>H?%+XB3_$WX0ZU:^'?%=S.+R]TV[E>WBDN5Y^T6\R
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ML3DOD_F]G]WX'QQ_P3Z_8'3]DG2M2U_Q+>VFL?$#5XA;S2V63;V-L&#>3$S
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M_P )6UY9Q?.\R"9I"GEVL8$>XY5BSD*"1M /ZZ45"C:*@W>VU^G]?>:<WO\
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MW]>A^?'_  3\^%W[6?PL\4:+X=^)J)IGPHT:PGM[;2YKS3YI$=OFCVM;EY&
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M^*/AAXLN-;\(VQU#3;@DO:*N\J"<["@.2 >A7D?S2]V3OU7_  1OWHJW1_\
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MC_P<AF\7_%?4_$1C*6\1EG)/0-(2%7ZX)_*N>?X6^+_%UY=ZA'X=BTA7!8P
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M:O#^J:KX]\.7%EIMY>6\2IYDMO [JG[W/) P..:Z;X\:5>ZQX%%O86<]]/\
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M95R?Q5LKC4?A]K5M:02W5Q)$ D4*%W8[UZ <FHG\++AI)'CO[,__ "-NJ?\
M7B?_ $8E?1U>!_L]>&M7T7Q1J,NHZ5>V$3V957NK=XU)WJ< L!SQ7OE:O9&:
MW84445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YR?\
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M ,-#?\(SXH_X:%_Y"_V]/[)_Y!W_ ![;/F_X\OE^]_?Y_"OI&M&K$IWOZO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X?XFUGQE\
M-/'%YJ;I>ZWX<G=G6)I&:.-6.=N>=A4\#C&*]PHI=;H>EK,\1NOVCGU" V^C
M>'KB749!M0.^\*W^ZHRWTXK8^"GP^U+P_)?Z[KBF/4[\8$3GYU4G<Q;T)...
MV*]6HJEIKU)>NG0****0PHHHH *@DLK>6ZBN7MXGN(@1',R N@/4 ]1FIZ*
M"BBB@ HHHH **** "BBB@ HHHH \2_:=_P"09H/_ %VE_P#05KU[0?\ D!Z=
M_P!>T?\ Z"*OT4UHFN[!ZM/L%%%%( HHHH **** "BBB@ HHHH \;_:9_P"1
M9TC_ *_#_P"@&O3?!_\ R*6B?]>,'_HM:UZ*%HGYC>MO(****!!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5YQ\;/!.H>+="M;C22S7]@[.
ML*-M:16 W!3Z\ _G7H]%)JXT['RCH'Q2\7_#Z2>VF\R8-@&WU9)&\LC^[E@1
M].E5]7U7Q9\8]6M\V;W;1Y2..UB*PQ D9))Z=N6-?6U%/=W8MMCG_ 7A<>#?
M"EAI1=9)(4)E=>C.Q);'MDX_"N@HHIMW=V)*RL%%%%(84444 %%%% !1110
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MI0 \=*>.E,'2GCI0 X=*D'6HQTJ0=: '#K3QUI@ZT\=: 'KUIZ]:8O6GKUH
M>M/7I3%IZ]* 'CI3QTI@Z4\=* 'CI3QUI@Z4\=: 'CK3QUI@ZT\=: 'KUIR]
M::O6G+UH >M/7I3%IZ]* 'KTIXZ4Q>E/'2@!XZ4\=*8.E/'2@!XZT\=:8.M/
M'6@!XZT]>M,'6GKUH >M.6FK3EH >O2GCI3%Z4\=* 'CI3QTI@Z4\=* 'T\=
M:93QUH >.M/'6F#K3QUH >O6GK3%ZT]: '+3UZ4Q:>O2@!XZ4\=*8.E/'2@!
MXZ4\=:8.E/'6@!XZT\=:8.M/'6@!Z]:>M,7K3UH >M/7I3%IZ]* /6/V6O\
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MBW]D#]N7Q)\1/B?JWP8^,WAN#P=\5M,#F,6X*07X0;F4*6;#[,."K,CKEEP
M ;/[8?[7OCKP-\7/"?P2^#.AV&L?$OQ'!]I>ZU3F"RA(?:0NY06Q'(Y+$A50
M?*Q;CQ#]MF/_ (1[_@IY^SQJNCKY>K7O]GQ71C8!GC-[+$2?^V;.ON!BO7?V
MWOV)_'/Q7^)WAKXP_![Q-!X<^(V@VZV_EW4AA6=$+LC1R!6 ?YV0JXV.I )
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MX'XB_$#]N/\ 9(\/'QUXVUSP;\5?"=M+&FH6MA;*CVZ.ZJ&_=V]LXR2%# 2
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MG_DAOC__ +&-?_2:*NBFN3$5G:UDG;?[5K>:_P"'.>H^>A23=[MJ^W3?R?\
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MBBB@ HHHH **** "HKNZAL;6:YN)%A@A0R22.<!5 R23Z "I:*3O;0:M?4_
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M_P#H=E7Z7T5I!JFZ7*M(2YK=WN]?,S:<O:.3UE%Q]$XM+[K_ /!"OS3^#?\
MRF:^*O\ V!W_ /2:QK]+**F'NU54\I+[QS]ZGR>:?W'S]^W_ /\ )FOQ8_[
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M/-#V:>ET_/1IZO[U\[N]C\TO^"B/_)^G[+7_ &$K+_TY15H_\%L_^2,_#O\
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M7O#?PTL[!]7UKQ+XG06SWT-N#-]GMT4L'),:GY&?. &V DGVO_@G1K-IJO\
MP3IT^WMIEEFT^VUFUN44Y,<AFGD"GT.R1#]&%?;-%8RBG2JTEM-?.^JOZ6>V
MG<T4GS4Y/[+O_7GYZ]NA^>/_  10_P"3=_&?_8T/_P"DMO74?\%C/^318O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K'\,?\>=Q_U\/_2MBL?PQ_QYW'_7P_\ 2J6S%U-BBBBI&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% #7;:C$=0,U4T:]?4=-AN) JN^<A!QP2/Z5
M:F_U3_[IK-\+_P#(#MO^!?\ H1JN@NIJT445(PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH @O9VMK*XF4 M'&S@'ID#--TZX:[L8)G #2(&(7I3=6_Y!=Y_U
MQ?\ ]!-,T3_D$6G_ %S7^55T%U+U%%%2,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "L?PQ_QYW'_7P_]*V*Q_#'
M_'G<?]?#_P!*I;,74V****D84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,F_
MU3_[IK-\+_\ (#MO^!?^A&M-UW(P'4C%5-&LGT[38;>0JSIG)0\<DG^M5T%U
M+M%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FK?\@N\_P"N+_\ H)IF
MB?\ ((M/^N:_RI^K?\@N\_ZXO_Z":9HG_((M/^N:_P JK[(NI>HHHJ1A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 45S?C#XE>$?AY]D_P"$J\5:)X9^
MV;_LW]L:C#:>?LV[]GF,-VW<N<=-PSU%<Y_PTG\(_P#HJ?@K_P *&T_^.5TP
MPU>I'FA!M>29FZD(NS:/1Z*\X_X:3^$?_14_!7_A0VG_ ,<H_P"&D_A'_P!%
M3\%?^%#:?_'*OZGB?^?4ON8O:T_YE]YZ/17G'_#27PC_ .BI^"O_  H;3_XY
M2_\ #27PD_Z*EX*_\*&T_P#CE'U/$_\ /J7W,/:T_P"9?>>C45YS_P -(_"3
M_HJ7@O\ \*&T_P#CE'_#2/PD_P"BI>"__"AM/_CE'U/$_P#/J7W,/:T_YE]Y
MZ-17G/\ PTA\)/\ HJ7@O_PH;3_XY2_\-(?"7_HJ/@O_ ,*&T_\ CE'U/$_\
M^I?<P]K3_F7WGHM%>=?\-'_"7_HJ/@O_ ,*"T_\ CE'_  T?\)?^BH^#/_"@
MM/\ XY1]3Q/_ #ZE]S#VM/\ F7WGHM%>=?\ #1WPF_Z*AX,_\*"T_P#CE+_P
MT=\)O^BH>#/_  H+3_XY1]3Q/_/J7W,/:T_YE]YZ)17G?_#1OPF_Z*AX,_\
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M8>UI_P R^\[ZBN"_X7_\+_\ HI'A'_P>VO\ \<H_X7_\+_\ HI'A'_P>VO\
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M6[X$_P"AU\._^#6#_P"+H^IXG_GU+[F'M:?\R^\ZVBN2_P"%N^!?^AU\._\
M@U@_^+H_X6YX%_Z'3P]_X-8/_BZ/J>)_Y]2^YA[6G_,OO.MHKF]-^)/A'6+V
M*SL/%.BWUY,=L=O;:C#)(Y] H8D_A725A4I5*3M4BT_-6+C*,M8NX4445D4%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U;_D%WG_7%_\
MT$TS1/\ D$6G_7-?Y4_5O^07>?\ 7%__ $$TS1/^01:?]<U_E5?9%U+U%%%2
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M67((.& /-;-4TXNSW)335T%%%%(8445Y9XV_:?\ AG\.OBIH'PW\0^)?[/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"_PWTJ/5/%OB32/"VF22B!+W6K^*SA:0@D('D906(5CC.< ^E?E=JFG>)/\
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M::UXWTFYU#4- U&R^P207LL CRKN<A& ;E%Z^E?1G_!3+]H[QM!XT\%_L_\
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M:Q]N@O?/WW$CR?OH%6-MLC.OR@8VX/(->*_\%)O^3 /%G_7#2_\ TJMZTO\
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M_P"".GP<?X:WNF:7>:^OBX6[O;^(;J^#LUQM)7S(0HC,9;&0 &Q_%GFOD/\
M86\&_$3]L31[KX(:_P".-5TGX0>%F.HZE!I\@^TSEV"PV:R-D"(,DD@4J5!#
M'!.S;$??DZ<?B2OY6Z^>EOG\QR]V*J/X;V\[]/+7^MC]?/#_ ,=?AKXMU_\
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M$KM3?^")&NW5GXK^+7AEI7>T$%G>*F?E$B22QLP]"0R_]\CTK6_;#M!\ /\
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MTMRK[F[_ "U/IGX$?$:+XN_!GP5XSB(/]M:3;WD@!^[*R#S%^JON'X5^=_\
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MM_PL]G\^WD?=%K=P7UM%<6TT=Q;RJ'CEB8,CJ>001P0?6OR[_:R_Y2Y_!/\
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M^U]_P39\#?#+X5ZA\2?@E'J/@7Q?X.B;5PMKJ=Q,MQ%$-\C!I79XY%4%E*L
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MA^))?%&N:9$^DQ631&"PM%3;;(ZR(Q==@5MB&, -CKEJY/\ X+>?\E6^&O\
MV!;C_P!'U^E'[)2A/V6_A$% 4?\ ")Z6< ?].L=9X2"EA*DG_.U]\I_Y%8AM
M8B"7\J_*)^1'_!.+Q7XE^!O[=%KX 6_=K'4+Z]T#6+2-SY$[PK+LDVYQN62(
M$-U +#^(U]8_\%N/^2*?#W_L87_])I*^1_V<_P#E*S%_V/&L_P#H5U7UQ_P6
MX_Y(I\/?^QA?_P!)I*SJS=3!49RWO'\XO\VRH)0Q=6$=K/\ *2_1&_\ L5_
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M^C8J^S_AM\5(_@C_ ,$Y?"OCIX5N6T/P+:74,#G"RS?9U$2$^C.5'XU\.?\
M!;7Q+I^H_%WX?:+;W44VH:;H\\MU"C@M")91L##L2(R<'L0>XKZ>\>>%[SQA
M_P $AK33[!'DN4\":=>[(_O%(!#.X'_ 8VKEC)QR^LX_S/\ .>IT\JEC:49;
M-+_VT^#?V1OV;?$/_!1GXT>+?$OQ!\6:BNG6(2YU;4HB&NII)2WE6\&\%(U
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M5OB/Q)X#F\6:CX:^'D$<&JZ_#II >]=69+>/GC/S2,"P95VD[2<8_4CXY?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<(5DPKJ "1C#3"U'ZO/>*@XOYWUM^GF2[U?K$-FYJ2OW26E_GOY'WI7Y2?\
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M\,M1T^P_X+3>/8[UD6>[LI(+/><9F_L^V? ]]B2?K7Z?U^*WQK^&_C/XH?\
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M0_77[!W[$WC#X<>.]=^-'QGOTU+XH:Z)/+M?-68V(D.97=T^0R, %"I\J)D
MG=A=?_@H1^PQJ7[2<>C>./ -]'I/Q,\.H$MR\I@%]$K^8B"4<QRH^2C'C+$$
MCAE2C[!45+6SDY6_O;V]++\24_:RK..G-%15_P"[U?KKIZ'G/_#K'XH_]':^
M+O\ P!NO_EC7#>,O^"84,'C/P_%X[_:TCN==C83Z=9^(K,&Z= X)\E9M1+8R
MO)48R/:M[0OVS_VR/ASH_P#PC7BO]G/5/%WB"U001ZW9Z9=-'*0,!Y6MUDBD
M)/),;(/8=:/@-^QS\8_VB?VB['XX_M(6\6CQ:9+%/IOAL%0[F,[X(Q$K-Y,"
M,=Q5V+LP.X?,6.U.ZJQE%Z)WO_EY^1C.WLI*2U:M;_/R)?\ @MV"OPL^&0)R
M1K%R,^O[@5^AWP_@2V\!^&X8QMCCTVV11G. (E KX8_X+#?#'QC\3?AS\/;;
MP?X3USQ9<VNK7$D\.AZ;->O"AA #.(E8J">,FON[P=!):^$=#AFC>&:.Q@1X
MY%*LK"-000>A![5SX?2->_6<?_2#2JO?HVZ1E_Z4?F#^U'_RE^^$GUT?_P!&
M2U^JU?FI^T?\)O'&N?\ !4[X8>+--\&^(-0\*V9TK[3KEKI<\MC!LDD+[YU0
MHNW(SD\9&:_2NM*.F%BO[\_S1%3_ 'J3_NP_4_+;_@FG_P GX_M'_P#7?4?_
M $Z&K7[4.I66D_\ !7KX+W%^46W-CI\(,C8 D>6[2/\ '>RX]ZW_ /@GS\*?
M&W@O]M/X^ZYXA\'Z_H6BZG-?FQU+4],GM[:[#:CO7RI'4*^5^8;2<CGI7&_\
M% /V9?B#\>/V[?!Z>'-'UZQTB?1;2W_X2ZUTNXELM/N$DN75I)T&U"K;,_,"
M-P/I2IOEC@G:]K7_ /)@FN9XQ7M=O\HGZI5^4W_!1ED\2?\ !0_X"Z-I>)]7
MA.E"58_O)NU%F4$CD8 +>P.:[.7]K/\ ;/\ A9IK>#=>^ 4OC/Q/;J+>W\4Z
M;8W-S9W ' FE^SYC8MU.'BZ\JO(KH?V+OV*?B')\:;[]H#X_W"R^.[AGDT[1
MS*DK6KLI3S9-A*+MC^6.-20H.3@@ 73BG7IU;^[!\U^^C5EYZ_(J<FJ-2G;W
MIJUNVJ=_30\\_P""X S;?!G_ *^-4_E:5^H&GHL=A;*H"JL2@ #  P*_.G_@
ML1\*O&OQ.@^$H\'>#]?\6&RGU$W0T/3)[W[.&%KM,GE*VW.UL9QG:?2OT8LU
M*VD (((100>W%%+3#6_OR_0TKZSI?X7_ .E,_*?QBZ^%_P#@MCH]WK6([6^E
MMQ:R2_*K&32C#%@_]=1M'N*_5ZOC'_@H+^PYJ7[24>B>./ .H1Z1\3/#: 6K
M22>2M]$K^8B>:/\ 5R(^61NF6()&0R^.Z+^V=^V3\/\ 1_\ A&?$_P"SGJ7B
MOQ);(((]<M-,NFAD8# >4VX>&0D\DQNB^PK.G*U&-)_%&]O-7T^?<*J<JOM5
MLTEZ-*SO^ASO_!;:[@U#6?@SHMMB;5R=0D$*#+[':V1/?EE8#Z&NU_X+-P26
MW[,WPZAEYEC\0PH_U%E.#5/X _L6?%WX[?M"6GQS_:3,.GS:?+'<:9X9C=&;
M=&=T"E$9EA@C8[MA8NS [^I+=U_P5\^''BWXE_ SP=8>$/"^M>*[Z#Q&L\MK
MHFGS7DL<?V6==[+$K$+E@,GC)'K45(NGAHTW\3GS/RO)6^?<J,_:5KKX8Q:7
MGHV_E?8]J\5?\H_M5_[)E)_Z:S7SM_P10_Y-W\9_]C0__I+;U]->)/#NK3_L
M/:EH,6F7DFN/\/)+)=,2W<W+7']FE/)$6-V_=\NW&<\8S7S+_P $S?"WQ ^!
MG[(WQ4N=4\"Z[IWBBUO[S4M,T/5M,N+:>^=+&(QJD3*'<.Z;!M!R<@<UVU9J
M&)Q<WMR_?[[>AS4(.>$PL%O=_P#I"/5_V_OVWK/]EKP;'H?A\QZE\3-=B*Z9
M9#Y_L<9ROVJ1><@-PBG[[ ]E:N7_ ."=G[%=W\'].N?BI\2%DU'XL>)@]Q(;
MX^9+IL4IW,K$\^?)G,C=1G:/XMWP9\+_ /A>/AWX^W_Q@^(/[.7C[XH^+I)O
MM5G_ &CH]_;V]I/GY9!&+9]VQ0%C7(5, @$A2OUW_P /%/VCO^C0?%W_ (!:
ME_\ (E84OW<7-_'+\%V7KU?7TT6E7WWR+X%^+[OTZ+_AW^BK_<;Z5^7'_!'%
MU'Q4^/B;AN,]J0N><>?=<U];_LB_M'_$KX]WGB:+Q_\ !S6/A7%ID=NUI)JL
M%S&+TN9 X7SH8\[=BYQG[PSBOC+Q5^S_ /M!?L*_M(^*OB-\&_"K>/\ P3K\
MLLDFG6D+73^3+)YGV>6WC(E#1L3LD0,,8SU9:F/[K$*4]I1:OZVM]Y4GST)0
MCNI1?W7O^9^EGQIO8-.^#OCJZNI5@MX="OI))'. JBW<DFO@K_@B'_R2?XD_
M]AN#_P!$5-K>N_M5_MUZ3+X.U+P _P "_AK=#&MWU]'*FHW<2\M;QK*%<A^F
M!&H."&<@E6Z+_@D#\,/%WPO^''Q#L_%WA77/"L]QK,,EO%KFG36;S((<;D$B
MJ6&>,CBJHP<9U9RTO%+[I?\ !,ZS4HTE'I)W^<7_ ):^IYK^SC DO_!8?XL,
MPRT4.HNIST/[@?R)K]*_B!_R(?B3_L&W/_HIJ^ /V?\ X5>-=&_X*J?%'Q;J
M'@_7['PK>07XMM=N=,GCL9RQ@VA)V4(V=K8P><'TK] _'%O+=^"O$$$$3S3R
MZ?<)''&I9G8QL  !R23VKADG_9M./7V?^9TPM]=J/^__ )'YQ_\ !#W_ )$;
MXJ_]A&Q_]%2U[W_P5<_Y,B\:?]?>G?\ I9#7E?\ P1U^%WC/X8^#?B7!XQ\(
MZ[X3FN[^R>WCUS39K)IE6.4,4$JKN )&2.F17M?_  4Q\':_X\_8^\6Z+X9T
M/4O$6L3W-@T6GZ3:275Q(%NXF8K'&"QP 2<#@ FN['Z\MO\ IW_[:<F!T3OW
MG^<BO^Q7XWTOX:?\$\_!/BS6Y6ATC1= NK^Z=1EA''-,Q '<G& /4BOE_P !
M?M ?M@?MWZIK6K_"6_T/X8>!+&X-HLUTL; O@,$:9H997D"LI)C1$&1WZ_4/
M[-_P4O?%_P#P3RT'X8^*K'4/#5_J?AZ[TRZM[ZV>"YM&DDEVLT3@,"-RM@@9
MX]:^-/@=<_M6_P#!/*YUGP7;_!Z\^)7A"[O7NXFT>UGO$,FT)YL4UNKM&KA%
MRDJ9^48"DG.E=Q>,J\[TUY>S?,[W^6W_  Y.'4E@Z7*M=+]TK*WX[_\ #'9?
M%;]@/XQW7PI\7^*/B_\ M(ZSK=AI.E76ISZ%9/<36DQBA:0+F65$4%E _P!5
M^5=O_P $4/\ DW?QG_V-#_\ I+;UB>,='_:[_;P\/7/AK7/#%C\#?AO<J9+M
M;I7-_?!>5A9&82$;@O!6%3SDM]VNG_X)!>#_ !E\-/AWX_\ "WC/P;XB\)W2
MZO'?V[:WI4]I'<(\0C;RWD0!RIA&<$\,OK2HWBZJ>EXJR_[>5W_P/*YI5:<:
M;6MI.[]5I_7F>?\ ["NHV=M_P4X_:+M)MHO+F75_LY8X)"ZDA< =^"#^%?J%
M7XV6?[,/Q\U']M3XP^//A]H^L>%==T;6-1UK0;_5],EM[#6@UV5-ND\JB)A)
M%(Q&258#JH.X>Q>)OVN_VT?&^D2>"M#_ &>[WPOXLN%:UG\1+8W MD)&"\$D
MQ$$9]&:61:QA)O"T8I>\HK3YLUJQ7UJO*_NN3U^XYG]GUD\4_P#!8[XB:CH[
M+/867]I&YDB/RC9#' _3K^^('UK]5Z^1/^"??[$]Q^RUX:U?7O%M[%JWQ'\2
M8;4;B*0RI:Q9+"%9#R[%CN=^[8 R%#'Z[K7E5*E2HWOR12?XO]3!/GJ5*MK*
M4K_@E^A4U;_D%7O_ %Q?_P!!-?F5_P $1O\ D'_&/_K\T_\ E<U^FVJ(TFFW
M:JI9FA<!0,DG::_/'_@C[\+/&GPRL?BNOC#PAKWA1KV[L6M1KFF369G"B?<4
M\U5W ;ESC.,CUHH:3JW_ )%_Z4C2MK2@O[WZ,\Y\8NOA?_@MCH]WK6([6^EM
MQ:R2_*K&32C#%@_]=1M'N*_5ZOC'_@H+^PYJ7[24>B>./ .H1Z1\3/#: 6K2
M2>2M]$K^8B>:/]7(CY9&Z98@D9#+X[HO[9W[9/P_T?\ X1GQ/^SGJ7BOQ);(
M((]<M-,NFAD8# >4VX>&0D\DQNB^PK*G*U&-)_%&]O-7T^?<NJG*K[5;-)>C
M2L[_ *'._P#!;:[@U#6?@SHMMB;5R=0D$*#+[':V1/?EE8#Z&NU_X+-P26W[
M,WPZAEYEC\0PH_U%E.#5/X _L6?%WX[?M"6GQS_:3,.GS:?+'<:9X9C=&;=&
M=T"E$9EA@C8[MA8NS [^I+=U_P %?/AQXM^)?P,\'6'A#POK7BN^@\1K/+:Z
M)I\UY+'']EG7>RQ*Q"Y8#)XR1ZU%2+IX:--_$Y\S\KR5OGW*C/VE:Z^&,6EY
MZ-OY7V/K7X#QK%\#OAXB*$0>'=. 51@#_1HZ[JN.^#-A<Z7\'_ ME>V\MI>6
MVA6,,UO.A22)UMT#*RGD,"""#R"*[&N[$N]>HUW?YG!A4UAZ:?9?D%%%%<QU
M'Y:?ML?\I4O@)_NZ/_Z7SU^I=?F[^U[\*?&WB;_@I/\ !3Q/H_@[7]5\-:>N
ME?;-9L=,GFL[;9>S,_F3*I1-JD$Y(P"":_2*JIZ86*?\\_S05=<2W_=A^3/#
M/VL_VN?!_P"R3X"_MK7W_M#6[P,FDZ#!(%GOI .3GG9&N1ND((&0 "Q"GX9^
M"/[+_P 2O^"AGCVR^,GQ^NI].\ J=^C>&X=T NH"<A(4SF*W/&9"?,D X."'
M'A/Q^TWX\_%+]K#5/B5JWP)\8>+=*T_4FCTG1=4\,:B]BUG"["W1E1%+(>)&
M .&9FSD$@_0R?M^?MEQ(J)^S+<HBC"JO@_60 /0?/65!IQ5:2][HNR_S_(NL
MFFZ4=NK[^7I^9^G>B:)I_AK1[+2M)LH--TRRB6"VM+6,1Q0QJ,*JJ.  !C J
M]7P1^S+^V!^TW\4/C;X<\,_$#X&S^#_"-\9_MNLOX;U.T%OL@D=/WLS&-=SJ
MB_,.=V!R17WO6\HO23ZF2:3Y5T(YX([J"2&5!)%(I1T89# C!!K\K?V&O%-M
M^R)^TG^TC\--9E-MH^E6=SKEHLC?*8;0M(A'NUO.C?\  *_5:OR<_P""JG[-
M_P 0[[X\Z5X[^&OA7Q'KX\0Z&^G:L?#FFSW;*R Q,)?*5L"2&1%^;KY9]*Y)
M.4)WC]J,H_-J\6_1K\3>*C.#C+HXR^YZKYILV?V(/@9<_&G]BOX_^(M6@677
MOB3=7K02LN=[P*TD3#/_ $\O)_WS7EWA?]IXZ)_P25USPI]I*:X-<?PE"C'+
M_9YS]J<XZX\LS1_I7Z?_ +)7PN?X-?LV?#WPA<6QM;ZQTF)KV%A@I=2CS9P1
MZB21Q7Y/W?[#/Q!O_P!N"Z\%GP=XD7X63^,3?OJ9TVX&DFRWF;/G;?*SY1,0
M.?O';UKIJTU+$2PJ^&2C'R2A)*_SBWUV,*=1J@L3+XHN4O-\R?Y-(_3#]D/X
M.7'PA_8P\,>%HH3!K=SHDE]<J?O"[N4:4@^ZEU3_ ( *_*W_ ()]?LM^(/VB
M[GQS9Z!\8M7^%>J:.;8W-IIEM+(UXC&4!F*7,/W&4C!W??[9Y_=Q$6-%10%5
M1@ = *_,WX[_ +%_QB_9W_:$O?C=^S8L6J1:C-)<:CX:W*&3S#OFC\IF430.
MPW!58.I(VCY0P4IQ>)E4DO=DK?X;.Z^6MGV0X0:PZII^]%W]>_SZKS-W_AUC
M\4?^CM?%W_@#=?\ RQK7_8X_8CT'X(_M':CXQM_V@--^)?B6WM[NQU/2([>,
M7GFN0)#,PO)7#*R<AESD<XQ7':S^VG^V-X_T7_A&_#/[..I^%O$ERA@?7+O2
M[M8(B1@O%]H5(HR#R#([K[&O8/\ @GE^P[JG[-MMK?C?Q]>1ZE\2_$B;;GRY
M?.%C"S^8\9E_Y:2N^&=AD94 $\LUT[J3ELDGKWOI9?KV(J6<5'=W6G:VNOZ'
MP9X:^!&N?&;_ (*,_%GP9!\1+_X8:]+JFKWEOJMA$\DUP/M'F"$!)H3AHVW_
M 'NB=/3ZM_X=8_%'_H[7Q=_X W7_ ,L:V/VY_P!A?QOXL^*>G?'/X&WRV'Q&
ML#%)=:>LJ0/=/&-J31._R%]@",DA"NHZ]0W)Q?MS?M@V6DG0;K]F6_N?%:GR
M1K$>D7_V$MTW%5!0_43!?H.*YZ5E1A3M[T59KO;JO\NGK<Z*K<JTJGV9._IW
M3_S(_ /_  3JT_P/^TKX1U_Q#^T_;>*?&V@WUK?_ -B:G:+_ &E<1HX9(_GO
MWD56S@':1\W -<!_P66TF[U_X]?"#3+"18;Z]L&MK>1F*A)'N@JDD<C!(Y%>
MQ_L5_L1_$0?&V^^/_P ?9TD\<W#R2V&D^:DCPRLOE^=*8R8UVQ_*D:D[003@
MJ!6#_P %,_A/XW\>_M,?!'5/#/@WQ!XBTS3_ "OME[I.ESW4-MB]1CYCQH0G
MR@GYB..:MQ;J8:G/^>[2V5XOK]W_  ]S%RM#$5(+[-DWULUT_K[K'AGQG_9<
M\8?\$R/$OPT^,'@K6KKQ-:P%;7Q!)(FR'[0V?,B( R+>9,JN[)5DSG)4#]:O
M@_\ %?0/C?\ #;0?&WAFY%SI&KVXFC!(WQ-T>)P.CHP*D>H-6?BA\-M"^+_P
M_P!=\&^)+1;S1=8M6MKB,]5S]UU/9E8!E/8J#7YV_L':'\8/V//V@?$GP?\
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M=>T+1+K0/B!8^)_'-Q<7-QXCU[Q9=7,(N-PC$*Q!(YV.W$FYG;<21VX'Z+_
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M4 /I5Z4E*O2@!PZTZFCK3J '#I3EIHZ4Y: '#K3J:.M.H <.E.7K31TIR]:
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M> -L8Y53DCJH]*%K4A3_ )G;\&_T!Z0E/^57/T'HHHH **** "BBB@ HHHH
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MFBBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *FK?\ (+O/^N+_ /H)IFB?\@BT_P"N:_RI^K?\@N\_ZXO_ .@F
MF:)_R"+3_KFO\JK[(NI>HHHJ1A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPJ2 !@QPV23L48\T_9W][MW\D^K*E*T>?[/Y>J[%#_@M[_R2_P"&?_89N?\
MT0*^G/VK_P#DPOQY_P!B<?\ T2M?,?\ P6]_Y)?\,_\ L,W/_H@5].?M7_\
M)A?CS_L3C_Z)6O.E_NN+]5_Z;.E?[QA_1_\ I9YW_P $B?\ DS32O^PQ?_\
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MWIG[1GQA^#GQ%\7Z[XKU'2V>2QEU_49KMT^S3M#)Y9E9B ZRQO@<$+FO0O\
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M 2 2:]Q_X)H_M@ZU^TS\/M;T3QHRR^./"LD45U=B,1F]@DW".5E  $@9'5@
M!PIP,D5]$?M ?&[P]^SS\*==\;^([A(K6PA/V>WW 27=P0?*@C'=F;CV&2<
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MH_[1-QKOBZ%3/)X=O=1N9[*0XR8T\\-"Q/0!HD7)^\.M>??LK_M9_$_XY_\
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M -+):^N:^1O^"5/_ "9'X)_Z^=0_]+):\:_X)N?%7QKXZ_:B^/>E>)/&&O\
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M'B"+X7?#WPL;B#4O%,<CI=7MQ-/).4B=!O!195&U"@ZEG^95'7_$O5OVL/\
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MT2\UB^N?&'C&&T@TFRDU6YDGDU'4/+R\TTC,7* J[MSG "@C(KP*&(_M7?\
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MSXS^)0U_X::IX4C;2?#IUZ^N?L8E6&2#_1Y8Q#'LC#+\C';G R*\'_X+>?\
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MON5E53#&@)QO<NB@$]6YK\\/^"XYL_M?PAP$_M#9J>X\;O*S;8]\9W?K6?\
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MC?1_%_V#X;:1I\%MK'AS^T[F/[;</=@1R?9E4PR;2\9W.P(V\=!7R9_P3S^
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M_P#H-Q7ZC5^8'_!#RQE3PK\6+PKB"2]T^)6]66.8G]&7\Z_3^NS$_&O\,?\
MTE'+0VD_-_F?._[?'P"U7]H[]FCQ#X6\/A9/$,$D6I:= [A%GFA;/E9) !92
MZ@G W%<D"OR5_99_;C^(W["MUK?@N[\*0:AI,E^;F_T#68Y+.\M[G8J,5DQE
M"51,AT8?*, 9)/Z\_M<_M>:!^R#X4T?7/$'A_6-=BU:Y>SMQI8B")*J;P)&=
MQMR <8#?=/%8'P4\5_"O_@H3\&K+QEXA^'VAZ@Z7%Q83:=JT45]/I[HW"B8H
MK*60H_RX^_WQFN*DI1E4E2?;F7W?\#\/GV5'%QA&I\OQ_P"#^)\R77_!2#]F
MG]K7PU:>#/C=X,U;0+![E+K_ $B62>RAF7(1A<6K).#AF&?+"X)R<5]Q_L[?
M"+X8_"'X?);?"6RMK3PEJ\W]JQR6>HS7T-P[HB^:DDLDA(*H@X...G6O@W]O
MG_@FY\'_ (:_ SQ)\1? Z77@S4=$2.8V#WLEQ9W8>54*8F+.KG=\NUL9XV\Y
M&Q_P1+\?ZMK/PW^(7A&[EEFTK1+^VN['S,E8C<++YB*>PS"&P.[D]ZWHN,U4
M459I)OSU2_R^[;8RJJ4.24G>+=EY?U?\=]S]*J***S*"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FK?\@N\_ZXO_
M .@FF:)_R"+3_KFO\J?JW_(+O/\ KB__ *":9HG_ ""+3_KFO\JK[(NI>HHH
MJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8'
MQ _Y$/Q)_P!@VY_]%-6_6!\0/^1#\2?]@VY_]%-7+BO]WJ>C_(WH?Q8>J_,_
M/;_@B'_R2?XD_P#8;@_]$5Q?AR&/Q-_P6QU7^V3O:PDD:SCE^8!H]*7R\?0$
ML/0UVG_!$/\ Y)/\2?\ L-P?^B*H_P#!0SX)^._@U^T/X=_:A^&FER:LNG>5
M)KEO!&7,+1)Y9DD4<F&2#]VS ?+M))&<CT*LU2Q5.I/;EMZ7BK/Y?J<-*#JX
M:I3AO=OUM)^[\_T/TVK\I?\ @L/!'HOQU^!NO:<HBUTK*OG1_P"LQ#<PO#TY
MX:23'U->W>&?^"QGP.U+P<-3UBW\0Z-KB1 RZ&MA]H=Y,<K%*K"-ESG!<H3W
M KYZ^'VC>-O^"FO[8&A_$_4?#MSX>^$7A.:+[,UT#LEC@D,BP*V,22R2<R;>
M$7@G(7=%.+^M4G;2,KM]$DGU^9K.2^KU%UDK)=W='HG_  6Y);X5_#$MP3J]
MQG_OP*^GOVK_ /DPOQY_V)Q_]$K7S'_P6]_Y)?\ #/\ [#-S_P"B!7TY^U?_
M ,F%^//^Q./_ *)6O/E_NN+]5_Z;.F*MB,,O)_\ I9X[_P $R+VYTW_@GS?W
M=GG[7;S:Q+#M.#O4$K^H%>:?\$0-+LCX4^*NK':^K2W]E;R.>7$0CE9>?0LS
M?]\U[-_P2/A2X_8NTZ*10\;ZMJ"LIZ$%P"*^4]"U'Q;_ ,$FOVEO$LNI^&[_
M %WX->*I=D-W9@?-$&9X2C$[1/$'=#&Y7>"2"!@CTY24,3)2=N>$4NUU9_CL
M<$(N>'7+]F<FUW3;7X;G[!5^4O[/UO'X9_X+'_$*PT9!#873:D;E(N5^>%)W
MSCI^^P?KQ7LOQ#_X+&?!O1/!TEWX1M-;\3^(YHC]FTN6R-K'%*1P)Y&. N>O
ME[S_ #KF_P#@F/\ LW^.!X]\8?M!?$^QGTS7_%'G#3[.[C,4S+/*)9[AHSS&
MI*JJ \[=QQ@J3E1B_K'M'\,8R3?G))*W?^O,VK-.AR)ZN47;R3NSEOVBK8_L
MV_\ !5;X;>/X\VVB>-Q!;WCYPA=U^Q3 ^P!@D/N:ZKXZ?\7\_P""JWPN\%*/
MM.C_  _L!J]ZG58YP#<9/U/V-?QKIO\ @L+\,)/$_P"SKI7C:Q0KJ?@W5H[C
MSD'SI;SD1/@CI^\\AO\ @-<!_P $H#JWQJ^+GQF^.OB2*-M4U.2'3(I%!PA;
M$DJ+GLJQVP^E+"ZN*?\ RZ<G]Z7(O1.7]*Y6)T4I+_EZHQ^Y^\_5I7_K5W[!
MTR_ 7]NW]H+X2W3BUTZ\:35[%6;"*D<GFQX_[870)_ZY^U0?\$Z[9_V@_P!L
MGXW?'BZ5IM/AG?3])D=>,2OA,>Z6\"*?^NM>>_\ !5E=<^ _[4?ASXG>&9!9
MW'B;PU=:7+, >9!%);2DX(Y$-Q$5]"@/:OLG_@F'\)?^%4_LA^%7GA\K4O$C
M/K]SD8)$V!#_ .04B_,T876FJK^Q%P]7S-?^DK3M]P8GXW#_ )^24_1))_\
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M&6M1_6OU%TRTBL--M+:!%CAAA2-$48"J%  'X"OS!_X+1_\ (U_ S_KXO_\
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MN_\ I*-*_P#S'?\ ;WYQ/U4=UC1G=@J*,EF. !ZU^5W[3_QQ\3_\%"/C9:?
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MKM?E)^WM_P I0?@)_P!=-!_].DE?JW3I?[I'_'4_-&M;_>'_ (8?D?EC^PP
MO_!4W]H( 8&W7.!_V%(*^D/VS/VO?@]^S+XKT>76O!MGXY^*:Q"XTRTM[.'[
M5:J<JCM=.C-"&(8#8&8_W<<U\W_L,_\ *4[]H+_=US_TZ05Q?[7MQJG[*_\
MP4ITOXS^+/#EUXB\%7EQ!>6DD:@JP6T%NZ(S?*)HF!D5"1G"'(SD9Q=Z6#BW
M9.._SEIZON:UE^^Q4DKM2>G?8]H3]N#]KCXE2)'X!_9CET1)1E)_$L-T8R#W
M$DAM4_'.*^>O ,OQ6N?^"IOPYG^,R6$'CF9TDFM-.,1BMH3:3&*+,1*DA?\
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M5Y-M#W"(PV23,IRK$<BOL[X)?\D8\ _]@"P_])HZ\7_X*1?\FD>*O^OFQ_\
M2J.N/"YICY9O2I2Q$W%U8JW-*UN=*UK[6Z&='#T7@N=P5^1N]EOR[GS-_P $
MBO\ D=OB)_V#[3_T8]97_!6S_DKG@O\ [ C?^CWK5_X)%?\ ([?$3_L'VG_H
MQZRO^"MG_)7/!?\ V!&_]'O7VL_^2QC_ (?_ &QGFT/^156^7_I43S;X/?\
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M%?#'_!/*TBN_VN?!'FH'$8O)%![,+2;!_"OV$^)/_).O%/\ V"KK_P!$M7Y
M?\$Z?^3N?!G_ %SO?_226ONLCKTL1A,UK4*?LXN"M%.]O<GUT]3P\QISI4\-
M"<N9\SU]7']-#]5OVFE#_L[?$H, 1_PCU]P?^N#U^9W_  2\_P"3H8_^P+=_
MSCK],OVF/^3>/B5_V+U]_P"B'K\S?^"7G_)T,?\ V!;O^<=</#O_ ")<Q_P_
M^VLZLS_B8;_%^L3B_P!OZXN+C]K?Q]Y[.VR6V2/?V06L. /:OH[3X_V_8K"V
M2TQ]E6)1%M/A\C9@;<'Z8I__  4V_9AUS5/$<7Q5\-:=-J=F]JEOK<-JF^2
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M7@Y((R<\U^U/\3OB%^T#_8_Q+\4Z.-"\+W,DFFZ#:+NV;4 >1D+ &3EE#28
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MI9W32MI9WN_GIKTL>%@L7#"4_J^)]V4;]-[N_3_ANI]B^*OVTOA-X%^)^I>
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M:%?"/_!4#]GK6/'OA_1/B#X=L9-1NM"ADM=2MK="TOV4G>LH Y(1M^0.SYZ
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M/^"P'_-)?^XO_P"V5?G)7Z-_\%@/^:2_]Q?_ -LJ_.2OZ.X1_P"1+0_[>_\
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MD'T[_P"(FJ_M2?MU>!;_ ,*Q?#8? CP)=6[OJ5QKER\VI7^P;EMHXRD3JKL
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M !1110 4444 %%%% !1110!4U;_D%WG_ %Q?_P!!-,T3_D$6G_7-?Y4_5O\
MD%WG_7%__033-$_Y!%I_US7^55]D74O4445(PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "H[BWBN[>6">))H)5*21R*&5U(P00
M>"".U244FD]&&QS7@CX9>#_AE:7-KX/\*:'X4M;IQ+/#H>G0V:2N!@,RQ*H8
M@<9-=+UHHIO7<25MCSW5/V=OA3K>M/K&H_#+P=?ZL[[VO[K0+22<MZF1HRV?
M?-=];VT5G!'!!$D$,:A$CC4*JJ.@ ' %244+160WJ[LYGQQ\,?!WQ-M;6V\8
M>$]#\66UJYD@AUS38;U(7(P602JP4D<9%:FK>&M(U[0)]#U/2K+4=$N(?L\V
MFW=NDMM)%C'EM&P*E<<;2,5I44K*S7<.J9B>$/!'AWX?:,FD>%M TOPUI*.T
MBV&D6<=I K-RS".-0N3W..:T=3TNSUJQFLM0M(+^RF79+;W,:R1R+Z,K @CZ
MU:HIO7<%IL<%X:^ /PP\&:PNK>'_ (<>$M"U53E;[3=#M;><'U#I&&_6N]HH
MIW S_$'AW2O%FC7>D:YIEGK.DW:>7<V&H6Z3P3+_ '7C<%6''0BL_P %_#[P
MM\-M+DTSPCX:T?PMILDIG>ST6PBLX6D( +E(U4%B%49QG 'I7044EI>W4-SE
M_'/PL\%_$^*TC\8^$-!\61V99K9-<TR"]$!;&XH)5;:3@9QUP*Z&QL+;2[&W
MLK*WBM+.WC6&&W@0)'$BC"JJC@    #@ 5/10M-$#UU85Y_XA_9[^%GB[5WU
M77?AKX0UK5'.YKW4=!M9YF/J7>,L?SKT"BE;J'D5-+TFQT/3X;'3;.WT^Q@7
M9%;6L2Q1QKZ*J@ #Z5;HHJF[ZL-CA_%'P+^&WCC61J_B/X>^%?$&K#&+_5-%
MMKF<8Z?O'0MQ]:M^*?A%X$\<V^EP>)/!7AWQ!!I6?L$>JZ5!<K9YVY\H.A$>
M=J_=Q]T>@KK:*2TV#S$    & *6BB@#F+GX6^#+WQK!XQN/".A3^+K=0D.OR
MZ;"U_&H4J MP5\P#:Q'#="1WK.UWX%_#;Q1XA&OZS\/?"NKZZ&##5+[1;::Z
MR.A\UD+9'UKN**%I:P;C8XUB1410B*,*JC  ] *\<^-G[8'PE_9VUJ#2/B!X
MJ_L'4[BS^W06QT^ZG,T6YERK11LN=R,,9R.,X!!KV6O(_C7^R=\*/VBM3TS4
M?B'X1B\0WNFQF&UG-Y<V[(A;<5/DR)N&><-FIES-JWS_ .!\RH\J3O\ +^O0
M^*_V'K"?]K?]M#XB?M)7VF26OAG2V.F>'EG0 F0Q+$I..K);@ENN&G&#Q7Z8
M5B>#/!6@_#OPU9>'_#&D6>A:)9+LM["PA$448)R< =R223U)))Y-;=:OE48T
MX;15EW\V_-LS7-*4ISW?X=$EY)!6)XO\#^'/B%HS:1XIT#2_$NDLZRM8:Q91
MW<!=?NL8Y%*Y'8XXK;HK-I/<N]CRK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X
M(?\ 1&_A_P#^$O8__&J]5HIB.0T/X/> O#'A?4O#6C^"/#FD^'-3W?;M(L=)
MMX;2[W*%;S850(^5 4[@<@ 5S/\ PR=\$/\ HC?P_P#_  E['_XU7JM%&[N'
MD>5?\,G?!#_HC?P__P#"7L?_ (U72^!_@YX!^&5U=7/@[P/X;\)W-T@CN)M#
MTFWLGF4'(5S$BE@#S@UV%%.]A6ON0WEG;ZC:RVUU!'<VTJE)(9D#HZGJ"#P1
M7":)^SQ\*O#.LQZOH_PS\':5JL;;TOK'0+2&=6]1(L88'WS7H-%):.Z&]59A
M1110!Y_>?L]_"S4=?.NW7PU\'W.MF3S3J4V@VKW)?KN\PQ[L^^:[Y$6-0J@*
MJC  & !3J*-E;H&[N<MXT^%7@KXDRV,OB[P?H'BF6P+&T?6M,@O&MRV"QC,B
MMLSM7.,9VCTKJ    !@"EHHZ6#?4Y.3X2^!YO'"^,Y/!GA]_&"X*^(6TN Z@
M,)Y8Q<;/,^Y\OWON\=*ZSK111TL&[N<MX-^%7@KX=76H7/A3P?H'ABYU @WD
MVC:9!:/<D$D&0QJI?!9CSG[Q]:^/_C7_ ,%!-7_9W_:OG^'GQ0\+6%I\*K^*
M.2Q\16]M/).8'A&YW3<RRJLVY&"*" .C<9^Z:Y3XC?"CP;\7M$&D>-?#&E^)
M].5BZ0ZG:K-Y3$8W1DC*-CC<I!]ZE\R::U2TL]K?H5HTT]WUZW/F9?VE/V+?
MAG&?&VCWOP\LM4"F2.YT#1(?[39B.@6*+S58]/FQC/)%?/?[ &FZW^TO^VY\
M1?VC)=&N-(\)@3V]@\ZD>9*Z)#'&#T9D@0E\$@,R^HKZNTG_ ()J_LUZ-JT>
MHV_PNLY+B-MX2[U&]N82?>*2=HR/8KBOHS0]"TWPQI%II6CZ?:Z5I=I&(;:R
MLH5AAA0=%1% "@>@%:0M"7M.MFDNB3W_ *T_SRFG./)TNF^^FQ>HHHJ2PKB_
M&/P2^'?Q$O5O/%?@+PQXFNU&!<:QHUO=R >FZ1&-=I12L!@^$? /ACX?V!L?
M"_AS2?#=D3DVVD6,5K&3_NQJ!7D_B;]B/X/>*/C!H?Q.D\)P:?XNTN^74?M.
MGMY,5W,I+*\\0^1V#D/OP'+*N6(&*]VHJKOF4^JV8?9<>CW"O/\ 7OV>OA7X
MJUB35M:^&G@_6-5D;>]]?Z#:SSL?4N\98G\:] HI=;AY%>PL+72K.&TLK:&S
MM(5"1001A$11T"J. /858HHH#8X[Q?\ !GX?_$'6+75O%/@;PUXEU6U18H+[
M6-(M[N>% Q8*CR(64!B2 #U)-=CTHHHV5@W=R*ZM8;ZUFMKF&.XMYD,<L,JA
MD=2,%6!X((."#7-^!OA5X*^&"7B>#O!^@>$TO"IN5T/3(+(3E<[2_E*N[&XX
MSTR?6NIHH6FP/7<**** /@C_ (+/_P#)JFA_]C7:_P#I-=5[]\ /ASX3^)'[
M)OP=LO%OAC1O%-E%X5TMX[;6M/BO(T;[)'R%D5@#[UW?QH^!/@;]H7PI!X:^
M(&A_V_HL%VE]':_:Y[;;,JNJMNA=&X61QC..>G KJ/"7A72_ WA;2/#FAVOV
M+1M)M(K&RMO,>3RH8T"(FYR6;"J!EB2>Y-.G:-.I!_:E%KY1L54ES2IM?9BU
M]\KC?"O@W0/ NDII?AK0]-\/:8A++9:5:1VT*D]2$C  _*IO$?AG1_&.B76C
M:_I5CKFD7:A+C3]2MDN+>9000'C<%6&0#R.H%:5%)^]N2O=V,CPIX/T'P)H<
M&C>&M$T[P[H\!9HM/TJTCM;>,LQ9BL<8"C)))P.22:/%/@_0?'&DR:7XCT33
MO$&F2'+V6J6D=S"Q]T<$'\JUZ*'[VX+38YKP5\,O!_PVMIK;PCX3T/PM;S'=
M+#HNG0V:.?5A&J@_C2>#?ACX.^'3W[^%/">A^&'U!Q)>-HVFPVAN7&<-)Y:K
MO(W-R<]3ZUTU%._45NAG:_X;TGQ9I<VFZWI=EK.G3#$EGJ%ND\+_ .\C@@_B
M*Y/PO\ /A?X(U9-4\.?#?PCH&II]V]TO0K6VF7Z.D8(_.N]HI+1W0WJK,***
M* /AG_@L9_R:+%_V,5E_Z!-7L?[-'P]\+?$;]C_X/V'BSPUH_B>Q3PUI[K:Z
MS817<2MY"\A9%8 ^]>D_&/X(^"OC_P"$1X7\>Z+_ &]H0N4NQ:_:I[;]Z@(5
MM\+HW&X\9QS70^#?!^D?#[PGI'AG0+3[!HFDVL=E96OF/)Y4**%1=SDLV !R
MQ)]32I+DA5C+[4DU\HV_,JH^:5-K[,6OO=Q/"?@GP[X!TI=+\,:#IGAS3%.Y
M;+2;..UA!]0D:@?I6U115-M[D)6V,#QA\/O"WQ#L%L?%7AK2/$UDIW+;:Q81
M7<8/J%D4BJ?@KX3>!_AL9CX1\&>'_"QF&)#HNEP6>_\ WO+1<_C75T4EIL-Z
M[C)8DGC>.1%DC<%61AD,#U!%<WX'^%W@SX8P7<'@[PCH7A.&[97N(]#TV&R6
M9E!"EQ$J[B 3@GIDUT]%&VP;F3XI\):%XYT.XT7Q)HNG^(-'N-OG:?JMK'<V
M\NU@R[HW!4X8 C(X(!H\+>$M#\#:';:+X;T;3_#^C6V[R-.TNU2VMXMS%FVQ
MH JY9B3@<DD]ZUJ*-@W.6\<?"KP5\3A9#QCX/T#Q8+(N;4:YID%[]G+8W&/S
M5;;G:N<8SM'I6IXE\)Z)XTT&YT3Q!HVGZ[HMR%6?3M3M4N+>4*P90T;@JV&5
M2,C@@'M6K11TMT'=W3['*/\ "?P1+X,B\(/X-\/OX3BSY>@MI<!L4R2QQ!LV
M#DD].I)[U8\%_#?PE\-[.6T\)>%M%\+6DK;Y(-%T^&S1SZE8U4$UT=%.[NWW
M)MHD5[^PM=5L;FRO;:&\LKF-H9[>XC#QRHPPR,IX92"00>"#6+X)^'/A/X::
M=-I_A#POHWA6PGE\^6UT33XK.*23 &]EC506P ,GG 'I7144MMA[A6!XP^'W
MA;XAV"V/BKPUI'B:R4[EMM8L(KN,'U"R*16_12:ON.]CF/!7PN\&?#6*:+PC
MX1T+PK'-_K4T338;,2?[PC5<_C73$9&#TI:*;UW%L<KX)^%/@GX:/?/X0\':
M!X4>_*F[;1-+@LS<%=VWS/*5=^-S8SG&X^II+KX3>![WQK#XQN/!OA^X\70X
M\O7Y=+@:_3"[!MN"GF#"DKPW3BNKHHZI]@>M[]3A/%_P%^&7Q!UEM7\4_#KP
MGXEU9T6-K_5]#M;N<HO"J9)$+8'89XK%_P"&3O@A_P!$;^'_ /X2]C_\:KU6
MBDDEL.]SR^S_ &6O@OI]W!=6OPB\!VUU ZRQ30^&K)'C=3E65A%D$$ @BO3V
M4,I! (/!![TM%/R%UN<)9_ 3X9:?XD_X2&U^'/A.VU_>9?[5AT.U2ZWGJWFB
M/=GWS6KKWPQ\'>*?$FF>(=:\)Z'J^OZ65-AJM_IL,]U:;6W+Y4K*63#<C:1@
M\UTU%"TM;IL#UO?J<[XV^''A+XEZ?!8>+_"^B^*[&"7SXK76]/AO(HY,%=ZK
M*K -AB,CG!/K6W86%MI=C;V5E;Q6EG;1K##;P($CB11A551P%    X %3T4;
M!OJ<GK_PE\#>*_%%AXEUOP9X>UCQ'I_EFSUB_P!+@GN[;8Q>/RYG0NFUB6&"
M,$Y'-=9111TL&[N<KH7PH\$^%_%6H>)]&\':!I'B34=_VW6;'2X(;RZWL'?S
M)E4.^Y@&.XG) )YK;UW0-+\4:7/INLZ;::MITXVRV=] LT,@]&1@01]15^BC
M=6Z#N[WZG$>$/@9\-_A]J)U#PM\/O"WAN_(Q]JTC1;:UEQZ;HT!JYXI^$W@?
MQQK>GZSXC\&^'_$&KZ=M^Q:AJFEP7-Q;8;<OER.A9,-\PVD<\UU=%'9]A=UW
M.:\;_#+P?\3+:UMO&'A/0_%=O:N9;>'7-.AO$A<C!9!*K!21QD5#XR^$W@?X
MBP6L'BSP;X?\3PV@Q;QZSI<%VL(_V!(C;?PKJZ*5D.YG>'_#FD^$]*@TO0]+
MLM&TR 8BLM/MT@AC'HJ( !^ IOB;Q)IO@[P[J>NZQ=QV&E:;;27=W<RG"Q1(
MI9F/T -:=<K\3OACX;^,?@K4/"7BVQEU+P_J 475G%>3VOFA6#!2\+H^,@9&
M<'H<BE4YW%\N_F.'*FN;8^&O^">_@74OCS\<_B)^U/XILY(8M9NYM/\ "\%P
MO*6XQ&T@_P!V-$A!'4^;7Z'UE^%_#&E>"O#FFZ#H5A#I>CZ;;I:VEG;KMCAB
M4850/8#ZUJ5K+E2C"'PQ5EZ?\'<S7,W*<]Y.[_R7DEH%<I:?";P/8>-9O&-K
MX-\/VWBZ;=YNOPZ7 M_)N7:VZX">8<KP<MTXKJZ*C9W*>JLSEO&GPJ\%?$F6
MQE\7>#] \4RV!8VCZUID%XUN6P6,9D5MF=JYQC.T>E=0    , 4M%'2P;ZG*
M>*/A-X'\;Z[I^M>(O!OA_7]9T[;]BU'5-+@N;BVVMO7RY'0LF&^8;2,'GK75
MT44;*R#=W"N+\1_!/X=^,=7FU77_  %X8US5)@HEOM2T>WN)Y H"KN=T+'
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M7,94*4I<TH)OT1%;6T-G;QP6\2001*$2*-0JHHX  '  ]*EHHKSMS;8****
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M X=*<O6FCI3EZT +3QTIE/'2@!5IPZTU:<.M #J<.E-IPZ4 .6G#K35IPZT
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M116984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45\O?\
M!1SXS^,?@-^S3>>*_ NL?V'K\>J6ENMW]EAN,1NS!ALF1UYP.<9KG_\ @F#\
M?/'?[1'P)U[Q%\0==_X2#6+7Q#-8PW/V."VVPK;V[A-L,:*?FD<Y(SSUX%%+
M]][3E^QO_P"2[?\ @2_$)_N^2_VMOQ_R/L&BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"IJW_ ""[S_KB_P#Z":9HG_((M/\
MKFO\J?JW_(+O/^N+_P#H)IFB?\@BT_ZYK_*J^R+J7J***D84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX=:_"G_H8/&/_@;:?_(U?8M%'^L>;?\ 01(/J.&_D1\=?\.MOA4/^9@\8_\
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M^%G_ $'_ !?_ .!EK_\ (U?7U%'^L>;?]!$@^HX;^1'R%_P[#^%O_0?\7_\
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M_H(D'U'#?R(^31_P36^&0_YCOBS_ ,#+7_Y'I?\ AVO\,O\ H.^+/_ RU_\
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M?4<-_(CYS_X85\!?]!?Q'_X$V_\ \8I?^&%O 7_07\1_^!-O_P#&*^BZ*/\
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M:_:N_:D^$?P1T'PW\-_@>/$_A"!IY;36/^$3U6\-T7F=G8S02K&^&)7(' 4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/X8_X\[C_KX?^E;%
M8_AC_CSN/^OA_P"E4MF+J;%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
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MS'[W,I7V/PS\5?#3XL?\$O?VDW\::'HLVM>#DDEBM-3>)WLKZPD/_'O/(O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L?PQ_QYW'_7P_\ 2MBL?PQ_QYW'_7P_]*I;,74V
M****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 5-6_Y!=Y_UQ?_ -!-,T3_ )!%I_US7^5/U;_D
M%WG_ %Q?_P!!-,T3_D$6G_7-?Y57V1=2]1114C"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HK\Y/^"P'_-)?^XO_P"V5?G*.M?H^4<'_P!JX*GC/K'+
MS7TY;VLVM^9=NQX6)S3ZO5=+DO;S\K]C^C6BOYS5ZU(O:O8_XA__ -17_DG_
M -N<O]M?]._Q_P" ?T745_.JM2#M1_Q#_P#ZBO\ R3_[</[:_P"G?X_\ _HF
MHK^=U:E7M1_Q#_\ ZBO_ "3_ .W#^VO^G?X_\ _H=HK^>9>E2+VH_P"(?_\
M45_Y)_\ ;A_;7_3O\?\ @']"M%?SW+TJ0=:/^(?_ /45_P"2?_;A_;7_ $[_
M !_X!_0;17\^R]*D7K1_Q#__ *BO_)/_ +</[:_Z=_C_ , _H%HK^?X=*D7K
M1_Q#_P#ZBO\ R3_[</[:_P"G?X_\ _?VBOP&7M4JT?\ $/\ _J*_\D_^W#^V
MO^G?X_\  /WTHK\#E[5*M'_$/_\ J*_\D_\ MP_MK_IW^/\ P#][**_!<=:D
M7I1_Q#__ *BO_)/_ +</[:_Z=_C_ , _>2BOP@7K3UZ4?\0__P"HK_R3_P"W
M#^VO^G?X_P# /W<HK\*%ZU(O:C_B'_\ U%?^2?\ VX?VU_T[_'_@'[IT5^&"
M]:D7M1_Q#_\ ZBO_ "3_ .W#^VO^G?X_\ _<NBOPX6I!VH_XA_\ ]17_ ))_
M]N']M?\ 3O\ '_@'[AT5^("U(O:C_B'_ /U%?^2?_;A_;7_3O\?^ ?MW17XD
M+4B]J/\ B'__ %%?^2?_ &X?VU_T[_'_ (!^V=%?B@O2I1UH_P"(?_\ 45_Y
M)_\ ;A_;7_3O\?\ @'[545^+"]*E7K1_Q#__ *BO_)/_ +</[:_Z=_C_ , _
M:*BOQA'2I%ZT?\0__P"HK_R3_P"W#^VO^G?X_P# /V:HK\:5[5(O6C_B'_\
MU%?^2?\ VX?VU_T[_'_@'[)45^.*]JD6C_B'_P#U%?\ DG_VX?VU_P!._P ?
M^ ?L517X]+VJ1>E'_$/_ /J*_P#)/_MP_MK_ *=_C_P#]@:*_()>M2+TH_XA
M_P#]17_DG_VX?VU_T[_'_@'Z\T5^12]:D7M1_P 0_P#^HK_R3_[</[:_Z=_C
M_P  _7&BOA/]EGX]GX?ZNGAO6YS_ ,([>R?NY6.1:2GO_ND]?3KZU]U(ZR(K
MHP96&0P.017Y_G.3ULFQ'L:NL7JI=&OT?='M87%0Q4.>.CZKL.HHHKP#M"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "L?PQ_QYW'_ %\/_2MBL?PQ_P >=Q_U\/\ TJELQ=38HHHJ1A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 UVV(S=<#-5M+OO[2L8[G9Y>_/RYSC!(Z_A5B;
M_5/_ +IK-\+_ /(#MO\ @7_H1JNEQ=35HHHJ1A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<US/"$FGEGFE.8G7)"F,8)/6ICS3J.*V2;?WI+[]2Y<L:?,]VTE^-_N/M/\
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M !1HOA2QGE\B*ZUO4(;.*23!;8K2LH+84G YP#Z4/3<%KL=%17->+/B9X/\
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MNT<L,OB:R5XW!P58&7(((((-:3Y5*R[?IJ90YFKO^M=#U"BO*O\ AK'X(?\
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M?%K7/AEH7B7[=XXT02M?Z7]@N8_)$3*DG[UXQ&V&=1\K'.>,UZE7Y;?LB?\
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M5#M(S\V>A%>PZ3\3O!VO>+=0\*Z9XLT/4?%&GJSWFB6FI0RWMLH*AC)"K%T
M+*"2!RP]16\U'FY8]OTU^7Z&,6[7EW_70Z:BN"U7X_\ POT+Q V@ZE\2/".G
MZXKB,Z9=Z[:Q7(8]%\II V?;%=W'(LJ*Z,'1AE64Y!'J#6:U5UL4]'9CJCN)
MX[6WEFE;;%&I=VQG  R34E9_B#_D ZE_U[2_^@&DW97&M6<AX?\ CSX%\4ZS
M:Z5I>N?:K^Y;9%#]DG3<<$]60 < ]37?U\!_L_\ _)8O#'_7PW_HMJ^_*]+&
M8>&'E%0;U/BN%LZQ&=X:I6Q,8IQE;W4UT3ZM]SD?&?Q9\*?#Z\@M-?U7[!<3
MQ^;&GV>63<N<9RB$#GUK:\,^)],\8Z+;ZMI%S]KT^XW>7-Y;)NVL5/# $<@]
M17RU^V9_R.6A?]>+?^C#7M'[,_\ R1;0/K/_ .CWJ'0C]55?JW;RW?\ D/#9
MUB*V?ULJE&/LX1NG9\U[1W=[?:?0LZA^T5\/=+O[FRNO$'E7-O*T,J?8K@[7
M4D$9$>#R#TJO_P -,?#;_H9/_)&Y_P#C=?'?B6S34?BEJMI(66.?698F*=0&
MG(./?FOIN3]C?P<4(35=<5^Q::$@?AY0KJEAL/2IPG4;]Y>7EY>9\]A,]S_,
MJ]>G@J5-JG*VO,NKM]KR/3/"OQ8\(^-;K[-HVO6MW='I;G='(W<[5< G\!5G
MQI\1?#WP\@MIO$%^;"*Y8I$_V>64,0,D?(K8_&OB'XJ?#N^^#OC1+..]>50%
MNK*]C^1\9X/'1@1V^M?0OBA9_C7^S/!JLT8DU:WA-UE5&6EA9DD(]-RACCWK
M*KAJ4(PK1E>#=F=V!XBQ^)>)P5:BHXJE%R2U<7;IO?6ZMKK>_0]:\%_$3P]\
M0[:YG\/ZB-0BMG"2GRGC*$C(X=0>>>?8UT=?%_[)GB[^POB,^E2OMM]7@,0!
M/'FIED/Y;Q_P*OM"L<706'J<JV:/>X<SB6=8%8BHDIIM-+:^ZM=M[-=3D/&?
MQ:\)_#Z^@L]?U86%S-'YJ1^1+*2N<9^13CD'K6QX5\6:7XUT:/5=&N3=V$C,
MJ3&)X]Q4X. X!Z\9Q7PY\8_$$WQ&^+FI-9@W >Y6PLT4?>"G8H'U;)_&ON#P
M7X9A\'>$]*T6WQY=E;K$6 QN;'S-^+$G\:JKAXTJ$*COS2_K_(XLISK$YIF>
M)H1C'V%+1.SNW>V][6=F]MK&U115#6=?TOP[;+<:KJ5IIENS;%EO)UA4MUP"
MQ SP>*X-S[.4HP3E)V2+]%88\<^'&T:?5DU[39=+@;9+>172/$C8!VE@2,\C
MCKR*YC3OV@?A[JE^MG!XFMQ,QV@SQ2PIG_?=0OZUHJ<Y7M%Z''4Q^$I<OM*T
M5S;7DE?TUU/0Z*16#J&4AE(R".AK(\3>+]%\&V(N];U*WTVW)PK3O@N?11U8
M^P!J+7=CKG.-.+G-V2ZO8V**\[TS]H/X>ZO=K;6_B:W65C@&YBE@3_OJ157]
M:]"1UD165@RL,A@<@BKE3G#XDT<^'Q>&Q:;P]2,TOY6G^0ZBJ6L:U8>'M/EO
MM3O(+"SC^_-<.$4?B>_M7%Z9\?\ X?ZOJ"V5MXEM_M#':OG1R0H3_ONH7]:4
M83G\*N*MC,-AI*%>K&+>R;2;]+[GH-%86I^//#.BWC6FH^(M)L+M0"T%U?11
MN 1D95F!Y%;BL&4$$$'D$=ZFS2N;QJTYR<8R3:WUV]1:*X;Q%\</ WA6]>TU
M'Q%;1W,9VO% KSE#Z'RU;!]C2^&_C;X'\67J6>F>(K:6ZD(5(IE>!G)Z!1(J
MY/L.:T5*HUS*+MZ'&\RP2J^P=>'/VYE?[KW.XK.U+Q!IND7=E:WE[#;W-[((
M;:%V^>5O15ZGZ]!2ZWX@TSPY:"XU34K33(&;8LMY.L2EL9P"Q SQTKX<\">+
MY=2^.&CZUKVK"15O]TE[>3 (B#./F)PJC\JWPN'>(DU>R1X^=Y[#*)4:=N:5
M226]K*ZNWU]/S/NO4;^#2K"YO;J3RK:WC::5\$[549)P.3P.U<AX3^-/@SQQ
MK"Z7HFL_;;]D:01?99H\J.IRZ ?K6Q<ZEH7C+PMJ?D:O:76DRPRV]Q>6=S&Z
M1 I\_P X)4$*<\].*\P^$_PO^''A3Q?'?^&?%O\ ;&JK"Z+:_P!I6T^5(^8[
M8U#<>M12A!J?M+W2TMWUW_ ZL9BL7'$8=81P=.3]YMZVNOAU5WOWZ'MU%<ZW
MQ%\)I>&T;Q/HPNQ)Y1@.H1>8'SC;MW9SGC%=%6#BUJT>U"K3J-J$D[;V=[!1
M6+K'C;P[X>NA;:KKVF:9<E0XAO+R.)RIZ'#,#C@\UIVE[;ZA:175K/%<VLJA
MXYH7#HZGH0PX(]Z5FE>V@1JTY3=.,DY+=7U^XGHKS_6?CYX T"]>TO/$MOYZ
M'#"WCDG /H6C5A^M=)X6\;Z#XVM6N-#U6VU*-,;Q"_SIGIN4X9?Q JW3FH\S
MB['-3QV$JU71IU8N:Z*2;^Z]S<HHHK,[@HHHH **** "BBB@ HHHH **** "
MBBB@#\Y/^"P'_-)?^XO_ .V5?G*.M?HU_P %@/\ FDO_ '%__;*OSE'6OZ.X
M1_Y$M#_M[_TN1\+F?^]S^7Y(>O6I%[5&O6I%[5]>>82+4@[5&M2#M0!(M2KV
MJ):E7M0!(O2I%[5&O2I%[4 2+TJ0=:C7I4@ZT 2+TJ1>M1KTJ1>M $@Z5(O6
MHQTJ1>M $B]JE6HE[5*M #U[5*M1+VJ5: )!UJ1>E1CK4B]* )5ZT]>E,7K3
MUZ4 2KUJ1>U1KUJ1>U $B]:D7M4:]:D7M0!(M2#M4:U(.U $BU(O:HUJ1>U
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MV KRPU=6E'^KKR9]]2JQK052#T84445Q&H4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!4U;_D%WG_7%_\ T$TS1/\ D$6G_7-?Y4_5
MO^07>?\ 7%__ $$TS1/^01:?]<U_E5?9%U+U%%%2,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOVI_B#\'?V YOB)\4?#ESI7Q(TR#^S8[35(?*:^NF<1V\[Q@Y (97=>#E),
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M5K_Y,L\1?]A+3_\ TH6OG_\ X*1?\G]_LY_]=M-_].=?0'_!6O\ Y,L\1?\
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MKW]HM"P#F><A<\D#4),G]1^=?IAXQNX;#PCK=S<2+#;PV,\DDCG 51&Q)/L
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MBIJO_I)+7)B?X$_1_D=N$_WBG_B7YGQ]_P $4/\ DW?QG_V-#_\ I+;U\O\
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MJ )%J1>U1K4B]J )%Z5*.M1+TJ4=: 'KTJ5>M1+TJ5>M $@Z5(O6HQTJ1>M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ,F_U3_P"Z:S?"_P#R [;_ (%_Z$:T
MIO\ 5/\ [IK-\+_\@.V_X%_Z$:K[(NIJT445(PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$P3/\('%=_\ L'?L3>,/AQX[UWXT?&>_34OBAKHD\NU\U9C8B0YE=W3Y#(P
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M7]G/X]?L=?M3>)/C'\$_#A\;^&=>FGGNM,MXC<R*D\@DEMY;=")2!)\R/%G
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MW431R+F9R,JP!&00?QKT>BI]N_8*A;1._P"?^84<DIT<UJ9JIMRFK6Z+X?\
MY$^%-4^'/BR3XJW=VOAC66M&UIY1.-/E*%//)W;MN,8YS7W7113K8AUH0@U\
M/_ _R'E.2T\IJ5ZD)N7M7=WZ;_YA1117(?1G%_&/P=_PG7PYUG2XX_,NC%YU
ML!U\U/F4#ZXQ^-?%F@?!OQAK&N6%C-X:UBRAN)TB>YN-/E2.)20"S$J  !S7
MZ#T5W8;%RPR:BKW/C\[X9PV>5J=:K)Q<5;3JKWM\M?O*^G6$&E:?;65L@BMK
M:)88D'\*J  /R%6***XFVW=GUT8J"48JR05XK^U9H&J>(O 5A;Z5IMWJ=PM^
MKM%9P-,P78XR0H)QR.:]JHJH2Y)*79W./'86..PM3"R=E--7]3P7]DGPWJ_A
MOP]K\>KZ5>Z7)+=1LB7MN\)<;.H# 9%'[6WAO5_$GA[0(](TJ]U22*ZD9TLK
M=YB@V=2%!P*]ZHKHGB7.O[=K73\#R(9'3AE/]D\[Y;-7ZZNYXM^REX?U/P[\
M/]0MM6TV[TRX?47=8;V!HG*^7&,@, <9!Y]J\R^+_P"S=K^D>)9]>\'0O>6<
MLWV@6]J^VXM7SGY1G)&>1MY'IQFOK:BJ^M359UHZ-F%3AO"5\MIY;6;:AM):
M23UU_';8^(M8C^-/Q"LH=#U/3]>NK0,,1W%C]G1B.A>0JH;ZL3ZU[_\ L_?!
M-OA;IES>ZF\<VO7RA9/*.5@C'(C![DGDGIP,=,GUZBJJ8R4X.G&*BGO8QR_A
MFC@\4L97JSK5(JR<W>WI_P /;RN?._[1WP"O_%^H#Q+X;A6XU H$N[($*TN.
M ZYX)QP1WP,5YKX7A^-\FG1^%K"#6['3]OE W=MY*Q)TP)G4$*!V5OH*ZC]H
MCX;>+-(\9W7BOPV=0EL[T(TYTYW\R"15"\A>=I !SVYS7)Z3^U/X\T'28=*D
MCL;R:%?+%U?02-<G' W'> 3[D9/?-=^'4Y8=1C:2[/I_70^$S>>"P^;U:F(5
M7#MWO*#TFN^RM=:O=7WUNSSGQYX5;P5XQOM#>X%W-:,B23#HSE%9L9[;B0,U
M]F_&[X7W'Q/\ 6]E9.B:I9LMQ;B1L*YVX*$]L@]?7%?./PX^%OBGXO>.X];U
MJTN$TZ6Y%U>W]S%Y:R@'.Q 0-Q.,<< 5]NU&-JN,:4;^_'5V[Z'I<*97#$1Q
MTYTW&A5=HIZ/EO+\DUKWZZ'PSX4T?XO_  VO+FTT+2=;L6N"%E6.Q\^%CT!R
M59,_[0/XU8\?_!#X@C3[3Q!K$-[KNLW\K+/;6L;W4L"@#:7*9 SR,#@8'/.!
M]O45@\?/F4U%7ZON>JN"L-["6'GB*DH?93>D7WMLW]WH>;_L^B_A^%.DV.IZ
M=>:9>V7F6\D-[ \+D;R5(# $C:PYZ9!]*^8O%/P@\>> /'4M[I&CZA=^1=&X
MLK[3K<W QNRI(4'!]0P_,5]RT5C#%2IUI54OBW1Z^-X<HX_ T,'4J-.E;EDM
M]%;\DOFCQGX?R^-M<^#WBK_A+K:]?6;A+D6T<\ 25T, "JL:@8^;=@8[UY+^
MS-X&\2:#\4[>[U/P_JNG6HM9E,]W921("0,#<R@9K[ HHCBG!U'&*7,K>FC7
MZCJ\/0K3PE2I6E*5!WN]7+5/5_(9-"EQ$\4BAXW4JRGH0>"*^"_'GP4\3Z%X
MQU6QTWPYJM_I\<[&VN+6RDDC:,\KAE!' (!]Q7WO16>'Q$L/-R6MSISW(J&>
MT84ZLG%Q=TUYK5?/3[CD/A-X,7P%\/\ 1]'*!;F.$27/O,WS/]<$X^@%97QM
M^$\7Q7\,+:QRI;:I:,9;2>0';DCE&QV/'/; ->B45E*K*53VM];W/4_L_#O!
MK 2C>GR\MO*UOO\ /OJ?$6D:'\8_A)-<V.CZ?K$$4K$NME:B\@8]-PPKJ"0!
MSP>E:7@7]GOQA\1O$_\ :WBZ*ZT^QDE\V[GOCMN9_550\C/3)  '3.,5]ET5
MW_7Y_$HI2[GQL."\*I1A5KU)THNZ@W[O]>EGYD5M;16=O%;P1K%#$@1$48"J
M!@ ?A4M%%>8W?5GZ$DDK(****0PHHHH **** "BBB@ HHHH **** /SD_P""
MP'_-)?\ N+_^V5?G*.M?HU_P6 _YI+_W%_\ VRK\Y1UK^CN$?^1+0_[>_P#2
MY'PN9_[W/Y?DAZ]:D7M4:]:D7M7UYYA(M2#M4:U(.U $BU*O:HEJ5>U $B]*
MD7M4:]*D7M0!(O2I!UJ->E2#K0!(O2I%ZU&O2I%ZT 2#I4B]:C'2I%ZT 2+V
MJ5:B7M4JT /7M4JU$O:I5H D'6I%Z5&.M2+TH E7K3UZ4Q>M/7I0!*O6I%[5
M&O6I%[4 2+UJ1>U1KUJ1>U $BU(.U1K4@[4 2+4B]JC6I%[4 2+4B]JC6I%[
M4 2+TJ4=:B7I4HZT /7I4J]:B7I4J]: )!TJ1>M1CI4B]: )%[5(O6HU[5(O
M6@"1>U2+4:]JD6@"5>U2+TJ->U2+TH D7K4B]*C7K4B]* )%ZU(O:HUZU(O:
M@"1>M2+VJ->M2+VH E6GKVIBT]>U 'MW[-OQRD^&6N?V7JDS-X;OG D#<_9I
M#P)!Z#U'X]J^\(9H[B%)8G62*10R.AR&!Y!!]*_*9:^J?V4_CN+9H/!6OW&(
MF^73;J0\*?\ GBQ]/[OY5^5\7\/>WB\QPL?>7Q)=5W]5U[KT/HLLQO(_85'I
MT_R/K.BBBOQ8^K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K'\,?\>=Q_U\/_2MBL?PQ_QYW'_7P_\ 2J6S%U-BBBBI&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% #)O]4_^Z:S?"__ " [;_@7_H1K2F_U3_[I
MK-\+_P#(#MO^!?\ H1JOLBZFK1114C"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"IJW_ ""[S_KB_P#Z":9HG_((M/\ KFO\J?JW_(+O/^N+_P#H)IFB?\@B
MT_ZYK_*J^R+J7J***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DW^J?_=-9OA?
M_D!VW_ O_0C6E-_JG_W36;X7_P"0';?\"_\ 0C5?9%U-6BBBI&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% %35O^07>?]<7_ /033-$_Y!%I_P!<U_E3]6_Y
M!=Y_UQ?_ -!-,T3_ )!%I_US7^55]D74O4445(PHHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% !1110 4444 ,F_P!4_P#NFLWPO_R [;_@7_H1K2F_U3_[IK-\+_\
M(#MO^!?^A&J^R+J:M%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FK?\
M@N\_ZXO_ .@FF:)_R"+3_KFO\J?JW_(+O/\ KB__ *":9HG_ ""+3_KFO\JK
M[(NI>HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX7 8F#I:VYD[J_;1K\;7/EGX.^"M4^*?Q-@O7B9K2*\%_J%T%PB_/O*Y]6/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.A>M2+VK]%1_P2!Q_P U9_\ +;_^ZZ</^"0F/^:L_P#EM_\ W77T?^MV2_\
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M0_\ +?\ _NJC_6[)?^?_ /Y+/_Y$/[,Q?\GXK_,^"%[5*M?>@_X)78_YJ?\
M^6__ /=5.'_!+''_ #4[_P H'_W51_K=DO\ S_\ _)9__(A_9F+_ )/Q7^9\
M&CK4B]*^\!_P2TQ_S4[_ ,H'_P!TTX?\$ML?\U-_\H'_ -TT?ZW9+_S_ /\
MR6?_ ,B']F8O^3\5_F?"2]:>O2ONP?\ !+G'_-3/_*!_]TTX?\$O,?\ -3/_
M "@__=-'^MV2_P#/_P#\EG_\B']F8O\ D_%?YGPLO6I%[5]SC_@E_C_FI?\
MY0?_ +IIP_X)A8_YJ5_Y0?\ [IH_UNR7_G__ .2S_P#D0_LS%_R?BO\ ,^&E
MZU(O:ON,?\$Q,?\ -2O_ "@__=-.'_!,?'_-2?\ RA?_ '31_K=DO_/_ /\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 R;_5/_NFLWPO_ ,@.V_X%_P"A&M*;_5/_ +IK-\+_ /(#MO\
M@7_H1JOLBZFK1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJW_(+O/^
MN+_^@FF:)_R"+3_KFO\ *GZM_P @N\_ZXO\ ^@FF:)_R"+3_ *YK_*J^R+J7
MJ***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %8_AC_CSN/^OA_P"E;%8_AC_CSN/^OA_Z52V8NIL4445(PHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 9-_JG_ -TUF^%_^0';?\"_]"-:4W^J
M?_=-9OA?_D!VW_ O_0C5?9%U-6BBBI&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %35O^07>?]<7_P#033-$_P"01:?]<U_E3]6_Y!=Y_P!<7_\ 033-$_Y!
M%I_US7^55]D74O4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *Q_#'_'G<?]?#_TK8K'\,?\>=Q_U\/_ $JE
MLQ=38HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R;_5/_NFLWPO_P @
M.V_X%_Z$:TIO]4_^Z:S?"_\ R [;_@7_ *$:K[(NIJT445(PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH J:M_P @N\_ZXO\ ^@FF:)_R"+3_ *YK_*GZM_R"
M[S_KB_\ Z":9HG_((M/^N:_RJOLBZEZBBBI&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\C]#Z*_/(?\ !6W/_-*O_+B_^Y:</^"M6?\ FE7_ )<7_P!RT?ZHYU_SX_\
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M#Q_P5&S_ ,TS_P#*_P#_ '-3A_P5#S_S3/\ \KW_ -S4?ZHYU_SX_P#)H?\
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MD']IX3^?\'_D?;M%?$8_X*59_P":<_\ E<_^YZ>/^"D^?^:=?^5S_P"YZ/\
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M_P"9"_\ *Q_]HI1_P4 S_P R'_Y6/_M%'^J.=?\ /C_R:'_R0?VGA/Y_P?\
MD?7M%?(H_;]S_P R)_Y6/_M%.'[?6?\ F1/_ "L?_:*/]4<Z_P"?'_DT/_D@
M_M/"?S_@_P#(^N**\M^!_P >]+^-%A=>7:_V3JUJ<RZ>\_FG8>CJVU<CUXX-
M>I5\WBL+6P5:5#$1Y9+='?3J0JQ4X.Z84445R&@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^&/^/.X_P"OA_Z5
ML5C^&/\ CSN/^OA_Z52V8NIL4445(PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 9-_JG_P!TUF^%_P#D!VW_  +_ -"-:4W^J?\ W36;X7_Y =M_P+_T(U7V
M1=35HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*.J_!3X ^-_'&AV]G=:MH=@;JVAU!'>!W#*,.J,K$<]F%<9^PK^T)XB_:=^
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M0!*O6GKTIB]:>O2@"5>M2+VJ->M2+VH D7K4B]JC7K4B]J )%J0=JC6I!VH
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M]NFFKH****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6/X8_X\[C_KX?^E;%8_AC_CSN/^OA_P"E4MF+J;%%%%2,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** &3?ZI_]TUF^%_\ D!VW_ O_ $(UI3?Z
MI_\ =-9OA?\ Y =M_P "_P#0C5?9%U-6BBBI&%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %35O\ D%WG_7%__033-$_Y!%I_US7^5/U;_D%WG_7%_P#T$TS1
M/^01:?\ 7-?Y57V1=2]1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;^NQFY7YE+W'K;]+W[GTI\?_ (L?\*,^#7BSQ[_9?]M_V#9F[_L_[1]G\_#
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M-=\#WWP]U"6ZFMVT3497DE14( <EXHCALY'R_B:^$/VA_P#E,5\*/^O>P_\
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M^,@MB\X]^H_.K_\ P1!,:GXS(RG[6LNF>8_8C_2\#\]W;O74U?$NIUC33_\
M DDR)1Y*$Z>_[Q:_._ZV^1^GGB'0-/\ %>@ZAHNK6D5_I>H6[VMU:SJ&26)U
M*LK ]0037YC_ /!*'6;KX8_M%?&_X+27$LNG6$\]U;1R'(5[6Z^S._L722+/
M^X/2OU(K\IOV(U,G_!5CXZ,@+*KZZ2PY ']H1"N6A_O-N\)W^237W/4WJJ^&
M;[2C;YWO]^S/IWQS_P %$_#GPQ_:G\0_"?Q9H<.B:#HFG_VA<^+IM4)!'V1+
M@(MJ(<EB7$8 D))Q@9.*\@\1_P#!8A+17UK0O@9XHU7P&LOE_P#"27MT;1#S
M@\+!)'G/0&7\J\3^._PQTOXP_P#!8B'PIK=N+O1[N[T^:[MF&5FBATR.9HV'
M]UO+VGV)K]=-1\.:7J7ARYT*YT^VET:>U:SDL#$/):$KM,>SIMV\8]*RCS?5
MH5GO9Z=[=7^6G:Y4U&-9T^EHN_:\5HOG=Z]['R^/^"F_P4'P*A^)C:E>JDMR
MU@GAOR5.J-=*H9HA'NVX"LK>9NV88<[CMKQ7_A\7'X=\0V,7C?X'>)O"7AZ]
M.ZWU*6[W3RQ?WU@D@B5AR"=LA^IKQ+_@D3\(/#FN?M'_ !"UG4+*.^F\(PB/
M2DN4$@ADDG=/.&1]]5B(![;S[5]Y_P#!1[POIOB?]C/XD?VC:QW#Z?9I?VKN
MH+0S1RH5=3V.,C([,1WIU:BITEB5JFN:W9=?.^C?W+S%"#E5>'>Z?+?S_P M
M5^+\CWOP1XUT7XC>$=(\3^';^/4]#U:V2[L[N,$"2-AD'!P0>Q! ((((!%?-
M'[57_!2#X=_LQ^(6\*+97OC7QL%5GT?2G5$MBV"BSS'.QF!R%57;&"0 1GD?
M^"<_CE_!G_!.:'Q+=LUQ#X?@UF\5#SB.&6:7:/;@_G7C7_!(+X8V?Q*UOXB?
M&_Q9''KGBV35C:6MW=H':"9U\ZXF7/1V\U%!'( 8#AC6\X7KRA%VC%*3[V?P
MK_,QA*U%5)*[;<5VNMV>G?#K_@K/H5WXPT[0?BO\,]>^$0U)@MIJ6HRM/;8/
M >4O#"R)G W*K@9R<#)'KO['G[:L7[6OB+XBZ;!X43P]!X2N88([N/51>K?K
M(\ZAP!"@08@SU;._KQSZY\=?@OX;^/OPQUOP9XGL8KNROH&$,KJ"]K/@^7-&
M>JNIP01UY!R"17YX_P#!$BPDTK5OC?938\ZVDTN%\?WE:\!_44J5ISG&2MRQ
MNO/WDK^JU79W*J)QI<\7U2]/^'_"Q^IM>3?M6_&;_AG[]GSQKXZCV-?:;9%;
M%)!E6NI&$4(([CS'4GV!KUFOC'_@KC#<2_L8:VT(8QQZK8--C^YYN!G_ ($5
MKCQ#:IV75I?>TOU.BBESIOI=_<KGAW_!*#]F'3O&^GZK\??'UN/$?B/4-3F&
MD2ZC^]V.K?OKL@\&5I"RACRNPD<GC]/Z^6O^"8T]M/\ L1?#C[,5(1+Q) HQ
MAQ>3[L^^:^I:]+$)0FZ4=HZ+Y=?GN<-%N:=26\FV^^_Z'S3^W3^R1X?_ &GO
MA#JX_LV!/'6E6DEQHFJH@682("PMV8<M')@J5.0"P8<BO"_^".WQ^U#Q_P#"
M77?ASK=P]Q?>#I8VL'E)+?89=VV/)_YYNC >BNH[5^A$C*D;,QPH!))]*_([
M_@D&/M?[4OQ>O-,&W1#ITVU0.,->J8A_WR&[URX?2O.ETE%OT<=;^KV^\WK_
M ,&-3K&27REI;Y&WI=I_PSA_P6-E@"BTT;QP9'3G <7D)?\ 6[B(K]*_BWX]
MMOA;\+_%GB^\(^SZ'I=Q?L#_ !&.-F"_4D ?C7Y[_P#!7SP[<> _&_P7^,^F
M0#[7HVI"SGE'!+12+<VX)],K/^=>D_\ !5WXS6^C_L=V=EIEQE_'5W:00&-N
M6M0!<NP]00D:G_KI6$F_J2A'XHMP]$VN7\[FZ2^N<SVDE+UM\7Y'QS\*?V=[
MSXE?\$Y?C9\2M0A-WXDU+6TUNWN)!EGCLF)GD'N?M%V#_NU^C/\ P3A^*'_"
MU/V/_ EU++YM_I$#:)=9;)#6[;$S[F+RF_&NQ_9S^"=GX"_93\(_#C4;5/*.
M@"VU*#'#2W"%KD'ZO+)7Q?\ \$C-;O/AM\2OC5\$M6E_TK1[\WL$;<$O#*;:
MX8#WQ;FO0LHUZN'CM9->;A[K^7+K;[CANYT:>(EOS._I/5+[_P"K&/\ \%*%
MD^//[;7P3^#=ONGMH?)>\1#]T7,X,Q/^[! &^AK]3((([:&.&)!'%&H1$48"
M@#  K\Q?V3;0?M!?\%0/B_\ $N11<Z7X4,]K9RGD"3BRA(^L44[?C7Z?5STM
M,+3_ +UY_P#@3T7R2_$WJZXB?]VT?N6K7JV%?(_C/_@H;H'PX_:H\1?"7Q1H
M,.BZ#H6FG4KKQ=-JF1M%HEQL%J(<EB7$8 D))Q@$G%?7%?C_ /''X+Z=\??^
M"OUQX/UF-IM#F:RN]0B4D>9!!ID4K1DCD!R@0D<X8XI03G6C36S4OEIO\M[=
M2_=5*<W]E)_^31T^:T^9['J__!8I=]SK&@? SQ-J_@*";RF\23WA@  ."2BP
M21@_[)E],XKZW_9E_:R\ ?M7>%;C5_!EY/'=63*FH:/J"".\LV;.TNH)!5L'
M#J2#@C((('K%AH6FZ5HL&D65A:VFDP0"VBL8852".(#:(U0# 4#C&,8K\IM-
M\-6O[(G_  5LT?0_"47]F>%?&"QJVF0*5B2*[1@8U'3:MQ'N4#A0 !P*NGRN
MK&B_M:)^?1/IK^'YY5+JG*K_ "ZM=+=;>GXF]_P4B_Y/[_9S_P"NVF_^G.ON
M3]K7]HC_ (9;^"VH_$#_ (1__A)OL=S;V_\ 9WVW[)O\V0)GS/+DQC.<;>?:
MOAO_ (*1?\G]_LY_]=M-_P#3G7T!_P %:_\ DRSQ%_V$M/\ _2A:Y%)PP47'
M_GY+\9Q1U2BI8II_R1_])9]%? /XJ_\ "\/@WX3\>?V7_8O]O62WG]G_ &C[
M1Y&21M\S:N[IUVCZ5YK^VS^UU_PQU\/=#\4?\(I_PEW]IZH--^R_VC]B\O,4
MDF_?Y4F?]7C&!USGBK?[ _\ R9Q\)O\ L"1_^A-7S9_P6R_Y-\\#_P#8T+_Z
M27%=.,_=3DH:6DE\N:WY'+A'[6G&4]6XW^=KGV[X7^*.F:M\'M(^(>LM!X=T
MF[T6'6[HW,X:.SB>%96#2$+D*"1G SCH.E?$^O\ _!7RPUKQ#=Z?\*?@WXH^
M)=K:L1+>)(UKD D!UCCAG;:>HWA#Z@'BO2/B]\.O$?Q5_P""8]CX;\)Q2W6N
M7'@[2)H;2$G?<K$EO*\2XZLR(P [D@=Z^6_V%_\ @I/\-O@#\)='^&'COPOJ
MOAN^TJXGCFU;3K19H9BTC,9+A,B59!G80%?[@Z=!K5C%8FK33LHO1=]7K=]O
MO)I2;PU*HU=RW?;1/9=SZ6_9X_X*D> /C/XYL_ _B3P_JOPW\87<WV:"TU5A
M+;23DX6'S<*RR$\ /&H)P,Y(!^TJ^,-?\%?LO_\ !0'QYX6\6Z9XVAU#Q5HB
M,T$&BWRV%_.BNK(9X98Q.1&PRI 7&]N3D5]G 8 &<X[FI?P+F5I:^ENC&OB=
MG=?C?JA:^3/B!_P4#T/X8?M57WPD\2Z##I6A6&F-J=WXNGU3"Q(+4W&W[,(<
ML20$ $F22, DXKZSK\A/VF?@Y8?'K_@K9IO@O5E=]'O8[&:_2,D%[>&R\YTR
M.1N$>S(Y&[CFL5S2K0IK[5__ $EZ_+?Y&WNJE4F_LI/_ ,F7YK0]@UO_ (+$
MH9;S5?#/P.\3:]X$M9?+D\23W9MU4#J2JP2(I] 90>1G%?6'[,/[7?P__:Q\
M-76I>#KNX@O[$JNH:+J*+'=VA;.UF4$JR-@X=21Q@X.0/7-)T#3-!T2UT;3=
M/MK#2;6$6T%C;Q*D,40& BH!@*!QC%?E+JOABS_9!_X*S^%K/P?"-*\,^,?(
M$FF6RE84BO-\3Q*.FP3QB4*.%PH& ,5K3LZL:+^UHGUOTOTU_ RJ75*57;EU
M:Z6ZVZW7XGZ7?&?XW^#/V?\ P/<^+/'&LQ:/I,+"-,@O+<2D$K%%&.7<X/ Z
M $G !(^&Y_\ @L+=:Y+>WW@OX ^*/$WABT8^;JSWIB,0 R2ZQ6\R(<<X,E>,
M?\%+OB;H/C+]N;P=X+\?:A<VGPU\*QVAU..V5W;$V)YV"I\VYX_*3(Y &17U
MIX?_ ."H7[+?A31++1]&UVYTK2K*)8+:RM- N8XH8U& JJ(\ "LJ;YX>UOU:
M2].K]>G]7UJ+DDJ=NB;?KK9?+<]'_95_;L^&W[627-EX>FNM%\46D?FS^']6
M"I<&/C,D14E94!."0<CC<JY&7?ML_M=?\,=?#W0_%'_"*?\ "7?VGJ@TW[+_
M &C]B\O,4DF_?Y4F?]7C&!USGBOS'_:@_:2^%"?M;?#_ .,?P-O98+Z&X2XU
M](["2S2619 &8JRC<9HGD1\=<9/))/U=_P %KI!+^SQX%=?NMXG0C_P$N**K
M?L(UDN5N5FO1I?<TQ4TE6=)NZM=/Y/\ )G7_ !0_X*H>&] U_P#X1SX;^ =;
M^+?B*WA26_BT1R+2V) WH)DBD:0H3@D1[<_Q9R!J_LV?\%1OAU\<=3U#0_$^
MGS_#'Q%8VTUW);ZO=+):M'"K-*%GVH0R*K,5=%X!QG!QZK^PW\)M%^$7[+_@
M"PTJPAM;K4=)MM4U&=(\27-U/$LCNYZG&[:,]%4#C%?G=_P4:^%6@^(_^"C/
MPZT-K46MMXO71XM5: ;6F,EX]N[\?Q&-5&?]D5TR@X8E8=:N3<?1Z_@O/5HQ
MA+VE!UND4GZK3\7?IH>^^-O^"OUA:SZA?> O@YXE\;^#M/D:.Y\333-8VPP<
M;AB"7"D8(\PHW(RHKZ8_90_;#\$_M=>%;[4O#"W6FZKIC(FI:+J 43VQ;.U@
M5)#QMM;##^Z<@'BO9=%\.:7X<T&TT32].MM/T>T@6VM[&WB5(8H@,!%0# &.
M,5^7'_!/'3(/!O\ P4B^//AK2$%EHEM%J\<5E"-L:K%J4*Q@#L%#, .P-122
ME5='?W9-/K[JOZ:EU%)4O:K2S2:_Q?Y#?^"C>LV/AW_@HS\ ]5U2[AL--L8M
M(N;J[N'"1PQ)JDS.[,>   23[5Z=XN_X*]6+ZMJ3?#CX.^)?B%X7TUREUX@$
MSVD*@?QA5@EPI'(,A0XZ@5Y#_P %/?A\OQ8_;V^#?@UY'BAUW2["PEDC^\D<
MFH7"NP]PI)_"OU.\%>"=#^'/A;3?#?AO3+?1]$TZ$06UG:H$1%'TZD]23R22
M3R:BCS/"K73GG;UNKW_"UO,UQ#7UBUOLPO\ ^ Z6]=3Q#]E']NKX=?M;0W5I
MX>>ZT7Q/91":YT#50JS^7P#)$RDK+&"<$C!'&Y5R,T_VT_VSD_8^L_!ES)X2
M'BE/$5Y+:L6U3["+4($)<GR9-WW^GRXQUKXJ_;8\-67[)O\ P4 ^%GQ(\&6\
M>CP^(9XKK4+2U79'))Y_DW>%' $D4@R!U8LW4UV7_!<$%O!WPH ZG4+[_P!%
MPUG*I>G3K06\N5KT:3MY/[_05.'[Z=&3O:-T_6+:^::.X\?_ /!7'2-%\4:K
M%X*^%FO>/_!ND3?9]0\66=R8;96!P3&!"ZLO]UG=-W4#&"?K;Q_^T+X1^$GP
MCM?B%X[N)?"6F3VT4WV&_4&\$LB!A;"-"VZ4<@JI(&"2< D7?@)\.=+^%'P7
M\&^$])M8K:ST[2X(F6- /,D* R2-CJSN68GN2:_.']OQ+G]HW_@H1\+_ (*W
MEU+'X9M!:K<01.1DS$S7+C'1C"B*#VQ[UK./+4CAHN\I2Y>;[[Z?(RIR4J;Q
M$M(J-VONM_P3O[C_ (+#3Z]<WUUX%^ ?BCQ7X=LS^^U-[PPM$,9)=(K>9$XR
M>9*^@?V5?^"@_P ,_P!JJ].B:6]WX:\7K&9/[!U?:'G4#+-!(I*R@<Y'RO@$
M[0!FOHCPMX6TCP3X>L-"T#3;;2-'L(E@M;*SC$<42 < **_+/_@J_P##BU^
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M!5# (BW^R)OQK[6^ ?[0G@K]I3P'#XL\$:DUY8E_)N+:=/+N;.8 $Q3)D[6
M(Z$@CD$CFNZU?0=-U_1;K1]2L+:_TFZA:VGLKB)7AEB(P49",%2.,5^5W[%U
MJ?V:/^"F7Q$^$&CRR#PKJBW,4-HS%@@2,7=L23U*1LZ9/)W'-*G:=1T6M;-I
M_P"'=/\ 3_@:E2\*?M;]4FO7JO3^O+]8*YGXG^-/^%;_  V\5^+/L?\ :/\
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M*GM7WS^R%_R;SX4_W;C_ -*)*YJL(PP*C"5US;_^!&CDY8E.2MI^B/@C4?\
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M^G/UKTC_ ()\<_$SQ'_V!S_Z.CJG^W9X5T7PMXY\.QZ+H]AI$<]@\LR6%LD
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M\QPL?>7QKNOYO5=?+4^CRS&\K5"H].G^1]74445^,'U04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/X8_X\[C_KX?^E;%
M8_AC_CSN/^OA_P"E4MF+J;%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M &3?ZI_]TUF^%_\ D!VW_ O_ $(UI3?ZI_\ =-9OA?\ Y =M_P "_P#0C5?9
M%U-6BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %35O\ D%WG_7%__033
M-$_Y!%I_US7^5/U;_D%WG_7%_P#T$TS1/^01:?\ 7-?Y57V1=2]1114C"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ\^=[;O]7[>]:4N2E4IQC\,(2C?U6GXD3YJE.LY?%-IV^:_1'U-7Y4_LH_\
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M7CO7O"]EI.IZ7JZZM8VNE+)MNK.WS'-.%D+$8$DYQD\1'UKZ!_X)D_'SP_\
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MELAN/ \R*5E'^WA>IQ7ZL:5I5GH>F6FG:=:PV-A:1+!;VUN@2.*-0 J*HX
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M=?LEZ=='PO;W.I^(+Y!'>:_JC*]U(F<^6FT!8X\\[5&3@;BQ (POVW_V*_\
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M]C[,U[Q#IGA;0[W6M8U"VTW2;*%KBYO;J01Q11J,EF8\  5^6G[$LK_M-?\
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M#EMX/^"7@70K)Y9;33;R.TA><@R,B6[*"Q  )P.< 5]?U\J_\%"/^2<>&O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *FK?\ (+O/^N+_ /H)IFB?\@BT_P"N:_RI
M^K?\@N\_ZXO_ .@FF:)_R"+3_KFO\JK[(NI>HHHJ1A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'QC
M^WO^QAXV_:E\=?"_6O"FJ:!I]KX7DG>]36;B>)Y \L#CRQ'#(#Q$WWBO4?A]
MG4441]V"IK:[?S>XFKS=1[M)?);?F%%%% PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** $ZU^>OQ/_X)A^*/#/Q.U7X@?L\_$^;X<:IJ,C2S:1.TL5N&=]SJ
MLT6X^43@B)XW (ZXP!^A=%3R^\IK1HJ^CB]4S\U]5_X)]?M-_'5HM*^-?Q_M
M9_"BNK3:?H3S3+<!6#8:(Q6\>[CAF#[3@X/2ONWX)?!7PM^S[\.-+\$^#[-K
M31[$$[IGWS7$K'+RRMQN=CR> !P    .[HK12M%Q6E]_,S:NTWK;\ HHHJ2@
MHHHH **** "BBB@ HHHH **** "OBZY_8N\;3?\ !1J'X_+JF@#P<B!38FXG
M_M#_ )!AM?N>3Y?WSG_6?=YZ\5]HT4XODFJBW5U]ZLQWO"4.DE9_??\ 0***
M*0@HHHH **** "BBB@ HHHH *^,?$?[&/C;6/^"A^C_'F'5- 7PA9QHDEE)<
M3B_)6R> X00F/[S _P"LZ>_%?9U%"TG&HMUM]UAWO"4.DE9_G^@4444""BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R;_5/_NF
MLWPO_P @.V_X%_Z$:TIO]4_^Z:S?"_\ R [;_@7_ *$:K[(NIJT445(PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH J:M_P @N\_ZXO\ ^@FF:)_R"+3_ *YK
M_*GZM_R"[S_KB_\ Z":9HG_((M/^N:_RJOLBZEZBBBI&%%%% !1110 4444
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MJJI Q(C8Y)Z4[]F[]K&V^,%Y_P (_KUK!I7B8(7A\@D07@ RVP,258#G;DY
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M)PGNBX34US1"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM #U[5*M1+VJ5: )!UJ1>E1CK4B]* )5ZT]>E,7K3UZ4 2KUJ1>U1KUJ1>U
M$B]:D7M4:]:D7M0!(M2#M4:U(.U $BU(O:HUJ1>U $BU(O:HUJ1>U $B]*E'
M6HEZ5*.M #UZ5*O6HEZ5*O6@"0=*D7K48Z5(O6@"1>U2+UJ->U2+UH D7M4B
MU&O:I%H E7M4B]*C7M4B]* )%ZU(O2HUZU(O2@"1>M2+VJ->M2+VH D7K4B]
MJC7K4B]J )5IZ]J8M=U\(/A9J'Q9\60Z5:;HK1,27EWC(ACSR?J>@%85Z]/"
MTI5JSM&*NV7"$JDE"*NV=K^S?\#9?B?KW]I:G"R>&[%P92W'VE^HC7V]3^'>
MOO&"".VACAB18XHU"(B# 4 8  ]*SO"_AC3O!V@V>CZ5;BVL;5 B(.I]23W)
MZDUJU_-V?9U4SG$NH](+2*[+OZOK]Q]W@\+'"T^7J]V%%%%?-'>%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/X8_X\[C_KX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!4U;_D%WG_7%_\ T$TS1/\
MD$6G_7-?Y4_5O^07>?\ 7%__ $$TS1/^01:?]<U_E5?9%U+U%%%2,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<>G#&O%_^">WAZTO?%?BK6)H4DNK"UAA@=ADQ^:S[B/0D1XSZ$^M>X?MK_\
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M-?9W[ ^D^%&\$ZGJ5C%O\5K.8-0DFP7CC/,8C]$8#GN64YZ#',?LD_ OPO\
M$+X+>)KS4K03:IJDTVFK=R ,;9%5&5HQV.\AB>^T#I7CGPB\::I^S/\ '"6U
MU=7BMH9VT[5H!G#1%O\ 6 =\<.#W'UKHJ.-9U,/#26_K_6B^XP2<8QK/9/\
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MZE)X\\0ZNB.NDPZ?]EE?'R/*TB,JY[D!6/MD>M?=U>9C*4:-7EBS6A-SB[]
MHHHKB.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% %35O^07>?]<7_P#033-$_P"01:?]<U_E3]6_Y!=Y_P!<7_\ 033-
M$_Y!%I_US7^55]D74O4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "HYX([J"2&:-989%*/&ZAE92,$$'J#4E% '@7BO]B3
MX9^)[Y[J&VU#07D.YH]*N0L9/LLBN%^BX'M2^$OV)/AGX7U".[FMM0U]XR&2
M/5KE7C!'JD:(&^C9'M7OE%="Q%9+E4F9NG"3NT4-3T:VU30[O26!@M+BV>U(
M@ 4HC*5^7C P#QQBO'_AA^R+X/\ A-XRM/$ND:EKES?6R2(D=[/"T1#H5.0L
M2GH3WKV^BLXU)PORO?<J48R236QR7Q1^&NF?%KP=<^&]7GN[:QN'CD:2R=4E
M!1@PP65AU'I7._!C]GOP[\"Y-6?0;W5+LZF(A-_:,L;[?+W;=NR-,??.<Y[5
MZ?11&I.,7!/1[_U\@E%3:<NAY?\ &?\ 9Z\.?'.72I->O=4M&TY9%B_LZ6--
MV_;G=OC?/W1TQ70?"OX8:5\(?",7AW1KB\N;*.5YA)?.CR9<Y/*JHQ^%=A10
MJDU#V:>G;\0<4Y<SW.0^(?PF\*?%2P2U\3:/#J(CSY4_*319_NR*0P'MG![@
MUXW'^P-\.$NQ,;[Q#)'NS]G:[BV8],B(-C\:^DZ*J%:I35H2L$HQG\2.=\#_
M  ^\/?#?1ETKPWI4&EV8.YEB!+R-_>=SEF/N2:YOXS? O0?CC8:9::]=ZC:1
MZ?*\L1TZ6-"Q8 '=O1^..V*]&HJ.>7-SWU!127*MCBOA)\)M(^#/A5] T2YO
M;JS>Y>Z+W[H\FY@H(RB*,?*.U<A\6OV5?!OQC\2IKNK3ZI8:@(5@D;39HT$H
M7[I</&V2!QD8X ]*]DHJO:SY_:7U[@HQ4>5+0YWP)X)MO /A"P\.6][>ZG96
M49ABDU)DDE\OLA*JH( .!QTP*\I\9_L5_#7QAJ4E]':WV@32L6D31YUCC8GN
M$='5?HH ]J]XHH56:FYIZL.6/+RVT/&/AQ^R1\//AKJD6IVMC<ZQJ,+!X;G5
MY1*8F'0JJJJ9]"5)'8BO4?%GAJU\9>&-4T*]DEBM-1MGM97@($BJX()4D$ \
M]P:UJ*4ZDZKO-W"$53=XJQXS\)?V5/"?P;\5'7]%U'6KJ\-N]MLOYX7CVL02
M<+$IS\H[U[-1114J3JN\W<48QA\*/*?B9^S'X ^*E])J&JZ6]GJLGW[_ $Z7
MR97]V&"K'W*D^]<)IW[!'PWLKM)IKS7]0C4Y,%Q>1!&]B4B5OR(KZ1HJX5ZM
M-<L9-()0C)W:,?PGX0T;P-HD&D:#IT&EZ=#]R"!<#/=B3RS'N223ZUL445BV
MY.[>I222L@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /SD_X+ ?\TE_[B_\
M[95^<HZU^C7_  6 _P":2_\ <7_]LJ_.4=:_H[A'_D2T/^WO_2Y'PN9_[W/Y
M?DAZ]:D7M4:]:D7M7UYYA(M2#M4:U(.U $BU*O:HEJ5>U $B]*D7M4:]*D7M
M0!(O2I!UJ->E2#K0!(O2I%ZU&O2I%ZT 2#I4B]:C'2I%ZT 2+VJ5:B7M4JT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-_JG_W36;X7
M_P"0';?\"_\ 0C6E-_JG_P!TUF^%_P#D!VW_  +_ -"-5]D74U:***D84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 5-6_P"07>?]<7_]!-,T3_D$6G_7-?Y4
M_5O^07>?]<7_ /033-$_Y!%I_P!<U_E5?9%U+U%%%2,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?PQ_QYW'_7
MP_\ 2MBL?PQ_QYW'_7P_]*I;,74V****D84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ,F_U3_P"Z:S?"_P#R [;_ (%_Z$:TIO\ 5/\ [IK-\+_\@.V_X%_Z
M$:K[(NIJT445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:M_R"[S_ *XO
M_P"@FF:)_P @BT_ZYK_*GZM_R"[S_KB__H)IFB?\@BT_ZYK_ "JOLBZEZBBB
MI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6/X8_P"/.X_Z^'_I6Q6/X8_X\[C_ *^'_I5+9BZFQ1114C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!DW^J?_=-9OA?_D!VW_ O_0C6E-_JG_W3
M6;X7_P"0';?\"_\ 0C5?9%U-6BBBI&%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %35O^07>?]<7_ /033-$_Y!%I_P!<U_E3]6_Y!=Y_UQ?_ -!-,T3_ )!%
MI_US7^55]D74O4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *Q_#'_'G<?\ 7P_]*V*Q_#'_ !YW'_7P_P#2
MJ6S%U-BBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)O]4_^Z:S?"_\
MR [;_@7_ *$:TIO]4_\ NFLWPO\ \@.V_P"!?^A&J^R+J:M%%%2,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *FK?\@N\_ZXO_Z":9HG_((M/^N:_P J?JW_
M ""[S_KB_P#Z":9HG_((M/\ KFO\JK[(NI>HHHJ1A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU%.<J.]?A..J\;9;A9XO$5X\L5K94WY?R'T%..!JS4(1U?K_ )F]_P -;_\
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MU%%%;$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %8_AC_CSN/^OA_Z5L5C^&/^/.X_Z^'_ *52V8NIL4445(PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 9-_JG_W36;X7_P"0';?\"_\ 0C6E-_JG_P!T
MUF^%_P#D!VW_  +_ -"-5]D74U:***D84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 5-6_P"07>?]<7_]!-,T3_D$6G_7-?Y4_5O^07>?]<7_ /033-$_Y!%I
M_P!<U_E5?9%U+U%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO6OSGPTA!8'$37Q.:3]$M/S9Z.:-^TBNE@KS[X]:/'J_PNUC<H:2U"W,9/\
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MO:_B[\0E^'7A.2]B59-0G;R+6-NF\C)8CT4<_D.]>*?LJ_\ (YZI_P!>)_\
M0UJY^UA?N^O:%99/EQ6SS =LL^/_ &2IP>9U<JX(A7H.TWS13[-U)*_JE>WF
M*5)5<?*,MM_P1Y+;P:]\2/$RQJT^K:O=M]YVR?Q)X50/H *[J^^!OCKP%:KK
MUG+"TUJ/-;^SIV,T0'))!49'J!FNN_9.TJ%FU_4BH,Z>7;J?13EC^>!^5?1%
M9</<&8?'Y;#,,15FJ]2\E)/X=79]V^K=_+3<K$XZ5.JZ<4N5:>I^?VM:O<:_
MJUWJ5V5-U=2&64H, L>2<=J^R?@G_P DK\._]<#_ .AM7R9\1=+BT7QYKUE
MH2"&\E$:CHJEB0/P!KZS^"?_ "2OP[_UP/\ Z&U<OAW&<,QQD:GQ):^O,[EY
MG;V<+'<4445^]'SP5XS^U1_R(&G_ /823_T7)7LU>,_M4?\ (@:?_P!A)/\
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M6]\8[348XUWR1V,K/(@[G:RKG_@.:];_ &7M&@M/ USJ*H/M-W=,KOCG:@
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M>WR.>O*K"FY48\TNBV.J_P"%Z_#7_HH7A7_P=VW_ ,71_P +U^&O_10O"O\
MX.[;_P"+KY6_X=F_]5(_\H7_ -TT?\.S?^JD?^4+_P"Z:^I^HY!_T&2_\ E_
MD>+]9S7_ *!U_P"!+_,^J?\ A>OPU_Z*%X5_\'=M_P#%T?\ "]?AK_T4+PK_
M .#NV_\ BZ^5O^'9O_52/_*%_P#=-'_#LW_JI'_E"_\ NFCZCD'_ $&2_P#
M)?Y!]9S7_H'7_@2_S/JG_A>OPU_Z*%X5_P#!W;?_ !='_"]?AK_T4+PK_P"#
MNV_^+KY6_P"'9O\ U4C_ ,H7_P!TT?\ #LW_ *J1_P"4+_[IH^HY!_T&2_\
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M\-?^BA>%?_!W;?\ Q='_  O7X:_]%"\*_P#@[MO_ (NOE;_AV;_U4C_RA?\
MW31_P[-_ZJ1_Y0O_ +IH^HY!_P!!DO\ P"7^0?6<U_Z!U_X$O\SZI_X7K\-?
M^BA>%?\ P=VW_P 71_PO7X:_]%"\*_\ @[MO_BZ^5O\ AV;_ -5(_P#*%_\
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M_10O"O\ X.[;_P"+KY6_X=F_]5(_\H7_ -TT?\.S?^JD?^4+_P"Z:/J.0?\
M09+_ , E_D'UG-?^@=?^!+_,^J?^%Z_#7_HH7A7_ ,'=M_\ %T?\+U^&O_10
MO"O_ (.[;_XNOE;_ (=F_P#52/\ RA?_ '31_P .S?\ JI'_ )0O_NFCZCD'
M_09+_P  E_D'UG-?^@=?^!+_ #/JG_A>OPU_Z*%X5_\ !W;?_%T?\+U^&O\
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M .#NV_\ BZ^5O^'9O_52/_*%_P#=-'_#LW_JI'_E"_\ NFCZCD'_ $&2_P#
M)?Y!]9S7_H'7_@2_S/JG_A>OPU_Z*%X5_P#!W;?_ !='_"]?AK_T4+PK_P"#
MNV_^+KY6_P"'9O\ U4C_ ,H7_P!TT?\ #LW_ *J1_P"4+_[IH^HY!_T&2_\
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M\-?^BA>%?_!W;?\ Q='_  O7X:_]%"\*_P#@[MO_ (NOE;_AV;_U4C_RA?\
MW31_P[-_ZJ1_Y0O_ +IH^HY!_P!!DO\ P"7^0?6<U_Z!U_X$O\SZI_X7K\-?
M^BA>%?\ P=VW_P 71_PO7X:_]%"\*_\ @[MO_BZ^5O\ AV;_ -5(_P#*%_\
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M_10O"O\ X.[;_P"+KY6_X=F_]5(_\H7_ -TT?\.S?^JD?^4+_P"Z:/J.0?\
M09+_ , E_D'UG-?^@=?^!+_,^J?^%Z_#7_HH7A7_ ,'=M_\ %T?\+U^&O_10
MO"O_ (.[;_XNOE;_ (=F_P#52/\ RA?_ '31_P .S?\ JI'_ )0O_NFCZCD'
M_09+_P  E_D'UG-?^@=?^!+_ #/JG_A>OPU_Z*%X5_\ !W;?_%T?\+U^&O\
MT4+PK_X.[;_XNOE;_AV;_P!5(_\ *%_]TT?\.S?^JD?^4+_[IH^HY!_T&2_\
M E_D'UG-?^@=?^!+_,^J?^%Z_#7_ **%X5_\'=M_\71_PO7X:_\ 10O"O_@[
MMO\ XNOE;_AV;_U4C_RA?_=-'_#LW_JI'_E"_P#NFCZCD'_09+_P"7^0?6<U
M_P"@=?\ @2_S/JG_ (7K\-?^BA>%?_!W;?\ Q='_  O7X:_]%"\*_P#@[MO_
M (NOE;_AV;_U4C_RA?\ W31_P[-_ZJ1_Y0O_ +IH^HY!_P!!DO\ P"7^0?6<
MU_Z!U_X$O\SZI_X7K\-?^BA>%?\ P=VW_P 71_PO7X:_]%"\*_\ @[MO_BZ^
M5O\ AV;_ -5(_P#*%_\ =-'_  [-_P"JD?\ E"_^Z:/J.0?]!DO_  "7^0?6
M<U_Z!U_X$O\ ,^J?^%Z_#7_HH7A7_P '=M_\71_PO7X:_P#10O"O_@[MO_BZ
M^5O^'9O_ %4C_P H7_W31_P[-_ZJ1_Y0O_NFCZCD'_09+_P"7^0?6<U_Z!U_
MX$O\SZI_X7K\-?\ HH7A7_P=VW_Q='_"]?AK_P!%"\*_^#NV_P#BZ^5O^'9O
M_52/_*%_]TT?\.S?^JD?^4+_ .Z:/J.0?]!DO_ )?Y!]9S7_ *!U_P"!+_,^
MJ?\ A>OPU_Z*%X5_\'=M_P#%T?\ "]?AK_T4+PK_ .#NV_\ BZ^5O^'9O_52
M/_*%_P#=-'_#LW_JI'_E"_\ NFCZCD'_ $&2_P# )?Y!]9S7_H'7_@2_S/JG
M_A>OPU_Z*%X5_P#!W;?_ !='_"]?AK_T4+PK_P"#NV_^+KY6_P"'9O\ U4C_
M ,H7_P!TT?\ #LW_ *J1_P"4+_[IH^HY!_T&2_\  )?Y!]9S7_H'7_@2_P S
MZI_X7K\-?^BA>%?_  =VW_Q='_"]?AK_ -%"\*_^#NV_^+KY6_X=F_\ 52/_
M "A?_=-'_#LW_JI'_E"_^Z:/J.0?]!DO_ )?Y!]9S7_H'7_@2_S/JG_A>OPU
M_P"BA>%?_!W;?_%T?\+U^&O_ $4+PK_X.[;_ .+KY6_X=F_]5(_\H7_W31_P
M[-_ZJ1_Y0O\ [IH^HY!_T&2_\ E_D'UG-?\ H'7_ ($O\SZI_P"%Z_#7_HH7
MA7_P=VW_ ,71_P +U^&O_10O"O\ X.[;_P"+KY6_X=F_]5(_\H7_ -TT?\.S
M?^JD?^4+_P"Z:/J.0?\ 09+_ , E_D'UG-?^@=?^!+_,^J?^%Z_#7_HH7A7_
M ,'=M_\ %T?\+U^&O_10O"O_ (.[;_XNOE;_ (=F_P#52/\ RA?_ '31_P .
MS?\ JI'_ )0O_NFCZCD'_09+_P  E_D'UG-?^@=?^!+_ #/JG_A>OPU_Z*%X
M5_\ !W;?_%T?\+U^&O\ T4+PK_X.[;_XNOE;_AV;_P!5(_\ *%_]TT?\.S?^
MJD?^4+_[IH^HY!_T&2_\ E_D'UG-?^@=?^!+_,^J?^%Z_#7_ **%X5_\'=M_
M\71_PO7X:_\ 10O"O_@[MO\ XNOE;_AV;_U4C_RA?_=-'_#LW_JI'_E"_P#N
MFCZCD'_09+_P"7^0?6<U_P"@=?\ @2_S/JG_ (7K\-?^BA>%?_!W;?\ Q='_
M  O7X:_]%"\*_P#@[MO_ (NOE;_AV;_U4C_RA?\ W31_P[-_ZJ1_Y0O_ +IH
M^HY!_P!!DO\ P"7^0?6<U_Z!U_X$O\SZI_X7K\-?^BA>%?\ P=VW_P 71_PO
M7X:_]%"\*_\ @[MO_BZ^5O\ AV;_ -5(_P#*%_\ =-'_  [-_P"JD?\ E"_^
MZ:/J.0?]!DO_  "7^0?6<U_Z!U_X$O\ ,^J?^%Z_#7_HH7A7_P '=M_\71_P
MO7X:_P#10O"O_@[MO_BZ^5O^'9O_ %4C_P H7_W31_P[-_ZJ1_Y0O_NFCZCD
M'_09+_P"7^0?6<U_Z!U_X$O\SZI_X7K\-?\ HH7A7_P=VW_Q='_"]?AK_P!%
M"\*_^#NV_P#BZ^5O^'9O_52/_*%_]TT?\.S?^JD?^4+_ .Z:/J.0?]!DO_ )
M?Y!]9S7_ *!U_P"!+_,^J?\ A>OPU_Z*%X5_\'=M_P#%T?\ "]?AK_T4+PK_
M .#NV_\ BZ^5O^'9O_52/_*%_P#=-'_#LW_JI'_E"_\ NFCZCD'_ $&2_P#
M)?Y!]9S7_H'7_@2_S/JG_A>OPU_Z*%X5_P#!W;?_ !='_"]?AK_T4+PK_P"#
MNV_^+KY6_P"'9O\ U4C_ ,H7_P!TT?\ #LW_ *J1_P"4+_[IH^HY!_T&2_\
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M\-?^BA>%?_!W;?\ Q='_  O7X:_]%"\*_P#@[MO_ (NOE;_AV;_U4C_RA?\
MW31_P[-_ZJ1_Y0O_ +IH^HY!_P!!DO\ P"7^0?6<U_Z!U_X$O\SZI_X7K\-?
M^BA>%?\ P=VW_P 71_PO7X:_]%"\*_\ @[MO_BZ^5O\ AV;_ -5(_P#*%_\
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M_10O"O\ X.[;_P"+KY6_X=F_]5(_\H7_ -TT?\.S?^JD?^4+_P"Z:/J.0?\
M09+_ , E_D'UG-?^@=?^!+_,^J?^%Z_#7_HH7A7_ ,'=M_\ %T?\+U^&O_10
MO"O_ (.[;_XNOE;_ (=F_P#52/\ RA?_ '31_P .S?\ JI'_ )0O_NFCZCD'
M_09+_P  E_D'UG-?^@=?^!+_ #/JG_A>OPU_Z*%X5_\ !W;?_%T?\+U^&O\
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M'UG-?^@=?^!+_,^J?^%Z_#7_ **%X5_\'=M_\71_PO7X:_\ 10O"O_@[MO\
MXNOE;_AV;_U4C_RA?_=-'_#LW_JI'_E"_P#NFCZCD'_09+_P"7^0?6<U_P"@
M=?\ @2_S/JG_ (7K\-?^BA>%?_!W;?\ Q='_  O7X:_]%"\*_P#@[MO_ (NO
ME;_AV;_U4C_RA?\ W31_P[-_ZJ1_Y0O_ +IH^HY!_P!!DO\ P"7^0?6<U_Z!
MU_X$O\SZI_X7K\-?^BA>%?\ P=VW_P 71_PO7X:_]%"\*_\ @[MO_BZ^5O\
MAV;_ -5(_P#*%_\ =-'_  [-_P"JD?\ E"_^Z:/J.0?]!DO_  "7^0?6<U_Z
M!U_X$O\ ,^J?^%Z_#7_HH7A7_P '=M_\71_PO7X:_P#10O"O_@[MO_BZ^5O^
M'9O_ %4C_P H7_W31_P[-_ZJ1_Y0O_NFCZCD'_09+_P"7^0?6<U_Z!U_X$O\
MSZI_X7K\-?\ HH7A7_P=VW_Q='_"]?AK_P!%"\*_^#NV_P#BZ^5O^'9O_52/
M_*%_]TT?\.S?^JD?^4+_ .Z:/J.0?]!DO_ )?Y!]9S7_ *!U_P"!+_,^J?\
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MM_\ %T?\+U^&O_10O"O_ (.[;_XNOE;_ (=F_P#52/\ RA?_ '31_P .S?\
MJI'_ )0O_NFCZCD'_09+_P  E_D'UG-?^@=?^!+_ #/JG_A>OPU_Z*%X5_\
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MT?\ "]?AK_T4+PK_ .#NV_\ BZ^5O^'9O_52/_*%_P#=-'_#LW_JI'_E"_\
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M'UG-?^@=?^!+_,^J?^%Z_#7_ **%X5_\'=M_\71_PO7X:_\ 10O"O_@[MO\
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M - Z_P# E_F?5/\ PO7X:_\ 10O"O_@[MO\ XNC_ (7K\-?^BA>%?_!W;?\
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M?YGU3_PO7X:_]%"\*_\ @[MO_BZ/^%Z_#7_HH7A7_P '=M_\77RM_P .S?\
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M<@_Z#)?^ 2_R#ZSFO_0.O_ E_F?5/_"]?AK_ -%"\*_^#NV_^+H_X7K\-?\
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M (!+_(/K.:_] Z_\"7^9]4_\+U^&O_10O"O_ (.[;_XNC_A>OPU_Z*%X5_\
M!W;?_%U\K?\ #LW_ *J1_P"4+_[IH_X=F_\ 52/_ "A?_=-'U'(/^@R7_@$O
M\@^LYK_T#K_P)?YGU3_PO7X:_P#10O"O_@[MO_BZ/^%Z_#7_ **%X5_\'=M_
M\77RM_P[-_ZJ1_Y0O_NFC_AV;_U4C_RA?_=-'U'(/^@R7_@$O\@^LYK_ - Z
M_P# E_F?5/\ PO7X:_\ 10O"O_@[MO\ XNC_ (7K\-?^BA>%?_!W;?\ Q=?*
MW_#LW_JI'_E"_P#NFC_AV;_U4C_RA?\ W31]1R#_ *#)?^ 2_P @^LYK_P!
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MS/JG_A>OPU_Z*%X5_P#!W;?_ !='_"]?AK_T4+PK_P"#NV_^+KY6_P"'9O\
MU4C_ ,H7_P!TT?\ #LW_ *J1_P"4+_[IH^HY!_T&2_\  )?Y!]9S7_H'7_@2
M_P SZI_X7K\-?^BA>%?_  =VW_Q='_"]?AK_ -%"\*_^#NV_^+KY6_X=F_\
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M_P#NFCZCD'_09+_P"7^0?6<U_P"@=?\ @2_S/JG_ (7K\-?^BA>%?_!W;?\
MQ='_  O7X:_]%"\*_P#@[MO_ (NOE;_AV;_U4C_RA?\ W31_P[-_ZJ1_Y0O_
M +IH^HY!_P!!DO\ P"7^0?6<U_Z!U_X$O\SZI_X7K\-?^BA>%?\ P=VW_P 7
M1_PO7X:_]%"\*_\ @[MO_BZ^5O\ AV;_ -5(_P#*%_\ =-'_  [-_P"JD?\
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M .+KY6_X=F_]5(_\H7_W31_P[-_ZJ1_Y0O\ [IH^HY!_T&2_\ E_D'UG-?\
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M7_W31_P[-_ZJ1_Y0O_NFCZCD'_09+_P"7^0?6<U_Z!U_X$O\SZI_X7K\-?\
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M2:382JQQ # ) R0!GMFL#X<> _$MCX\T"XN?#NK6]O%>1L\LMC*JH W))*X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %8_AC_CSN/^OA_P"E;%8_AC_CSN/^OA_Z52V8NIL4445(PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 9-_JG_ -TUF^%_^0';?\"_]"-:4W^J?_=-9OA?
M_D!VW_ O_0C5?9%U-6BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %35O
M^07>?]<7_P#033-$_P"01:?]<U_E3]6_Y!=Y_P!<7_\ 033-$_Y!%I_US7^5
M5]D74O4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Q_#'_'G<?]?#_TK8K'\,?\>=Q_U\/_ $JELQ=38HHH
MJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 R;_5/_NFLWPO_P @.V_X%_Z$
M:TIO]4_^Z:S?"_\ R [;_@7_ *$:K[(NIJT445(PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH J:M_P @N\_ZXO\ ^@FF:)_R"+3_ *YK_*GZM_R"[S_KB_\
MZ":9HG_((M/^N:_RJOLBZEZBBBI&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !6/X8_X\[C_ *^'_I6Q6/X8_P"/
M.X_Z^'_I5+9BZFQ1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEE_X$']JXGNON/U5'_!57X3'_F7O&?\ X!6G_P E4O\ P]3^$Y_YE[QG_P"
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MDTO_  \Y^%W_ $ ?%_\ X!VO_P DU^8E/'6C_4O*?Y9?^!!_:N)[K[C].?\
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M?^!!_:N)[K[C]*_^'E/PR_Z 7BS_ , [7_Y(I?\ AY/\,O\ H!>+/_ 2U_\
MDBOS6'2GT?ZEY3_++_P(/[5Q/=?<?I/_ ,/)?AG_ - /Q9_X"6W_ ,D4O_#R
M/X9G_F!^*_\ P$MO_DBOS:'6GCK1_J7E/\LO_ @_M7$]U]Q^D8_X*0_#0_\
M,#\5_P#@);?_ "12C_@H_P##0_\ ,#\5_P#@);?_ "17YO+UIZ]:/]2\I_EE
M_P"!!_:N)[K[C]'Q_P %'OAJ?^8'XK_\!+;_ .2*4?\ !1SX:G_F!^*O_ 2V
M_P#DBOSB6GKTH_U+RG^67_@0?VKB>Z^X_1L?\%&OAL?^8)XJ_P# 2V_^2*7_
M (>,?#8_\P3Q5_X"6W_R17YS+TIXZ4?ZEY3_ "R_\"#^U<3W7W'Z,?\ #Q;X
M;_\ 0$\5?^ EM_\ )%+_ ,/%?AO_ - 3Q3_X"6W_ ,D5^=(Z4X=*/]2\I_EE
M_P"!!_:N)[K[C]%?^'B7PX_Z GBG_P !+;_Y(I?^'B/PX_Z OBG_ ,!+;_Y(
MK\[1UIPZT?ZEY3_++_P(/[5Q/=?<?HC_ ,/#_AR?^8+XH_\  2V_^2*4?\%#
M?AR?^8+XH_\  6V_^2*_/ =:>O6C_4O*?Y9?^!!_:N)[K[C]#1_P4+^')_Y@
MOBC_ ,!;;_Y(I1_P4)^'1_Y@OBC_ ,!;;_Y(K\]%ZT]:/]2\I_EE_P"!!_:N
M)[K[C]"1_P %"/AT?^8+XG_\!;;_ ./TH_X*#?#L_P#,&\3_ /@+;_\ Q^OS
MX7I3UZ4?ZEY3_++_ ,"#^U<3W7W'Z"_\/!/AV?\ F#>)_P#P%M__ (_3O^'@
M7P\_Z WB?_P%M_\ X_7Y]CI3QTH_U+RG^67_ ($']JXGNON/T"_X> ?#S_H#
M>)O_  %M_P#X_2_\-_?#W_H#>)O_  %M_P#X_7Y_T\=:/]2\I_EE_P"!!_:N
M)[K[C[^_X;\^'I_Y@_B;_P !;?\ ^/TO_#??P^/_ #!_$O\ X"V__P ?KX#'
M6G#K1_J7E/\ ++_P(/[5Q/=?<??8_;Y^'Q_Y@_B7_P !;?\ ^/TH_;W^'Y_Y
M@_B7_P !;?\ ^/U\#+UIZT?ZEY3_ "R_\"#^U<3W7W'WN/V]?A^?^8/XE_\
M 6W_ /C]*/V\_ !_Y@_B3_P&M_\ X_7P4M/7I1_J7E/\LO\ P(/[5Q/=?<?>
M?_#>7@ _\PCQ)_X#6_\ \?I?^&\/ )_YA'B3_P !K?\ ^/U\'#I3QTH_U+RG
M^67_ ($']JXGNON/O#_AN[P#_P! CQ)_X#6__P ?I?\ ANSP%_T"/$?_ (#6
M_P#\?KX1'2GT?ZEY3_++_P "#^U<3W7W'W9_PW5X"_Z!'B/_ ,!K?_X_2_\
M#='@,_\ ,(\1_P#@-;__ !^OA4=:>.M'^I>4_P LO_ @_M7$]U]Q]T?\-S^
MS_S"?$7_ (#0?_'Z4?MR^ S_ ,PGQ%_X#0?_ !^OA@=:>O6C_4O*?Y9?^!!_
M:N)[K[C[E'[<?@0_\PGQ%_X#0?\ QZNK^''[4'@[XF>(DT2Q34-.OI5)A&I1
M1QK,1_"I61OFQS@XSVK\\EJS8WD^GW4-S;2M!<0N)(Y$.&5@<@@UC6X)RR5.
M4:7-&5M'>]GZ%0S;$*2<K-'ZPT5X_P#LZ_'"#XL>&Q:WSK%XCL4"W,>?]<O0
M2J/?N.QKV"OQ#&8.M@*\L/75I1_JZ\F?74JL:T%.#T84445Q&H5C^&/^/.X_
MZ^'_ *5L5C^&/^/.X_Z^'_I5+9BZFQ1114C"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!DW^J?\ W36;X7_Y =M_P+_T(UI3?ZI_]TUF^%_^0';?\"_]"-5]
MD74U:***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-6_Y!=Y_UQ?_ -!-
M,T3_ )!%I_US7^5/U;_D%WG_ %Q?_P!!-,T3_D$6G_7-?Y57V1=2]1114C"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R;_5/_ +IK-\+_ /(#
MMO\ @7_H1K5HIWTL(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:M_
MR"[S_KB__H)IFB?\@BT_ZYK_ "J]13OI804444AA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !116#I_CWPQJ_BG4?#-CX
MCTF]\2::BRWVCV]]%)>6J-C:TL(8N@.Y<%@,[AZT;NP;*YO445POC#X\_#/X
M>ZRVD>*OB)X3\-:LJ+*;#6-;MK2<(WW6\N1PV#C@XYI72 [JBO*O^&L?@A_T
M63X?_P#A46/_ ,=KM_!GC_PQ\1])?5/"?B/2/%&F)*8&O=%OHKN$2  E"\;,
M-P!!QG/(]:JS8KF]14%]?VVEV<UW>7$5I:PJ7EGG<(B*.I9CP![FN,\+_'CX
M:>.-8_LGPY\1/"GB#5>?]!TO6[:YGXZ_(CEOTI+5V0WHKL[JBBD9E12S$*H&
M22< "@!:*\_M?VA/A9>^(!H5O\2O"$^N&3R?[,BUZU:YWYQL\H2;MV>V,UZ!
M1TN'6P4444 %%%% !1110 4444 %%%% !117!^*OCW\,? NI-IWB3XC>$O#V
MH+]ZTU77+6VE'U1Y ?TI7'8[RBLCPSXOT+QKIJZCX>UO3M>T]C@7>F7<=S$3
M[.A(_6M>JM;<E.^P45R'A[XP> O%WB>]\-Z%XV\.:UXBLO,^U:1IVK6]Q=P>
M6P23?"CEUVL0IR!@G!YKKZ72X_(**XOQM\:_AY\--1@T_P 7^//#/A6_GB\^
M*UUO6+>SEDCR1O59'4E<@C(XR#Z5UUG>6^HVD%U:SQW-K.BRQ3PN'21&&596
M'!!!!!'6A:JZ!Z.S)J*S]?\ $&E^%-&N]7UO4K/1])LT,MS?W\Z000(.K/(Y
M"J/<FJ/@WQ[X9^(VD-JOA/Q'I/B?2UE,)O=&OHKN$2  E-\;,NX C(SGD4+7
M8-C>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN53XK>"9?&[
M>#$\8Z _C!1EO#ZZG =0 V>9S;[O,^Y\WW>G/2C=V0=+G54444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 45RD/Q9\#W'C>3P9%XS\/R^,(\
M[_#Z:I =07";SFWW^8/D^;[O3GI75T=$PZV"BBB@ HHHH **CN+B*T@DGGE2
M&&-2SR2,%50.I)/05Y]9_M(?"74=872;7XH^"[G5&?RUL8?$-H\Y?^Z$$F[/
MMBA:NR#97/1:*0$$ @Y![BN3\8?%SP+\/-2LM.\5>-/#WAG4+X;K2TUC58+2
M6X&=N8TD<%N>. >>*.J7<.ESK:*** "BBB@ HHHH **** "BBB@ HHKAO%OQ
MV^&O@'4#8>)_B'X5\.7PZVNK:W;6LH_X#(X-*X['<T5B^%?&WAWQWIW]H>&M
M?TOQ#89Q]JTJ\CNHL^FZ-B*VJIJVY*=]@HHKE?&GQ8\$?#?R_P#A+?&/A_PM
MYOW/[:U2"SW_ $\QES4W2&=517+^"_BEX,^)$<LGA+Q=H/BE(O\ 6-HNIPW@
M3ZF-FQ745336XKW"BBL'Q=X^\,?#^P%]XH\1Z3X;LB<"YU>^BM8R?]Z1@*F]
MBK7V-ZBN+\'?&SX=_$2\:S\*>/?#'B>[49:#1M8M[N0#U*QNQKM*JQ-PHHHI
M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!$A\._\ !3CX\Z):$I82MK0,0.!E-2C*G'MEA^-+^Q_(?&?_  5H^,NK7/\
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MF>=VY5'I7@S_ ((I?"S3]&@7Q1XR\5:UJ^W]]/ITEO9VY;_8C:*1A^+FLO\
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MHW*=5RCMT79?UNS\\O\ @G1\5O''P6_:0\6?LP>.=5DUNRTP3C1YI7+?9WA
M?;%NR1%)"=X3.%*C ^8UR_\ P6 _Y./^"?\ U[#_ -+%K0_X)Q>&O$7[2/[7
M7Q _:2UJP-AHJRW,-B'Y#7$JJBQ(?XA%;X5CZLOOC/\ ^"P'_)Q_P3_Z]A_Z
M6+71'G=? NI\=XW];2_2QR5>54<8H?#9V]/=_6Y^L=%%%0;A7C'[4?[5?A+]
MDGP=I7B7Q?IVM:E8ZC?C3HH]$@AEE60QO)EA++& N(SR"3G'%7?CE^U9\+/V
M;;G1[?XC>*/^$=EU=)7LE_L^ZNO-6,J'/[B)]N-Z_>QG/'>OSB_X*C?MB?"'
M]HOX.^%=#^'GB[_A(=4LM>6]N(/[-O+;9"+>9-VZ:%%/S.HP"3STK&<GRWAK
MJOSL_P!32,5>TNS_ "T/UHT#68/$>@Z;JULLB6U_;1W42R@!PKJ& 8 D9P1G
M!-7Z^-O '_!3/]FO1/ GAO3KWXD>3>6FFVUO/'_86I-LD2)589%L0<$'D'%?
M5/@'QYH7Q/\ !ND^*_#-]_:>@:K +FSN_)DB\V,D@-LD567H>& -=E2*4Y<F
MR?\ PQRTIN4(\_Q-7_S.@HHKX@_X*4?MA>)_@3IWAGX??#8X^(?BUL17,<0E
MEM("XC7RE/'FR2':I(( 5^^".:4K625VW9+NSIC&]VW9+5OLC[?HK\RO#G_!
M(#5?B!HB:]\6_B]K^H^/;J(2,\!^U)9R$9"M+,S/-@XR1L'4#UIO[+7CSXQ?
MLG?M;I^S[X_U?4O'_@[4T5M,U:199_LB,I\B=&;<T<3%#&\;,51N0< EMHQO
M/V;?O/;L_*_?\S&4K0=1?"M^]N]CHO\ @J+^T;XYTOQ?X&^!7PVU"?1]<\6^
M4]Y?6LIAF=9IC!!;K(.45G#ER,' 49P6!/ O_!%7X96>@6O_  F/C#Q1K&OL
MF;J72YH+6UWGD[$>&1\#IDOSUP,X&U_P4Q_8^\:_%C5_"OQ:^%J/=>-?"T:Q
MRV$# 7$T4<IFAE@SPTD;ESL/+!AC) !\M\"?\%D/$'@>[3P[\:/A5>V>LVGR
M7EUI9:TN >VZRN ,,1R?W@'H .!C1Y>1I_'=WOV^S;Y?U>YO6YN:+C\%E]_6
M_P ]O\K',_M1?\$^=:_8L\/_ /"Y/@;X[\00#071[^WNY4^UPQ,X'F+)$B++
M&"5#Q.F-N22P!%?H)^QG^T$W[37[/?AOQM=0QV^L2![/5(81A%NHCM<J.RL-
MK@=@X':O//AY_P %#OV</VBK+_A&K_7;;3WU5#!+H'C2Q$,4ZL<>6[-OMWW<
M#;O.<]*^F/"?@SP[X%TLZ=X8T+3/#VFLYF^R:39QVT)<@ MLC &2 .<=A6T>
M:$91GJGMY/KKV_7T,)<LI1E'1K?S733O^A\%_P#!0W]M7QAH7CO3O@+\%C._
MC[5C%#?ZC8X-Q;&;'EVT!_@D92&:0XV*1@@DE<3X:?\ !&;0=5TXZO\ %_Q]
MX@UWQ;>GS[L:).B1+(P^8/--'(\QS_'\F?3U\O\ ^"?]JOQ=_P""E'Q/\9:R
M!<W6FG5M0MO.Y:.1[I;=,>FV*1E'IQBOUYK*C%>PIUGK*:YK]E?1+[OZUOI5
MDW6G37PP=O5VU;_K]#\NOCE_P2('PY\/S>,O@5XT\1P>*]&1KR'3]0N$\^<J
M,XMKB%(VCDP#M!#;B0-R]:]O_P""9_[9^I_M+^!]4\,^,YDD\?>&0GG7.P(V
MH6K?*LS*, 2*P*O@ <H?XB*^UJRO#_A/0_"5O+!H>C:?HT$LC2R1:?:I KNQ
MRS$( "2223WS5PDX\T9:Q?X/NOZ_X$3BI6:TDNO==F?(O_!1O]MV[_9C\+Z=
MX5\&".X^)'B*,M:NT8E&GV^=OG[#G<[-E8U((RK$YV[6\)^#W_!)K6/B_91^
M./VA?'OB*X\3:M&MP^F65PKW< (R%GN)EDRP!P8U4!<8#'MQ7C.W7XS?\%G-
M/TG60+C3](U*!(()>5"V=C]I5<>AE5FQ_M&OUZJ:,5[&->2UG=KRCTMZ]?-%
MU6U5=&.BBE?S?6_IT_X>_P";7Q._X(M^#/\ A'YKOX9^-/$&D>*+<>;:+KDT
M4]M)(O*J6BBC>,DX^<%L==IJW_P38_; \9ZMXZUGX!_%ZXN)_%^C"5--OM0;
M==.8"1-:S.3F1E +JYR2JMDG K]&JRM.\)Z'H^JW^IV&C:?8ZEJ#^9>7EM:I
M'-<O@#=(X +G  R2> *NG)PD[ZQ:>GGT:[?TNK(G%2BK:23W\NJ\_P"O(U:*
M**DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.'2@"0=:<.M-'6G#K0 \=:>O6F#K3UZT /7K3UIB]:>M #UZ4]>E,7I3UZ4
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MZFCBTU'J^G77;[^A^AM%> ?L3_M/S?M5_!N+Q/J.B-X?UZTN&LM0M$5Q \@
M(E@+<F-@>A)*D,N3C)\#^+O[:GQ5^+OQTU7X-_LS:+IUW?:,6CUGQAJBA[>U
M=6VOL#?(JHWR[F5RY!"I@9.DTX35.UV]?EO?TL1%J4'.]DN_?:WK<^^Z*_.#
MQG\3_P!M?]D#2E\:_$>[\*?%[P/!(G]J1Z3"D,UE$6 W;H[>!ER3C>4E4=P!
M7W=\(?BKH'QN^&^@^-_#%PUQHVL6XGAWC#QG)5XW'9T8,I'JIZTTKQ<D[VT?
MD)NS2:WV\SL:**\:_:F^#GC+XZ^ ++PGX1\>7'P]AN;]6UC4K-6:XEL@C[H8
M]I4Y9BF?F48!!R,J<Y-I>ZC2*3>KL?)'[<?_  4ANO!/Q-\._#7X0:[ -7M]
M4B3Q#K4,$-U%&"^PV:>8CJ6YR[ 94@*#G<!^CE?CI^WW^RUX!_99@_9_T/P5
MISI-<ZO=-J&K7C"2\OW5[/:97  P,G"* HR<#))/[%UK!+V"=[OFDF_11V\N
MWW[MF4K^V[)QBTO^WIK7S=M?NV2/AS3/VD?B-<?\%2-3^$4GB+=\/(=.\^/1
MOL-L,/\ V='-GSO+\W_6,6QOQSCIQ7W'7X^_'[XM:W\&/^"KOBC7_#'AN3Q;
MXGFL;;3=*TA"0)[J?388X]V.=H+9(&,@=5ZCVOQ?=?\ !03X<:'<_$*[UGP9
MXCL+6,WESX)T^TCEDAB W.G$*.^P9X2X=CC@M64)+ZO3D]K:OSN_TM?LK&TX
MM5IQ77ELO^W(_F[^KN?HO17A7['7[5.D?M;?"2+Q596?]DZO:3FRU;2]^_[-
M<!0V5; W(RD,I]R#RIKW6M91<'9F49*:N@HKY[_;3_:YTO\ 9&^&4.M/8KK7
MB;59C::-I!<J)Y0,M(Y'(C0$$XY)95&-V1\Y^&E_X*$^(=(A\?#5_!5C;S1_
M;(O &H6L44SH1E8B1"60D8X>Y5AG#%3D5E%\UWT6[Z7[?\,:-<J5]WLCK_!_
M[2'Q%U7_ (*>>*OA+=>(O-^'UCIIN+?1_L-L-C_9(),^<(_-/S.QP7(Y],5]
MPU^2'[('Q1O/C)_P5,USQ5J6@W'AC5KG1IX+_1[K[]I=0VL,,T?K@21MC.#C
M&0#7UQ^VU^VCK/P"U[PI\//AUX<A\6_%+Q6R_8;.YW&"VC9_+1W564N78, -
MR@;&9C@8-?#2HK>4ETUN[O[_ /(GXJM5[*+6^EO=C?TU_$^MZ*_/C4O 7_!1
M".SEUN'XD>!7D"&<>'+:VM_,)QGR0SV6W/;)FQ_M=Z]/_8#_ &R=>_:>TOQ=
MX?\ &^AV^@^/O"-PL&H1VBM'%,K,Z@^6Q8HZM&RLN2,X(QG :5[I;I7MUMY=
MQ-\J3>STN=+\8/VQ(_AQ^U'\-_@I8^'FO=2\4&.>ZU6XF"PVUNS2* B#EW)B
M;J5"\?>S@?2=?B=\>O!?[1=K^WSX!TK7/'OAZ\^*5W'&_AO6X($%I96YEN/*
M25?LB@E<29S$_P!X<GM^DNI_%WQ7^R;^R5+XO^..L67C'QII*2+<SZ,%BBU"
M>2=A;11XAB"_*T:LWEC&UCAL9,0DEAO:S>MW^EDO-;/S>ERZD7]9]E#M'];O
MT?3R['T917YR^"O%/[=7[4/A>S\=^$M>\$_"GPSJ0,VFV%[;!Y9[<D[)/WEM
M<M@CHQV;OO!0"*M?![]K_P".OP>_::\/?!+]HBQTG57\0E4TWQ)ID:1&1I"R
MQ./+"H\;.IC(\M'4G)XX.L8-S5-Z2?1]^WKY&<I)0=1:Q6[\N_H?HA1139"5
M1B.H!K*4E&+D^A0ZBOR2_9U_;S_:5^-UKJWPZ\(Q6_B[XCW6HR3+XCU6RMK>
MQT33555W,L*(K-YA8Y=6[ *Y; ] \<?'G]L+]B>XTWQ-\8)?#OQ5^'US<I!?
M76BP1Q-9[CPH=(("C'L7C="1MR"15=G+1.UF]M?^#IVOH5.+A*4-W&]TO+^K
M][:GZ6T5XW\2?C-'JG[)OBCXG^ M4"A_"MSK6D7_ )2N8W%NSQL4<%=RL,%6
M!&0017PU^S[^T1^U[^V#\-K"V^'.MZ%H%SH)DCUWQKX@M+=/[1NFE=X[>*)+
M>1%"0M$#B('/)89&6TU*4+:QM?YW_*UO5I*]R=.2-2^DMON3_4_4FBOF#Q[^
MTEK_ .R-^RMIWBOXUSZ?K_Q#^:T6QT4""+4+LLYC13C"@1J&=PH PV%R0I\&
M\*WG[?GQYT.V\;:/XA\&_##1[]!<66@7]G'YLD)&48A[:X==PQ]]T/? XI?:
ME%:\N[Z OA3>E]EU/T8HKXP_91_;1\9>(_B[J?P0^.?AVU\*?%&SC,ME/9#;
M;:G&$WD ;F&_8"X9&*L W"E<&Y^V7^U]XU^&WQ-\'_!OX0:%8ZY\3O%$?GK+
MJ?,%G 2X5L;E!8^7(Q+':JQ\AMPP2TY>77FVMU_JS^X(Z\U].7>_0^PZ*_.C
MQ;;_ /!0'X,^&]0\;:AXT\$>/M.TN%[RZ\/VMG$7\E06<@+:V[-M )PLNXXX
MR>#]9?LE_M#+^TU\%-*\:RZ1+H&H.[VM_82!ML<Z8W&-F +1L"K ^^#R#32Y
ME)I[;_/KZ$M\K2:WV^1[+17YZ>,_VS_C-^TI\8]=^&_[+^F:5!I6A.8M2\<Z
MN@DA5LE=R;E9%0LKA?DD9]I8 *#65XN^./[8'[%JV/BCXPGPW\6?AY)<)#J5
M[H420S6(8[5PR0P;221@O&Z$X4LI8&IBU)*3T3VOU[??YFDHN+<5JUND?I!1
M7F>O?%:S\3?LZ:Q\1/!>I"6VN/#=SJ^EWPC!*D6[.C%&!&58#*L."""*_/W]
MFG]L7]J3]J#P#%X3^'\.EWWBVREEDU[Q_P"([:&"TLXW8_9XHHH8PI?"G)\I
MR<\K@;J-?:2I6UBDW][7X6>_YDZ<D:E]).WX)_C=;'ZG5ROQ4^(5E\)OAMXG
M\::E;7%Y8:!IT^HSV]J%\V1(D+%5W$#)QW(K\[O%7[4O[4O[$'C[PT/CU<Z%
M\0O FMSB%]6TBVCC\G'WQ$\<,)$BJ=^V2,AP"%(Y*^\_\%(]'^*OB;]GW4=4
M^&_BO2-'\&V^BZA<^*K2^B5Y=3LFA0HD!,$A#;1+R'C^\.?2*S:HNI!]U?L[
M=32DE*JJ<O7U7E^7KO8]8_9!_:"N?VGO@I9?$"YT>+0?MU[=PQ6$4QF\J.*5
MD7<Y W,0,D@ >U>U5^97_!)_PG\=F\%^$]<B\::&OP-$^H*_AHPI]O,V9%W;
M_LV['G8;_7].W:O5?VG?VV_',?QLA^!?[/\ X=M?$_Q#V[M3U.]&ZVTWY0Q7
M!*KE5969W.U<A=K,<#HJI0E",5JTM.NVK?YW\UUT.>DW)2E+9-Z]-]/\C[@H
MK\Y_%6L_MZ_L[:#<^.O$6N^#?BGH%@AN-1T2PM466" ?-(X\NVMW.T \JSXZ
M[2 :^Q?V:OVA?#W[3?PDTKQSX?#6T5QF&\L)6#265RF/,A8\9QD$-@95E.!G
M%0E=-I[;^7GZ>>Q3=FDUOMY_\'R/4Z^?/V]_BIXH^"W[+'C#Q?X,U3^QO$5@
MUH+:]^SQ3^7ONHD?Y)59#E68<@]?6OFWQ5^V)\<?VI_C+K_P^_9BMM*T?0/#
M\ABO_&^KQ++&S E=PWHZ*C,K!5$<CL%W<#./)?VU/B%^TA\,?V>O$'P]^/-G
MHWB_2O$GV9=*\;>&U5$BNH[A)FM[A1'$!F.-BI\I3D<%_FV\\VY4U):7M;S5
M_P!?/<ZJ:4:O++6V_EZ^G7L?HC^R+X\UWXG_ +-/P\\5^)K[^T]?U72TN;R[
M\F.+S9"S MLC557H.% %>O5X#^P/_P F<?";_L"1_P#H35[]7=7256:7=_F>
M?AVY48-[V7Y!17Q[^V=^VGXD^#WC[PM\)OA5X:M_%GQ4\2JLD,5YN-O9QNQ5
M"RAEW,VV0\LJHJ;FR.*\WUCP-_P4/TBQGUV'XC^!]5:)3./#EG:V_F28Y\I6
M>R09[?ZX?[U<JDG%SZ:J_IO]QU.-FH]=[>NWWGZ%5\U^+?VQ4T?]L[P?\ =/
M\/-+/J5O)>:CK-S-A8D%K--&D,8Y8DQC+,0!R ISD87[!_[86L_M:?#SQ3!K
MNE6OA_Q]X:F%I?1VRLL#F17\J4(^YD.Z-U9"6Y3/? _/7Q%X'_:5B_X*&>'M
M#OOB%X;F^.,EANL_$J6Z"PBA^QS-M9/L87/E"1?]0>6'/<:6<:\(/5/7U3C)
MJWII)[:?<3=.E4ELTFO1II:G[=T5R'PBTWQCH_PT\/67Q!U:SUWQI!:JFJZC
MIZ!8+B?)RR 1Q@#&/X%^E=?3DK-JY,7S).UBEK6L6?A[1[[5-0G2UL+&![FX
MGD.%CC12S,3Z  FOR;^"O_!1[XO:E^T'X4U_QIK'E_!3Q=XBOM(L;*33K6);
M904$?[Y8Q(?*-Q;[BSG(WYSBOJ3_ (*M_&P_"O\ 9=O]"LIS'K7C*<:/ J'Y
MQ;XWW+8ZX*#RS_UU%>,_M'?L</X7_P""8'A;2X+8KXI\$0Q^);K:/G\R7+7J
M9]%$I/\ VP6L83Y)2KRUC!J-O763^4>O1FTH<\8T8Z2G=W[6T7WRZ=3],Z*\
M(_8A^.7_  T'^S3X/\4W$ZSZS';_ -G:K@_,+N'Y'8^A<!9,>D@KW2>:.VAD
MFE=8XHU+N[' 4 9))K>K'V4G%O;KY=_3J<].7M(J26_Y]CX+_P""BW[5OQ,^
M&_Q \$?#3X+ZH+'QE?V=UK&HF.SM[J0VT<;E(PLT;J,B*=N!GY%YYY]Q_8._
M:(G_ &EOV<M \3:I=I=^)[1GTW6V5$0M=1XRY5 %7>C(^%  WX XKY0_8<5_
MVJ?VY_BY\=;U#<>']'#Z7HOFJ2FV0&&+;G@8MXW+#UGSWJM^Q7J4G[*7[>_Q
M0^ ][)]G\.>(YGO=$1R0H=5,\ 7/'S0.Z$]VB45.'3LJ<_BG%R7DT[J/SCT6
M[U\S2ONY0V@U%^=UJ_E+KT6GD?I]7QK^UK_P4#/P@\=VOPL^%_AAOB)\6+PK
M'_9Z!WM[%V7<@D5/FD?&&**5"KRS#I7U=XZ\3Q>"O!/B#Q#, 8=)T^XOW!Z$
M11LY_P#0:_./_@CMX+/CG5/BE\:O$+#4O$^HZD=.CO)AET9P+BY8'MO,D0^B
MXZ&H@O:U'"]E%7??5V27J]WT*D_9TU.UVW9=N[?R73J=4OA3_@HGXF@.M_\
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MO;QZ'H$,2B]M;L6;>9)(WD*2I*S8S,_WU^4=OM;]C[P]\;_!'@G5;SXY>.=
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M48R)+:;_ %MK.IVR0O[JP(ST(P1P13DKPE*+VW\NW_#D7LTFM]O/^NQ\W_\
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M@AN,JRG S@.UXRDM;;]U_7?83=FDUOMY_P!=CU:BOR9^!W[>G[1WQ:U7Q/\
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M'RMJGMO[UZ'_ ,$W/V4?&7@76?%?QJ^+,,L'Q"\7ES'97:XN+6&602RO*O\
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M4?V,_P!JJ\_:$^$/AV;Q5X4UMI)-=TBUB:4Q&4AKB.1$!<1NRB595!"./F&
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MDKOI9:_C>W]6/HO_ (*,_#(?%+]C[Q_9QQ&6]TJU76K; R0ULPD?'UC$B_\
M J^&?B-^TB;G_@D-X*T:.X_XG&J7J^$Y51OF6&UE:0_@8HX%/_72OUPU;3+?
M6M+O-/NXQ+:W<+V\T9Z,C*58?D37X%?!_P"%6N^(OVK_  G^SYJ1:;0O#OCB
M]N)H'4_,B&/[0Q]FALEQ_OGKFN>G!5:LL,]%/E?_ ("_>;\N5V_IG1.?LZ<<
M0MX<WXQ=K?\ ;RO^1^T?[)/PO'P;_9M^'OA)H1!=66DQ27: 8_TF4>;-_P"1
M)'KX<^*EJW[._P#P5X\%^)8\V^C>/XH8IB.$:2>,VCK_ -_8X9#[L#7Z?@
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M_*7Q)_RF]T__ 'X/_3+44?\ >Z?_ &]^1T/_ '>O_A_]N0G[:'E?\/7O@O\
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M[B#M!&%(^LM'_P""V.@>']*L],TOX(OI^G6<2P6UI:Z\D<4,:C"HJBUP
M!4T>6456GJ^BZ+S?=^6R_.ZRE"3HQT[OKYI=EY_TOTT\!^ ] ^&/A#2_"_A?
M3(-'T+3(1!:V=N,*BCN3U9B<DL<DDDDDFOR[_P""P'_)Q_P3_P"O8?\ I8M>
MZ?LM_P#!4VS_ &F?C3HOP^A^&\_AZ34HYY!J#ZRMP(_*B:3&P0+G.W'4=:^?
M?^"SNJ#1/CI\)-1,?G"TTY[CR]VW?LN@V,]LXJY-PQ6&JU-G.]_E*_Y&+BIX
M:O2I[\MK>K5C]<:*_+C_ (?DZ=_T1VZ_\*)?_D:G1_\ !<;3I)%3_A3UT-Q
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MV_:=/P(>VUJW\9AS&+B:VC6Q9OL_V@ 2>9N.4Z?)UXKV'QAX \,?$/3?[/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%7B#0?&OB>[\8>+(/"VHOJ6K7D[3-),UO(Q17;DJF0@)Y(7)Y->(_P#!&?\
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M_;1\3?MA_ _6].^&/@'Q#I/PRTU4U#Q'XDUR%(1((Y$\NW0H[I_K&C; =G;
M^555B3%S6(IJ5/M&_P#=LDG?M:URL+!T*O+/N_\ MZ[NDN][V_/0^^/V!_\
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MXN:)9ZC\+OV;=-T70IT4VMQXDO<*T1'RN@>2URNW!!4$8Z9KP*?_ (7#;_\
M!3KX+S_&>\T1_%MRD$D-KX?QY-G:-]I582=HRV[S"3N?AA\QZ#WSPA_P5_\
M">KZ59Z(GPG\=7GQ 6$0OH&E6<,T1N ,%%;S/-VY_P"F.1Z&OG77K_XGV_\
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M\E.+?X([(M+%N_6$5]\6CT']FSG]G?X8?]BQIO\ Z2QU\-?M0_\ *6[X$?\
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M())7D*GG:54'')%?1G["?PQ^*GPX^#F_XP^*]6\1^+]5N/M36FJW[7C:9#M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K\XOB?^W)\5OV0OVK=<TCXNZ?>:_\']2FFET.\T[3H$EC
MA<AHA'( @E,7,;H[;OXLGC=^CM4=;T+3?$NFS:=J^G6FJZ?.-LMI>P+-%(/1
MD8$'\14ZJ2FO/1[._P"O9E73BXO[^NG]:KJ?$GCO_@L-\#M \,37GAP:YXIU
MIHC]GTU+!K91)M^42R28"KG@E Y] :Y?_@EU\"/&R>+_ (@_'KXAZ7+HVK^,
MWD^P6EQ$8I'CFF\^:;8?F1&81A >2%)Z%2?M'PY^SW\+/!^K)JN@_#7PAHFI
MH=R7NG:#:V\RGU#I&&'YUZ!6D&H-S7Q-->B>_P!YG.\XJ'V;I^K6WW!1114E
M!1110 5Q%S\$? 5W\2['XA2>$]+'C:R1XX==CMPESAT*-N9<;_E)4%LX!.,9
MKMZ*-G<.E@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S[_ ."U'_)M'A;_ +&F
M'_TEN:^O?V;/^3>/AA_V+&F_^DL==-XU^'?A7XE:9%IWB[PSH_BK3XI1/'::
MW817D22 $!PDBL V&89QG!/K6QINFV>C:=:Z?I]K!8V%K$L%O:VT8CBAC4 *
MB*H 50   . !54WR0J0_FDG]RL%3WYTY?RQ:^]W+-><_M ?'30?V</AE?^._
M$UIJ-YHMC-#%.FE1)),OFR"-6"NZ C<PSSGGO7HU9OB+PWI'B_1[G2==TJRU
MK2KD;9['4;=+B"49SAD<%6&0.HK.5[>Z5&U_>/RJ\?\ Q?D_X*I?M&?#WP+X
M/T+5]/\ A9X:N/[4URXU)%1Y%R-[2!&94RJF*,;B296.  <?K'!!':P1PPHL
M4,:A$1!@*H&  /2L3P;X \+_  ZTQM.\*>&](\,:>S^8UIHUC%:1%O[Q2-5&
M??%;]:*T8*$>[;\V_P"K(S=Y3YY=K+R2_P WJPHHHJ2@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3QTH >.E.'2FCI3ATH D'6G#K31UIPZT /'6GKUI@ZT]>M #UZT]:8O6GK0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:_W&^E
M.HJ9*Z: _-3_ ((Y?\AKX^?]AFU_]"NJ_2NBBM&[QBNR2^Y)?H#UG.?\S;^]
MW"BBBI **** "BBB@ HHHH **** "BBB@ KY^_;_ /\ DS7XL?\ 8&;_ -#2
MOH&BL:U/VM.5.]KIK[S2G/V<XS[.Y\I_\$N/^3'/AU]=0_\ 2^XKZLHHKLK5
M/:U)5+6N[G/"/)&P4445B:!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%07L[6UE<3*
M6CC9P#TR!FFZ=<-=V,$S@!I$#$+TIVZ@6:***0!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-_JG_W
M36;X7_Y =M_P+_T(UI3?ZI_]TUF^%_\ D!VW_ O_ $(U7V1=35HHHJ1A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!4U;_D%WG_7%_P#T$TS1/^01:?\ 7-?Y
M4_5O^07>?]<7_P#033-$_P"01:?]<U_E5?9%U+U%%%2,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_!_Y'Z%T5^>W_#VC_JE?_EQ?_<M+_P /9_\ JE?_ )<7_P!RT?ZHYU_SX_\
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M?^30_P#D@_M/"?S_ (/_ "/KRBOD3_AO[_J1/_*Q_P#:*</V^\_\R)_Y6/\
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M )!%I_US7^5/U;_D%WG_ %Q?_P!!-,T3_D$6G_7-?Y57V1=2]1114C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K^<ZY_X^9?\ ?/\ .OZ,:_G.N?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FK?\@N\_ZXO_Z":9HG
M_((M/^N:_P JLW<'VJUFAW;?,1DW8SC(Q3;*V^QVD,&[?Y:A=V,9JNEA=2>B
MBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.'6FCK3AUH >O6GK3%ZT]: 'K3UZ4Q:>O2@!XZ4\=*8.E/'2@!XZ4^F#I3Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRN^I,91J:PV[O\[=CZ%M;N"_M8KFVFCN+>9!)'-$P9'4C(8$<$$=Q4M? ?\
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MQ3Q-OBE0.C8QD$9!YJ5JKH;TLGU)**\TD_:0^'47QLC^$;>(L?$)X?M"Z/\
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MN#8R@_16MW/UKT)66-C".TDZ?K9>Z_2ZO\SA3<\)*I+=-3\]]5ZM.WG8K?\
M!0JW/[0/[>GP1^#L2^?8V8BN+Y.H"SR^9< CVM[8'_@5?J(B+&BH@"JHP .@
M%?FA^QQ;#X\?\%*/CA\4I1]HT[PV9=.L92,@.6%K$P/O#;R_]]5^F-<]+3"T
MU_->?_@3V^Y+[S>KKB)_W;1^Y:OYMA7Y+_\ !637]?\ "_[7/P=U7PHGF>)K
M738I-,7RQ)FY^V/Y6%/!.['!XK]:*_+_ /X*(ZA8:5_P4'_9OO-3*K80RZ>\
MS.<*H&I'YC[#K^%1&//B</&]KS_21;?+AZ[M>T?U1Z-\//\ @DAX U+PQ+J7
MQ;UG7O&?Q#U=?M.J:I'J+1)!</DMY7&7()QNDW;B,[5!VUX)X(_X2O\ X)A?
MMFZ%X!?7[K6_A'XTFB\M;H_*L<LGE+,5^ZL\+[=[*,.F.!D!?UUK\K_^"PSI
MK_QI^ _A[30)M?=YBL2/\X$UQ;I%Q[NCX/L:VIRMB:45HI/E:Z6L]/P]3*:O
M0JN3NTKW>]^YTO\ P6]_Y)?\,_\ L,W/_H@5]4_M,?\ )BOC_P#[$>X_])*^
M5/\ @MRI7X5_#$'DC5[@'_OP*^J_VF/^3%?'_P#V(]Q_Z25P/_=L7_B7_ILZ
M8ZXC#>C_ /2SQ_\ X([?\F@G_L8KW_T&&NS_ ."I/_)D/C__ '[#_P!+8*XK
M_@CK(K?LANJL"R^(KT, >1\D)YKL/^"J%W#;?L1^.EED6-IIK".,$\LWVR$X
M'O@$_@:[LPZ>D/RB<V7:/_MZ7_I4CGOV#O%5UX$_X)FZ3XDL;;[9>Z/I.N:A
M!;X)\V2*YNW5>/4J!7R;^P;^S1X"_;FN?&/Q ^,?C#4?%?C<ZDRRZ&FHB"3R
M2BL)W _>;"69$"%441XYZ#[0_P""9MS96?[!7@.;4I;>"P5-2\^2Z95B"?;[
MC.XMQC'7->"_$G_@DO\ #[XK7USXS^!WQ*@T.&6XEDCM8&34-/CG5N4@GA<-
M"%8'(/F%3P,8 K;$^[C:LI*Z>GIKO;SV%2]Z@HIV?,_GY?+<K?M _P#!+;6/
MAGKOAOQM^S!?:KIGB6UOE6;3[C5406Z8)$T<TA4[01M>-B^X/P, @_I#X,FU
MJX\(:)+XDMX;3Q"]E"=1@MGWQ1W.P>:$;NN[=@^F*_)?QE-^VS^P%I">(]6\
M7)XW\#6T\:W,MU>G5[1=Q"I&_GA;F)2<#,>U<D#/(S^FW[-_QJM/VA_@EX4^
M(-I9G3UUFV+RV9;?Y$R.T<J!L#< Z, <#(P:SCK2ERNZ3Z[IM;>CW_X%@EI4
MBY*S:^3U_-?Y^9Z77Y/_ /!7G7M9\+?M*?!'6?#J>9X@T^V%UIR&/S-UREXK
M1#;_ !?.%X[U^L%?F#_P4SO['2OVU?V:[W4V1-.M[NUEN&D.%$:ZC&6)/I@&
MN=1YL3AXWM>?_MLC9RY:%:7:/ZH]"^&__!)CP1KGAR76_C-K.N^-/B/K:_:M
M4OTU%HH[>X?EA%@9<KG&Z0L#MR%4<5X#HEMXH_X):?MA>'_"L7B"[UKX/^,Y
MH_W=XW'E/((C(RC"B>%BA+J!O0C@;L+^O76ORO\ ^"T;)KGC;X(^'M. EU^5
M[TQQHQWXEDMDB&!TRZM@^Q]*WIRMB:2CHI246NEG?3^M2'!3HU.=ZI-\SZ-=
M?ZTU/H/_ (*=?M7ZS^SC\)M*T?P?<FT\:>+9I+6TNXQF2TMT"^=+&,??R\:*
M>V\D<J*\Z^ __!(WP1<^$[;7_C+J&L^+?&^KQ_:]0A74'BAMY9/F*EU_>2R
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MXJ_\$Y?%OC'2MPT[7- M-0A5_O(LDT+;3[@D@^XI/^"5/_)D?@G_ *^=0_\
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M#P<5G24OK%!/XN?1]M)6O\M"YV]E5:VY=?PO^)[&O_!:KX(,P \+?$#)./\
MD'6/_P F5][V5TE_9P7,881S1K(H;J 1D9_.O/A^S5\(0?\ DE?@G_PG;/\
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MH%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?SFW!S/(<8^8\'ZU_1E7\YUS_P ?,O\ OG^=?KWA
M_OBO^W/_ &X^9SK_ )=_/]"*GCK3*>.M?KY\P/'6GCK3!UIXZT /7K3UZTQ>
MM/7K0 ]:>O2F+3UZ4 .7I3QTIB]*>.E #QTIXZ4P=*>.E #QUIXZTP=:>.M
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M 'R/^"I^2*K?[K+_ !T_S9]X_'O_ )(9\1/^Q=U#_P!)I*_-?_@E'^QMX/\
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M&7Q#'%?_ !L\*:7J<VI>%K#4;6[TIY5*[D=KB,R[2 5+I%"2,#I7Z:U^6O\
MP1LU*QUGXF?'K4-,M8['3;N:SGM;6*,1I#$TUTR(JCA0%(  Z8K]2JZIW<*;
M>_+'??:VOF8))5*B6W,]MN^A\,_\%C/^318O^QBLO_0)JU/V-/V$/AYH'P:T
M/Q%\0O"VF^/O'7B6RAU+4[[Q1:I?F'S$#)#&LP8)L4@%A\Q(/.-H&7_P6,_Y
M-%B_[&*R_P#0)J^COV5/B;I'Q<_9Y\!^(M&N8KB&32;>WN$C8$P7$<:I+$P[
M%64C![8/>L,,O=KOKS1^[E7_  #3$-\U!=.5_?S.WZGP!\;O 5C_ ,$]/VX?
MACXQ^'Q?1O WCB?[%JFAI(QMXU\V..X503]P":.5 ?NLIQA<"MO_ (+4PWEQ
M>_ R+3YGMK^2^U%+>:-RC)(39A6##D$'!R.E3?\ !1G4;7XZ_M@_ 3X0^'IE
MU'6-,OS<ZI' =WV1)I(78.1T*PV[R$=0I4]ZG_X+&?\ (T?L]_\ 87O?_0[*
MJHQ52&'C/5>T:^5]O3>Q4I.E5JSCO[-M^O++]$KGU]\+OV+?@W\+-!\,6NG?
M#[0)=6T(PSPZ[<6$;Z@URF#YS7!&\MN^;&<#H   *_/SQIXL\%?M??\ !0;Q
M+IOQB\9Z7X=^%7@ W%G8:;J^K1Z?!>2Q2+$R!W=<M)(&=BIW;(U7@#(_72OQ
MO^&/P)^%M[_P45^+'PV^-^@K?IK6H75[X>DN;^YLE>6:;SXU#0R1[C)%*<9)
M&Y-HY-$92J8J-]=).W2]EKZVV,W%4\-*W>*OUM=W^7=GUE\3_AI^P[\2/ =]
MX=CU[X/>&YY(2MKJVA:OIEG=VTF,))YD;@O@X)5R0W<&N=_X)(_&O6_&/PQ\
M9_#C5]336KKP+=I!IE^)?-C>TD\Q8T5QG<BO"^T_W74#@"O2-=_X)J?LI>&=
M%OM7U;X?PZ=IEC"]S<W=SXBU-(X8U!9G9C=8  !.:R?V ]3_ &=K_2?'OB7X
M$>!?$'AJVM3':ZI-J+W$OVO8'D181)<3 D DX&UOG7(Y%$6E[2[T<=?+727E
MU5^S\@FFU"RU3T_5>?>W1V/B_P#8U\;? _0/B[\3XOVH-.LKCXDW>LNJWOB^
MP-Y9*V]A,A5E9(WW\[W4#;M"L.0?L#QO^PI\&/V@_$'A'X@?!;Q1H7@.^T*\
M6=]3\!0P3V]QL(9!LAD6..16'W@"2"0P.!C6\*6'[,?_  4LT_7M:;P:FHZG
MH]VMG=7=W%_9VJ8V9CD+P2>8T1RP7S#C*,-O%?'_ .VI^QKI?[!.F:!\5_A%
M\0M=T+5#JJ6::=>7*&<[E9\Q2(J%XQL :-U8$-R>Q2E[%4_:+EY>6S6W2SMY
M]O/7J7*/M95'#7FYKI_.ZOY?\-T/K'_@JS\?-;^"O[.=KI/A^^>QUOQ;>?V6
M]["=DD5L(RTY0_PEOE3/4!S@YP:Y3]FSX2_L9_"CX6:-8>(?%/PC\7^*+BUC
MEU74O$&L:;>NUPR@NL:RN1$BDE0% .!DY.37"?\ !5#2M>^)G[(?P<^(][IS
MQW-JUM<ZO;*A5;<W=JA)8=5 D4)UX+@5[#\'?V"OV1OC3\-/#_C/P]\/XK[3
M=5M4G#1^(=3)CDQ\\3@7/#HV5([$&JA"4'74K74DG\EHO1N[]?QB4XSC1<;V
M<6_Q_.UCYE^(7BCX:?LA_MH?#KQG\!_&.@ZAX-\63?8?$GA[P[K$-[;6ZM,B
MOE8W;RU(D$B*<!6B;;A?E'J'_!;.::W^'/PMEMY&AG37+AHY$;:RL(0001T(
M/>K'Q4^"?[$OP+^-/@_X=WWPSU74O&>N30FUM]%U;4+C[*[R*L/G WJE=S'(
M #<*2<#&:O\ P6S 7X;?"T#H-;N!_P"016;C&=&C"[:]HE?RYXZ+T=_0U@G]
M8FVMX:K_ +=EK\U;[CZ/^"?[ _P?\!?#G3]/U[P+H?C/Q%=0+/J^N>(K*._N
MKJZ=097#RAC&"Q. F/7DY)^3OV8O"5I^S9_P56\;?#/PB\UKX/U+3'8:>TC.
MD8-M%=QC).3Y;,ZJ3DA6(R<G/ZAV7_'G!_US7^5?FOHW_*;76O\ L$#_ --,
M5;P=\4K:7C/T^'].ARQUPC;U^!_/GBOU9@?\%6?ASX3T?XV? FZL/"^C6-UK
M^LSMJ\]MI\4;ZD?/M!FX8*#+PS??S]X^IKZ__:>\4:#^QI^RKXZ\0_#WPWHO
MA.XC15L[;1].AM8?ML[) DS1QJ%9ERK9(Y$8!XKYB_X*V#;\7?V;'/"#6)\L
M>G_'Q95]$?\ !3+P)J'C[]C/QW;:7"]Q=Z>MOJGE1C):."9'EX]HP[?\!KCF
MW'!::+FDGZ7C?[D=L5S8N-]?=B_5WE^;T/E?]@_X<_LRV/PNM_'7Q@\9?#WQ
M1\2/$LDM[?6_C'7+*=K-6D;:C03O@2MC>S.N[+XSCKS/[<EI\%?@YJO@_P",
M_P"SEXS\&:5XXTG58X[O1?".L6LD4\+(W[S[+"Y"J-NQPJA664[AWKT/]A/]
MD/\ 9?\ VD_V>/#VOWW@F+4_%MG']BU]1KFH1R)=*2-[1I<*JB1=KC  ^; Z
M'&U^TW^SG^Q'^R=H^C7WC7X<7T\VK7!@M=/TG6M0FNF 4EY=C7J?NU^4%L]7
M48.:[*]Z=56?*TU:VWDEW37W[G+0:G!W]ZZ=[_C?S3_*QN?\%'OVH-0TG]BS
MPIJ?A6XETVZ^)*6L8EA?$D5G+;^?*JL.A(*1DCL[5Z?^SI_P3X^#WPQ^$FC:
M3KW@/0?%WB&XM(YM4U77M/CNYGN&0%Q&9%/E(I.U0F. "<L23\]?\%4?A7:I
M^Q_\+-6\'Z+=:?X9\)W%O&EA<%VEL;*: )$)-[,V598D.XDY;DU]]_!GXFZ+
M\8OA=X:\8>'[R*\TW5+*.96B8-Y;[0'C;T9&W*0>00:$HWKN*M[]M=U'E32^
M]N_G^(V^6@F[^ZWY-WW];?@?EC\1/V;M._9L_P""F/P7TKPX]RG@[5=1M-0T
MJQGF:5;#,[B:WC+$G:'RX_ZZ<Y.2?V"K\P_VKOB9HWC/_@J+\!O#^DW45[-X
M:N[6VOWA8,(KB2=G,1(_B5=A/H6QU!K]/*BBV\)"_P#-/[M+?@%56Q<_\,/O
MUO\ B177G?9I?L^S[1L/E^9G;NQQG';-?"/P*_8&\.?#+Q-XV^(O[26J>$_'
MWB;6;]IH+W5Y/,L(HC\S.\=RJIYA8XP0P144*1DU]A_&/QK<?#;X2^,_%EI;
M"\NM#T>[U&*W/21XH6=5..Q*C/M7YC_L-_LG^'?VZM%\0_%_XU^)]9\:ZX^K
M26 TQ;]HDB541_G*_.H_>?)'&455' .<"*:<JDN5:J.K?1-VT\V]S6=HTX\V
MSEHN[2OKZ(3_ (*3:5^RE+\(1=?#:]\#V?Q$M+R'[';^!S!MN(BX69)EM08A
MA26#/A@4P#R0?M?X>:7H_P <OV'_  3J'CG1M-\7S-X2AOBVN64=WBZ6T*^>
M!(& D^]\PYY/K7R)_P %'?@'^S_^R_\ LW2Z/X0\(Z3H_C7Q!?6Z6$DLLMY?
MB*.0232)),[O&F%"$J0#Y@'>OK_]EQ2_[!'@55!9CX*4  <D_9S6-1KZGB$N
MC7W\KV_K<N-_K-"_9_\ I2W_ *V/EK_@C3\,O!_B/X0>(?$VK>$]#U3Q)IGB
M=A8ZQ>Z=#->6@6V@9?*F92Z8))&TCDDU^F=?GC_P1/(/[/'C09Y'B=^/^W6W
MK]#J]+$:22\H_P#I*..C\+?F_P V-D=8D9W8*BC)8G  ]:_,3]CV1OVL_P#@
MHA\3/C/<9N?#OA-6LM%9OF0;@UO;E>W,232$#HTF:^I_^"B/QN_X49^RMXMU
M&VN/(UK68_[#TTJVUA+."KNI[%(A*X/JHKX[_9@_X)'^"?BI\"/"/C#QQX@\
M4Z7K^N6GV]K/2Y[:.&*%V)AXD@=LF/8QR>K5QT;^UE52T@K?]O27Z+;UWZ'3
M52]DJ=]9._RB_P F]'Z':?\ !7/P1J7@C5_A;\>O#2>5K'AG4H[*YF5,\!_/
MMF<C^$.LJG/7S0*^_/A7\0].^+/PW\->,M);.GZY80WT2DY*;U!*'W4Y4^X-
M?!WBC_@BI\,8_#6K/H'B[Q@^NK:2FP6^N;1H#<;#Y8D"VX.W=C."#C/-2?\
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M)1:R++X#_LB_ +PG8>'/$NF_#&WFM8!%)>>+3827URX'S.SS_.6)YPN ,X
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M6=;O2;W3=1-M<QMN2:-;RT02*>ZMMR#Z$44$_KJ\H5/R0JC3PS:_FA^;*_\
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MV0%24!(4D<9K[HK=OFITV]7RK7OOK]UON,DK5*BVU>G;;3[SX1_X*Z?&36_
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MI\A"R^1-(9$E"]=NYG0^A7GJ*[YJ^*K/JHQM\WK;Y6^7H<>U"FNCG*_XVO\
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MX8DE#*@6)4Y SSC. H$7[<7@BX^&O_!+2U\*7F/MFC:;H-C<8.1YL<UNK_\
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M^RSX+\9+X3T-?%[2ZA$WB :="+\I]JE3:;C;YF-H"XW=..E>M?MA*7_8@^)
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M37JF]%_P;?\  /T^HHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\W_ /@G
MS\*?&W@O]M/X^ZYXA\'Z_H6BZG-?FQU+4],GM[:[#:CO7RI'4*^5^8;2<CGI
M7Z044X>Y453RDO\ P)6)FN>G[-]T_N=REK6CV7B'1[[2M1MTN]/OH'MKFWD&
M5EB=2KJ?8@D5^5MK^SO^T?\ \$[?B?K^M_!C16^)OPWU5@9-,5#<2F,-\BRV
MZ,LOG(&8"6(,I'+ 9VC]7Z*A)QGSQ=GMZKS-&U*/))76_H_(_+/XF?%3]L7]
ML_1;CX?Z'\'KSX4>'-258-5OM6BGLW>$G#JT]PJ'RB/O+%&SD9'()!^W?V0?
MV7M'_9.^$%KX1T^Y&I:I/*;W5M4V;/M5RP )4?PHH 51Z#)Y)KV^BM(M0345
MOOY^7IY&;3DTY/;;_/U/SK_:U_9 ^*G@#]H:']H7]GA8[OQ!*WF:QX?!16E?
M;MD=49E66.51\\>0X;YER3E..\<_M,?ME_M"^%IO 'AWX#ZGX OM2@:UU'7;
MBRN;0;&X?R9KG9'""-PSN=L'Y2#@U^HM%91@E#V4M8]OT]/(U<FY>T6DN_Z^
MOF?.O[#?[)EK^R1\'UT&:YAU+Q3JDHO=:OX ?+>;;A8HR0"8XQP"0"26; W8
M'DG[?_[%GB[XJ^*O#OQ@^#]VMC\4/#@C'V<2K"UZD;;XFC=_D$J$D8?Y74X)
M^4 _<M%:5&ZDU.]FM5;I;1?AH9TTJ<7"UT[WOUOJ_P =3\RKS]LO]M'6O#Y\
M(6?[/-]IWC*3-JWB7^R;I;13C;YB;_W"MWWF5H\_PXXKVW_@GI^Q9JW[.&EZ
M[XS\?W2:C\3_ !2=U\RRB?['$6\QHC+_ !R.YW2,"5)50"<;F^R**<9<K<DO
M>>E_+R[7ZB<>9*-]%K;_ #[VZ'YP_P#!1OX5>-?''[5_P#U?PYX/U_Q!I.FS
MVYOK_2],GN8+4"^C8F61%*IA06^8C@9K]'J**SIKV=/V:[R?_@3N5+WJCJ>2
M7W'YJ?#+X3>.+#_@KEXK\8W7@WQ!;>$9C=^5K\VESK82;K%57;<%/+.6X&&Z
M\5^C?B&)Y] U..-&DD>VE5449+$H< "M"BIE#FP\</TC'E_/_,<'R5I5NKES
M?E_D?G?_ ,$=?A=XS^&/@WXEP>,?".N^$YKN_LGMX]<TV:R:95CE#%!*J[@"
M1DCID57_ &L_V/OBI\.OVA$_:$_9V5+K79F,NL>'U*AY7(Q*RHQ"RQRJ/GC!
M#AOF7).4_1BOS4^-/Q'_ &C_ -C+]IKQ%XS;3_$7Q6^"^KR3W45A]IFG@L$D
M(<Q[@KFU:)N%RNQD.!R3MTJ5.>M&;?*TK)]-$E9_XON%2I\E*45[R;O;U;=U
MZ??^)./VJOVS/C7IJ^#_  S\!IOA]KMTGD7?BG5[2YM;>V4_*TL/VD*JD9SU
MF..BDXKQW_@F%X$OOAY_P4!^(_AB]O\ ^U[S0=+U2QNM0&1Y[QWD"-)\Q)^9
MN>23S7KNL_\ !8P>,-.?2/A?\(/$>N^-+A&CAMKG$J0R$<-Y< =Y0#_#\F<=
M17H7_!-C]DWQG\))O&'Q2^**&#Q[XR<L;*1E::WA:0RR-+MX6220@E!]T* <
M$E1K17+5=5JRY9)ONVK)+TUO_5HJ-.DJ:=W=679+=O\ K\S[GHHHK(L^#/VU
M/^"<E]\5?&Z_%?X/ZTOA'XEQ2+<7$1G>WBO)4 VS1RIS#/@ 9^ZW&=IRQ\C'
M[5?[=?PQLAX;\4_ \>-YXX_+?4!X<N;XS@_WY+&3R&XXX4>]?J?141CR1Y$_
M=[?Y=BI/F?,UKW_S/PIU#]A']HG]HOQ)KGC&#X1:/\,XKN!IFTJ#_B46TTB@
M'RXK625W1G('W@L>1DE>M?6O_!-S]H?PS\+)=._9S\1?#?6?A]\1S/+)-))
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MQ^]N-D>I2Z+/J4S*.!NGL9=C\#JP+'N<UA^*_ _[:/\ P4!FLM$\9:&OPQ\
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M1]CW3++_ *[SF\S&W'W%ZY]J^CZ*(^[/VBWLU\GN$O>AR/:Z?S6Q\B_M._\
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MN%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-BBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$X&3P*;%*D\8>-UD0
M]&0Y!_&@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44UW6-&9F"JH
MR6)P *$=94#HP=2,AE.0: '4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_2MBL?PQ_P >=Q_U\/\ TJELQ=38HHHJ1A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 R;_5/_NFLWPO_ ,@.V_X%_P"A&M*;_5/_ +IK-\+_ /(#MO\ @7_H
M1JOLBZFK1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJW_(+O/^N+_^
M@FF:)_R"+3_KFO\ *GZM_P @N\_ZXO\ ^@FF:)_R"+3_ *YK_*J^R+J7J***
MD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %8_AC_CSN/^OA_P"E;%8_AC_CSN/^OA_Z52V8NIL4445(PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 9-_JG_ -TUF^%_^0';?\"_]"-:4W^J?_=-
M9OA?_D!VW_ O_0C5?9%U-6BBBI&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%35O^07>?]<7_P#033-$_P"01:?]<U_E3]6_Y!=Y_P!<7_\ 033-$_Y!%I_U
MS7^55]D74O4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^3OV\/V
MLO%W[+W_  @__"*Z=HFH?VY]N^T_VQ!-)L\G[/LV>7+'C/G-G.>@QCG/R?\
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M:C_@I1\33_S O"?_ (!W7_R13Q_P4E^)A_Y@?A/_ ,!+G_Y(KY,7K4B]J/\
M5S*?^@>(?7L3_.SZQ'_!2/XF'_F!^%/_  $N?_DBGC_@I!\2S_S _"G_ ("7
M/_R17R>O6I%[4?ZN93_T#Q#Z]B?YV?5X_P""CWQ*/_,#\*?^ ES_ /)%.'_!
M1OXE'_F">%?_  $N?_DBOE):D':C_5S*?^@>(?7L3_.SZL'_  48^))_Y@GA
M7_P$N?\ Y(IP_P""BWQ(/_,$\+?^ ES_ /)%?*JU(O:C_5S*?^@>(?7L3_.S
MZI'_  43^)!_Y@GA;_P$N?\ Y(IP_P""B/Q'/_,%\+?^ ES_ /)%?+"U(O:C
M_5S*?^@>(?7L3_.SZF'_  4.^(Q_Y@OA?_P$N?\ Y(IP_P""AGQ&)_Y OA?_
M ,!;G_Y(KY;7I4HZT?ZN93_T#Q#Z]B?YV?40_P""A/Q%/_,%\+_^ MS_ /)%
M/'_!0;XB'_F#>&/_  %N/_C]?+J]*E7K1_JYE/\ T#Q#Z]B?YV?3X_X*"?$0
MC_D#>&/_  %N/_C]/'_!0'XAG_F#>&?_  %N/_C]?,(Z5(O6C_5S*?\ H'B'
MU[$_SL^G!^W_ /$(_P#,&\,_^ MQ_P#'Z>/V_/B$?^8/X9_\!;C_ ./U\R+V
MJ1>M'^KF4_\ 0/$/KV)_G9],C]OKX@G_ )@_AK_P%N/_ (_3Q^WO\0#_ ,P?
MPU_X"W'_ ,?KYG7M4BT?ZN93_P! \0^O8G^=GTN/V]/B ?\ F#^&_P#P%N/_
M (_3A^WEX_/_ #"/#?\ X#7'_P ?KYK7M4B]*/\ 5S*?^@>(?7L3_.SZ3'[=
M_CX_\PCPW_X#7'_Q^G#]NWQ\?^81X<_\!KC_ ./U\W+UJ1>E'^KF4_\ 0/$/
MKV)_G9](#]NKQZ?^81X<_P# :X_^/TX?MS^/#_S"?#G_ (#3_P#Q^OG%>M2+
MVH_U<RG_ *!XA]>Q/\[/O/\ 9Y_:<_X6K?7&B^((+33=='SVWV4,L-PG=0&9
MB&'IGD5[]7Y-Z7J5UH^H6]]93O:W=NXDBFC.&1@<@BOT/_9^^-=M\7O"X,[1
MPZ_9*%O;=>-W82*/[I_0\5^7\5\.+ /ZY@X_NGNOY7_D_P 'ZGT.78YUOW55
M^]T\SU6BBBOS4]X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Q_#'_'G<?]?#_P!*V*Q_#'_'G<?]?#_TJELQ=38H
MHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 R;_5/_ +IK-\+_ /(#MO\
M@7_H1K2F_P!4_P#NFLWPO_R [;_@7_H1JOLBZFK1114C"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"IJW_(+O/\ KB__ *":9HG_ ""+3_KFO\J?JW_(+O/^
MN+_^@FF:)_R"+3_KFO\ *J^R+J7J***D84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?G)_P6 _YI+_W%_P#VRK\Y1UK]&O\ @L!_S27_ +B__ME7YRCK
M7]'<(_\ (EH?]O?^ER/A<S_WN?R_)#UZU(O:HUZU(O:OKSS"1:D':HUJ0=J
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M445\D>D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5
M-6_Y!=Y_UQ?_ -!-,T3_ )!%I_US7^5/U;_D%WG_ %Q?_P!!-,T3_D$6G_7-
M?Y57V1=2]1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&BJ.B:WIWB71[+5M)OK?4],O8EGMKRTE66*:-AE71E)# @Y!%<Y\5_B_X/\
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MX8_X\[C_ *^'_I6Q6/X8_P"/.X_Z^'_I5+9BZFQ1114C"BBB@ HHHH ****
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M -TUF^%_^0';?\"_]"-:4W^J?_=-9OA?_D!VW_ O_0C5?9%U-6BBBI&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %35O^07>?]<7_P#033-$_P"01:?]<U_E
M3]6_Y!=Y_P!<7_\ 033-$_Y!%I_US7^55]D74O4445(PHHHH **** "BBB@
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MYWU/T)^(G[2/PY^%'CWPMX+\5>(O[+\3>*)4ATBQ^PW,WVEWE$2C?'&R)EV
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MY\P;0$9LG&,Y%,^#W[9/P:^/GB"70O GCJSUK68T:3["]O/:S.J\L46>-#(
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M4_'QY(O 7CC2]?NXU,C6*.T%V$&,OY$H63:,CYMN.>M>1_\ !4G_ ),A\?\
M^_8?^EL%?!G[<WPJ\"_L?_M-?##Q-\&K^'1=0DNOM5YHEGJ)F-E+'+'@X+,Z
M1S+(ZE&.TA6 &,BOO'_@J*V_]A[QZV,9:P./^WV"LZUIX=58]96^YK_,UH7A
MB53EV3^^_P"1R/[&G[0GPY^ /["'PLU#X@>+=/\ #4,]O=^1%<,TD\^+R;<8
MX8PTC@9&2JG&1GK7OOP@_; ^#?QYU Z?X'\?:9K&I\[=/E$EI=2 #)*0SJCN
M .254@5\,_\ !-S]@SPC\3/A/I'Q/^*ME)XN>[\R#0-&U"=VM+.TCE==QCR
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M+<.%!=T+$ # YXKU?_@IM_R8]\3/^N5E_P"EUO7YY_LB_P#!36\_9F^"&E^
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MSL?>+4****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY.>GU=_P3<_95O?AAX2O?BMX]$E_\4/' -[<7%V=TUI;2MY@0GM)(2)'_P"
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M_A!_95]-#?>,-9E6]UN\AY3S,82%">2D8)&3U9G/&< H.\IUOLM6_P 3NO\
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M** "BBB@ HHHH J:M_R"[S_KB_\ Z":9HG_((M/^N:_RI^K?\@N\_P"N+_\
MH)IFB?\ ((M/^N:_RJOLBZEZBBBI&%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?EM_P33_Y/Q_:/_P"N^H_^G0U^I-?!
M'[#W[,/Q,^#_ .UK\:_&?B[PU_9/AKQ%+>MI=]]OMIOM DO_ #4^2.1G7*<_
M,H]#SQ3HZ8A2>W+/\4K?>9UU>@TM^:'X/4^UOB'XTMOAQX$\0^*[VSO-0LM$
ML)M0GM=/17N)(XD+L(U9E!;"G + >]>8_LJ_M;^#_P!KKPMK.N>$[34=-32K
MT6=Q9:LL27 RBNLFV-W&ULL <]4:O:KFVBO+>6WGC2:"5"DD<BY5U(P00>H(
MK\S?%_\ P3[^-?[,WQ5U3QY^RYXEMAIM^3YGAF^FC214+;O(Q,/)FC!SM9V1
MU' )/S&(RM-J:T:T\GY^3V\C9J\$X[I_>O\ -?B?I%XJ\0:=X3\,ZMK6KW,=
MGI6G6LMU=3S$!(XD4L[$GL #7Y@_\$5]#N=1UWXS>($M&@T&Z-I:19SM+EIW
M*#UVHRY_WAZUI>-/@1^V_P#M?0Q^%OB;>Z'\-?!+O&U[;VD]NR7 #9SLMY)7
ME(ZB-Y$0D \$ C[V_9W^ 'AC]FGX7:;X(\*Q.;2V)EN+R?'G7EPV-\TA'<X
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M*^<O^"(WB>PG^%GQ$\.K+&-3M=9BOWBZ.898%16]QNA8>V?>OK3]G7X:>)/
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M6PTBSCM(%9N681QJ%R>YQS6W6]2?/*_DE]R2,*<.2-GW;^]MA7R'_P %7/\
MDR+QI_U]Z=_Z60U]>5\Y?\%!?A+XK^.'[+/B?PAX)TK^VO$5Y<63P6?VB*#>
ML=S&[G?*ZH,*I/)[<5QUDW%6[Q_-'72:4G?L_P F-_X)T1I%^Q5\+ BA0=/E
M8X&,DW,I)KXY_P""WW_(2^#?_<3_ )VM?=?[&'P[\0_"?]F#P!X2\5:?_97B
M'2[)X;RS\Z.;RG,TC ;XV9#PP/!/6OFG_@J?^RW\3_VC[WX:2?#KPS_PD*:/
M]N^W'[?:VOD^88-G^OE3=G8WW<XQSVKT:LD\=":>GM+WZ6N]?0YL#[F'2EH^
M3\;'WS9?\><'_7-?Y5^7%_\ \IQ+7_KF/_3":_4FU0QVT*,,,J $>^*^"KO]
ME_XFR_\ !5.W^,"^&<_#E4 .L_;[7@_V2;?_ %/F^;_K?E^Y[].:QI.V*C)[
M6G^*'3TPE2+W<5^<3FO^"T?P>O/$GPO\'_$33X7E/AF[DL[\H/N6]QLV2'V6
M2-5_[:U]<?LB?'W2?VC?@/X9\5:?>13ZBMK'::O;*V7M;U$ E1AU&3\R^JLI
M[UZGXH\+Z5XU\.:EH.NV$.J:/J4#VMW9W"[HYHV&&4CZ5^97BO\ X)H_&G]G
MCQW?>+/V:/B$UO9S$N-(O;O[/<A<_+"VY3!<J,G!EVXXX)^:L:<O9\U.2]UN
MZMT?56[/?U]-=*B]IRS3]Z*MZK_-;>GX?J37YX_MC_MZ>._!/[3_ (.^%7P5
METO6=8W+::M9WMJ+F"6\G=!%"S*0ZF-06;:PQYG/W>//;WPC_P %)/B% ?#^
MJZI'X<T^Y4Q3:E%>:/:D \;O,M-TZ_6, \U[_P#L1?\ !.32/V9=4?QKXMU6
M+QA\2)T8+=HK?9=/WC]YY)?YI';)!E8 X. JY;=I"/[R,YOW5K;J_+T\_P"G
M$I6A*,5[S^Y>9U?_  4N$H_87^) G9&G^SV/F-&"%+?;K?. 2<#/N:P/^"3'
M_)E/AC_L(:A_Z4O7IG[=/PQ\2_&/]E;QSX/\'Z;_ &OXCU*.U6TLO/B@\PI=
MPR-\\K*@PJ,>6'3UK$_X)Y?"#Q=\#/V7]"\(^-])_L3Q#;7EY++9_:8;C:LD
M[,AWQ.Z'((/!^M30TE6;ZI?FBZO\*BETE+_TDTOVR/V0?#'[5_PVO=.N[2VL
M_&%I$TFBZ]Y8$MO,!D1NPY:)CPRG(YW ;@#7QW_P36_:[\3^"/B%<_LY_%RX
MN(=1LIGL=$GU)LS6UQ&2&L7<GYE('[H^VT$AD _4:OSR_P""D'[!?BGXO^+=
M"^*'P?T\2^/(9(X=2M8+N*SDG$?,-TDDCHHDCVA3\V2-F/N\S"7L:E[7A+1K
M\FO/^MKW)1]K"U[2CJG^GI_6]K?7?[47PJ?XW?L^>//!,"JUYJNER):!^GVE
M,20Y]O,1*^'?^"-_QQLK+PYXI^"^O3G3O$FG:A+J.GV=U\CR1L%6XB4'^*-T
MW%>N)"?X3C[L_9YUKX@:W\)="D^*/AP^&?',,7V?4K874%PD[IQYZ-"[J XP
MVW.021C !/RG^V!_P3'C^+OCF3XE_"CQ#'X$^(#RBZN(W:2&UN;@'(N$EB!>
M"7N64,&.#A268TOW%:3WC)6=O)W37Z]>FG2?X]**VE%W5_-6:?Z/\]#[TKY@
M_P""@O[5/_#+OP.N+[1M2@M?'>KRK:Z'!(B2MN#*99C&P(*(F>2,;F0=Z^4H
M]#_X*5>%H1HUG?0ZS:P@11ZDUQH<S%1QNWSXE;URX+5J?";_ ()@?$'XJ_$J
M'X@_M-^,_P#A(YE*2?V';W;7,DP!W"&67"I%$"3^[AR""<%>Z<'4T4K+J^MO
M0:FJ>K5WV/L3]BOXF>/_ (Q_L\^'?&?Q&M-/LM;UCS+BWCT^V>!6M-V(I&5G
M;YG +Y&!M9< 5[I4-I:0:?:0VMM"EO;0(L<4,2A41 ,!0!P   ,5-6M22E)N
M*LC*FG&*4G=GYG_\%O\ 3)Y?AQ\,=05<VT&K75N[>CO"K*/RC?\ *OT,^&U_
M#JOPZ\+7MNV^WN=*M9HV]5:%2#^1KP+_ (*2?!:?XV?LG^*;/3[<W.M:&4UV
MQC5<LS09\Q5 Y),+2@#N<4[_ ()M?%B+XL?LA^"93.LNHZ#"=!O4W9*-;X6/
M/UA,3?\  JRPZM"O'KS1?RLU?[]#2O?FHRZ6E'YWO;[CYS_X+>_\DO\ AG_V
M&;G_ -$"OI3X_P#P='QU_86N_"L47FZD_AFUO=/ '/VJ"%)8@/\ >*;/HYKS
M7_@J=^S?\1?VC_ ?@;3OAUX=_P"$AO--U*>XNXOMMM:^7&T053F>1 >>P)-?
M87@#2[G1? ?AS3KV+R;RTTVVMYXMP;8ZQ*K#()!P0>0<5A"GSTL1!Z-RC;_P
M#=>C_$N4^6O1FM;1=_\ P+9^J_ _*CP1^V&VD?\ !*'7-&:\(\5V-TW@BV!;
M$AAG!D5AW 6W,R#WB%?<G[,?P;_X45^Q+I7AB:#R-4.@7%_J*D?-]JGB:60'
MW7<$^B"OB,?\$ROB)_PVG)*-!V? ^3Q0NMO=C4;;R6@7=,L1MO-\S(+- #Y?
M 8GH2:_5;Q?83ZIX1UNRM8_,N;BQGABCR%W.T;!1D\#DCK6F(DZN%JU;>_46
MW56CM\Y-L5.*IXB%*_NP;L^CO+\+121^<'_!#W_D1OBK_P!A&Q_]%2UZH?V^
M_$GA7]O2Z^"/C;2=#T/PA+/]FT_5]DR7$CR0K);,SM)LP['9PGWF R,&H/\
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MLJM\=*':+;]6]/O1TM%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6D_LVZ1XUD\&6'P@\,MITFLS:'%'%!#80G=(7(C1%&Y?G^Z"=PR,UX_\)/\
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M0:=:ZM^W'^S'87]O%>V5S>VD$]O<('CF1M1C#*RD8(()!!&#FO6_$7_!(+X
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M<C+=%"_45AKFG:J[)9:A:WCJ,LMO,KD#U.#7P=_PY4^"'_0T_$#_ ,&-C_\
M(=>X?LL?L(> ?V1->UW5O!VK^)-2N=8MH[6X77+FWE151BP*"*",@Y/<FNAR
MYW[VG]:(Y[."]W5_U=GRCXD_Y3<>'O\ KQ_]P\U?I[7A%[^QQX+O_P!J6S^/
M<FIZ\/&%K%Y*62W$/]GD?9FM^4\GS,[')_UG7';BO=ZSAI0IP>ZO^,F_R9M4
M?-5<UM:*^Y69\4_\%>_^3-]0_P"PU8?^A-7N7[&W_)I_PB_[%?3_ /T0M:?[
M1W[//AS]I_X:3>!_%-[JEAI,MU%=M-H\L<<^^,DJ 9(Y%QSS\OXUU?PS\ Z?
M\*_A[X<\':3-<W&F:%80Z=;2WK*TSQQH%4N5506P.2% ]A4T5R1JI_:DFO11
MM^8JGO2IM=(M?>[G35\&?\%"/VR?$?A#Q+I7P+^$<@/Q)\1".*[U*.4(VF1R
M\(B,>$E9<L7)'EI\W5@R_>=?&/QA_P""5'PI^-WQ,\0>.?$'B?QO'K&MW/VF
MXCL[^T6%#M"A4#VK,% 4  L>!UJ)1<I137N]?/R^?Z>9<9<J;7Q=/+S^7];&
MM^Q=^R1\._V5M#;5;W7]*\2_$G4H\ZIXAFND8H6Y:&WW'*IGJQ^9SRV!A5^J
MK#7=-U61H[+4+6\D4;F2"=7('J0#7P=_PY4^"'_0T_$#_P &-C_\AU[5^RU^
MP-\/OV1_%.L:_P"#]8\2ZE>:I9"QF36[JWEC5 ZOE1%!&0V5'4D8[5U.2F_>
MT7]67]>ISV<%[NKZ_J_Z]#Y7T?Q!8?L9?\%2?%\_BV=-&\%_$FT>:UU6X^2W
MCEF=)-SN>% G25">B[U8X'-?;?[3W[1?A;]GOX,:WXKU;5K5+B2SD72+03*9
M+^Y9#Y21*.6&X@DC(5<D\"M?X[?LY^ /VD?"\>A>/=!CU>V@<R6MPCM%<VKD
M8+12J0RYXR.5.!D'%?.7@'_@D1\ _!'B:'6+J/Q%XL6%Q)'IVOW\3V@8'(W)
M##&7''W7+*1P0:Y>1SH+#R=DE9/^[_FKM7]&=#DHU772NWJUY][]G8I_\$B_
MA+J'PZ_9HN_$NLPM:W?B_46U2(2C:WV14"1,?9B)'![JZGO7AGQI^,GBG_@H
MY\=;WX/>!/$4/A+X-Z%+NUK77F"#40CX\P\C>I8$119PV/,;H-GZ?>(?"UIK
M_@_4O#:R3:78WMC)IXDTXK%);QO&8\Q9!52H/R\$# XKX9_X<J?!#_H:?B!_
MX,;'_P"0ZVJ2]I7YI+W$E9>FBOZ67J^UC."<*32?OMN[[7=W;UN_-?,^IO@9
M\-_A=^SKX!M/"7@F?2]/TZ'YYIVNXVN+R7&&FF?.7<_D!@    =!\6/"%E\9
M_@]XQ\*6]Y!-!KNE76FK<1.'1'DB95.1GH2#^%?'/_#E3X(?]#3\0/\ P8V/
M_P AU]8?LY_L]^'?V8OAG;^!O"U[JE_I,-S-=+-J\L<DY:0Y8%HXT7'I\OYT
MJB5>,E4>Z_X'Y"@W1E%P6S_KUU/BS_@DW\:M.\#^'_$WP%\:3Q^&_'&B:S<2
MVFGZ@PA:X5L"6)"?O2)(C';U*N",@$CM_P#@K)\=O#OAS]G[4/AC!>0ZCXU\
M63VL,&D6S>9/%"DZ2F5T'*@F,(N>6+< [3CV3]HS]@SX0_M.WYU7Q3HMQIWB
M,H(SKVAS"VNW48 #Y5DDP  "Z,0!@$"N>^ 7_!-7X*?L^>);?Q'I>FZEXE\0
M6C^99ZAXEN4N&M6[-''&D<88=0Q0L#T(HE_M"BJVEK7MUM;;M>VM[]2H/V$G
M*EKNU?HWKKWL]CTS]DCX:7_P?_9K^'GA'55,>J:;I,8O(R<^7,Y,DB?\!9RO
MX5ZY116E2;J3E-]7<RIP5.$8+HK!11169H%%%% !1110 4444 %%%% !1110
M 4444 %%%% #)O\ 5/\ [IK-\+_\@.V_X%_Z$:TIO]4_^Z:S?"__ " [;_@7
M_H1JOLBZFK1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJW_(+O/^N+
M_P#H)IFB?\@BT_ZYK_*GZM_R"[S_ *XO_P"@FF:)_P @BT_ZYK_*J^R+J7J*
M**D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM2+VH D7K4B]JC7K4B]J )%J0=JC6I!VH D6I%[5&M2+VH D6I%[5&M2+VH
MD7I4HZU$O2I1UH >O2I5ZU$O2I5ZT 2#I4B]:C'2I%ZT 2+VJ1>M1KVJ1>M
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\,?\>=Q_P!?#_TK8K'\,?\
M'G<?]?#_ -*I;,74V****D84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >'?&;]D+P=\<OBWX!^(FO:EKEIK?
M@N>*XT^#3IX4MI6CG691,KQ.S#<H!VLO'OS7N-%%"]V/(MKM_-[_ '@]9<SW
MT7W;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ,F_U3_P"Z:S?"_P#R [;_ (%_Z$:TIO\ 5/\
M[IK-\+_\@.V_X%_Z$:K[(NIJT445(PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH J:M_R"[S_ *XO_P"@FF:)_P @BT_ZYK_*GZM_R"[S_KB__H)IFB?\@BT_
MZYK_ "JOLBZEZBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YR?\
M%@/^:2_]Q?\ ]LJ_.4=:_1K_ (+ ?\TE_P"XO_[95^<HZU_1W"/_ "):'_;W
M_I<CX7,_][G\OR0]>M2+VJ->M2+VKZ\\PD6I!VJ-:D':@"1:E7M42U*O:@"1
M>E2+VJ->E2+VH D7I4@ZU&O2I!UH D7I4B]:C7I4B]: )!TJ1>M1CI4B]: )
M%[5*M1+VJ5: 'KVJ5:B7M4JT 2#K4B]*C'6I%Z4 2KUIZ]*8O6GKTH E7K4B
M]JC7K4B]J )%ZU(O:HUZU(O:@"1:D':HUJ0=J )%J1>U1K4B]J )%J1>U1K4
MB]J )%Z5*.M1+TJ4=: 'KTJ5>M1+TJ5>M $@Z5(O6HQTJ1>M $B]JD7K4:]J
MD7K0!(O:I%J->U2+0!*O:I%Z5&O:I%Z4 2+UJ1>E1KUJ1>E $B]:D7M4:]:D
M7M0!(O6M;PWX>O\ Q5K5GI.F6[7-]=2".*->Y/<^@'4FLR&)YI5CC1I)'(54
M49+$] !7WK^S'\!D^&FB+K>L0*?$M]&,JPR;2(\[!Z,?XORKYW/,YI9-A75E
MK-Z17=_Y+J=V#PLL54Y5MU9VOP6^$=A\(O"46GP[9]2F DO;O&#))CH/11T
MKT"BBOYMQ&(JXNK*O6E>4G=L^[A"-.*A!62"BBBN8T"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_#'_'G<?]?#_TK8K'
M\,?\>=Q_U\/_ $JELQ=38HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MR;_5/_NFLWPO_P @.V_X%_Z$:TIO]4_^Z:S?"_\ R [;_@7_ *$:K[(NIJT4
M45(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH J:M_P @N\_ZXO\ ^@FF:)_R
M"+3_ *YK_*GZM_R"[S_KB_\ Z":9HG_((M/^N:_RJOLBZEZBBBI&%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'Q7_P %(/V=_B#\>_\ A7G_  @GA_\
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M]YG_ ,^Z?W2_^2#^Q\/_ #/\/\C\JA^Q)\:1_P R9_Y5;+_X]3Q^Q-\:./\
MBC/_ "J67_QZOU2HH_U[S/\ Y]T_NE_\D']CX?\ F?X?Y'Y8#]BCXSC_ )DW
M_P JEE_\>IZ_L5?&88_XHW_RJ67_ ,>K]3**/]>\S_Y]T_NE_P#)!_8^'_F?
MX?Y'Y;#]BSXRC_F3O_*I9?\ QZGK^Q=\9!C_ (H[_P JEG_\>K]1J*/]>\S_
M .?=/[I?_)!_8^'_ )G^'^1^7@_8P^,8_P"9/_\ *G9__'J>/V,OC%G_ )$_
M_P J=G_\>K]0**/]>\S_ .?=/[I?_)!_8^'_ )G^'^1^80_8T^,0_P"9/_\
M*G9__'J>/V-OC #_ ,BA_P"5.S_^/5^G5%'^O>9_\^Z?W2_^2#^Q\/\ S/\
M#_(_,@?L<?&#'_(H?^5.S_\ CU/'['7Q?!_Y%'_RI6?_ ,>K]-**/]>\S_Y]
MT_NE_P#)!_8^'_F?X?Y'YG+^QY\7AC_BD?\ RI6?_P >IX_8^^+H/_(I?^5*
MS_\ CM?I=11_KWF?_/NG]TO_ )(/['P_\S_#_(_-1?V0/BX,?\4E_P"5*T_^
M.U(/V0OBV/\ F4__ "I6G_QVOTGHH_U[S/\ Y]T_NE_\D']CX?\ F?X?Y'YM
MK^R)\6AC_BD__*E:?_':>/V1OBR/^94_\J-I_P#':_2&BC_7O,_^?=/[I?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/X8_X\[C_KX?
M^E;%8_AC_CSN/^OA_P"E4MF+J;%%%%2,**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &3?ZI_]TUF^%_\ D!VW_ O_ $(UI3?ZI_\ =-9OA?\ Y =M_P "_P#0
MC5?9%U-6BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %35O\ D%WG_7%_
M_033-$_Y!%I_US7^5/U;_D%WG_7%_P#T$TS1/^01:?\ 7-?Y57V1=2]1114C
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K'\,?\>=Q_U\/_ $K8J.&".W4K$BQ@DL0HQD^M.^EA$E%%%(84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ,F_U3_[IK-\+_P#(#MO^!?\ H1K4(R,'
MD4R&".WC$<2"-!T51@"G?2PB2BBBD,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** *FK?\@N\_ZXO_ .@FF:)_R"+3_KFO\JN.BRHR. RL,$'H11'&L4:HBA$4
M8"@< 4[Z6$.HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>May 05, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BICARA THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2903745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">116 Huntington Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">468-4219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCAX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,703,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0002023658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 323,462<span></span>
</td>
<td class="nump">$ 96,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">7,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">216,291<span></span>
</td>
<td class="nump">318,116<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">544,915<span></span>
</td>
<td class="nump">422,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset &#8211; operating lease</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,910<span></span>
</td>
<td class="nump">6,910<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">553,599<span></span>
</td>
<td class="nump">430,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability &#8211; current portion</a></td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">39,340<span></span>
</td>
<td class="nump">28,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability &#8211; net of current portion</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">39,641<span></span>
</td>
<td class="nump">29,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 500,000,000 and 500,000,000 shares authorized; 65,547,037 and 56,600,724 shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">929,370<span></span>
</td>
<td class="nump">760,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(243)<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(415,177)<span></span>
</td>
<td class="num">(358,966)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">513,958<span></span>
</td>
<td class="nump">401,452<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">553,599<span></span>
</td>
<td class="nump">430,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,188<span></span>
</td>
<td class="nump">5,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">29,948<span></span>
</td>
<td class="nump">18,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">2,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">$ 1,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">65,547,037<span></span>
</td>
<td class="nump">56,600,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">65,547,037<span></span>
</td>
<td class="nump">56,600,724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 12,742<span></span>
</td>
<td class="nump">$ 7,455<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">60,242<span></span>
</td>
<td class="nump">41,788<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(60,242)<span></span>
</td>
<td class="num">(41,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,083<span></span>
</td>
<td class="nump">5,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">4,083<span></span>
</td>
<td class="nump">5,014<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(56,159)<span></span>
</td>
<td class="num">(36,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (56,211)<span></span>
</td>
<td class="num">$ (36,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per share, basic (in usd per share)</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per share, diluted (in usd per share)</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number common shares outstanding, basic (in shares)</a></td>
<td class="nump">60,717,041<span></span>
</td>
<td class="nump">54,456,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number common shares outstanding, diluted (in shares)</a></td>
<td class="nump">60,717,041<span></span>
</td>
<td class="nump">54,456,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on marketable securities, net of tax</a></td>
<td class="num">$ (486)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss</a></td>
<td class="num">(486)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(56,697)<span></span>
</td>
<td class="num">(36,846)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,982<span></span>
</td>
<td class="nump">6,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 45,518<span></span>
</td>
<td class="nump">$ 27,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Equity</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,440,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 491,875<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 712,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (221,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,846)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,528,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 458,957<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">716,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(257,862)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">56,600,724<span></span>
</td>
<td class="nump">56,600,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2025</a></td>
<td class="nump">$ 401,452<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">760,168<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="num">(358,966)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, and accompanying pre-funded warrants, net of offering cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,581,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, and accompanying pre-funded warrants, net of issuance cost</a></td>
<td class="nump">$ 161,763<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">161,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">366,416<span></span>
</td>
<td class="nump">365,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 1,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (56,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,211)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2026</a></td>
<td class="nump">65,547,037<span></span>
</td>
<td class="nump">65,547,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="nump">$ 513,958<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 929,370<span></span>
</td>
<td class="num">$ (243)<span></span>
</td>
<td class="num">$ (415,177)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (56,211)<span></span>
</td>
<td class="num">$ (36,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,858<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,089<span></span>
</td>
<td class="nump">4,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(270)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(37,508)<span></span>
</td>
<td class="num">(28,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">101,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">100,940<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs</a></td>
<td class="nump">161,763<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">1,582<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">163,345<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease)/increase in cash and cash equivalents</a></td>
<td class="nump">226,777<span></span>
</td>
<td class="num">(27,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">96,685<span></span>
</td>
<td class="nump">489,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">323,462<span></span>
</td>
<td class="nump">462,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_VestingOfEarlyExerciseStockOptions', window );">Vesting of early exercise stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">11,725<span></span>
</td>
<td class="num">(2,116)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">$ (1,354)<span></span>
</td>
<td class="nump">$ 3,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Incurred During Noncash or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_VestingOfEarlyExerciseStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting of Early Exercise Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_VestingOfEarlyExerciseStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization, and Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business, Organization, and Liquidity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Description of Business, Organization, and Liquidity</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Bicara Therapeutics Inc. (&#8220;Bicara&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in December 2018 and is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The Company is committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program ficerafusp alfa is a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to a human transforming growth factor beta ligand trap.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has operated in the preclinical and clinical stages and has devoted substantially all of its time and efforts to performing research and development activities, raising capital, and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, risks associated with the successful research, development and manufacturing of product candidates, competition from other companies, dependence on key personnel, protection of intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if our product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically has funded its operations from the issuance of common stock in connection with its initial public offering (&#8220;IPO&#8221;), issuance of common stock in connection with its at-the-market offering program (the &#8220;ATM Program&#8221;), issuance of equity securities in a public offering in February 2026, redeemable convertible preferred stock and through debt financing.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2024, the Company closed its IPO, through which it issued 20,125,000 shares of common stock with par value of $0.0001 per share and a purchase price of $18.00 per share. The Company raised net proceeds of $332.4&#160;million from the issuance of common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In December 2025, the Company issued 1,604,000 shares of common stock with par value of $0.0001 per share through the ATM Program and raised net proceeds of $29.5&#160;million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In February 2026, the Company issued and sold 8,581,250 shares of its common stock, including 1,406,250 shares pursuant to the exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $16.00 per share. Further, in lieu of common stock to certain investors, the Company sold pre-funded warrants to purchase 2,200,000 shares of common stock at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. As a result of the offering, the Company received approximately $161.8&#160;million in net proceeds.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. As of March&#160;31, 2026, the Company had cash, cash equivalents and marketable securities of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$539.8 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and an accumulated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">deficit </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$415.2 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that its cash, cash equivalents and marketable securities as of March&#160;31, 2026 of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$539.8 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Summary of Significant Accounting Policies</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements include the financial position, results of operations and cash flows of Bicara. The Company&#8217;s unaudited condensed consolidated financial statements are denominated in U.S. dollars. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of March&#160;31, 2026, condensed consolidated statements of comprehensive loss, condensed consolidated statement of stockholders' equity for the three months ended March 31, 2026 and 2025, and condensed consolidated cash flows for the three months ended March&#160;31, 2026 and 2025 and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s condensed consolidated financial position, results of operations and cash flows for the periods presented. The condensed consolidated results of operations for the three months ended March&#160;31, 2026 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December&#160;31, 2025 included herein was derived from the audited consolidated financial statements as of that date. As permitted under U.S. GAAP, certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s most recent Annual Report on Form 10-K for the year ended December 31, 2025 (the "Form 10-K").</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Bicara is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. The Company may take advantage of these exemptions until it is no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Bicara has elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, its financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that Bicara is no longer an emerging growth company. Bicara would cease to be an emerging growth company if it has more than $1.235 billion in total annual gross revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and it has been a public company for at least 12 months and has filed one annual report on Form 10-K), or it issues more than $1.0 billion of non-convertible debt securities over a three-year period.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, and the fair values of pre-IPO common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of obligations of, and issues guaranteed by the U.S. Treasury, U.S. Agencies and U.S. Government Sponsored Enterprises.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities are classified as available-for-sale and are carried at fair value. The Company classifies all available-for-sale securities as current assets. Marketable securities are classified as current assets because they are available to fund current operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any unrealized holding gains or losses on debt securities, including their tax effect, are reported as components of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statement of comprehensive loss. Realized gains and losses, included in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statement of comprehensive loss, are determined using the specific identification method for determining the cost of securities sold.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Declines in fair value below amortized cost related to credit losses (i.e., impairment due to credit losses) are included in the condensed consolidated statement of comprehensive loss, with a corresponding allowance established. If the estimate of expected credit losses decreases in subsequent periods, the Company will reverse the credit losses through current period earnings and adjust the allowance accordingly.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in accordance with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 730&#8221;). Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes salaries and benefits, stock-based compensation expense and the cost of services provided by outside contractors.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes advance payments for goods or services that will be used or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed. The Company also records expenses and accruals for estimated costs of research and development activities, including third party contract services for clinical research and contract manufacturing. The Company bases its estimates on the best information available at the time. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or as accrued research and development expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to the Company&#8217;s vendors. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation expense, related to the Company's executive, finance and other support functions. Other general and administrative expenses include professional fees for legal, auditing, tax, consulting services, investor relations, IT and office expenses, rent and insurance. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based employee and nonemployee compensation awards in accordance with provisions of ASC 718,&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 718&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. We use the Black-Scholes option-pricing model to determine the fair value of options. The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends. In applying these assumptions, we consider the following factors: </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company&#8217;s common stock is listed on the Nasdaq Global Market and its value is determined by the market price on the Nasdaq Global Market as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term:&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The expected life is applied to the stock option grant group as a whole as we do not expect substantially different exercise or post-vesting termination behavior among our employee population.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends due to absence of an active market for the Company&#8217;s common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We have not paid and do not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was&#160;zero.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For awards that vest based solely on achievement of a service condition, the Company recognizes expense on a straight-line basis over the period during which the award holder provides such services. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with forfeited awards. In accordance with ASU 2018-07, the Company accounts for share-based compensation for awards granted to non-employees in a similar fashion to the way it accounts for share-based compensation awards to employees.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses warrants to determine whether they should be classified as equity or liability. If the classification is determined to be equity, proceeds received for the warrants are recorded as an increase to additional paid-in capital in the condensed consolidated balance sheets. If classified as a liability, the Company records the warrant as a liability on its consolidated balance sheet and remeasures this liability to fair value at each reporting date and recognizes changes in the fair value of the warrant in earnings. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is determined by dividing the net loss applicable to common shareholders by the weighted average common shares outstanding during the period. The pre-funded warrants to purchase 2,200,000 shares of common stock issued in February 2026 and outstanding as of March 31, 2026 (see Note 9) were included in computing the weighted average common shares outstanding used in calculating basic and diluted loss per share. Outstanding common stock options are e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">xcluded from the calculation of diluted net loss per share when their effect would be anti-dilutive. For the three months ended March 31, 2026 and 2025, the following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,874,116</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,271,217</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in the table above reflect the common stock equivalents of the noted instruments.</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews new accounting standards as they are issued by the FASB or other standard-setting bodies. The Company did not identify any new standards during the quarter ended March 31, 2026 that it believes will have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2024-03&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses (DISE)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This new guidance requires all public entities to incorporate disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective prospectively for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption and retrospective application are permitted. We are currently evaluating the impact that ASU 2024-03 will have on our condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviewed additional recent accounting pronouncements and concluded they are either not applicable or that the Company does not expect adoption to have a material effect on the unaudited condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Fair Value Measurements</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets that have been measured at fair value as of March&#160;31, 2026 and December&#160;31, 2025 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">216,291&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">216,291&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">320,694&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">320,694&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">320,694&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">216,291&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">536,985&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">318,116&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">318,116&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">93,595&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">93,595&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">93,595&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">318,116&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">411,711&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div>As of March 31, 2026 and December 31, 2025, the Company&#8217;s cash equivalents consisted of money market funds. During the three months ended March 31, 2026 and the year ended December 31, 2025, there were no transfers between Level 1, Level 2 and Level 3.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The fair value of available-for-sale marketable securities by type of security was as follows (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">March 31, 2026</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Marketable Securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">163,516&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(74)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">163,444&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">163,516&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(74)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">163,444&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">53,018&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(171)</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">52,847&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one to two years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">53,018&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(171)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">52,847&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">216,534&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">216,291&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2025</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:center"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:center"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:center"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Marketable Securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">233,672&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">146&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">233,818&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">233,672&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">146&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">233,818&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">84,201&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">97&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">84,298&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one to two years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">84,201&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">97&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">84,298&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">317,873&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">243&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">318,116&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The following table summarizes the Company's available-for-sale securities in an unrealized loss position, aggregated by type and length of time in a continuous unrealized position (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">March 31, 2026</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Less than 12 Months</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">12 Months or Longer</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Marketable Securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">156,241&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">156,241&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">156,241&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">156,241&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">As summarized in the tables immediately above, the Company held </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">eleven</span> debt securities that were in an unrealized loss position as of March 31, 2026. The unrealized losses at March 31, 2026 were attributable to changes in interest rates and do not represent credit losses. The Company does not intend to sell these securities, and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis. The Company held no debt securities that were in an unrealized loss position as of December 31, 2025.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On August 16, 2023, the Company entered into a 2.5 years lease for 4,617 square feet of office space in Boston, Massachusetts (the &#8220;Lease Agreement&#8221;). In October 2024, the Company amended its Lease Agreement to lease an additional 4,744 square feet of office space in order to expand the Company&#8217;s headquarters to 9,361 square feet of office space. The lease required a security deposit totaling $0.1 million, which the Company has met with cash on deposit.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2025, the Company entered into a Sublease Agreement (the &#8220;Sublease&#8221;) with J.W. Childs Associates, L.P., as sublandlord, effective on June 4, 2025. Under the Sublease, the Company leased approximately 9,682 square feet of additional office space as part of its corporate headquarters, through June 30, 2027. The base rent of the Sublease is approximately $0.5&#160;million per year. The Sublease required an immaterial security deposit, which the Company has satisfied with cash on deposit.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2025, the Company entered into a second amendment to the Lease Agreement (the Lease Agreement, together with all amendments, the &#8220;Amended Lease&#8221;) to extend the term for the 9,361 square feet of office space leased under the Amended Lease through June 30, 2027. The modification of the Lease Agreement required the Company to remeasure the value of the asset and liability in accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The base rent under the Amended Lease continues to be approximately $0.6&#160;million per year. The remeasurement did not have a material impact on the Company's right-of-use-assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands): </span></div><div style="margin-top:10pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:67.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,516</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,085</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">12,615&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus and payroll related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,913&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,041</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,666&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">591</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">238&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">181</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,948</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,898</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2024, a complaint was filed in federal district court in the District of Massachusetts by Y-Trap, Inc. ("Y-Trap"), naming as defendants the Company and Biocon Ltd ("Biocon"), captioned Y-Trap, Inc. v. Biocon Ltd and Bicara Therapeutics Inc., No. 24-cv-12678 (D. Mass.). On January 31, 2025, Y-Trap filed its operative amended complaint. The operative complaint alleges a claim against defendants for correction of inventorship of a number of patents, including patents alleged to be licensed to the Company relating to ficerafusp alfa. The complaint also alleges claims against defendants for unfair trade practices pursuant to Chapter 93A of the Massachusetts General Laws, unjust enrichment, and civil conspiracy. The operative complaint seeks, among other things, damages (including compensatory, enhanced, and punitive damages), an order correcting the inventorship of the patents at issue, costs and attorney&#8217;s fees, and other equitable and injunctive relief. On February 28, 2025, Biocon and Bicara moved to dismiss all of Y-Trap&#8217;s claims. On September 30, 2025, the court denied Bicara's motion. On October 30, 2025, Bicara answered the operative complaint. The Company will continue to vigorously defend against this litigation.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have contingency reserves established for any litigation liabilities as of March&#160;31, 2026 and December&#160;31, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholder's Equity</a></td>
<td class="text">Stockholder's Equity<div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The Company has 10,000,000 shares of preferred stock authorized for issuance, par value $0.0001 per share. As of March 31, 2026 and December 31, 2025, no shares of preferred stock were issued or outstanding.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Common Stock</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The Company has 500,000,000 shares of Common Stock authorized for issuance, par value $0.0001 per share. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">March&#160;31, 2026 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">December&#160;31, 2025, 65,547,037</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">56,600,724</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> shares were issued and</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> outstanding, respectively. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">February 2026 Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">In February 2026, the Company issued and sold 8,581,250 shares of its common stock, including 1,406,250 shares pursuant to the exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $16.00 per share, and pre-funded warrants to purchase 2,200,000 shares of common stock (the "pre-funded warrants", at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock in the offering, less the $0.0001 per share exercise price for each pre-funded warrant.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Pre-funded Warrants</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain requirements, the pre-funded warrants, sold in the Company's February 2026 offering, can be exercised by the holder at anytime. As of March 31, 2026, there have not been any exercises of the pre-funded warrants.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants meet the criteria to be classified as an equity instrument under ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and funds received were recorded as an increase in additional paid-in capital in the condensed consolidated balance sheets. Funds received upon exercise of warrants will be recorded as common stock in the condensed consolidated balance sheets as the exercise price represents the par value of the underlying common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">At-The-Market Program</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On October 3, 2025, the Company filed a shelf registration statement on Form S-3 (the &#8220;Registration Statement&#8221;), with the SEC covering the offering of up to $400.0&#160;million of common stock, preferred stock, debt securities, warrants and/units. The Registration Statement was declared effective by the SEC on November 26, 2025. Concurrent with the filing of the Registration Statement, the Company entered into a sales agreement, dated October 3, 2025, by and between the Company and TD Securities (USA) LLC, acting as sales agent, to establish the ATM Program, pursuant to which the Company may offer and sell shares of its common stock from time to time. In connection with the ATM Program, the Company filed a prospectus with the Registration Statement for the offer and sale of up to $150.0&#160;million of shares of common stock from time to time through the sales agent. The Company will pay the agent a commission rate up to 3% of the gross proceeds of any shares sold and has agreed to provide the sales agent with customary indemnification and contributions against certain liabilities. As of March 31, 2026, the Company had remaining available capacity for share issuances of up to $120.0&#160;million under the ATM Program. During the quarter ended March 31, 2026, there were no sales under the ATM Program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Stock Option and Grant Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, in connection with the Company&#8217;s IPO, the board of directors adopted, and the Company&#8217;s shareholders approved the 2024 Stock Option and Grant Plan (the &#8220;2024 Plan&#8221;) under which the Company may grant equity-based incentive awards to the Company&#8217;s employees, officers, directors, consultants and other key persons of the Company and its affiliates upon whose judgment, initiative, and efforts the Company largely depends for the successful conduct of its business. Following the effectiveness of the 2024 Plan, no shares remained available for future issuance under the 2019 Stock Option and Grant Plan (as amended, the &#8220;2019 Plan&#8221;). Any other options or awards outstanding under the 2019 Plan remain outstanding and effective.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Plan, initially allowed the Company to grant awards up to 2,453,616 shares of Common Stock, plus shares of common stock subject to awards outstanding under the 2019 Plan that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated (other than by exercise). Each year starting on January 1, 2025 and on each January 1 thereafter, the number of shares of stock reserved and available for issuance under the 2024 Plan shall automatically be cumulatively increased by 5% of the outstanding shares on the immediately preceding December 31 or such lesser number of shares as approved by the Company. Through March&#160;31, 2026, the Company issued 5,239,109 of options under the 2024 Plan. The terms of equity award agreements, including vesting requirements, were </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">determined by the board of directors and are subject to the provisions of the 2024 Plan. Equity awards granted to employees and non-employees generally vest over a four-year period but may be granted with different vesting terms. Certain options provide for early vesting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees and non-employees expire no more than 10 years from the date of grant and are generally service based. The 2024 Plan allows for awards to contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vested period. No awards with performance-based vesting criteria have been granted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2026 Inducement Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In January 2026, the Company&#8217;s board of directors adopted the Bicara Therapeutics Inc. 2026 Inducement Plan (the &#8220;Inducement Plan&#8221;) and reserved 1,000,000 shares of common stock for future issuance under the Inducement Plan. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Inducement Plan has not been approved by the stockholders of the Company and provides for the grant of non-qualified stock options, stock appreciation rights, RSAs, RSUs, unrestricted stock awards and dividend equivalent rights to newly hired employees as a material inducement to accept employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense for non-employees and employees in its statements of comprehensive loss as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,225</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,141&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">3,633&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2,310&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,858</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,451</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Stock Options</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation, measured at the grant date based on the fair value of the award, is typically recognized ratably over the requisite service period, using the straight-line method of expense attribution. When utilizing the Black-Scholes option-pricing model to determine the grant date fair value of stock options granted to employees or non-employees, we used the following weighted average assumptions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.689%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.7%-3.9%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.0%-4.4%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Expected life (in years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94.1%-94.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">90.6%-90.8%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Expected dividend rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Fair value of common stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$12.60-$13.77</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$12.30-$12.70</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">A summary of options award activity for non-employees and employees of the Company is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average &#8211;<br/>Remaining<br/>Contractual<br/>Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Intrinsic </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,850,977</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.03</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,389,555</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(366,416)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.34</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2026</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,874,116</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.74</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.56</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">108,757</span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2026</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,349,637</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.36</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.76</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42,004</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and expected to vest as of March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,874,116</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">10.74&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The aggregate intrinsic values is calculated as the difference between the exercise price of the underlying options and the fair value of the Company&#8217;s common stock on March 31, 2026 for the options that were in the money.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of options granted during the three months ended March 31, 2026 and 2025, was $13.15 and $9.60, respectively.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised for the three months ended March 31, 2026 and 2025 were $5.1&#160;million and $0.6&#160;million, respectively.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had 8,524,479 unvested stock options outstanding as of March&#160;31, 2026. As of March&#160;31, 2026, total unrecognized compensation costs of $72.5 million related to unvested stock options are expected to be recognized as expense over a weighted average period of 3.1 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">2024 Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 5, 2024, the Company&#8217;s board of directors adopted, and its stockholders approved, the 2024 Employee Stock Purchase Plan (the "ESPP"), which became effective September 5, 2024. The ESPP initially reserves and authorizes the issuance of up to 507,383 shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034, by the least of (i) 1,014,766 shares of common stock, (ii) 1% of the sum of (A) the number of shares of our common stock issued and outstanding on the immediately preceding December 31, and (B) the number of shares of common stock issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire such common stock for a nominal exercise price on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend, or other change in our capitalization. There has been no activity on this plan to date, and no stock-based compensation expense was recognized during the three months ended March 31, 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesDeferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements &#8211; Related Parties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Significant Agreements &#8211; Related Parties</a></td>
<td class="text">Significant Agreements &#8211; Related Parties<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a master services agreement on December 15, 2020 (the &#8220;Master Services Agreement&#8221;) with Biocon. Pursuant to the terms of the master service agreement, Biocon provided services related to research and development, clinical trials, regulatory interactions and manufacturing. The Company incurred $0.1&#160;million and $0.0 million expenses under the Master Services Agreement during the three months ended March&#160;31, 2026 and 2025, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;23, 2019, the Company entered into a contract manufacturing agreement with a wholly-owned subsidiary of Biocon, Biocon Biologics Limited (&#8220;BBL&#8221;) formerly Biocon Biologics India Limited, which was amended on November 6, 2024 to extend the term of the contract manufacturing agreement until July 23, 2026. Additionally, the Company entered into a material transfer agreement on August 17, 2023, a quality agreement on October 12, 2023, a service agreement on October 18, 2023, and a manufacturing service agreement on December 15, 2023 (collectively, the &#8220;BBL Agreements&#8221;). Pursuant to the terms of the BBL Agreements, BBL manufactures and supplies specified quantities of products to Bicara to be utilized in research and development and manufacturing as per purchase orders executed from time to time between the two parties. For the three months ended March&#160;31, 2026 and 2025, the Company incurred $0.1 million and $0.0 million of research and development expenses, respectively, under the BBL Agreements. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, the Company owed $0.1&#160;million and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$0.0 million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company additionally entered into a contract manufacturing agreement with a wholly-owned subsidiary of Biocon, Syngene International Limited (&#8220;Syngene&#8221;), on July 17, 2019, which was amended and restated on April 1, 2020 with the amended and restated manufacturing service agreement, as amended (the &#8220;Syngene Manufacturing Services Agreement&#8221;), and a master contract services agreement on July 24, 2020, as amended (the &#8220;Syngene Master Contract Services Agreement&#8221; and together with the Syngene Manufacturing Services Agreement, the &#8220;Syngene Agreements&#8221;). Pursuant to the terms of the Syngene Agreements, Syngene manufactures and supplies specified quantities of products to Bicara to be used in research and development as per purchase orders executed from time to time between the two parties and performs additional contract research services under the master contract services agreement. The Syngene Manufacturing Services Agreement expires on the later of October 31, 2027 or the completion of services under all work orders under the agreement. The Syngene Master Contract Services Agreement expires on the later of November 1, 2031 or the completion of all services under the statements of work under the agreement. On December 16, 2024, the Company entered into an additional master contract services agreement with Syngene, whereby Syngene agreed to provide the Company with dedicated research laboratories and personnel (&#8220;Dedicated Center Agreement&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Dedicated Center Agreement expires on the later of December 16, 2028 or the completion of all services under all statements of work under the agreement.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, the Company incurred $1.8 million and $6.4 million of manufacturing and research and development expenses, respectively, under the Syngene Agreements. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, and December&#160;31, 2025, the Company owed Syngene $2.0 million and $3.4 million, respectively, relating to these incurred costs, of which $1.3 million and $2.3 million, respectively,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">were classified in accounts payable-related party and $0.7 million and $1.1 million, respectively,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span>were classified as accrued expenses-related party on the balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Significant Agreements</a></td>
<td class="text">Significant Agreements<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IQVIA</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 15, 2019, the Company entered into a master clinical contract services agreement with IQVIA RDS Inc (&#8220;IQVIA&#8221;), which was amended in December 2023 to include global clinical trials. Pursuant to the terms of the agreement, as amended, IQVIA will provide the Company with certain global clinical-development related services and laboratory services under separately executed statements of work (&#8220;SOWs&#8221;). In June 2021, the Company entered into an SOW with IQVIA for lab and clinical development services, to be invoiced on a monthly basis based on work performed by IQVIA. Under this SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $1.8&#160;million, of which $1.0&#160;million was a refundable deposit and $0.8&#160;million for investigator grant payment in advance. In December 2022, Bicara entered into an authorized to proceed agreement (&#8220;ATP&#8221;) with IQVIA. Under the ATP, Bicara agreed to provide IQVIA with an additional refundable deposit of $0.9&#160;million, which was paid in March 2023. Both the initial deposit and the ATP deposit will be held on account and reconciled against final invoices. As of March 31, 2026 and December 31, 2025, the refundable deposit balance was $1.9&#160;million, which is included within other assets on the balance sheets. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2024, the Company entered into a second SOW for lab and clinical development services with IQVIA, which was incorporated into the master clinical contract services agreement and part of the Company&#8217;s FORTIFI-HN01 Phase 2/3 clinical trial. Services will be invoiced on a monthly basis based on work performed by IQVIA. Under this SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $12.8&#160;million, of which $7.3&#160;million was for investigator grant payments, $4.5&#160;million was a deposit for services and $1.0&#160;million was a deposit for pass through costs. The deposits will be held on account with an incremental return starting the month after 75% of the budgeted costs has been paid by the Company. IQVIA is eligible to receive potential additional payments and it is subject to potential penalties based on certain milestone targets. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025 the Company incurred </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$9.9 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and $14.2 million in expenses, respectively and paid </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$7.7 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and $12.3 million, respectively, to IQVIA. As of March&#160;31, 2026 and December&#160;31, 2025, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$1.1 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and $0.4 million classified in accounts payable, respectively, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$9.8 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and $8.6 million classified in accrued expenses and other current liabilities on the balance sheets.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Collaboration and Supply Agreement with MSD</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2022, we entered into a Clinical Trial Collaboration and Supply Agreement (the "MSD Agreement") with MSD International GmbH ("MSDIG"), and MSD International Business GmbH ("MSDIB" and collectively with MSDIG, "MSD"). Pursuant to the MSD Agreement, we provide ficerafusp alfa and MSD provides pembrolizumab to be used in combination in a clinical trial sponsored by us. The clinical trial is a First-in-Human, Phase 1/1b, Open-label, Multicenter Study intended to characterize the safety, tolerability and recommended dose of single agent ficerafusp alfa and combination ficerafusp alfa plus pembrolizumab. To facilitate such collaboration activities and information exchange and pursuant to the MSD Agreement, we and MSD created a joint development committee with an equal number of representatives from each party.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the MSD Agreement, all clinical data resulting from the portion of the clinical trial involving the combination of ficerafusp alfa and pembrolizumab is jointly owned by both us and MSD. We own all clinical data resulting from the part of the clinical trial involving ficerafusp alfa alone or in combination with other treatments that are not pembrolizumab, and MSD owns all clinical data resulting from the part of the clinical trial involving pembrolizumab alone or in combination with other treatments that are not ficerafusp alfa. There are no accounting considerations for this agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text">Defined Contribution Plan<span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently maintains a tax-qualified 401(k) retirement savings plan for our employees. All eligible employees are able to participate in the plan beginning one month after their first day of employment. Under our defined contribution plan, employees may elect to defer a percentage of their compensation per year, subject to a maximum limit prescribed by tax law, and the Company match a portion of their eligible contributions. The Company provided matching discretionary contributions under the 401(k) plan of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$0.2&#160;million</span> and $0.1&#160;million for the three months ended March 31, 2026 and March 31, 2025, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-70/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one reportable segment relating to research and development of its product. The segment does not currently generate revenues as it is currently conducting clinical trials and has not commercialized.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Operating Decision Maker (the &#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and expenses by function and the CODM makes decisions using this information on a global basis. The CODM monitors performance at the consolidated level such that the measure of segment loss is consolidated net loss and the measure of reportable segment assets is reported on the balance sheet as total assets.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended March 31, </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Manufacturing and process development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">23,208&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">18,655&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Clinical operations and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">14,570&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">10,026&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Research and development personnel cost and other (including stock-based compensation)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">9,121&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,096&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Research</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">601&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">556&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total research and development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">47,500&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">34,333&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">General and administrative personnel costs (including stock-based compensation)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">7,963&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,832&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Professional fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">3,560&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,504&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Facility costs, IT, office expense and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,219&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,119&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total general and administrative expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">12,742&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">7,455&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">60,242&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">41,788&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Operating loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(60,242)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(41,788)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Interest income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,083&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,014&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total other income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,083&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,014&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Net income before losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(56,159)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(36,774)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Income tax expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(52)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(72)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Segment and consolidated net loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(56,211)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(36,846)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included within facility costs, IT, office expense and other are depreciation expense, which is disclosed on the Statement of Cash Flows</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"><tr><td style="width:1.0pt"></td><td style="width:126.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:69.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:90.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Name (Title)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Action Taken (Date of Action)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Type of Trading Arrangements</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Nature of Trading Arrangements</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Duration of Trading Arrangement</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%">Aggregate Number of Securities</span></div></td></tr><tr style="height:132pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Claire Mazumdar, Ph.D. (Chief Executive Officer and Director)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Adoption (March&#160;31, 2026)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Rule 10b5-1 trading arrangement</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Sale</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Until the earlier of a) December&#160;31, 2026; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Up to 150,000 shares of common stock</span></div></td></tr><tr style="height:132pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Ryan Cohlhepp, Pharm.D. (President, Chief Operating Officer and Director)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Adoption (March&#160;31, 2026)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Rule 10b5-1 trading arrangement</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Sale</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Until the earlier of a) March&#160;1, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Up to 180,000 shares of common stock</span></div></td></tr><tr style="height:120pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Ivan Hyep (Chief Financial Officer and Treasurer )</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Adoption (March&#160;31, 2026)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Rule 10b5-1 trading arrangement</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Sale</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Until the earlier of a) July&#160;8, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Up to 205,000 shares of common stock</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"><tr><td style="width:1.0pt"></td><td style="width:126.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:69.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:90.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:120pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Lara Meisner (Chief Legal Officer, Compliance Officer and Corporate Secretary)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Adoption (March&#160;31, 2026)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Rule 10b5-1 trading arrangement</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Sale</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Until the earlier of a) July&#160;3, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Up to 173,789 shares of common stock</span></div></td></tr><tr style="height:120pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">David Raben, M.D. (former Chief Medical Officer)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Adoption (March&#160;31, 2026)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Rule 10b5-1 trading arrangement</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Sale</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Until the earlier of a) July&#160;1, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%">Up to 104,000 shares of common stock</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=bcax_ClaireMazumdanMember', window );">Claire Mazumdan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Claire Mazumdar<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer and Director<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">March&#160;31, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December&#160;31, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">275 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=bcax_RyanCohlheppMember', window );">Ryan Cohlhepp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Ryan Cohlhepp<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President, Chief Operating Officer and Director<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">March&#160;31, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">March&#160;1, 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">335 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=bcax_IvanHyepMember', window );">Ivan Hyep [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Ivan Hyep<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer and Treasurer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">March&#160;31, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">July&#160;8, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">464 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">205,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=bcax_LaraMeisnerMember', window );">Lara Meisner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Lara Meisner<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Legal Officer, Compliance Officer and Corporate Secretary<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">March&#160;31, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">July&#160;3, 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">459 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">173,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=bcax_DavidRabenMember', window );">David Raben [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">David Raben<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Medical Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">March&#160;31, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">July&#160;1, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">457 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">104,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=bcax_ClaireMazumdanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=bcax_ClaireMazumdanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=bcax_RyanCohlheppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=bcax_RyanCohlheppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=bcax_IvanHyepMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=bcax_IvanHyepMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=bcax_LaraMeisnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=bcax_LaraMeisnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=bcax_DavidRabenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=bcax_DavidRabenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements include the financial position, results of operations and cash flows of Bicara. The Company&#8217;s unaudited condensed consolidated financial statements are denominated in U.S. dollars. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, and the fair values of pre-IPO common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of obligations of, and issues guaranteed by the U.S. Treasury, U.S. Agencies and U.S. Government Sponsored Enterprises.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities are classified as available-for-sale and are carried at fair value. The Company classifies all available-for-sale securities as current assets. Marketable securities are classified as current assets because they are available to fund current operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any unrealized holding gains or losses on debt securities, including their tax effect, are reported as components of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statement of comprehensive loss. Realized gains and losses, included in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statement of comprehensive loss, are determined using the specific identification method for determining the cost of securities sold.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Declines in fair value below amortized cost related to credit losses (i.e., impairment due to credit losses) are included in the condensed consolidated statement of comprehensive loss, with a corresponding allowance established. If the estimate of expected credit losses decreases in subsequent periods, the Company will reverse the credit losses through current period earnings and adjust the allowance accordingly.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in accordance with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 730&#8221;). Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes salaries and benefits, stock-based compensation expense and the cost of services provided by outside contractors.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes advance payments for goods or services that will be used or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed. The Company also records expenses and accruals for estimated costs of research and development activities, including third party contract services for clinical research and contract manufacturing. The Company bases its estimates on the best information available at the time. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or as accrued research and development expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to the Company&#8217;s vendors. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div>General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation expense, related to the Company's executive, finance and other support functions. Other general and administrative expenses include professional fees for legal, auditing, tax, consulting services, investor relations, IT and office expenses, rent and insurance.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based employee and nonemployee compensation awards in accordance with provisions of ASC 718,&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 718&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. We use the Black-Scholes option-pricing model to determine the fair value of options. The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends. In applying these assumptions, we consider the following factors: </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company&#8217;s common stock is listed on the Nasdaq Global Market and its value is determined by the market price on the Nasdaq Global Market as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term:&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The expected life is applied to the stock option grant group as a whole as we do not expect substantially different exercise or post-vesting termination behavior among our employee population.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends due to absence of an active market for the Company&#8217;s common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We have not paid and do not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was&#160;zero.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For awards that vest based solely on achievement of a service condition, the Company recognizes expense on a straight-line basis over the period during which the award holder provides such services. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with forfeited awards. In accordance with ASU 2018-07, the Company accounts for share-based compensation for awards granted to non-employees in a similar fashion to the way it accounts for share-based compensation awards to employees.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_WarrantsPolicyPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div>Management assesses warrants to determine whether they should be classified as equity or liability. If the classification is determined to be equity, proceeds received for the warrants are recorded as an increase to additional paid-in capital in the condensed consolidated balance sheets. If classified as a liability, the Company records the warrant as a liability on its consolidated balance sheet and remeasures this liability to fair value at each reporting date and recognizes changes in the fair value of the warrant in earnings.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is determined by dividing the net loss applicable to common shareholders by the weighted average common shares outstanding during the period. The pre-funded warrants to purchase 2,200,000 shares of common stock issued in February 2026 and outstanding as of March 31, 2026 (see Note 9) were included in computing the weighted average common shares outstanding used in calculating basic and diluted loss per share. Outstanding common stock options are e</span>xcluded from the calculation of diluted net loss per share when their effect would be anti-dilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements and Accounting Pronouncements Issued and Not Adopted</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews new accounting standards as they are issued by the FASB or other standard-setting bodies. The Company did not identify any new standards during the quarter ended March 31, 2026 that it believes will have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2024-03&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses (DISE)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. This new guidance requires all public entities to incorporate disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective prospectively for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption and retrospective application are permitted. We are currently evaluating the impact that ASU 2024-03 will have on our condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviewed additional recent accounting pronouncements and concluded they are either not applicable or that the Company does not expect adoption to have a material effect on the unaudited condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax</a></td>
<td class="text">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">For the three months ended March 31, 2026 and 2025, the following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,874,116</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,271,217</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Financial Assets Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets that have been measured at fair value as of March&#160;31, 2026 and December&#160;31, 2025 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">216,291&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">216,291&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">320,694&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">320,694&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">320,694&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">216,291&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">536,985&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Description</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Assets:</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">318,116&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">318,116&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Money market funds included within cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">93,595&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">93,595&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">93,595&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">318,116&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">411,711&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-For-Sale Investments by Type of Security</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The fair value of available-for-sale marketable securities by type of security was as follows (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">March 31, 2026</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Marketable Securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">163,516&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(74)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">163,444&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">163,516&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(74)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">163,444&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">53,018&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(171)</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">52,847&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one to two years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">53,018&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(171)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">52,847&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">216,534&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">216,291&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2025</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:center"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:center"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:center"></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Marketable Securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">233,672&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">146&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">233,818&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">233,672&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">146&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">233,818&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">84,201&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">97&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">84,298&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities with original maturity of one to two years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">84,201&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">97&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">84,298&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">317,873&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">243&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">318,116&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-For-Sale Securities in an Unrealized Loss Position</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The following table summarizes the Company's available-for-sale securities in an unrealized loss position, aggregated by type and length of time in a continuous unrealized position (in thousands):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">March 31, 2026</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Less than 12 Months</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">12 Months or Longer</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Marketable Securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">U.S. Treasury Bills</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">156,241&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">156,241&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">156,241&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">156,241&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands): </span></div><div style="margin-top:10pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:67.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,516</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,085</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">12,615&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus and payroll related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,913&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,041</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,666&#160;</span></div></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">591</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">238&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">181</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,948</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,898</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense Recognized in Statements of Operations</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total stock-based compensation expense for non-employees and employees in its statements of comprehensive loss as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,225</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,141&#160;</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">3,633&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2,310&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,858</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,451</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text">When utilizing the Black-Scholes option-pricing model to determine the grant date fair value of stock options granted to employees or non-employees, we used the following weighted average assumptions:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.689%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.7%-3.9%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.0%-4.4%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Expected life (in years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94.1%-94.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">90.6%-90.8%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Expected dividend rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Fair value of common stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$12.60-$13.77</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$12.30-$12.70</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">A summary of options award activity for non-employees and employees of the Company is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average &#8211;<br/>Remaining<br/>Contractual<br/>Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Intrinsic </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,850,977</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.03</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,389,555</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(366,416)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.34</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2026</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,874,116</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.74</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.56</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">108,757</span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2026</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,349,637</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.36</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.76</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42,004</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and expected to vest as of March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,874,116</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">10.74&#160;</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"><div style="margin-bottom:10pt;text-align:right"></div></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The aggregate intrinsic values is calculated as the difference between the exercise price of the underlying options and the fair value of the Company&#8217;s common stock on March 31, 2026 for the options that were in the money.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended March 31, </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2026</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Manufacturing and process development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">23,208&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">18,655&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Clinical operations and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">14,570&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">10,026&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Research and development personnel cost and other (including stock-based compensation)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">9,121&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,096&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Research</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">601&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">556&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total research and development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">47,500&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">34,333&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">General and administrative personnel costs (including stock-based compensation)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">7,963&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,832&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Professional fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">3,560&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,504&#160;</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Facility costs, IT, office expense and other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,219&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1,119&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total general and administrative expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">12,742&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">7,455&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">60,242&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">41,788&#160;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Operating loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(60,242)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(41,788)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Interest income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,083&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,014&#160;</span></div></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Total other income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4,083&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5,014&#160;</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Net income before losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(56,159)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(36,774)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Income tax expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(52)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(72)</span></div></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Segment and consolidated net loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(56,211)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">$</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">(36,846)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:right"></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization, and Liquidity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 16, 2024</div></th>
<th class="th"><div>Feb. 28, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs</a></td>
<td class="nump">$ 332,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash, cash equivalents and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 539,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 358,966<span></span>
</td>
<td class="nump">$ 415,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bcax_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">20,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in usd per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_ATMProgramMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,604,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_February2026OfferingMember', window );">February 2026 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_February2026OfferingMember', window );">February 2026 Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_February2026OfferingMember', window );">February 2026 Offering | Common Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,581,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bcax_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bcax_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcax_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_February2026OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcax_February2026OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>segment</div>
</th>
<th class="th">
<div>Feb. 28, 2026 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bcax_PreFundedWarrantsMember', window );">Pre-Funded Warrants | February 2026 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bcax_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bcax_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_February2026OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcax_February2026OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options outstanding (in shares)</a></td>
<td class="nump">11,874,116<span></span>
</td>
<td class="nump">8,271,217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 536,985<span></span>
</td>
<td class="nump">$ 411,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">320,694<span></span>
</td>
<td class="nump">93,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">216,291<span></span>
</td>
<td class="nump">318,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">216,291<span></span>
</td>
<td class="nump">318,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury Bills | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury Bills | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">216,291<span></span>
</td>
<td class="nump">318,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury Bills | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">320,694<span></span>
</td>
<td class="nump">93,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds included within cash and cash equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">320,694<span></span>
</td>
<td class="nump">93,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds included within cash and cash equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds included within cash and cash equivalents | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Available-For-Sale Investments by Type of Security (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 216,534<span></span>
</td>
<td class="nump">$ 317,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(245)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">216,291<span></span>
</td>
<td class="nump">318,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_InvestmentCategorizationAxisAxis=bcax_InvestmentsWithMaturityOfOneYearOrLessMember', window );">Total marketable securities with original maturity of one year or less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">163,516<span></span>
</td>
<td class="nump">233,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(74)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">163,444<span></span>
</td>
<td class="nump">233,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_InvestmentCategorizationAxisAxis=bcax_InvestmentsWithMaturityOfOneToTwoYearsMember', window );">Total marketable securities with original maturity of one to two years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">53,018<span></span>
</td>
<td class="nump">84,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(171)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">52,847<span></span>
</td>
<td class="nump">84,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury Bills | Total marketable securities with original maturity of one year or less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">163,516<span></span>
</td>
<td class="nump">233,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(74)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">163,444<span></span>
</td>
<td class="nump">233,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury Bills | Total marketable securities with original maturity of one to two years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">53,018<span></span>
</td>
<td class="nump">84,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(171)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 52,847<span></span>
</td>
<td class="nump">$ 84,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_InvestmentCategorizationAxisAxis=bcax_InvestmentsWithMaturityOfOneYearOrLessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_InvestmentCategorizationAxisAxis=bcax_InvestmentsWithMaturityOfOneYearOrLessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_InvestmentCategorizationAxisAxis=bcax_InvestmentsWithMaturityOfOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_InvestmentCategorizationAxisAxis=bcax_InvestmentsWithMaturityOfOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Available-For-Sale Securities in an Unrealized Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">$ 156,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Unrealized Losses</a></td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">156,241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized Losses</a></td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">156,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Unrealized Losses</a></td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">156,241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized Losses</a></td>
<td class="num">$ (245)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Narrative (Details) - debtSecurity<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition', window );">Number of securities held in unrealized loss position</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Number Of Securities In Unrealized Loss Position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 03, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 02, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 16, 2023 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_LesseeOperatingLeaseArea', window );">Area of land (in square feet) | ft&#178;</a></td>
<td class="nump">9,361<span></span>
</td>
<td class="nump">9,682<span></span>
</td>
<td class="nump">9,361<span></span>
</td>
<td class="nump">4,744<span></span>
</td>
<td class="nump">4,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease, base rent</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_LesseeOperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_LesseeOperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 13,516<span></span>
</td>
<td class="nump">$ 13,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_AccruedManufacturingExpensesCurrent', window );">Accrued manufacturing expenses</a></td>
<td class="nump">12,615<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued bonus and payroll related expenses</a></td>
<td class="nump">1,913<span></span>
</td>
<td class="nump">5,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 29,948<span></span>
</td>
<td class="nump">$ 18,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_AccruedManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Manufacturing Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_AccruedManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2025</div></th>
<th class="th"><div>Feb. 28, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,600,724<span></span>
</td>
<td class="nump">65,547,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,600,724<span></span>
</td>
<td class="nump">65,547,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Registration payment arrangement, maximum potential consideration</a></td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bcax_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_February2026OfferingMember', window );">February 2026 Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference', window );">Difference in offering price from common stock (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_ATMProgramMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,604,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Registration payment arrangement, maximum potential consideration</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_SaleOfStockCommissionFeePercentage', window );">Sale of stock, commission fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Equity | February 2026 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,581,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Common Stock, Exercise Price of Warrants or Rights, Difference</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_SaleOfStockCommissionFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_SaleOfStockCommissionFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482804/825-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bcax_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bcax_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_February2026OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcax_February2026OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcax_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcax_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.15<span></span>
</td>
<td class="nump">$ 9.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,524,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation cost, period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="nump">507,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable under the plan (in shares)</a></td>
<td class="nump">1,014,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percent of outstanding shares</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcax_A2024StockOptionAndGrantPlanMember', window );">2024 Stock Option And Grant Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,453,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage', window );">Percentage of increase in future issuance reserved share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcax_A2024StockOptionAndGrantPlanMember', window );">2024 Stock Option And Grant Plan | Incentive Stock Options And Non-Qualified Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Option shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,239,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcax_A2026InducementPlanMember', window );">2026 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Share Authorization Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcax_A2024StockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcax_A2024StockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcax_A2026InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcax_A2026InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized In Statements Of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 5,858<span></span>
</td>
<td class="nump">$ 3,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">2,225<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 3,633<span></span>
</td>
<td class="nump">$ 2,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Weighted Average Assumptions (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Expected dividend rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">94.10%<span></span>
</td>
<td class="nump">90.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice', window );">Fair value of common stock (in usd per share)</a></td>
<td class="nump">$ 12.60<span></span>
</td>
<td class="nump">$ 12.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">94.50%<span></span>
</td>
<td class="nump">90.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice', window );">Fair value of common stock (in usd per share)</a></td>
<td class="nump">$ 13.77<span></span>
</td>
<td class="nump">$ 12.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions During Period, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Options Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">9,850,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,389,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(366,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">11,874,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 9.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">16.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">4.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average &#8211; Remaining Contractual Life (years), Outstanding</a></td>
<td class="text">8 years 6 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 108,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in shares) | shares</a></td>
<td class="nump">3,349,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 7.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average &#8211; Remaining Contractual Life (years), Exercisable</a></td>
<td class="text">7 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 42,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Shares, Exercisable and expected to vest (in shares) | shares</a></td>
<td class="nump">11,874,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable and expected to vest (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average &#8211; Remaining Contractual Life (years), Exercisable and expected to vest</a></td>
<td class="text">8 years 6 months 21 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements &#8211; Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">$ 39,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,982<span></span>
</td>
<td class="nump">$ 6,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bcax_MasterServicesAgreementMember', window );">Master Services Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bcax_BBLAgreementsMember', window );">BBL Agreements | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementsMember', window );">Syngene Agreements | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bcax_MasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bcax_MasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bcax_BBLAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bcax_BBLAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bcax_SyngeneAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_OtherCommitmentLiabilityRefundableDepositAmount', window );">Other commitment, liability, refundable deposit, amount</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">60,242<span></span>
</td>
<td class="nump">$ 41,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Contract Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_PaymentsForOtherCommitments', window );">Amount paid</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Contract Services Agreement, Refundable Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Services Agreement, Investigator Grant Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Contract Services Agreement, Additional Refundable Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Contract Services Agreement Deposits For Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Contract Services Agreement Deposit For Pass Through Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Initial payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember', window );">IQVIA RDS Inc | Master Clinical Contract Services Agreement Incremental Return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_OtherCommitmentPercentage', window );">Other commitment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_OtherCommitmentLiabilityRefundableDepositAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Liability, Refundable Deposit, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_OtherCommitmentLiabilityRefundableDepositAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_OtherCommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_OtherCommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_PaymentsForOtherCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Other Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_PaymentsForOtherCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcax_IQVIARDSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementRefundableDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementRefundableDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution, plan cost</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule Segment Profit or Loss, Including Significant Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">$ 12,742<span></span>
</td>
<td class="nump">$ 7,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">60,242<span></span>
</td>
<td class="nump">41,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(60,242)<span></span>
</td>
<td class="num">(41,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,083<span></span>
</td>
<td class="nump">5,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">4,083<span></span>
</td>
<td class="nump">5,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income before losses</a></td>
<td class="num">(56,159)<span></span>
</td>
<td class="num">(36,774)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(56,211)<span></span>
</td>
<td class="num">(36,846)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcax_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ClinicalOperationsAndDevelopmentExpense', window );">Manufacturing and process development</a></td>
<td class="nump">14,570<span></span>
</td>
<td class="nump">10,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ManufacturingAndProcessDevelopmentExpense', window );">Clinical operations and development</a></td>
<td class="nump">23,208<span></span>
</td>
<td class="nump">18,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense', window );">Research and development personnel cost and other (including stock-based compensation)</a></td>
<td class="nump">9,121<span></span>
</td>
<td class="nump">5,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="nump">47,500<span></span>
</td>
<td class="nump">34,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation', window );">General and administrative personnel costs (including stock-based compensation)</a></td>
<td class="nump">7,963<span></span>
</td>
<td class="nump">4,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">3,560<span></span>
</td>
<td class="nump">1,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_FacilityITOfficeAndOtherExpense', window );">Facility costs, IT, office expense and other</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">12,742<span></span>
</td>
<td class="nump">7,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">60,242<span></span>
</td>
<td class="nump">41,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(60,242)<span></span>
</td>
<td class="num">(41,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,083<span></span>
</td>
<td class="nump">5,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">4,083<span></span>
</td>
<td class="nump">5,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income before losses</a></td>
<td class="num">(56,159)<span></span>
</td>
<td class="num">(36,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcax_IncomeTaxExpenseBenefitIncludingAdjustments', window );">Income tax expense</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (56,211)<span></span>
</td>
<td class="num">$ (36,846)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_ClinicalOperationsAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Operations And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_ClinicalOperationsAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_FacilityITOfficeAndOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility, IT, Office And Other Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_FacilityITOfficeAndOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative Personnel Costs Including Stock-based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_IncomeTaxExpenseBenefitIncludingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), Including Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_IncomeTaxExpenseBenefitIncludingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_ManufacturingAndProcessDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing And Process Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_ManufacturingAndProcessDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Personnel Cost, Including Share-Based Payment Arrangement Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bcax_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bcax_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>140</ContextCount>
  <ElementCount>231</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Description of Business, Organization, and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity</Role>
      <ShortName>Description of Business, Organization, and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockholdersEquity</Role>
      <ShortName>Stockholder's Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Significant Agreements ??? Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SignificantAgreementsRelatedParties</Role>
      <ShortName>Significant Agreements ??? Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bicara.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicara.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicara.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicara.com/role/MarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicara.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicara.com/role/SegmentReporting</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Description of Business, Organization, and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails</Role>
      <ShortName>Description of Business, Organization, and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Marketable Securities - Schedule of Available-For-Sale Investments by Type of Security (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails</Role>
      <ShortName>Marketable Securities - Schedule of Available-For-Sale Investments by Type of Security (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Marketable Securities - Schedule of Available-For-Sale Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails</Role>
      <ShortName>Marketable Securities - Schedule of Available-For-Sale Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/MarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Stockholder's Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholder's Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/StockholdersEquity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized In Statements Of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized In Statements Of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Significant Agreements ??? Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails</Role>
      <ShortName>Significant Agreements ??? Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/SignificantAgreementsRelatedParties</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Significant Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SignificantAgreementsDetails</Role>
      <ShortName>Significant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/SignificantAgreementsRelatedParties</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Defined Contribution Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/DefinedContributionPlanDetails</Role>
      <ShortName>Defined Contribution Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicara.com/role/DefinedContributionPlan</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bcax-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Segment Reporting - Schedule Segment Profit or Loss, Including Significant Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails</Role>
      <ShortName>Segment Reporting - Schedule Segment Profit or Loss, Including Significant Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="bcax-20260331.htm">bcax-20260331.htm</File>
    <File>bcax-20260331.xsd</File>
    <File>bcax-20260331_cal.xml</File>
    <File>bcax-20260331_def.xml</File>
    <File>bcax-20260331_lab.xml</File>
    <File>bcax-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bcax-20260331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="445">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bcax-20260331.htm": {
   "nsprefix": "bcax",
   "nsuri": "http://www.bicara.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "bcax-20260331.htm"
     ]
    },
    "schema": {
     "local": [
      "bcax-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "bcax-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bcax-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bcax-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcax-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 210,
   "keyCustom": 21,
   "axisStandard": 18,
   "axisCustom": 1,
   "memberStandard": 20,
   "memberCustom": 25,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/ecd/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 140,
   "entityCount": 1,
   "segmentCount": 47,
   "elementCount": 462,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 445,
    "http://xbrl.sec.gov/ecd/2025": 39,
    "http://xbrl.sec.gov/dei/2025": 31
   },
   "report": {
    "R1": {
     "role": "http://www.bicara.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity",
     "longName": "9952156 - Disclosure - Description of Business, Organization, and Liquidity",
     "shortName": "Description of Business, Organization, and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.bicara.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.bicara.com/role/FairValueMeasurements",
     "longName": "9952158 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.bicara.com/role/MarketableSecurities",
     "longName": "9952159 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.bicara.com/role/Leases",
     "longName": "9952160 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "9952161 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.bicara.com/role/CommitmentsandContingencies",
     "longName": "9952162 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.bicara.com/role/StockholdersEquity",
     "longName": "9952163 - Disclosure - Stockholder's Equity",
     "shortName": "Stockholder's Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.bicara.com/role/StockBasedCompensation",
     "longName": "9952164 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.bicara.com/role/IncomeTaxes",
     "longName": "9952165 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.bicara.com/role/SignificantAgreementsRelatedParties",
     "longName": "9952166 - Disclosure - Significant Agreements \u2013 Related Parties",
     "shortName": "Significant Agreements \u2013 Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.bicara.com/role/SignificantAgreements",
     "longName": "9952167 - Disclosure - Significant Agreements",
     "shortName": "Significant Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.bicara.com/role/DefinedContributionPlan",
     "longName": "9952168 - Disclosure - Defined Contribution Plan",
     "shortName": "Defined Contribution Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.bicara.com/role/SegmentReporting",
     "longName": "9952169 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.bicara.com/role/FairValueMeasurementsTables",
     "longName": "9955513 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.bicara.com/role/MarketableSecuritiesTables",
     "longName": "9955514 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "9955515 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.bicara.com/role/StockBasedCompensationTables",
     "longName": "9955516 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.bicara.com/role/SegmentReportingTables",
     "longName": "9955517 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
     "longName": "9955518 - Disclosure - Description of Business, Organization, and Liquidity (Details)",
     "shortName": "Description of Business, Organization, and Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-39",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955519 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "longName": "9955520 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.bicara.com/role/FairValueMeasurementsDetails",
     "longName": "9955521 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails",
     "longName": "9955522 - Disclosure - Marketable Securities - Schedule of Available-For-Sale Investments by Type of Security (Details)",
     "shortName": "Marketable Securities - Schedule of Available-For-Sale Investments by Type of Security (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails",
     "longName": "9955523 - Disclosure - Marketable Securities - Schedule of Available-For-Sale Securities in an Unrealized Loss Position (Details)",
     "shortName": "Marketable Securities - Schedule of Available-For-Sale Securities in an Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.bicara.com/role/MarketableSecuritiesNarrativeDetails",
     "longName": "9955524 - Disclosure - Marketable Securities - Narrative (Details)",
     "shortName": "Marketable Securities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "bcax:DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition",
      "unitRef": "debtsecurity",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "bcax:DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition",
      "unitRef": "debtsecurity",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.bicara.com/role/LeasesDetails",
     "longName": "9955525 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9955526 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "bcax:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "bcax:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.bicara.com/role/StockholdersEquityDetails",
     "longName": "9955527 - Disclosure - Stockholder's Equity (Details)",
     "shortName": "Stockholder's Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-87",
      "name": "us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9955528 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails",
     "longName": "9955529 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized In Statements Of Operations (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized In Statements Of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails",
     "longName": "9955530 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Weighted Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails",
     "longName": "9955531 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails",
     "longName": "9955532 - Disclosure - Significant Agreements \u2013 Related Parties (Details)",
     "shortName": "Significant Agreements \u2013 Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-106",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.bicara.com/role/SignificantAgreementsDetails",
     "longName": "9955533 - Disclosure - Significant Agreements (Details)",
     "shortName": "Significant Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "bcax:OtherCommitmentLiabilityRefundableDepositAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "bcax:OtherCommitmentLiabilityRefundableDepositAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.bicara.com/role/DefinedContributionPlanDetails",
     "longName": "9955534 - Disclosure - Defined Contribution Plan (Details)",
     "shortName": "Defined Contribution Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.bicara.com/role/SegmentReportingNarrativeDetails",
     "longName": "9955535 - Disclosure - Segment Reporting - Narrative (Details)",
     "shortName": "Segment Reporting - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails",
     "longName": "9955536 - Disclosure - Segment Reporting - Schedule Segment Profit or Loss, Including Significant Segment Expenses (Details)",
     "shortName": "Segment Reporting - Schedule Segment Profit or Loss, Including Significant Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-129",
      "name": "bcax:ClinicalOperationsAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcax-20260331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "bcax_A2024StockOptionAndGrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "A2024StockOptionAndGrantPlanMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Stock Option And Grant Plan",
        "label": "2024 Stock Option and Grant Plan [Member]",
        "documentation": "2024 Stock Option and Grant Plan"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_A2026InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "A2026InducementPlanMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026 Inducement Plan",
        "label": "2026 Inducement Plan [Member]",
        "documentation": "2026 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_ATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "ATMProgramMember",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Program",
        "label": "ATM Program [Member]",
        "documentation": "ATM Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/SignificantAgreementsDetails",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r749"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net amortization of premiums and discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/SignificantAgreementsDetails",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "bcax_AccruedManufacturingExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "AccruedManufacturingExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued manufacturing expenses",
        "label": "Accrued Manufacturing Expenses, Current",
        "documentation": "Accrued Manufacturing Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "bcax_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expense, Current",
        "documentation": "Accrued Research And Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r50",
      "r101",
      "r546",
      "r578",
      "r579",
      "r971"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r14",
      "r428",
      "r431",
      "r486",
      "r574",
      "r575",
      "r875",
      "r876",
      "r877",
      "r892",
      "r893",
      "r894",
      "r895"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r749",
      "r1032"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r593",
      "r892",
      "r893",
      "r894",
      "r895",
      "r972",
      "r1036"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r784",
      "r794",
      "r826"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r787",
      "r797",
      "r829"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r788",
      "r798",
      "r822",
      "r830",
      "r834",
      "r842"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r374",
      "r383"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r77",
      "r97",
      "r120",
      "r121",
      "r122",
      "r156",
      "r169",
      "r194",
      "r198",
      "r237",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r418",
      "r420",
      "r469",
      "r533",
      "r534",
      "r541",
      "r628",
      "r709",
      "r710",
      "r720",
      "r749",
      "r753",
      "r754",
      "r765",
      "r926",
      "r927",
      "r988"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r102",
      "r120",
      "r121",
      "r122",
      "r237",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r418",
      "r420",
      "r469",
      "r749",
      "r926",
      "r927",
      "r988"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/FairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r738"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r245",
      "r540"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails",
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r716"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r245",
      "r443",
      "r462",
      "r463",
      "r465",
      "r466",
      "r530",
      "r685",
      "r738",
      "r741",
      "r748",
      "r905",
      "r976",
      "r977",
      "r978"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "bcax_BBLAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "BBLAgreementsMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BBL Agreements",
        "label": "BBL Agreements [Member]",
        "documentation": "BBL Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r686"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds included within cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r465",
      "r466",
      "r974",
      "r975"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r56",
      "r119"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease)/increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r56"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_ClaireMazumdanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "ClaireMazumdanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Claire Mazumdan [Member]",
        "documentation": "Claire Mazumdan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r99",
      "r100",
      "r120",
      "r122",
      "r147",
      "r148",
      "r150",
      "r152",
      "r158",
      "r159",
      "r237",
      "r276",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r290",
      "r291",
      "r293",
      "r294",
      "r296",
      "r299",
      "r302",
      "r303",
      "r306",
      "r309",
      "r316",
      "r469",
      "r584",
      "r585",
      "r586",
      "r587",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r616",
      "r636",
      "r658",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r853",
      "r886",
      "r887",
      "r896"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r158",
      "r293",
      "r302",
      "r303",
      "r304",
      "r306",
      "r309",
      "r314",
      "r316",
      "r426",
      "r584",
      "r585",
      "r586",
      "r587",
      "r721",
      "r853",
      "r884",
      "r886"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "bcax_ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference",
     "presentation": [
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference in offering price from common stock (in usd per share)",
        "label": "Class of Warrant or Right, Common Stock, Exercise Price of Warrants or Rights, Difference",
        "documentation": "Class of Warrant or Right, Common Stock, Exercise Price of Warrants or Rights, Difference"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r124",
      "r317"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "bcax_ClinicalOperationsAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "ClinicalOperationsAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing and process development",
        "label": "Clinical Operations And Development Expense",
        "documentation": "Clinical Operations And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r70",
      "r543",
      "r615"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r270",
      "r271",
      "r681",
      "r923",
      "r925"
     ]
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Agreements",
        "label": "Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Equity",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r756",
      "r757",
      "r759",
      "r760",
      "r761",
      "r762",
      "r892",
      "r893",
      "r895",
      "r972",
      "r1031",
      "r1036"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r616"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r44",
      "r616",
      "r634",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value, 500,000,000 and 500,000,000 shares authorized; 65,547,037 and 56,600,724 shares issued and outstanding as of March\u00a031, 2026 and December\u00a031, 2025, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r291",
      "r298",
      "r545",
      "r749"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r108",
      "r110",
      "r115",
      "r531",
      "r555",
      "r556"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r697"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r120",
      "r127",
      "r128",
      "r285",
      "r304",
      "r493",
      "r511",
      "r539",
      "r687",
      "r688",
      "r689",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r967",
      "r968",
      "r969",
      "r970"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "bcax_DavidRabenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "DavidRabenMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "David Raben [Member]",
        "documentation": "David Raben"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 Months or Longer, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r250",
      "r716"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 Months or Longer, Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r250"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 12 Months, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r250",
      "r716"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less than 12 Months, Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r250"
     ]
    },
    "bcax_DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities held in unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Number Of Securities In Unrealized Loss Position",
        "documentation": "Debt Securities, Available-for-Sale, Number Of Securities In Unrealized Loss Position"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-For-Sale Investments by Type of Security",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r248",
      "r716"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total, Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r249"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails",
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r716"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-For-Sale Securities in an Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r716",
      "r922"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/DefinedContributionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution, plan cost",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://www.bicara.com/role/DefinedContributionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan",
        "label": "Defined Contribution Plan [Text Block]",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r24",
      "r117",
      "r690",
      "r691",
      "r693",
      "r695"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r338",
      "r369",
      "r370",
      "r372",
      "r728"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Assumptions",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per share, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r116",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r145",
      "r147",
      "r150",
      "r151",
      "r152",
      "r155",
      "r289",
      "r373",
      "r411",
      "r416",
      "r440",
      "r441",
      "r532",
      "r557",
      "r698"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per share, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r116",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r147",
      "r150",
      "r151",
      "r152",
      "r155",
      "r289",
      "r373",
      "r411",
      "r416",
      "r440",
      "r441",
      "r532",
      "r557",
      "r698"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r154"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonus and payroll related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized share-based compensation cost, period of recognition (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation costs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r88",
      "r89",
      "r90",
      "r112",
      "r113",
      "r114",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r157",
      "r238",
      "r239",
      "r263",
      "r288",
      "r318",
      "r373",
      "r401",
      "r402",
      "r408",
      "r409",
      "r410",
      "r412",
      "r415",
      "r416",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r486",
      "r553",
      "r574",
      "r575",
      "r576",
      "r593",
      "r658"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r784",
      "r794",
      "r826"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r781",
      "r791",
      "r823"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "bcax_FacilityITOfficeAndOtherExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "FacilityITOfficeAndOtherExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility costs, IT, office expense and other",
        "label": "Facility, IT, Office And Other Expense",
        "documentation": "Facility, IT, Office And Other Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r454",
      "r738"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r454",
      "r738"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r467",
      "r685",
      "r748",
      "r983"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r453",
      "r454",
      "r456",
      "r463",
      "r498",
      "r499",
      "r500",
      "r685",
      "r718",
      "r719",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r738",
      "r741",
      "r748"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r449",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r529",
      "r738",
      "r742"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r320",
      "r325",
      "r327",
      "r444",
      "r454",
      "r463",
      "r498",
      "r685",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r738",
      "r748"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r320",
      "r325",
      "r327",
      "r329",
      "r444",
      "r445",
      "r454",
      "r463",
      "r499",
      "r685",
      "r718",
      "r719",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r738",
      "r748"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r444",
      "r445",
      "r446",
      "r447",
      "r454",
      "r463",
      "r500",
      "r685",
      "r718",
      "r719",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r738",
      "r741",
      "r748"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r453",
      "r454",
      "r456",
      "r463",
      "r498",
      "r499",
      "r500",
      "r685",
      "r718",
      "r719",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r738",
      "r741",
      "r748"
     ]
    },
    "bcax_February2026OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "February2026OfferingMember",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "February 2026 Offering",
        "label": "February 2026 Offering [Member]",
        "documentation": "February 2026 Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails",
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r251",
      "r252",
      "r287",
      "r314",
      "r426",
      "r437",
      "r461",
      "r468",
      "r471",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r538",
      "r554",
      "r716",
      "r738",
      "r739",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r750",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r917",
      "r918",
      "r919",
      "r920",
      "r973",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r788",
      "r798",
      "r830"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r788",
      "r798",
      "r830"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r788",
      "r798",
      "r830"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r788",
      "r798",
      "r830"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r788",
      "r798",
      "r830"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "totalLabel": "Total general and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r638"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "bcax_GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative personnel costs (including stock-based compensation)",
        "label": "General And Administrative Personnel Costs Including Stock-based Compensation",
        "documentation": "General And Administrative Personnel Costs Including Stock-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "bcax_IQVIARDSIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "IQVIARDSIncMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IQVIA RDS Inc",
        "label": "IQVIA RDS Inc [Member]",
        "documentation": "IQVIA RDS Inc"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_IncentiveStockOptionsAndNonQualifiedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "IncentiveStockOptionsAndNonQualifiedStockOptionsMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Stock Options And Non-Qualified Stock Options",
        "label": "Incentive Stock Options And Non-Qualified Stock Options [Member]",
        "documentation": "Incentive Stock Options And Non-Qualified Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "verboseLabel": "Net income before losses",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r72",
      "r76",
      "r533",
      "r535",
      "r551",
      "r692",
      "r694",
      "r696",
      "r703",
      "r709",
      "r898",
      "r900",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r266",
      "r267",
      "r422",
      "r423",
      "r424",
      "r425",
      "r448",
      "r450",
      "r455",
      "r470",
      "r471",
      "r473",
      "r571",
      "r573",
      "r643",
      "r684",
      "r685",
      "r732",
      "r733",
      "r736",
      "r737",
      "r740",
      "r748",
      "r965",
      "r966",
      "r1002"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r422",
      "r423",
      "r424",
      "r425",
      "r448",
      "r450",
      "r455",
      "r470",
      "r471",
      "r473",
      "r571",
      "r573",
      "r643",
      "r684",
      "r685",
      "r732",
      "r733",
      "r736",
      "r737",
      "r740",
      "r748",
      "r965",
      "r966",
      "r1002"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r123",
      "r388",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r403",
      "r405",
      "r406",
      "r407",
      "r537",
      "r581",
      "r589",
      "r731"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r86",
      "r120",
      "r143",
      "r144",
      "r156",
      "r177",
      "r198",
      "r391",
      "r392",
      "r404",
      "r558",
      "r692",
      "r694",
      "r696",
      "r731"
     ]
    },
    "bcax_IncomeTaxExpenseBenefitIncludingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "IncomeTaxExpenseBenefitIncludingAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit), Including Adjustments",
        "documentation": "Income Tax Expense (Benefit), Including Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r389",
      "r390",
      "r396",
      "r397",
      "r398",
      "r400",
      "r583"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for tax",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r58",
      "r881",
      "r963",
      "r964"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r879"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r788",
      "r798",
      "r822",
      "r830",
      "r834",
      "r842"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r846"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r846"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r846"
     ]
    },
    "bcax_InvestmentCategorizationAxisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "InvestmentCategorizationAxisAxis",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Categorization Axis [Axis]",
        "label": "Investment Categorization Axis [Axis]",
        "documentation": "Investment Categorization Axis"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_InvestmentCategorizationAxisDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "InvestmentCategorizationAxisDomain",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Categorization Axis [Domain]",
        "label": "Investment Categorization Axis [Domain]",
        "documentation": "Investment Categorization Axis [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r172",
      "r198",
      "r709",
      "r878"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Investment [Text Block]",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r856",
      "r904"
     ]
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and investments",
        "label": "Investments and Cash",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1000"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_InvestmentsWithMaturityOfOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "InvestmentsWithMaturityOfOneToTwoYearsMember",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total marketable securities with original maturity of one to two years",
        "label": "Investments With Maturity Of One To Two Years [Member]",
        "documentation": "Investments With Maturity Of One To Two Years"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_InvestmentsWithMaturityOfOneYearOrLessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "InvestmentsWithMaturityOfOneYearOrLessMember",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total marketable securities with original maturity of one year or less",
        "label": "Investments With Maturity Of One Year Or Less [Member]",
        "documentation": "Investments With Maturity Of One Year Or Less"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_IvanHyepMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "IvanHyepMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ivan Hyep [Member]",
        "documentation": "Ivan Hyep"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_LaraMeisnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "LaraMeisnerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lara Meisner [Member]",
        "documentation": "Lara Meisner"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_LesseeOperatingLeaseArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "LesseeOperatingLeaseArea",
     "presentation": [
      "http://www.bicara.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of land (in square feet)",
        "label": "Lessee, Operating Lease, Area",
        "documentation": "Lessee, Operating Lease, Area"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.bicara.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.bicara.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r120",
      "r121",
      "r122",
      "r237",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r419",
      "r420",
      "r421",
      "r469",
      "r614",
      "r702",
      "r720",
      "r765",
      "r926",
      "r988",
      "r989"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r71",
      "r548",
      "r749",
      "r753",
      "r754",
      "r884",
      "r888",
      "r921",
      "r984"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "terseLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r94",
      "r120",
      "r121",
      "r122",
      "r237",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r419",
      "r420",
      "r421",
      "r469",
      "r749",
      "r926",
      "r988",
      "r989"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "bcax_ManufacturingAndProcessDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "ManufacturingAndProcessDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical operations and development",
        "label": "Manufacturing And Process Development Expense",
        "documentation": "Manufacturing And Process Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "bcax_MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Contract Services Agreement, Additional Refundable Deposit",
        "label": "Master Clinical Contract Services Agreement, Additional Refundable Deposit [Member]",
        "documentation": "Master Clinical Contract Services Agreement, Additional Refundable Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Contract Services Agreement Deposit For Pass Through Costs",
        "label": "Master Clinical Contract Services Agreement Deposit For Pass Through Costs [Member]",
        "documentation": "Master Clinical Contract Services Agreement Deposit For Pass Through Costs"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterClinicalContractServicesAgreementDepositsForServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "MasterClinicalContractServicesAgreementDepositsForServicesMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Contract Services Agreement Deposits For Services",
        "label": "Master Clinical Contract Services Agreement Deposits For Services [Member]",
        "documentation": "Master Clinical Contract Services Agreement Deposits For Services"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterClinicalContractServicesAgreementIncrementalReturnMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "MasterClinicalContractServicesAgreementIncrementalReturnMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Contract Services Agreement Incremental Return",
        "label": "Master Clinical Contract Services Agreement Incremental Return [Member]",
        "documentation": "Master Clinical Contract Services Agreement Incremental Return"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterClinicalContractServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "MasterClinicalContractServicesAgreementMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Contract Services Agreement",
        "label": "Master Clinical Contract Services Agreement [Member]",
        "documentation": "Master Clinical Contract Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterClinicalContractServicesAgreementRefundableDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "MasterClinicalContractServicesAgreementRefundableDepositMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Contract Services Agreement, Refundable Deposit",
        "label": "Master Clinical Contract Services Agreement, Refundable Deposit [Member]",
        "documentation": "Master Clinical Contract Services Agreement, Refundable Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterClinicalServicesAgreementInvestigatorGrantPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "MasterClinicalServicesAgreementInvestigatorGrantPaymentMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Clinical Services Agreement, Investigator Grant Payment",
        "label": "Master Clinical Services Agreement, Investigator Grant Payment [Member]",
        "documentation": "Master Clinical Services Agreement, Investigator Grant Payment"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_MasterServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "MasterServicesAgreementMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Services Agreement",
        "label": "Master Services Agreement [Member]",
        "documentation": "Master Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r272",
      "r273",
      "r274",
      "r275",
      "r333",
      "r364",
      "r365",
      "r366",
      "r384",
      "r447",
      "r527",
      "r570",
      "r572",
      "r580",
      "r606",
      "r607",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r715",
      "r721",
      "r727",
      "r732",
      "r734",
      "r735",
      "r741",
      "r742",
      "r746",
      "r747",
      "r751",
      "r928",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r272",
      "r273",
      "r274",
      "r275",
      "r333",
      "r364",
      "r365",
      "r366",
      "r384",
      "r447",
      "r527",
      "r570",
      "r572",
      "r580",
      "r606",
      "r607",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r715",
      "r721",
      "r727",
      "r732",
      "r734",
      "r735",
      "r741",
      "r742",
      "r746",
      "r751",
      "r928",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds included within cash and cash equivalents",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r930",
      "r931"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business, Organization, and Liquidity",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r161",
      "r699",
      "r700"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r59"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r59",
      "r73",
      "r90",
      "r92",
      "r106",
      "r109",
      "r114",
      "r120",
      "r121",
      "r122",
      "r126",
      "r132",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r149",
      "r237",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r289",
      "r292",
      "r295",
      "r300",
      "r373",
      "r411",
      "r416",
      "r441",
      "r469",
      "r552",
      "r635",
      "r656",
      "r657",
      "r692",
      "r694",
      "r696",
      "r763",
      "r926"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements and Accounting Pronouncements Issued and Not Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r788",
      "r798",
      "r822",
      "r830"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "terseLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r889",
      "r890"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r899"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r714",
      "r899"
     ]
    },
    "bcax_OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs included in accounts payable and accrued expenses",
        "label": "Offering Costs Incurred During Noncash or Partial Noncash Transaction",
        "documentation": "Offering Costs Incurred During Noncash or Partial Noncash Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails",
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "terseLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "verboseLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r692",
      "r696",
      "r703",
      "r898",
      "r900",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, base rent",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability \u2013 current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability \u2013 net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset \u2013 operating lease",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial payment amount",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r891",
      "r997"
     ]
    },
    "bcax_OtherCommitmentLiabilityRefundableDepositAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "OtherCommitmentLiabilityRefundableDepositAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other commitment, liability, refundable deposit, amount",
        "label": "Other Commitment, Liability, Refundable Deposit, Amount",
        "documentation": "Other Commitment, Liability, Refundable Deposit, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_OtherCommitmentPercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "OtherCommitmentPercentage",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other commitment percentage",
        "label": "Other Commitment Percentage",
        "documentation": "Other Commitment Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Axis]",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Domain]",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on marketable securities, net of tax",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r7",
      "r68"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on marketable securities, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r553"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r7",
      "r68",
      "r107",
      "r110",
      "r140"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r786",
      "r796",
      "r828"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r789",
      "r799",
      "r831"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r789",
      "r799",
      "r831"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_PaymentsForOtherCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "PaymentsForOtherCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount paid",
        "label": "Payments For Other Commitments",
        "documentation": "Payments For Other Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "bcax_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r302"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r616"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r302"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICAL",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r616",
      "r634",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of March\u00a031, 2026 and December\u00a031, 2025",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r291",
      "r297",
      "r544",
      "r749"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities and sales of marketable securities",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r709",
      "r763",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r485",
      "r536",
      "r550",
      "r749"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r272",
      "r273",
      "r274",
      "r275",
      "r319",
      "r333",
      "r364",
      "r365",
      "r366",
      "r372",
      "r384",
      "r447",
      "r501",
      "r510",
      "r527",
      "r570",
      "r572",
      "r580",
      "r606",
      "r607",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r715",
      "r721",
      "r727",
      "r732",
      "r734",
      "r735",
      "r741",
      "r742",
      "r746",
      "r747",
      "r751",
      "r757",
      "r924",
      "r928",
      "r977",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r272",
      "r273",
      "r274",
      "r275",
      "r319",
      "r333",
      "r364",
      "r365",
      "r366",
      "r372",
      "r384",
      "r447",
      "r501",
      "r510",
      "r527",
      "r570",
      "r572",
      "r580",
      "r606",
      "r607",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r715",
      "r721",
      "r727",
      "r732",
      "r734",
      "r735",
      "r741",
      "r742",
      "r746",
      "r747",
      "r751",
      "r757",
      "r924",
      "r928",
      "r977",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r781",
      "r791",
      "r823"
     ]
    },
    "us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RegistrationPaymentArrangementMaximumPotentialConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registration payment arrangement, maximum potential consideration",
        "label": "Registration Payment Arrangement, Maximum Potential Consideration",
        "documentation": "Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Parties [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125",
      "r126",
      "r206",
      "r326",
      "r330",
      "r490",
      "r491",
      "r542",
      "r549",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r633",
      "r665",
      "r1033"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125",
      "r126",
      "r490",
      "r491",
      "r492",
      "r493",
      "r542",
      "r549",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r633",
      "r665"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125",
      "r126",
      "r490",
      "r491",
      "r987"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125",
      "r126",
      "r987"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125",
      "r126",
      "r206",
      "r490",
      "r491",
      "r493",
      "r639",
      "r640",
      "r643"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Parties [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125",
      "r126",
      "r206",
      "r326",
      "r330",
      "r490",
      "r491",
      "r542",
      "r549",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r633",
      "r665",
      "r987",
      "r1033"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Agreements \u2013 Related Parties",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r491",
      "r494",
      "r590",
      "r591",
      "r592",
      "r641",
      "r642",
      "r643",
      "r662",
      "r664"
     ]
    },
    "bcax_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r120",
      "r127",
      "r128",
      "r285",
      "r304",
      "r493",
      "r511",
      "r539",
      "r687",
      "r688",
      "r689",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r967",
      "r968",
      "r969",
      "r970"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r684",
      "r692",
      "r693",
      "r709",
      "r996"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "bcax_ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development personnel cost and other (including stock-based compensation)",
        "label": "Research And Development Personnel Cost, Including Share-Based Payment Arrangement Expense",
        "documentation": "Research And Development Personnel Cost, Including Share-Based Payment Arrangement Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r782",
      "r792",
      "r824"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r783",
      "r793",
      "r825"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r790",
      "r800",
      "r832"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r65",
      "r547",
      "r577",
      "r579",
      "r588",
      "r617",
      "r749"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r238",
      "r239",
      "r263",
      "r288",
      "r373",
      "r401",
      "r402",
      "r408",
      "r409",
      "r410",
      "r412",
      "r415",
      "r416",
      "r427",
      "r429",
      "r430",
      "r432",
      "r439",
      "r480",
      "r482",
      "r574",
      "r576",
      "r593",
      "r1036"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "bcax_RyanCohlheppMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "RyanCohlheppMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ryan Cohlhepp [Member]",
        "documentation": "Ryan Cohlhepp"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_SaleOfStockCommissionFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "SaleOfStockCommissionFeePercentage",
     "presentation": [
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, commission fee percentage",
        "label": "Sale Of Stock, Commission Fee, Percentage",
        "documentation": "Sale Of Stock, Commission Fee, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering price (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense Recognized in Statements of Operations",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.bicara.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125",
      "r126",
      "r490",
      "r491",
      "r493",
      "r639",
      "r640",
      "r643"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails",
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r337",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r372"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r63",
      "r64",
      "r65",
      "r98",
      "r99",
      "r100",
      "r158",
      "r302",
      "r303",
      "r304",
      "r306",
      "r309",
      "r314",
      "r316",
      "r426",
      "r584",
      "r585",
      "r586",
      "r587",
      "r721",
      "r853",
      "r884",
      "r886"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_SecurityDepositLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDepositLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Security Deposit Liability",
        "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77",
      "r156",
      "r166",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r205",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r268",
      "r269",
      "r413",
      "r414",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r706",
      "r709",
      "r710",
      "r717",
      "r752",
      "r1001",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r156",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r181",
      "r183",
      "r184",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r205",
      "r704",
      "r707",
      "r708",
      "r709",
      "r711",
      "r713",
      "r714"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r201",
      "r204",
      "r705",
      "r706",
      "r712"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of increase in future issuance reserved share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Share Authorization Increase, Percentage",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Automatic Share Authorization Increase, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions During Period, Exercise Price",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions During Period, Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseRecognizedInStatementsOfOperationsDetails",
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r337",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r372"
     ]
    },
    "bcax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares allowable under the plan (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options Additional Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares, Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price, Exercisable (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average fair value of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in usd per share)",
        "periodEndLabel": "Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares, Exercisable and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price, Exercisable and expected to vest (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of outstanding shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option shares issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r342",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average \u2013 Remaining Contractual Life (years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested stock options outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average \u2013 Remaining Contractual Life (years), Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average \u2013 Remaining Contractual Life (years), Exercisable and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.bicara.com/role/SegmentReportingScheduleSegmentProfitorLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77",
      "r91",
      "r156",
      "r166",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r205",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r268",
      "r269",
      "r413",
      "r414",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r706",
      "r709",
      "r710",
      "r717",
      "r752",
      "r1001",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r99",
      "r100",
      "r120",
      "r122",
      "r147",
      "r148",
      "r150",
      "r152",
      "r158",
      "r159",
      "r237",
      "r276",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r290",
      "r291",
      "r293",
      "r294",
      "r296",
      "r299",
      "r302",
      "r303",
      "r306",
      "r309",
      "r316",
      "r469",
      "r584",
      "r585",
      "r586",
      "r587",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r616",
      "r636",
      "r658",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r853",
      "r886",
      "r887",
      "r896"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r44",
      "r47",
      "r48",
      "r88",
      "r89",
      "r90",
      "r112",
      "r113",
      "r114",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r157",
      "r238",
      "r239",
      "r263",
      "r288",
      "r318",
      "r373",
      "r401",
      "r402",
      "r408",
      "r409",
      "r410",
      "r412",
      "r415",
      "r416",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r486",
      "r553",
      "r574",
      "r575",
      "r576",
      "r593",
      "r658"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r157",
      "r290",
      "r291",
      "r293",
      "r296",
      "r482",
      "r528",
      "r582",
      "r594",
      "r605",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r637",
      "r638",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r658",
      "r694",
      "r696",
      "r758",
      "r1033"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r157",
      "r206",
      "r290",
      "r291",
      "r293",
      "r296",
      "r482",
      "r528",
      "r582",
      "r594",
      "r605",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r637",
      "r638",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r658",
      "r694",
      "r696",
      "r758",
      "r1033"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r785",
      "r795",
      "r827"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, and accompanying pre-funded warrants, net of offering cost (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43",
      "r44",
      "r65",
      "r584",
      "r658",
      "r672"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.bicara.com/role/StockBasedCompensationScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43",
      "r44",
      "r65",
      "r348"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, and accompanying pre-funded warrants, net of issuance cost",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43",
      "r44",
      "r65",
      "r593",
      "r658",
      "r672",
      "r764"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r44",
      "r47",
      "r48",
      "r65"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47",
      "r48",
      "r60",
      "r618",
      "r634",
      "r659",
      "r660",
      "r749",
      "r765",
      "r884",
      "r887",
      "r888",
      "r921",
      "r984",
      "r1036"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.bicara.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholder's Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r301",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r318",
      "r426",
      "r438",
      "r661",
      "r663",
      "r676"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee [Line Items]",
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.bicara.com/role/DescriptionofBusinessOrganizationandLiquidityDetails",
      "http://www.bicara.com/role/StockholdersEquityDetails",
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcax_SyngeneAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "SyngeneAgreementsMember",
     "presentation": [
      "http://www.bicara.com/role/SignificantAgreementsRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syngene Agreements",
        "label": "Syngene Agreements [Member]",
        "documentation": "Syngene Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bicara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails",
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r287",
      "r314",
      "r426",
      "r437",
      "r461",
      "r468",
      "r471",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r538",
      "r554",
      "r738",
      "r739",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r750",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r917",
      "r918",
      "r919",
      "r920",
      "r973",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://www.bicara.com/role/FairValueMeasurementsDetails",
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleInvestmentsbyTypeofSecurityDetails",
      "http://www.bicara.com/role/MarketableSecuritiesScheduleofAvailableForSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury Bills",
        "label": "US Treasury Bill Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r160",
      "r162",
      "r163",
      "r164",
      "r533",
      "r535",
      "r701"
     ]
    },
    "bcax_VestingOfEarlyExerciseStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "VestingOfEarlyExerciseStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of early exercise stock options",
        "label": "Vesting of Early Exercise Stock Options",
        "documentation": "Vesting of Early Exercise Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "bcax_WarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicara.com/20260331",
     "localname": "WarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicara.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants, Policy [Policy Text Block]",
        "documentation": "Warrants, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r152"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.bicara.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r152"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-70/tableOfContent"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001628280-26-033429-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-26-033429-xbrl.zip
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M<>F0 DOKU$N1B2@K+SRF&F%-"I.=%SY(PE]+GCF>6"ASV7<C%Y><$'_5-\\
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M(T(^EMX\>\S[I^F/OA.?70UY-[RS*=X!?.=^HUY^-H)I$ULW\0YESW<#G+8
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MM"@6P.%,5AHEM7F+I,:&3:<EH2T3M/1/>!/?]H"*B.U5LI-2O8ZHR<SM?P_
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M._<>;"<0P)N;5MA8^#OQ/**/ H_ZOB<-K$*RQSV0"['^?W/"#6>!O'JI5].
M1?9J67%(;1-T/:Z.8>#^(."'D8A[%UC#G!!+N7ZC>H"7;BIWPR$6;A;0+CEM
ML .E*DBJ2S7Z"<6F-V=9%/5]EY($DS9*O9;:GF?1RN:CXCVRUOW(L><BOMC
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M]K&N3,P7QP_/B,NA@ !=S<2-,P(Z\L+)^5OJ1W40/AZZE,0"PK.1]0V'283
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M!.D"=B*UF64&>HHGM3_#9FR)W(-IC]#6\71P QB>+/,G^"@C3+< Q,92&H;
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M[PQ;&VLSHOS+"<(R<58S;&&B'A K2_>Q3.ZEVJM0"F88*_&"U4QWKAL+;YN
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M1_="R87OA_CBR4:%ZUZ76V[)_E;VOJT&GE;X[AM&O.^L01#%.J6&IPQ=9ZR
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M*":&[>Y M+>H3>.(#[JCKE8V6_G))G?4FSF@>MDQR5'>?+A[^'C"GA?[.UR
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M04=@O_LK;4JY6=F,;>"*Z*>]7]]VE#M3N==<"UD(7.8P>IEP1G.!EPFKQ59
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MTOU67#?A@#\9V#C+^639XD?X7!Y;;88#IQ,S%/D,UFP^4Z@7[?GG2=!B[W0
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MJEND:WAC"P\0/A,=<\>[ZVV PCH*;&:MXMN>;KBP)^!$+JZ)= -0XI\4WE;
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MP&)077TG,HLB 5T^[?$3F]NA39*AACX,KJP+HS#WDK1K]+09#+:-OAW&-[N
M?Z-31.")ZHB(@.\\1D>\V394,'T4L-=5##LXW/>,FCC?0>^7WIQ_*&(HT_/"
M38W;A[OCQ3;VQI%[%=20!RK?XS\G0Y:96)?-'54_=?2/ TF.1UW?(YAB 9/R
MAIF4.J?@L!]0U=;T3,CWCF:^Y7L=$)ST-?04""#]L_, QKUE<63_@ ZY&\>Q
M1"XF82*=ZL,-&31\SX1NC)-AX+\4V))RAWH4*T9\J9\R7",W[GAS!R,,Q$;H
M0P1TL5.&MMJ2L(K<*2;9\&2U8V1AXWOY\7,;?8$:YB0#"!K0,3I(D! D0/#\
M! U#!8I:XRJPPK0\DZ>1NZ>3NS<&X(").A0Q!\?U%CO"$BZ-L*^,2KXFO&7
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M&IE*T !5?VD9>E6Y<O6"QAM_>$D#CACS4"JFFYJ!QIJCE5)5Y4;=H"$:3C;
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MM?S_V?OVY[:-)/]_92J7W;*K*$6DWO9>JKQ.LNN[3;SG9"OU_>EJ" S%.8,
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MV"M;PYV2.SS$WTR^7U6X^SP,5,(]"89*XDTZL[FMZI*0^;EQ0-SWO7M$DY4
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MKG"=>@+'2_==&"WCG1*-2L9?FGEW933C ICS8@Q!T_#W90#CSHL@DK1Q]TW
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MJ6JG;9L9PH?\&VZ /G_9O<RB?9GPI?*>=%$O+*KCHJG@)]7+5_?@!W^NH)=
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MZ'_++VPXZKZBQT"AIM[^E=VK'A)2H$^_U?)XN$R9_G^G93C(' 3_8%P:_?%
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MX10S#0YDUJTT1CG9!<NTSR>8J&^'H^[-TKGP(8K\@(0[F8+F,L22WYYU4C,
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M*$IBG7\68':> *66BZ.ZDRZHJGX$D9KU@7N?A6?ZVQ1]*5LE356%:$OG.EN
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M9N3M$M3VAPYJ^WT[U!.@@L9F4A"L4F*)('!X9V +O\UE$P\X4^U>V\I+\MA
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M'8@DAMR]LL_AAD'49]/O_%>3Z,:MN/)E:8.[8[9"C*]6S79 I6VLE_GFGS
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M_N);4""'1V%R M]L-=7E9ED;>.K1&A+W@Q7.@&/1FW6R_AU-@%MT6-\6>>A
M]Z@H)O2@>+=\\T,X!>3G_VG$0"_3R/N7@=L&RJU9:W=-AE63XX5'4*AO<+(=
M[_C6;W/ G__V@_JUXZ(7__KUS4OUCW^\'5!5T7E]0;+P;F[3UE)B$!BA/H#/
M'/C7&F;9@M'?_CKHDWZ>$)<8;*7_^C;?=A1[::;LW;IXKGQFB7T";D-3=9_=
MPE(!B[IW9*]K/#<-3_O<A +0/LWN)UE38)[,U>HC^J/>AL%=@="JX>#LZ&0
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M(@LPR%":%8:?#*[, J4I0F.%;UJ)LH(?-NHF-R$*6"+(/,&:@J5'!.B,LXB
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M2 0KU"D+W3N([$][Z/*$)M8RELTJ\$.!E8(**: 2A:_/KXMQF)R0C!_'9J;
MI:7&B<Y&]L#U';U5<A1,) 8KC$=!1#85D/,TJNVX]DMH (<!3F,"I@#12E]-
M B-LF ! GIN.M;(C@<NY*D4PS9$6+/8306=2Y)0.E]!T(';4. 3:1D7 ="Q=
MU53ETL+'V)!/NZ:2,]8J*?V#U4QMA8)?,=R*1,<0V54;?D\)]+BVO=(/8+V-
MH(D(R$_TNZFIQX*EK%G T<=%VD8F3Z5OB*99UD07Y QA8V]!!&A 'P<&B1<
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MK4M./"+%'DT/M:!0HE4W#K&JDY_/4P2[+^&-FVXJ./.PD,?'C2P!"<YEY&4
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M7('I9MMVR<XQ)K= 0JN!K4XA011:'_]&4%YJPX"S*BF\A;W>8W^&$@EY7+:
M8T#F7A\U((Z"EK#V&"8?&^B#_32\/WK#:YF(_'.62SPOV:""VW=80B&,+8^T
MS4&+,557.BZUKCG\D50-Q4#V#87><&RJ_A)C$C_G&DSP>4-A1EPH3K1'WJ$^
MJS0!49H'VLO@(X@7)EDROT[\J;Z[!\/S0!E^*0+6HG]<IQ=S]'2$F-@_UU-F
M4%U<>*ND_!=/GUXH_ 6M5X/]&__E%]*ZW>G7?CW_K_/"XFYM"4]=4J:#@\5-
MK7FI9T[>2Y(^%Q%?N,]/Q"1'MN)E.$M?Z0(+3_[KXJ<G+U]%_&ET_4;"Q<F)
M;'PB2OJOF(&?W4]_S><./9C7[+ZD:H-VS'1D[O+8]'U\\-RU\<^_P8Z"&HC]
M$'[C/]@R!)H+CC(,,H!LM.&C<S&@8(/P.U6/B@QG'7,2B#=BDH2]:6F/%#Z;
ME'5<LE21<;46D&U<DG5D5Y>2-::L$ZPUSMI7LBJ,7?X:$@D]098,>2/ATI;^
MI!5%=2:D\O?@O<DN;[:,1(]]C==30JB;GCUH$$GH$25+>YM"[TF:;''IH]ML
M\:KJF74;PK6"$L1B86%Q2C=D[($7,&-$HX"C+>6TGL=6\U]1F<(_[H8<Q+*6
M/-C1D:!D'<$A8Z_25#Q@I]BN[,X!,04'\3KJUF5=^^!4'CW=INSN0E30]S3V
M]% ZZ: <3: @>WG8D>5;ZP+LO/^%,^!_WQ 8E!9/U:W/X$@YR 401WBJ@\_4
MP;\]U<&/U,')_B+:CFVHF _,CK4-ZVEP83O=<HDWR=H1?-#$!W#<',]G-1U5
MWF(ZX%JKV^NO&8L$U(/B-5N-M  *14P,%8=(=R7 42#S,W'U^. RXAZ*AR1@
M"S3I[^&J_NSY\W=_^?[;;Q9^O&NX[5?_^W\]^N[/WS_ZV_E?];.??GCY-;SA
M7_Y/ FT"V\YBB_5V(906- ^4WF'K,SG>^2(>>;!K&"K-II]:*:1S#"SFD#(N
M4AVJF$2S;M>LDE"#70M]S)#;[B?86B1A^Y<?$^:TW+EU$%^5'-4..EN".,&Z
MW*$@8N#J1D\W/^CGBU_:YBQ"*RG&,SC-PT1RF>D=410 Q)UX+>1,LL5UWHZ5
M*H>3TYO/TD%^.9TVO\&I8SQE=ON"%VT)*/<C3J%?;RL020?BJ*K?]90XQN)P
MF/VH^-,'1X!25.K_$B9S,W%K#3X.XRK,#*_=%1(%,T.?\2Q#!3EDUC%@8V5(
MRF-<Q>ESO(QDW-7"'<Y10B?!.--]M*4/MFZ++JBV@)'J+K/@4Q)">*8B=C/(
MT:-O$K>$(2[5 @%)^B+.J.VQ2KF2;;OVCGF%;4EMZ%,KK.,94,G9='^ ^JE5
M!>=.L+=2QTK*6PS];=A8$]NH?TR-X^!7&!"$O?M%*869:"B*P=+8"\ :WW[S
MZ._>-D/J=-!O:N8K/1B)O%H,(6H]A\X5HOX=@=E86,C]#,)HA!Z:I[_><&TZ
MM70J#3 '2R?K=D^(&O^??KE"Y"PDS,(KYPB"$G*#.6]"Q^19LWCB5K3U*;DW
MS-Q?[QWNB*3\@^,QOO+ONN:(0:\_?4PXV/KJW>+@2O]PT&Y=VT?X\Z-"29')
MC2G#Q CC'I=V4)>\I**EQAMF2 F9T4O("VVI#=LRV.O^@9E4!F)@G:%0!H?)
MJ,#1J;W/U$^7!PY)*/;0 OOJ5P;M4"[T:UYF,+3LJ3WY%=$2S>(_Q\8M'OV#
MTJKGBW]6+.ZKB8LXM!=#VL^F@:UKB+^+'$< <!"H1X5 >))Z$\31C%&VC >2
M%B4]B&9M<4%BL-CM'!<UYYY+3PQY*/%=&6:YZ:"=S ^R]/W*2F9[?L4TXS"L
MMD;*XV[/H3!<R O-Q40D%*(V/X1W46V&0 P.>SPMO[""5/TA4/LULF4KK6C0
M]S6I'Q?]&&J",PZ%>@5ATN,D@6M$^N](<))HV65"$DLJKL;G-?TIT]#$[NRS
MAJK72!VM3;H=RH7NVV;.4(7=*9HWLI\CI-FJ!GI3\N2]Y?4^!.J6S%M-."#,
M*[+W0ATX^(/.9 HBG&X:L'T%:XG:5Z(>)GCMK\U>X\ZCY%O'7OGHFX*B'^S9
M_2@/!K$?P(=U;M6I)-/SC# PO"_0NKV1KUZL_:&W'G=_NI *@QR+M&CZV>W_
M&#VK?I+<C*0O=T#QQ2VZPM-O]B@WQR$5@7'N6D1?U^1W2?\='ZF_LGEX?<ZQ
M"Y]G, CY4XI-"T&:R'>@9/6/ JI6DVX^D4$8L%2%C!&41D:#[Q?OHT=H\/_,
MIXO^5%!O?3CS8EAMWKHB;X4;KH%#?0@O"I:*"S>:E;7UQZJW':&XMDIFJ0T]
M?D]_M7H\0^80D%'4X\_X5U]=\+!^;=+</;Y[(7$IOP#,;I2>_O6_SL*X_]!5
M/M;F@YI'V$?4%1B-%ZNA!<_AT;<TJJ@]<1TI8+9A@<=#F#V6\+9L7CAEO(GG
MF"=.IZO48Z8DA2L)R(*Z#4?84?5W579=1>8!QAM,..T),G\_M]=.A[UNF^T9
M.$43+RLL'SI+>].S@/N#-GU9 R7N@:CV]5A3)7HU*M#5^2GWIAV'NM5UL##:
M^V%.H*B#"ET!D]WG"#<6OL2&,*E$D%4R)%NV-UWE%/LD+V_,FO5=8QK]CO/F
M@2Z*?"'.5Z<,!]R)O\9,E&9N\AW")+\U8/ 1>0WX6M$03/OE=NT:JB?(&YYD
MCC1:7EAJU6(Q>H\?SMH,KR.24G.M<:*O0E2/C U#S:+J2B[>M?^BGLJ+]^K+
M0X:/ )'ERK'T9) F&((H<KTB4=EG'@Z9MD-3<F_:[QR5*W$X'2GA(N>PY ;@
M/:*N7: 66D5B"9&&@LT'>8> X4&VNR1<&KPRMB!)(9:[A_!-Q"V9Z6 L0NV^
M &D<1!57S;]&_3!DDENH^*ZW3(UQ$;!:)+E""_SW)1UO:L[]7'ISC]N_"!H*
M _S+L]>+;Q=/$**/8J!^*O"S MOD'.0:I9@0 T#(PH0N/B4Y4+X/N$[XNWH4
M?C54.]XMG+8LJ5RG<7Q\)_XEY$<@%*5'7A*7/E)-^OTQ[LCL88DB8@0QD:WV
M<>BSX.[7&C<ONN3-D 2 TAQ]XH7Z1U2<%['/]XSU[;G<>T97-GTH"5U)!"(U
M$HG<"TWL-&O.[1!$CU*/D5P5#,&J:HS $3F],#R45]+"$[5C1(E8P%<'%JPX
MC50VX2WLHQ]A\OOVSX\VW]XCCZ _*?X0'L'_X__N)]$J[Q7%($MK4+P$T]R]
MMGG .J=@Q4R E*11=\ O@ %0[+!0L"K/C"E40S=',]LO\DAGJE BUB?R42VR
M+/OWH]6R*__5"L37K@],':#*JHEFL%X>Z@@6-V.=&]ZM*-+:Q_05$:P[*4"<
M3RL2E^6:LX7J\O\-7?Z_J(>/_AG=$9\T]W@0>3 JF+(+FA[#P\5;9@ IL]HM
MB4%H^D,J5ZA!!MY1D3&,)GU4@T58E7MG+ [$72I2Z8W,EJLR47[)ST?+8&54
M+YYRGO#"D\2..&7&.!G$(.-N@RL5YUU.H(894,.?3Z"&&4NH2,K%KWCNTZ8+
M,?>TUE6N(:&/3'FP_Q,P *QU\ $@AE8%2D8(/ H( >^=?(M @-#-/XQ= W;L
M<\)TWI%@9:;/4>%=&407P_#W0*P"T.X(-<;%G-'E!'&UY3$GS?B@O5\3V[*:
ML(N$X8E:BM)2U >EY!(Z3M/>GSA%-V [O3\+.C=H>Z<=?R3:/;MLKWT<W- C
M>.,O'\HOIC>.&WE-*OSW/V;QH1_0KK]D^4 K/"#*L09'D+W)/, 1N71UY:XH
MB;+$=2B\\;@P;7;LUB...T2%?D@JD ")"ZED\4_P^-4_SFPAY.B"QJ<IZA*+
MCD0&YW<PZ2?#$49>27HM ]'76KXA1XPX$$-&)V(_".2($(Y\97H,7KWHOXZ:
MI[5T@L1V351(J[I<U\_82R^2>5)Q.(AR#?U#,^1V,7"H$DJ. 03[5?\U*=OZ
M&23Z,CX*PE<X7[-63*_AG8N_J4DD^PK("0WA)[\)+*:W;C_$CROU&&FVYW*]
M29\PX7(R4W$R#B=<R)\UW\5M?<+LB,/5'- [:\B]QI8+S%%-!FC*M0<ZOJ2R
M8%D)H%,7<KJX5U P#5LCN/?/^Y0'LV.XD 8OS,"S(9U=V!(PIU6W&G=05%+,
MBT$P"Z%,NU-QA\F%Y$8)"5;5*7UWH-NL#\1>%WT$2P^(WP1K0ZG64'+"?YO!
M),<#@Q40\@K8BV@RN:&5R/90-L@028[$MA!S;L"HQJ:F/7Z"1N,0^ 6%1;'0
MH9&EX<,^R/ "EYT]DT+IM*9VW^R3",5G?@^FX025>HZ8&6M-Y.H]#HSAB?!_
M4-,*K,R\?JUP*ZVMBO<@B?HB\-V'P^PEEAWT-4L!2Q!=B*B*KU5J!865BJDM
M@WMW90%D7Q63&+JG_(J5TBI'N5* @O5BK@X+$5N%1TJLX$;B[0;M3IKI"L)1
M) K7(@X5+T2,[&7#C]AV+"@UO7#8F,[%].C\9#N^5:FJBU*URS\H5[?P[_+R
MQ!)M1A:G,??-4$:G;>3/W-=4YK#/(D\RQUD=V%.1,Z2$XIN2]UO&:L@_W+3C
MF*C7QQA5IWWY(H89H4KA<8R2^(0J[X[RY%\.'O4I@FNP*@5E@HJ71;)BE F6
M&)^9\J 2TO,[N&15'^C\"RK_Q%S^W@?M(+F)(@/,\T  (*% H*;%.8^* 8";
M(75[Z?7(!EVA\ !L EOOH.Z@\.^46J$B#Z0?G/>4@,RUB7S*Z?I%_Q,># R6
M(&YTV^,!6OEW!P>UHDP?G_O"@!H;1#"GNZI'F(L_AK@$1;DJO:M)52G&1\#G
MNFNQ)5Y\C3L>BK-!RF=909DR+7#_?<"!UB@^@8E@'#%R?W/+@3*V>0]"@*L1
MJ0E"7 BO8Z\#P.,U'&A1#P>O&7:0 DQ5'N[ !IU<5B;#!R^%B-@V2!0Q"<UB
MC"DL_Q+KQIN$BS>TO^$#9(+MWMZ<3#L1G\%;,O]T=M!FK8DDHS2];MU7&M%V
M > V[^0X<I0!>+ANB76:>!AU/Z+?#GB@-254"#5%26.U7QCI\HZAU4!5:GU[
M?G%V*G#@=5#TN;\0N08PWCRQ4)C"JIF ,&*X@P J2L0P,2\\^#C O;^B,N7%
MLT((Q$P9-VX1[_=,"*T5XY #I^WG>@IG2=$.<%,!\HE''_!#Y=@U0HSMO5YP
M/C D,WV4S.^/%^8B_YQ_7LQF4KA+*T.:"']!,AU^V]!@8&0;IKT#6"45^J '
MGK#C-)>0( ;1H8MG"U5B,G/OE_NE+HGK)BJ2<HL*%::T0=5?B PM:26!/;.8
M[LA[#7[MT"+QP:^2A8 \D*7/ U.&I:BH,%1$V)!B\>Q-,1<(A!)20=7HPJ*2
M(A'X(I[C=.%E5S3UA3%DPJQI?R 8^IR"+V'@3*3#  ^_K(";9V9[+N"&(]2C
MN<@-1P[1.]#:A94(YP2$F1C%>S<F6MQ(U._-P*J$' %)2T&-;!C*U=LHP;5K
MUYALJ?P68<%N&F;YY&N4"KURWE>EOBC\<^W*M^46NZ3 *:IQ?EQS576M &K@
M(2WO('U J')0$%+E6;/,F!P5CWTEYJ!U9@T<^;%L"N6TLM\A6KHMQ#48'B-:
M*Q?CI:+R8(S81^/1"-QA2(G6XE!OI^9HDL[(W4ZVX?0O?OJ0TH%& 3@-#P0)
MX3:.1&*,./EIH("TW\@ZW11_$V!_'=#B$)'2(2]#3?OSLW1 )UH85+6&W$E@
M$S+(,,*@C7OO\P10HT#7[-[VXR:&UGF3MHHX\B.)DD7$:[<<N[5KE/[.DDD5
M$PMLBLX8;508%)491J*GOX+^2IF@"> O%\'H/+-&!UGF&([M7X;^Z;?5N 6F
M:\)<_Z40"(3%JT% I>"?\MJ;G4NW'FL:EX![8)!9I=?T%_P.XZM0T&?^PB)Z
MBC".D![9@1^.9[>]KVD,>U)MP:5:O-@UU7(DM"CUC)MG3O [1CT!T4&8UJ,N
MAL"$X)^G/X!B!YLU/VQ^6V*'\0D", ,!^,L) C / 9A;<F&AL=> %7V(*/VV
M1NN"!AT@3?O:IHE3>S%JH0> UW1).CP5L1>!H$35LFU"JST2N>Y!I#, /:%3
M]]+O;+ ID48!;$[.V%-1*.ZH+QMM1ID 7A^X,QVQX;-U,E EX_M(:XBPFAI4
MTHLKQGCN2V__H(.SB)@FR_45#-1::D6F@8LY'('7Y=^.F L"!RGK;?I'HI-+
MP?B=H4<R'(;-U+^*2<%[-\"! 6ABPD (&1@3W,)';[IQMU]<&%P*=]F2:!RV
MNLK/=E1H!9PIET^3-D1"BOOG2)F7);8H0Y,K-P#]M0"^R=5(C?' PF X]9Y*
M_TBY^$4.[I=43?XQ4LZ8.0Z5VNEUN]B4G92D1$P59XL2]DA H*D;B ]&F.TZ
M4&0&>HRP9BHB[F^8W)'PJR4?\"MT*NS&VI?#ZM+V1_%IR*AS0KCRW8S @72C
M$,*%YCRR+B*&:?DWAR")UB8">R%(MFV0&/()_"AP\4M#L<8'A 'TMVM6K--V
MB6S6"J/DJ'Q-5$1MX$>E!HA!NX_):<+-87B#V3(68C'97Y:K1OBI2$WRL_1T
MH>!NA3KAD!@[='/;;M]*(@"=?7+0!M5#P38VV/]6?$V.*SU0]->2!]\Y-P1^
M6%@\J4Z,L9@HIK;VH]-%Q.EAYZ?]C;/:58;D?5FBD"&"RCOBE/?/CF@W/ QC
MQM!V?PG/2MMMYY=/NTYLCT:9D"U#&(JHG29JG52MU6S<I>.J"5;3JIZO,J??
M,0/]F T7DT8C\YQ;Y,G#)>ZG!Z/[7G(Z2LG><G,+$W2)-4#)86KGQOPB9@L@
M^@<.>S0&/$9H. F_5G839AO.]HT!U:$RHA>V197B <E=<SM/VLL3,^^ #A]<
M $!,S-<?1=9V4*%IEYMK6#3&="CE-6O(3@@L+Y.U_.2#XCP \A4FJEZ%8!:[
M4:7.@</R)&Z82%&-?CW\2!7\ERP&^KA4,= O%UGZ(LIXBW^-8SA1C6??;S*T
M>)X+%_9$:%7<HXF&**,?#)NTB+<FG--6H!6MUNZ!>^(OXG%CBQ=&)Z$U0\^G
MY3HMGB6(^$>-4B)38<TQ)%3!LC3CO.!K-&/@&E]5A!;%HEUP^-*0"XM98TR#
M$0V]'6]-I&?VDY%ZSLP[NG-X9^L1-LCAAJ]&B#M!V$RN4$R1I=+_#)4_64WF
M[?PIFUF9MWW*V38+$'65NT%A,G/GPG;W&+W<(OHQX5:LZ+*E7LOL@TAZF'2?
M3;8ZZ=Q<NYW_7XER0,5;6G$:)NSV[LDJ4(]7NR5 #VA91#QV 9^02$2/6C?&
M0DSZ;KF121:43 $>@,NQJM=,Q5K:+]G>*DYO!K5.RY,-?S)1>AA"B8*X^=W/
MLFY"6 ^R 9E7FI=%7]8?B4?KXZ>Y(*,23U88;K85N5U^BPUD;!#JX9&IVHC
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MUPLVO1Z(\@3L+<%?E>3$0IB8X6CB&\%O3O-V#_&ET@AA;]B&:1CFFIBQXY=
M8D#*\WDV-!"'HD*?=JQW%*0YN/S K=D@+%4PN-R"P3?$\W=9Z5>)#  O&A(L
M$?1M[?W  _%M00.%*9\QS#8#]F2I= NNS: \9V$'4@F'QP\]Z,=(N9"/)H]*
MR@!88DPAI^O7+<O< 9D>G<._ YDJF$]D9\P-T;EW&8C6+SM^2/>O?'_7HLA[
MYSF*TJ7QC+0&(WL7.&LLY7%\5@*],(RL$ PK8C(BK&+](\.G ?[,>R"$(YI*
M:)OFVTJL%9.Q&!(0N.[J$LAC*< :?@?7R><"XW^<@]Y2MP_*5]6H,G 0'8M$
M1Y>H4U54JAT')/-7&N*J 21Z5IS-+'5>WI72LLCI8!<TMUTM+9.U$FC=9(UN
M7/\/O"_@36OX6"FBZ*LA:W@$#VA&@T^3N5P2[";@+ @X\+!-D2J3I_QV=E8)
M1#-&!MMORXW?P7O1V*0B ;;H0L,D79.U?#;E5=O-PF_.%X^36\/EPQK%AP-3
M#\$1GJ@D*VO@DDKY  V>H!V9KN3SQ8^L#057HKX*9NE%0D++/1P]C.X0Z1/C
ME9=\2R@EC34+%EUW47:KR"DHA"U3 ,/<C(E"%FTH<YUY/ 0^BA\"?D89)7CO
MMB$5)IQ,QD7D[MQ.GS&'663;3P'4#>#QI=M6V'L\H/(R:=A2%T;GU@Y.T((Q
M> N5188.P!%[K:$UFT0(>KD(6YB@[P' =*;\H*0K<Y+^9HC@S/3X*SO4'A_!
MRW7(O8)=,TI3G9LK0[V$\\N31]1Q,:1)/(Y,S\?$")J$P-Q)KQC[__C@)^ I
M0GI_R (9!6XQN=56,@:$25&1.6"SB"Y6H[1/!LB233*?LA;W4SR_ <HF\/X<
MXJ18//,G=#6,;*9?N:O*/^</+368 TS\U0_T'Y;7DUB;T#Q4P^ ,O:O2N#)Q
M-?52"PR][8(W@;0;Z?E%=)L$IDO_AMS (IL'JY$^!K_EM++^D)4U@XB<*G=R
M3X+Q!XB4@'/E07%V:-]5*V*ETXPYK#V20Y65;/+?;8,T[]Q=MP<..&1CX1NS
M:S)=::<5<P^(VR/>);(*8!$"?#3O Y/S42)9M("I$2P=RII$W(X>=7[;QTJ:
M\#?0("E$WIF)WX5#P6"VP?F.):-"7-*X;8ON+)=FD+ [)J4K?5RS17D7A]D0
MN"N#)/313@OL'@HDMW0TB#B3%UD/W,E2(=\39R[XPQ GKJC*!E^GB^#TE\R2
MA/0OC:B;L.-C6\AMJI38FXO(+/:TR,42%C-8\09N<K-+!O(R1VZ-O A+/P1$
MT9>,B,W&B*#::8G>SZD9PD%!T83N@\V,KPW\5$ ]"T4^_Q*0!-5& %Q4EKE?
MA:4.9%I7W5@-$C-3?,KH+;H[*I!U<KF(M$ H,$)SM"5Z%MYU2OJL0>22Z?B)
MF"UM0BHD1GP'M>A#- 2P]F.'#NVD#ZC]JJHX(EWY[0GI81RG:1:$KA\_Q31/
M,K2KEK_*1,JJWB 8)Z,..@"+#QT+<E-5"EU7/9*/"NH>B9#]_C+RX-/;X]XB
MM@P_"GY6)[T"Z3APTN"T'^^C.F@Z)MD1F-E_?=U>9_<?'A>R?T1I:MVAT,(0
M_(N,O;;G4.>04@RU#@ ;HNN.H5=GXYY"'":'X[1I^C"G17(_^!_UX8R@/=?O
MK4*5G5$K-&9"H3@^Z8CIC?CBY$I0DK:LNJ3S5)E60>H++()LD3HJ_B3'B(9A
M!K,&$ FOXT4J1C2X$9&TWC62S6#G>,Y2DT=D0OG34KR_&*JFN"3Q)PM,Q\!G
M^0Q,.IVY! Q U'HB22%E/*#*-ZM(M=_ASR&O[L.@"A+1)*P5>0S@OR;HN2/;
MH03V":9A*8?8L!(R 1%005AB;$Q,2%@<XJ(_K;][@)$?*^W%")$&*B)43HOZ
M<4SUP:BC&/2!AE@@O^57AR/)QYB?)T(E(- WS^J$^V,6-7%:(O<3X@C]?L)(
M9B/9P?4:DQRK[\Y#TMDOVR+-9LXQ.R'4YQ#JWYT0ZI_5GKN6G!8HWHS=FIGL
M_5>]B24]*,YE<A,D"OUVC=)6 R N*VQ<BE,(5IT3YWFWX79N"&;[,_Z%<FTB
M9RTRH@1)5O1EK?&(LB1L2.!8HI ;_ R#AJ9W[$JX$K\^/)KTONA0E$MTA4\M
M:1_QH""FQD*(S7%-0(3#6+H-E @J9,[U_RW80/(XC^,EM; 9?A1XRDR>=2;8
MC\0O,; 1- ?BM.?16QF#?UHAO].LB0KQRI_P6\*9)'R?U6#1700?A:\]?O[B
M2)^IQ,@D\,ST_8+UDX1_2+T'4M$LJ*;E*RE-VJK<ERMIM3/>ZMYU0*YM.082
MLE42EC1XFI2^2S4$Y6D(:=$/T'LPP5(]0-3H36)[#$]N4'S =5HIW$SK_E4O
M)XJ+SQ3D\AE[D0"#X:1S:<,1A"(;\+"DK ?6G V^C\)-MA: G9X>:3Q53Z!D
M#5/]FLZ8YVT#2'CX.>(E5!'JR>OG/Q24 -:;F6?,%=4IN9P0X I1S--?*9G]
M'' X8#CQ*7X.72DOI4OK58B +K9:WL+?_OSJHK@)#2*RVTDMGZOO5*WGN>BY
MA4PF _ZY'JD(90H@&?+5#0,@C8W.9+$JK 2WW?I6.864?@T38'A7J@S3[LK<
M)@9SAV37[Y\K/]XW#3>'Q]2L0DMVI]+B;;03+MO:KR\# HRY+E1B( [%"SO8
M%HU;2G,X64AR_,H<,IY,,KY>$'HKK; ;WSU2#"$5%_Q+#;H(\#("EMR,G/TQ
M /OIS)POGI<J@"#+2%121?B0]9&@J9)PCL*LQ/@B21 <Y4@,N$M#]"[*2\1+
MT51$O)4#2<[E2D@ZZG= LZC,&T[$:,VCJ(0\ RDI;RA&=EPC[!#)!7WB@GMO
M&']*[P0)F;FSSHB$_$Y\&66LJQZQ%X&&)=F%_#0";8Y5M%0;!Y?J]$FMFA_W
MCK!=";U\NC($-3TMPK,6DC<(S5E=+ETMHD:3.UXTM_TR'%UMX]\;17J0J=S6
M30D['6(L%&E>"&^=_6;5<Y(K9,=B9M=IP1^&I<(+^:-==6:T_KGN1D1K[_W^
M=,O6;S?(Z R'O0BRAG>;>D(.DC\-NV W/PIF@-J=&]!]P!7A@\06"AL!0[.&
M(P85L_P0OYB_.4+^ VY'TM+8_"S5%.R)1B12N=T&KG4*&)WW"%8BL(C*B%R@
MEC)@N'@I$RWS %*T,M4TJ?IK?Y!0%I(J/?UAM_<^%[J-N!^K'8^\=PG!PO!A
M2=\NKT'IB2.B,-,X<P"F8J.K)4.8KLZU*+V@3]!CT8 Q!J[LZBE?<^N-1,-G
M,?O9,.U(LD3=5:X3E;WD/11\@"I>2](+:N6U /L)NQO%B6210B')/'*L9S\_
MPYEYT!T7;9?I;)"#3JQ[05\ #*$\T_[RX%T7D,;%- /W%^6] UIL.#>A>5*'
MFZTL3OHZO*>Q.&S%>)<$J2(MQI&X[+9KQSVHOCEM4#F@'B^KEH)5J-UZZQ)C
M)^K3W"_Q\A*0"H_^]&@I&9T6!Y"Q2WO(M5-1N01Q%7+<W)H/_U=/'S][_6;Q
MZ/Q1P&" 8BH.96#-%.?, GJO+UL5')6Q"M_5@=&5N@ A*5:UHK/##HZI'K"H
M$)=.+]MJQ5DOB--D0KNQEL1RVT"' SD>&_-&=!3O1Z1N!;$X>#_"D!BGJ"=V
M%=#W17OD6'@6$39V^/Q2:V*[K:,4?9&6#]"7;2H:00NA[LIU14!76J#S?<@/
M-(A[29J:D^4P%S^CMJ_KKG#]]9AX(;VZ]575PP\)^PT><<EXH5$B>.BD 6-9
ML8@=U3K)WJ[*_C(L)73.FY[6$G8U-0U' .A]8! #CP&+"?M-";Q!M0%_^\MJ
M'WCM1;,XNFHH:HG-)^)6*NN#0%E=80O0AFR 'QNJX^=\)$I/@CGF<PN]%*7G
MMX\53##IJ;NU<D+'WI*I],L7ML*AA\X?>%/24PM*YP25"NR4F>J_[/#_&6&J
MVX8=2_BA/T]K<_74!1K\N;21G__+M7L?*OMEMHZ%T&+M,NU:ZMR_XO@M<L&%
MNA[\/H*8DVP:3G+F&G0K[83BK(,NL[0[]*[MW ^\YY-ZJ[/H; Z:.$@JDL"^
MD!I=&CS/MX!J%*9:.QB('R.YY0X\[ KGU97TJLVJ5S&]JA7,.W(#?&VW3AP2
M^/6MFR'Q4BI-3LP(/;+_U-Z#7X,L9,IHB"9%(C9IYCR2NH3OA]V2#H5VT$2*
M0?@C'249G?/%:U-\GX1>^,JT,S *+@&,EK(]D#(@@DHEUS2TO!F-M)'WZR'K
MY2W;@#KM!S"1%:@@<NU)5<;0CL$8"6.@(VJ.:;/Q7'BM&YW[(:_59ZBZ=+AN
M8#68&7ZRMPE' ?N4U 0'JUDS2'?:_E$]X%M.AS]L(H"CQB52J\2^Y@YA'73L
M1]T3DR$MS($'D7FEO1=J-Y+-NGMXN:&<A-V\L<-C*3[Q;D%^ZN>SW2.9 89W
M\R[CEPY_^-N#A#]\,AP>OW$:C<A>T&1*0JTXGE$K[M*3/]^-[^-RS&,/JCDH
MSN:=.?!#9RJ""$TJT52"/KG@Z\N;H<615YZ\DI&KQ&>1K#7\-_O JR&N0)AJ
ME%P#%: IJUDGHTDIA9AS=S9)':J+DV&C@9ZJ:'Y0E9)#)J4FC!MZWFJ_@I @
MX;M1>(@,%?X ]J$V^-&8:@MO*W?.)<]4L B<, G^X06695_1TKM);536%/K<
MY-S"=.""H6RV#5_I(&_,/: *R4^(SUS6D)(?FQJ<N:^JKT-(C-F^$ 7S$8_3
M%%J<< WA9T**O =$?P7,]5]5?#D)$QSU)$-VBS) .D9QSH2ROJWWDOXMV8:!
M&N3!"1J[?@37'4*@MEW;2J?<V8_C3X]?%HN)1+=_)'XF&$/(Z/&K^7&F[+R^
MOE#T #%-<X9!OZV?2H8%!WW?80\"4)^!*ZYE%*@<\,T@,_OH;]_W4XJ:4,>R
M=6&#Q\%^L] [9E6N&$[J_X%B]'X,H&D'S1YR#BWAH0:N'MY@=S &D1ZM+,UK
MXG:B/9*+YNL122:E;N$944%=W%7^>:29J^EK9R^K9@.M#7,&+2'7#AG'L4/#
MHTFC&TP%QN^W-!>XU2;6>-:8\9N)/4N&P+ZH)-P^Y,,J#Q\_,"5__%/[Q35P
M5!C[V@@WP@IJ*/\)/-'FI):$<V;A+D@^GF&"<J>GK&VDD3O<^2B59@UN[D%T
M&Z%2.%-!R.K!%H9DL6X2DA[->QZ=A ?H[=S10WV)$4KHRI[GML&66(B6SK+@
MJ7FB&YXPO@%8@@JU1_;IK:O&$J(=N;ZT@<9$.L+:2'4%4V3I+6T4%$DB$-@G
MZKB^N70V>Y*;L=D9&>+?3@KS+]]C^LM.9+M LIZ ".2NH&L E6[A#L#3':Y[
M6.PAAU&NVK?^_09 B^$YS1^N#XT?-/Z0SE_HE>FP-HHO$<O7;++YIT%+VU 9
MYW./F</ZX&V;\8!%^%XK/;D.KC*Z1D%-Z6?]"I@U Z(Z'?GHE*QXHXB8][3=
M_*Z;(L7LZ;ZX\6"T&Y.I2]L9[CS.ZII$3T2>AXE-%N,3U9I\0]+F.#^B/#/X
M8MCKJR MS-INL&USW-*,+T.M6A.OF#QV7&4GEVV*43$8/#Q(&X-1XX6*0(BR
MEOL,;G794$72S\D(3/'J(Q$P():X[]VP+%=OX_FU V%@2<22RNGC';+16_,)
MJ[8*VHB%UM^X6A=N%%E8>S,ZL9GG4=&S HICM >3]4>I7,[?A@=ZX%4<80'.
MG371WBBB?1T10JJC?924^4AUXIS L+I+)Z=OU.@%0<H5N=Q3],Y!N+I##3/B
M6$$?J&!Q \-CF*5(CNQ08M;H3=[_N%&LB%"+WH!%N[,?2&\;0)H!&^7-_@YN
M5%A[8(\<8R. YISW>J#>N$2&:H? *_0C4(0+QL[PS2AH!4 76"RGUS3W[ _]
MX'9X<8-%];^%YP C"0G4<\$C)P+&QGO)G=]3TA[L+W5'WU+;1%*E>L;'1B(X
M,IG^NGN(;KVU8).T[0B_(?;T.--IALU4=B4#$"7(#O1C0:E[<N[<[T:-ML24
MH<M<+I"":\6\3]E@L/"2 74;F+"YXK[UWOS!]IU1.7#V<+0F/2WE2Y%2NH?K
M@P"$;JPE%?F"75IB^G))NY_!MJ]V/" .C&U3=H<XNIIEFL6>W*8=,0_:"= J
M ]TQB&:_KA#Q)BD>3#,L'5A8(>VI664C/C)*O^"&0M)72M*&*"M._Z&#Y!>=
MF^E%5_? K%J!W1 SX2<75OV8CK7N=9F-BJ>8,R.Z<^7SH=V?P77#5NGNM!3
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M0VGW[F*;4-X%[]H>8-&4\%ZL;+U"CBN3IH%B/F"+Q@;.(\Y&M+7K*'OQ,;I
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M@^;0D!;=JYQB>H1K[6Z^O)=%<'R4%L%/ACHNJ@=2%:@?2B':2^ML3&B&Q16
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M#R<D!0,".:'CW*?*PK'/FD/A(</NAF-'%KL?^B>NI[$6!<U9^%")8ZK]1%
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MR:4^OBKHY\& _ LVX9NOOW_S(CH<Y.5NML--HS5T0@!HRY2"7:C9D45G>H1
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M C]!3:>=@NI(9D>U*O:[)\/ZR7984H1$UJ$ ^\R, ^H=%U-C:89W783GE?
MQWI_R/5&,&$2;V>'@_3S$9EBW36J.!=U>-8*HF'='NXD/T_; ]#=S[HYNU:-
M/W/GGD?]8<SFCC@>+EV:J*5F?T<WGI@_YTX)S*-E1,,173P##5X+VOL\C0\S
MC44W6%('R_TX"OV19!'"@X:I&T;*P!I/+8.WV<%2%"SW+U^2BWL6^GB0R=OW
MZ_IZ8+HV8R:5 (00]X,O8C_]6!4[7KU#VMU!@]'E$!$ PEI)8!!UO#J"6>!
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M([BNQ&-;.6X&R91NAXF1'%?U?^IQ18^J"X2O=E.'PV!B-C,'IU;0GLLGQ"O
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MH?1E+QJTHM.KKL34Z:XL>:$,=VJ65SV5I*"W3@SEG73T:(B@"$^/>U4L,#.
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M\^Z%2]_7IU>N=K<I(Y>K,=6"PW<*G6Z]/L/D.2%C97,0S4PCJEM,7N,BTP7
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MC_V(LU-68?NC>,>+^N,X_5+HRE#2NY26'EP:<D^9H">>@_.I*Y]F*DS*V81
M%&7X/;1-S^EE3K\6E5[$>9;*,])I$AKV AYIB 6,9"LHY&5%+W2_UR(C[.;
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M4 @S\J=-#(4<)",ZL(+('T"9X?<<!K])9E01;58:4GX, 9](YJF+H+&:HJ%
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M=-"E$XH;",4U$8)N":]?0BR7Z=;I^G7ZO0:@H.L^W+XFHMBF%=X96DI?+QR
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MK.;.:KX5JWGO?JQFK&X>'-Z1U3S<O=YJUEO3*A1/47%=HZ#VKS>I079>?[B
M,?]]J1KF]+5V4?L+?",:OB0QY_>&(]"UG(5P5S5,YV!C,ZF3CQ^0CQL;U@<_
M8%BW"%"[8?WB;@SK3F+NUNKNUO<63/)N$6_'7F]1-JOL]<.MUTA^SMKFL#/7
M?TP0.UM^?5O^X)YL^:.MU\/=_=NPY9\3^M?\O8;R[HI#37'HBX=3' J;Y!4N
M&U3YSJ##C'>8\0>'&5\K// 43:%K3)X7UT< ]G:W7O\6YF'P4<5%VN*&7^?#
MM;_##P+L#700X#>B])< 0(\*K9.8""+<H,")]($C!L9<E6&^[)(H=RP>-PT
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M+<'Y,'.91[NK<YG/QUFTA/^9E?/D]?\ 4$L#!!0    ( '2 JUP,"B6UQPT
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M+(9O'Y+UG'W*[@-L7M>Z+BL]1W#.S./7/X\'>66$T!J31S(CJ7$:?C@7_S6
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ME&E)K-2!.&E=C#[$9-A2/%_AIOUY36%]HS^B=E<*1S["I?,S:5J!VO?^G>)
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M__YQ.?WENZ^;237[RZ_H3_#77_S,5FXR^_J77__^Y1V0O_[O__BW?_OW_P'
M_WGUZ?TO;RJ[N/2S^2^O:Z_GWOWRQV1^\<O\PO_RSZK^??)=_W(^U?-0U9<
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M^-(T37K5G9:FVOCI\MU_+1KP5>MO__H\CRM06HPB5G\:7S;_NE],"-5 *&1
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M+3&YEXM#"CB-PHQ,XB\0I3R/&O5QJ;H>>6<&C(?18"(IZD804YYHBK+G('7
MV$?L,8^6VCDE@T1<(A<MSE35K!\/X1 8*"3@R8?1CA,=<GL-ZQB.1M^#A%O
M!CQQ;BE(/3W7$W<Z>ZV_3>9ZVIK0;-KB$AQX2[R7@7IBLV\N=4,Y&M7G$'6)
M3"%K%Y>+97[[<K<S,O1;[2]2?<UW?SJSU:5_7S7-1S\_"U_TCY8A*U)4P_LH
M!T0=0H)+F3T)^7$0CX<Q!553P([\Y.=16-Z]U?4L&K?-"OPW40EVTI*&4 A(
M0CPP#G&/C%'$H^SE*-M0'0U?,BN@@$79'G@K2DH%T'Z90:.A4<I8QO)7\J^C
M.!H*#!1P6^6\=*I#"Y^#0'+J@$54*D&LQB3WG+ -T]&G-CQ*Z+UFY[__MB:?
M"/[WC#U1/G^)/S^\_?CE\]F[UV<?SC^]_5O\SND_WKX_^YRO1\KFNY3IF?*(
MD8W60\5 "F0J9I%.4\N1@DCDCOF.W4,%<Q27-NL!TB+Z4IQ:1'+[+8?:0V6C
M/A_70V6C&)]_#Q6?LO],_&&$T 99A@S)[<,\]QXJFRF0K8?*1E7LI5E&)Z*?
M/52>I+]'=\W82?A[H056T2H/2$3#S&*IL/;:YZZA>O8]5#*S8:/,"[.@I\,'
M94 +)H"!TF"$$3+J9?;3V*R;1_?3V"C8 @T7=NKGHE(O6AM=Y\"X)!YB#7WN
MV,2S:9?S*(4/%V^!Q_LN0>>FHKNWP(0+ Y2(C*2*.>*LB\/%I;*DUL$<8BSB
M4:Y%'C$7:9?4^'C!U/;AC?_NI]6RL/,&96M"0M'^]7%"@HX*95307.1^]C<"
M&I\'F137FOMS2;W E/!7/XMCGD9L)^XR"CB-=S[Y[GO@,1+G0(<(0%0P!#WV
ME.G,I-@"Z5AHD5/R)7/L;P?=6KR(B(.%'%"HI4Z-ZC7,3846B&-1_C#IEBBI
MO@5TO\O:ZOWC-="4,!!-%>^5,,ZAW$&C#AC'8PX\4;1E>F56#U'=]OCI*Q-
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M=C+[Z0M[+OT=DS-/EW6!6IW'A.*@B*/$A@'*+25!4NY"[J83NP=%2X3VA-/
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M]W^=I-P!2QR,1HY/ATL[#CA26,-@H<F^79P+>[X:OX&([C:15R5IG(K+=V#
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MYGU>M-VHVMRF\^DL[:Y,OOL5LZ^)$#]6L_]<Z.DD3&[J,&X^ZC8#56HCZ%4
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M]W>U]Z?1/*M],_\4G?:66\X),!(+@ W#%E-M),E]4ECQ01U#".9QCL%!T:1
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MI%SRZ(2@(-DV6[_[TB-7BI>1?Y5-> 4">F?S"U^G\V8G\^L5LH/ B',@!:>
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M GAL[>3-V^F'T8W_CW_[_P%02P,$%     @ =("K7(B;/FU@^@D ;5P, !0
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M,U/.H,9HHU'9S'S2@;:_P,^[P1-/96#[N<]T8[QJ=E:G>K(-!+JPX(#378W
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M$.Y!W3MD /ZZ?][*.]T2W9OHD_ 33IZXCI<+2_%?N \4 /[BCPP'Z:]%_^E
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M^5/)!D]!>M&S\-L6"S,]3*,1*L;%,J$SUT)">CC/*!26%DWI %>"R8 7163
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MV8V^M,NS^Q,.]<"'T#? 4_G+C.3F,JIQ=05]@K9H0E?\T6&DH'?4C_RCB0+
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M5% :O$J>+O7?I>K-[*L09+-D Z)903-7*19[X]H@^YLPH/@I\]/]V)=U&D0
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MTW2"4(K\"=6W#I!^3@&D; _.3H/WJ*[=W_KL1GX;_^5"/%7D">B! LZ>W-'
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MOIP?:I8& U6X!C 1,N5?\Q;_!B@O)B%+E&W73OTO;KWX/MYTC63>O#P,M*<
M8EBS.9L%2S:OO$-CXYBJ*A*CO%<R>F[3?&%?9,"^\!H405"E@7%&6@=-*L*Y
MH[2J*D*-9\QO[7G0LWLJV-("W9)/4Y2U[FT]!+*,@*U 0FT&?9/F5?HCQ[KP
MTI-CFT$*P'82CT2H()8<2D]L(2U$,QS+(@407?^!M5EX;,:X]!!KOVUSL,<W
M9%XZ!ZWX$[6X?*N<3$_NSZ+%L3F[>G][Y.E9;'8S_/C&,X/D-SR/IAH,#-0?
M#K()GQ-8!*TS!D'MH.'D,[^TQ-@ZY='3W^BYV1Z)Q\N>._/B>1DS%=6',8R[
M]AC7=KSOM 5NYI@/VH1E?U/ENMO,K$ZR1T$GHF:8%UBS!'V%1P_ (=GSKIO
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MG\:<L(;-)AT"L%=$9JO-06U(AL9;)Y[Q,[8J/*.+=/>9.AC>WRLN!@*8770
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M?_N!4K]LJ,I[2\XR6X\5%/'* CD.PX88N8A8G$-G8)Q1^W(;YQ##+3G4.*%
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MP31B1[ S"XT(5N%7,L0=/CV]D'"3NES7+^+%%R,R,D2^,QM.J#_E)B_A.=K
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M\[S,F^T&=,]R%=M*;DHK0[5@3H^(IX1%HE./DS(.;J(Y_9S?\16O)86W@,K
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M *4>'T=L*H/^XG. GAIH?#^'3 />(&RF,0M]*H9T]>SN+TL#/F"1&+S$.#T
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MJ#2P P:9*D)TD@_C:$K*V76M-OZ&721H8IR[,0&F?) 'F[ P1!DB?)4,RZE
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M#>(^Z$/^,N*K:;P29HH2&J B+YCC[&U"/"C],1,Y@BY=TKFJIK U@_0Z)VS
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MDV.C6Z1N[SW 7H$*U/3B=&0%=&)G=.V PF1B&5?GN6I'6O;;"R7]R(W>Y/;
M40S+7;9J!MTM@.A-$N=Y* &DWFIWG>-(T=&0+T:)U;XZ[+Z?G,F(9Q='[Y69
M)&W'Z\XTL;P9W@#2VJ@X-@O+WI7Z$_. AYHQT "RY4(A@2OF1)W^3D$,S(*Q
M$T. +>>2/@6H (S="3 V\"=VSISD!,X?\@B>(R#1#58Q3(]Y[,']G!_9M1RG
M6B\AS:+4_==TCMAO"B(DDVXP;W%V,V,&ZN_0#^2G0_:ZR4\T/*R.=XB+;QRM
M4\J_CKYT&F=E*]J?^8XEZA'^:!\^Q<+ZK9>D?6+VCO42%_6:=>U7H3")_BIB
MHZ(S<3=*4NT/4?JRG+<ZBW)R?<U=9 _&UJ@>L.AFLX@O*>(!ZZX25ZJ.75,9
MB9CI&EX=W?$H,'5'4.!*K&?(1NEYZ8X/ 16(<@$!WUZD*I_&.-OM7["M^FO$
M"?MS<BV;[T&]HH4<MV-2)V@O>NQ=E$4H4=I<I0:L+9FU<RGR>9:'VI]V]5+B
MB^M%=(FG+_+Q%/$$6/CJV?-6?G(&)SR98XT96CM\$ J5>&=>YJ:GN5WP,<NR
M*MEK]64J+1K$"TZSC6;MJHVALCN<4O,5VW)>'CL3]LH^-K3L#>EBYY)2TCL>
MRD7FK-X<)'2EIFY+G.^H6^=34U 7FKJ*!AF:S:]:$67_-_9KVL76]QQ?V2 =
M=0HYW39*:]MA?L[ ^(!;4=<3EJ)=L90%$$R'/0[5Y&Z1L)O,YE#@I8G-V$N:
MEV;US>>QZ[I^= 4I3V>=N.9@JO5087ZT T7PL%&BBU K\VFI%=#WN**KD8/U
M>05W0B/L&U>'!'5D?A9EF^*Q 5V2\FI$X6RN7A+;,(K]GOSF\(>+K& XM>'K
M)Q(FM&ZSMECK:Z-NN[2^]KP)CP21Z#,/!4_&?3R)Y.Y$:O&2R@&;QCHDUWS<
M\]RR16YUS!KWCMT.4L_;GO:+4#;-UWM0\M#P@WAQ_NP)>6Z)C0IG]]6L*Y D
MK+7NOL&3746WO86E;.=70:L8A.X0Y$2C$*C?/10V*B,NUG\G.2QYQX[FE\,N
M7?K8+_@1VV-%J1=V;)^6T=*MDQ4Y/)+HCL@T=9U[;N$X]3;O?G_=4KOMV-Y&
MQ3SI.9)7/C=4-5D#N[4N8$LVT>Q\[8/E>1>EUFJ-/<WUZ'XJ6A/P-=JMU^]R
MSN-2A;X&7V.Y@^K'>"@%U07G&VZZ:R_-%%USO- 5$7:V6;TX;7HHAA@;81F4
M%/INU,Q2?2M$' \X_UFS(<I?NJFPV[K[ZT:9TY)JQI]E[ZZS*:=Q^A> DG.L
M-SY#5TA)%;(T>_JVX&'=99W'I9S,RI429W2O"QRU,1\8J[!1:G\<,-Y7)\"%
MKW*Z&=<S(\K[2<'?5)?6W1FYI![]^!D/=7B!^7Q_2O2%UV'E;]_K)R?93<85
MYO4415C);C2MJ DG%F107KZ,&?&[14_JOY= <SV3I3]MVSJIHNTK[E9INS5&
M*NKIDZ"OFCB+.6QGX9>%<S;[6OT.?MMW'F^I6E.)$]J[[BL[Y1 ;?7(*<AX6
M*+.1NN97QCZ"YG[DH2;,GB!?H1GS=&BB89"'.BHZFF9ZBG)OA]D7)V5S)Y=,
MET;:@=23!__.C<)]XR2"K&)[T2[:X!EB>;NW]\WBSV)-.2]V*1V14G^K?K1R
M@S3FK!*5O-1O;P>RQ:=,<U6[0"#CR+?&70-9]Q_YC_J%SV^Z%:DTYW2N+2U;
MYL#HF587VX]9N=KR'VLZ38QZ.AIL=G-S]Q=N'PHJORG=]6CC7S\9N*V"\RN7
M7-)*Q.7XQ:RV=9O[,+_-OM/&5W/TEOQ4XG1"+B-_?&3_%<-*T_?NB2UD#P$C
M;H@K]8/OSB)S5T\?\2V"::?T<.]HDY!,SNQEU_W")E/>V>2/SY<,7MOOKN2Y
MS'N96;K/$T8V,XB4H.OJ>^5-1?GR&YSK$H2%%Q^7_EQ)DOES>= #GV37^M%'
M!^IJ"2=EZ5M[%T?B8V<[\R]*&J#%@(@U)+[#HC6.($HTA3MI)SU4I\+WG3Q2
MU7#&A>MA+7R=^ ^U^G."U2&ULN6+Z5VOLU?\GFNU""ONV/VD-Y&U?(,9$3[)
MG._'W55K]PK8U0%EN;C*[2TEVL4[CZ\1K',L]9@X?S;A7!'WI42^0989Y+X_
MY>R&A/JS^LK3VDW;_GS4U C\\(.)!6/,(<-BC4!'FKW*"O_"0]4!TDT31W3E
MJJCB<#&ACP"]*5J*2"7U\U!<@9_@?Y;@HG6ZL!H.%%\VNI>'ZL^%D"U$AI8M
M#W5D]M=CKHQ[(DA U;0NN=EF"0\EW$*#D* %B+F+R$/=3_BSL?^?:_'J/4@?
M<67_]924<354^$_"Z4=+IF8OM.)I%+P@>70:X.CG6]!#,X8R**$CLG@/18XN
MT"18VP6B3C/^$%3N[Z? 0Q&+S7BHY5/(_M^/>:A,#Q6V0$Q/^7]UF>KR#GB#
M$-6TI/=A>L_HH9FT(]WS/8-S[[).5?.=53*B,K43 W/QOG.)HK.*L(82U1OF
M,(-X*%0"#S68#967E8A#C>3[6-HJ+*)NR@V)Y:$:0_W+D!;@O\:V!:)A,W[O
M;V?I_MG,Q1%H=@!_';H"7#<ZSFE\-T9Z]I:'"KP'JQR_+%:RV7W)YG,U&L2+
ML6XF/!1U$!*&Q@0'2/ R_G..84Z;ZRCPIY@>Q;@+,7"Q;MM^LQH*C4Z^1YY;
M1C=#_K*$9DY@?CO&3JYN0?ST\%W/5%ALPGM'4A3Y]U:Q?_SP81^.1=^$M'Z&
M&EO]C4_X$7@H]&::+E=(=A/\"G3C*53^U6\=#W6LZCYV&Q"V>'9Q'-08PH2>
MD7,^X&?G Q0[-IA]!6$Q@UD&-64.H&O0R"'@C)#/F+F=/D$SP!T11@CI,G&6
MBF!&,%V=P#:RR$28TA#$]$4'8L?.TP6&P5!*OP=8]EG?;V?6AY RR8K'#(?X
MK8JT90!9G4(\P+ J8ZC()=_<Y5!M&Q/H1(:H*+T1UB"6X^<4QLE,$5$,;0;T
MK.GY>Q#<IX _V^HZ$#]L,=],&G:6[M\($S*321$0=0CA[XA0 X%8^BR9APIY
MPG1"[O:"._QU*8%K50^-EG,Z6"&,$@$D0"6??R=547H4B*?4XX9D!YK.:Q7K
M/N<9!<T]P8>2L=3A E?N2C.(N0^/J)I\<CH S8S2":P''%L@N+%8 42WZZG9
M%X@VTZN&W%4BPQOY;Q9,0&0M <=H"@:T+TB5_P)*8.V+;L0/V<-#[8&N]6-'
M1T'$?.6<#6.2_C@71'!_8KN2B(3?$C?YEU'SIF>@=8*("91Z* ]FP;;(1>['
MVR 3B,#O<E,WE:@4IF\,UQB",WBH!54,;5:%#=IC6?-0/Z^2YO%JX%0L:S_$
MV@PY7P#WI:K,: V\*9$!?HF%VL!_:Z9Y* \ /.B]/-1[5QXJBH*,)'#-ZD%$
M-R*&&$0/F_L!,SM+BV%AW(SP ++*Z\CCSWFH86!P_GL"K/'1&'A[30L/M<*9
MAZH<CQ&ZW(A8@<AK!GW5F%[RMYOZ-IA]YL=0/0ZYJXZ#-^;Q4%+ 3^8IH.\A
M5T#?#X"^WP!^NM:-^$.+%T/._5@B#1KRIY[PPP #=[8"=JR=#8+H.40O $,3
M1^2N]"(R][DB:KKL].=0(PF.PXY@NGW0HS"&A?$QPB\%AGP^Z3ERW1D623K^
M;$C?5^X%]QAAV @JKX8-0,Q[1?%0=_:V0>]C23 'SUS/0^V%\G9C&YG[IL>5
M^C%,7VPH-';Z&YFF8($%@;45=%6=O]4F%IC\']?L1GI*>:A]G-B%>5$:&@1M
M!7E.\0J>*;+KJ"? *WFZQQ0'>W=.K^#GK%WL[(_PW5^$@O?Q0[X#64:NP^9=
MQ]8A(P&!S?AX$$D8*>"2CT"NUT"_\JR2AYK;R81F $Y'F$+O?9-F5&!!$6YA
M(.*PL&]N;Q@,,#KD$9."!!/1"!@,>@TP50L,[6N'<A[J*0\%NQ/F<?N1$Z"K
MFY#>SQ PE+WQ1( /#MB&H0\>+\,(,[T.J>^K4E_"%-2=?4\$L!.*GUM&(R%_
M 0?.G#A+W=G,C5IXK<%9WLNM&FL39=6"\9!B N<=P?%WX&P%M4K>Z#_Y#9AC
MXG&ZF5/.N?5_>JD1DCSR,F$AA,$0*N00FM\KS<8@4GF#BMPE<R18%,1GU390
M+J>8(%^.\%_6NMP# CUOVUE5!-%4F$NXQ7>1A9Z AT;X%V1:+WDC=@R="/5G
MN/)]JN9:B6,O_8%G*CU?!*^4RYJ#_-<TEZ*G)A472@;GKH;!P_])X]1LK<-7
MH>+L;\X5ML/8R\UVGHTV;^-]9<9 +V?79 @A?3S4;4SW)YLPO!M;]42 .\@6
M/!S 0[TR0\X08;Z]9"87-$F"7V.9X+Z#Y'@,4QQ&(;WET,Z2::;BWPX2AN@<
MY Z>=0SB;](!F;' _8L\<Q<4$5UV4@3B _7C:4LYWL)P%H?<3TPP,1M5@55Q
M4Z( &ZOB8[PTR,4,/%I\HN603I4VF[]W9BL'1'L3'Q/+["#Z>VS;*0>+[ YN
M,2AEV+S=W,TJA8C@ORS6#_@&(DZX#:+%8N"K!.85E2X\<J> A(C(\5 /C9#W
M P ;IK"P(/];&RYG$'TNA8;[-3Z2!HP8T%N75![J[M=?;][5"6CQQA0\,&S7
MJ&*9U=)*=STI+9TYC0,=206RE@C2F::('.7F:R/^C8!\! 8\_+<O%)B-3L/*
MV*Y:Y ZR YA^#(OHO&_'B).OWK_DYG1Q(#"XVKE$Y&&)"PC2*1SW7(4E<XY,
M4P30^H#C$@.SB3WD.J[<&_(AB.J&M./GT*"0K@>E;@;@Y"<>R@D0#?[73017
M L"4C&&GWP<&_=T X3\:D/S/&W@&?IB='B##&W0![H%"8SJA\F"=/M3=" =Q
M7)YW/47^8SP%"5/V/)06 B+I\W&([]13D),*:X&.1U;)+?HI510[IA##WX&)
MPN:^!N<Z+$"?L3K)I ;\'^>6V7+, 2\!TH9FA.'7&^YY *-']Y,7XSX'S9K%
M_L=P7D':+4C37C[I!^!/G/W7;W%[4^.+W6!@;W@6#Y4"ZM7F9B1=M61'#+(,
MTZV4*/B_LG0C,-D8CV@G('MKD7=D.$27G<-#&=T@TS8AG3Q4DLB_LO)?_V:H
M3=FG0K4XT2J0/"U#7JQ&6-"CA8)YB!GOLASX ?4?Y7[H:U5<P/P*V,V4G!@8
M]@$6K  TF]Z%I:[AII%'![] 3#5 4B*:D0P 'Z]J\,RUD%,C<F?T?WSA)AXJ
M)ZKQ9TG+P.L1OUBDZ^&>>*V%N#WSC1N@LA>@B;'-@#8I 2@8BL.V=2D-5'[#
M,V;X\-Z>S"C'_?Q[.(R).3'<91H@EX+](/B)+KR]$41HH"P_0DNPB'X"UP;@
M;I,G0&GH&>0$SGMUA0O8R2]G;1CEA\)1M"A$Q8/!DP?9N<J# 8;B54@8F48"
M]D<Z\E!F'T *RH"<_0L/*%4;-"8)>8!Z_R]@<N8F@EJX%:0[]126.86AU9.S
MR=QE.7AX>P@/)9/ 60J2\^@<,@_80@I(7@>NW]^WWYBWF*'1(.R#=__BP@<0
M?KZO!_G^#@-[$297*W(%6A8I4B+$7DZ<G_F[WY<I  <"+4C(AG*^DWFHU0D<
M[7&HN+!->5G0,.8*?8E7E<UK@G3\''2AOYW)ACKJL#E[9'9G(26Z?X?4ZCL
MUP+)+&N(GH!L7 I@;3DTPW\AFBY#3  )HG+]RCDX$0"0_]-KC.E5P.^$>ILF
M7\A[RJ*"T)&Q6TI&X(<NO#L&8/]J4)SW/U_<1A@2DTZG<<B<"\BW+W-EM8 -
MW?Z[:)3A0='8 XK&-S[!^./"T!BHJ0P+6- U3-=Y,GMY# 7D[M]@<;=D+]1D
M>Y*_"Y8"NQ"8%Z '@/!\^M1^PTB(.ZB5J*XH'7YGW4_-;4A%;<'(NK]OSU_"
MX8#R]W>TJC\9,..N@ %FW/'&_OH*T3]_8"@##J$-P*L?R_T .0Y"8P":0&5
M_QIJF6JZ$A(4(,K_J!+QUU>6_OD#1QPT]?HN1,,@G=AL-_(<: I B,!8V]DG
M%BT#CQ]/3SUNC;*_\G3MK<!]^'@\[2<.T (I0 N6]P ,U+0B((+DP3=A^(H2
M6;/2'M&D31C;X7! 56V'#?P^0[^LLHWO-%NLK5H\%-+7@AV3 ]0)ZH =__W
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MT.G2AO5>73TBS"6RAKX.L/HM@$3[F$&S0: (MR2  ')E2N@EP@8#8J<>?K9
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MER+VY4Z(C2GDS1+0NH[4@9;5L-2" #0P( !8O/PC"!X0JS=@D-"ON!1$R '
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MD#&(2#P'&2Y(9)GP,[P5*A?Q S7^-4#N'3%D^";!N1R:'><#1;7 QP9L/(;
MDG7[;Z;D;Y+@/<"GT^SU@/,H+$X+_G;<?M #\3/A=(">R=;RYWP?<<C]LJ;_
MC]J-LAE%5AE03US?!<NEU3P;JMZIYS''G]F?IS!M ;Q2YN0MH/Y3_)G(M.Z
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MY_<WJYX+FN\,0@=E8.<8"YZ$6,Q!R%#AB)X!_(?7(46TUPELNVI"_SBDCYI
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M"SS$H\45(#CE4(4MKX"P;P@LYB1NUCP+9\VH&6U>R!?/C4?H-;\/0]%&PP3
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MB_NL8P*NT_V<O:_M!J]3KU_FM5CYS)/'-,^S\07'W-[Y6#XW?%33XEIU^76
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MIB>4\*1YR#>*Y?F)@SC3/(?IX[WG>IJE@K<_9%J^C5I)U7<O+]-+$R51L&\
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M=-M'C2I:,(HY4J^LZN49%>E227Z^*^6=W(E3+U2J5]5/?#/8\?Y+BLAG+U0
M'(I<N-SJ%T4(F!=^=RQ_.).O\7602<P[3;M\PAY=K=-;$U,=SQ7>ZOH8H$IQ
M"0@U7?M>8[6&O86LB5W'VE[29_+*^SZU%(D5NC'C8A=4:YH=76\T?6LI?OAI
MXQ&^M?(NB:9& XA!XUJ+AA2SU AI<G(NWX;0I)5"1N:10D9:B%]-QJ(?7R3N
MH7_J:;4GQ7?3F$U%N*^FB TC(C4HJ.F%Q9,7@Q5XG?-G3F5>+JGS05*JEY\[
M\.REG9=KW)O(2*,2(MU4.$=+*,'8#:74YOQ%Z)1I^ >8,\]T@$26!BTUS:/9
M'1*M'7=ZVIN0^R%(1Z8AS=@^H41.S1>@N <IC)X-;>W4V#8B??+E<:,> F+=
M2C>W1]T"VYS7>^A;UHVV;*0RR[POMQH?7>71<D1ZN<OC[V*C<=9.*8"=3&5T
MQT#6=NU='0KH+W_>/<P@0IL32*@I86ZPL();D\YA5,[CRP'Z7Y]D7QEJ^/O=
M*7L6*;C'''S78-+;5YB'C20_FLRUEDP1K6@(R=QTV>;C?6K$)O-VX0LN#XD?
MI0JOSW 0 @52=C=VOZ1E/Q"H?/'Y\A3#]--TNXAR;2WV^=$4/;M$W>09V]J#
M99;)_D)&IX6$HU(\L-KT;:^'F%H![Y)FM4;3_Q89_"AN%B]\-2:IZ+(:\)=2
M=,:^*2S?0)'8.J402:(><M8_XH<(K&V*%S)2K8SK>YX_N>*)*?<TV\MSOXO8
MR<[3ED.;QIW=5F#V'"1J[>,UD^RBV=OO>EN?Q_/T 06\<_:I >INYLY>WFU:
M]>?6(F&Q2"M+V_9ZYW$C?]/-""\^-^$4O499#F*C 3,_/&XS2Q;VEF;;-Q_"
MWRS8G]JQY06:F&<8=\VKVMU&*!7<9.R 0=<[*CT_GI66%5#9HCER@'ZOUB]H
MU<K3K[,B+!X'W7W3:J7X2CT-'=VZL/::(0"I+O?^C#)LJ -<O0>_]\;#.Z\M
MTQZQ(X]/3L_-WM@]80?N\8=H8[/+Y;4%?[WR<*D:/+3C17S:9@5;.W%I#H*\
MU:Q0R#BFUVC2H&/N=E!0.JQFI];^[O1D^=OX'?5:4L85J'DY8*'0@ 2Z05+6
MZW<>Z"_PX*]Z@[M[ *NLNM?REQ.#A$^=W;D989*88F^6A&&$.S>V/_V\EV$*
MVX;W>O\K\ZK*UJ>,^V<]S\YK4%>.(Y])JS*X?DXH%)V_[['E)C&WMQ'VD4UF
M'UK:9#H".O?<(QP^*'P^J-7TG:'LQL=VKKFR>PT'[6$U.W_REW<+><]0)$)2
M3_23+UM<2MJZ&>EI*U[B)R^P.Z2K@X>8+JKT FE0+QZ\*2,S5' N43A-RWET
M:,);T[VJ=8SL(OZ(H)S%/> H_SL[=JU>NUIJZ_2JR"!$7ZJFJ(?FQ'5U2.A;
M_[/0O\/MOF4(#H=GY28,9D<;O&LS;_UDZT2XL<6CY++FS;6FT7)VS<E&U[X:
MX ]4G QR/P'/5O+R==!.Q*_VWLKVD[4$79SJ: D;--V;Q>$S7U6?(O].CVY]
MG>FO6^_SS1$6YC?O*P]I^[]E^'UO&_3R??O<R= G^<2F[36UAX6]@F0O[C*8
MU.VXK2L'&W59[=]MSW_5)AQ&"6-P'T;A Z&(-'-H,VQ=U,*8#'#P5/;YH2O_
M':(-T7\; ]H90$D<1(?R<PHXMZP-+"9,29G.:#4T_G?8F%.-A!X1./<]@^66
MS*\6A(YLPG$O=03^;;AHBKU@I=]@I'7B\V^._W_:_[3_7[0T[I,E27?4-!SC
MU&7+H8@H>K\+!X%%LF4COU@9!.U\_>;<XMCTOUCCV<%!G.(@QJ*K:036S5%"
M%Y:Y(647H1&8?YOAH\A!;%5S9HA =^V+RO.B,_\;Z#%?= [K]C@P_("#&-CQ
M[#58OJT>RL5/) R1)_@+.(A4>$DOHR_=AQ?V ,W]7CEYY$&2UW^#=/Q_VO^T
M_]?M?YZK_==K_XOG:J8:(P+7+[KP/10[T;),8Y_VKCRW? OS3_P/+93X]*;>
M#>R.C_YOX$W^I_W7;+Q!4!TJ*^HN>'&<H0-29.NS"H_-7Q]%78)(MT4/>&J:
ML:$+:=V:U[I%!ZZ'[J<2:#/ 77!J-Z.9@T X G.R!=T0_S(.0BD*HG(0\Q>Q
M,1'SFXX016_81-:58M#1F,(7V8^QX9K8+4\QKZQ/=35&Y'E*33^ )$FT,,B?
M+,9!= G *KN=6\;5AJ$#*_%X"$A;5<]!A"=/W AB(J<5=T&GP2X=D9E4F;SY
ML"9%AC?J,\ 4\7'@(&X>P+$B=%@:8104F[](F8,HWH*&]/ 5K49-83_ACK"3
M[X\5=7,Q$I=B/+<8HU\0T%"0,'>1@[C%^Q,ADN'-^WD_!['O7\.20,H(:@TP
M8$7'0XA6<,+4[^2Z)YE@DB=ZH@HV.<C1,VBW650RF3;-0=P-A"Z2Q< %E-S2
M9\U%&\%O^=UHUK),V$:]8[V4L&M8 DJ@38_?Q<%<KO_)Y2A(,I_VF$O^SZDP
MO0+JKG%L_4HPDGL7ESW5&_^1;<E!!*;Z2',0K]S+< P>.PZBXA22(=O_V>0'
M^<"O589'>-5"\;U E2)K-9#EHM'<[I<"D]8$<8O_<FE;_H,V@#(,K@'A929
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M"K- %2PWSC"Z9=Q[7G^B>Z"_Q%(J+[U9B,O3,K\MX#?!4NPOC.6'ZI>8/&V
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MF'JVVT'SEXX@8&)!AD2K&"I[LIM&]OD&OY@P'"_P,I)\Q7_42!QD5 )E1W(
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MTA7U&%6.Q"X:??B38WP-B_+*MXF[+-_SL30  V45_'D&RU!M"@<'T@:(Z+I
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MZP[;AM<I7^Y=^[ B+R*&36EF@GYZ\5F$VA02UQM0N+&L.V8P6<"6P0DC672
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MQ]CQ/C#I$!<*WI-#ZK*ZB&\"$R1E96H =E/OM.D?(RZ^-%^F//^0L9723!O
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M^YU L->+XDRE3#F-%W9_'M2:Q3B46=+>FFE:+&U(967',4%*>_/1P#[A/$W
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M973['&0]D0E:^LX$_4Z6!).L@#1=*> ^N7LFJ>-BPJ*GP2Z&98)"GP3PMNM
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M+H+^!3(): >,4WLJ9'\;GJK1)Q^_<!U?MGRBXMQS7-R\X(Z9ZLQ.<.V"VWN
M2M5&\5<#A=FHPT!:3E5ER+3IL_9#>?F=\N_RC7HX&Y(N0M:-LE_QB(BJ$%[3
MP)88JHHZ3HY*Q1SKP07R+Q2.G,8&4XH>=@)OY5EJ]RY$RW($Q$D=PIUV":$;
M;S'J4HSZ/^8%ZTKN^&+4>C7HKS&/1,4I#X"T&:Z3@%N'<MJHP,O$)"A7Y1=S
MN9Q-U#?MMXWI6K'\]^>%CGO++J737M$C*[E.,7H0U?G95%58=![9[ 5BE=N
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M"6FR*$TFZ.FPLN%M-_&:XUJ6RHE[,VB25<DA3W50H(=FT]@ &>K50)^OC)-
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MVX*F?V+'JX[2CFQN#1,30<CQ9V;MF HHC=>'(5#=_B.@ RRR4A@XU2J/:J]
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MV*N G:X;P0_\"NYAAG>_)ASJI9G(R]</IOA >*6*56]X\GS\:%=O;PYT#[Z
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MM4C7G$[E'7W(I"=&47I8 )U4@W7O&AK@@1@T+,JN=NSJL=0OJK72U84^+5?
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M:8#Y=42*EC/%654HU%R.E_Q3S2_!C6A7[,2;O%TYK?O:6SUZ];(@:P1ZK4-
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MM\\24C"B\+^+WO#;&'W3Q@92%E1]VL)?W]C.,[6Q^: [PX+QNYG*UPB':?:
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M-N9AU?WT0:@NT7=)JVTNFYGC3$KK86[^2 BH#UVD9R":9MQ.E@IFF&CV(0B
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M$U!1I$@S*B!"! 1ITF(#1 1$I)?8J)$N10B)HO0F(* @1"G2>Y.62&_2F]1
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M-0R&S8<VS5XJ)UTK'+RK"BO,>MO/.PIA"V\1E]K-YB'6.=,!KSX[#Z<N127
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MJ3&'S)ZY$M779&2BX]EZTIWUU7FSZ&/WLD;.%T^5Z_G,=JY-V*1JRA!<X^;
MQ]=L+XR7&!L,5OX2Q*ZMCG[4CAR9OREV"&"7>,U>+#O/A;N 7U_H;<]A>P/3
MHM;*I,0U3E)#EC$])\TEJ;M.GW&NGU8AR>@J7UP.MF32G[,1>'MHL](0X+3D
MZE 9)2#^D8TC?D857U#[@1EXV5ZX;%*GE/&+74 O/B%]H@-LJX&'PGO[>RHF
M\_(1WS>>.1>Z.'XK3' *F-3P_KT[0+#[F/?TPKV8O$TZH(="!^0<6FCQF*WD
M5/XCB?W_QW\]X)Z(IL?@Y7@Z8!I"![PHV(E':S-2TE+@CBYB4Y8.J#8YZ((,
M3HO2 1<M@<1]6K+HO!=XOY:"%F.\._#5,LL_5&:XK^K=5?V'ZI?_72;R+XI'
M_Z3M\Y?>T7]'..F?*DD>J!K=X&AT&AG]4ZWS6=78J24;(/TOM2)_7]'1$DM+
MK76]_U=5'G]7$;+\AU*<_Z@M=6BG^7>1)DO&_,#_2E7J3^'/7[;YJU[GK\J7
M(V/(^R)._[GNT?_30J5_,\P_%*[\6>L_UMG\SV2E_III:$A:^G_;9)5AL\O_
M)+?U[Y)1?YOEWVWGS53$<_(_ZCW]K:3G[W53_XG['<U(>@P02P>(K./<)D+G
M'N!M/Z9?&IL#3B4[I?I9(SH*=>@ !U?:VXB=K0G(G YQZ:>FW'A114[S5*%T
MMJV$!QT@?6SSR^X>^!Z9 WUNX>2%93?IYA[#:CJ B-DAUR,-DQX7.>_QYQS0
M >^-M'@/!':;_KMW-OW3X,7K4'B8:!P:!?"?Z;*04-1)_#2_[>64;E"78II1
MC9656'#0NV"#YX@/GRLNLPEK^B6#5#H*?+2T9<RV-?<S\AQKN&U^$\]T3V4G
M'9N9.MLEQ:[H4QF_Y"K[]?/S'%[Q$4:B'1_$V"Q'(T [Z_,E%!ZD%6F>#/7S
MG3<+;5!C?3NWU#@B[>9:8M6':KQJ9="MK7G7#/9XSE6":5G@8AAYCU>\7I^2
M-$?]=2]S OBETBR!-H+DHG@1=.9"P]25\9A6)#Z,U(S_\6(/4=-OM\CRZ9PA
MYD;1Q27>Y"7A%;8@Z%MJ&)P=]I@D/@_F_D5Y0MBB2-2EX3:\?DTSXLRL,\0A
M3"=$?_QRMN?TO.?EV,;>0&D2C@H+LEV+KD+/!4K^92-1]YQ52!2Z5+:C)!PE
M1ZVO[&6"D"*QO5XW7^T]F+3-+K:QMBR]:W_YN,$2_.$188\W$9*T[9)RFU1R
M$'Q)PF37*7!E8X;'+!T^:)F]'$X&P^Z/O%ROW:7>&FY1_4#<]RFO]&RY.-G9
M_7OMIBGST6/7F4V])3;FE@]!*4-O"QXJC)LFS_J+\!XPD@WF&!*&((0UQ &Q
M)ZZUS8().A$O?S7(>7B(I%<53L_>BH],M3O)K?/X+.N3SP[' Z%[DW4.^LUR
MR3L@FC0\5-WNYR2.IDO[J@67H["0]@C*Y@SPFJSU1P\L#'4%A>\BQ!0YOX2F
M>:[I@<4%5Y[#=3U3^9WG/=Z\B4DD7[>XC<D41/<R)LCNF2F0LD'/_?&]NP:L
MAO<HWM1,]%P&4@"N!G-L('GCS^G-*-_E?^A$A/SR6;^4F<\CIC#KQ-R*!%V5
MK''>[ET]:7OXSF1*6F?&R[4+6/;2#,L?!N,B!U+.#KK"H 7.=,"I,_K#[Z<-
M1?V^*CX*9Q.?_66ME\B4\.$'(.$U: -!NM3/\%HS:G:Q(M<1$M5EJGTR,&?*
MI4K-\1TH]T>VJ3ZAF-?N83?\ =-1]TRGOH%8C1';@J]1V5WV8[%ZR #&AF$)
MYC%;P%!X8Q>0K;&AX$IJ3.(\.$Q3"H]*FA6N3"NL='%>'CIS(66.7U(H?_/"
MHS-1> W0=</$-E\?BA"5,^I50B"Z5W:$^BZCC"*BGFQ[>F Y12?%Z<ICWWCM
M*S_;%<7B_>,#QMK<5#SUFW9]Y-[5SGVK"^8Q>F#^)V+]T["]1K:#3B*#Z0 [
M1(1@=73NS*I@47JPAV+57A3N.%[%5D#DKIWHB/!X&QV UY&-3%<E(0LI#PW/
MDH9;-:7UU (UBI*M1QT:3_%!H]N8BZ>\JKQBOI_[8$Q=7&+Y\Q 0O,U.?F^\
MB3M ?#IT^=N>)Z!Q560E^ !$D.+U90UQ3%.2#FAFR;1T:I_=[J=QB]PVV,G9
M$6CH31HLK^E^]/PS(2:1.T%?K(:B0(O3O93J]FPC I1*<LE8HPF1?.>C)5KY
MZ8#)%%S,)Q<71."*.L;Q^]W$YPD!K_MKWZA]/.J5T/LRL1*;*<&SY?K-P]5(
MOX"%88@'1EIP+P;,N@^>^X*2('%AK2 AR!,.H08$T<GLY;RB+H[[Q+"5???6
M&(XM.Z%/'X59K3T]KWT8L;2Q#?O>U+U5=BBG!1> 6IKA9N8@;#5M(L86I$BG
M+[=/H9,L]N@ A=NGFS#BH9]_AK&)*=RXW'<#,#X#Q.O+3F5:4',5BAR:;56V
MQ0C5P4=M9+ZZ";;619>Y!$\J-A>&M=UV.7+7^\=9Q<&SUVUDPUVC[!2%]#8:
M/^U+\QXT,K(!>2J:8HSW:DO"<-#.VA2G895J8A9,QT3#[5(P/Y?5_$S>')EP
M;PL38]/_+B&ZV'^:-$6<H'XHVD4 2?6VA+2D.(14(03_WKGE4:7/DP8MQ7J]
M\^]*F9\D"KV-.MU^*B5EV5^;B/Y4B<4>^":6N$G3 :+[#R,(B E^8FPI-4^3
M;?6<2M"L!OB!?8#&PS:@YY1-1_0:ETT6KW>_FK5#"F6(FLDP*%(0X8B('D><
MU&2UP:Q:RC4D& YG##R2IGU[\'ZXD@[P%SNP"!EZ8YPL(<"O>/G1HX<-R"4,
M)>RM\;>UV2Z$*04X#>\>A 2G@TB?R$[PMI3BN$(2IO6<5'45*OF%+E;$1+%'
M*+[AX\=/=H_$F'X\AST/DHL['";+PH<.(3A^,G@5S7V<,TN^0]ZY.K5&.@M/
M!Q0!]JV?C*OCGJ0[D1OB<]/C,)VI58JL-5,_B?D@0M(*,8.:Q5@X0D21BQUV
MD2 R_D9=[53\\JR06OMP6U'&52.-T9\W?OYL>\][/ZKTB-^EC#&$H^QD*(U]
MAO#V[J"F.*D8 73DCZAQ8]FCI$0W4E&X\E?\9RZG7.=//PE0$;>XVQW2T$#;
M4AJG-2"G'^TN+^W7^I:1P5KV?I!64]NK^+&$$J=X@4K<PR'0E-.Q)L>L&[\]
MID)X<TPN?Z\1< V/^A#_P>>)%L^C#_]3J,N[!*Q"4%)U6ND ,G_)GW;,@O$/
M?QJUMUV C B_8<MPLD%]&W/(?@0""_DXMK+(MM$XQ\7#.,/",%P-UPN[OEJ2
M0F8R1C<'GG->[HQK =Q\?"]WZOW91.8%Q=U^W!]I\A7\>!/RK1E- 8\,\TY=
M+SK?OC\V67%G]<K]M>#,[85;[_C8V'P%BB5H[$^/4+_)?%^=)Q<B,)W0K?XI
M)$T?C)6E^N708F+0MOT[,%M.M:^A+3U)TLUK/;,-A5O;PYT'UB6<]QH%NO-1
M1?Z.:"")K>M/H0M0Q)G-DM#_-ON[DT)_A59^$Q/WG8=LVXMVN]."ZG3 =U ?
M8BX#+:2(CD"*9)%\OTW?51!A]=O(J-!5RNY=/X+2$6B2LGK<?U]Y/]H-T20.
M7JP@==!^,!+P>T]+D&@G'.<&'5 5&KM+-5T@*PG%<M_?GOZ 66RY4M^:ZGGM
MG?NOSOXB?Y[22H<V16==J*"SWK@6HG[G^C-3]^Z5;MR6U>(H!AN8Z?"7QL2P
M'POW2KM_N=]HT;YB*_3T<-(+![</QC^EN 1VCFBXJYJ]H_V@ _@88>0-IO(U
MR3??YNJ@8N3!R\AU/L]!+?^L+,\O&U,#VH;>KEY5'FN$/\DBMV.2.4VFH+U;
MP 9V_?W-WS?)-A:DOW2"\,MI"W3 "5+F#=)"-@E)YC*N&1&<TA]^AE#N2K1N
MMY&9<O594%'IOSW4\'WYH^!'F):PJ]J4-M3AGE[B.E1-L][?/[7_A,5E5857
M=N<:NC#C;FM+&))428>TX:VR 4U!)WXW)]8\)F?5LO#2H6;@"Z,SU*'N#9W
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M@#0<F!&9J-\-<:_FHB&Z8T6X7628O]CYF>QB4\[OJ5(U<C'W*-/R.T&/WH8
MX-KP7W0 )TH,)DH:..1J _(CFIVP(64A2]Y@'"B5<F.#9@UW:2Z@?'=+/BN
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MR47H 7ZO/6=>TM5NR-M<D#-5EP,VJ'J5F?>ZP(_.)F%!2B;#QQ"DR(47AW1
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MS$& 8LA[55>!8EL^'AJO'JDC^QBRR#?1$UK7EC?TZ$&LE*?%G:69#R+/1/>
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M9L'8*=,2I% %:F/A#;\FC&.I=LR[B!&X*/5P:/M5]J&QB!6J+%BH%2+D.*8
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M"-/5+-24P/Y&S$<^-Q;J</NL=4"TK[*%GI#4"KGD2_\>_Q[_OQJUE%K&^0]
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ML2GQJ6XD"Q5R#?\..X5AH3Z)FR&]P@4+A!$O\UX4HX&%FM5O1OXA678Z32G
MEK;]$ NULX6%HBQGH:(' MSY6"@,NJ<A)80AB*$%-C"B?A DLE"\/,Q[P"#
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M^1:Z_KZJGG5RQD\8/-Q#&(0^JDZC41AN;""%W;>3!D]GIW'[GS<&WM*Y16)
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M@_]^ QV:Q=UKTK';K^SQ0Y24WFKJN!N@@'!=TFH1OH4//#Z0#:+9PYOKI52
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M;Z@ )TO8:\PB'B'G[W=*]NLMETX'6O+(F7&[X!+;Z^M=( (-%Y(2?MDGZ$R
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MD%3SOG-I[;9M:&1 /Z$4]S!(I:Y6IRQ^;6VN(:H)$J^ 3ML-2#BO\:W5%>=
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M8$L[+):V:A95[U7-JW1=*Q(<O+7"S,PX-*2M?@>L"FO70CHPD'.:;RQG@[O
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M#A#M^F_$O7=44V'T+1A%I4D7Z40I(DV4+BVBTH6(2"]1:4*DMP"!*"I(C8"
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MPAQT&S4MO?@ )$"E)XXT[7WC4XI7MI*=-HGVOO '0J43^4*67F$C7@-O(_#
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M#N;M 4@GO":$CV>FM8V ^Z2A1.KEJ=ROY>N/5U"M_J< X#X9Z*= 9;8MW9C
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MK5:6B_1__78DO;6Z+:C3R,PEI\M-LFU!U3F[Z^&"T9V2@)VTY50& &]R6PJ
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M=H1+/9622@T'_FG_M#\V>(1Y @!^0'.25R3DL_F81& 5TH]]Z1:!%FW0009
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M=UXI#"A&-GQ#97'+ C\Y5S. 0\XKN"77]NG"F,]3Y$>CR>\ZC2&7XXJN D!
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M/*]P6$CAC+0:5]B=[EK*=4P6D<[_G.;+E&V3+>XN;#V=LA_,)W10].2Y@N2
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M40]OED-_&#[?5 'I]M *U]<H7/NT9X9]0#W54X"N,/(2O;#=@/=+_!M(8]T
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M!<':QXG+.,MAW/GO<"<_YIW4!\F=MIGJ1$0JZD 8?E'0/<[V"()GN:6C;ZY
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MNE77NX0;MM<$?MSG434?@H)PD63A13&X#@D\!RG4.FA!RJJDJ<G!LD.*.\X
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M2NT6_U!?CK+9C+]7K<D63I4D^O2JB-2T7;&N)S=90W>?G;*.T%+?S:93'%@
M^AMO^421$/%#]*ZPS#1JE],D1&>.>N$$Q89)B*&*XWR7Y[ Q/V9[YUA:)T_Z
M[_8-+FT(?5/.4Q3WR)VTA!NYG6*+/_F&9!N<S$B[HWR^ONA+ @#8O*76]Z+
M/)[D$($F:+:G6$X\7*780@QPY*U,5PQ,5S4?APJ/N;=8Y>I_7TSGFETSAWUM
M5Z)7HO^X^<H\ 0(L(-*B&7DQV98SOT:JM=<"O0%NZ1.E^F75-(<RQ:S7-N4$
MD>3/ /US/V&HJ#/ >!18R_PWJ!I$CFLJI@3"*3PIAW[NTFE'4R,>G=$2/R3^
M?S/!_]],\/]",T&I89@+^N+V?ZW"G&"?J3PX"ISPJ;'TGU*JF5F;J];Z,%XN
M?]>;TUM[[;/0]]8'T5$=)C$?M_/>)8=_37NR#B2**W4@>,@,E/0=U5LKY4 2
M&SCF17-#B&%-E]?GA8XG;=Q^J_Z_W3:W),J+E90"5MO6['@>/;((0K;.2V'V
M/L&K8=U@-EH8/J,*0\R1N+T9\KF?FPA/IU)*TTP+ZH[E#R'M+X/JSEGVN4#9
MAM%Y!1.MA8P?]=5@Z-K08J3([":E5ROVMO@?5;'R&<OB3!\?.]6[-Q_.8_DO
M\*JR:F^#Q6 =BD@G-EXR!R5;U7QI-*I-B-K3^L>O.7TDL25L8Z0V:9HQ:N%R
M?(&8P.LL_&0BV-%(1[2UZ,_)1,RAP8I[&WBW&6'UDMR)$]\9);VD=D$E\(*1
M'<Q 5K(N3J;2V^-&S9_=&U'Y[9VJ,:)CG,D>U[XMI(2%/5QB&8U!5GEB54C6
M@0SFK<3691;NA^X/>JU:Z=J%."4K7[E>YQ]2DE>1BW]7(*=\$G\9DGSZ1.-F
M8\&0>*AT #)MQ+>MRS#UU?CD@/O&\5%M0@K2P7"&9 7\A85W[$53!4*9L%C9
MFN8YC::PI6\.&5KQ)H'64U=$7]SOM__]P'P4Q@9EILZ< 2K]LM'AZMRS@>;+
MR _ZW<DN>-?D0GUGWBCQM\ES55RJ7\T3SPT(),,G9J5T!GX7_MQ90\(/C^1C
M35Z7["8W[2./[ [ZNM!5H#[8;.:*;#@91M*=_Y?!$$F^*]'P"^?Q:?GAQ$6S
MV1Y+#5/'I[=[S=]P.S/=!VI":5>N$HHBV4#N16HT-?,I?3YLY-O0FJ8/(4<Q
M=HG$?U?JW 6L<KY0WV4;,S'1N?7(N#8)94!"3S74\Y+T%K#[V,U2T(,6E8 S
MP 5&HEY>!X89S!RHM"Q6GO5F$=U=7U^IL/B2YX7%KOL,#A2M'2/@K5.Q0M"F
M?&H!8V1C+=/ZV.*%1.KPYMUS8VB'^AJ5I5\RS;Q#[L]?:I%JGS[_W-CQ-@[I
M,6YY2U$F=*VBU0^]=[U'>5]:9&Z?22(_MT"DE^OJ5@[']$ZY\4AC8V4.3[*P
MAW]<6&P.@Z@?(AFTE :O/DY .H$_JM\<:[ON#,(E;-5G'-AT>!*&0K)QF8'/
M[_VS]P/*W>FXOU(4FJ)QY5CLOFQ-$DS\75I+/EP3O5@&:?WO5&3BW15@ JA:
M?R-"E;G@#.#AMN^:FL;L0OCA?L GSZ6R[FLCI_S;K4.5!9=,Z*5\(5\O#O3!
M.!1'0F\&&H0$%B=HXP7PY=-1*KDN&!;"9],OVB-A50^R["57-PZ]HS]KS1SL
M(Z,6R$EF9&[XM]63>4^":1HZY Q@&01D@OX&58*[/:^0_0SCT34V]4YE@;__
M:!'4/[S&8 ^7S_U]B>A7;1VIO?IN/B#-$='T+[^V+?J6A4RXE?G-7?31\?7D
M)X+=LM=^5&G<2/'U^M*.>R38 _5!0_MA0*3=7M2B,!ZT,^15&)C6T;33YDN]
M-+W^LELZZ7'<'E_5=P.4A1'N\9>_ Q3^_.K:HN'L'+1,SR)^S77[:!=J3!V'
M5]5C0TA6@3=7NH%7R@^M0<\G(,@=P\A9EGF))-U]R1&%)-41GAO2W5SI<[&
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MBG*SZ[R_%+7@TW"YY-Q[U9+3SNC&D,,_]]W<W/Y8DD)7$?[%-?&9FY-6GL?
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M(MA<=(FY,@DVSZEEDMQ'@_"RF]7-$PF1-;[&HH-V#JF0R^'G&M\FC@'4?*S
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MG_]]#^][']>E/=)YN/ <'0#!3%B[GAY44CM3V=LW+3/%LO*$9MZU-J76X0[
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M)3*Z%.I-5H4JCWL=\1OY4T".0A.3DY)O2]]=/+34?;S-[DYQ(K7.#[S'LA_
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M_^=AEPT;RKY)S:")^XE8X14:O&1V:@8JL9J3-M-IS\Y7?3[Q\JV&F"YGL[\
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MA]%UWV"#V;>HF;3S?B9VI" DO WTW7YST]%3O:KNY]Y%LM9?RS=##?%IO$L
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M3:XX\^VZ5'U28]Q)"9;_2P[@<<XQ0ZWV5CP!.<P!(EPG2-^&+5;F)G<MCC!
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M-';&7?&=E6[%>-XQP4(=S?8#9^?ZE)2V*84+7SY8Y5U??!O(-C*IX0"%HY!
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MC0.X;;2F6$#6R[>NI<PV.T+&L->CD^9F(8%>]B]> W8LIWP.T#[IV0GWNW*
MAB@(S@1>N1!63!6\=^G*>(7%@\\REO:1S@[/.H%N<7 2, R] ?GG308Y )2N
MV$]FW>OG *W8K 6N@5$HG" "?A9:X@ GM5TC+?@S6AY&BS/G,6S%.>7'RYB7
MW]ZX< #$,B$133V-Y$4]1ETABM@?_+KKB(J1M5F^M=_D]O!V@:V,6RT4FYU,
M&7R'&H%JI(^SIG8,2M<0MEO7.[\L6LS-2>VMXP#V6 6)/5MR1 RW;\^2SXJ_
MM3O$Y/-F^71GIY<3>H:UNKD3JB7II4]/R9J=ZRN^93A*HB0MF\'IN!<CC>D
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M&Z"SC$P*Z-O'_4D+/:AMQMQ54[SAH+,7W<-N;JDT&1<F?Z3Q4/":R7%#:LD
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MX8'S$#3D@:WS-X;5K5(<M?M?^6?PY9[],PWL<YK)+!+8"%DS]PAN2;V3)I-
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M4DE*79%?V]]>,H[9<HK\1!?,QJZJ%#7E8%FXJO\4'-NB#%<C0HJUBF#_3B#
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MD2P9*QX[J3=[WM(TX=[?>P4?M*.4_9Y%?$EQ4@7X)X$_8/"Z5,"T;H<@./X
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MKH["K[&NB?/6V;3D\*3UJJ3\^AHK=E4^5/S,$,,H^BH5 #7^7:5W&BE+EB%
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M"0\<1>&EB@\?5XF>?2 F>NG<B1B%^3/)!((YV\+_-XL3;S=^J'F#\''4MCO
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M%<WY/ W*2*R[3S![G&$H&5VL!?N*G+Y9Y4"H^/"_M3T]0TQ0 ?A'=BJ'WOC
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ME+A^/V2 [\U]4]F)@&T7UT,??-!?ZOU!;[K<#&R6 3C%S$#IFJ40_F"$]7"
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MY6N@V@;B=&XV$-"OJ#J.4\;#3WY8G^PHO>@J[M:J*U<P@4J3L[B-)"S,Z-R
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M!WU_'UMYZ!H]6QB%A*W1+>VH?47%?C^V<LRNH5>"ZF@<_>BW.01S[[ %Y.8
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M\SA9_ =$U=S&SN_*E9S,VZ=X?9.:O<[03S/MM+AJ-W/);R#IJ7J.3+&<M&<
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MQF2.$'0V'.$QE8/VG@K\-CUU*-2%Y!K;Y[3R"L$ %$O#RFZ+@[:LEH/B HI
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MEJ[#)>[)!<?Q#@L?'YGL,ELWA1YG?NPGP:&G@>PP/S[_M)HMI(")M,@/2PG
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MB$N*P(B/@L*\$6@EM1]W6C2!EXG,8=H;&W%K%2E%F^5+$_M@J=RH4S/*<')
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MS87=X8H0"5FT4EI<QV6H=K))["PWP%<V7$HR'Q/ERPOYZ=!R$+HPEX3=7&
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MG4LQ!$/7HP1\]%\&_^H+,""3#63]'/SLO";!!6B'^QJ9?SNO4E6@S?C"?08
ML,;DUUK@CK<H/P-0^0U(DZA'5L"?/C.?(KTDV_%Z<BL16CZ4Y'VGR 7LJE+Y
M!G#8N!8)V !,>+A)#)?ETFD;Z2@>'2*O9,(&D3#LK/UYS5SYB<!_,06R&.U.
M4]G5)_,0-LQ&Y-TKT;6$K9R3G>5_GJH[)WLOG$TJ8_FO<\\?W3&VR#A@5IK\
MZJ\MM5>G#O_]P@QD@;>^0"^:DA\Q & FA1Q=$YKYMXYKJ QX96%[6!%?YMBP
M5:571'U;=-7'QSG>'1S%HK40^AD^ JH+SM,D11@"L@8;.!!=ZS)02%_1F&^F
MH7]+#3C-YR6\O\PM:+_PVL"^Q9[80R0Q -5_L!Q04]XZ4D-ZZ@DYR@WY_-6X
MP5\L=/& 1V\P)T2__<@3U.!+P68KC/U>N9-B481"B6<4S*#G8C9SBR<V@-7
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M_/*/$8"E1[*^TJA)^RXZC6Y@*3C9)+R%OCD/_N\=O&MU%*'>!,A/CE.HN*:
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MVW0.1P'+WAZ2/YG_L"?:@Y782(SH[_R(>-F%5FO2I:A#0VFO=92#WW1A692
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MO[<X:B9O<^11P2E+.ME1"*I1\;(R;MF_@06Y$P?'KBV7#*BST!R^Q_88#&V
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M\L0/GX]=#I6%<)FI.2](G>> #7@Y,H8I=6;/?)T SWZ2M;O!02OP[O;)C6Z
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M[J73S^(O=.?$?)]^S,0@8/IUP.#45YW'ILW3F 7RRVJ%:P7IAE5+9"UB'>Z
MR"34GG$6U]L1JDH#-5)E898Y-!D[\#918'.ONB)76WE^4.K+U8N@+MM>\%PN
MD8F^E7P5MV%]#=C'7?6I&'T<.S^D_^-';0I1\D;LC-5I+^L;=^ZZ-]JO0_)8
MC-5V+"8FG==M=#%HW6V7<T=OTIVS'?&C\B:X"?/)^]^;3HFQ"JF#Q/)X0"#0
MN12SV!<SMUFM%4Z;F]E=\@VX-FP(V]]&MB9)AA#[@%[J OO70/CTYH]+;JI
M3D^5__F#T6W8S6239M+>D?S:DQDQ>^VNYD&TJ\8"F<Z8<!]J4E]6#I3@!C'&
M Q((Z',]4X/1[- :IABKZSH7I65JT*8K^1&/F:+O6Z7&O5[KER-ED$& )=X1
ML,T%1)L?=5^7&/^6L;84J.^M9 L=O 2Z_NH,=9J@6=,62(44D2FK754%6,TG
MZ@(&"T^DU.I&I- 5PI4C(C_*8[NW+Z>8B;X7?J8;L/!13/_4V*H_JV'=GP(%
MJGS=?^#?J>CL0((5'2[@_4AI4(,YQ'B_!578H]M<<&P'EL[E:+1?_O*;J@RY
M>^SI"GUMKUIOGN3DX#%MH7J3ILNJ-XCRP'OY7&S2_&94Y-/)K'##6/SN@^&L
MCU'02OG.)N"DL'20T+%6.60&%Y%R+45V[EK<B\O9WG58DFI# T+1$5Z;]/=K
M?JD*F &(#@5V=@4^H;$Z<R^/LS^FA"X5J0FE1TUI5Z=7,6FZTJZ@&U'![/ +
M#:< \<:C=7.,]8LCD<HD7Y=P;3=Q835^UWW#SE>^>9UKXK]6<N'N0RL4D"YJ
M6,'IB3$%Q.ZQ0UC@)S(QM/HZM ;AW!K=>"=]M)0WW4]'Y7BX.UY)Z4T+]\MC
MG4()@QY?NG5]1+_UF$\*$<(GA[U24NB#FH^PE@<JO/$^+[?V"]>K2LM#[<[H
M#95VR1:9BGW)+%C$:I^"?1MXE!G_%IYM&1=?G;RKN4%#D/5!X!\#(F]GM]D@
MJUQ1N?(EJE]*5\ITKPLJ1(F DH4BMGXZ .Y#*3OZP/7@("BX -8SJMB0Z\5:
M7)VS_HA76%YA2O9=T0"#FY0T_]&B^%:DR<#V7FV/V=(+NPSV2'L-L4<) I<T
M!2+V60_5"JE6BNJI(&$U^V'0!\!8[KJO^E?[L*WMQ\-R?I\O+:A:&65>[3MS
MYY/G=IAQ=0F3@:]E$D0?H/-?R.E1NRVU[;@.WY6C@&9#*: S)]H6HL.\OT-_
MFMX9LK.97$J<"R;?X<3;0 J,FZ$7 ;FY[7?\].52)X!G"D_$=4*^)#X[7\5T
M4T*XE/&=^>=8]\:^,Z 3M35K2)%K(KRQI>2Z:<S//SGL+%-5KA30TH&X *H?
M!5QU(#*OSXMN.N(\[N+T/\@ASCM.^ >%\J5>]YT>:35,9GN;+7+_E9;\O/KB
MI]<,K$?TZJ^[Q?04AHC(H_2;J6&.7D,X_3UE_7G-)A6/=OY2OJ_8XKYU_?!6
M!3ZV\'NZR8ON+T3-F*3; MC'$Y0W^I1,@ZCR>HN*!AAX89V*25'%RK:%/GZ&
M>F_$;VT&!7LHYYS7,)PD_K9MA[:UR_S:0U7E(:LQ%>FNI0.D3?(W,3K#2-;R
M-T1P)X @GU,B, ,+>'1J8_3LM&G+T8M?)E@K"LC52I^- E+JFBSK#GJPT/-R
MF5?3XD@4;P?8%$#9@=.S\)/KWFS>%I7!N2(Y/R?\:ANWZ&[?72O25!GV%Q]:
MR0NN9C]=YDWU;3^K"3L1,ZN62R2!8O!\?[/^.:(;5C)KCH'3T6#MB'<G6II=
MQ)SG=:G&0KR7<A!_9\R3CZS28;%E7*Z2*\18 $$U39JX4XII@T1%X.,W:\>M
MQ0['>1^[JD36C?._B@+N;2_E#I82N:E?NX\;V4ZG@.@<6J,97@!&2Q>X!OWO
M>;R9_G-6/BI=!O)=UDBGNW%ZNK\;_IL"PON0"M'V;A/<VECEA[0MXH3*FA&I
M)/8:Y>^"2],RP0'/00)S'&E,O"8-=:1RN WX'/FWHDID6]LNX-RN^(RCR*O3
MABF0\?:-7CZ-O3ZMIM/:PCQ,#$/Q1HAM(8Y^DYI],O)+UI9VMR(D]QZN3)=J
M5D6(AJG69EY2O,#=(75,4%V%@M'4A_U+Y5K9A+>(2%@2N0=>VA%( =E1$3H:
M&^EC;E]37>VNFE,X_1X?OOJN_4_'N0)I5MIS=&NZ-_$Z8L-3S^9KMG3#7AOZ
MGVB0IXX?3NZ",(.=(X6:)D0#*M ,CA97$I0/DGZM>QNU.J059#_(O"K<:2R]
M+[1]@"I]461_6@GR[5M)7.0&3!S>DJ"J0 ']&L(>OUM[1@%##'XBVJ(/"'6T
MNYV!:F)S0Z2@>K/F+_>0%H-DSRITO;2L^X.H)K5R4"7+@O#Y U8"O;HSW2UM
M;=>('-9;/^J3E^'\JJ>HYCX*L,\'A-I&MR53WX8*_7@?T.\H3>K*?':14WOK
MK, GM5-AQ H<+9%1=-Z*3]"G',P'&!+NSLA/KYWX,['N!FV.T:H^?MF58+KA
MQ1H;9OA'(TJO(P%Q"]9& 97H4S7 MO\L9M(<HQ "-2B4KLPMUF6(^R.V;&>@
MF3C.M9B172(<]TNJ&U()(3);+IAN*A#4?(([Y%5%L2^YA-<O5"8[YV&FBWY9
M=G#0F!N.Q#,1)FFB)=^BAKK%E@E=^3W?,&/[PY^I<=O-]6H 28VO'@,8"NB>
M?@L%1.3 P'=X_24(('B3(ED8UHW@1D%MYWO=FB>BDN4C5=-*7E1Y2_\4?BOX
M5"MVYF858^7#C9U;J %%L3D%6J\_#?O/[%E%'$AFAVA\#RD$>HWP%'#MDMH6
MQAZ$[578#WFM^WS(8:Q^D1,M]#,BP_W3XYVS/6>(Y"'X;"B$>0D'"GZ$V_Z
M+%=9Y)ZT\9+KZ^OH?!'CL?F'+$<04K?GR%/*TM;N,L]0)]R$_<Q@)B7 N-7G
MI.BO5UT01C@.RRD5O3T8.P5Z4M+\#G0NZQWM:VW56G76[.P_A]D.''GB0JWP
ME_KC!0P39;-477H_:4QNK2?<-QU5Z&7_'-//]XKW-9UA4?>KUPH.:4^QZ!*W
M)L0$_6RW]0J<K<[[BT]+,UN-I[P%;V7:UNX$1Q_HC=^+Y/B.][M*,>4,OD>9
M82&2FE<:1DF5%:27CTE[<:M5_MMNNHA3/L=/97L7I((Q+%[Z(? R_=8$P#E_
MS:YBYGV>1F]NV4V1[W<[S[\5#ID1/:<]<:>1\YBR" >T$>[X)&FA2=]@TNKS
MZ>PZ23^C6V:X0MI.44 FC'=*XGY]#ZDVO&,_&_VKYFK8(VW7Q+'1F<"XURX;
M,_A!<@XO_;TAHDSF;T<NXVP3+OL/="[.SB<VHSAB[A9<W0"!C->N%KAT3<?&
MZG1>S0R[=^YJYKO_IR;FA-FAK_M;Z:#G5-<C$*Y_] ?=C2B$=TKNDG^@R0&.
M*:+$  GP>@H%)(8JE<Q9NYJ9_<^/ZOZO:M;W"&8^S!U@1M@I(%H;<)FG[[_@
M,VZBA)3?:L<AK34C6SX_"-,8$ QZ^%!:PZ?7=Y^5.5JQ8N.Q??>V[<["'(+(
M2MM. 97U![M N0EJT)LX72"H!:I;+'UH-!/9<7KP4<%OGK<ABS= "]5_J/C.
M#&BB@$YKI=[#2E$5.=B4S "XL*[-6*\?%=X,,JPV?BLRD?_A?.L]SC>V@1FW
M2*Z9R D7Q3#\6&G-96NZ E=,^&U44,:)(3(;41F+"=S+['CX:P^0!;CTZWJX
M3D_-+'.J_JFQN%H0G[:X)/$[B_5L'O+X0(#(:1:#.Z>AQV6_SF/![4CO.?+'
M>?T /H'1(BI(89C2E=B*R9HNU\^;K"G6BE9Z[M-]XE* EO=D7--1>UBH>O?H
M&V?#.4E3/PCY8O"?C.,\5U1TL^)C7\U6S(<,H0&BHS-7FS);FZUVSCD:6YXF
MONN(N98%%3WW&K< ,C7>>X!^X7;69ZB-3%<#^&/A+4S"WRTQVV?F57J$BEZN
M?/..S\SW>A12&+'%K["VSUIN[Q16:+TS\@;M!]?J:L=Z#@T4JN(WX:LA5(1^
MX[0$RV,6%@-UT+]KK(>3\RX7T$_1DRE2O!IH>T %9^WV?2TV.I%7QO"-9!$I
MP7OKU4.0^17R$BS4X+[_1$Q>#>S:5H/_D=*-I'HZM7TBUS@1,5/\X=2-4SR!
MO\(LKGXY$?8_M$(GD\@\QS&3?.7$7F5]C@RV"5SLV:EL3Z';9XH&C*[FB[(/
M.Y9O17='GR4/(\K9-YCG^R_Y^"UX!]7IXI2:^A5)X:T[5MI7[Y_^CK.2+OWA
MU713J[O[SJ*G(C\+>#;'6H:41Q0I@*H %["IK=Z*WZIHOO\863ZA61YUQP!;
M$A"SI,WGW/GU[:TML,'*UXX)S=CBPBUTWM!BDIP$'VES!3I). GKJ0*7YC;Z
MP1F<F5K H?M*N2-RSZM<<!TR8@6MR"E!P0!?MBG-4Z:#CPTL^ERSJY/C!;[R
M/?Y;Z=K3W/ZT#\I&BO?-9->UY)1:H\13?\\:IW@^V#!]I7#C2>\[?>XHQ9&U
M?UP5AAZW8/1.*C\5OHW1H?=&6&'9 ^JW5G72P4LF^R/HX5383H[^'^^] :E?
M5,NF_A^B^7>-/Y&*!7;2="%'?\![S<[[BF'7<IT>Y1 +,.'P?"/H/N_#5:EJ
M,^J5]S_^TY7_OS16:PKH4<7@IDAM?770X*C(M/!N)^,EWT1E&BOCW([M(/:#
M'GMG''^S@D+$&V2=Q6:AEOX7@RL>%LT).J$_U&O?F%XQ- #2H_!A3HJ=8=U-
M"4'W3GY25RR]^E],K,7>;7#&.M%9-4Z<5)BL&P.=ZMR(UUFDM[]R.V<!F0U
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M;G:H0;Q&I *DUT:GZ]ZOWM;,7)^B[NZ=?T 1ILMP(FLPO@:WW>B)#0ZL.UV
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M\ES6H>&WNR%3T$GT*#]TSOJA[.)HBHJ?8W4%1_YC;0JHY1"*!]^".[B-%W:
ML4:H2\!8!^P6D.R5W99K+6P07.'\B^]._](]S@0VCH&["YQ]OEYR1_M8[CD=
M* .@-N=VXEO^E2I2Z N)5(,4&6XK^?FV[D27ZNL^4^Y#<L N5;,.2,FJ5Z'>
M6.^P"GX:J/-H ]NXF1.CFH=]SM03C2I7VRG>#S(:=">CU.0.:#<7"&Y ^.R%
MY2 R*U2V_(G'?''M*9TJ)O5ETB<MZ(^P=I]81P[>KZ5GI!L7SZVGYVO(?JE:
M*C=!UKH=IGVO-U<L\ZZ2F^D2W_#O4H>]^ UKQ50JA)<'X_AJ"=I.7 QA#@:*
M+Q(GD/,30HSIL1SG6C]X"MZ:]IF-L8"4'FRB</IS'9NG$"#XB]_/DJRJ$USV
MT(P?M,87W?;%EDYDE^@V9[\[<_[5N/"&0;0L*9VT-4V,6^N.1_+!RPY]B]L8
M (EM8BP%% 3'<U930 ,G&M)(A1308C/Q+07TS)W:(PZY20$UN<$7DX@R%-#W
MWGYR".O>\B:$ KK"OM!/8(XFAUKLYI#7P_<A1R]7(=L<<$T**"?#^U^H"?US
M(6SP)D'X8J\LFG">>OU*D[4*+AK?!O02]&&_N)*:$..E+SSUP#IO;8:AC^;^
M%V7O&=54%*V+1E$15%"07J("HM*4WB0VNA !Z24B781(DV)(% 4$A @(" A1
MBM00Z5)#1P1!.H02(!3I"4((I-UXWAEOW'/.?6^,^R-C)#N[K#W77'-^W][K
MFRM8/;[&^&I*2N-'R_[1*U_U+O!I+S3=O^M;ZLSW?(AVJ8Q^KCW:T/S#XD8R
MXEU66M&AER[</>0U69M>T<SG6=#IQ$/_4@T2]AY+K/KK:9T1V5=TD4WJHG&R
MI#GJUAHJ^_B+X T^ZI,!JGV(=8<X/RGH\V_XI3]F@MN$"CE 760,6$=%.M 4
MO5._LO0X[US#D\4TQ:2H"B,R$R"__&MGLM<CGPGHH_+'TJ98@?$)S9$TFT[5
M@SE3-$@"G8?;L7MB<MG&0D%T/>]:<*7I[YZE=-NW7!5=%-&S=9@[K"/*85"2
M=!O^M8[ ;QA?Z5J&="P-C):\#LZ9[CD^'R4ENRZB=W<I:\Z![<?3X-(5*>%G
MA=46U<V^^.@_7B?K'F:IY<9O[UCK+.0T*[-.9@GS&8/?8/PR[USP<6<"'$GB
MKTJF;:9GUVK!?@&RT)A<C\0>EU<2%WI6Q;6L/S(F\.<;O4G<Y%V*(=&Z9?;Z
M.$S-[60LP5&8J^!F>HHK5-,R[:>;7,VL:/R,]O"Z_4_1ZB_Z!QGC/27XK>DN
MQ2:-488]@PN??JBD"WM%A3.F@A&5)]*^4.Q;,YZ&;7=@>4@%4T;QU^PZ[!^E
MY$(R]#T.S+3>=ZSXCA'I(F05>@5<<A5$3 [!D.-&8!(+(A\[2'^>:\;W^>D9
M_#"TFN@^[2I^4M=O*\SJ!JRG1XX_[>_.MN_7"H<:\[ F'T9X(W+H4.9O&CF8
MCFF6AYVE?WG*.,H8DCN1&URLJ9]#^7H]M\_C9WN:I9FLN>(FUT--+'?V<SH'
M-00^3H3_P'(ZCVR@G4<:G=%&8QDJ*5VPSS^/)(7>NO#AEO5+?]L/KD<- IZ<
MM>2M?V'?/+:WS;CSQNUJO8\MIO?%H<VAW;\J656('3/X"29@:I^14(V&'&'T
M@6H@W5CN*<I^!Q,@7@T&0)Y<1X\F1!^?Z?S.&7I;F;]+/>=':Y?82]!U]DO-
M8'J5MC,I!Q(C?HS(W7UR4[[19%[# >>=&GMT+945+RH<"BT?G99E\[$848PR
M-ZW*&9-_XY9K;A>^OKUSV=PTTEK,(H$)")Y?AI-O,W) ^_H[1=?402/ZC#\,
M2ZF[TQ]A5VAU_QXI7OU,80TY)S+V4/\F/->:@-P<)RE84D#_2N@/:3M^\21
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M2O#Q<[_O>UN*WL7\ECE)52*53HYT:X1%DG5@9E@_3@5/:VSB'@Y;UKGB.%!
M4R;YC)8.V3NTYCGVGO]=IQ\_)G#M9_O[VX (F8(R\,(*+0DEC)C@WV<"[MT,
MI=2,B>="?OY[W,R%L>/8AZ13[A+ODBOI>4%HEP=$Z!MMKP4\/Z6@T^QREJM"
M=>BV6W7[=O#+^TL2_L6WT^+COB\& 7-0WU8B=71HQP;ADB&]Y$2259- U.Z,
MNH/]Q'K88ECST1-)7NVE%1]PA><O.'^O.S ]@DE S,5G:&NF;7J$!TD:2JPR
MA!N_QWST?^<6H8V$&;3_,8%_0+3JXPY8P#Q6&HQ?"8\%4#4/($^B?]%4?0=J
MO!O.24?G;DHTQ.'=2B!1& 9G7>\=SB8W4SMYMT,$1&)."X*3)F>QL'4LS&YT
M%_P&1^]NQW-Z$0:.]A_L4C;F>\Y5_QJYT+>C<Z-<45W=048%'$#5A0]CB:8#
ML8>78T@!3FD+P#=!YU: 5;/5AS-W.&.$9]<L>643%V'(R$6W9ZTE'5CG'TS
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MWH7M30Y23S,OH[_"I&!"I.!;!!, MF%,%FEZ]'V\?W#VUG4#MVO/RQ:F-X6
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M0Y>41R)F3@G"5J?8[U8,$\1W/]BF<)T,'I *[BYU+O-H&?,T^NN$5>63W64
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M--'S[4U7&,!853@]97*L#T:R8 =W0$D&@#B?OU&)S6< A%SXA@V" [TRT<8
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M!6DB($4B*EU E(X0$!$0(2I= J$(*%5 0&F1)B ETJ6&CO0FH" E@/224$*
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MFHU:NQ?)(F$PO"%2\R7!]=NE2?OKYK,G#>A [%##(?/G ?/?/1:?'TWU'5!
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M-#8]!=IUELP+Q?;GZ;^T6QZ][U8=-C# 3P)S+6$BG'AEG*BJL@_%5D$PYD"
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MD,1(J+.1UF%G*F+P5LCJ5=B"5CL:NPI^&4)^),V+F/7,HX#.#<<2SI]M4:>
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MQJKK)T[OGFIWN^M48H&@DAIUN[7G,,[LG0!#(*7D2'_L9J6&Q)KM?=]&')_
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M3EZM=\R4CO*\]E#[DJK"@^@QC#'S@(0V8X[M&X:)MH26-'ZX;P[Y)Z12L6.
MN=,>"YW52 Z#GQL+8^+[OKLB$DS_QG62L_>CQ/T+W$SE5 (7==W<BK6W_"&)
MOG#T0*E1K(ASBY7G)G$ R-^#W1'-&JIZ1SJ$EAW,5ANS6B>9C;O(YK#'?"1;
MIGBXPUB'O_0AD,@HS'8%7A=VZC#L0F!-P02@1,%6S5% H4"!)K)S=&.'? 9-
MV*: [E6!54B&6X@EY.&FO\JXTO$^7D NR%R)V9(C.>(#LNO6\-Y]_D!Z2M-%
M ;WQ;IXY7/M$ 4GHUAO?]7CL#96<;OPT\:(1\]+M7J%>)<DC=&-YZY,\8O8=
M!#N"QJE30*Z(KD:$H[5_)%D=L3O2<X1<@:ZY[Z,%)6[BZP!KDGPZ.N=VT?1J
M)U;.K F>CU@[4IXW4YAQB=O<"0N;D*[5/7-3)8R'>3M0$9R-MM7Y54D*5>/7
MI^\=6MX_'<)S\'*$]?#X3?52'&0.&JBF$LM-5,'ZXBB@&#:^ K5FT63W_,]L
MQ+*^7TT]HIK;BHY4WM=<7I#QDD,)^_9^^R_JK$G[ >$*X*D6\2X7"0L/2XD?
M_F,V>=^/=YN)/'(F?ST,2R@D.F/W&FLP#3?LSNBM67%J=HI>^?+YX,';?!$&
M*@\QYV;4""(8PE-_#;>%>10^/\#<30']4,X1-92",T@NW#75S@'-7I:Q]7L6
M]T8=!6 XP8X/))500,[0T,/8(%63(U6HE;-B6:OLEQ%5SB(M=_9.(<\+ \+Y
M*R&)JFP2/R&V E1SBBW([Y'S&>_GH$QK9,YOEQY\D][-EZ]C*%IX/H$0E4\T
M?B,H^W5>9.QR:C1C>;Q91.W.I!;)8T?QSF*Q+BN"O9SH249_Q5! 3BR$BQ10
M.^0UE'L&,[.^8AMYIMZ%[YHN$T=CP[>%^V$^P]>'.EE.J8L;C$Y;:%Y?0#BC
M)ZCPZ=C8]:TY2#BRPC#8I!A^CU_6.4"LFNO3T !GVSWN7PI%@VDYKJ$M$&IB
M$[\C!=3,N=N@O(./P9E,=6>O<F7PQ14KGDJ<>L;XM75P-FC7?@T:@&@V\(AD
MML*+$<)@P51.2<D*F[,.YZWR@^=_+J"&HC5\_$ZI6HVM;I*K1LJ!JCTHE^'H
MB7[VYH^<AB<I:,_B]P!QB6>6R->19R%K\_I \NPFL<>+ED+,AD.VJ0DUQ\<:
MP<@ASZ#YHS.O">,$^^/S6\+"AO<0[W<&-FJ.+'\$?$4RF+5)V F6SDGJSJ\#
MRYU<8O2O"8N<-S'P"BJ1TSKB-7QE:@S8@<X!P@6Q#B1]%XZI.2D,PJ"_J,=H
M[IQR5SB+O:XK9D&^+5LH4'/]S761\1EP%73#"'N$?X!EKAR/KBB=<RFVR!"
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M@2])E7[>_L9?-UZNE0ZH[?H,@+G+17T9*W8I(8ACVU'R=USR#I3D3AW'G/3
M<<%Z]<,' NJ>-Q9&JN7Q; \2JAS=R,>IC%=S(WR97,,8W2&_P#A3&B !PD4\
M+@V1(FZ4VF+;?I5E*\SV3^HX09^]%JX0YCK'I1KX[)/X=_?VF$N*JG?_<AIB
MX=(&@EV&\)KRJ:KZE<U.45,V*S/\W'<RL^/%?K;7*HQ\T@,CY=TA=DM;>S'*
ML)T<3W^\Z=#-D%"EF'K,F%0A%V-L;'C_(R'1>US'H<SJK:O-SC+8D<@V3-O1
M!C(3/NB0UX+@3T.W-B 'H9O3L HLSA)]+!>J2>VT )Y<L*1C&P8+&B#M&5Z'
MDH@$GNBYV(')/'O4A]A'-,"7L6AJQ-@/:#L/>GDBA(ZD'=Q[J:DV%@' X_AC
MZ*[<*V-RXS$=]ZVMLW.;W O[7Q!BQ)+]+R,_2C>Q^ZRM-$"-# WP.=N1[I2O
MQAN?K*)_5&['EP?%B9=?,M'B!OQW^^_VOU.S $6!EGXM45' $XMN!Z(#5747
MM$7'L\6FD_'EM5K<9@GB!7& _S^T8TLJBR5.N L&I $<57:$.Q[I06M<;"+X
MNY1]P!"\@S77$MAB^MI3E73 &RV(-[47B(Q.!+T LF]B6; +JE3QT5T%L::&
M6A?16G38PIA)8:J,Z)1Q8^,320YMXTN4CH*2;)\5Q;Q4+(Y.S<VFRB^5()*P
MR<=UQ[.4L@)B84E(X(BZ$!F,V\ 16A8SP\')1F;[/_TVKB8*3>B)__A2-K7F
MQ6CPQA#2#9D"U@W =PI)BMTO%[:FO2M/<;0L;/5XSOQ8E4/P13](O<NRNZV?
M]SKNY'F<AX09#T?L;*"[IZUUZ*#A@QSSMN;92A!HWZ9-]>@WV9@" [E[QF%Q
MQE*LCXAN2WN11]E1.0*C:1,VKM[JN:*M"=# %<,5W;0'/Y78/R>D:IYS'>R
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MRPBMB.6(F1?M2PG9>#I61 -0?ZN%JD-=[Z(D0Y1Q.X,QJER$\MV=&JF=N>"
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M.N0<M*D"JF)#L8;_\"1*@\@AY*LT@+<9U0^AX#@CWD[).E'/0U)3JD6#,B3
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M1TID=6)%4GN8K1@#=SWYN*PJUEPKHMJ?5G1A=HIY0 )M\#;W9G<$B0:P0*1
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M%'J(3DM[G9S\FUM%Q.!%4 1BQR26U:'$+1,I!RL0B43KNUF^X-3R\Z\W>3*
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MQR[K@C$0^1(^\C-996FP\)1=XNRHGV+=DY]66BSR2>8&YSZ_F ?H;?QFPZR
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M%ECI>FNJ4UI;&Y/R5M6[O1)R 8^,#@DMEBY?2 Q^B!?\T.LZMZ&4,GO?^'/
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MQ3/X_58S]$3;JFIJL&#CGR2X"3I<_TM36W/:CP9D8DD&SFC,)-7KKBK'V/<
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M?IN;"CO0Z(,TYBIH,G^&I2<F2FV7USOSRII($'Q'BSYORW"]$>K V8"1>8>
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M4T%"Q8MH\@^:%V1$$XT(5)IK)<L#Y;14XDP%_1G.9C'19^"]/VRH.K$S1L-
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MAYE!XXJZA95N=;RY4+_$H(@T\5BVG]%?^/UM$0V(&>2_%\+;4,XB+B.<N_.
M\#F%8$E]J\@_!1:QRWE:AKP^LZ$6?Y"X37 TY""@18H*^LF#HCP99^=8\ZTN
M^5)&YH_IZSK,+"H0^1YKVVPVLX\^_+-'!@'9% 9/HE602ZL'UGKP,HP+7U)8
MP;C"_4HU7. FW;+E]^?O/H-8KW.#YJ6+$:TOT$L8568JR.$^%;0NU!F,Z8
M0G]=.JY*HA+0'F^3GUS/&9%LTG6\V"XJ$/S.>330X;J/J3^=_!H$9]6Q1P6Y
M0$\+;Q-A#]\$HDZ$NN7, ]LU/L_IF1_[BDNG%M<5%ELD1U=X(\(R,;_RB4J(
M5O6JA&FCGR'2G:B$D+EJ["YK4%*72HR:@GA73?6/"K&+#:)W>51N39X1G8W+
M64[X!>8@G5J$3G(1^F):$6=(NL',)&&%6]9N0QC9'N^ W=."V:<LOW_DU!;O
M[O]"FB*_ >A/6Y$N /Y,&B_<%@:43%WN@)WCT7<@4.BQ'O-/HY/UK[2['-;;
M_L(U\4W3C4N1:R5SEPIBKA_0L@&4S$(+"J5%<EL69P[0@""XS1K#:"L=4XUB
M S*Z&L(_HV#&PE]-'OO\;8KB/JLCF4P<V!Z4\.A!SW^D"."Y:.AX6@"[^M-3
MPS3#=,C/J-K(BQ<I=7.[;)R!7UYP:_],M [?*!Q2*'_L0*2QP[[':%?I(_]!
MLO(]RT>!'7M^+[,RY2SLO:MU1-[[AA9JVS7,44'!/8A62R$\$Z0&W?995?!W
MUDU;_I_KDE=,VG:)]Q=[K]T24"$<+HZW1.&T2:PB"YF#$4)U0%H)\*;+3F5T
M=+#0XXVQ:XV-HM3S*RKUD!#;I:R7MU^O0&J]LEUR_FVXA':)*=5PK8J7% _V
M?96S\?B5+H%VU^A'Q<HR]F9&37EHCEJ/PP.M3U&*4<MKV?144-+A02UVL)?Y
MG84=C:Z%N\.G3XS:&C&7;3;M+\"<).R=N426S3)_&1O5[N3TBIY??LD=++#S
M;@<Q7ZLH:PE8+PCB%::>CZ)L>;A;&1C^M005YQ&)1+LC7U'X1[B=)HQ257,@
M=_91#D]\M 4D$J)I%@C', ':"Q#R6RCZP$8^YF/1L[5>=+"I-]I:2P_C;8K-
MCBX\4_42/=!EH4P%O</@].WI8(\!)S?L8$Q(;>3A;I2=>&V"^6BUZVZ'I)M$
M'[@_3B%%1>.L2CM3_.G84^_^]0T&,%CHN0TD,\09\L9']QO&0Z&F)EG^;<1-
MUMF9GIIJ;=[OF;$V\0&O;H?_I$0#;F:J2KEBKXHD;X!.O3K7^@\*5$G@ 7L*
M(Q=NUWC\DS RP ]3J=HDBF'_(,Q,#B![?,]QD#!0539_F^\A69)<04';!KOI
M&;?_;H23GOF19E'DL.X*&&WVX4HDGC^DZWRHF)UJ-'M0O*OVM+\HRJ#$6$];
M^/R?EU\/]AFS(!>.!SN4 VG5*!E<A8Q(UL,+49IQ'ITFGT7*FY1F62L$B4-W
M[:L><',[WFV,.'6E!S4I1NKX9\:-&GM<)$Q\.%#</0DS]U?PJ5-3;KR\PQ:C
M+-E[V[*OI'#TG4[Q1DIC?K8]*NSB-SWYZV(^6[,G>:E')'476N$^^RU+!345
MTW;[ 58G!Z]Z*;[Y"H]U^'G4-S_$\2UK(Z(P#2CF]1TC*!<&7=0SB1PDF:J&
M,[;WBI]HBJIIE+Y=0#_RV+@(ICSD'*'T5M!BL"*?A8-)6%8\!TWH,N<W#(KE
MS=J!$$/4_^F=:9BQ]R*>"B+'_OOI;LBBP@.,TY>>PMB.H?S%!QG=9>WL#(_8
M[HQ[?;S=R.GP"N!-_HGB^1^N:Z3,@6O*THA"P*GG/RYO("[[?YJ2"Y/Y_4#C
M6\,G_[W1 S[;.MYSXBTWNVZ;N._T2IWD?B?&WNI['!,]O4V1?CR/F>F>9]XB
MXZR(>H 3#M4Z00/;G60OU^_Q<VI6*XM$)9NXC&Q,1.K#N((0NOJZ:9Y=Z"0;
M02V!H -8J)5]"Z0Q\BN;VQQSE1*>GYXYF;">[[[/YGN:_"0IZ I='PU]92+*
M\PKGUZ7@BB0+RVKI:#LA3*!7>N2L0B9[4U4\L^X2/7+GYDRKA/BN<D[N?2E6
M^#[0*"UTTH*J-?WKH:LG/FL="(<>V'\^]J7!BDH:^6\@9T,VL0BR="K:0/7?
M#T0KQ52071(5M'8.+8N83_41):,0KE42=)]7K_OVTCU*%CD$9\(_!77M\#"?
MWPQ49)50P$T."B8I_31C*1<D@L0'D:280BIH KVO+$H%M8Q20>!UMGUMRGG:
M-UXSBD$>XO-H@RMR+&*X#Y \0;64"YF+@^< 1KNT]JO=T2LQ6G5C3^E_U51Z
MB =[<>NTGM%F\[N6I:7E:]=.F[$2%?1!I'/P!*"!3Y[H-S\?_>,*UA#VRMA/
MBY\GLMX3Q61(42CS' =51_8: G35M7-F:.OWE=[VB\:EQV--&9XB>R%9R$4(
M(##8.@98%#Y9"[0Z4)>*&-?UK-ZDN>.MWCLFIOJ7C?G;)L^(173C7=*/(01V
MG%$'>,:BO1+&A]>.E_=4G#]Z$]G27/WC V-QZD?LW,@OS_:^Q^SQ7\.+WW0%
ML).SQ]!+'*'_^^$W^6-_VKSO_]L>KPM]5(5:#;8YL)#7:YK.9=\>/JK!)/1L
M%-6[=GD/%5J17QQ-G/PM) ;3$NT=.!^M)G$'XJ472DY:WA0!/AXN60Q0*[],
M?L>$7TP8.1]QY5MBWJW'ON'JL^0H=4EW*HB3"G)$G [JMKF]H3RROM?N+S*7
MNJ$?[/@6W0A)0?J,#=#&-4 O=;<((R;$I<E2M650"L,,EGR;QI9);)5M+<+C
MS@HGA@DNQ?:S?>?T.OF6^\OIZG_>X=MX)OW78B5$!)PR4N^;EY%]I]3:^W *
M>0<F24YHN4'YB[X*<UA$3-\'<P 6]T:\5$M%VH<C:OHJ66^\:DBY_+THPI$[
MX,5.C^ )_3:89HPD0)^^#<WB87?*T[K=[OJPW_&NYV+2<9EGF96<=(5FLH3B
MV9].S\+OM78QL\PCIA4)]>0F^5G?1X!2X'>8+$XX4ZF:2[&8QRF2J5!PD*E"
MM5%'I$_ST?G!1X;O.XP $2JH*\Y^83"*= __GO!Q7-[@ML&(ES]C*6N;_N=2
M898'@[6R^E=%^P[WXIZ9*?O)V41I44*]3EHH3B.PPT/80'-#B-1L@@TM-VC#
MGN.Y.HVFT(]^X(6_J1?[+I1:5LU8]^=+WZR1T;XA(+-<D_J48:U1VQT(("YT
MQZO+(%IUU"6">%JODKLC>.Q'#QD-7,QJP7+*+I]0D/O,OXRY0'&=X<G5<6'_
M^IKITHHCSR(51+PR007I?B]S(:B-2FQ#YHO1_)ZKTU)>WT:'9S__T.4*V.JC
M]S%EHX).R<_<*5S\1EM&]24,LI$+A;([4GHFPL1;[W>$;59;EU13#E!3[(#@
MM&B3KVVA"Q/7:<:?R\#*11XKDR:^.[MYMZ;R?9?]O%%P>3'[4G4GS1UD*'>"
M!EN1["0GHCQ)JR6)0@6UP[V'A=,UKD?>71!ZS5?O&IV2="M$U&N2[B +?;.%
M+05O1.),Z.(ZN2U!,+\8Y)4322I>GA1J^MQ-5E"!5V=R*T82/-=%>ZM7V4O7
ME'O%>-?=<WE@<\4K\)*)S_ 1S)XGD@.]93J&.$BR.IC>EYX.I1A48FO)T>DH
M2I*^S2?DO-$01=N+C8Q% FDKL#":H1[1TE0@'DF.HT'.G)I#&H",A,DL(B.1
MN,>0Z"PZG'1D'BYW,'K7B\:JG]2>Z87FOV;?3[D6SG"Y"*?E6WN-U6.#&;CQ
MGI2!COU'-Q%DH=HR-L++*%KN"&\G63K;?)H?M33Z1@5I<Y.BRC8*5</D)9LS
MCHD_AH[5D(FMW'<6!!?1RL>APQ-C?OMJT']/T2C!F.MP#](-XB8BM^7QW'ND
M>Y) DOUM7JX8U]BRD *S.Y1KP2A%VHD:, V\^3LL%11%NQ'2/83P-X>%0+>2
ML;\5T[I\[?>\>8.7!&3,&?]<[@:5HT;<2?FT:[P0?;1\X0H^JD:0E7,-SLU=
M;SO1D_5$O+.]5*$7GC2KIWS2>/OP>27I'BVC\NE3FG.IH#\77?^+VJLD%U=I
MU@!1;@)C,]!G@-1VZ_)X;J^MOTUN+W.Z#,\OG69&6!WN B\05Q%_;M/&^1F,
M!@Z][?^[\FL=/^8V\M%TX1?\8INELPK/NT)5*9DA/7,WK:, JYV$04@4FOT0
M&MV0F4LHA;I ):NTV*T%_4UN9P7>]AT("_PO6BX4%[D2LN3S![W9B3YXAG(E
M?Z:"EF)<P994T$'HA+Q;5]"5/I:*E1DJZ+0:+(;9FK'S2K3\!E%7U$.X%/%Z
M.[!F!@D&PE=4I*-/4CH&*JY4USL&M-XQ5A*<#[68V*.,("XNQE8 KW,$ /.N
M19']V O 44>-6P')9,Q34*)\L*2?C7V#SO!>-UK^8(T<K\K)3'I[2 L_Z&4J
M")\^WO!]S80P4"I7^UUU*R(/RF2N2)2ZG+1Z5+\[9UZ=OJ]*MYC?L=8B'C0D
M+?$T25)]^KKGBXJ$S"Y=B;OK22%AXIOH\#E69!OBPH&!P*,$+G5]755#]?7$
MSWTL&W1/R1<?X8RV#N?1I^V[$6X.0H<D;9F_[JS!>;<WBE]])2X*C#>+-9$T
M0WQR"DSL-G;)P4AHHF-0DX)"F=NG >5*\ZH ?:,]W0!;V\'!A"OK@?8,%/%9
M3<]/2R/2J=C1Q%>/7P9104Q/X?X$[0YH9, )I(T'PV:E VJH,*\4W+,S.P5A
M:82\"^K>3IS?%=O5QLO)X,4RQ"/HZOJO0R(6@ M[!J'8L*YJ7'8[A?4YS1A2
M]2E+SX/\-B^3%.M(9P/VP@+>*8ZI0 S1:5B851<55%1':F>JBLT>8+; S8Q\
MSJ>PY9%32;PP8[RRY'U':8^<ZXT!SSXXJ6JIUPNAYSD(LT&#6\7S&$"+PB.<
M+1?J=1AET"KHN\R<*D,%?5,D7:J&0];@MR>:Y/,UY@NE;Z#UF_=YQ(?<Y^RZ
M>,O]>WIYG>N]*PF3\?I3DI!?)SM7V_5%>RCE6W_S!5>&9S&.+>;'-2%Q08K;
MM @3W#2D@GY$(]:8[1RHH NKB[LD\B8&>$2+*G!9/R&F>K2DA0[0PSQQXS&+
MMO9KN*V_4O_Q_DS%L4J\[V]#=[/SPX7G\I!--8>WNUPX*GD;N0SS./V2\D6"
MA9/WK+R"D3\'W]6BN5)7#1M'5\MQ<QFB=:EW7EJN?'!8IG\5D#]W;9%/*9\$
M!\!NN,\',Z6R!.RN8;,D_TQSGL[L7353T#WZ/WXH$W),-^FQG: :90),>>5*
MKH(L6>)6R7!:.?AJ$69U>#W6%'LP@M?N,^G]X;O@$E_(,U8)FP@T3TFR,[?F
MD]Y"8PO]P6_/[JY(-3S<FWGOD'3#S((.QW27<+K%-WW5@OR-(J4!%<(D23L[
MO8'K65L72-PO"WEW9K$>Y43^7#JW.P^-GH_T2M*/^6B\8=!PREZ%I(![8:>.
MSXQXK?Y=#EF=9E;O"OMURZ0U8,>NKMLNK^CC\W*S_#$A(#\0X)U*O='\(E^L
M76Z9N]EL>Z /FX0VX-_U!&O,P$4H?5:![TC<P26N(;E;1^8LW'D1^PX2!?0#
MM>[A.4Q9ONM6B KF#I6!>_+,#!C#D6Z/RPT54C[&BF?]!O,L=?@J/-2I(()B
M]?"V8$,S_J]":CE3T_YZ*PM]H8/ZV0#[,Y334P!]!P;WX0G0<!'.YH4+#B#T
M%05>]FW2F\N4>:)7K63\1>1Q1DV"[W2;4]T)=S63(<_9PZ!2X12=WCLM-0TA
ML$/]PD5P57?\+LP6?W55*UY;.2!-9.I;[>-V?9)G_*IJV-D0]43BU?4]P/EV
MP:9%HL<@_\JMMPIX)7"@&T\&W^TZES\6T4$X*N@I"3KFU'2FM*7"):R]*/@U
M.B7LF+U055?P!;_BJ92/2Y=#6!Z;YQ0\<Q,SG+! ^%!!,DN33 J!Z8L;*S*K
M'YWZDENB]^S#=:6Z5^EC)>0-P!VU(<[EX@9A^755SLZS>_E]7\$/3R6\L)B#
M0T:JR0X+AV,)$<X1&/.Z=PZZ+A^^:E[S$KM[YX4C<RG,&C_XJ'9,73HH%3LV
MKF/PYVZ?#X.9&73,(,P%C\+",(PMX)DY2ZT*=PLGS]*FUA2MF:2EP)]\:MYF
MT3[%6F]J4/D9Y8/M6>UT40,.2M6&7#83$RE*@B.[GDV#?$ @\<;<!IL=.G85
M:1"MP'C&"C94V;^Q'/F4_@5+\C9F *Y 4AZF< -%/!?!YLHI31^.<U2*]1D=
MX\HLZ%1=OI:-T'#E:Q*4J&%MYVZ5'RLE>5"W<NM'XO3=P5<=$F)F=UOY,T,G
MKN/;%_S?M\5Y&(Q('#+X<SM7[Z\$WR^[A#W'[L<;*-SP3:EH0U[,8TI281?(
M.@=AB A6+;^BRA:GDE=DJ/^9. Y8S$[/SN7_Z6ZU /.WG 5,5)IM2Z3,6-VD
MLIC5<APO<O?,-675#\#RYW?/4T%MEHLQS)?(J"VT>[T"%>2V=[2]^?MO[,%Z
M.M%E7L+.J!7%5*@T4 @=F*2"K(X%YH](:1?I*6W:5)!S":[2@\4N?4J%(DU*
ML(:T#I7JBZ/,%3,US_?.;I3R*>Z'E!H5R#%'0'"%%"8@7XLR3!G;O]98OT]*
M$.'YRECKM4)9M3E"(1%.S,?BXYC#50@EG%8V(NWWK@<E4%HGP">2Q4M&4QH4
MO<-:<O @+1M$K[09FG$$ZVXLGN@0?'])\G(ZI3Q;$[\O6V&%KN8_<L140\)G
MVC L5%"UYY]NMV*1:8ZTKY]>+AXK+MH_)DG@TX-F%E822IO>#"1=K!5$-HK!
M4$C#>Y#[XJGDW";:50SOVU7JOQD<-1@37SSA%KI[W$W>3P8N''<O#';6JPK@
M\KNLSG_*'?BC5<[=>LXHR40]FIWB?\N([>U20B=]?C8%?6JT]!(O]D*UNYM6
MDPUZ>VT6G3E2"R1J=RAR@7DHBJH!6P/\WT(D%P0R4S>[=K]J2MJ-$1\'S=F?
M!:QU</&Q70-2"S/7(^=+&T!%KT[XWT^%;6:2XV%LA$Q],[Q!1["^$Y&OF*6+
MP/TAX66C-HEIC'E&=OH!/N^=$K@AZ>=WI$F%#.3D<EET-.1);H0]$X+&C[^K
M6H&?9']P\'V?:[4+'_*IK/681>DS _)$F2=!FZTXC^F=W$"OVHRX*DXA]J((
M\?I^<1=!?A"O0U;0@JIN[@855%G;:6JK3OI%F!&)MO%D^SEK//%G/ERM0L7"
M%K=*L'V/%7GC1PX!<S(:^Y6V_'6CN'SLZ]1+W=<*";E474 %5=@E\^=,AY*T
M*ZP/NS;-*^^)]O3T!1^OKELWX-ZY^8Z.V <,GE!!MU\[76F8"F-XBE--/K(J
M*NK:+=WV;UFW6SM)UAZ[/GX0(ZGU=V5NYTR6+**A[PH\HLQ<^VT5&- D2>>L
MT: AT6)2TJ%FG_!B7Z& ISPY=C'/P&/BMU':Y[WM/^2Y-P5KK>/F*2ED3Q26
MW5CS7MW_M*W-<>__()W40O_W/0 . FE1TY/ZGMQ,!>7V #:#Y!V$="_S_R,J
M+-X<O)7H?F\ZV^I#P%<&SER[,=;1XNE7@G8I_T[(_8_J<-WDTC\-);T5*#'D
M/\+%E'_"17J]Q)!1!]H9KJ<UMTU*'S07F7VE1_W?PDH=Y=&8X6P^=\WUNZPH
MJY"#/&G:VU<&B])_*LE_3?%I8XW&3&?_FPCM>W/XBN0+Z6D'_\DM_R^MXS\]
MYW_^R)6KISRJ_Z]A_:G-X5R[:M:#0HO_+N>D#>8QG6-7=>H&H9#SG[+RSYEB
MVN>4JX1"KER03C-M'O]4G"'_5<7Y_XH[SZV^A5D4!HET*(3\3G[IN>MIH_QC
MK;WAQ\[Y^6CR%4 ?KV$(E"^(RH?>*/\K)=!8_=N*P;OGA/_K$<?QU^HY&#]0
M6  3QMLHYY:MERQU!*9^_IFNND\#PGSW4+%8FPBESDLA>F,.M>D4BY, Q.W1
MGP[\G %I;4<T1SKX'MV/&XSRV^5:,P]I27DI]<+K@ZJ7<L(C[>?*+%8I)/P=
MO2]?A$O&UXAO1U/^&&MRT/W_9[<7IO^IH7Q5'A5D2@7MI _@T*17V^AY^Q.6
M(N*-#?>A_P-V;1)S___8"QI9C.B1VJ?4H2GA;NDBI'!)R&8Z%22&JI#*W1#]
MGO/L/QV2_P]ZV=AW]3.66LQCXK=*2O.:FNO_0+^%S\W)[NEM>RT8F_K\T@6=
MZA5NU!,7JQJS\LD[R6O9U_,E^,9.:/OBF0F/@"BB";P'SC?A!V6$#\Y='RL]
M#*UJ_'R(8-B(7>O+ -E+/^U2NX?RIX+>OX)/H0]>'-D#.AX0DBT\>\BZ7DFE
M\DJGIB7XTS37]B;QN?UF2%CIZM:LKZ>;?(?W@ PN]4>+%>>I#"'<+08E58M_
MSP(8-'GCK3O4N2H #5SQ3[C8.*;CGE9UV7JZ0?NTIM= M6?+G\+EN-7/#$\Y
MSC$S>1^9<; 9?W'@K#+<'0@XD+KT*#D]3&XO;)"1G(QV*F4DO "8G>8USM;D
MAH:R&:#^5IRSWOS,Q?HF\==36#0SKF!0<**#GPDPP]^F,&P37>QJPTE<6.15
M$B=>2<.G@3/-MX#1VMFW-O!C7%3I9,WM_JXPZX0Q97'#P.T4KT;YH;*YF'RO
M"'<&8[\0^,VC0\A-Q'Q50Q">.9Y"_Z0DXE08W\$-;8V/&,F"WL=OND)X+1SR
M8"_)/]".VY+JX$W(>6>@VR%?FV#+TWE5K7F@-97C2NROIQ8B='2L$M#6?L4Y
M52J(Q"E.T?NG+J2";'=H]/[[,-K$0UELTF]D[C&Z=WW?(N2X?#0%?TEV_8K\
M/HVRB3CE)QX7XL0)VD W40_^)]VE&SQ]_WR5M>UU;(8.[L>I)Y]^ X_[F.8>
MZJP&7WH8V\YTR]>.9O>SBC0BKTM\%"32'C(8?B;03@+7/KB\7OFPG+%':-+6
M>/(=Z[FX\W_O7JM5Z@PKUV35[9*)CY;:F"6>M.2VU@T,;,PEC-1^7Y\D_<%I
M;Y<2[=>L)&O?52.F4.9X^BC)%$\+FV2#IIK:CP47^$W8.SH6A5(?/,X"<6"1
M-2);I41CTE-<+K(3$9EZL11(1+$95N' [R3F#JL:%2P<A"?U7^\7O7ES7:75
MA>=^PE21:/KJ$;(3LU\Q8VOQZ_I.:/'"-A5$WX](W$-L"^0!,5@+$ENQ6>4(
M2;YT .NIT6X.6H-,#=.*O<3"5]D'GFV[<SD*6G,=!\48G($1_>;<&7)"T_7L
MH+0'HS"5DGO>L.'UD]*<U%J6B,:4CU4^H/9KX;)*9ZZ>1$</]1V*F5)"824S
MY(>CGGJ9TDO_=KO5H+T#-X_"21J+5- 4V&Z()/UU RXXMC0J82LA%Z,D5<9G
M[B_QP#N\XU3O'6PV&:D.0D:B<;3%ND@2Q__^C/AJ5.!:,6UK;6]5I6AN0OZN
M':_!_NIR7ROOZ7,OU3PV]<0YSFYM/ XIK,+T/JG!5+TSRXYV@\U201I[[Q<,
MCK;__?^!5-. DP,SY@+E\X(-21X,<I'"C=-7EF,ESZW?,!?QUG58J-"2U45B
M4_*W[6F+S?K> !>0C^N!W0!".0X"%9,W9?2APLOT3%C/BCYV5C.!V-.3?X/.
MP(N'+/ ST\3Q&HJU72L.,T6L12\VE\%ZB9JP*PAZRL\Y4<!M?H &_ZV3#7'3
M;JF<J:G;:F,CU^\E7CUM.4F[X;_CS"36Q5;^&P""*+S> (GVN_BX/:1BH[9"
M/J+<2:AD@;O57*;GVX]07E][FR$#Q6TQLY#Z'&0OYE"HT^<^H^:Y:6()_!G)
ME)Q 48#WVO-7V\<@*SV;U*_]J79)LJ:"&"_G?K?PW*6[;PE;J_6)4&"5>GGN
MW*)#![*Z>_LS/D8+P0! "&&C)(:2V8X_1F482YN[ CVMKHX-+)TLF^&=^)DO
M5\ERWRN-]2Y\K(Z>"@Y .^CJ[?MS)H5209F-2$%$*X0*>LY&% ER,!MKTD9<
MJL33=UQ'5$EY3C:9#YU^<H_GQ]G>YY9_7]?-.UQ@P!L(+!C%?:>"PEO=^6\C
MZ#W6YPE1X<#KJMZN+"."27=G%T9ZEX0.1?%Y'$1'SQH4%>4[#MM*C,766U2F
M0%8JH67Q"_;IR$I(&Y37%?+OD2^X^"B)!WM1I6WBC1E1H3XP=Y#C(W$Y,J]W
MZK3"/,,5U7DL6F^MY'N]>U'SQS3*6>B>7/)*WOJ1&[G5[)!/?<9\9.<%]+I^
MALJG=.YO'YP<M<[()OZ]K%/,_F@XJ7*2S6T6G+)-5(8/@7%&]M'JU_#T/[?Y
MX((P^7''?>$_!+E]K==1#Y(XGMU,I),M*?<ZX],.N-M'85BI((_=&>B]C(7Q
M9)S/YH)VA+]DN?MT1#4[(4[0<MG*<HSY8]#?<JW?WK$?=""%?H]2L-F/Y_31
M2QA3A6V1.ZX8Z$" RV_,)9IE$^B#% F&R'G/387</'?.)*G\@J(S2:'UYQU\
MOJZZ69B*7GHI<-<W'BX)A"T@ID<H#!,%[G9\.,P;R((W[';Z>GZM@3*#U!6V
ML>SX&\ZO)T_5ZZD&_Y;UZ3[TBLZ_J1S_/:09[-S@MCQ".7U=M,@]PTK2(O00
MH9Z_;-'1B_ 8!$2%JOB9Z@ _##V%7_=E0H$"BK>F])K)%6[8=L6OK[%%VE=X
MRNMPYXG$^8F?<3R$((#!#4=L?VY=("&1Q_QRDSC3_YYI6.]GH+,(W8^??.)C
M:P4?'^>*&0_IP[<*:HJT<JJ7I_PH-(PQC\RD@G#:]N_F;@,.\YBHET'=;<J[
M;U<:T16A08<#"A["G\V5--A9BW9 B4G*CA8S2!X)J6K[-W"5BHJ:]#W"ZKV6
M",;0H/Y>\>K&=YK&_3*"('K!]&W1H@XJJ*JS<]T?VM9&@Y:5O;H>+HBNU38$
M3@?Z7ET"<,,)=#8@8DC2)8 Y!<'2A+?:#('5^/2"I[[RC#F:"?F<[UF\=F*1
M!0L@QZG+P'_31N.C@KIH6:SZ^9C#Z')2F'Z[8-GR_J7C[+VICP:,/V:KGR@G
M*<33,0^?B!7I_LYQ+[UJ?FPI73]C?$^T=20D;Q? X-;@+IN0&NWM%/QM&ME_
M:]^&KJS)7F!FL?D6;AMP9%@?+=I[19K1)A(;^Z9':D<MP8J0 (A@MN2#B3*6
MF^K2^)IOG)5XZ0[=FITG.;*Y7X1JJYYK_$I26<@\82TZYUW?TO,]LD5K*16E
M?QQ@BQHUL>G5;.8RVM^!0X%N6O25H>=1<#[\1W7FB17<VT<=@O@S(8[;3]^Z
M55P_-R^=JOZ<:]?_SJ9]#KNQ,;//%S<"&KMC@U'3A@BV+#OL2U,N<.",%KDB
M$.ZHLZ00P';!.H'[HM3XW&T/)]>C) UOQMZ]7B@WJYQ7_+FE]8C>Q[60IY1N
M)!?E.LD-,/,N)1GBU+I?P8S.Y4I^&W$9\7JAT<;"+61:U_\A,/&#3A]2PVY5
M4QG1^":_80PE/(LY#F$S]ATP<OD.#S"0WC^\ $ ))^2()GU\0J>52"?Z[72X
MFSW; 4?"T471]]MMPAA&P??+NA^6+E)!XJ=/";@._OUHJJ?HKCN5[T>4'2U)
M=U]?&SK.=R!Z4B;G>(>-WLLCILJH($N\S=V[Z7^5S18J ^A.+;'0L;D4WA23
M5@6)6Q,>DR-;1(*Z%]<!,E'S;R<5Q"!A$I-Y^ZXEJU;T(X6.O1=" CII9P5,
M#+<XKX7S'%A%3\LNIU75-F-JOZ_]6N9W)4(J9]#%6S"C?_)T (%-B )7&B;D
M OKM(>AH_SLD T^5*=<:UKF'Y3&A'VQRW#M$);+O=.D<HK(ASI(WB'?)7]2Y
MW-)S4[HR"BT!!X/:^LK&J._I#.;3\HY^3R_\N!9^ON=&LVST)W4=0_"O$6)*
M3,;J2T1?.G&V+5HT1^ 3\,U-_1MNI+.FYD>OKZ]Z8B#[H[9W<]JN-F)%\;J"
MKT"H&%KH?0!?;++%#<ZOQFTU/5OP]&A+2[N*2^<)@QJF_]9U(*HZA)04Y93=
MX^9UM)@[,&WU,?2E.*;]W6$[6KQ"LS-TU_P.)M;^0I51'!7$!-.<A[((M"27
M6E4WE?(K=DPQ)0D'_8WGB @M0/VB@B(HO.02]/R7DZS"A0&ZGR@\8J%Z8"I]
MUJ_'J7XIWC'JAJ1DXRW&9EMNV3N#<Y 2TT?)L5^^;X>!/QL4:FKI>UHD0VZV
MW%BWKZXEL6MA^]O2!U];SZ^V/VC016GE,]7\(NI<S[4,Z']ID5006=C($WGM
M%AD,".%"[P&,N,J[.)'W L]RW3@ICY)L@I-[=-V$8-[U?ROY_\Z_/!MH:AY5
MT-DFKEV\?WC;K4_/)-1S"6X/NT_^1%&"=V# _IAH<.5X?,LMG%V=':VJ,FF#
M/PV)RSC0W2TIVRC1C<,>?V3-<5#9H]P$%@G-Y(:#1-S.X +?1!N"P4[5P;QI
M_%K6X,#=J>O+F<;I$J\>>FO]\@[7$;38*.7X\ORC@V%(YPNTD9S;3461.^LB
MC>0PH]OD+_ S:YC*P-9MNI]6 M4=RGY.9=)\ <VS[9G#?=J>OPSI[YS2=@<P
MA&KR!W6Q(#I"Q'O".W(6IPKZLMZ<<_D"SMC*8J9&V]39+%7)%(9?N@/][&/X
M^, DNK#>\'MQJ*X_64TU*OS1FWR/?++]Q"]2 WYP6X;H1/G3PIGQDY\/8"X$
M3A--7I?Z\P5@^U;^O/ "]Z:O.KX,5V3:"6@]UKDC?XC94B0*6U%ZP?03]])7
M^/0[E7.^'UFA7X$E5V;>1<O>%;[3#?K ()1!%T _9&JF65!HZ2&)65_3MQEO
M'/*DP/-79G?;$G@@)$ZIF:Z8^6T8<$?K%/[\\"IE$(P7DJ&"NO^#!9"AN][C
M:)V9%(B>E1AB>=0-(5:+Q6RX*0X:C^[I[YA#Y!'S'S$,)&_<+G:W*V:0 U#L
MX+]2B=Z#=WN7K/M.:_O&1/7N33]X!)SAO]W*7WTXN(U>F+7H1%8$=LP*:(Q(
MRV=:[>JZ;I?($0.S@I$AF8573_\*6CL;&L>1HN>>Q_=LKD\5C3Q.X=Z;2(&7
MV6#2CL$W$:TR) X4P$S0P!%BL''T)KB=4KY#HGZ^.\''ZG?1Q"53&B;^>=E'
M5HEC'Y) !3F#XQ'ES-UQOEC[+7R.=$P36VEJTE$[2Y>SZ\=R![J98O&&8E:'
MH"@G;A,96ADL,.E>Z5BO3_9)K#<\?\1Q_"R7AC^J(%MG\3P=T_:=<8RTFL8)
MYS,2I0SBF29D']Z(57F1*,5MX^7T0DZ6X]J[5A!LN@\V]A'5M^UXHL9:>4BI
MJK_\7I);:\*BN6%G=B+_L' X* V+WO8E.JPIVITK!RRD6R&,]O>?3E23W1D6
MD%M+8)GG;.<G(VP*GPQ%]9P=9?7(HD$V?LO>4T#_=>X8>-IEA G:8Q <2=K4
MQ]*3.$0Z(6"28@$@/:_8AF"U V+,7Y?\+I2-LNK0W4M[@F7Z.O]%I:$H2^>:
MQ3#FWTXEVH_(*7"&_F=8X;< VJZ!,C2Z^+HCRO,=(_NI]TS&/KK</)D_=$"9
MKL2L<0-+N923VE!R+ZR%[%MTG'TAL+&9S$JV+C]4N\Y]1>VF:TD,1 'A.@B(
M<,63&/$FT!AT)7\M^36J">4/>9^ZX-F3&&]CW4C9SO;MC; 1L6&]E1T_@?!
MSNC*9: 8@E $KRK\<UJY+[-;;3TZ2IVX%@N^W?OQY_S1S#O46(B8 /\3H@JQ
MN3&$ZZ:O/G([<'<#SN .QAE"I@4Z3T0B2<[(BYXP>??AL 8(D[6MA$\?@V!I
M=7GBY(NS/Y)NO> 5=>B$)R!::2S5'4E'NHM;1K==!/],SV]'L@7I_207WZ][
MM_3Z=)TE^/>U6SX[C QFUKY?.%OE"6'&,?='GHT+CV6/;#N,N40]33U^:JR:
M6"ADC.2)#M<%?6%*GV9=-N0\0O#DYN4]3I#/): 95>PU/@-CN!-P-!5TOLEA
M?GV4??P@(X-#!+!=O,ZSP>-&$M_+H#"@B+=A!K14C,01:O%<K5G".$K4?.F-
MI?5*CX:'A _'L3NLHK1XZ?;_-?S2Z.&)Q98G!SL5%&@\:FN&/I=\:/.K"-F4
MOX4)I5C8JYR%.R%:K5I 0:L=<XHXD00*;Y"+#?Y<T8G_W+M"9N;UO=D!7B'K
M9TYQ3]XY9BTHLJRIB1^,1_]^N>I&""1#A-T8ZFP#S2DM+J\I;8CS9>H,E+ZY
MT[AE\I>:J^V6F1K&M76Q.>5_#;O,M1_W.#)=?M,S97>LR3%D A_V"OL=\G(I
M.M("2P5M6^!6.S <B/GBJ[7OF[A*M1=V.96G[=RL8NL9.09:/J:Q+,4N2EZV
MF5]4:EU#N(KOT> ;Y7&4!Q5DTTWY9."BISKY27Q&-VS=%I*L+.W.@3Q"$);\
MCM UTMO?OJ[GMQXA*DN.LN1LK!-89MR.V-RV0H+?]PN?#MUA.S.(>]T92 7]
M"-PR6&1^SZ\R 9>#N: -]+$1#8)[V["Q3Y-1EYP"_8Z98D&/"O>^.YX.? 9?
M^UXDN^P5<)1>3<HBV$J/=AFOZ$%<0D,\ Y?@4 H&<P'FN2@] YT7;ER@<?;-
MDY6HO/ZGT&I)Q8=9V.E1J>SFIBD6O3RN%97(GZNY80E$,]B%&$(B<!&+ E4/
M/YEU?U0\-=O#H./EX)\D_,*WUN?5Y.H9;+-S='=B*/-30A.2<F87\%/PA4],
MEVZE_2T%#B$BZN=(#\EED.=0YH2(0 R=OW2DU=DO27RR8<K3H2FO5%*O>TFF
M:LJD"H77,2GR?KC#.[@=C.,A9)"_J_.+T))1Y!Q?@X'Y^(;X1?J%U7<E.4U)
MXPR*<A.RW=R)'S,3PW4E?&[_$"LD1WTO<QL=#^E''XZ52J\\N/INU,_P!&$K
M79J0#M,E*FH2[\+;LZX"+JB2:<X""L_( Q.;G^;6C)-/8PN#?I]OOVEN=XGQ
MTD48 I>&M=]^0V1=NP53&8,SS<&,<"U?AH4_^^>TJRUJ<V+OYQ 6\)P^9DZQ
M=^AY0>SP8F,K0R\S%S.WWSL31@ \;>O!C6P]]KFF1G4T;DY[&1)/X:6,8' F
M8!; UQ _^'ID@;E=4@HWJXQY@/M+%Y?;5&^4(='(>/:85:9N:05MW"2_L"G-
M$.2K_^=@LBE.Y6%U].]IB55'XZ\/P*].5Q7DI,<&WRC):-R'(_*?>J3;[(5,
M]_<BK-_!Y2A3R$LP#;P]Y4)LRU5<UH]T^J@=R9(=N0$M@]9G]>'=@[%)3656
MUQ1!WE_F%^D)5FC))F\JZ&8Y;I#\D@;4#'S,C6TFT\4(8U30NL0TX9LE+2RI
M("]M;7_B,_@4A7TDX<TA>&K.T[KK9HP?7B@/Z2W_)BM<:T_W;?)HHE@!I(V>
M8P;>ABZ'Q#5QX,6M@$5\P[$\<U3#S^2>"EG! :<5)EW!>*3()XLETX3E!SWT
M7Z3GV,W+T\1]:YO&4$M'%>OP/-D$V26BRLQ(/9X&P00(/$WD_(-MGLZL"RWO
M=8#DA;$9-\&**TF$RS/C J(KBEK] GYG/_&Z^ #Y[Q$O$#,B"_#8EBOXP*W=
M(F#0ICKV'F>M2[Y-3\7E6_PN-98W/JPF&7\ CZ,-1$NP7]BB0]0\5Y>GR0:"
MHR738VX(:?75%<76A$GBHO8VA/C #7D5XDK4\9-4U O*&R$I*!3W"'CB.FZ8
M0\4X?"S?QMI&7HM5V#A _1.\)7"2] 'N^4WF\T'V5GC; WX!R^7J(;ECE% \
MI.)WX]1S\^L^/QWQ26H>.R<W1_5>FHY'J9!VD'/;_XN]]PZ+:DOZA=LCB(**
M2(ZM!$$0,"$26U2R@&0EM0H2!21)IA4$)+: B)):<K8!"1*;C(!(!@&AR;FA
MR=UT^G:?,S/OF1G/^[USG_L\=\Z]\T?QG/:LO:M65:VU?E5KK5VY'WY8KRB8
M&A'%<6:S]<>_FRW#Z(@,CWV=Q;/F*X(MCP]OIZGS>U3>Z.ST/G[T3- 7_GH0
MJ9Q\&K?8"L/J(@)3A?KD.6=X+9L3?9>RM^\5]R^F]H];9PAT+-QYI7LM[[BK
MRJ&.&=0=D:()E4VF%@^]A4HTV=I@>FU)EL&&#]I%#$1=HX LG8/YKF%11):X
MV82P702=PX%JR"Y3H7_$_?K^Q9!OJP$9##D)5T14?WPH'M.^(>@"S7QC9( 6
M,C1\%DL!-<1'6>'SJOW'8!X4T%=BU:^W1K[QR>"V"0^)5\JQY!?(E).+:N4#
MZWY:#[-TW.RRJVH_"\W''!GZSGDOL!D4U.;P 5S.CDG!0NXXTWI%3%FAF#QJ
M;A,4X.$[!9I)!;[Q/!<^<3\U[)C:>OC$?^JDPTYB^"L)-=^K.S7."QM;Q8N2
M=A#;X0IUO_AZSUXBAA0+LP2'35[&X24QM(3;LJHS5C Y]=[CX1B:=^/<U6GG
M3ZODS$6>'L4GT?AU 2%3"+!T0<+JV7&6[$&U A]QI:9RA/8J+4:MQ-T/1FJ!
M"4QBCG1T-+N-R#XNT<RXNY&&;TSL?.3("O?TG9C?3!9EU^\Z-QVP7.68Y&70
MCE:VBA'/,#+B.!/,26/<"<'>U?D> AO+:3Y0K)O6Q+G#7J7RG-@[MFC)X^G"
M7--A1R?2&#(7<$,PZ/EXZ$B97FY=9E6%9_6653]IT,#3J#(?<IDH0WA 'H71
MNWM@*X'Q:5.DWS8V7_CHJ$>7@N*"X>L7S[<5BF//,]YY8]43X&J'.DJU920%
M5"[<WGUE%HP18^$Z]SY;WG69S!;Y<9GU)"Z-24PZ[JCEVY-M*F<"92:@V8-&
M,?'9^0I6%?ZU&/374):IY2+^_1U,0'LS#&L,"0T0Q<41%'#.6EAXB ><U9[)
M*Y9SKJSO@E!MO #;"*A*;>B566GD+*? <%V7!G:] +RF[IBF^-ZK^CLNH$)5
MZ]JZQ&T*:)0@CY3DKES'/YN5F>5$NJ87OY')'<KH=R(G2ATDY8T5R:*^%.%^
M$'<!U]''@=LA1ZAW:L**9L"T#M7GRJJ3$RID+4JR>^RD)L=OCS'Q'KYXH<;U
MPW:["6ZDR6:V$%6FW-,&#H-]0L(#SJW.0,ONWYNTK=P;?A9WY @_\]I&E0"/
MH!_H:;L+*R%/V7[<(]XI3["VL AFG)-5=DE7(RZKKP*=,H%9QN]"9"'3,X@R
M3Q(78P0*RZ!' <UI[*-&A?<2<6F;LRVR)#B\GGX5RG!AAW!OH:)F2'P]P[32
MIE'YRBT.P9->@B,#;_2UA/./G1N.;I^W:86.]LR.K'D0]+WB9L&-D)-@;IR-
M1:+W>EF75]37\+@O@F\G3=WY]6@0E^7O-QQ6:,1(@;G)P]"*]03A%TG353CV
M*?/;_@B+X=U[V=&[4Y!5@;#'1^=DYQY:+J;%*,F0P.F?(O4"<\0?5>A4.DO-
M[R=J:'4/1L?ZEJ-1<=L$^+<-G*!S$R,;D1_"OD;4F3;W;7ZJ!;-^>]HA\<EP
MR,I5PHT?(<IW9VE=C>'O?(88?R&>WRS/(;)NM/)=1C0>$!5/)7*^##@3=R?E
M"4_*M:O<3O1XFP5:+Z</T>4'2LKVV:1,>P43N.1D+&K*4N3\S;LFPD*259.M
MYKI<6M<PAII7;DZ)< IBI/#M%!"--TYW%A9BC&9/:N,[N4GW<AA?ABY-<=-,
M_6+F*.U;BY(R?B8MX9+LQ%=^H*5\!RR8);07C^).[-C6WPNP([5_@V+O4D#T
MJQ;72-'U9Y?J>?LV=C&/5L0N'4G)-JGK;FEU?F ]RO5+=[">-MT-'?M9F*5.
M8&)T)?6>(?4X3Y?F(%'2-W]YK"+%TR[71*%\J+3'PY4U$HB?,!X/8[X(E""1
M2WGJOK)O)@?*R>K(P8^>ZZ9K%2/=DEN0L_7'F@F&%%"C;+F"6Y,1Y)A$_3DO
MZ;MU#F6.7/T.9=Z_O-Q.C_UQ1;G*\)"Z/NX(: YAL&F8@_$D/%MRPQD;8[,2
M&A A(P5)>&=#,OK9\\6.2Y^.'14\>>UVYB^<K_ ZR^(LFOLQY5H^L'@"^3;2
M8Y(+9L[8 \$)@@/E';#()@KHM-_Y69TC7A%-GZ(T&,;MRJ,D'&PEE%2BB'F\
MOU0=D9)G;OY%K$$*.AHT6_D*YH2,4)3"'HDKQ.G?Z]M 2O4PKG*E)EW@"LB?
M\1I8ZW#A?Y7T-5S]:(=HH]IUFF)21'I>Q4I;I2$;B@:).RN8H6U0E.%)W"'>
MQZ?-0,8HH+V^3>T$X< =^.C,1O.DY#NIPGI^388@&\XS@=C:G"\W94/LS/VC
M?&V(S(M[@O6D]U>C;%H#KM7!C7#O9W23\+'Z%S^]JMAF3_2.&27;@=/.''HM
M+?W=73]BKC9V/S5A:PL3D-GA=E\Z?9GL3PRLW=X+[]^00HT29JQ3<DQT<NW9
M S@'/U26E8=EOK7C&E8VN'U7\Y(@"-1QKNYD>%NF0B8/V-#21]\]7R5]:8
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MP\[Z<5%S)O58,%;S#JQ;FP+JI*. W ="B:?'P=OZL*T7@*VOPHI&)8G4KG8
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MS&0E-L1N-RS>>)1=;_=/<-KI/_0?^I?I/Y<H_LWH_Z%+%/^A?PLR_@:IH,,
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M+D*W 2G.A5) @N Q+YU%(A@/3G,W7BP&I"JS(=M!R6904I<V&&MD1@%U7Z"
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M_,P>BEOI]8Q@K,$30(^ Z3JI20XWJN,P0K;O ,Y0!P@P^ ?:F1@T;K(DT[]
MX+,1> M &?94KTD%!$"2C5&$1/BNJBP%A #CKT+P9_[F;83\<)P9K%%[&[#&
M" 4DAB9U X;4CP0$N 8(L 'PU_VY9MQTH2?@N/,?80M)@-T\ 8OG ?[W&&!/
M >'-J?S_P!CKHF+3@%?07@24""=^!)0H)0]KU'0#)%@$)$"0NG_FX/XURGXJ
MD*DLJF\"3>-[R(N VYQ7A"VDP.:!?ZA:^@-_J[!%AM,16>(@U*_#;U4"&MRA
MFI ?X(XB HO.OL+/3;A7Q+I)39C# 0TNDHT $Z8")LR@^HPOP!]%7ORI!?O2
MZR^"L;K)@ (5  4".G4;""6RF$*V=5!;Y53N?V"_T3+CMB R_7D$/@>--P'T
MYT.UWRN .^ M1BA"ZA\8\%PX;@K6> L82I?IR$:P7Z5, _#\^\. ,B&DGI\J
M,T+9SPMHQ@DTH_NM&6#UNX#;?0T&^H8@]_WTJ2!EOT#(U ?JRP&,(08FI;^!
M-=X '/4RF&P$(2C_7)&[&-8M$1(*L-%EX5^;70]  U9\S_S;*W[>K8.9\"TT
M,#GS[:"BV-@MS)%[VD7V;A*IV_B<ATLKX\8"(]$G?.+])L483&E-#"XQS<=.
M\.ZLW"PTF%I_IZO,^L7V7UT/_NZF1\GO+X$85#Q:>:+[)ZCHP2E] ,SU[L/.
M@ WGZ!PIH%^ 4"_*[I^C6.H-B:$_ W@R^(/8% (,Q]?FBR07&(EFX*H.GL8$
M-B)%-H1:F6L._@D2"_],8HFXI!E3)"U1>M/XU86,$-,),8WJ^D"YYW>>;-[\
MEO;\3'QGY%10]$RZF\'4HGALU=.@/*&CZSNR)F);TM22NRRK>Z4XI(VGYU1/
M$)EOT[ H,U LK S.:.]YGCGF=:'>VG.7;R<\8-@?L$I)$G<1DGQ:%@5,YL-1
M4E6)=FL!&7W09# #[ E\7+@%S2POG.F%F)*JB)GN(AD-C^@-LC<=9*J,C<X;
MOC7?>&KX+,VRZL5ASC/A)'"^B[TH,-5KPMXAJ1>L<D7^,#F*E"#ED$564+2*
M(!RZG8NW+F6X*.T[=X&M!XWGBQ^7(V4SQ)AZK%G; II09<*O4';HYVP6,IM:
M;Q,>%FC!W.Q[EYG4>0Y9/F )CE5]<D!$QXO4>VN(>66B,YX1FRQF(F!V9?4:
MB[UO=)4O_GQTY/O4C2\?:&$&'YJHG?$VD+YY,_8*WD!;@\G5ES^#74;D8U:G
MV&P/3E@:$SH+&=MN#I :E+?,MC5Y,B8T4<:VFC;>?;KZ2_17:'?BG>3<MJ,;
MT(?# T%!G[9@/E5OSF5_K!WYL08XK-)_G1SQLFF!CA$:$8P!"CBYJ>UF_SRO
M@1;7-IJ[RJ4,UZ$NI]4%/+ZH-'VP;)=S/>&;PC )OSR&\1N>VDD0F^P@IC;^
M[3W>DAA5PNUE<.E&8[=INT]=<C5B=$*\<&?)3,#<[,O3F/4S&)[3IG3TF<^U
M#^$*IN 8 D&7:+W9'ISU"2=DI<CG8)+)UEW8F&XO\=I4OE$P 6/A_+;QT"-3
M:_0;["5ER&1/K*)FYYHPX?-VUT') ?0WGOOMD.@ )E*J(I\]W\7-Z/2WLA[%
M8L?/!$G-M9PN;D*T8*)30#2Q($&O2B+SQMZG34F,YQ24'1?1XJ,=GY$B;7+M
MVK,#$XU+A\($H9=2QMVBOE](4VJ?8%%%NVJFUQ!1=Q.JT]'&C_$(0UWE %.O
M'#*]/D'9*W16%4X\C\V8#@F=U1)N]LEJ392JB(#Y/BUNOZ(2J_'P,[TTBWSP
MX?Z<]VXB'G:H:O2"L63UXH#R/@74#,Z[:CS?3I0&8[HH()55!PKH930 SSJD
M#N@("EZH-CX%W)5IYU->A)O0$UY-!Q.9@^Z9Y6^_FZH)/F:8[_RZNA5\_9'/
M<')1:]<!N>RRJX8&L'9/P=XOO3%N1I5M$%D"%AL@+./3JHUHVHY-Z1FN2R%S
MJ@OJC@X7.2\=G>&>?\PI&:)\Q[4EA&%A -:HKBA'I-T\D@RQU0EDLJWG0<58
M:FDJA=_SJYU+*=SJ9OD($NZ:C'J1/*B4-UJ4VKV$R-FU5!=FR*F>\%!=-F>-
MF$)QVJ)/$84S<0G-(WTK/N<*GB08);CXCPH\?.T]Q]?"IT3#I^S73K "%M^K
M\-$DLP%Y]ND>QNY9=)CLNULGPQS.,CCQS%PYUVIMXQ95(M)U4MWLXXQSK%FI
MR>3P:D CH[^;JH,%675XT'C!N@2 0D=(>>3CXR; #-3>P, -I>DT_HK0"5P8
M5CM\BOUK?/9[2Z<;#/P2.CS&DXA?R-(XZ%XHSB[+"]TDK:,8[T=?=N7YIW&-
M6OG+N<(.>:N!2AQG7BM=2Q]S-9?>VCW;<2YNM?(]ND^95>B?<I*L6S889X ]
M+\Z;< &M.3T?".7$39^ZLI3HU\7SK(H3;)L<PA0K0\^:]%KCN1(R$38]#:U@
M#(/,.$RC1KMD:9ZK'TIH-BGJJK5Y;608PXI;S\,9M&F8%-7LG&]M]^\93!3;
M'IG*(;)VW1JJ?9!Z$M<UU=43?+"86+'AMX9Q8,DI;W$5[7"Z$JV-O?)6])#4
M 6C_A'?VU0/W7HW^)HLQR^V6EH^Z]?J=._)\JCY5PAS;Z[6OM&1<U[H,C%N@
MQ3J8QEGX&&3&ID7RL)]R'Q&2OIK*$RG/9/M:Y]BCN*O2AUH^J:<4/FJ[-+BH
M4#^1/KEF51%;O<- Z ^]5P.YFXZZ@+)EQ(FIP@,XR+V3HEA4J)_T=(I.P]B1
MXD2KD81K"9+NA(O"?(]^7'@8(=BHJ!W1.S6RPI>09[HJ^S@[S4:TV\Z37N=X
MN"LOYZWSX+O*(@%;L06\".+UQ74#]ZQJ,N*'27H]-?YX21X^&%F+PB)O#1,O
M66;96YP=*C<L#4'?BU8_<^K5Q)Q_R9=(M;,@?,FV<261<5,R3-X&"VN</+/I
M7Y0"#Y,REV!87357%([FL#!@+#&<^.YX_% 7GU*ZXL&;A%$[B-''T_MF^@3U
M\JUG<N%_G6K%9L%C(WO?-BL;H&.>TY!F!..R#^U"V$R'.-O!K%YERKKEZ4GO
M$_.7[X1?K(WJ_'$0+;:V(K#1/";^<:3;249"?4MA#8$NUE5F.?K_N^.&C$#9
M@\=5V] TU(HLP1#Z,@7)&]78_?!OR9(?/1B\)]<ABG@,NM/J_=V'+$Q5W,F+
M N$$E61C*2G=)^-0J<]S5<)?]DMAPOF X*\#_[88X]W(],P$75S!GA;N5CJN
MH$DV )Z[PEX]Z.,>X_"TZ\+-:R'&@D?G(]>_.GQ3:Y0WSOWNIS?DA+*^KBB@
M4/=N&-UTR^+:-'AMTOO3=@5FHL9Z_5+-]8U4>YXW=M\*QKA)(\0(7:?,\[NI
M:'_4E<%<9!QJ*@55#H] .<!"^80WZ2*O8MBU:OMW'SZDMWVMQ>((CH6_/=UU
M5ORMPE$.#/3><&D$L.X0/2Y'OHD?V74$1,[[@V6W_A*.E6#C-3[CB6G=9)\:
MSLM:8B-S8.<\ >^Q<9:=K JQC9%OMWM_\G;H=:5OLKI@G_3L2CM4[ ]'DY,9
M8\O^!+#-;V8 4'%DP,5:G"\6WC9Y?B ]T/'6[3Y)#S&O]?A$X5@./N63+($&
M\9P@*D!QO1N1-,I^5#;N;O3&K>+T>@"I!7H'#"E>(!4ILGH%M4Q*#NPX J&E
MSK"I=KC"Z6./PC).M9Z[IWXA])F5?."12ZW^^J;:)T_V=)!6%G1C8ZO)A=1U
M54F9]184%:?16\[]/;"L8KC_SHLV@W@]%9?Q<*U1,SLW.7X2ZR:R$3HNV89B
M(HLL\7$/[M0=8>"]:1U]7UQ\\;X!C35>\TYS+J\2LK0@N_Q8;RE"G\,@2G,K
MF'5;&J-.T/+*F()'[!2)W2SNE\"LKP7T8W)OB7UVOI0 R@R_%,Q;,$RFP1'N
MXA!8Y.U-B8(3Y74D[)L.WL32EFN=2Q<YW^WH#B9:M 5T&"W[!L#FI*_FK$TN
M^BO[B<U00./(]FJZ"*DB";0:=G9\%*KCR*WI^-0L7ZWS&/_3*R^^TW^A@$)?
M^ $QZP?I$ B6#0BTX2.WGTKEL I].F=H>>QZ?>C2"=;-A&8D3H2FTN<K6^J5
MWB+')]9/BW+MGLQ^Z7D6U<7&]_G)BUZ^^#5P&:I-YS11&&L$GW&F-[4SR4YQ
MNQX^H_E]+OYF]7I8;V9$8R/G8CY91N>$47(&I_C.K>![W_:6?!U9@?A_#4E0
MM8?RJ-38(4V6]TRR0A,NJ.=DI*LS6)V^5<,3<A@(:4\A/XC)EF6IF,7]>)J8
MBSR57J]'RH0XU'E.J[:H8-$AA>Y)@Q454>MS@_SQHX^?%!N.\D_1BGJO.TS4
M,^ RH)N5S>;LT$WQNI3LG-P6)[\(C@D!M7<(R1!K&;&@D3KIF_:QA7L/%MZ0
M$/J5Z>%BAV_\<Z)XAGP9UT^81C<SGO*":X5/^F(4?VBR>&IT,_-V*C[(TI99
M4^:.$JOAS0+LNE9)N(/+F/6,E'(4,R_N%Q?'7#C1?PUQ/'>^ML7L]-;%-HX]
MY%U<]^9V,YBF[/O<L&#LHM[GF\/5CL5?/UE&QGH9]FR"&YA;G?5>+G?K.Q@]
MIH])='17.!<^JWC2:WUVQKG9D;UE_UK)J%9N82RWU[O2-IJ/^9=]DD4Z=GL.
M9_F1",H!P_62.-5-Q>WF1,6D=+/OS<['"X1VF.4SJ^?F"O,OX72YF.-UK"HI
MH+/;K< $""\2*70^XG#%*Z+Q@*W M22K=?<ENU[AC9?'-PM.?8AUB6M3+TKL
MU'5QDOPP*R2861W,HJMW]W_YN.-_[@O^*_<%W?F.;K[-F0(SWW=(O+W T&7T
MI1%O#@OC\-2[SH]2"V EWAE0%,5IC-\?2!:+*5WXCD@]IFH(^<HW@[J84.0C
MV0B)J*26;;C/2I3+&;#AEUN]LRGHO:+ X7&D7BRL].C"CD*1$&$)LX"*)Z<&
MY!0DS/)Q^97BH-,+ 6]T[T_R;=*&AI>9:AG?^6R:Q)W;$J-6U[CFWW['* HF
MWWGY9;)58=_><O;'P']UX^IWN_)&K;_?K]<;C<@K^3.<N+'ZR8<MLGZ:!S$>
M9=<W^A/L[!W2_VERPX#T\Z]@&/K'>$C^&;)3_T139"#(ZCB."Z. 'JVG44"9
M_<;>9N!V%/XL@@FR9CX(V4G4F .Z6S-( 3$0HY,E-Y</D%]Q.N2CU#PT8D:'
M%#)% ?6Q'NA"@]#%/6L3FP.SL)>U6C!LTDP9BM%]G'MIJJX<;EI?3+B=K=!)
M<'P3TK3Y=J$^$5AO8>11U(X;.Q1GO HA*OM();D:&_4%J&TO9:;W>PZ1GY!4
MD>\ACD  WP(I/1F3OHHE7E&4PK;NA(S-ZD>87+/NG,T7R!F=PYL=#ODAHW>4
MQ^8KZC%X5&PO!J>YF:2]"6Y!1+GAQIM>F_Y058PF\P\B::(WXZ-JJP;/CK7P
MQ,4 F!<<ACAY%1Q1_\LP$3SC((7JD_*UKOC\:A>TXZ'P7NUXT??GOL8*AD*L
M(G)UF ,_8%Y>RA*<&QQ.@NZ*^O'AD!^(SCB'#[CQ9F.P;;^4KXO\@YCZ<TN;
MUWEY.2['K)SP&_$&IOSCB@*D KI&2 B:D0*:EG][K#;J5LMA$X)0>=HM<NR\
M<FU2K$1PY8F>K1?)S/C-?*(!KH8"HID=5!0A'OOT>F)\M;/4-O&CVL4+.0]J
M*\W J6HO;E;AK6XHR6EO]*%PPO U#[JU&FRQ/=>/8\(M$":5!*Y:3(B#P<K;
M\.;2Q0M*>(3\:W9NU;>9=66PT/$:LL6!Q^K2CK=F8K+_FWI%DC@1K9BB8)3=
M@S$EV*D2)(G*.,MI;[]SU42+J]4.GBA_X[6(!S2];69YP?MPM!.A:]]G.V86
MQ82:*CQ02(C8->>>MFG"^,YT9\=^K1RK>XEQ?O+YNB2GVCEK>-!V\0V7F)A
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M6<7)!M[4=MUY 2*)Q77NX;]3$V-I/Q1WH8,"&&<!T5-I!!MD-0I/ 9#[E2F
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MJYXR=^G<HOFFS)&68:T/"3#1ZMR"?RV9LGC443$Q(@;O(^M EHM#1I*CJ1]
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M:0[V&W0Y*-<86QJM-!)ZOR/>8OQ8W75O5Q9UV[#(_W*5UN>DQH-](J=ZCUU
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M^LICDG?\3CLE[79E25F@[77WHE+++%3B49@#4F?;.P+.W2Z-74&1<U> %[>
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M,AKWJ+NJ1!E$?![[.!^]Q/-CE<6N@Z!)#&O$'Q>Y9[F54 #/E]P.JRSF<J'
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M77S?9XI_XP< ,-MR?T)W($UK8[M4.LA00P'<9H1TWR9E)#C_LH<,C.7OMI%
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M2N7GN'Z[[;%UI<C7QT:^7D8K,=5 \5U\&8I8M_?P<+G,DOL-?@59FW/4%?0
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ML)X!1 XE'H! 1GZ@"?<0NR("3,7\SA2,/BGK\RN#V4;LB04%[[);E;LDGS,
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M O=9=>#MV_XZ/%F88-:(+5YO"I=J4&4K=M(3:#Y798>5:\Y[N?'CEXNG<C+
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M:9R3Z,&Q%\NJW#2S@<;K.&QDE8W<GRZUJ:W.5<V,N:*<8CE:N^Y:$V=#7/N
MZ])OTZNIA>!YQXRXG 5WTX7? Y%4P>1,@;&"H#INPJG!$33[%LN:L,]"M&%@
MLCE7L?15&6WE:(B[&;*)&Z]_L6FHN?L$BUZ+Y%:1;QW*ICW/Y$AP?(!7/P/X
M,@,_@[:'DV]1S7U2X8U@TGKQ.U7X.+1V_*/"Q$:WXDR^%_B4L@<#8#W7N)3G
M'TP!OT)Q1L_OHKWJ\+G4W'DPAI.NTUI(7P7OB4G\@C_[QDJHNJ0%6/^NK5+)
ML<FGD#S/1;_8^K!0[F:V,2DQI\]T+BNU5%OA"3Y72?J![RL"(?%" 3:FQS3U
M>W $];J+\IMI?HF>;JP$OM"EYYO"LW*.MZ(7 ]@N1FSO92B6K%Q>ZE#R]%(.
M2O2ZW:=^Q\/K2!B;RL^^\<:WDD(%'&;+>O88G57+:,,'GI-*A*'91E[XF27C
M'_J'W2:;?\*!H<KAXDS3I*==^CJZ';^<;RSV&JIS9 6$= _5J&?87P+C5?1[
M]#=5%S!K9R6Q>LW/\LTGQY<O++DY*9M= TM<N<ION:C)$9_-HMV@;>U2E3*6
MX6F@SH&<YO]],?YH1M;AL[RZ#B+'_6*,W/:,<DVO._S((X4X[TEJGI\=-#,.
M(4<3J]7)7F+%HICD_-=ZZ5?.7U110"NY+P7XY[87, #''O::9LR2HI6T7>"7
M)Y'!T_SP&!_VV)EFWWG*EYT)FU]L,@YL1*67!@L0$WMXL>O;5RO7(_8P_A8S
M(.4!*^6'R(?O'OJ[0X)PLE>%IW_$.,X-V6I\LLXO3ZT*2Y\H'Q/86L*]<-!(
MG7^^B0>14(,S,1JY*1@#=N4$!?O/?KA0NRW4*X(!XA4<M 1W[K>[>AX?RW)T
M[)*K!FCP"0\!&PX_>+V'U1NFYW=K,R5DXI.5A=;<H"#?42.?J<B/VBOC? 3X
M865=-QSZ/<;LTZR:W\62+THRE?74B%,><[_4$F=W:Y73%*/B$[1U#4KP%^)U
MEO>4<FG#/D--AOEJ(RD9Z#OX$Z+I2Y R :X24XXVA+*<@W00G-WAWL_3)U_:
M-.>Q]98ZCD$PR_=8\%<?5;W;BCIV.I/($:ZXE5/.\U(O?W6@4%_2)91C 72A
M[AH#:"RH&'A,;Z</4!Y7V^%53;O2X=_'NIWZ5A;8,#UT\/Y^>E:9= >(6$ME
MD,B5'^*/OT?-Q;L5%_EUB*3I\7\6OY=KKN&X8MRO>@[ZD $$IJFF@4B:)+LQ
M#EZPPZ;7F@@ML$VGE&@W'4<5I_"KSE!D*0;XE]?]8'USS^N/W<2,K=A84RXS
M@+:=]^B51'!7[JCJ;U39?KJPQ=CXLOM$?6Q!_V\E'D;:7#=_Y2]9/;ABZO3E
MQ9"R!H_3BJR%=E;^MX'^7^@39=@/[N$\#\JY46[PN-W$A494.)90[)&;#Z9P
M4A3:WW9OJ@[-K^V^;I67RO<-?P%AHY]<1)^64PK%RRS3?;Z%=CRMCN2^U:[L
MK+X0LNZT)&,_@WN3R=>M8U(Z[S@Q4:;M[!(L;*<W".O$+9XWX3>V'GAU8UA/
M]U[IP(P+1T'F@S=[%RXE9'@'ZXS<X5<P*AX\2)MQ4M1%%/0[#9%*=FEQ,O-X
M?]B,A)(-1D!I&H5QI;,CSSKZ&E %X0X4CJ:&!7_T,UHF=UNLVU8'RI1@\ &-
MDR84).71$E:13F'HR'G7L4WV\%'NI24(+_4^ XB*GH;L,8"$??NR;=< WA6&
M\3,5]1@#N.-(1;W=_-ETO6TZRU;<78-70MURTBD5\F%EYL76XL"[K_GN%:DA
M$MO1;:K0"EI>78_;%0@A9&VTQ9V6%C;% $;$$70>+#W#@)K% $@Y2\]HL50Q
MY7XM3% 1]VAA<Y\MDO+4QH>8.57V@;#0=*$J-L$CRT"YW.F0Y*_WG25I91J#
MQHE9ZY!W,SG$,LO 9"EV&^5"BS%C&*3=_\B-*<>NV^Q#S(9_J64 IUP9@%$F
M_3Z<8@(B##. ;7'XG"8#*#6+@0H3G.,0R@[.Z8YG>TZ51&K-X;^8;.1&=AR&
MQ:PQ ,*/R7,,X&M0,0. ,XEBQB3"+'1&>>9DX0,+HIMSOHE<.:U*\7M]7YS0
M#*J'VKV)*P]G +A'WA;\=JN0AYM"WE2$PL_6@; U##C&0^[-%/*HN3?K+836
MP%Q%/$;!CNWECY[8F\I9A[;R]VAM1W/SY(0_>&5W"K@2S=V=O^V,WVE 2LG.
M8=8FDPZ&B!84_>VF4EJ.4Y5+,$]'MN.%*NCS%R@/F6:VWL+S\:;HC)6LKF_+
MIO$!J$DG\^%[JM7:>;7Y"N"G/RNK(9 *:,%(6>">^/]@[[W#FEKZO>^EH*@T
M09%>MJ"(@%A E!;131<0$"(@1$5$0+H(8F I""A5J0I"1)K4B%0IB?0N4B.=
MA-X3:H"4=['W/O?QWGN?ZWG?ZUSG?>[[>?ACHM>X?E,^\YN9[V\2UTC&OWDP
M\C@]6L1_KYD6S\F/JV(KV5DR?.0GAB5'UKS6WKI?O,"A^I@_C[*KE3-+C_-:
M5(23M3?B?9<Y7+,/&DW#RT$Y8$;O]#7>1<>1_.?.=TM>':7=)>0[*+GARS:>
MG\>(="Q8*^TC5(2^H>W*XH6G[L]TC3-\(IE%K3U1E/NZ6.VP28W_86-6N&6G
M+$^'KKY!06>RF_^3+STB]=^/B,H=>F=;V^38Z&ZE57P7\2'KA]WYN-3/ Z86
M5QX[#A[SO30#<M3*7^N66GFCM#5;(H7_IM3\\H@<I3'IVTFE^>D!J?X\NZ"O
MP00F_XE78CYB'6)N7XVQ+R+)CCD_QK62X:'=[0%7)!I$?W09YFA_KI"0D!$'
M&QQ/*29U&:@]^/_\K<].^I]/.]^L_>NE_VN^61NER=B%)U-D2:PM-NQK1@=%
MBY:@S>!>;E6)3-@KY?JJ!.]K=U^TMWW7?$[S+5=:<PLP"HZ2OS[I1-F3P',W
MP5-\T,>F/DXP<"VW\+9U'\&3 %._!<OQ7K=W$(PN.$_\J'E'E>_$U&&670@F
M\EFB+4VFW?'&TSS+JK'$KQ?0%?;+*-9?]CRKT47JV<)^+:#T3DV$;FGFQAQ8
M7@PW4_+"5LU;N09$=$FWW*4#^TUX8>N-M\FX]SAN4MRXM \W^>7 "+\5SV;>
M 9BAY,K-S8.)1D&ANA7OH+&)>4PVZ?8T+Z6TO5(ZE*GU@8Q5QX3@D\I"L:Q?
MA3OEYL "\*G[/+S&D.S;4]W:(?W@FJ[+I/KY>2G])G.7&84#)-;=QU$6G<FJ
ML4_>=+&[5F&^D\OH@%AS#6IU8I4,LHW\\I8X=#[Z7I=M8ZO9,&=@G)<#V+*>
MU?4PSWE\RPR9BS1*F\;Q89(<K&V%X]U=CM8>?N*[<,=YKQXPV8,)IZ)4^#PC
MO])$NA;<*^3GKNG:B8:6D\>:G9AXU,7?HP^07>B *!T(A,W]PD0+D%PH7:$H
M-3JO;K_:T#"V(%U"33+7_,*QS$):YTRIP$;T8[4MKGPM&HS('@:[C]B0Y*O?
M^D0'IE(R,:R=Y0@2LY8^\U1+M7;1O;C;V.9@*;>W[*2'(VZ=Z48FV)\?1]M1
MWV3?*28_7-_W7L?E\2^/ZL7O R#*B_09F7./HA5:K>=XND+C%-SFV#QWF4]K
MP7!2NV5^<D"Z;&''D)D0Q^BPG^4O9 \;KHGWTKD/!GWY@R\RGSPSQ>^:P;M:
M)_F9&D_[9?B&9XP,F\5-I3X'PB??B_PJ5Y_>=5AAW'W&LI*TRD4[-%L6X'Q4
M],=&!N(<4D ,J4^<8(-U!"[)]1KM$>(AE)\2WG4\R:!J&A,9&:R/P<%[^_,$
MZ(!Y99/QD4PZX/ME33Q82=<6TEQLPW;K*1M'&LONS\RW7W\2<8EB/XK@],RJ
M01Q1TN%KZAAL4XJ7?O +K"Q<F0N>KI>R7'^\HG,MLRNEF!@0?2_E^9?R(?("
M![MP/ ,9'D(1(.6^'A'F4LG),A\8R/S:7B5M8!K=*$!IJ?@,XUL@S%5:+9<^
M5C]>_+FZ;F"QV\W'Q*#TD==KO_2Y3PL%HH^5L:+Z-ZD)Y8BD*72&DDFL/=]B
M1%^/X=*'9Q'.UQG"U[2R8'MH9Q!DC1N%':O\L27?TUTX3+6L'FCAH]9X9Q3@
M&6#U=;(^[5E?&Y4<3 ?"<"U]U.[4B;*/-VU)Y><-![3$.!J NY=K/HIP[F(0
M9/7D]4>6!;I$G2F'O9A .,I7=!2%Z\9AD[OMB]4N=-5T1ITY4VQ#?:2RVJ7W
M</:#PF-=2BB2Z;;'&JOZT*0C'3AN'.GH\NZ@RR:\WX>U:]B4;)\ZI)6P--UT
M(W'L^'ZJ)+[J['#H$YIHCPO:-T=MUE:6YG)_LIEKNE5S6NX* ?&B-&&M:$V^
M+SG_D%@14>GEP;GRW8=W?8>W(_+E X8UB+*XY;VF<KS-F9#NB?(IR_J.W)_4
M3W:KW-3U+[@C&S;(?.M6K,@1\8$(^X= ,@ H9\U_9CL8IA/L.=.=H)TKK8@N
MZ'-(+^O->9+H(\I'.CAF\+FDT,BD,[E'-JMYOQ:'Q67B1<%+UB)T0*%8S9NJ
MJ9XM>#$K+9O*.YE&6 A_AM3%]P_OGRWV,J;<DXRW.>F)#[PG]#Y,S4.%@YJD
M!,??%RV*N5_X1/.K<=BJEKO0LTJFY59ON5&G0#[V&F;C8'C^\,G=1TM?S,7!
MDKV>"(3;D60X?)H\B/DJ@=FJ[L)B5[S2Y!DZ7<<.D0_0?&J<<\%J\DN3QK1Q
M)DJ.Y>#A#RO1Y>BAALT+!.*/-ZFFII#CGOM(')[7>3_#\GJ6S_M;Q*2?E$W;
MBR?O@&JBD679A]E2\$6VX?K5\H#-[A+.*GR -WO2FA*N!G.2[$30WQ.ZB8F6
M*^#]6G)3BT,9XR[&,/<X:_A .?AX1/APWX"&I+>OS8V%D;:F*;USX0;O_"P3
M]>MY-GD:;KF5/BK3B1OXK#O7UXO^-0=3QH/[:N3L?@+6M66XML:J\.U)V5O&
M\T3UCD;1A\8,8K3+&&5R$BG8A.SWL=7)2;;(2\3A4V_=H[=,]R*%/5%Z?L49
MZZ@^&7BD'MGBX:<SN]?NYS1+T#AUA%M.P?B([,_,I/@6:^:/\T=SJG$\"0TY
MNU]-S*>$DI453"K)KI9+JB8_7E)_-&&?,VPY+>W0C173.W P]?*-MY(8%.YM
M>A+MF]#IGH+:BC.]TWB<J^IC2:EL1>=,EQ4Q^.E\SV0\]\NXTYW3?"$WI-XV
M:5?D4TZEDRBS"PK$X3ZTFJ\3R[1"[O=3MTJW5.9<#;K#8+O]EN7:4$0??K&O
M2O52&2>Z4FV>+&;JW\W>G$Z;J;V=%X$VZC762O,8/D 3[:=H$D?*]WU"7/[5
MPV3&E:N,@]8X ^/H*X]<@Z*D<"C8@B(["3H09\(]A\ULMAV=#3X&^U)6X%T]
MJ FY'^Q;,6@/(T.AU3#5%;61^O#>1LIR&,OF("*T),,K(Q5,I,$_?5J)9K'W
M[3?WKJ(U8DE4@LSF)/NR73<U&QS;#ZF_37(L'5#EBOZG2!Z^E@?)$O% .C!+
M0% 9#;.@38D1K,*N$#5HZOJ;6^+2VW>G-$QF@KB7D-SJJ4 3%FN.D=WQ%V7N
M&$=>2R@/OM&?MG3V1KB: .U*A6?Z'%2 :&(&'; 4AT)=LR];-Q!ELWU<,?JQ
M7/DM3 _R1^G W8S*"7?7W'W^7FR=R';]?'<Q]$ST_(2$H;'+4LCV=<D1_95H
MI";I;%T.M$0.%@\]:J1HX:^SO]]=EK7X#*- Y,J<[7&MZC0+E\/FIUO)7G+5
MVJ.N\9$WMVQ-KR/I'F[UZ/MOB1:E*+6+5ALC/L8K:M;5 [R!]>.?6LYPW<OJ
M*H^*)+L_\NZ?&:04#&3K*5R?*771B;:=\0'MS2KJL%D6,W!KW>ZN %-MEMWU
M$2Y]F$8RU!4Q=#5V]2NTJSD@CB/5.@CMR,=HTTM)(@%+!GQA0:DO&8A[,?G_
M_.!-C&"=<XO+ZPS2,33ZW)?'"17OI#P.&ZCYK"")\!!:M_"2"*3UUCCUJ=S'
MGLAYMLT;T(&C>U%TX+88'6AWA=>[!%)>Y%E":[2VQB-F*@&&N](("2DZL'$R
M!K9:Y40%<+CN)?:Y83IPS+#^M[?[O^?;W"P/9X?TL88P26=9K@4,HW(L"<\?
M@Q[17J150%[PW1X'6D-EB!N!N!74Y@'<:Y\.Q-+U7,@!AH2I>RL\UA!T(,)=
MG@IJ0>7E(-&0]FZT> ,.Z%,O'D+STB9UQNE 2GX&N1/J:W$-8G61#N1+(U'$
M,IJV3"!L=E.&N@_>(\P'CL60@VD54 >MT9$T;K!1C3A)!=7H0-*!"_DT[7(L
M#6K,=!T/8OTD:FU]+#R'=@JJZ"Q)G/JX NF 1W#HXI5].DV*0^^6%$J1LJB#
MM9J,6[O=PNVVQ F+E$@93A 7CZNW9,[3U:G=/);]]'#<VN%;7@=OPF$")S\3
M6 [?UXEQT(A>0RZTC;6>/B6Y7_Z8N\>&Z'?<2&PX1N02I)2.!\[+2TZ<1'PS
ML1&\=."PO]#3U^%VR_:*@T:5?8MO&2.F-Q.B4OEMJT4E*HUF&RJYUAMX> 0E
M"<+!F8<(3B\!'N$';ANXA#K>/6S"_BSW#KBNA>G-EQ7-^]BOR^QY$2,>Q\69
MU_784I[Z04Y+[(K H_,_+'(G%&_H*>_5LL)=$)\Z<],CC"8T*\Q6>"%'[GKX
MV5RRS;-U#1%!9TVF\,N[T%"D8Y.C+.5SQ#;D_=Z2Q_?<9G1>4Y[FBJX5&*S)
ML)Y7<3KK@JJ41*O@,Z]_EIF/6SVF=.5:5+R7O/SA[K)3#LJ*]]7Y#X^_6./0
MTKB.@4-3$KYF1Z(NOI2-'^0W>+MPK[.JX)RF:YUH7<>3D3#E4'<4#T:\GMA?
M/4/,;,VRB(C)DS]Y9CVA(D!#L%%H=0SV.9P2:H:C/F:G\D@RKT5V6V/)\2X/
MQC9,3$AJ?&N\%F,TATUXGM&+O!LJ[$G!AM25Q3VG2K6U:>5YPYBTT]67/7LO
M#\WT#'O,?#/\UE8K?*1<T]AL]$;734>;:-H-G+*6TM$M%G;M::3&EB*YK#K.
M?)AG7HYGU&))PTI2Z85B0G86BLQFWT,'K.?YF/49;LZ<])N7][B:2YZT P!*
M(RSTB;14UC/GQP'F+";G4Q+L\@PG, --L]XK=NM>&WMN5CV<*:D\99RTQ%VE
M'^H5Z^O._$10_;',0^Y;H0*A7W+JUU^M,92NH'-O)2J^$8T3YU0[&JAA].IK
MB*\DP2F$3TQ%F!R9VVN>F;+;Y>31D#UL243E@#EX)[C+W58.]-^\TJ2CM&M^
M_= [_SM,T\_(<,3NB3<9QC5WR8UNVJ%S0[F-2X4^&>=S^M;Z>D*J0CA#[TM*
M@-7)H[/U2ZM:P[S]YP3 KUGO<3)*6B0-L[)NM="%E.:ZYAN6UXM#'JH^=6::
M;5R\.9%,!WYA1FW.#+?@^H4/R/(H*1*W?BT*.!VR-JV4PG+$@_\E+!&V"Q'G
M'*9F],(*#FVZAY.:C\>:*GZD-L*F$]/D#W[J,#0H3Z M8)-&$?M.">/15<.<
MGJ6>.C>U1(J+ ZX^-=5K?TU;=AL^8-^<G8/4('G4)EY[NRIMZ/S-[/'NS!-C
MJ_CK7NQ?X3TP;J0X+ 2Y*V.Z2)L5SRPK\<[)_5:_3\INE32,?*><A5&50D-)
M?ISW.<.B.\^?%7Y?.:E*546[!4$!0>^-D".(H E/356D@ILBQB/WW>"#H9>+
M.2VG(]8^)=PP3\!@ QM6+,S7;$@!;],;'P9445][\#\Q?=.@@=RKQKC%L)(M
MXX\Z5"@<6+K"T/9ZY:T8L_O]L:@^?2FF>X*N,+Z9%>&^\)I2SU^[<J16KPLB
M; .ND-'-VPKW T6%C!V!'42(,6@5$M<R%&W67ZES:H@7!.V%%KG[+#@3<[]&
M2:LI7 /IV_,>4IR'CWFMXASNW!<N&TO9<0$U%>M!H<K#&4I:4@^$Y*\U52<Q
M):6WJX&JJ M<H00$+QFL?'5%_H7<X+G+ ?<D#L=%CSV:%=T5<?@+[X4YR7OE
M;FN1U$00GU2@RZ]'&Z9]I7TK>1)^;@YANRQ_:L"JY:JWJSUZ_P$NR;H+;Y<J
M%^:?(,.\EK(..%ZW:CT5; 7%(?ZS1!PMB-L?)'HXT(':=CK C,.CJ8=E#M"!
MD85^.A",CL;B>[&KAK E?SHP* M6YX,S*> X\_;7U#,^R:_ [W>QQ/W@:P+5
M1@Y:U-WIP#.9996,_V;1]S?#5"%!$4$'OAZCJ:Z^P]&>X6B,V);-=!HWNAJQ
M><*2BPY4#A;3 6X-B@PB +MRK5R2#OB5.=%.84R@:!3:RKHUZ4 3-QUX"%7-
MUDH',E_3@2@9VG3RS$4FZEX=.@#$;C#UN"$VF1!D3CIP;@9%ML2R@E-)GM"B
MQO1HF&(A3*SPX8/VR\M$-(UM'DLNW3"G"<;3 6,HWCV!H'9J4!3E:9D:M&O8
MK;3PCV/"*[PRE-V(,6'35G!*$!S1H;1E@G@O"L3E@S\>01'L!TD/P:I5LCT=
M4&.NPI(5B^@ 87;<B?S(B7H]G)($KNL*$^>&-S.$-RYO_XI2Y1]X7WGOT-VA
MNT-WA^X.W1VZ.W1WZ.[0W:&[0W>'[@[=';H[='?H[M#=H;M#=X?N#MT=NCMT
M=^CNT-VANT-WA^X.W1VZ.W1WZ/X/T76/Q@^'0NVY5?!.:Q1"4G=UX9+#O1]W
M7=J&T7%TX"<><OI0$WT=Z8#M%3$4,4^I(H*'1'WY;A1+01I!=)S6&\$1J-F_
M>-O(_B?WPO\F=UMO#1&HM#^*WOF)RLZ$V:&[0W>'[@[=';H[='?H[M#=H;M#
M=X?NOSC=]-A1=+75H6<DYJJ4$3K08K=-,QOJ)=*9[+8WU#'"DPY4D4H&H[WO
M_>!8%NJ?G?" 8DV;!^I.Y!L;7]LH3Z'V9MF"1%WLO"3/ HB_\_C)\A(=N&/#
M(^:^I5$(^SAVA X@8VF[9):X>]P@4F5HRG[P[2KJSZC#_TP,F?,GUO_$2^<G
M\NRS%]%4AM_+U?]OEJO1Y<J^R?);>]FS)[ K;%CB,9I--^S/PP?[<[2^5/SS
M"/X\# 8-L*FS"#(CMD$E'PK<ORM GAB[@;H.@?W3^$W]Q=5Q3<,_CR+L9R?_
M.0 7V?P&E71IE@[L1DQX&_UU@B3_Q=D1DO\T2_[LZ*L"?C2_8W3@J0[%;X?O
M#M\=OCM\=_CN\-WAN\-WA^\.WQV^.WS_!_CN32>UX<OC'/K0-<+,YV3U=H?:
M_8AP!OO3IH4%, )JJ7W)E$O$SZ=#=N?DF.^&D38W7!=I^S/6S$W3H+Z%EC6K
M>V-_>'[;"TY.1#33]N>L-6O:;/]#?LNU?O#3<CCE3?JJ@._PXN^G 9<WO]F"
MZW]$PNB=+T3_/8\P=NCNT-VANT-WA^X.W1VZ.W1WZ.[0W:&[0_=?B^Z69+7/
MF>]*-@[2]8&KK?(6Q?Z4+\<Z'4=+?GU@8WM"DTE@I-W29>L\K8T.$-M\^+L?
MHN87Y^E \6 P6G$.O-?[G+E8R&HRS>VU&K+HU&&)GBCGY0G?WC[<AM#@_NL)
M<B?;QV.O>U$/&]P,P&_?:WC=??"X]!,U3"<4_AIY,'RM%V20X*6<@W_,GC$*
MO:_]KKM3%Z8N.V!FGT3<6YP\2'8S+>M$'ZSVL)4(K2]1ULB;8?5V(3H1$F+#
M"ICM31<XE5W[3D?VE]U.^4H';F#>KZ_((0B0EY@[O<@+WI+@;+[Y\M'+FSX+
M[H)<I.]AK62W.A5K7/DN KAW(!),&3+C"5-KN6^FM/F26W05/3ESL/4"NZ!!
MIEXNGS?\>I&'UE*CQ:"R$$;76X :<WM/3@H67;*5AG&F)M,D3&>*IO&AQ_&.
M!F*<EFV'K,]B'YU^,K+DO8^AI]P1/$(.-_&;,[)72!V37J(FZF2(&<T7Q$TK
M\1,U:E5.EX0?X;2-^96"\VBPNJ9LK"]-9GD2--5Z(4NP9D7((OKVW:B5R&&]
MP8B%_O[+]_$2^&/S]OIW)K^R[],A. GWW8PZWJ9[= 9>SQ\X@*BA Z((;:0%
M'8BP)NAO+GM]&8'MML6R%XAU/AP7%T=V8H??TH%R\/T\G&+T(9R#;'^]8YU1
M/J;C$L^*8=,EV+-:'_^8NYQ-K@>^(+UG(D/ZBTVUSW]>,I.)7ODRJ<^924@V
MGHO;BE0Y\9>7OI-E3(FTPI'06VK>]B[IEN:-I1=Y-1G]JD4?BH9]J)@<80^C
MP*&A.&PIZ#@QLU9CQB$0 +S*"KCIW<T<<0X71]8#6F_[1GWVZAK+U-.=_[ .
MK_6&5_=G]+]I=Z-NVC4>(T/#J-2V!CER1%XV6,9."])>E^E-IVD]AZVNRR]S
MC0T+*G$36!$$QRQWJR0[CZ+<3_.)0]^T./(X_0( OP:T%14E&S_/C>\RZ?./
MKO5O^!(=(G]&ULE7G8V'P9P8(U2H<J*^ZQU?\%J,@R)LJ/ZCU3%N_[1(R+=3
M8FC*=*!1'(<=#*8#ZJG(>J('31L,A,W.@Z_1&2IRTS@S=+6T74]3GWUSQA'E
M5^9U%OV<21<,&D?X-OKQ^L_*M=*1:M]/.5)@F7W]:JZ\$W%-O_[*HQ0!WQTF
M5MV#XKYE=YFU]HEDF:+,D$I20)3)@0].B"=+&EFTKLVKL3XLG>A71\QURK7"
MFF;4P=-,HY;*1,4KQ/672!MJ+('_MAMKC91T5PLI7/:@2_0M/75/=&ZY:I*9
M9[Q:><=B9$MA:4C=B+O0\R=^OLJU2+]1T(]VG+@W94G#07D\Q $CJ-ZZ'V"H
M?. :F&Y)W9]!:"G*95)(3_!&]!L\F@S-+;A9FJ42DV_7B%;%G\PL$&1S-)7&
MGIM*HZ(H0)!I@<AAE@@GQPMTH"&ZMG<*NQO]+L753())&%->^L+G056YSSJA
M+;2P0J[@\6I65K '0OJ#9I?F:-*>: ^!]<:)4O1S.K!KU8G#+J8OX(O-\83D
MFLH6CP,F.B&NAR7&& 82!R5/7DQCEZ\S2HJTOC[.1+K8&52<,/HPPF)AJ!'A
M>CU=/3[:*Y<JU;M2$?/V=K*G\8.5@NN='XIN[T[QKZO:SW-'2S3Q"]H/<M.;
MV,4#U-WEP7P/276HI<9H XUBX #96T70\Y-V.HTCU(8?.R4L0P<.F9/] S*,
M.'ROB_3=[)<N#'<(C&D]H?\6Y32-6F+=OK50 EJ"@PJ-5\;O=LX;/S/A."$2
M<M#Y9*W/..PE2E'P%9R?Y$4'3#N0#!F(*;BT VAWQ&(J:*R.QPG_3/ L>& N
M\^)(V 3O+]%'-%,,PT+.\G#X[D/#!"][9DMK'Y[ 2QR/BLS7S1%*",UHO&RG
M:R$ZVL9$L2.QH0A4A:T;/6CTPY5([H.R*4E7*A69&$,FT^TVM_2[' KM3SA)
M389-]%BS"^2=-P[LP5B0X[>4[3;W)BE/!N;<[9:-O=/,")/]#N879[%?/NOM
MK1_7;S<D0HP*9ZV82$_6U&\5<&W<U5;"",>_=>*80)Z<N;4<=#:NHBO> ].G
M-:A]JL\^&>NM/%-B=J/L>K)8>+[/L5D%R^"1!#,+BP_G.\S+=5C>M.1>]S<6
M_ :>JLC"SYH_/K60Y"MR]7.)&D.&V(C)I\ :2[ERHV)#W*GP7>%O%6E(7"F2
MB\SLD6SG;$\3"[T=QX#IJW>^D],[$+97D=VRXLS-$E2N2X^-^D/B0@+/_;$M
MR_EA'4PC& _G9L$$Z\$CI]RA":\,[8A5O(1K=U'Z![^Y#-LTU2])@0<V1D=P
M+V\1T346Q]>F:QYEMS)&" 4)<#6N,09M&7J*?@G0M%:+D#B<G,P2P'C+5W(\
M_.5P_C?T>X3^$_RLS6^LG-C,/&&]_=V!2;PJR5\V$V6:SY0@OX6!S]+;&AWO
M%K</K9GUY@@673QM+/$MY%.W(#IOU?#3K7TB?@VB%9[B\\8$<_>.@IP]8B:E
MCS&XDPQ-(H99J PK.H#$1=@.'Z:XX"7UYSZZVY=ICO(S<G-(%EA]=S*$3YW1
M)^*J];F15[MU&XN_6"<4ZV8,+^Q?'1C(6^-%G[M R" )<8P_MN1S3)E+?5C0
MK1*ZUETF5KC2$\!QVV;>7LOTP2/8YYYGTI/!BX5W4LQ[^]^L6_DNJ#.-L=KY
M]( D.H#';H[#EK77AG>1CU9_%1(*U,G;0UIN562/@RO?@,3 #WB$3R>&KWMU
M:W!70<7)=<,;R6\T':2'KKV5")EG$F3U^H+1-9+$LW]4<]-U+79P'.A\M&3N
M)?D6/YM94F\P54@)6>R5I\'*U: )AZ<YF&$+PRG/E&!T  %IJZFC;[?.D.WA
MWV7D>KI6L@8OW@T3"5@8) SZ]M:-G#-#% P]R[3?5 F(NQ?O\;'<K<'"0<16
MVS>9<9Z)*T&;"^Q2TWF][)HCM4BQ[']^%UMP<_LEUG;.=. SFA+FE4[U1%%9
M[8W6/G4(.JT(7I,X4VYH?NX1X\&O/HKQ2\EK=L3<PO?D8L-XH_;%E2G+ELQ&
M#SN2A"+NZ0TV^SX*.!*O+TR^-ZE9YB2%$>+]VABDNGZ#C:HI^CTNFTW?_-Q(
MPZTH!Z,A6V4Y8[%YM'MZRUMXJ)1;?#]MM]*5-2,2XY&^L/SDIIF(@4S]?>*+
M7 VW8+O91^RG-M)T/!--+:Q"#^<K"NQAB-!"OU#2&$$=0I[KX5IP6) :>[:N
M"CJAI//:H^N71C:#I@JH]@1X;<,A];"EI;7:%Z;"S3>2&&AQ"A\;UL0FO^-0
MKUR,'Y0Q"7S(Y72MN3PC(;W:&;=FARN<6X'+U=P:-4S.3HNRA&09FV*]0I?/
M45),8<9E-];6@0AUS3HCE_[-.Y@O?WK9_#G/MA$:%K]X<,!VTR<\TZ[H>XIG
MF6^3AA9/76K1JY*O=S3PB&M(D;POG2K\]TV*8Y;Z;M;O9V>9,NA:=-RG%(3<
MXU][>UG*IN=]5VG9_>%S%:AK+3;[._W\:-F/9 W4?$8\?[$\MW4=;'@&C=4/
M+=C*S>BY[K'A@L3@C[.8?7E^NI]*N\0M5 4_%/BGWL+<]!,[(<XKBO+:$))^
MGGGWS1M5BX("RX_SE059M=C9*W78/[^<OOZK,)/]IGQ-O&+.E2M=V0XQO,_B
M)CHTOW,&,HCM0ACA(K\^S#1HM.)[;;NLHY[3A3MMBW-X+'S4I\,.3@AM%-V5
MDR0Z/%Z_@C:AQN2.QG[U^"3)( 5O,7WRU-@9O+)A#/:)XDV2",.?9TME63T>
M.W!'*F=ZKX=P7CFQH"H>EBXJ*#E)!]@](VL2=W??I367E'8LFH]%'!*6GFO_
M)$([BH5Y9KZ3J"&'6)Z*2E H[[%U3.F*1M_MLVNU$(KTK;MMQ:-LC-UC-0/V
M,1D%ZI%-L\0^,T9,U3/J))H&9XCX *@J#((,Z;ACW-6H52HW[;ED>3!^/0PC
M?@-ACSD>0ZZUMY>*B5FJ+])*^:&=[0*<W@_U.K$WFSU0B($D'1XNRQR,8IOI
M62-9JK=)%9W-?,_:*)8+9+3,6)W3._IU=#PP2F1<5WW6TEAQR*1O'AM3=B#.
M7TI:VTZK#(:I[T1P@V-O/2-IY4.8*W^2>G,R0><]^ *KVPZ:FU4>:ZTI"LNK
M/L#MH?*430L=4\XP(G/(E#RLFCA:'5=P4,V;N?SSC:;,((&[$7  7EP;)7F=
M<)41O[=CK$RKUX?T!F_-Y?LQ'H=H%+:!U\"@2&TLC1Q)PPIAAM#A/A)D[IJX
MP!I=GPE<=5].:WGQU?96UJC<,&559E_)LAHO+ON1J9,&KNN)C9C$7ZTC#*)R
MVY)\]H"-)[^#LU"(-E6'5J;FP,:$\>C-6=B2]@K*C\^[)Y:(4RNL*(KKF)!U
M)K;Q:B 2PD\^YJJ&%CZA;O<M8?;<V#1+.]W#D;Q[4M@EKCZO>^07,H++J5G)
MO(XW-7IN'BLMS8DC!%Y![>VH'5R/G7'][?7U7G^\OEY\[6W[W4Z,*'\'>R3H
M(! T^#GYMC!Y"O8B-VO-AE@$K4&Q\%BC#IF5J<3O)Y4'\VNR/?R>WF")6PU_
M"06H4C0Q,K+W*F%HB?-NX9<Z9/$">V;B<V]VNXVFBUS(?K^/MY/XC?VB(KPL
M,MIT'Y4Z#CU:51@Z*NOR.;)WFBSJ2XVAZ#BXX^U;#Y:8-YOVW7J^U%YT4?@R
MS,"R5RSX\(.%2@[5>_<N &PI<>3D&T3Q$ S/S(>I/HL^)2:)C[V.]U^LLE6<
MF_JA\B$43D"$ECO9R9:%ZBW0N#=T"PM.ING?X_@HO7(Q>VE!+L;X67KLZ.G\
MM96.()//C]HM-W.D$B(7>RJ-=LW;*;R*&_>*HIWP#)+A(F^9=<WW>Y?GS[^L
M)QU]&@0>?$_;OJ_28K<^&U*N?3[-,+(A -]=ZCOV2?@UUR@=V ^S*=MJO<QJ
M7K,V\:WIJ) B[X6(.PI.PE68^LAYQ%4  %AV]56$[6MT\32%M[J0QC/,[ZX\
M<GI;5&K1U^PM-\@S.EN%+,B82:8#+#[>=K"E@U\@R99#:?7&XV4VN&01FTN!
M4-R=@[P-$A=KG;R=F_$)UE$--1RW3['#%G!]EMP!.B"K[1GM4($,VP.E%ZHE
M]NUB?"0WZFD3F'/Y M:>B7]+N1/1-M O%W47;^--!RZGAR@YI)"Y]<*V;B3,
MSX^!$KQ';<_^$!<^<6%$J 1]P0^*QU@Q<IZ!6R<=CFLM]IU_6!;S"X-*^W>%
M(H++-W8!OA44'UF]N5Y(H*Q#YAG'U;,1)S:27=9O>+-/G%7$-6!.D&\3V@+-
M4.]Z8H]?X$<J1+^XIZ=P?GR</:\2G41XUWRFF730_71[CM^CB75'2F=%QT)"
MQ+0;R[&3[B(;=T=A1C_<AWMUM$I8^M3SW>]27L5JYI_R/GO^%4QA V?1<9RX
M4.R=IC>UW/N-J%CCFAHU*K+I8N%&<22-MQ;_P!;G'GB=O^Y<]YD.#-_VL!F^
MF.4#D"4(,@)V+JU/H!#/-F1KLKS4,'OTHB*#:\WFRJK<AHF5QJX:GJ#KY"=,
M%[1IRUZG8GH;Q4HK5&QR](Q/DYP.R6X)ZR&ENG+EP,"X/8/]W"41W1[Y[@^<
MV0E ;F:6;2F23P_E8&WGJ_C$L^=$UZ-KIT^V@OH=(4G[ZO3FCZ'!<^-"Z$L?
M@B15__??_[V3_BG]? WD@Y\NB#26?E,:?]A 3;/JMVM2_W737EU:QO9_48_'
M@QN[^L&OV!51,R,P$US7O4=&T"X]&B;*4/=U>[]VE[O_;W!?/9><T\:>(1 '
M[:??=<_]2@=>J:53W1#C^MW8,>['D#I'0&I?MO403?4(:K45C(;W<ANN'C8P
M//TAZ 2PDW;2_TDI&V0!ZQ/JJ4C82DY0/;&>\G@ Q%73 >W4?&ZC._\&E[L"
MC=ANV%9:/E*&#H@H.I&A6,!>VVE5GS:=/<Q,!QK8^FE[Z$ 2'_KSJ;2<?X-9
MO#LM!^I(6=LF@0YL[D^[CUK:MWVR9D_)V"RF^"["9H,A[7[\[0>PX6@G[0MZ
M*7/KZ(SEAZ"3ZM!& NRDG?1_4N(*QX>3ETOH #J0%IUW@\9#!\(5PS?)X/3U
MHCLS#_X=+FGF_=NKLVW_JJB,U]2ZNO\=)O+U_T(GP?[VEFUCQ%T+G:Y_ Y&[
MD_Y%$T8*)$LR55T8C")[U'TQ\@OFUZ=IHPMF-[Y]@9:#M^ P[!OV$EXI=O\[
M!3I@IKODVO>M?QFQI'2SF1O.W#BW.;P"@X/X.7 ?M'%:D- TH ]<,I:A* ?B
MA:G,&#DZ\/6W AN;/&<126#&8_VE9FB6*NG/W]1W7Q?.AA%7Z<!SU,JI[6LW
M 0?8QLE8FE %\14=:"D;U:?L@G;GL4S*>T';T1SA&4LCRF>H0+\M^*%![_J9
M*3K@FXL\!EO^3^,HL-($PXG:B$7:TH&G)BA*-"(JN">QXCX=,%Q"C<?2&(7[
M2A)G%V F&A0N*[P$'7C[I XD[X&>;KR>3#N00WP#U5PQ"J/L_KWFCV9>*\E4
MG28P!D$^"-H1GJ!+J,;"1&/$\WJ:]2(O'1CA2M^^II0.5'?1#D$5E]O\1\71
M]AV)"@:TU'%8LPQE'ZS011DWX).Q_:#/(6B5JAB5^:,2!-D+K K?Y*98_\.T
M.E7IX9^KU:<#@6F4$Y#< NL0OS=9%DM<P?K#5F3(]1" '-C&<:Q4H)GGK,9F
M;!0=D,(216C=->L(E\U8.L"N138$)Q"D<-HN,W!)%RK'-P5Y$K;\DZUTH)G7
MZI^KU1 F7G?RUZ!!C>/YH[MB'>'DD^)5^73@-#L/.,*%AK)PXQVKZ7\=(\C$
M-PDI"5L&2(%0Q71@21=R#@;\;3KPABD$1F3#T8$(^Z4-+Z-Z;5A7>?H&5,TS
MIK5<\=*M<&A0R=!*6%7]1SV"V_5T8O&36&9P:A>DX"@,A1"_.,I708G1U#]7
M/;U(45K$.U$!)6@E??H(2XG4@2!<W#[7OB0,1:>_%X>;.*;D_N<N7X1(QU-.
MP99WD3QHN_I^;[02#@\UY@U[,/:/1B^+N*>'%?S#I=E_]^@TR(MLB.60%S'5
M#I.9[+='"<JR_N<LN8TW%;9_':8[L)$T819VRM=R\S_:K T;21W^IQQ$'+.^
M9=2?JTW%$I?: L1IMRRE(02*")I6*M2):.09V/)NDM/OG5#SL6.+PG>$K\I(
MT$S!$55JULL%S.@*FB9D1&RF/;64^MU2<]LRDG*6#KSG#H81.;<[*[E\XV%Z
M^Y]\.1+RY48?: Y\9Z]%D?=#NV_C8:@9L  ;VBT?2:@P'2>:)KHUJ2=1X<^F
MK\/)$NS55Z"!A7%!0W&L&!H*PW RY)1_RH1/+*VFH\W^[!KM)#JP1XAL!TXP
M$; 4QB+(#8(,H"R!W[/0?V11"'\S??F%B0;H@'K:K<23?[1QN\,AR/.P9482
MG+;;'(1(N<EH>T[_97S.0!YTA.P$>9 ^%_A'JZ$FU_KP0Q .U<)^A\"UT:%@
M%/@7=VY'D#UCJ\,W=WM"4VB7-';C*+34B1)':4\Q$O\!ZUM[S[N_P'H!55%-
M$T!M^)*3_["$UKDK/O_(<8!RL$I,?S-Y686)U["!D%M@(+1?S;?["N6@ C5^
MRD&WJ<WJ_X7P]]<0SGWDA^ $,P&D[(%PCJY ?LQ*G(/\F+\&FIK,$(?ZV66\
MEQ'N+Y-O"IHOA_"]T'R1?TD'B$>&H;T$FKDC"';8%.MV>1"ZT=6--86_F?;?
M9<B>3-5MFPR>\=M]@VJBRE#DUZN'?\[Q 3OK_])F+!:/51%";?B1?[8<KAZ%
M7 KDA%Q*&DL'A-%/Z\V<_S+WUG]0,3["PI!M['_8GJ!6T(11/^<@6?YFUJZ7
M4"M\_OFY$]1R"@!.L!/T*7M_ZRG1L/.OD(9 XI E %O>1Q*G,4#3F[2)(#NQ
M ZB-YY[0U-J5\UN- G^'J!R&+RMG@-PPG!,<D=ON%.3" 7-$;NIN)0UHG>B!
MUD8?#(>@Q,J?UXE'8+6[)S/MF9 HU Y[D :#%D76]I%S$*%P#HC0;X6A_37^
M9A-9UZ#(PYZV4:J0:E 5WT'2IL&6*YD%<@?Q&@29E6G;,.!OG' KRF? AQ&V
MO)_$36-0A7PF*XOLLG7-4Y%@\R+RUSS=*WJ8:*WG=@8:?"T:Q Q3_HGZ"Q?:
M["A+9OE6CU50[JRM!3E[:DZ)A?UZP?J6ZSZY4,?]S<?T#%);><TUGO1N<K'T
M'TQYE]V^6:WF20?F9DE5[,%"_$>*O^5YAM7N'JA'K39_UTX>+IFS_R%)8KG'
M5K2[_--J-S06LXTH"^UL>U4]]NV8P(7/?^<@^5\J[1PD[Z3_7Q-Z4F&2I@*M
MLD@ZH$ +L?\Y K(D0MEP*I11+'PN 6S&HJ;4] 5MHT@]6(3*+<]9Z.]^.4KN
M[YG0T/J7)@-]O&?*4?8R.I)8<6)7,Q0'&'%#BOX]4U@4J>/-]HH._&035K Z
M>U70=K;GJ1"TO5RU+(",T9#\N&H)/?WTMPW@UK2^X(E=*Z2>M_J"]W>-0F9I
M; 6DGPW^4=MHZH6':6&0SGLJI& T[9>J OT)[96W9K<M9Z%8R/:W@&C7+*0B
M:]/1VH#72GI85.UO%?RGK9B@;76.K'LZ6P% VK;Q@\K_SH#+4=ZV+@!6I[>M
MMS\ TG;OF*#F7F*'Y# 4YEUB_T_;54A9W('B D#9=K;C3<$J]-"V5C_]$*H2
MLD1=A;:H[0H4.IF@'><2VS:%-PJ=N)\,^#',))_4$7V.7GNOJQ/,S?"!,^VX
MTD\+^T:"J+QD8](Y77(67M+;2O]6!!W(^E(D/N%[[:+1_( 0 7N..]6+O3(\
M6)X.[%>"LR7MG5Z9?A&VUGF!LSXQF9K4Q4?&'&^PBO^^%A6[:%4<1X-O/O))
MSWI:IR2[84W$5K=013_D(Q4)_.Q<4T5Q16^=B\_+&[P4?>W-;C6E<5E2&YMX
MC/>RWEF3^UL/.^&J/Y^?F?]\M!8E_<;]_(E_@Q67)9YJM'VSNGP5%"PP0(KO
M&3BE7G@_W5M*Y$.0! O4!>!?.65D@0VGEFDE6)JO;9PXQ5<:-AM'!TY6J"E.
MWX:ZIWE[^T?__W:)RR^=O%[-APUR%V;Y00[7JB =CPN67@MW\CX<&_/Q1U]'
M%4\IPQ?G&RP+0@6.<_R2\5T&-V5"5)0HY\A/LHM>$] O$@\1>[(_?HYGM3(O
M*G@GZMVS-.;\X\+(:!Q<DVTF: E-MA?V%5XQ51&F W@#*TB?V1<3;<(I9TC"
M6MY&53ZB'4H&:6)I>RO:G3Z4/=<$CC'7M<@#JG5N#:N9^7>^5*BI>H,.J;VM
M'H]=N%*S3UJ:3CJ_"%*(L?HJ-%'2QDSQ)-N.AEIMB5>C.)0D"*QPU(J@C'G1
M%U08]NA%IXZ([E[6J=QO,T$2O-&'\P]F[M42!PX 9I)M\^!]??]8C @?%[8&
MO4\_EU<)-==0.&OR9?C=@Z7G\<4V1><LGVGH!)K_O3/#H1@P'&1!,F><3R#H
MOQCB)*Z]QWIU&N.D'5*%KS_>196X^4BQ25*T6D7F>[E]6FXR?MY)#U>P=H';
MRWK X\RAN2E-JKUE9L] U.(G@YN!@9C3GLRU0^(5Q"'_42<V>\NCGY=5NE-L
M^PHK:@>$S!DCD2?&<?8'TT5NO1.R1Z=VC"X=D PF%==A U&L<CRR=(";O%RM
MPH5-E%&1M'"Z49P?H[FDOFHJJ'73]^R%!I5HG.F0^<SY5Q9F;8*MV5.?:Y5.
M"8JI\YJ8"!Q49>3H\<\L94K./_XA?Y4.'+3U.=R>N^KM9)C?OA(O>W9@>/C;
M*]7=;-E+%P\D#\0ECPP+D6T(YU_UH9]3-%+(*!W3J\?7U3%!"QPB0-0P_]D%
M("1D\O5EW*T?0__K/7'<B%#L:TTJ\SRC9/4>%G+8NERE]!W3-0:;MZV8Q7,+
MR&&/=.43@[U,.@G&_V^6&*ZF*R2;K^M"\I&5KSW;JI?(54J+Q$V[5X*JSO'?
M'-8W_,8V,(MZ7G"XQJ_5.;[_$+9A!(*DIECB8T,>*\,VL1"NZVPID=_A*%-:
MA_!^=\';#^,102K,7[IY*85Y@37GPR^""\\Y'=N*3IB5B?3>7#&3V,6XFTUU
M03*2%%C;MINBU)5=L,CEV5D]Q-LE$S"KHVME[-MA_BSA2ZB8LWGB!:;$$S.Q
MSM-N.7]/!%]N3NK'HY^Z,]PF@"]\N(CCQ%G[+/M'/9_#R2QAK))A]6YJ=\CP
MNB%!TE "-0F? ^J06 -<UG).+BE^S)\N/7^T*#.N:"S=VS=(,IJ47AO.B)1?
M@N:=-"D\D"(]06V;SS%D5J8#^F=BY>0U;8S57&G,Y-21MI<<S>+/RRW>DU./
MTH$;?:?264?T,T+CN;J,97L(%55!DDRU0RK$^NJM7=Z$<(YI%?[/XKLGX9B@
MGK/@T.NG&15!A6OR'W-E*H?Y500IOY;;PPYXKE<+B9<9Q/BI]T@OC#%T93O6
ME6EG'7+^=UCI_ZLD^;-D2^:CN>6"HQ.(];9E-*X<-LQ%!QS!^?J62<32XN0F
MAU&]F;62.QK7]N9_H8]<?]9'2@_3V+95V4\VHY TZF3Z3?)!ZJ^3.T<9,OY/
MR<?V#\GG#:DVJ%;@G^7B'P;_49OGM)Z@1#*DP[;%XB:D^[;U(6E;%$&67MMG
M87>V/P"O3ESJ&4@C01(0$E1GO'[3E/^PW<]DYCRKNZW# "5WZ'&HI98_J['M
M,YLSVQ^ TK84JX2:>XUA>C3G;*+"=X;Z?]A"'>O9/JB\Q&[FM9(FK>QUC:%^
M6YAN:[AMRTXF;>_M"L(**GNV+;?/CR%ANOJS 6Z;V?9IVB6AR2U9BCL8T-?0
M7FC[@^RXJ1I1?[3G2AUI*AT[B7"O/:G+I\6?_;J$)3?]EV=3JN@FU0Y,'C4*
MHW17=23'Q\=G(=Y=%-Q^66JO/AX110+9G]POKV<6?HS4<D>TSI1NV'D+F8:.
MV_EKI.LOJ>3\E[^]H-@^:,OX]_AZ<R?]SR>5@]0<.C"2;BE,=G/S&!%^[EP<
M1CNN?Z:S??X7VQPI&W'']F?Q+Z\XBU[-]5F^ZZ#"0 <8 TM)K(OS^B1?IR.M
M;K @<]U7=A&6YZ=#OU>HGEJ>X>&H%X!/.56Q]Y[#!U:R<]@+B1*' X^JB'?G
MWBLMP\GTMY7=BVXN34X4O5ETONZP ,O8,H(9K(1DPA@%O$\'-A<_TH'I[YU5
MN6;-\:87]&B6"\W-B,2$%[6*[8\Z3CH7HRK*: 6X+YN1B/#-V$H'YK4Q.N";
M2#'^7J[Q^&,M/H=O2"W"XI1QF/'YK#V?+K6$ ,O,0N]&<+-UR=Y'WJ8/#.E5
MBA2_3'L=;GU-"_8*7=WV(Y* KO,V(K356AB-3#Z;1^J,PH[H3@[8>R43VC3\
M)V/@-@/&.HIGYUF&EQKPPN^;CL3\8F'9'CNTHK^\<;//(W1O9[YKT(;EO _B
MV5H;Y6+XB#YU#\6!#O@I.M'4T>FP>XN]Q578S[BG-L3 YZ?D%!-.V4_+[?4V
M>QB#.--]^*G!0:M]Y5:X.#*,P%Y+!_KKUTR>E=\>]?].$_%4& BHV)).R*]\
M\'RYI+^>I;&>O^&N@(TR>_]P/F)>#8_M>S+RG=06V#YG_52)+RS6&9^2]^57
MEO8(E:575R2!LRG.;)=PJ)AWD]P?S'*+AA%E2V==RD>/%#[QVA!F1-[I0FK1
M@3U'J87N['Y]/A7N'RCBQ)L1\6OYL-D0-M&X.Q?AKU.=3BGW'OARB[V%/0MY
M!R*MC)0M(S(N$CN6;Q#70Q^268K@\O Z3Z?C!J_R=ZM<KKDE^^119$+V7LEO
MX$C0*Y5"0GAHHEAI"\ZMPM<[Z44SK]"$!J7!")&QDB"N'2(Q+WF\;V$5.^AP
M7M;]8E;KXN&Y6!V9Z5EL"SF8MM]IZ]HLEA_#.^O#2LKI6D^4(]YL=)#K[C^D
MW)KER%'P?*E#5#3YS!A^OUB$?2/6:3'(\C3U ];6B976++2[VURS<\'L.&E/
MUU70LY7W;8QNBF/0B4NN;W>]?0I["%?<8M1$*D*]OT!>_F#&&<-95,!R:<1:
M[D33NR?6@:,Z6\(-2!OHG^^3F[-NTH$4K70Z\&#CK,T"XY>@7GTJ\1%-3OO'
MV^_O>B+\XBT&O+R4?Z3RWDZV/ VR1!V:^5)**=1I6%.VHNWK)YK,?M5-F<;1
M?LDC':U!8@\V>AZ[%\NT5_/\BR:;S(\F7^M&'N?:T/8GD\KJA%C(\:/ZO<D$
M-4I<0!;>3?(^SJC!XOFU3Z8B)HYFRMD1ZNQJ PH TU2WC[%G%DT")$O'A$N_
MAF9-08B*5\97IW/:)WI7M]Y3[Z?*K_KK5AR/*T;UKFP<NH"^+9&#MP$E>]$)
MFZC, O@X-X6KLTX>RPZS#7]&D^AT&"WKDM5Q^=AOWK)?ZU@0Z:[:K8N5)W?5
MRPV&DX\SA8#WO?<CS4G5HVQE;J.AVK^X":%L.2L2(Q;.C3/>Z[L\9FW%\505
M0%68&CFFRMC%FLI\Z36O6%U9S'#3/C3F9!*YU3T\Z#[[@WKT _:(SWX*@IJB
M<@@))^G/Y>.'.5C-+<JZV*+3[3:ST6>G&H7,=#[*.TKR7Y)_?I&YTJ#LXEIX
M$):HQ6K865F*"EFA R&61TE,M?S,'EB%@)04Z;'7&0Y!6RUY>74,L4BAH3##
MH+0LQ(#=.F5EB3/8[2&J+B&G<Y&&&5W9#"+'T_;K;FEXQH^V?9U'Z),"DL\7
MYGI:4J7JTEUU=%T<Q)Y\./ME:^% 0VJXV!YQ<3$R>EZ"A";$SH=N&0_2VL!]
M2AKR_DIG/LB^GO6J34$S:UM5#92'/;\8REN>^E*3;7+B@DANM.B)Z]>3L^SH
M@*3E8F$D;O.N442"O*'9L?1O:Y]7[:^LL@51NB&=YJM##L:?BE#2)8*CIRK2
M*6J?0[X)/3RRMOG<#R5SHE?MCH+61,94-6/<4AOY^' 818LD23O /8KE\*SK
M493ALK@O[S+SB*0QGGE333I;[_S8_,60L8=,%PA!MM<SYCI[6JE-FQ[+\VEQ
MS^-#+LZG=FQMT1)6YWPP[1U!2\-]L75PD!VT87_I<[1SH!Y,G^*.Z-=42,$8
M,3I5OH#YWS;Q^?8NO?>\@Y[2\C7,'&6-^@&T!8.P1</U_8O/P%VK^V7##Y@J
MO9HQ:RUH9>J+.<\LN]2"/=LO*9CYLN7MY*-Q@VE+%JB+$DBISI7[W+5"9TDF
MA5GSU)7-AS%KC\:Q/T(_O XD3'R&-IZ7EOOR"L@ZHU"0N&'7ETHKB#/7]EFJ
M9MPO8K!J[ZN?RY3J$X&[DO)1[<ICV7CO!?22"=@3H-+>$QG3KIM2(;O5UD@'
M0ND 4==)@-;T""=\"&L3+F3?J9]<NQ:<<\K&&'LZO67<4N[& G?(&[,SK]B'
M8=+>[EN 3Z^+3P\=8#V%,@E@9A>X+_7*KJ>(HG'VDXI%BWTOPGXWMJKI"0?"
M\', X\%]2@?MEX37KA8CGL&()L*\9&YM.J#6[JX3:E@K?6A!ZOBYQP>>7MBX
M?$+(3[3BY%G7S"F=ZZ/'R]^Y@^+4AWFFQ_3[-=3C]%MA2\6K.:N%P4[D>VUD
M*0O_IH\%[4A;A1*&IX1-47YPK"^2#)\5]+D+5MXM/^:.#]7 "]<.2BB5S0M?
M4T!&/FMPO^WF@+K5WDH'O.%#-'%R6>H4;+<[^\OX[I4LD+VH]+F0H%*XW*5-
M(HROZ="URD$ZT%Q\;*HX'.]F6MO&E4XIU]JL2*%M";_"%JD'9OCT8 OUZT/U
M-=^F=*KP>3[N.ZX:;9WOV0,M)=Q/TGAF/V,U8"/QB,,@WI96/\14$F<@30L^
M-.5Q<\S/L=^J[4MP$RS4DYO"J8A'4,10>S#BGJ,UK_G+PH5FC&ZTB26K>)=*
M/@ZD[1%;9J M%MZB Y5BJ[/H &$N%5D*2W<JS*X#/;36:Q[:RIC6]XB!FK3F
MML)5P:.@,],Q6*G3H[V@O_ ZU/8D:IZC5[>>-FBK)H-1P;Z<'2;"PU] @^U/
M:_3@DS(\7$I2SW!(!]*9FB[;O*+"7#/!8;0I]1F-&ZQ*ID9@!*<Z:FYCOGSB
MR_EQ.V#94>N-WT)2-S@B1YJD')YM)8]OF5-8R1+WV\3TIEV\7D?Z<Y_SOZ<R
MS5I6W)ZUNKNG3U+RAL.(JL#I]Z$<ZKL_\@ ^7 FL)[ZE+S<-G\B26_:*-3?[
ME$[)PWXSAY6IZZAQ;9R#=@L$J2B5.+Q60;Y(2!#J41R$]J [Y?G%;W7$(H\-
M^!]^JBKR28"A54,NT\@?(^Y465$ZGV<G_WP"TX0EQ#:[K<8%489B:?NM"</A
M?.*48\)\F+.SN"$8-GA^OY,#9[--:D.URC63!V<S1%]04GE$O'!MX"[,:5J'
M#Q/Y-0'L15PBB?>[SX9JK93I>ER/GE00N+9PKHWA]+U][2>LF19(!7OMVH^/
MSV$&"RP$BW'-F)KS7[PSR8JK. =8FD]'.R(6Y,&.1"HD/AMQ,*^/DZ]CYY@=
M/B2;92LGCNE21125V]W,U!1H/O3.N788E:M1!HVJ%'@?S8GT)C-X<P<OCG>O
M+K+:B>LI1%<.2K?LE?.,4Z>)\UI+/?Y%52Q"RUD;V;19>YS*7SQQ-3Y<LBC"
M0>8Z>D/X7CLBA@X(TU0HIE1H0;"SN#(B7AE^L!4O?&#J<S,;.J>WA5@.+4PE
M,5H' Y>ZVV+RDO@;-UZRG)]'@)5\\,L=W";$\#IEKV8"RP'K\.MQ["=YK>L\
MSV#CC^BI."QHW!2*?F<>Q652@2M^5-:_N=4J%A&?ABHOGD/9K\-T/J+;],GB
M]?,NHUMM069T8&Z+E&9[JMP^Z:5)M5'I+4?Q);#GBB0TDXSRUU^*FURKB:Q$
M<T(+VTO/V1J0%3N2G,A(8O*;^]"%--[K9[LWUEYA0>-+G$Z)54/#-[Y++J_8
M3ML-1:0E9R:V/LJ?7BJ>O<,U;Q2OP=JYX;XQ-#E;R[51[0WIZ;<XFHQMA#TT
M\WS.V_<-US"G+"-_'#UD^J-AX$W[W0>EDH>>)EZKWZ7FBOA47*O_$I6_/A^<
M[=.JHD(2; LJB#@>K!\S81,_MZ3!U'?4T[3Q[LL1IC.3!VJLF!Y-[EO6[\4&
MM:Z;.:%77;3ZA-IE//0MD-@LX8R'\!IH)ADZ]4LBJ(FRT@R5"/8N^1H8UYBJ
M<]Y+RR;62H8/ @'1 _-7?55,+C1PC=*V^ZUFCSI4<*-<@Y1.P+V08^>WO"QV
M_SU8Z/VRH4$C\9Z5A(#-_4O[1#A/VU\HEAV++4U #ZX6/W&?LQ5[WV7>/>LD
M _M.O8#>12VG'?4,QFO,O866_<.>1D:1ZKBY]\7F]E.O30G+IY)>-BTP,N3]
M8 @)&;OUU![/HR)"V1:>%DAGXK _Q8'0CWX!V[M:Q\Q:V_MH*<DP2_1R[K?O
M6D?&K3CS-$P$O\%QV)&LX7SQ0"606&9,)FQV;\[0!#JDI;+G<EKN=1#$RX45
M.5/S@V-$&=GVV%AV?$AG6BB^M_58CHRDQ)VOGK:XK#/4GMH^4TH'$"\7A(FZ
MNAZ&)-B<S8@N_$;7J4('PP4+=?/@_NDXVS0WT"7&XXZ.L*O]N#0WS<@MX[<O
M;#L5>E 4SL6U8\0RLCF^;9Z!6I%%!ZHTV9+H "=VT#M\<< ,= ,'-C#K"$?)
M&MC]0;?Z31D*EU&-+;'\DI+[QT:G--O\F^_O/DOOO!.:=G'D@;I-(R/K%Y%1
MKJDN9,G8?):1R=S02Q^-P_#S?)F8.$C%]N- ERU]-1\'>Y"HD87EFW:=53E)
M'B2PVA-DDUMIN%*_;\6F"O[5#=8B0@Q,"(OD5''*(='1X9HG["$J2E04[;@=
M3H&Z&,A),%=L[NTCW!#:'R-QA[.XA20XTUCVWBAD-S#A.QF9#GJU;I@ZH5^[
M(O.,= 9+$3Y]PBE=\*_#Q&O#?:/UEMRDX0 ?1B2_M' -^R$IT+;K5GV"742>
MYH<7B1S]+*V_;+WT/:TW/BJ[2!:U)1V/ZL.&^9RUWXP-7SBHO1G%\;C]RGG%
M@FSK-PP4\V3Q[R;.CBYN.H-EECE.UN/4AY@(;6G5"@?PUS4L>K6+*O4!>Q9F
M,QP&X\):H?HB]:@HS%ERF#X/V=SR?J<J;F'<]FY(4ZW#X%U71+.'T2'UL;E;
MYQ.2I>@ 63JU_X>G/9ZUZ]:YZHRAAJ123D[.<QM&[Y)YJCYXA,3!YW,2$W"W
MGEM+-,6;1.C26-&119/3J5P;T7@L69P[&&OGQ'P#:49&D6Q,.U5^\?3=MZJL
M,E0U[%X4RN*'O):9'\!CB#UYUN$BKU6,RC-H3V BKT)^_A3#2G;_?]A[KZ@F
MORA>, J*%$5 NA(5$*6*5&E1$1#X(P+2A:B @! B2"<D"@K2.R@(D292(S72
M$GH5D"X$"$6D!A)*"*0P\<[+S)IYF+O6K+DO\Y25?$G6^?;9YU?6WN<[Q(R%
M_S(+<JZ13NH5 <_W-X2DQGJ&2?)A#)!**9_89U23;SYX9F[^/E=R&^T1='3H
M1Y._+X)L0C9ZX(^V1_=T]O.PJIZ(^7BSP'XC$^-%ZRYNWHTYI9R;N[-=K)5Z
M5RY6K,4TO1%3<U&*#T=_@LF.,PU"J\XQ  )E@P$GM*!^2PH 2HZ]S96P^9YG
MBD]Z?G7+>FNJ)5TU.C<?JWMBT$?Q48+*@Q'H7+#\ /E'P?37=<F\\0-T"+#"
MUWH%3Q/(9YCDM^')RNU,-X16^8MG/P8X8Z- Q$>@TZN,VY3:I7+C-AV ZC".
M\KI-XTX/5<MPN;SUG/\-2/U<S\_#03-_CD%!I'9&VPA-X> P&!.18H24Q'=D
MT2 '[MC^XJ,L/?@=RC&@'2L(FD_!GX<IE:WFW,20NEL)YBN;.VL!L>:R])6W
M>;+]%QI/.*=K>4G[W.1 YF'GOR'/*1\#IMG(H!&,!.45YY3RJ4C'ZA]Z_89%
M,U>C#+Y/#_<@-M)N].IGU,87:^JD[Q]ZK'V[)V^IG5H#<0@Z@NWMU!\4\N]N
M;PJ3BAB"Z$WT?#E\$0&RKJEC](Y%W8;6V#,VJT,:WJ4PV,#R_YYH18-^HVS8
M4>R)G.WFPBH)?"_-'&?OO=M3^&//QD(QKJD(U?KB832<IE&2Z@<I:-J>W!H;
M3$TS\BJH,52E,:W(+[I$7CTV8HYU%",$ Q&WW_F^V]F;Y6T3/</F4_G%H7MF
M26HF<^UZLI&)WBRKO;=)J=*RMCB9G]%'1RM@W< 4$QJ^5A!$C$<X+WEM*$*8
MW*F#T%9#E)(/4*4R.\@VT$Y6W&OZ&G9OL)9I64_E3(+;&#<I?&6=O$/RV:]#
M RMOM[R^F!Y_ :D;^_B&I $W(L+0OM>!3N7O6[:K E_PHCM@6?8%HFDS(XCY
MG&/ >9!',R^N&PN$2V^H3L=7G\%4$>L2A 0:[CU0T\]REKS+\9C_,9MXAE.*
MHP5QZ?&_+C#657HU[0H1:4Z*P\=@+E(R[6TNHS]C4_X\Z7MF:"[PXKSQQ2];
MOU_UW1[45XZU__9MR%!;$.5Q<,W<<6 \HM(.^Y 1N3%PP>R1V2&(JK?AJ$C'
M8B&XH3<-H ^NO^ 7 QT-1!+1GF41)[%NV:-OQ:.$[K^MNO!F=KIYB<G@81HT
M]F;BVY&]0YC!UPU.,?')<WF2J1AU!1ZP;.P^1VE.AQ^JTA<;P>#]13,-6#11
M:YN61R[*U+AMJ80XZ A5_+62_HFZ]<V?M229_<^W/7Z+16PG^"R,GRA0O@04
M6#=;R[R6Q9-L>)$VHD;L%CD&\%6V6%Y,]E#P23LE#"4C PZ/%)+R?;*MKQ.&
M_<$3F[0=YI!\85;,-(9.ZW8BJ]GB_6Q5&N5N/E0.*O3!NP;>":WTZN4Q9)_C
M4S?/9_FKTL_,L*>@/TL,YNJ:_'X,&.DLYV:B3D23'O4!8Q)\'N0N][+EMUNI
MW$_5*X=GO:5+9!\@/NA!WSNM]V_',L%-EHWV&=$*.B(#CVQJA\4"P"?780%Q
M=(C"2+>DHZ6!4"YQ"C<Z2_>"5P[K\9]><%2DFC'&X;ST9-BEPL",SB/_VF*;
M=;6EA]':O&=<TIP5FSX]DZU\\R-VA_UV-W_ 4@;!EEA-AM0/$QCB@?D,GBD_
MW[3-#*K.^L: 35\DZ$<4>2F8ONFJ%8 :5*!(JQ&BB)'D&(KF@@/WPDH,=N'*
MN&SM<O./<*KJ#L[YZISS;(.;F>G/]9OL6GMEKE+]@1XEM,UC@,6#3L<1YJL<
M]T0<BVUX1_"YK%)[V2@( G)IS/CZB;:&B!-O)%Q975G'CRBX%B#1 C2%ND^4
MBMC;P$>)F2Q_S8) M1"_[5(\DZY:/DORO-O*EN@-?DQAZ\X49&J>TVLZ,L2!
M W+.VY(6><\MVJ>KNTX2;W 2EBZK@4_/^C^.MLBXQC25[1=KOBZ?V:69@&F#
M8=$RB]R4&P:$]XN(MQH!$7 @3%6=$KDXT6&MV"&9/G)R464GE?2W]\IT01C
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MOF, !#'%8@06H1DT$HLZMUE:KR)>&A2T)0ZX\#Q5\XJ?._TD)6Y9TFSF!#@
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MNA-<)]4-G$8NR6.)5/+SNI&:4);V'2$4#5K:4=7UD]VA/5A#6DGFE-G%^-:
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MW&4[O\6L,^B*?(F;TQ+X>.<2-L!/@66T"EQ)(=?#Q9F9""F:2?8I9P<O99/
MEV[,"Q;SW9SZE@VAO2#E%2%ZV "R'>H(+4UGXM\T.$[DJTRDEUS\N!8;@!\E
MOJ67J>TA  # E2.(,&33 X9XL#MYF;C0ZBRIOBS%.Y*R0T 6)5H6%X=%_FT!
M$P)*'#M<95XG#V1"3#Q'2(TS8OZ9S9WA^'1S^V6D,_A,,C.SI+V=#:#)Y[>B
M@*:LE#R8O&;QD\F-0OE7[E*Z<7E=86:(#R--2+)1;\SF(O* CL',JD'0TB?5
MX?D?5\MV<Z/Y[_$CEPM_@!/"%FT)BU;Y!NLB17L-$%+KGV_6A39/)K!?^A W
M(&E LB7=>)T-X #0V/RXQ?N\,%T1-TTNJZ9E2.'VKL^^S2@;D$)G?F0#EJLS
M.?I4JQ.X#O.C8#H-O[,!01@6< A8J+9K1]=C SK=6.>1DQS@-&B'?$O]?SQG
M8<K< !,*=Z45D'5@2O.FQR*FA6_W%,.$#7@P@68*#.TN<UJF82]#'O(:MLRL
M.@I>;T5$P3E$,HFO!4T]4</!43/()SSY%GB7T^GXD2L:7*S8?),7UJ6X&B#S
M4ARVV8AAR0;TW]5F'5O LH0]VD&KBDB_E9C ]0949?="P,+Z2B\14J2VZT._
M#C]$JZ*+L@8S4.VX"#U@>FNCX'!>F@_$H.+U/*Q^_L0S@22YWKD*E/*CZX&G
M-P$"OE/UG.W=B?1;5,BE@0G#."3EZ%-7,WFO^G^NZ5R?$W3&GC[;6+D9\B@@
MG[OP7KY P[\BM?FZ8*23V. ;ZO8%EJAV?O\P8RA1OTV*,^'PL7_H,2<X418(
MW4 V,),G-MD 0!NRK80U4IT$V4=H[E:5-7,%(WAHR50SWR#/ECE-KG?E#>5@
M+ZFT@7X#[A5G"A&#WGQ<UK_VCIMX%5G\R9H-2#/R6.O7^Y;WZM"K^\*K[IS.
M]8(FQP;<5T4S+]64%!CT%T;F[EC6;?CNP1/A=YAY.F;&JQWN"U#H)M@2NI'9
M<IG#L(XTELFWFL",N,K[-#%#&8P\BASCZPZG"R+XF"J#%FQ :#ZG;!!&^O^U
M^LP:;KIG,(2\O1[.!DR(L#@%\UHN%;?&0>[9'\OM>YU,)\QK-H"0BR\OQ='U
M_[D *9AFDC )&,4K<I8_UF4#'TB.70#<3M2X8 R\&C\;1UD_QF%$ ;W1(8HN
M$K0!<F:+D)YZ1>RM_@FY,<3XS,OUPTUW;E&2\YIDWP)^%N:I%M"%*9=,]@J]
M2W:\S8RQ=N,E5O%V.<Y,W_V6ZL/BU!"/$9'%!H#H^BS^"QL5.PQ<A<F\VX2>
M"Y)G'0Q]Z \FO-ODY=!Y3M>.A-S8Q#)763Z?7JQG[/Z!:]'V3\@MVA2Q]PQL
MXI<=\B3KI&>DJM#.PY$_47&5;WBU<LP5ZVSN?,L^;1TDXE>'\P5'BV%;>L?.
MM+-.DTM>U0[)ED6MK)R]7]EXJ\]T3GK'M?P45^D1=\O+:4+Y*L.6EECK+R68
M4LZ65<NYV"5J:!%B9+K7H:M[THC%_8P-N*!)7EXN0"Z&M<*KOHX;[=^]5U?G
M=?2.?'\^'3_Z$^D8P>*NH#\W)8S!C] UH(U'?Y0W.BUWW2@V@[G"LJ:A+Y.=
M5!U.U+^CSQ1<6[7SA^R:]>3]5P35G6673.^OFC:HYO.6^&>MQ5>J'NP,K#T'
M6RYOX*G>"6[[=RHSG*WOY:SL)?V*?^XXF;([LF2 N,_JQFV\-W^#V]XW>]8.
MV2QD QJ-&(+@BUF"R"DT+7NW@G.^/2$GX?H4%$,PXGY__1&2.(B'-NU 9+4/
MJ1FZ1Y^M==2PD, %'WJU(66\.-S(T5;1SYDX-N!?(\R(Q>(\4"@R8O& Z&=A
MRRW3NN2==F2$ER)'$>VU4KOU!H">'V].9'\2U#%>4BD!GA^\""!$=/[C +.#
M/C%!8A%\JO$4M-8O<?6MT?G4RD]WK+H2\RY8R)Y%$ULB0S(N_OBFG$_-"?!=
MSG%I\&$%UF)3[=3(E54K>YAT<QIT\]-ESKP#6$,X 98TS*KUDRXMBX Y#?DG
M?*JAJMEY4C;),(6;I\!4\/#L(X\&'V23WT^_8W YKNQ!$&[KOEHJ69\8U(:<
MB* 6]K/4&,9]:GPQTX?^CLL\_-HQ/U'58E$.*_EB.[XA<U4HV3+;7LABA+=D
MO]PX\&9$U&!&^G'^B>K2A6Q#%=N= 6QQ&JL!ISWIK[C<8Q&TXXC+=9E.QS.*
M$<DP1P$LN2U)P)O_V@K1QF+T,(!G-Y0ZQFQ80;IGK@)_.7+%Y%+0+3[>RN<_
MO8N_=4]&V7C\^N>ZBA_GW"S2QA'N,V!+V N6P2J(U>#*!OP]@GB,;#)BG8 ;
MD[E6=0GKX\ F%PET:^WCM+1D9Z<FWQV@^Z>Q+CZU,_.GM=P6)"Z=2-:[/Q5$
MW\I=%08%4QU9U9KD13IOJ\MMK<OK^ODQK1"R!3"N\) C+>@7_GB)Q[UE_T5O
MGHBQG S3#P)T@6XXC@(F[K2"8]#8WI\3?O%2FA'M+J"&(7]HVX_*($\E::W7
M-M&Z'2*'+G9'&8B^:+=$9/<A">75C2IE;\S)F":P("RB[?ME<'EQ_AE#X \^
M"1^9 YPM'4.$R#$"WY!VHCAL>3T2+-*H->9("PP+<JQHK!X@A77EC8U/W8+G
MWW_[WI8/^\SO8UHS_]%!W4EG81_---P7-N#5Z(N@;!L-C,+ -L*ET6@,2'9$
M[:JC>)&C WRLY,F1,<@!8AF6!B13=4%^5&]8J+G0A#(*M$)975R-HPVP>.\L
MRZUT$PTM19U:3YVZ\5MF!:LVAS_(!OBLQZ++(;_0/#2[&:[F!"MG\@NO,F=8
M4&N(=C@&JNAJ_/GQT]-Q1R<2.CL!1^P?)JH^>J=@L+C.$;@F$R/8G,O??:T?
M5>UPH#S/;Y'EN8.C*7*-(HFHRXU#J$JDKSTSY5IO9GK/54Y),WK076I+Z/*%
M:"+%8T63O'!S9+6[.RV?^*BB)APR@TU6OQ]V_ F8<R!MPOC]*-EB*3"Y!PTE
MT'MC./NP,A-=95+@XJMP&6'W[G9GD>J$AKSL@\CI( F)D66N&!WP0R*8;S'C
M0OK!\<5:GTK;P#*0,2GAYA?49X!EE()%P3=0HLE$A^'XWI9 ?DCEE ;9H&@7
M&Z;+]V>==GZM!DGFI<;1ZNBZL/! VW"2Z?(AN4XIXV-&3\&+Q2<$(L:U,JDF
MKW!0".TBI@4=OW-VDN;6-%=<^=BM1N/4,'4.UG;<2S4WT$M@I_0%BZ>"&/:"
MH-&..\KP)S\3LG-LB-_3G?J5S_O\+"Q"73D-=OXL<@3HO3?!XLXC7V<(,-\Q
MU+&!\R?\6CZ,8)HO'3_>V7C[;8A/E-OO;26[F)2"5*_UNSJ-WT/DYM84,$N;
MSA<U;HM;>[LD.5;-UU0BD[;-!"PL+7;-B<!=L[8:UA9^S\.10T6.%&--<:?A
MI\/OK*0YWQ"7?.HR*);_/U_SEP,F?6S [Q'R558CB W8<L_STB?^1$[@/KZJ
M+G(=7V$#9+9Y^M7BA@4LHJSO 5:4(6E@LE6ZY[[_R=AV4ER95O!AB=-LP!EY
MYKT(YBWD&FH.DHHC6_7NZIF/T9<Y;7BQLQRR#D-26,G\ ]Q.#. WL$W!E[<?
M#YK?,*OS;@O.7^6BZ].N4CUI80$DO"B>^6G,)'&X4T*M>VOT=YR K*_;Y,<C
M$LF ;H0?S)3(!K1B:/+K+:9^PK2Y4ITS9+!IC5_9J)/RP2<2*C=^(*B6>G8_
M'E8%\UR3U_-@?@5[9P(3V8"J^&E%RM?,(!(RIE9R<WQQ6J*J@2[?Y2%^*N?/
M^ 1\^-[:S;6SJX<?&N]U[7]H,_I/"MA?O-4-(KQ9W OX:'JD*J^T/JGUN/>5
M@F]*3SGT^8B9E(.![2?,EW_U^*"Y[XRU[^]D_[7?7<=D.*>CMW!F.EP$W4-$
M5*0JCI<&N1-A]+?R]RVAZL 9GCCME*'W'Y/;99--9#,8=9SW^HGL:&><X6BM
MAYSJ>>.R2%?B, (K3IOW0B=H@9K_(<1[B8MJ%Q?>>O,5E_Q$=;[.;6LZN*#]
M;#  @T82*FH_]^EIP64'[R">5@Y\FNF:PB*Z/H_V/B&5FC4+1A=9>6CCYQ18
MAI?E8=Y;A>M=T) JM^VV.,8/-B!F=A&_9>2+(W^!L SS.=,^TC:0FV3%$MC^
M.WF]ER'+8<._ARS>?'SG5J=([YHQ7\&1FZDQ/_H]:#%$^WJ3R^^2SV>:!#WC
M2_XN>)DK57I!6[@TQ&X!R!#4IIK03.E@N!CY:Q69,QDR+<BJ?F2X)S1V_?)C
M$#?V Y7D(,+W06#V. 52\K9C05_B?=OV"=2=. IN'$6U)J>O^A!6%9I=0(,!
M)>KM=W%B\9:>*<T")6<39II%7=\*ML2\/-"C62Q_8V-<S!NGC1NL?1'?L/ -
MNO5W Q.#)]\%CG4YD(6CJWA[H],&IIV]T@:Z+PVNOPKR3'U/,$\TT5589 ,.
MP8#Z-"A1$O2+)5;F?/5F/U&(&@B5^2T=SW]S[;G]MJY)T?C1!*X854D-DVHO
MJ?%?X]KV&9:\J08\O*< /9R?HNT1V]M6Z1>Z]\W<!K_,'-MDF"";HQ!6B-$C
M? S!(L+?(67J*7^(7#<=1]F^/(F<,!_&V4*)>-HEHY4@DE]B($*,]H8\ZLLY
MFS+T.NNW1DJ3/"S7X#NP3;<4Q<]);_]H$:0"P.Z.J1Z5CS*W*B"%?XFK7M:Y
M61^_]&__I<>5J?G%2@G_#:#K\EI1+B3E0X-B9:L'?-=)<?,!2I4JAG]$HPF&
MUY>4(5D(J7V>M*1WI$_X)JV(' $98(1!15X3L6R 8>+:=>6:+Q_TFU-&N;4H
MBQQR[K$>@13 ^?"-M]]E?D8HPES]CL+ -Y1-LO^-Q';(?I5VG)*Q._!!<+2S
MO^S>RM.<PY'#RO,%R;00' @$!OWNL9R+\"/]XVB0TOP1"FL"PC=!S0(?E)IP
MQ%+>OQ#YD3&N5OZ8#AX'\ =G)EKE=XS$48$BL$/-P%-;> [2"-!>F%"4HE]0
MG5W:% HVEZL-I!N!G*./834W7J%]F#$3G]%H6HP'GZH,>+.J?J6SK#M@-NMO
M+V\Y[WS^E'S[_+T?FO<U4O[AR+9L0!SZV)-S?8W*<,&:L.?GRJ8KNG-T?HA,
M_NWB#6\OE+<))AJX<8G>N+1X'H=^C"O1]?52N]A#ID&(4^!ELFX1E8-;X8Z,
M<Y3TE_7Z)309(ZE#%/>\8FR9'EJ!&1=T2VG.Y!!_0;[(GX?&<F!U=8[NI,E@
MV[*0)/#/]5,P)Y>ZS'N08]/-?OF3/:8JXYV1N=JH>_&H^$^"+_\=@6$3P7Y^
M*&1U>K0O@Y?L1SQ"C?(HEAF#0$_?V8EZ^"P:4EGY3-]7]#FOLAS7W%G"R 2Z
M#+?R%?T=TN3)T X*.)E-\KE-6!)KG6J$YRC?*Q)X1'AG #AXO6/RZ=5758(7
MY3^.&^2Y+X0Y[GKM[(S(EY@-6$QI($V?L)##&7 9.G 2L\*1L$=,:*\()3Y1
MN2%;XXEHS_ZG(EWR4^.<B52)O=0U?36,<U$@8F@742OGBA!_A<4\6E#1 R6H
MEFY^57-9<RIR]=B,#V4E_:SL/WS :T!$N.$!J=.<S2T?T^;WTM'?19(V00[9
MN3>T&O.N-G?>3-KK%Z5F*!LVQU'$$J'6"R]#/A::R%_)49(0!GV;4MM9WMG7
MG]^+)*VWM\(0SJBA0EG['(_ 8W&\5Y5_ @(N--YG?@#[X8ZS!M@ 0;@5(8RW
M6:NJN%9N_+'S Q.)80VAOC_2B6:[MK8I3Q]DFHON)BJ0UF.16*/50_2G_U)H
MPH3U7Q-LP,E_>Y^A9OH6%4EKN9ZC#Y/6167BID2?GPS6/?0B@HI?.4<7=T#\
M1I^0JZS_$6%-^5K9H5=1<)TOC2?B^[3T]0NJDY-O>87<7OT4LWI3EV4FXR-L
M2]\#M=N,]CRWM8C^WMB0S 9H, /TI&DS6JP>,-D.S0=KMY>>N#GBN^H[/'_W
M]+F::G7+&MWP'\_#HA!U$4E)OS'I2#_D:.,(M8X6X)T1T"+FD:BJLK$HC!4]
M?5OD!'7C+?>Q">MH0.J#D\=D@?$,;GH0H@]<CDC@BT"H,!0&=4SS%KV5GFR;
MMH<ZW+SXTP)6J*C!\^WHL=V&^]2>=^^\Y,_TM5$WWXS!<;V=>S9O4LU])*UN
ML\P"=M>97GMXB.(_" <$HNIOT!V7@ <5X1K?O,52&P8<VDM&306JVXR)FW*;
MUJG*L;_]9?WF0DZF;LC%@0G?@"(X3UT5)"^#GV84^A6JX=81=G?81 T:*_AC
M\M7#6['A"$;F2PE" / &LDD+]Y"7#1AK.V'4CCMUWA3_.F364#W6="%!7?C!
M6O2=MYO: .=79]T 'Y/]\X46NG7/INPVIC'O+,AF=YUXQ-FCPVQ -I7Y_X>+
M;_^?+]IM9KU@ X J' F*S$(:JC$6[K,![7]PZ^@%" :&;%1@3;(!$Z@//;@Y
M?.^6]'_%O$(PZ"O_PPAM9-\33O@_*;'#GQHNO=F/AIU;-)>\].8_3FO_PT3M
MO\>T_[=YFDOE?V)S__X/\[23_YT4NP=;OL,9]3^28O][P/]^-TK_1RTKH]M/
M_Y,QN]74C]X/HITIN;+_?OM&<"Z5K?_E"9>/N>TZ,)*W[PG7?MMUZ[^B:/_7
M6/Z3E<3A#*V!F/^XUKGL'VG#?USR]D<[[H?E8O;'_,>WCC.[B/\XWOV7L]Z^
M;]W_&ANRG5^B'#(P_%*J<GOQCF/(UO\M^W?1_.O)=WO_TQ;OY']G /_O ?^=
M 2SU7QG SJ"7.MR%#$.*VM?7>4:UP8DN-_7LWX8M^#UT&"KBN1(@KVW@C4^R
M>)-I$3>4!?G9&X%%"M7?*_M>KZ64S1?J?PT0: ">!G^>;UPA7\[TR?F'?/@]
M2FE5:<Z3]/KHP0+ @3NT4(+252(N:E75^;*.P:D_*5=VYY&DP!UPGO/_<*1C
M^9,D-H*[ V?R+C(4MA%^9$?@L_!?BHIJM$]LP.Q^L-J&W%<!"P/ __H5W+W!
MJ1-SL@U'D4SH$SPB,?D9P[W.V,J!"Y_P4H^\U.B&?VH./SHJ^\@59[>\R<OB
MX7#-2Z>8']B Y74.Q1O(NR.=_Z:YS4D3TVF8_BS;H600:>V/)\]BHO!;>C .
M0SV/I V%Q#2!:>?-FT 1+G(5E.-E2RS5H2=3CZO9@,@XD@8VW&96JUG"L_C%
M;WZ_0^&:HICR?R4R<L+^;A<+%:[.K],N]C(^V+6"]LAO.%.4+L;3+AC$"X'+
MY9I1TN=1/8EK7LJ,NWX7.M3R.%,190-2Y&F<1RZGD8NW;*Q8W)Q6?,&$W,5J
M6,-ME7IG:'.:.Q9,W?C&4+7CM*N+:!UDDR,A'F[.S/#@I>-7ER.G5A?&).R&
M\-5R;: H_!&],]4U%'/]"LK=#^=_AK?KUY1'4]8OWTX6Y+>H?*C/WPXX,/F6
MKY-#&GIW+^X;,3#CA8%[6FVU>)J"W0IS!A0//EY_C@0ZZI4N=;:&G+6RZ?R/
MFB2:ER%J<U6Z3>7115= P6'B*%4M837&<>Q%YWJH0MOZWK:&B18%MP'*O)N7
MWGOKT3]TU?JJ#^7%K8I!A#"BN];W3?;=.!]?'9/0*,_87>=#'=#4B7"><.4!
M-8(5&_!KGYR%9\&%T3.Z\[$LI1ICV>B19MK&DU7Q5?FRE$IW;'!D5F\SW_LM
MJ5TB'TV!LPS;8?*]M\PC65KUM)=EL9#K_<7$#)FG1WD4@C_Y<A!F0 *E#]%:
M'N'HM%6.J,[&'4'(P;WZLLG/*+;9Q_JW4-K! SXV?Y3U+_ULCI"O\/CXVX3G
M;M^(&;+*<L[QA1*DUT]C%[+0:H'[-C3?M]$@W(4\OSM*MZ)N,M_HW* ;3<-,
MV]!\]09\T8W2-(O7WS/FIB_.FY$,F$M'/:<DA*S"3Y).:J'0; "Q!.<#'BL]
MA9!GR*+:M4Y\JYCT'K9M1J;AVD;4W8FQ;A_KK^^-5+"FE2C+1&P+WT&&#<U.
M'4M"\GC^.>-,=LE2C-;\Z0IOC[[B:. ?:/ET@D?&K5 B%-GT",Y;8*^>E0M7
MIG H>4*6SH_*JSY<:2,B;(#M(P?'.Q[QL2]8W<\'?&X4Z&&F\//IZ/0_2QEW
M3;/\'5<W<.GHWSOXL2YJ)QFWZD1&M2"DR7D-/>D8S^$>T);I=RFHUYT[?:GN
MQ!G78L$R[O'GG^/MYM,99[I:D978:(;&C+,3(:89=9PVC;<8E#%SLASQ=3,9
M?G2S2V0J^(#":X?&15&W7F^Z!HL[BJX.:R9&)\VLQTKI]AM%;_M)3LE28/YM
M;NIO%6[OPGJ5T[QB3W^RL?8X3(!51:=09%C<?I2)UKW2+$*W:3OD(,,"-.[B
M?$ETNDE?V:SEH$SRE16TGI#!1/1A>)WVS8KG.\&?TY/35C46=DON5&4I&$W/
MI7>78/Q '5.2O8DZ7G0$_";Y<1TQS(D ?HDV'7[R>& M,HA\="/O9D)EEO7+
MI^V'([I#A1EG0(21%N1+/* *Q,TPZ1._.2@](E=37JU1YLQ7H6,A$1UM9$%O
MDCL<T?.L5T^0 F;QO/K&^JMWNH%LM+)*WFS#(JX.S:C'6/^H-IXP,]IUM&>\
MEAW_*24;>#UR32[>;@SW'=F,D8 KTV2^>('Y=:S"2.MB)K7+]^IQ== 4WIK?
MKQZYFLH?/[Z0\B/Q6%$^[%MR56GR]O!>2! ;\-+,,#/2+U2=J5K=V(!EF#_\
M$J>@TMO-1U/T8"0 *_#,J'7DEK8\$X3Y?WDNWY0YA4Q$TCVM68K()B!3/GNW
MCI@@U;SOOS8(JX;^[C=YHBI06XE'I4%6Z)X;NE3C[;V;UV6XDB!O<9(8A/0_
M(-G&3X2&)D8G-DI3@#&JR\Z6SF>>\14X\O)ZKIV[?M2A\[;QH8_Q+_\<1+OO
M?[Q< ,LTJ"5CFB&1C:HU-(S.XRG5$L-6'H<_AKQ/7H\[J$L%OA^X-EOBP0TY
M86;@G(>U*YKH6$4L6]TNKPK6^.*M1=V1R5_>_-O*.<#[9_O WGSCT!O]9!U=
MOV\:*1)(1:_OU#F9 \@I1;TWD*^"&^:,,YE4RV'D8WRT6'7^S 6^_>RK^R6L
M;YDM"4\^:Z3S7I.]&KYQ]73;@LS'1TP?IVOT:S=3@I[%F>VR 3\G9A]V]UKF
M&53FCF^Q 1&X/PQ.*85'>3@S<;C'/GQ6SGMG:RM2+4:?! /O'6CC*T@\&_9<
M8:NS49WS*A2K<UJ6MD T/TZ;(/Z3(VF\6C.;BSQFX[*D]'ON%%;*M=YSB8_K
MN%891I6\SA D#=SI.TM>CT><AO7PO;%H.YMRH[S")IJT("+"?R7CRD)6HU5J
MS]&51W.&)O>H())ERK9EA>WZV&[&T)N L&]C;0I][4:(D<D2HI)TU_Z%JEY:
MSHIG.;.HN6W>_;Y;-_2:!O ) 5B(N<\LQT$A,9"*A1;S$UYDQK48DE^;0Q_$
M^'ME1?S4>$ZY 1M@O#%]RV/W5ZYW:TW/WQO@"ZPV+/Z46B_MTG0V!GZW?T*?
M$HC-GERR\DI4K\I5T1<-E\Y/G3AUHZKQ(2J32VV4-=HH0<&L=--AGNC*2*G3
MC11LN-2T6AU=PIWURZ"\*LD^2L]B_%9<=Y3K[=D7MQ6216!F8]"@"0>ON=)T
MWD+STQ>+&I06UIHA&3NHV^8):*Q=BY>,%)"F0#0_N)BN/]= .3(:7-+TS\'L
MYQ.4_H&]0,S^!0 K4*P2V!LYSC_2*DS=0\4FC7IC;>U/F0=BDU\[ VS$3=-E
MYB2D(O)"0I!-ENZT[J_=7QC':#=FS(5@G43X>XAU5;0XK\;#5XK]1HH1WA\E
M-..E5JIFV0"RZ93X?=I#NAO<FPQ)+/V"E-!%C5\> SZ?O"WG<#Y ]L38YE"M
MO^SPH!65[M6EN[<XT!&P#5&$@B?],*KJV\M[\)Y,:C8;\ X+/\8&E 7DLQ+J
M,95@;T@<^*0>'^/L8+T!1?]NU3!<4^"UF)>=^K.IJKFFGM\Y<>:I'XF)=P&
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MR3!H]&W:_=O.(ZRW/;C=U\U(#M0L>F[TTF3;&1_,H\$KYPJ0BZ8COR#?\6_
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M&K%UW)QQ;&\$P]E3=U3?*$&H<K0DZJ M755]Y$KYSTOR4P:5J#^H;+4-N_
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M4\R[>%*X7>QWJ7:Q/:<G;9$;AI=LU-A(0@6CD:=]N1+WR*3=_W\*,&W0O)5
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MY(\%H>>C_^ O'.2/!6%:HG_)WY%(X >ZYCS(GQ+'[\^!VT!GY:]__0)+(!(
M#9D.:,24N']_#M2OUZ RO  -BAR,D?8+M#V1 )CSG=N:3' +35<-_.O4'W_!
M:+I_KLQK#/YE;KHF)_,MC/X.38T$E6O'7W[_A33F6N1^P 'DTF8\;/D#F#/(
MUE%I'?1F[,85,)7C^X46]RM;-9.HF^!S^ VKK>?&:2@GYDT$/0],E7XYDXO<
MCS>T0/ YY!_/S54?#!Y(ML)H6B#39I,5Z1)XYXU#Y:X$+6&39D*%W:?Y(%?A
M[XHO+V4=*Y&Y_6ST _J!VS/1.LXS,HT!>&FF_K=54UW4A^G0K9=J_^-?;.XT
M9N:P(",J*>/HC6W#Z,_X50EK\W],'GJ#XKU5;J=%QH?^=[_$_!? K_+G"0&\
M%_]#T/^/3S8\I]QV@'E. +O6AGYF-2AHMO8_()_[#_R;PG]*1/ZM2D1<# ;C
M'\H>^_QC_]USV2 ),CL6D8->I&;*8D*J2-\4E!QW53\BPZ'M^WD\[;/WVASB
M;/^$WN-WHWZ!%B4]Q;3PDJJ2.".^SI?\UQ%O"#NT3UY%V9'3;"<.][F=C=WL
M?F/)W-S,"WXE1RXX/KZ4W>,WK\3XGIJW@=B U<P,;-++1!;2YUU@_FZ3 <9\
MIHB45/)/'L&RX6=?8388E?/A?\(;BIM_\MHH<ZY**.#FC3QG']A@Z<EAY,II
MI\G&4PEP>&->1FA/V?\$MG+RT,T**\R/>.8#YV1I^@-YV!P8]1\K\N48RG<,
M]R&<%%)U4&MN.-TR/.\35U.!3GSCZR"4.W/=6SHM\IC>/]:E_ ?^ _\[P/]S
M.41G#/I,/XRRHDB;VNB?&X4N1?[^V3JD23#E\%UA[,HAY2NEJO?/37W]%\4'
M9WXN/OBK7?T;SB]L\5_J*<+_6D^A#9I465(^Y.]K,?X+X2^S:=[+XGK:V?7R
M]TJ,(- H;Q5?^&WY(A!3*P TPR<#_K1<C_0S+MO#?#7OS*TCBRU/T[]%*>[G
M4H>M@Y+G6]_^\AE1?^_*_HK[9ZY,\UXFUW]]NM0_NK*ZK=(2CK_WM'-=Y?@P
MPOX26)B];''?:M,&2<,Q!/-%\R:]F8"P;_RDNW68=*SXC?W+' NK*,O;V5]J
M+YH&I*_M^!RLUJU]Q.]&ATU7!@&I3F^&MQW 5,8LRKW!=<#N(X05@GG]GOO/
MK]Q6?9<7Z%ZY,"]IRAC?C)5;Y3;N<?,.Y P<ENV:[!IGBS<6:BE/?62U@ME_
MTUOICG%B\009W[F!:_):?'^E)#++ER+?JO+S*<2'GP\H$ JE3F]Z!OYCEOX#
M6\ _5<W+>*VYC81_/"H%!+[VBY6'-XR*PD]9=(\_N&.S-S?NEHS$#4Z(Q94X
MSUULHB@8S0A=HZ=I03G0,)14@QO$UUD7?""NI]II+R$$?JA\LAP\7'9^_:RF
MT,10SH.STZ16%F0,,R2>-8X="B<R,?FM4Z[JP2GR&:NISD]0E-%< ]]4F^/<
M6IN=Y]>[$2T]R2N%U:EV#,,"1K0B%<='+UC 81W66BHEB%,+7\CZ8_#H23(V
M5M.]7#'B<.29'T7"=@OM]1Y/I=Z$]DMZ14]6C>*E-'>0RVH)I8IT?DZ2,-!J
MR"20,Z/XZY%W5@QYE1,G.=68MP=M<BNX B\7./?&J%&?;.@*:U_I]I8:44Q!
MDZ<&8.15]& 4,Q+)O*0"9^KAW(!3E.[/6TVT'DU0%.^KX!<8O')918&X0KC;
MXV<6+WR^1GSGL/>(#>C'L"!U12R((W93BHH'E*M9$-+:/'Y7\&Y ;DPQ=((\
M=7]5F<R,DF^UJWKGU7I"Z;V%XXA$D2>/7[M:OD.K4]OR&A[QC.F(3)XEP.;Z
M&K'UW(_M^0#S\1D5PD$@W(3<%Q>]?V36BG//J3@#W2\;S\?&]0R;ME<ZU,+(
MIMR#_4W"JP':211]8Z,9$1?T[6';@0M-:I\3B9(8Z;*V-M39S>,$LAE^F 6I
MMU:-P+EC:K&0#4J3 _*P;J):!H_;WA,664\%%+3='A?OUXE?RVK$ $?A-= (
M/%=!,9+;3Z>U)GE58+[<\4,&TO#(4^ZD=J$CMR0AP\L#TFSBKKN^T&3Z$\H3
M<^07"%/#FP%?%&_/Z,X6NRT$$Q2F^K+GCH29"1DT'_K!<W54DG(Z?FR!:^5J
M?XF1EJ!!$5R)R&1Z/]AEU?LJ G)OUG6, $ABFHQ]ZX/W4Y"UW )MDD/](=(\
M@R\(]Z)<[-)O[]:Z8'9X1Z?=V7%=?]Q">KXKNE1_X<LX>K#.I%>ZNU(DW>")
M2YL;W3/BMY660-YX'F&G0QJJ^:[*W\?WF- WL[KZ*I#=N-2D62>!IT['RCW=
MRPF%:S,3ZU [:Q:DQ@#M.(??OT](6W9FSN?F<N67.P6DTG8/;+'R$7G\ K*I
M*HC_[2Q5G?K"-<<YJ70S]I6W<!O2U_E8*U]SW;'F68-K^H<>1F[@MEK7N@9W
MJ./NI]12Z+"2[IX+9O+V?<X[WXB,A4BG7BF*,_&I_L&".(E:?<633:#"P$-J
M$".C^G#P5VVI'L2E[CL9J5.Z"3IW$XZ*SG,LOOOV,0EY]O+Z#:/PXY,S07FG
M*Y3+5OF&H_E-D@S7K89[&&?2/F%Y4"9DWT<J#+GS_957WTPGC^:V) >G9,]>
M&OX^>NJ$[O[&>6&=*Z';SOT@Y5M2LAH5(7353P^&&ZI5R5.A!=(B:5'6O?GS
MH^=FT_3-T'NB9CSGO5<MM"2N=M//9P[/JMNME69D?9?Q<Y^?O'KC62"_MR3/
MXCY/84P3-BQ _S%W.(YY!#!I17 =4;=H+',3ZUOI1*6-%RU$!OD'1&5LBHWP
MW0^#/(SS9[NLVM\W=.MEOV\2C[5U;<9$JN^NB/0<1\UMB[<#W#GM'D\72->B
M1;5%@74K-[DZ;1@9'U&BRU:2^.3=L)T)9/:BWL3'3<NP5Q2-FJ&F:$64U'5B
M&]=Z@Z7,S?)O"VLR-ZO+3,OD);=%98OT)W",BJ=A#JF[R&1^^:-W[(4_>L<^
M,2Q^-N!^'IUM/6-I/FK_O<[):;O0T8\?XR0]LH6.?_6#<$U6^U*LZ'Q.U+MD
M][=4,)7A6_TR99^?86,[RQ/,.]QP!/JYOX:PG^Y$X6#NP=(,9V'<FM#\UM<H
MZ#=))2.UO=?\3*F,7 LV_\+FNG73A.TAJ2?F@QO(3G1>+-6+7!K#GK'^2(%N
MZA=5:JQOV>M^H1!K]K[2 P/LV7/)["F_?EJ@KRL^WLPC>D0ESX8*+\.NK5"7
M'H$6B%"+CS6>\!-I"E"-4* *[8L^M>%[7=_RA(' 6:T68I4Z7@7MH@A(CH9D
MW#X%=(Q)-6:,8_BGYZC-RB>#CG_X?I")7/5_%?W!N/%RTC6#'1/MLVLPX"AR
MX45.<%<J>P_])$FV#R$.7#=O_W2,![< ;RE28D$Z=*^7D$^VI+YS-?#LF30%
M$DN7%Z,GVDS:;;04IP93U\;@0TWC5O7XR("F.@R77];"J$K7OMK1&3/G_KO*
M>KO9/&.6Z[.'KX0L?^@PC6\+6 B&TZW*8$48.C\+4EM]"+'J)M%H;F,P<-!,
M@>1ZYA0+XI;DOQG)N)83CM?A#ZC(8DJNE24VP+_G'PM2=NW,5YSTPS7BAA7'
MIN8I1%<$-^HL)6%:N*TM=[3!17FN(NWZ\9:#SX_<53(-V\T1^VPN8&?5=>(K
M3I.^>WE/J[K61/P6%]P=V@=O>.^-/M6^)\X?U]"!L=];SBA&.V.&$/6);LJ;
MOO>59?%%R:?B;A;=//M0[$*JW3!W@>M2!R"%;X "5]$?UD/'DJ_+LR!A$RDZ
M'Z?B/HA]P]!6),^3T\*7;J]4S;_%UPX;;DX_*%N<E<DO((+F-@$YD<<LVS0G
M"M9#N>G'R/9YQ Y^%[FW -HHJJ.R\O;H.>&;>Q=T'1T2=O+Q>G45!G.C7,G(
MI@X.#!]PP,H->4Z5VZ4LQDGKO?,!D?M7XP^&Q#<?;-?S4UF&T054B:KT(]C"
M-6P8$67KEW[UP4B_YO/#.WUAZT,78&,6JXKS"'(E2HR1%"SF=VM\&7FDBU11
M:4\DHMID8'IQF,^F1@0+26:K84!)X*8-_%+.HKJ'S9?3# %L$ NR8V@Z[=.K
M0*+OPTIYHO&INJ'^*&4M"43OGJA]QU@0LS#.O*JV$E3VBX?:-B'%HJDRLTEW
MIP>[36V=HH-54%J =W9#%H!K2A4B-]!SQ37LG*Z4%3_K63U\TUO2RCS3)3&@
M]Y'@4-!W0:IYMI^[V]NK$O%PG7=O'V@U<%K<XS86FB*(L"#.W.&(HK"D3!<8
M#TJ7!=FUEIIQRF;(B"J7@E/2M?MZDLU=7ZQY>Q5O(U7L8LOHXB"]-3"B[PJ!
MS=U2B(,COF8) ;IT&\*&% NREP69/^7%@J2Q!X=,JX^^&L>'!=CGY1&&9@+L
M4I_M75<M*SI^HD:X/N/52(3%I3.2+_=$FDW%6"D625:;J/9XV19F\5.?H+T^
M])A>L>>B$,*JC]QF089&^2A<SXA!<E]O!X^DVS?X[EQKG""(*"T*"0DU-^?0
MS8DCG)^'Q!I+B,:N<#(3@RQK[U&QR5[()WZOL;H7JQ/] 7)SV8 ?:5Q?M1#C
M(B==.RK_C>[U9MC57J3O'@NR_W:_1F6,OE&Y48J_SP?+X2.\^6%F7-QL/$/9
M?MU$Y,-J$9L&#^*2P.U@@0<.$1-])3)W>CM>*RD]!"XQ1@[*^ZA;RR63G>H[
M..CZ98GHW7ZX"Y0+/**&"E'9=7XY:R>+MMG):]AXV(_K\G\%HK:6^3!NQEJ\
MBMC&?:%OS?)R]^J(OEG8Z"3EQ0.9,-5K7;SU,GNXI<6<O8T^TMN3(TDH)PIV
M'(QYHJ;O5%XEX?;YV2_?(O!7%^4-#QG,S>9)Y$C,V&D_R1N8&[HG'/8B$)D]
M8 LZD'RIJS=^7FE]1YNTW\=*'U^OBVI>T+0AX<&A9L]].M17$A6H?WU60-_,
MV9:K)?(K>2I2&7G0V=0E@"O?(7^FD 7)J^PN,",*;JKS<H\YI\I2W$/'W+A(
MUI2C)5D 6K]L>,I%.+_'IX_B?BVO7/^PWI7[2OZ2>Y#&-:X?\G6]S.F_D8/*
M'AVFW!R5ZSQ"+FZ6C+(-TN/_$,^]+=%S>)?VZRX_.2+Z8;#4.>51'G!H8O8U
MM43C V9A% ?M: ?')I*^9<6>3>GO,]D%-HT$?DU^<N<AM"" /T?.M77ZXH8T
M?_#5,+8"U6C+Y,\?[S@PS3S1=;CWGIAUDTW7U*3<B/J$PN$GC'Z=R\R=H079
M2./V R3T@CR90+U;W.5>?03 ,'FF5:Z*RZG2]K7U)S=ONQXAX?EQKS95O1]T
M1/J^2#[*:2#C[/1 XSDACF0Z&&@_(*";T\DIS%I5PJ:",(UV&<@9PX6EBG1"
M&Y@GOJ%DD@0^1-C8](P5\8[O]-EX]XDN:X[JF5#MLJ0?.)8V\91W3H YY5">
M5J2I072#-FS^II[Y,._*7,!-PBSNWMS3CZ$LR,@]2>CG7I!'4AV6^YYC+]T<
M-Q,LW&71=Q3?I^A0?%\CJ%?)H,8S<.^*,:TBH61@..UC&YID5=>QQ]G:)"L?
M6*E3UT[):RQR[D_:;*C</]KX6:E289$M\AP;O^1^76]KGPSGO(&:P.O>^Q9>
M3DM&$D?/27K*3K=\CM/_F.6$BRNXFO:1($2_#021B8L:< %@J<Y>L#S.W4 E
M_\9HVT! :'Q/\@BY/W(5+C1C.IL*[5-F^/Z6M&@_DV3HP<D0V\VQ\K:D=]],
MN@Q*#X@:7WI4O:<794.L.D^3JQNRO6%3T7'$L#+C.)]8?-Z9B?MCXB56X_ &
M[!Z4.UD7$T7GSP5]DY_/VEL#1>V.XR(M9_0WI'0]PLS.[,CB)V')IM@-)5PD
M8FU<D/E4UQ9/Y\UB_H:I@:VM9*-G;A;GT!;3T$Z)! T6)-Y"\/AA*6H*PO,W
M*OP1O@1:!XT-ENFG:XQA#J#=YM2YT,5NU37>R!_7OZ(#KL3;3+*AWC(M9DN6
M<?-)9,ZQ\%ITI+AV7_5!NCX+\JBU/J :7:J\M- JLO0AF/&2N3BJXL?TM)J2
MSE3O+_*+HL8 \/%]+DOZ_=72P*D+O0LBMQK"THF<1H$1-I!QDO\.V1H.-M\,
MCH"[GD!RQ0):\8C=QF3BEYF9J<D *?X)!+D/Q@:;+D3!0&>=UL2"Q/9M53FI
MTL\ 3W*-,OWTFYB"%),,OJ-$,)2_6EKYX@B;K&=\Q?[7A=$DH>MSED\"=S:Y
MZ7J"2/R5!WQ)SI4B'-'*NRL1NX["N9MR/O=/;^?0R*_S?SAQ^)/](_%G/5TS
M=^>NI7V"<=.MR:I1FG#T>!5W8[!X'THW:TDU60^;>TYKI+1I%_.FS$2WZ_ZL
M0]?BN%5.YVP%@]"H=YIR.7Y%Y[OIIL%OYE>-\B\>Q+E?3M@6N_/:XF[+'SO6
MX1EBE=05CHRE;J_,M(]X0;HKX$]>-\.84. 8S9/C^3J7A.158FZ,=EEQO-DM
M\0!];.ZX"J>=98M(J]QSI+ST68JM3;/X&;[58W5_-5Q7TCZ>H\R-QU,4Z1+I
M1,5''1&:'=(T:9IG_T+@2DRU)8-6]2%Y<7K$]K3/GF/5;\" \[27'<&VSLEY
MSU)"X./M>@][GY,Y^BJI'=07 "S;1?:Z*\6F1E"U?5B@#\HS6)E1%,W.ZZ3=
M(V\7=Z<@P,(?&8%W)H2E\@%-;^ERO2@C*D)\-D]D< 9V[1-:69N(K;KRU>A5
M3&_3Q34V[_CSLGO?*>TZPV8U05C@9D%D(P%3%L2>"MW<UR S9_U,M3C#:1VV
MS$>0%WXF0+%"A&S&Z'J(2P,39$*-^D!GI2Z%HW:(Z_V !+QG+<_5]6$JML)W
M7T=7A4;@<]RA6#\IP_'X\V_CW]^ZI;5+XH%LOL6WT=BO"7$O]W9U\<1Y=3VI
M*M[1PN0*[D'OU8:Y!E#CQQ0/H)$NP@*$A5W!6\KM[FCZM?.0NVEX"_SBFO6&
M%54=8">?'UN/0?EFTV4!,)7>78W+\T</4;'#B>KA Q3):+Q4I4OGQ(NF=OA(
MDP-"QXYN0O;!DC00'"/@LI=2W+K\$S?W#CV512N-Q_ZX7TH]:'EF1QKVHD??
M_NH%U[F"NL0GR3;265DOP @%'L540YT!@G(54HA8*("HLXZZW^J4-W>ZKVA_
MP/X$-5B&=[E[EM.[@7-!62,U0;?4=Q_^5!IG*!H9H%28L&N=3][B6VKLUR)=
M?O:%H2M7.[P44!\=G$5V2$-NLB#'S%QDRPJ%C2LD,$ 6I>(S@JWX^9JBF%^1
M$;GA745E//JN@"&5,<[GH'A82%1&.GD9N1M,/,'@Q@DJ['IR)L"W0?ZT7 X7
MWZQ/F35*D@7IMXF(AU%F 2.J.7"40#:%#AD1%>MQT3>8<^<ZG0SRZ;#C"6>Y
MGW?YG]Y@4]+E/2QEY>QXYTFKT_Q2-)9LS!V"Y:5S^V8XB^_[0'8OC5.:V6R,
MS.>L4= V/_*PU*(9$LXV]G*_/^?H([Y9^=[Y,B-ZTV*+^_Y #40&"]*\62B4
M_O&QU.,^@U?GY=XT7PO8'QBY_!CF0@B-1R$1C^2)T:@+3CPQ(C3MN:6#*+K_
MJ-4S)FZ2QASQP\6BQS"(@RBC'&=Q3<"(:)2C:%[+VW3T95>S[7!C.Z45 OMN
M=?:RSVA=YLDI,,-:3LF&S2W 5MML]$X^<[D;5>F8 M^D1?2:Y<G*7133[.@+
MD$DK.FBJBVJ@760.X<D=4!&F$$H3-(&J3%YNP%@Z#+J@N  O"L($M=1@%;^@
M3XF4!4W,8 ($BF)4*E\EX59#9H3@:5;!X=W%6Z^]]DW\$ YZUV]EWN3FMD=(
M*MEI5\3KFT4'/D-\552"[< %,6<> K!$1!,^#%M4&I-W^G&Z:[Z3"CVEI<E#
MI:WUO&#R-I$$K=#:J43W%Q;UU4XRW0\JW\Y'7CS]],=\6D%'/NHJ"\(NR'B)
M$LQ1"7M#@1NE>L\.692TIPLRZ*61%QBNU0"<=HD.[K=##S\S-3M+YKHR&K&B
M3(O1SM[JCD-73VCY$"OA-0CR1>Q@?VWYOOS$]'%.#!^B,<2Q9TW+;.;6BXI7
M\0;QN,[+07#KC3(J9:M)H)_^6%E=("8*L=/&C)R8-?[B1OFG[C?X9(ME^F=-
M0-)'2?_(*;F@Y1-<$(DDV<;$HEY?1&H5^\&6S+A.*CI^$VM@<,E0;4>.RACV
M?4?C@A7U/B,9C/PQ^R44(^(,LV9-OA2UI0H,W&HZJ% A>A_2*NJ!$ C^OG7S
M(Q:,U/%#1X:IUP%C/ZKE=M*\]<@/I:>"7NPC2LUSS0_X]WW2'[WV^6'HSER]
M2[G9#?9PI D3.VE\1N_>R%4-*3P.:8-UII]C5#(AJ!,]]G4( )O.67\CX5SF
M;F^!QR$U5@)?CM9R.];D(T(1I8@:>$S (VOT0^:1Z<W$#+D[X?"/3D7ESTEJ
ML4*]8@!S6H6(V,."C"6@MU7RC,\%H@\X"U9K]94^U,[(1L#OA%*:8P]*ZEIT
MG!T>0/OU[Z9=0M=(,L5=F.P]*IB'5*O@ Y3@5P>^#SM_"91OR*?)C$Q@SPRF
M>T7+R;&S+6=E/S8TLTK-\0'%?=D\>T$,^F(3JHNR8$'8/@$T$B$*OTOQ'CS"
MVKWD:,;XNL&[2MT<ZXN/<ZQ+=7)>A$DF*F5<F9+DDY;VP!7_B+^AYWLM^W7B
MC;N0M7P77?/ &?S:YHM:6X;*  47@RZ%U2P-#M=;!G#70X6.AN2-#',VN^EA
M?>\U\GY]\_B!-&?"NYT&TCNKO Q[W51&%#K,NA=Y%VN7^3Z6?8R8N!73H_1>
M^]%^5XH/;9RQ3N=#D,H6Q$A1*LE+8!H2<P1 .IS8=]Q$H(T/W7UE[&5<8(MQ
M4 [(0S(P3>"'.4:@3J(])N=2]V!I\KTI4Z>C.6U.BM]'1J/[A9-E>S(GY*5N
MR:&]2Y_1J?36?%IYHHU= POR6)*Y<)7:IC+B /*5FR[U?&R;":Y%<9B#A,3
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MU4YS0?SA))@HX#O>%Z+]B?C*"TY>Q.QD2QIZU7)NSY//(L]#$OQVY"P@M#&
M;/A\ES<<C/D :X'J8!9$T;]KB?X2S*L1$HY:ZPZC"<X5\DV.SP97U_CCQ^&"
MMX,UOLFK='"Y4-478WPR7N.["WC];D'&%KPE1?>?6ST4V9_KG.5XT7GV0>1X
M\$FZ.]GJ,_<N#)_?NC6SYEM,BS4GKK##B];/ECL?*O9IR+]1K4".B%[X0-8?
M^YZ,LE< 0APR;0G#3;[[WEJN"UIME^53TFC8ZTX),]LU*JBBV8I/Z@@,:KC*
MQ,OCUE,)NAZP/=4J?H*DX =#32&:IEE^R36[KEJWV%;NU=-I%:IKK/<*A_3"
M'A.@* XRTIZ<&D/:YTN3,*/8#7[H?$T376'D7NLL&.G4JSF3>#+IF+9[I:BY
ML8I@A93V+6^&C=>W;-QN6)GJ9RQPU6B,'\!D&A+#/@D8N8F::Q[U'+YP8TSO
M^DC%1"-]*K9D-E@+B!E'AE:+I=A1T!'*+,B^:<K^?/\<V^,R5U9-GZR<G$^7
MI/*KVN8&0>U#KZYXKLW?NV?5;L\';O+'P>VIROWF^MW!LL[QHQ5NYMG#M@.U
M)AXARA1)-#PE>5->[*;NK6LM=8=#FH_DMO=/&_?.JT<N<T?#2OIKEN[[MEXG
MX<1GDA7>GI4V.2?5.[1=Z=VWL[@C#]0%+NV3KH4.K8PM-451L@!HTY!]4<[+
M9]UO5^3=?T!N/@WS-CRX[<NQMWM,UYEB^HJ^Q&_4/3(X+/,PDP"#: NXKMQ.
M/0(D93;DZDR>>=T]]A&_;"NJ=*8L]FSTKD-Y^_4#K P'?'P^K;+S-Z%. '5C
MV!CAW7TH;F*0:OVF9URAT74UG]"(YJL'EO0&IEPA07FG2!P+[&/0^W'3GL"2
M/;,68UU!XP^AB34TO5+E0"XZ!%7IRX<L7>XVEJZ.6AI>FC;N-K'J#$YA-*69
MVHM0;*BC@ @97L_]!J@C'GV5-<=S^LL[M^NIFU=$"@8M1\_L=8JO&^M_@U($
M:L;P,?:BPDLA=*,L(,EHY,/DAR2/QY17"8?K] 8.+5SCVD5\&C31)G:)4#Z_
MKA[%T.N^6)PP2YT4T;A"J0Y\O/W(C[%;F!T)QQJ"C=$UE_#.6 X@A02M!9?T
M=K7<QU>:8K@6IG1W F?V>&GBF?R6(KE#5U_HM#U(H3S!5'7,2-<@,*ELC#3-
MD]Y$Q?"A);JDL%;^\)4V+^J9A=*OV;'F=SK3H8D7SNP071OKA*\_9;P-Q%<8
MP?2#MJ,K<IIIBG@;G(7#M]LX$0!/NX$2 O:!B:>C'ZEITST^=Z]@-_$J4L&!
M[:9@))OO6?U#[X7RT0^QQ7B0. RYA0FA9*809:_#E6P,7KPICSD5T\86<M/B
MRPXICPM!"P[91B- L=;I2)V[_XN]]XIJZHOB/X.(-"6"=!#X29.N]!Y1:2(B
M76E1Z2 @2"<D"M)[5Q!0BH"4(%5JI#<!J9%.0N\))01(F?B?>9G_/,S,6K/6
MS,,\W)=DW;O./7N?_?WLN\[96V(#P4$&=-Q#.",NX8L):N4$H_$)LT0C<>W:
M,/3^[25E\:,'/+U%?$S/[-O%;.T6=)W=C]7RN:#C("8H/\$,L]$5"NL&O\"6
M1%LH3<B/5L\/X-[MCWT],I'C7DN)^MU5HOZJ318A\P]'6%PU_]6^S28-<X]$
ME%FY<VOO9>9*U9_$#\G+_=?6W"51)I!4#/UBKJ6D;99)& ?C&<$3(H7&55M]
MGL] !'I%BAI0-"D3 B:6DE@A-'Y1?7DJXW6,O5JW_JK5(1V9WJ#IPO7KE@ES
MWAUE'E*#^FU)I@6MM*B^O3T,+;JWC2D.A8@)=I@MVA>,G'L:MF(DIZ)L%C_?
MQ^DO](Y-7[2ZJ@27BM];)@/>@:X>*, Y=T91.R$HD7S[MS?KCN1LY67EW=33
MG4P/;_Q<ONK'IN"PI34,QVOJ^2+K\F_!,,#'#9,>,M+2+RB $K1GHZMNW,]5
M\(J:YHV*B18M[8\K%<@U&('% )>'$?U D"K'\_3DB7]2#T7#V>1QBHWLC98L
M=G7)W5]G'1.2V?U>9[T)R:L__VH]PIL94B[3/E!_V)3N5#2[<VY;1/)G6".)
M0 PQ?1U+E[?MI+&)Y7QQJ 45\RHOAX35F:;.VW2QO[MK 9?"@JH*$*JPY>\D
MV59\!#KIPU+M8KC<S0<]P:T<V6$/?0: GU:[?@)1\^--HP3LE6K(B'$),-90
M^(@,$/;WX#,K5B'<-41DG;4!ZTF,A& ,_]XU5$@2,T03.=&MJMTV\=Q =<[0
MT\31_%6QR,.7764C=]YV5)$0LC '5U/<?8JAPPC:^)L2]? /K<\*R(#[B??]
MZ2]Q?34G QH\Y!U.7=(MM^I?GSG2F46.@Q.'09]BUTW219MAD5O$I;*8%7X>
M? AJ/5RS$9WP]LG_IEC%X]:=1<<\G]^G_6$JJ8><+V%,@3/%?@]*\F,I>D7,
MZ<V"O!PE^ATJVB_Y:^RL(A*#KQ-_()9+]#%)O>?UPUGO"%)N0HWC+S_VX'K9
MQT8%P+A5V1?59ZT_^R\S9U]HP);SR8#:3A=:77X&^1LNID-'#'J>WCNXA$7/
MT%/GQ9HH^2_?-8J_VUF#U]VEGPU/6%<2/4(@2:\PNMW JP2#/_;3!%'X5KO0
MN)"PQ:E!LT%T(]/WY_I=5P^!@FV^;&=)RTLS<WW@'TI[6U][,"T/L(KUF+<]
M[BQN,3052(N&N_U[7/K%@*J7H342/^:9HX768BZ N$EB81K.%D]=%=C)FACJ
M<[\9FN0E(W[J0UU=O5]*K:?[YD- B4JG?(9C[?B"9V[EZ2Z.]3]1\_&0S8/Q
M46M"<VYC#S@IGZF=[GEQ7R+!L2C002]2[TM;TZ6@=+^[G7*"*\0,A;5V-HJQ
M$J C?'>G3)],D,2VJFU4?GF83.\8Q9%(\P^C0>SP;,0K^%]!/7P?JMPK88EO
M=J>O70)KIR!A?>V)_^&M]X@I_=LFZIU#8:50[?OEC8F:G_%I9,#E<SPM5K1+
MB?LA@DD>#!S<M+AIT#5=]O(M]0I5EP[ 1Q75);9_S:Q0W,K(<DIF\*#L;KJ;
M^[46Q,A"TE</SV5$?>SZK,N^U+J6T-N''2F3\9&7WVC=[#$ 4U'BE1J!$=N"
M@^!35O(_M$N/G4B9HOQS).&%@8EKZBV^R7<D5KU>?US3D317NNPG&/8L"];Q
M".%JQ.EJ=?H!2D60:DY%]I+D7:;W#V<&#6A::S@+$WA](G68GO>)1\/:DDMP
M&EFM&Y[FM4B$U^%%%.,%:>*)P<+QQ'=2HV8\OO#B-80)+U<V] U?B]9,<2SK
M)-E,*^8YGG1?(\X(-NIS 6NI3 CBQ-IV>H+[9.%$*S^60V_23\7:P8)#Q$#B
M4TZ58"S*>(ETZ5J0Y2Z1,D]=>#D,K"LSO!O*5X>/0F?&AS::(0N.EIT%/)FM
M&^S-:)6%Y,Y_?%^J"R#<H$7Q]R 8%X<H<0HX0]# IAMG52/&S.9FZ]ZQE,DS
M'KX6Y7)\NE(JRBF47XMO.S":^*E[FN.Z<X[3["MHOTHQM"-IDD\2VYHG@9?!
MJJ*MD_@"A3_=:FX)17*P8P=6^U.5L*U&=5[;@SN?D_4O1JJ,'PVK?:O*]WWD
MT<@E(;^+_&@!3% /0<$CSWFS1V-/B')=P8\=).RV&UV]V%?& E0 :7_]Y/,T
ML56?,$L=W*>Q]66M":(Z-=FDK3YC7I=GRP&BG-1-MQ#2,&>9,.X- NL&6J<-
M&[XB\A6* -;M3->,M:JXJFG?L+_Z4H>WR*V8NAFU:G\:.?%<VG6X\R;;W&X#
M 7RRI.OR(,_6-G6?H@A2HS\V*&_U"3K,?I[RPRN6O??-A=*W#"C6F=0<S? _
M L&B.A56KA/&)G^W(E"M.QL<4]<Y=VTZRS>M0%&NOB&MOEIW\(UN<5 Q8E<#
M<V7N(6G0Z .45;%%'2%KJ,*WPMEWCOO]Z70A/QAOOQ+P*\&91#]SH8,'HOD[
M#&P]*:X(%6HEC4X2Q-S7%^7LUT/\>%O?%RZ.9<[WCZ7]C&?X>=C4RS*^/W",
M," #P)A7CVRJC+<J6YO_$@VG3JQM&?7;)N'%AY(5RR$Q:[/6#B[%'Y<O/0&(
M IQ^>H7!ZH#O8"YPIL4=!-#O *\G7ZY6Z*C1]W=?JN$QLTW53*$.2**LGW.C
MT@UB]M$&<@O[X3N7A2$#]IV?^"^> /7P?LTI+)# _(!DN-0+P\F#2*ESD^.M
MV^8?VG^;GC4]>UL3H0*OF[W(&/VS??]^F#Z 25^^_M"9P-IYBGZ-J$V?I>W<
MH[::/M$(/GGM=^.KM;XZYN^N?Q85U0O>#_?O751TM6GK*_=NV6[A6[COBYO4
M^NM:KB3A;QOM8C%'UFEZT]#;KI'GLA;:$U+[?I=U:&FL#%R*[FEMT_?#+?!@
M;%('/W?=C0H\3_>Y5TS=VG\.J9TOAAF9DVM$K_'8YU90X>!,Q#R*@?/S::'L
M!,DQWUSG7]S 6(*6<(6/6W!)M/Q?N$@J*IUC9KT\Z!&]@/@*X.KJ:GXJ5 C/
M8T2,H-Q8R,]8C'<:W[+CPJXF6VUK\L7JN!@[_;Q0CRT?F,G4?\J[YRCPX@53
M!&NYSH?<^=PT:S"A;@FS^6)U37\Z=DQBYL#K"&E_8A&$K@_3_Y;R7Z2"]*%>
MA[G9U53]3< !6-6-#, 8>\WT/<3^]V<?*K;E!>'5<:AO:/I9/T &E'Q$NW@?
M(*BG6T$DAAZL)3A)"P_#@#L;C5S+"/<GM=M64YHLW+V%O"M$>?=2]75"'SKX
MBK2-=BQAC!#O2.QX5X_EBZ0H;O:Z F1_T]0)HWR:<6Y_UQ#N<U#*#Q5!^]M@
MU*]+/Z+D"[9#TW=;9Y?&YX*S!\?<;EHA"K:.0L[Y3E"C+%M\=_[LGN0RFM9.
M^\9UL\R!GSVI?2![7DZ!K*_? @M[@F7"Y"7:W+M5ZS.C"F>ESPY.>#Z$T46^
M852[3BO$U&8(]8-V-0:0 36(O3(L/\XCW^0G I,QJUCVA5AV./8S0<3&?^C^
MJ@HGS5=::I%FX)P7BK];9C8.UXAWQDP?:&-I&CNLM:V'#2QKZM-VDS1G[ P/
MWQE;OY+4L]ZOJXS?[R@Y"%$R<LL!?SM%%'^26,#%EOS=0[I;3^^0@&"?*!*#
MX86B4=4U8:C8LSBXW. 17R?6XVAGX^/#9V2 .V51;U8";2<@1D56;K.:7]V_
M;P6DQ%3"7W][_O434$?7Y 'U]K7 >C)@5P)SA;)$#U ->&-4].MLH("M5DE1
MP.#==YV;0+6 T)ZCG>PS01)]4H4;@IX,<)5)@ $BR[TK BVU\M [3USG I+_
MS$<_B[\JYI?"2/6^6?;>ZM3]B9SBZ6&X?..Q"&0LJF[+-W_4RW2/#$@$U?5U
M@6?:1_6;\0EH<\RN:D6JMA.TQ]O'T0& &+KL>8\J*Q6P:ID*ZQJC<+S,N1CB
M[-X4Z(R[E1&'G?#05(0N4?!CM'.HGX4,,&@P+@//ZE'K"AG)J9=V_;P[DQR:
MW=Y,!D0*XVG)@(=1G2"\>!Q!0C4@ ^1RWB33-(>5SRT$.376>&V\K<!+8(]^
MY=?I1DJW:F,N;,F #^&Z]2WN7%70/HV&F0SF08]L>?O#_B@!^[Q6[F/NM?:;
M!$E,5*<A=ZAH!Y1WHO7N-R.5IM2)QXW/[(,>?<\25TO^+K<K%HY&OD]*!*$8
M^>0P6&RB-QE =XHKXI_EWR:,XD^7UD-'\_>)B\$6-6N>?TAUR//=^VUPP8J"
MV-CU=34U5T\1CY2'$0O53UBOIO4XS<:VB(DLI$BQH54Y]N 4@@)?DX$*6!&T
M)M"8A.(=UQHWCC^C+E9K]L^O&O?)NPHE_)A$L=6.J/*"4+1[A1C+E9%V7]#E
MP/,^B^DWSR5%PT)4U@ LD+H\>=D7EY[\7KZ:764)M78G@H9,K/7?:B2Y%[3*
MH$OV>C!RRXTQX"Z2##ZF9.M\TOGUM$6U48@01;>U6WV"_D?:6(JG1LM$:HH'
MOD)VVS$C7T.T"VQ6=4->WDFAOVFVDO%RX0G=/LWMBZ%LU:\(OYE]2NHN@>5!
MP\/;F5W <YKR6.E/J(0[#=T_)_<MF 67<Z/IAQJHU,QN]#W"[$F0&"PO%-RY
M*X+]$#T\ROM"'N_WZ^;F K5.,_78[V@,4>FKM4CU3F4L]DWX6MS#.B6)1N1T
M9YYBEC9?_5F2PN49CAL ;.=6#D^YJ(Q3:H5PPSZ@RV2 BU$4&5 'CCJH1T3E
M_6=T?:O!$F3_,]UJ]/784#W853^%9[]:I1>HCG&K++>U(-G2C&DFV8^Y5,CP
MXE<>X-U1U\ ]FL*3-PS^^.;X-[>V^CHSZ[0]F:+Y>$YS.>T=E4(^IA8-CR I
M!-[JZB%=FP1;8/:PR=9V;473BYY]M[N%^I/>#>IXAR>*27EYYI=J2$%+K+79
M>B'&^*%E6%@VRPZ?"E8G!Y6@,? LC_2B4HXJ]<>7(;V_&PST1;-6/XH6HW<W
MX53XMQ<A$"H\'$U79W2-8# A,B7BS:MXBK%Q77<694C)B5YAZL90<K3Q-B^T
M:+<&-4HW[ 3,'EAP<GP W/*.@4NO-&0N=^>$[<^PU";3<W5^OIKV2^1SV]\C
M@X?"!YK/MD<28]<T.0@FF,9>V&57D@S&J2)[*<KKE)B'O94JM<9;>"E5O#EY
M4(>3*<-HA;873D.XC'D;6-*7/>O"S3*2N>3F(OSY$UC-3$AO1+]#G0D@A+F=
MU51T3'=!!C"5>&F_<N&3&VLU7+X LCU;3-IEW)&?_*^U.6$O:F:&NB*^)L*!
MYPGT!=U!+ 9V ]:ABW B ^C=:EQ/EUB/M_:O+[=_<@Z  5%2K4^B,&[\+=*Z
MB!=VQT&9?>-^ZV0 ,\(%'H6@;_5 @>@"X=W\,W:WL&8[7H4SQ%BT5[W>N.0+
MKT3%AV<+.C:E&QIR5OP,[4J!P)7(V'/X>W7S;_B\$:D"KQ^&GP2D!F/LE0,'
M.G[YT<;BP20&*3) M/[B-NRO&Y"H;&U^7PI]>RQS(M5H[%OW+,Y<7*8&?L9?
MQ&J92W G?FFENE#%0[NL\1%P6">H>,F642*(U.?]MOU5/,J_BZ?ZS#A1CSJQ
M?I,=R;PPUZ-NV"[V5%7Q;K*.UGJQ6U7D<4VH_FVX?!HN&>_'T=M/8FZ,_H&E
M1UW<WR0#7C:MJ1=*0PYD!B_>??8:]6RU]$,#F5WM6,:J3D+?FM:.'><\E)T'
M@T>JM1B Z(!7EY)\7&U]CGQ)R7MP&?"1O O\XPD(+^:U.U6TG?02U,.CF\OS
M,L1#]CSP[9[D&UGF?1ZV SX /@4%CFWGB[/%P*+E#UA<6>YJ!7R;E^SG!#Q2
M! YV"8J_T0EBTU>L:A"NR\U;7\ 5NG[3Y<W*>CHKE"IT>Z+_NGS\_8)+P3^$
M *JIWA;NAW*X$6(%@0:=/Q>RO%CR#3^(WNGDHY\L("V8NOM7S]CT!"Z^#9+B
ME.Y@O396[@"@4C@/QV2A*3$8JH(71_8LTDTA&@@:;X52M(-PKI6G\J_->P>,
M>5^$J? _,B,#0K3-;9?F*YTW#[YL0_?AM:%9BP=^VY5E,_\^?%GBEO!<&$O;
M-&TLK-M6L<LRIL'0WI45.7%O:2'#8_P!%^XU]RZ)!0+!!V&7#+*>8H!Q=4LW
MM.BN!.X)=V.<U2#]S^@%1YB4;H]<8S[-6/E.N]]B\ !1$+O6+@IY@D%VC%)O
M0^]@(XN)*:AA>4';Q3.6T;6H%'MPJK"SBK-Q9UY[>HZ^;8*HJ&-3-\&96*5Y
MG30:'-$6E43PMO_J)O<E1=)"K*KJ/E_BV+W$[1+:J[^HPQ,S_D+$\?4H4$([
M8QW6*ZS^924^>&]1V8N=_B53?\\SCPSS2#K!E%D$/P72RW$P+&)O"ZN+%NTA
MWI^PP@C__53'Y:<AOK^_&'"-]4UF([.<-T/#Y6C \<C=<S\/+(7RC'XA&"%*
MX[L*//ST>%CO8&V@59_A6)5@V.;C_N4*[P?1 0J=_(N7U\XVO<TF,FZ/6 _.
M^GN>@]2DVATF7<W2!>L"0L>MZM>J-EJ-M8/R(T"N_%&:2OA&..'NF+HV;HG7
MY:[Z;&(6CN<CX8..MOUZZRO%C@S:P3[XCZ+Z+/$ERT-K1)9Q&]MBW]>E;8ML
M&S&IO4G%%/48AM;#RQ;_]JRD37U\1VNB=ZD"N1JPMW1A@>?H 3?P=P3YPCEM
M; .]?C4?&Z)O0X?]DV=LM*#M[D&&G$=<QIR>\8KW?HG>0NC()\V6HSS;,'9D
M 'HX*5:=#(C"7=UZ6TX&."](=U:5=@W<I7_"E?XFJO*V@BK?+&Z*.#@-33QG
MTN^%U^R4+!Z4?-=PBETGW80\Q)SV)-&XVDEAJKX2RU%[)G(*N1MI0IIN5\2?
M#+#9^!3YT#Y:UQ2'CO,SM3,$9G4N\F/SHQ$_ZF$W?GL<Y\"JYT=Q68LQ"6,Z
M@_GRI;)KNII]K!,FJR%[GHV[CUS[<C64$ 8!&M+_5[_S,_;!&D&_\B.A8@V8
MC1C-6UNST%I57=&9#S>&5Z.HLD8"5QP_)&MU1^C1BA3++V25C/IDNUON'&HL
MQO9.0YR_!+[M8@E,LIBND!\%]M#]#'URB+K5^*S_LDI*]%,F':809-AS"O3I
M4B!KAPRX?HU;)C;89Y&+DL^YJ_VLK-W!17W03L(UKBSFSZYMR]0._SDWB2TO
MWLZT6L]Q+W5%)KNQ<QA73)]:U%2D&/)<+2\L^R\]48OV2J6I:XF3T,%W!C&N
M,#&G_RB)P!, VU%?-&CY*[@6$:EN M& 80T>D<99@AY[O/S9U&@Q<@?)K#-V
ME:^HG19BM@#.*K/P1SQHP]+N_8?9Z5SB//:*H.0Q[4,K"Z_8?OX8AW;YD'SN
M)(>O5S@)DP'FHE>7">TKFEG@CP@NA3:U;@3&TNC]>54*S..[:U8V6QT.V>!3
M43W,(XRUI/#N);5P\#<DQ]WG<T/JAT77'Q:O9NHPE'YQ2#4"4"U^]BL>E>*7
MSYHG \K3I,0/==VUB:OIEL.SIP16=]P;S&+KK/9&CX:B0;U'Q*Z'=-7>$1E@
MBXHIZ&O?M6S&R_7Q\>'C4#L>(9VS"U'1ONZ?SRS//3I'&9/?Z*P).?#1;0.O
M9%O:#+ULNYFWOL:VK@DD%D-Y\$?H!@0&^1#+/POQ^E*15.K*\G?^%U9<MOSZ
MH4[I,H>=<<Y_[[EXD=^.BW%FS1J6V;2%WB&5/06MHRC@GB!F9V6D$"W!3X6/
M(K'0$T"R<]LZ:CP?[2/^_@3H2[HEI?&$=LY?/1:4Q/==&!*D\( 46"=LQ5:I
M:^)WNX._CYRA[]9GSV>W+)*KM'C"T&FN0DNV44YS!GY-6R=Q*T9<+F0 4%VX
M(C"_FR-_YIPOQ5UX;P^9?ACTM"#3?_9=[0OJSK!0FB!$Q\$<]?)27]O#K<4K
M6%Q.Q3;LKJVJ>>;X]KTKSXKD"M3>J0B;O3>&SH(.7<$<E&3#<A)T_,#,PJ?X
MB6G#0$V9L(F;THY]$]X4Z]R9S]/*;$\1 1HWQ)S=S397%L;1VJ$KAXG&)'UC
MFY?IB?>V>ORF#I7^]WOAZ_=@G A7> 0"8!^-O^AM=HXJR5#OWUUURMY^.*(D
MR7PEN2JPW\;2,+ W?=[37K\YI:V%Y*^A&HO-_P!NT.V )<Y^&2?<P%(_GJJW
M&,TJ^5TS,S_T/FVM1U6P'2"T1QM[/,H=.*2+#T))V7>3!%I)HW^.XY[+>'FV
MEJ0-1K#6-DS2Y #X6&]L2HB%Q!Z.L;=MN&P/?Y?HJ@?->2U')F!&M;%$,J";
MD0?$N*-C7&)CZ/6F=N',A'/U[APG <>PK:5V1WE7)T#S&G22#&  N7")1/WB
M4YJHO_AIUO+W'>[T43@ D2);E*,EX#F7&#Q1VY)0;WW&L"6T9#KE4O4 C>B!
M,T" &.V#.(+'=S+@%=Y_>$7_0'-4\H);ER[<06_$YS<M-4+A5^ .;AHOC$%V
M95]I1(.B5:&YSE4S#\I<QX+DAOP4ZLJ;5:##O!ZR$M13R0$WM<J::Z'^9P=>
M)A6XL[P%[:#1SJ19"51C'S_3HGL>'38QIVJKX8'?2N%'AWJ;&Y\*DR5ZZ2P$
MFM_=T\S8D/G7'X?X.:T'C$GBCVTVFB.,2HQ<G^?16$2X'1+B8?4(OA,+-YNV
MD!LA59Y18^EF%HUOP+-=;SWD ]@G!%+%"E[T;^L\$..]KBL0>S0:SU_GU67T
MSB)Y=(4,X')MYY$K"_0H\4]==Z2E2:7KTEOFD_VN;>"FMFEB,^<6K,V&7J(C
M UX?A"%N^GD7X2703#G?W4;TDHQ^ZK^N<OHE=.9M(^0A\L^L ,NRP):>8,OW
MZE+E^"2;Y@NFA*+9@9"@MVNM>69WRYP]2AD5 :(,]!H1*B'?#\<8-(_6$BN0
M!:TF7G,&R[GPKIMRZ&NCW3=51SNS<QYG*EEZ&UY%ZHB*"<0N_'E\\>P%"FC_
M)S9G^6 O#N.^LEXQ:_D>$E*RPUU*DV64J5*Q[P!P2(_UU7D#&!!G4IO0;T W
MWO<0#OBQ6V_59UPWN1(DN?^U)4'()7<Y6=G2--)$]SZ=0.(7Y&\$YBEB]D87
M_Q4256#.@TF(H3?J@!V?H]<:?L_Z697ZS+>G7\.&6)BY^%X=_FX+/H$+D %A
M)B2*6NUKT@6JH6[AXP*Z]>:>-H7RSMA@\B"UGD>M"(G]Z]X(C6;LH_P#WO'-
MK-$0XO2D'RB LW&*#.@*/7@(?4^1_(U>^"SM+U!M^_N7E9#[2 2*?T)FOR>A
ME0RP_]FT=%?G3<O+A/[_E7#K_ Q^CGO9_]F$,^'A%YX0(%X03?4U< A]+?)3
M!8#Q[UR'QFKUZB7UJ3"ENZETRA#>Z^YC4&Z")2:@5X;I6\LRG,5U47@\[K5[
M@N8;DO7RS41$$,_EFQ54&\6,BY;6++,6"-.*@MI6+;241*>5PB*\RLT_6#/-
M)=(Z;N=LFNX_+<*3W7O&^X:0K3**NAG G"I%S4+H2;=GU3?G&.=<LR:Z\EWM
MWR<GO?E;[+O0G.'LGO_$W'U/9^)QHHJ,]-<Z?2$]XY)D 5?.B(>73U[I ?R$
MT#\HS"78B6"#:+"W+%.4TG51:%SH5=B!X<_GR7< Z:_Y,R)US);C#R4.N_YO
M,J\\$ELVGOEY9'3 #YJ_'D$&2)>8J!Z6G[<O(9V@Q9 G^%P4/#R/=I+P<N6:
MP85@5[:+3DO;H7#^$/!6+T+HT8C/2&&$1J@X. K,K*Z!M>^PLHR#2)3"W/ A
M9O'#SD&K \#L][%I-=J6O&6\[\?;GQ(;H3)XW95\PHT2-']<*W,YS ,?O$I)
M1#=FOC7.#Y3^JE)\%+URF;G_W!PV\P"7C;>]T"1U(^B6T+3QQP=,0YJ?!+M<
M1<ZJBL!UOY4JF"7T+ 42.KPI+L+5M.7,VNZ*F+@'L\^R/@*3%M;(@-7<T89-
MN 1>[L*8($[\,MP) 6&K\M&,.7Y+4JDQ4OLILE>.+@^F>@Q0^\\[)+J/U0\'
M&&)&4@*^[W!'5&44S_0Z-;6U?7H9R7KS^4(T VV9_&J3^=H7F9"'=@7MSDT4
MSTXC#6=FS[D:81_U5&4:20ZP1:QFGHW(BCY[[ "K;^$[.2 Q8S/#5_8NS=E@
MIFM?PC>1 A^]CN?2\[CNO'FSK=>O<ME?\,J''(HF*SD[-]5JLYK\/]XO[?_D
MHAH(I$4IA4/9OQ6HBZ+:0/=#'Z'V#TKJ/M!7%3M)CDI&26Y(0K'*(U=HH-X4
M;Y:G3"H!1I'E\X-2,F#K#W+;$&H-^S_\//&5=,1&'"#IC3*3]LF /B#Q-E%C
MZH1U7#YG[HSJ[NROHVKCU/ME]H1RK SN)@:QQX65Z$7<^(:WU2@)*T)ZIN/#
M>V;;FEB>IPFE<OXW^..(MU^?2E81_OO39=($?JCGW.B=NF@Y/LNVR5V*0[\^
M%8=;>QGT^&EO<6[#K=K_$31Q5;K+7GO7EF5F05U9LZ==1)>=8-N,F1]Y3O69
M"YE/8_$SXN7V3"J]0,V,Z[&XU#R<1:/#$EBT@%3A(4+,3D2&G/L?SQ/P^!*,
M(*Z?F"$?-QIMQX-?*B,\FI#O'QXIM _UTQ@JDCC26W)LDA44 *P6TE(G*_>?
MG^(4B? *A!O%.3CR1!13MC1%QTZM=KA])9\+?A19RU0_6ONY2IU*YS@PEW8L
M4B_UF5OC.#M<IX'^<L(;I]X.3M,6_Q![%?@0$'^K)]PVL'S%IB%EL/GJC^?W
M(YH=V@:T3NB,C,#!^H,%Y0]@_ENX8!+0<9W%."S"ZT (Z4NAT98S"N LQ[#W
M7ACC1RL&'Z89BN3R?US-6EU0<]Y^1#(_SP%G(#!Z'/S =A6"'SZHM*:KXOX8
M=.NGTP4E\QQ(^OH)I$HT=F(H2GNG(H0TU-=Y6J(,D;[;N.",GX_,KC377SA2
M(]&N@7;%EV; &#-X(DZQ:Z@^I;['I>^) F<T\>U9=L"NQ3#:""^^U+NG UO4
M*)V.]Q )N&V]^=(FE'5EZ\F_.A(]9  C/^X8?X)E^$WO^\X/*.VK8N()[^K6
MXO5);BK&7RK#E) 8KV%Y=":]J0/C+A[.?I([RHE(//$^,7]Y;A'H@:&$UE'*
M!2[[)EQRD@,;_8O(>GMB@A"'^%Y)HLC_#\QNPQ>=4YVEX3Z>1M?7">=4X.]3
M9Y8EU%AK$J/QV[<E[[T=495++BE,]T/SGS KZAU_ZB0&EA8'Q!5[9GF-26DK
MO59P/[&PJRR'?H,1V&G!4P2)"QT(^S1$<TYA3W-BSRKD-3#N0XM%_)XZ_T<9
MVLJ0I##$<NH24 %^=: ,8C$-T5X!10=WOUHQF[8V<2&49W)YW;9?[U#^G7/4
MJ$R]!O]7]K;X5Q:H ;B[<S7<U\?0,UXN/KQ4YQJTV.QEZCD\YS/)[O0)<F<S
MK"Y_6FI,AU]#]=SWQ!F%[ 32$)[A0R^, I=PYAB9Q -Y#UKKR<5I,L D27BY
M-N9QI3?G9;JUP#L)C3PQC"GO=)%D  ML.6F)=AFO_[T#E9,;/-'38.$SZEYA
MNT3?>I;!*#[,_B>'GE.-3>_DY) ,^$ &'&;#.(E>L./%C/,8M-<9AP+X_#B+
M#+BGP,9S_D&<6,+8B#0H/K28&T[,R)-]<R'NW_@D@>1_)HCBQPO">MH"^O(O
MJ>NB<MUPH?=!#-MW.TJ&WZS-JKG:SU>'!<W&)[W_>X?Z'0";%'?:+D&9AE32
M;#"\4T,-W/RGG14O^QPZZ]'T7#V*>4@%W'S86N(04L,&?:&)\420Z"!RR^#8
MOSO$0GLRH*"X0@8OU!KWA31!!O#573/^$$P&_'[LX[,QT);BM'K4I??I/';_
M>SHV.3X#*:HTK*U&*A$64T:)WF[1A(+3THPPNM5X)(F.B/E*$ G_E0V/5A=;
M4;M\]%JA;_+QW#Y'NFN6RZ]YJM_6=.J)'T'*_X*?'Y###81YZG6S,<E3J 6;
MT1X3ZOA]]#;/8J!H0T3,+T#^0J+WJ-W)!0TXDPRH42QQK(!U6$$5Y[?V4ZUY
M0DWN;"I+9RGVDP'XPT:-'6X6=];"L4ZO?5L-+[Q@087EU,'4(PDL&? .6F29
M3$(N"K5@DG:;L*86U2E?6QLQ>P=IMSZS.L6DWSGEJ<5;PBW9L+6_J-'P3B!W
MH-J;A/KA6SM&NAILJS$9UIA70)3-W_0U'5=_6$K;E8QGBGO?":-1L.68=I[:
M>OR-E=R@6\:EX,"X79^AI(]]U^H>Q^7?<TXF*9S+@#-A&%U@;'6@G 4^'&/:
M[7PAVNU>JECHZNSCWYJFTVXX*<"_8B0N]WZ :E1;X=R:PL2\KN!KZD!X8*U-
MQM=Q>6LQK_V\.XQ!WF5.#/1<]O%4>?IL2S&??<MA 9G2I!A1_#?OL?BJK;G%
MEHFIG),SX(7&0P0#;+EZ41*SGW61 #)OGWH1^ KUT&>N?MDF^(HV(0(:!9$@
MUFA>)SA@I'^@$4R!G6-U1/8IN,(SF;=>;U^R5*V[OH+<;&5N\BD*HU(XVR$#
M+F_6MQ,+$%Y)T0ANS2%)5>$<NT6=PZNO4[?B_;'\WL"/1A=Y)QF<]7&6UO<#
MSHJ]VD=ZIEQ1CIXU"6U^A*JJ8&<".^P74C&/$^^(!3V^(D&D-0^A%]4ZNIU,
M__55*-ORZY"VT$_H?T>'N45WZV%8-PZ=>CX.TESC1E1 (Y ;*CV(2'B+:,SO
MXL=;@VK W1[LRH]/JUV'RV;%XQMS7S]<EFEBSB #WENN(Y,0+@-^7GAAVG<0
MGJOK'LY/D3Q=:=U1&XJXU-"O]VX&*Q20%(;*OUI]"&BU.C0]M28#?M43$G-D
M/'0J&FJ-1K,6R8!QSY036@(S&8!ZT4#,A9BO7'OUWUN_E5 +QU3](+FY^U=A
M2E4.(4DC/V7PPB-?O3%&N(_X!8S$TY0IJ7VAEA_/ ^<]OMUEYSM@_:$T)G&0
M/].'*H#<Q#,O&UWY+FY0Y,J.L?'@O*9R;T)I15"%X+Z</ZO8@7"F.+'X1N?H
MS5_?KLGT=BY.K_4Q'/Y4E T_MFA\>P*_;_'L;Z>:OBJTP6[GN!GQ&V4X2B^>
MNJ  TCBQJU0+^EM)"=$,C: ZX-X61G=YUV#C[TQTE4Q:*:-ZN^,OP=G%O_QX
M-FC!+4F7TG?BI;^HO["=?;W@M08F\6-,DA+Y68OY729:%1TG*AP%!51>NM^@
M/KC6BCB=@GY$:DC=J4,>V<'P-^;V#0Z4RJMNP1;JH&OE9PUL9__20@?D"45Z
M2$@0K1^80?03VMU644R^Y[#[4].%_=DSTPZU'QUHA)4$)0R2& 1+G[F",4]A
M,^U'IN(-UX=*6G]O,'QQTUW7[(*CC#F/T&^P;7#0N';C4%357HCNB6[AO\.;
M87J!U":8[N:LGC9G.VQ^MX8M=.*[6\JV%(O6FS.I->\L@<^>:?YHN7JM.3OZ
MY23\(XI<?P0W>$8L<R#WZQ$?H/+9,E*>28,_AD33:]DNRM5E&D-N=WU3YJ*"
MV;H?(DB,5[?@!%<\$+4G3U]_&A3;G73T7J&G6;NOI7#Y@GOV<V5,,5M!VII[
M<<4Q0>/Q-_C]\K261Z<A2TWCE CF!5O-(LB1 =7#HZ1HMA.CO;MD@(@$90U?
M,.^#CE/;S2CCGR\#1\"N:JTFV"WS7V DMA&S]J3'EGUD $YP'K8E_ 9T^AJ,
MSR+EJ-I7"5[;) ..:RG_+2<N';J(DGHEEHA7N/\=1BL#'3IH@L@ :!<98/"B
M2H)$MW.K<3=RNX)1)AK^ !#$+R2:O0M:_L[Q9@[:#55][O!LUK5",/[&D-+<
M?\I\^,ND*RVU3'G)A(*WCK.@BV#PN5EB"(X):XY\#UK^U&P4(^G1/A-2N*6Z
M_I6FG?[((79];RKP1)P&DG-QA33,=XG85 6QQU*O\,<K\+/AY[<?UVRZED8+
M'3Z2H)\'+KX6_G3]/S-C/I5-S3^4-W::GWE.ZK"CSC')7&2D,3083=W*>$6/
MNXC?E^J]BU181E#T,Y4, +9+@&WPH\L!W:7RRHX_,_7V7CA,RN,W+-8$\CBN
MT5G0"IQ%&%%S7FKHOO@Y6Y/:'!SLWM:*8Y,)#HOUAXQNK!W.5U[<HQA!JCXI
M,O@@DN!Q<0?LUNP<X^&5X32QKV"FY?E1R)!WG$U-B\=.4>8GB!H0?OY@>:"^
M/(G.)16?NLAC=+TM7=0X;.:TY^9(Q_H'SYT6?^ WB4-PKRET#E3-GIPG.-5J
MDZ>$4:C#5OYNM"RQK+/M%M<A!5I_3/]\M:_>Y]ZH(.C;4BVLM]QHEG\Y*T)3
M8/9YKH9?SJO#F<REU<>)8X/OJY4 F[]XK\9SCZB.9TDT&U5MU3<6+I%HPJS,
MXE)KW5=/",BSL[PL<!H9@+',#7F.:=P3P^@^QVP'Y0E,[$5,?XX$R?D-VDD\
M5"0#.$8X$D_..\ ?01A3M8N;$K@I8O:!G^+#B<K]/<>?KDRL.LWQCC&:'Z\T
M30;]4 Y<1.:3Y@2=I:W8BF=!WS4840@"BWT']T:4\#1)SEWU($%3<,<=5VE"
M5&"/50N)6OOPC,NGJ7>+D;KQ/S-O.^H"Z\!"$KWKQ<M 6.>/P+ #*SQH1:60
MN+#BO:8>)BAXNS,&]>I#\_LVNF7/3E*;'WR0$L&D>$2:5KS"-/DFWF6!,PX>
M>Q?>Q&<:.$2_\!TJ?W'!_VB1LIJ*"@O2TZVVG$-!E7IO3 M-<[?3(*.%MK!*
M!<UPBN_D0J?.1W=7,#F/Q@C\/A[JKNB9HOJZEG@G P-?Q@T#SKZEH=[8$"\A
MGX+6G640@46I@T/S1@.2)+O-/1H'\2KOP[7=9YODN^VQEK8N;@L+DGR7_VFF
M^LD;M7QARM/_;,GEQX"N%+<VN=^4MN:)LP\L1_3[90L*OD])94M>$53>LROT
MHNC=3_PG/R_6/U DGV0J%ZNJZK.%ZX,Z6OS8NUNQO;%M*N;NEB+P&2G)%C!L
MJ'1;OY'.8[_$<X\,R%SZM+I41]L!ODYQ2TFH -X9G=3IQ;QMN4@]!<_L,_NC
MH!).^X*+\(GA755\F&&B)<0Q^/,J\=\Y<#:L;50B99WGV0EA13)$<[ZYLV>;
M$VO/>Z2F6N";G>U0?"%E7*V(QC$/07S2A>U\3Y&A;]GK/+':EYZG/-8N6IJ%
M=0.-T+LC2B'(*M+,(DTX*HG LG[0Z3^["A5N&*M;$!F4LF.ERW+)>D-UJS0
MP!P/&#XI*R?MKXCZ%U5NGH*AB]_J+"\>"[.YE\"4QHA+TWUAI"[8#S<2<HF>
M %H!Q6L*3)WPTVU^GU6*(,C9>^-"?,,$&Y[SOL_/?IR4Y<[R25*'-8@,V"O'
M",.6/R]QD_CPE/?9A\.^S6T[!<0.'KZ]$ZMG!9)E5Y=/UJLI%>_.XUE?M3_F
M(=%_H@#@KC9FS-[VZ]>6MR-!2FEIY]EGE,0BA@*BL"MDP$Y[.:%2HIPE5_WQ
M2UJOX,66!81E6233W4K#LNULF%"::Y#5 %\^9HY$'X/RBM6\:<0+\9LF:*V
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M9/- R1"X*#=?)!7-M/6/C6X)6@BX$F2_2!A=X#;U7^?4<A5V>3':O#-+([=
MQ;);>NN^C,T.>Q;W*&.0"Q'5#""9HE:JHZ=-YJMJ"T)&$)(A^@%UHTKLK-,[
MLK/+O;T CDO.:2+<*E\(+6?^V!)E\"JT,2 >K5^^ "3=#Q8B\TQ?H VN_)FF
M#LK^)L>!-G6.M*\C,V&XMY(2HQ%WJR@>I%+%@BDWFO28C;CTTU>_I;/<?3>$
M!U+\;BT%(8<3-WR,.LH?U_K:[C5/[&)7_+NPK27"(;-%*Q^.M75T'Z$NT0%I
M_M9T -((=G#&WCK[_\J<[TR@G:4"EP+_T*YHVZY [_T+]T>[H-DCO!H)H*36
M\!+9A ,8SYQB54;>QMF^9XTJ76*AN?Q[39/?OG*R[NC*?\<R+ I)X<:7_'"\
M.P_["8RUU_[P2KT+E3D%CWOB($?YU6'$V9OVJFPC..+':3_5S^P'= #IHAGE
M+9:!=9-=Z!-30<M_.3FP'DV2(QWPM 5.Y5.H/8<.-58P=4=2V#I!_0Q,/$\R
M"S7+=MBG"3<N1<KB:XG,I&OSP-C,K$N-.%/^SNG.L>^1MDX35X9W3G:6)U1Z
M95\Z:55+>RG D>K[RA2^X5Y(+(-"!&^+X@>ZW-'SYX<.A1@$K0:R]]O6ZDXE
MC6#Z)9?,4@1]-P7K_@P\[(=E0/UI/T![,' ]F/IF!W8PKRAW:Z%RJ"LL8'A\
MI*_$60%6?;GM. ]9N7MTN!,&[H1/NIJ3L&3'DI_HQ.:==Q41<L->;\(@L5FA
MSFZ?K%_61.5Q>JT8B<3U_"<0E?\5^F=.B)K /]\='Y!B31,.@9+L#:M-YSMK
MX5:-'R]/_FHHZ)?6X!YFO=Y^]@4J#,+M"&N_"X/ XG682 D+E5;&>%!48;,8
M+'9+Z:R^+N3FS++U:_/?=BTHCB<Q9SD%3VR[L=7@K7KRM8BK!-G40.#I]1:U
M-AV;1X>;/;N9CX+2Q*Y8&0[5UFX#F'HN?5\MYC5:%\JVP=H<'GKMP,DCB>-&
MA61W;^TK?B"\/I#?R1-1:Y:@EM07U]0P'''WBDVUT:_$RQ<2[R1MM[8XC\$K
M?1$U J;DRPS#N8>2BQ#[2/V @2KJCP;8S2S?L0W RW-_OK??%7G_3@,:EP#:
MNQL!HP.<Q1CZ2LT:1!&TZIC <K5:X^'$F#\7(=M =H\A.^Q'DLI=='_\-=K.
MO2'$R193F.#SO,22&]IB%M#T1"-*#N+0/_:]XWVM>8D1/Z=J;YK\*D,!,+D1
M5O("\8OM()8(;?(N;\2=\?F&<Y>7OZ3>^Z&371P"8O(@2\V;869!\YH8,\X0
M31/S*P':.N(B,R+*U0"ER,EE>),Z'MX1_@ODN4NZ[-.XN!DJ;(XWP)A>Y(A4
ML8X<:AN-#T+<WTU?K@&MIMNN]3N;7K>8"&V47:N#%R>@/Q4NE=B:YE?N0P_0
M>GMB.U+Z+ZY;BTH3!4F'>->?:$XZP L^W==-!_#IZ(0,WAZA*.89-\R=Q^_&
M!\9[/<E5OO;S]I74HB%!S9NIHLOBWW^!OME>Y<AV?_KLSJ\8-LE%05(_F07:
MCV9I!1,:%V =X!0G,<>[75G6ZV)W_GIH!IFJW!N^LI;$^55DL>^MJW2I]$LN
M/;4YJ7Z]>I+C25%CN7JV"3=E68"J/C)4C^Q;/AC<UL27$]5)!?AWCVOPV 04
M7XA5ITU#^E]WL;BXP$B-7K.Z,KZ$"PFCQA6W+47X]Y\_P4W8,H!NG93C2[:A
M=9V4Q&KY7LEJZWS=A&\[[,3XI&^,Y5F)7]OIN!'T?,_X^9Z_#4T:U@X"/3=[
M,\<TWNJX  %<0N2["_7[^ZMZGN2^9&'_,LLUT,U>/IH.V'2$;YW&,AV:Q8@5
MM^!![2?=;[348:4JCS$5/:JM1[SY4;W/<WT %UP<1,\&,I?Q)F>X:5L9;S8T
MH/O=[OW-7S=U&PF*/)A9VAID8R")10C<G.2[P).$J*4#XEVDK/'%E3+;688O
MG\<WOE.] &K/B.FF!@V&,90FDT 6;%J66$12(&NY#]=.:?\:#^R,I_Z:T7HW
ME<ZZ^I3!%&R*J"7;$T0&,D4E411)&%XAJ"BA _;,,YTZ.7[_RI6=L%/5E4MT
M0 -GI >8)!OS!E''LGV+T$A,0"?WN&CONX7Q?\?I[:T"#A3.!O4A3MS&'F97
MK0V$[5U:WN20*7GQUYY64:;\K.RK>[\/6.96(S*CR)\!J3[ *70WL,ZVO5]U
MG@YXI:5;1+(U%?9M*)(@9/ M3*O_? E7%%_FBFT7D1&JN8(Z0_N%!K3*/OU7
MMAW-Z;U2_TI/9C7)],V'"266WUO[E.6$58Y7JJ\ /Y 2C([44EP(KG'+)'<\
M&C--0?$/4UQ\+VY,MUJJ&?3PZ9U+^7SNGG/_BY>LOP"2;"Q#K4S_3JNEYFK)
M%DT7EW_QT+G:ELP<OFUKG0NZUH)08D[1()\+V3"S'\A99NOW6CK<F+:!R9!V
M'FZ+ZDM8SN2;0=!X@UY$K3X2O]L.PEL+C.BP;Q#^4G0F*GR\Y\2%TBJCD_2S
M#-^BY_0RS_7JWQXX]0-I\V^T83W;T%X@42R:#G@@-+:$X-S187@,#%9+LR1"
M9>2@[59'F/%C]R$E.%\W1'IH_5W"1T'RZN\K1>3M 3/[0S1)KI&2.['%8-9/
MOX(.YKT=_M26OO(\1G,,8&/G'-(>^5%=8(&:F_FP3-0+.$6HA6;(\AJVY6%&
ME?Z.1+?>H ,N$AD.TJD:MG8:Q1B!J''[?MFM;5S?FX1<$2TKT;0?\_Z>+YFA
MQ:@UAK%Q* M2=/#CM<5_]8*?PHIG_K9K*39)B*E?B,96NIK86VL5HT60>_+(
M;A.*,AU@#-*&T '+ZD00D84.^.M@VT;["ZPQ2T9[:D-^B%DW)GH%0.+LK=>:
M)P+6I3.4E/9Z.;KK14VNA'?L7#B]-/$[5XPPGK;XOSQQI[4/OF"[J1FS$O&/
MCV]J?5NO2,?!=[Z[G)16PDER!DD4 P*<B"+YDF\T)BJU G&.+Q3< R][(_K(
MGOW2GS5= ?<$!6M:9J3/<[HR]9MP"%0MS;9$6'K0;*CL7T<])MX%&<M3:2(E
M$!!)]@]-FN1-%J%H#'%'+W#)SE]Z^[9]6>10RIFX]\59QQFHG0UO2Y_:_9=P
MS!9>2?)G\+L&URX8*T5[;'D4>G[6KC^R:&=?0\O74;]:<S!6QB;X]L_GJ::1
MFO-(DLS1U@B>_,!DUJ##SY.Y0_5*<RJZ?*"O7O_1LEY G,C9S\7:Y<L0DJQ&
M_3SL7TZX/E093)(?&,!T6*Z+O1K^,H([]T,QDSAFGL_)Q"F@N>CP9T+PQ>[.
M VK#,!U0\GN@ C9%K+&$5U%!X+0\L@]%'F^3\:_4!XFIZ%$(Z';M\&%?TJ-
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M]H?",;NGH-W0T]1J-7B<#CLILMR(H&GPT?%NF9V'9J.-AE57BM25Y*/G/GK
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MKXQZG:>;_@6>]>D)7PYKJ O><U2?7,^F;J3N&85)']KL1T8,?@+A/C1CX[1
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MRQ:_:$M%! #CG6[@!W(6(;PAKV5"]-&GYV:FI@LKS_L:"+SZ,L\AU 7U.@U
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M]?-S</$@QQODE8:/HPMUDA\X[>QOC<G.S<3&"DIM'^[\*I6+4 X$W61V'3D
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MUCCV,T\R^QQT@'BBA1\*T,?_#G$/#GAU&?O.6UWA*^V#Z0>N5%IW=/-)?2\
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M^5F+69!C];@=$@NRP_/1%;W&7<&"E+C3/S5VUJ7D_Q_!!?^G_$_YOUG^JY]
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M4OA0/9#W6\[+.HTK[C)KV!X7CFGDE4G-K0!!K";WICF> \#6\N2'%"4XM(D
MCE%$<#OZ]Z5>[E/+4LJO>B7^.F3$0[3=N=[!.,C*_5J1NV[>?FK.A+.G1G5.
M$P!-HT:H ,3^8#G'3&<M0>PI-.71,C$."+:@$01' 1$9OJ84J'HW<M] /6?T
M0ZQD?'1A>PA_,ON75XBS_D0+B:]B8U"RK;)(%K1HU=,\@^I'RV\2H/?9"(:9
M$W>CA0:-5S)E9(2ULOZL!"]H<QYN9XLO;XV/3TJ"*?MJTUE9"1SM^]O^7G.^
M!6V759WYTM$?M9Q#^GDWQ=*:=R5#L-RG'5W317M4BBO7^:028TI79D0'UJJ=
MQ?:Q]X?DGCS$HV5$'S[)NLIKKF5\^_#)F]P_X.9D# [ 2/237XG01*5)5X[?
MKTY%!L17ZBRKZ S<=.#'S9IP!1M>9N>$H\Z&</<3_G@KFK?68 @/P<$IY&"'
M?H<YBA/TBCVIJLY*:Y*70C'SD)UA@/YLX6&V5'5RPBPJEG[Z,Q$2[E5LC;C9
M9/W39D+#M-$D++2$X^B#8\RAAS[I5G^O$:U"20X,:)Z)_)=5$'/5^8WH['/D
MA[-O4*?(]=;EA/4X9WK%[KW7=S+5S]BGVXYKZ:ZQP_WFT.1+]LUR'(Y0I\<<
M<6K0$]N-@U6%@V+[K#$Y"*IW0:9-AWN]%24]=B\#5T ]8X^#=:D;3NH.-IA,
MG*UWO]663XYELA>)USED=NONW?97AXO3U2,"E2Q4JHNO&$,?Y31YD^TI[F2>
MN2@\*YK*5SE U<TCUVL%5&49F$T<QW^\NL[=_B*EGC^LT3U,BF4^/Y#+N#HV
M>;P8?2L[V2V@%%QH!),-&H(1C""1B(H"9"D</%=ZI3VKK%0]UO'(;^^:S2Y.
MU;I/7]-]NVT_OP7Y"F<[_48PD;L,R%&X/M8./L4$V;22\=L(QW60[9E" ?=#
M*BK"PNK/D8T\*FOOFOP9H!26@ JC@$:$W);6(G<[W)&,^0 _2GZ,]MUJ+W;?
MOXKD[%4TTT&K1;PS,E9Z9GKI82K;9_Z=$M?Q7E+H3XP#)O*5[W*;A4UY_O,Q
M'H7)6UE3\IJ*D5>JWQY?>.4\G?1V6<HW1V/+P7,*7)<2Z*E=^#^?)?-=[L).
M9+0B*INJ<8%@F\^C2LZ6G=>1))<,^YRV,Q6\RD+K"(4'S=:#[[M%M@83/ZE;
M5NP\'FB:H'65_S\^*&>RDV HPZ73-&QO[BMS(2#F[&56;LU+-WJ85 2KYU$5
M_7@/P&@G5MLF9LIQ-&6K(6?/N+RJ=TK=%V/&QY5#<R2?'K$=1N:SSCC+QFX,
M_.:8K@STA&7BM_]A738LLXA)Y18;&=K':G1(C;\-!ASGF9JLNR%>&_S@LL[
MCS$N'C653EO^I8B2KV=)K@NUS.M=F?@<"DE]/78/0$8%M.H&#HH0=/9U@VV^
M;YBQ,Z*?(OD3CTL53[5EQ_1EJ=E_M[)5Y]#;_97'=2=1@0G4IK$]V. W.E;;
M!W@D!XTZ9$ZLY/^-#OPVNC )$SQKJX3*!\3=&!DEUFFP_N68]X.YB?J16Z(/
M,ASK<U"9G>YM\3LKQA.Q]5+R[M[:'XRLQ)LWXBV4NS8BZGB0<'4GA'WN*HM(
M.L'1+<=*0I?O2J/1M+:$O_P\]_1H<ER86_KO'PK&YI9 +#&^9P2#T(<P-;4A
M#) =NU-KEGU<%?J4H[*@R%90]X1, ^<G/V>^VM=/LQ2NI;D%^X.[L$EAA8]_
MQO^L1EZ?P,-'<=L9TEBWX7_7KIER/-S^ UR#,,( 1</UBRV>9XF&!SGW[:SE
MJ.18X9YF+[P"_=$%/<TBMUD"T+*+RC3HU?FYNH;H7>EX3F)XS?-+^A1RX]"E
M@5XD^5A@D=B;Q3^JJAZ>&K]S&E9Q&7B6@UTA8@C#6<O!:MJN91.W6E6CTRRD
MX^S5SSYXRWP7ATL*"PO5O$_+Q3QW/1GT'<PN1NR*?5&M3Q.3+BSE$Q"46$#!
MPR,NZ(HX)5[;PYP0HZ&Z/F(3L;X?-JC7 8H_M<,G'4N6)]KKD)<)F#:ZZD]G
MM+-B@LNQ[!D!S=.RIV]7/!X1&.8O^MU5[5WM'A<'*/)UCZ&4T7C$7YK\E]'T
MU>YRG43@L&NK?F+OYA@@GE:E8>LNS2%AI_H.W"F!4Z=/7PA5:_W:SRVKZZ+X
MYM>NOS2.)DQGE2> C4>$J[X,4AWR;_1586T<TO$G.#9.<[<U:<1"JP-]"&_F
MM4,UKI$?PV_CH)P/?5/T9,H7JI\(\G1ZZY\'$6LN>]>%A;TU>UM:G',MV5O5
M0CJ4O$+,T*2A@KA7FR!$[E+:.C*WQ$"-[ZF#:!N+J$[&$\"JLFX8/G!#Y1\\
M@,!13+[( -VJ;>>@\CP Z+3=L[PW#IZ*BPZ2GAH,4$[3(2A9!MI,\F)NI4-N
M&+(*7.]EPL9]V^<@!="^!)T.&E(N_>BKVGXW:[]K^6K,I^;16CMMX^#%IYTL
M&I97F<6Y<^+2.UWT5+-W-;G;J0_(8SC7D&S^ZQM(->CCV5+%Y/+&*53#N^">
M![GW;+2Z5(UT287.FM;I*2[=^$)TN%<_^5)ML[.X2?+@F"$QO?KP6]95 =FC
M$5V%7%9:Y/U"M#>9F>(*%Z3EN8P9$A"Q]YPZU-IR'-V42I?D4ZHM%U- _'LO
M?FV8GEG\)&:@[3$CD1-[^X0$^B(1AH?,0MG@_H2Q%G))M;-/I\4PNS=QY7*'
MR/47(*ZE:=7NCTH7.*]&JIW4L.NN3HZ=9H#:Z#>V#:U/KPZ;1QV\QU&]'(9Y
M:LU\>Z3A\<?5K+2:<G?29]FH(PIU=;)S5OJ7'K$)M@.E*I;Q]CC,!+8UJZ81
M-QEHUBHC2WAH->%TN8.[M?S&'XIM\LWRD O\RU)3;G<"Z2ZP2DPZ=BG4!O^U
M#D\&/+[ZQUCI7H@#QX1J*ZIBN<V'6! WC_DRU#3"G6I69^76XZ&&?BMU*3'V
MY:?O[FT1ZOXFW_2DUO)YQ)_ZO^.>A574XJ-P_1-;>L1C'W#X*]9#CP?$8UDC
MQF1F8][EF=E)+AJ(:9U9%O%&FQ''D-1KA*XVGFPAHDVUW2R-\^<SI]6].VYE
M_B"HF7APKD@V2*S,:9SJCV@1XIB '\P?Y=_H2/A] &4ED)EG\0:E+RX076,^
M",AYEDHIQC2%SCU',4 ":"A9X*_LJ !QP[QJP!/&U9/K&XJO:<DCATY-Z$MS
M!1?NR:MR^FJZ=WW.D>R?95$2Z,\_F/_S4#PK88OD__/)"/V";\Y0&VF(LX:H
M6V<9%RJ?=$:"%\O+>U&'EU<HOUK@H:YRCOK96++"!IU5E2 V:>3T?-OU_'3K
M^><-47=K3E^F$]C=P6#3_NI  <)Y4A,92M'U^^S+T_$*]N=5UU)?WK06:2P)
MS>LJ=8.UL/MHBGNHMI+N->D<2R-O^XJ_\(IY.'T$4B,7!GDJ<Z5M=T9^2&E:
M3\;%X7&M]<D9WH=\2L:3U/'<YKU.^>R=K5JJ!AH713N!/04A6-LR0#UI4GKF
MM;?>6E0&0C&_T2%K"%P5C$EV/3?6FJG+S*@<U*_QYKF1>K?^1]=NOOTN'!+/
M0:"08@D+==B_O5YSB^SC$P-6EO(__J/7>YXS47?%77<\&ZG)O8P5#%+Q=25Y
MDF'%OEL=,,= 84/YXIN/8G>Y5.MR\AR_?WJ0OMX6;.A;LBC*[?T\):5"_5@L
M 34.(WTC@/%^'U?';-C#S(>6!IXE2A?+N)S+0;T(3DVZX]Y]0J#DRBOW@L3,
M7<>!CBZM9WGYGXU,E*8## A-2+]B)[Z(FK3\\?9G7QL;,I]$GN%/]WER..2/
MTSQ"$-%B@[!G@(XY.ML_]IB3._?B"=KM_4K<XN&3)_GF='PXO+K5$^R_HUT^
MIGM_)35R;T);860IY6:Y.+YW-9D,$ O[<KB2=,;I-N98&<T*5<'.I_81")SA
M%9A%,?.];[<E>8\('B_EMS!_YJA;SZIYQB3UWU&D:W0V+]GU8PMB+L&[ZU9U
MME=-R,:SX_:9B6=5AC?7 Z1"H?DN-H:C-2EW7^EZ$G.OMYR<WCQUI=KGE((_
MVRMUG;P)W?*=<B7N!6QE%_[*+,>$^>U1N0:EL_D?8;]K^PL<L\1J#]]$V"HD
MRU\"0)J*RD6D%O^I&SM9'[/H]2F! "W.^W^3=#%MI?SKNE\"HN419"F9 9H"
M:-^+XJU4+_3O]=,,4)(,!P7PY?I)A*\HRA0=EBS8Z*B)-SI8'#$?RWXL-!Q6
MK55] 7^#4T:O\9-HD7DU2*=1ZJ" 7E+ O2-Q@WD"CDH'*V.'A+:+>$JU@&NK
M-SA/I@GM%';I_9T8R;>("3 IOL%A,R(U?+"R!'IUD)[1NCX<=Y"8.=@^_.#/
M#4[T?\R0'.1C#AH"U*NC:N)D?!(X>9 [LOBKUH,,SE\7#](SA1GY>@<[?N?K
M-3J*KABC@0H.TC-:U_]*%]F, $TYR/0_/ZR)-Y;1:ORD^9[%'/@MI80WEM,#
M)?D#[3A(26V_9SE82OJD=) ?^NOTWYFJ]RQF3:&TC"!5U*$_1;.-CAX'N\VL
MH>K2D&<KLAF@]92QH5+X?M4.WL;[<7!NYN/%R+(R%&Y?:2GAM]D[ED^OIL$E
M)[[]X=6Q$[X0]DI3!MY&D83[7:\ZY2L'^]JWIE]K^#5U2PJY]Q3J+="H+5"\
M\H?NT*<P,6XF]L"QUQFE5:<8N"[8(*\XH@/@,!O=P?_MY^V1LTCRUA<&"!U%
M3RM_0#_' "%5D?MDQ(I)S9,_+XS^L\RV='^0.M7E)\8>%I'5A6S0=2BT^;W_
M,-S@6!J_NY5RIE1[O>GT&>J/*^G\]FB]/58ZV)QPFQ[A&@TFRY8S0 O?4H><
M92-4JE+^<EC1#=R _PXA,\WU&:NJ[A*5PP=^#'B5.D0_9JXQ:*@\O2,L6$UR
MC:+>SB=7WJD85;2^-6DVZ'K 0E\L/GR<R:%E9GR3>:)JT1MS6\,NP$OQ[XW[
MI=\2F=MA;+[F[7QGPXJ=:J[RS=1+AMT=LGL=F(,/OC1CA? -/B1:'M*ITYW[
MR;HMUU[[?RNMJ>WFP?VNH;)?ZN81/1O=IX\^Q1[3%2& !%:Y6@35"1OMI8>4
M^EF=SF:1XC=[C_B0%/Q>=1._:O^:CSR4&A\?ELB2^W+R?M#_R"1M(2<XYFM"
M*%>IEX:I@7-.!GH4[:&%2,E'@T\ ?*[PK;QL)&G _\N/!V[9U?4$]-S5-\2
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MIJ:S!SN^ROSL9AYI\WWRM2>/OOW1NGU8Y4*BAPT'19,^!6-!/&/-&VIX7&8
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MPRL9H"-&@_CWM'<-=H4BCZRGR.]FTRBIB:-3[ZELR+TL&GM9SY"),)_\VIM
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MZ>5F@%*<R*R:W$1S/'"7H_SUM-0FZ4FR+$?$EF^'Z-#%8425\"C[>^,-H;V
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MK4WEA,XC8Y;>= +("F[G)0/,S+"'*,,KW=:X"-'+_2XLRT]T/Q>N\2>"0.Y
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M^$B5(KQ]U1PJK_$AK\W/0TRU8;!8%>5N "\"F@RXG% _\FT G_C,0\-GF W
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M-P=I3$L>]SO3NNUG8_1UP,_7SH=(71D)&U>?^)5_KZQ(K!BWZ5I V\4ZS[)
M@*)RI]BC,[!HB,"'%F_U#L+P$-'SA,NK]/R0E$O <NG"E?0=PHMPF"-<@A'=
MPL4.1:>LHC&X#GGCM:NA8.^GE1<!ZKLV3VY,GDNQ>G)8:\WA0C_(@@5Z@AKC
M[6"!ZG8[WE[5-J;4>C\S3:\,R'UT[57TE/XIE\#ODV=>-J8=\R_3):$C:S<X
MF%.XJLE/+WQC7#)G!2)KR<*\H5#E^R_?G[H_*'MP31"D8\E34.=F;'P\3:;
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M7$B>11_VN-)$.44:KEB3BJ;^H8846TT4'N._$IEPS$"(O$$_Z?NMY1P#C?1
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M-[T^OT:_7$STP*N/3DM_2D8K79CCZ$D\<.#EH7G%7C[\" LDCGO"1@9$ZDO
MK0PPZ&Q1JVN.#@VVUQCO>)&9XZPS*)4M3%,R2TL>^OA=@S-N,8%8E>B]CG$=
MQV)FJIKRF\N+ZG(QBTQ8TN)DAOHH(3>]>3ZWTR8H\_BGS_T<,4FW'Z:[/FSC
M/*8KYK7(INU,'BXRDNHR>C=FUM1\ZSY%4KZI02G\X,3$C4*7T[S7]5]%\(\^
M_2-!XA3=:V1R1])N>ZHAJW"=A2,^]F:P&.YG@2ZNCPSKU#94]/JO"9Q]N\W'
M]="$!>),!(R*0WH[G)2 F=ER][H-,<_]M<YCR\$],BF3-PMZEM -ZYN?+VH0
MWO,=?#8D[SV2)KF=8(D.-7%EAC6<TO<PMT@9^?$MJ&&2!<I\)D7]QL"V"#-'
MD%6RJ HML5)'@E=]C<=0WX>52T>4A96Q-[5:A;+$GB6D!8TGOW-Q6T7_"66:
M\LZ(,.(ST/L@3!YDNA)<0XR&V])T/"$G\H<4*^".,Z45;Y?O=94J]M6F7E04
M+!1XQR%9O?C&DG0@"1'#B,'-_6XYCOSSU8,%>L\39WK-JAK;#&;(L$!.6/E\
M^/;42@8L>XA"^Q0:!3]'B:3J47!KW#3X7Z<+E(48_A*RR8UJ,]>34YT#)I+=
M.)<,VBY]"YTS?RY=\&22POJ^G*+LZ1W[%P3\7H!<8_N]#:8',^;R+#':29#2
M'[&N)5,)A-X=AJMK@=V\U>P#-ZTNAU?=V#NR:G/(D/-!')WZ[_5M3QN=,T J
M965F(3=4Z</TI(CEB:5-31^KAUJ_-[A&#6<3W@5N?GL!7AN@^4[^S5PCWYIN
M\@=R9D<;B&-;1L6(+=J%:QT7I% 0G]#P4[V73QUL]J(>8Z1\8*0PCR%=8:9'
M=Q-4LZQW[9MBTK8NOXKBGBM\D)PZDM5_NO6"9D]@2Z\U"W2R@4U7@G'(+B^/
M4P,T&RA=@=W*"=T]+=(L4-I$2"BS";DKH(K(PY-VUZ#DC4ZD$#MKRCUF?+E#
M6C9:7S 8K\"/*8<BOZ?:K0YEC7LD#D3/6]^*/GMY[5NH#5T30TUB@0I:*,',
MP\LP>J:%$3:F.)OIB\9)V2V%!FU0'[+Y45XDN\.&LD"IZL.0557V)Q]40S-7
MO5F@\VAR//-;&!MEWU9$N"$FP-4B7>!(R$$?N!$)2N#M!!_?OCJL^-Y;P.QK
M4TC6Q)OJ1_8Q#I60QCRO[6ZJ&ON 4$"/!7K4@F:!\H7+(HQS@_*V4+T3S*Q<
MZXDEQ[!,%JA(_ >,&_Z<D0)_1M-C3DZ=P#>YY1N4POE_7QR^G1AV/,F(TUM*
MH:T)TJ_S[8D<W^OWE*%U@IR,1U>8,[8BFZYT%,M]JP4=A_S0%Q(_@XV"VTZ/
M-<F6 \&F+>3ASXS<VE)OB]59K0>'[CST^Y-P/#SA$4X+,IVF;A&B3BI9.T F
M&C9F[[;9Z></WL_T_HL2^_E9@0/=1"F;2VJYMXTQ8S0@?=BH+P!Q% XV@IM0
MD X/'R%K#'(8J4W.V,/^W.W;NEOUESA>0%:/TB255W/)>5Z.UO<Q<%^,86;V
MY+"!OQ0(WAC@.WN_0UU[[-VV9"[7\U_8L1K8K ]Q_^[NNOSHO41P70 +U)XY
MWU>'RJS5EARB_F!'91%0+2#4GMT=J2-*Z#U:G.[?N$8P=)3L^#!3HY6BT0]3
MU/U^"H.%> J,C;/I3"VDK?E9>T-7NI=,S]CW?=/%-*UQWO2;CT+^^!<\!85W
M*.E.X[O 9-.71#(!5R= "&;4T.Z2BM5(M)OP13'F.D24H92ZKO;BP:@*2NUP
M6F@7"Z0VU5+\COZEH7I-0?EV1DP'CFRX$;^?V0D>R][HR"ZL"/P(7+D7I@:^
MO+DP\L:()R543D5BV]*,4,.^VZ@_^&_9X"[?URR0,.(Z$#2XT45(^K#@/CCA
MT!%V]L*W;"-GGI_'PN?SUP^DVW" LF=PTPD S: ;6K.X"AD7SKL[L1?F\R)H
M"36(,\)@*FH;%>)[>U]7*"J2/![G!7.?=2^X^+/[)8@SQ:NZL$(55AZQYWB>
M6+[\T_)B28R]'"XWQPBAB8CY"2:;;;QRX@>B:!>!Q?L4?K2GJJ^ 1[7G=:<R
M,[UO34L]^3C'ZK/GG&*>DB2.]R+:B*<QVVA U@=-@IXTDAD,L;\[7&]T><'>
M2S^UQX$F?Z2;EM\D0$T !F91@)Q(Y]^6PW3A*31_ .W5%XI(W-Q-Q46>"0T6
MJ-A8]T*NZU,!GL;R95^"_4Q7%AG*Y%XBH0^'V)T4SRH(L3.Y@ W;=>*LOGRJ
M5VW1>?D^0R':/(!<5U8AF!$_  G==OSU*FUEL'AG_@5];9W98L!NDFUJ"%$@
MU(&,C8-X;,3MV@7VQ^ZLV2V8>,,<TH6/Z@AY5QLFGB,D]#=S('DDK"1."&"9
M@^":Q78(<$']U2,LN3])2U7V]7;.VSGH2>#YVH[1='SN;Z-YX\("CC>\#RYQ
M<7T :$QN(DWZ%NT^7&%H!QE'*"XH@VN0*W[NN\4TR7D'4$<WC7\-.4#E$J)E
M VBZYJ?6VC0M.? ( J[J;B)-,N11+ZFDU:39H.TZ.MIGFA:4ESDX<9/\0_+]
MT\$:C3-C0J3'+J[.K6V3>,>;.:\>5PCU>@40^O;7!S<P%CQ*@1JYZL_5%8B5
M^\JFF=E#'_8MII4%B"'0-M'#L:7+FU[[T3G.APKW/U4]]PVAO+=04+(_5)6B
M\ERUV0E)@] M4:3@-MCAD"4)^\?XJW\JB\+O6LM5Q=X#WYAY217Z*V1EF6XD
MMQ&,-)>[UN#WE- S%:XG:*W_X?_%+(KC_/\\+*)"#C<"H177P)59( E-7T"$
M^<JSY7M#=NW_!J;G/-E8>L0&9"6>!?I[/BL?^5URB/D5LUFR_/\P5N+?-,D7
M_XO_T?UO\64SCZ6?A#*AW504>VG[*&;N440AO@W\>7>U@W)EF@5:\Z)@NA!*
M9#P5&MVDI[CB$4STK<]9.\A&6ZHZAG-N#B40%=2M?L&_2Z_-0_W[*<;$Y[F!
M+XXJ[GT M*%U+>> P?&9[G"M6[.-XYI]-WMO?\ZYEX>'ZH7&2L7R?DZT31-N
M?W>P-13_EMF#J\.Q.ZL7AM?K^N*K-54QU:OE VY^KN47C9ZJQ*V<_S/9-=H+
M>C8BVERV0%#H?>Z]F'@^PE).VE_):CCAF.[R$<Q/H@@[^768JLR?1*% J#BB
M-T^F7M1[3\<MVK<X4=I2L?%[9\>/[$O/ZG*3AY]R0RZ_[AGR]-*OW40@H+Y2
MCS&<I ;D"_:R '2ADSSE<.X,A&^9,(IY)I:77F+7&QBHU<F9)&W^JS.OE0/V
M%D+6"^-?-,,CKH2$*XH>/?R78*?W;DW)+OB"=E"!$G)*O*Z(! T'U[-W,(P/
M(0SDA'Z@JY)-FKQ#?3VT&V5:C[Y;Q:;8I"7EJR<?>R/ >5"'RLAE@D*<J1Z
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M2:/<+;9<$M_2FG[*K'HZX5_5>FUZ]>\3=F7 7KQ.@TFES#ST*!6+1]:)M)<
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MU5C3801J_I3[I\EXPR!/NX*1:*O13=GL^QR[I$TOFI:;W<=MK^'L1PHO/;-
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MY&8L[N>"4&=YD;:,SJHQ7H6&N!K_'E=KCOX&(E0T$=H\DO>AHB_A-G+AU^A
M]"]?X"Y)_$[=FQS]7<1]?UG7-1R2(1]2H0E2@T,3E&WR.Q,DSSIWCQ0 6Y9
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MF7A*M6<;.ZWPL\M-?G;9)ZFQ#(86;LF+V,(> _]FLOP32&AM3<)D:"[<(PP
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M@A/+RK'KQY$5^(0$.2BV:YZDZ6@-T@8;M&DAO[8T@94R)7"3LXUZT0!ZR&%
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M]$I)W?P(VZ8N_!7(;8._W[F%K9R#E?;W=<DOT$Z&;0%^SC3[[9K-Y1KM^;Y
M+><B[*;'N[Y=^]M KNE4L##SBYXZWF9BCD\U;\2%8BG/=97^_;II-C3[L*GY
M7:@@(IANQ!^[RO_;^OXG*6"!$^ H#'T<QS'O*)U&Q(7UFP2S8'B%X;R(/DB\
MUV3U],26C(:S@3;/[$>Z;>C!_MK^NFK9$^N*6)"@"\OYDT#=%!/?=;%K)WY$
MTCSU:?Q;*<(5L_LWGXNXG8L3?N2=GUMRBX(LMP*;_7[55]%S^]ILV6U$H*N0
M26/-4V70=-4UA3.P;.U298!.ZI.JCZ1X6OK'AG>7@+70/7S)X#6*H&.D#].P
M"+KV;8>#+[NO&A3L9-\S_-09?>Z2^49%R4BCHNY;YB'TUSPCMFR*5 3IGYRN
MK2#'Q$HR;+D>]0(G"3,W!O>S,\*JX7W./J%A1[=-9-C9?OG\CP7F37(U_BYF
MX\U7;<[_Q?&\:FXY9Q1EG:WES#"Z? LYHX /MHHS2U&Q4$G1I*N*MU.]R6?[
MV35C#>U&8_;#W,:Q9]G8SP.')G9B>014PU@S?X87@6WU>GZ</6E>><EVC4_M
M= *KH&B>(SG;_X;(PPS^GE$.NXSY;R;M?]>3PDS6@2%4==5QT<S=LA5?S$![
M4AO&$!G%K3U]X&.V^:_L.+KG;M@F\P*Q>8+CT+5PD&29$R:1E<1268T FJ;M
M;,L!VK$ W%=+@":Y0=8+!7"G>XP"ZIE"O?'-"O+JVG-*4%QV\R@/P<DN$/"J
MFCGX2(I:[ M%#D9S66:]0M2?*>&TLIORCO?3X=XK]H!H5]#]4R1S?2I*>KVF
M3R?IT#1)<939(?:=,,C]S":.!RH_I94[PR:&\[H]P+?LBBI-/8;1EF/$=A<[
MGO<M(+:_:#,<?^6,(\$Y,*!3[YS*V;4WFRF8!7R320(;32-@:C*O>GE;U! ;
M@?789)LAHF;<K\NTYIEV'VC[W^M27#@\5BLV1M-ZC.^J%2^4P;>8Q_L^WXEP
M9#DYMJ.4>+GKA';B0,PWD+[IB^6.&_3#EI\?1?67'DO_AK87%)PMU/$%-+]0
MU.4,K$$L82;4 (Q@ ZD(AB83"*6^J)%3A.;8C*D.H](W<>Y,/'8D[IO:K:.L
M?\>ZO5&]K8N4'N?XA': (R\-L&T[3A02-Z.!U*%V09Z7V+&^;&MG'<3:\#B/
M39/Q$,XVWD,RW&/)"9VVF]_I-"U^-;7?\?;]R:@5I@LLV4>;("'0]S?7D,Z9
MW]V<*S;B_,[F'MCM<]%9F&X>N@PK"_8B713;P]:FRY*&EP+A;%VFZPU9K5YO
M29']T@;W"J;:S<O=N@37 (&-:GC9/C0&'5>(LX5>FC^BMCMACS5T1]>;6K)D
MF *&T^NP6?A@RZDB<@9*?Z@AHE3S TAJL6(?:A#TJWPHCO!VCG)Q37SL)/>3
M&,<D#7F/!LM+<Y(2"HIXT,;9@@[R"<=J>YG^!B[O=G:6<W>#,5=W=9\!]YLX
MKP^@^8X<URU?_W1.ZP,X33BL#PDHEFQ</]*ZY8&-GPX73[)<#Q/+3[ ;.J$5
M^P&),U HPB 5PX9/T&QK,P(#N88QD3-19TL*,S>MD"T]D2Z:ZFX6/2F0K@J+
M@S26K:PX)>9)1<7)AU4+F;UG@]2\HGI&O_UO^GJLA$ELX<0*0QR[.4W2A&19
M(M5V;I2"807LBG=U1)&@BAA9:,VR8URF%5&+M# E! NJ4)YL1)@SZI(=C[AP
M0;(1@4XKD8T]"/=2W-**5UZ2=3]TCQO6DMNK&U%I2]Y1L!5CW@.@( 'LRY]E
M'G0\/V)7Z=R]'6.Q _41T_V3\O&?5&[IR(K'K_+;(7;N?BH:WDSE(Z6WE$U(
MN28/XF";$1([.'!)B,.,G6ECV_>Q[Z2\B)<7^)%4:I<D/=,AHV2USS*_$-=C
M+1,HIY1?C'5L0"Y+YC&4N=32B@SP0HJ#<I.WM_V\",@.%,: J/UA!!7(]8]6
M=!2O;LY&"7C9(BWS]$7)_# +7G)(RW1X02'_FF+\?)] V119UPB/G8]I\<)/
MRO<U*1M>L+0J.Y/HA[R"%#.)N45QDF<!SJV L&UT&&2PCB0@ZDL;R!X_O.*3
M8(A'4:[W+ '#[D%8RQV+C2&H8$BKGHGH@W?7 ^]> CQX5+X*"+KB\T&TEXW4
M5X'E)&9?:1"%I@?<:W?9W.2W=?W7^JK,;O*K?ZQ?+W^OL^;/=;G.KDOQE^;C
M*ONE69</C)NL^5"S'U[J#-J,40\UTR>8NJCJMJ47X[ ?_L TK0M);"L^M?4G
MV_9_E^4KZKVY?B1K_NH*K2OTF=(UNGQ^7O%R\4QC?^D:I'+IBH-HBO>\TCP;
MD(\!Z+:@9Q+G#V#+SQ_P_/:=3)WFCH]Z85?K^:"'A>6:0&B%[* KA-Z1X2;[
M9K-NUJ3D[91Y\\JKNA97V$]K62L\.H#I&XP]7;2O6\+(5R6M-LU1?-H3;^PE
M;P/'49DW:UH  5YT:,0"9$MF954R#^.C+J;QLX+UE7C^8;A>WM?995VSU:#U
M+T@JX^%;AC6P'_2Y)2FO8D<"SNN5NFPP96);X5:1(.*!M&98$B55.1IJ,?T8
M%J&O%"-/*'HXNIHD[!!SE'Y\7>95_21HO'OM_C@8TY2'&4Z<U,9V$*26Y?N9
M#[NF5^#!M+>C5ZGE-(^^Q]6%",KNGE *9E*9 $GGAUE8@2X0(XC"?2'JF.CR
MB"APL*Q?1!VB$^_(&4.IUEAF^S,1FKYIBI(V33=V<_FM.*E8D-B\973NXS3R
M/<OQ C?*0:U@)ZF9-E$=*?0K)P8U.I,P29H77<(##8FDW IE<B7DT581=XK6
MPL5O)<0^K7,K\Y*:"K]?D88=V_]"^"YQ?5.+SK$'&2.[/S;=7QO[^.XEH#Z.
M[3S#-+%BAU(>M02Z>U'BPK#*"Y[X OI[2YC!BFI.^6)?*?V9L]9[IMD]U"CG
M>9XW,W+6Q#C>,"NS@_HO>ZCO6J@/,^AZSS2[A\8#/\%6Z2Q<-%DK-1X6M6)G
MP71LW<X;3%?UCMN:/I,B^T!S6M<TN_K&'4WTLLQZ8:#'13Q<)V [&BO'.8D\
MZC@Y28-$H3>!&C=2ZGAV?X*.$V;R! MM39]*.>I:$7@YJV801YWE/+:0=MP(
M1/LAWB9K>4  ,5;20XJ)-Z[L 0%JOL ':#2XDU7<WEU]J],VHU_2R7KXEN'=
ME$H5A '1YMVKZE+!E+LM3ZL[P7]< B6WZM%0B[E5AT7HNU5'GE!-J_A8K&C]
MGJUQ#U7]>KQ.,T1P[,8I]K/83]S$24B<PI(J#L8WK2IMIH$@B;8TH?D4AX!,
MJXT&,6&Z Y-0(9%B4(XSTB@.QULXB6)0F-,4BN''SO(*B$BKDS[N0J?2S&.'
M_XQB0GW?=MW 22-0 ;M3$DN=YP5)Q8;N \" 3MR*XBH>IR4E53TF#PBC]PS<
M)_ 6!]P! 4=.KT-/PM>R3PSYU>UC5=(OFY/^[4SI/#O <>#;V,L=.TV2.+,B
M3W8A.Q[<L+H)<DC00RU!^27L!(?Y]>L<Z6#:!1 ,M'*-2:"T;)T,MMB:-29&
M?\$:?4;AZ).U$8=DY5G.RU#Q>-G3T-Q IJ-0=O018^"'EQ][!>0!QZ59."1.
M4#J1 !ZJ)D P4"I(6E*UP]?LZ,N=QV0%/3BB2;^DD/-XV/3^?56*WGI=9^'F
M\J&FXL;K WVNFF+]L:IOV3I[_UA7FX='WD*XZ<*SCRZ9'=O'Q'%XX[O(2VP2
M)XX72B=&:F+*L*5HN41;-M&63[1E%.TX11VKO$XPXLRBCEO18US2=ZMUOJ;-
MSUO- LQ*Z9N ^9!X<S,!2/Q\@QE1RPY=0#5@Z:.:D9O,,=5%:[E$5,WH'&2K
MZA[[_)9^_>CU.[KB%W*"T$E5SV:TA1_Q0AREH8=3S\["R(L=ZDN5A]'$C^DH
M*WZ*'JC+J]ZB3P5S.8?.@DC"5J?!HL6]&' SS:@TP6&@=YX*-V_6*^\,Z*9Z
MXYTSK)KAZRK>;5NE']FQS'%PY"0!=H,TS$-FR9( 5)CS<'C31W.%0(<C^>5L
MBKI4P&-VVY[)1*OX81$TJ?71X(MJZ;!@QTHW\I2:#HE:D$)9;TF]?ATX\:8\
MK-K%L>VZV$E2+Z&!G6>P1G"#5 QKU)XF$D1ANC6,BYR*G2TM3-..!=68 RTE
MD2;%&Z:QJ/Y-BGFLAM,/P[W,/Y=9O7I]^,HKLQ9LO+^O1=C"^\?RX3:53C&>
M'L6PRC'BE%'G^3];!M!G4O^=KKO0VO>/?(LH[VJ>P63>SZP/#IA.2B*Q*R:E
MQ]<L)ZV2HWEFZ,6\S'(B]EW,DF]H3&W81S/T$Q@L2G#BAPFF>4IRXG@1L>RS
M$QB6#6LXCIT_+\)A$#6Y)583%C"E/@,&/5D")N,@!BF]?<2_5&3$Y"MGE#,7
M)>C6H]F&ENWA),@I)H'OVF[D9$D,VA8/$3&LRFT0>(^F4K;A(#IRFGNNS#"5
M!8NK5M9\1!Z=5<V/22Q?U'Q$R,&:YF//FKO%O:/YILQXPG'G;A^^O"5!@(F5
ML479BY.,N':8R(4W:>#E^[FSY2U%MBQN+ZGT7P^.3<FTH5@8:)@].1-C@W>Q
M8V#KOX+5 +KQFU?0!V[DNG4&)1VWK&,DOKO+U1DL5.Y4YX8\LTO8_F)CY*(T
MQ:'CI9@0-\6QF]FYSQ84:EE*G;^&J!E>+'H5&KLF06*Q5FS;-0B7W'Y0&P@P
M0]Z3OT?8T,6EE(RZ^V0-TGJ;WE=38H_VLYI\2;66S'$/]+'+0S]+,(EXHYS0
MCO(D]2S/ >GV.*DEXALZPO^&J"#])V@MF5&8Y'1:C_ PA6[I7*#+];HNDLU:
MK/SKBE^)B(@$ _>0\V)J*RXS2FCARC)S I^6E9E] WY3(HJ[?EB+>K#'-6 O
M2U[[-;LN5:ID@P<VK,O;FL<?>(E2F9K*/,V?O]265U:K:0U'=_X:QBBP,#NA
M$5/-Q::505*ZT(%36^R.1QF(_K6/^B"J^>&76<:^NZ;[SZ>BI/:)]RFQ,+$M
MWO^2A@X-XB"TI3):)ZD8MD)=)G5'\6+[ ^*TT4TI>9T[C=.T"=$F/7!+H2JX
M0C;YA&!GY)0/C;IP9OF$8*?YY5,/ZU-+YU@M(X_BV'(S[$5I%"6N'=A^<*Y:
M.F^IEO>_5^>KI7.&6H*DUZB64X)K44O'B%HZ;Z^6#D0M'46UW)X+[FC#-E#I
M(UN)/] 7NJJ>N?NIJUETXFA+ QP[F8O=(+ 2+XEREX R$B:I&5;3+6VQC\SV
MU&%'<A!>-$]QE%$+IU[B)'$>$S>W?EM7:[):&J\=36F\[ODKJ%X -3E?AC8L
M8$;NX+/I$=Y6=-/GQ9 24),C8YK6HKX,*;&/W1ER+REF,Z3IYFDC DJW5^C/
M-7UD(Q<O]+I,JR<Z?*5M!1Y.:)I@*\T"GT;4\6VI*VTP9<.FLL<'V@5N[#E!
M+2OHAT]5TP +W<J#*V<5C$ &LQ"7-^^O1[V=VB/ P0+K2L>0IKMLI@84CI,D
M#O  "J$SMS7]N"DSFFUKV^X-2#\R-0P)3L+<858D(EZ0VF&6R!<T&"%BV%8P
MJK@ENRO6#(BI& -F6OEUB0O3\P%)5<)(QD0&Q(=H$%TM\ ,RV;!@CAF1)J,T
MQMY=+OQBAON#N(JY9Q7#9)]%>]3RX1,O0ONI($FQ8@?&+XSY3<V7HN.S2>P&
MF-AQC/W ]:,DL+PL VU69BD:-CP[^F@EZBZOMAR@?_V7R+'M?T<E7?/;A(X=
M)/JC0//+YW&5VZ=H10MFM_9 "=H7:$?] NWI:PS$E1555U3N++UE0W1EQ3^)
MUY5^46$',AB@SX.#JU)<#<_4X/]0Y#EE/*3"QY'E'LEQZJ<^#B,GP;'+-BX^
ML5TO]:/(LZ1\0GK9,FQL]H3XW6/%_\$5JFT)PK\!E JFVR;NRNU -$^5Q"[J
M328 9K\F&H:TC&Z;O\NT#[E >Y;?9$X V[PWF1NUC>'R<P3;7FJ'<G)#JH_:
M<EM8[0@=;'KUCZ[8.$$$D_"0DUUX(ZB#PNGKAA>>7F ,$0HF.!!!,\"^"@.2
M3Z\/FH0&.M-$IX6]D+W(((T-%\8E4N^\,##FLBT8QH4ZZ<4P\:CJ[?X=?2AX
M0&&Y_D*>3F["/-_!Q'=R[,9Y%D1N1+T8&&]S2&"9._T]3<2)0F_RCS"95C<=
MDL)T#2BDPJW]L"1G7-@?#;CP7?VP.*?7]"//P9>LK^N_W];I37W?U%?-NFB[
MNGZFZ\<J ]>\EAG+L%:U+0JZG5^-[K_>H3TKJ.5%?E63 F=^B=.-"TP'92 Q
M4 P;(K32DBA%8+'U$2)N?[$$O:>8"K.KRM>OV]>KX?CN]:1PGUC#=TOW9=-L
MGI[Y6\U?*-\NT^SRA=;D@?Y2K=AHW(ETQ];ZX^OJ. TPR6F$(Q):6>S&CFLE
MH-2:Q5@W;)?VQ(#Y.<O-G9R7^?N<$:!%[)4T[4MQ4->4-[(?*GW*9;GH9Q/T
MY+E 6XE0)Q+:RX3NIDY4\(RDQ2="5X;3<HPOFS&U^(2<9& MS\'"*])-RUN;
MHW-9BLZ7*>]$6_%?=2X>'B ST/"(!W\[-HXB/\$D\ZR,V):?A/$BZQ&0<=.[
M9,YCLW.5BH@B'GQ(.ZYX>-$+XTO<,HC;!6@0UF(S;'C5,CAOBZ]9-]M%JDMQ
MXS-^U9MQ_NN#;^)"6T.JMYJ'MUZRH&S_<RQ8BI.A;;E2I:^:O["O_'K/>&M(
MRLE_*DIZO:9/)Z7BLMS"B17GV&6_#UR/NKDEU1Y6EJ#AQ>'NH,!PCP'T*V<!
M"1Z 1>1F,90SXSJ1@9G?,T%1B-27DU1;L/X,N87C]>6$/PW9EWP/?@/QH;NS
M_C\;-C@O]WM'>;#7L>Z[88+C/'*QDP;$\W(K#A(IA\<$#=-Q)QU5M".+6KKR
M5Q%CX,S?1F@0&:;'<&E!=Q(S\BA=2XR-N=C-Q(Q0_<N)N4<5NQ[19-W5="YH
M<_E"BA5?W3]6]5>RHKQN6%%NJDWS<UE3LBK^FV8\;>26EPKCZD]Y(R92VLYG
M]N1C<])Z.DAPXMH^]G/;"I,D<%P+="C4RYYA=>?DT)K10[:#6HH7,C?@2TR,
MW";@[> &FAK&)]HS>H%VK.*\JC%G]@+MV45[?A%G&&TYOD #<Z:QTY(1.'4U
M7M++W+)]F(P >]*6R0R5<[HT#91U:T-Z:>YABV<OAG:2XLA/8^PX;IA2.W 3
M.X:D+8]2 IE/Q91EE=9-0Z#(V3LMHL),5TORX)9#HGNT8G.G"<FT]GD:HO,&
M+9\FQ!WN_C3U CS>HVU&DMU26O^YKC;/'TMPF,?$$(8W+QUEQ$DC09M]HU6U
M+BM(K.(4!-,JJ5%ZF$)."6X@=D-"1J60C:EQ%XO4D!"N'Z A\SA,#1MV-&;G
M(C;5CZ2ANS+'[ZM-R73BF7LO>%#7OK7,0<&/F#>BB!/LAXGGAAD-+%^JM0R(
MJFD][A$5$8' YC(P!*=UVA@N0 V'0R*MTDHB3JV];,#>NLO^M5=S&*U%E%Y)
M_*T)4'M9L4&CN*ZXR7=I>E_I@RC5W67Q!Q1;F6WA,'5MG)"$&8&4V)[K4)\$
M4K'.LY0,*WY+ER<95+N4T:8C#6S:.(J5W*Y:"P(P%=\+O\^7_3HG/+Q_XYQ@
MNGHXCM)9MH_CG+@GO1QG7U"NZ5-3<8'YQ+/ _UM<9M[D?-/.;45S66:W-7TJ
M-D_-=<F#*W::W;] R(,8$^+Y[)P<14F4V6D41+^5](%?;-R#ZOPH<"/U[<?M
MMW_"D[P>T#4B/;:X1CQWS+1%P+9<(O;')]%*482H-#L_![@BD,K42![/S2&M
M=G;?\H-^Z'/T(T=YQY2 ><O6!>HQIK6,T!G Z*LII,+$T@6&S@!JH-K0.:,I
M)#UF?[NO;FG%@S@4O DCKQO>B#"JFU9T=%^AVZN;@Z J%:_"& SS'@4-" !-
MA*3P!CP+,[*JY4:.C+E<;N2T4 >YD3./GA%/F\Q'4B4CD50WFW6S9DL"VPT=
MA?W>47ZN8;_?=F?:D!5;\I].ZBK'U,-)Z 4X#;(TSRS7HK$+#JU=5@;#-N8D
M%V!;-6C'$.IQA#X5.44_O%)2-S]>H)XX"I&W"W\+<CNE[WR&83949SQN3["!
M#)+AKX6+ISDN]VVF1F>([L(2+!^M^S93-!BX^T:L:(WA;=Z]]O]RU/C9"]FZ
M%E@V3F+'QB'UB6>[U*<NJ/&S/&G#R]$VA)4?_;Y49=V+:"VH6F]H *QR2X09
ML&"6_3R<=$7Z3HAL-N9WB/#W$/T[ 8AD'/#4"/!C[WV=,8MW76;WQ7HE7>+G
M\"W#&B]HR)]@CR2:/[BJ"P/32#:'?*WH;ZVXSRHK7HI,[(4FY02=3X=%4CJ6
M'@VUV&ET6(3^(73D";@.["[%15B46//;!H!WZ_+R:2VK%#/#&-:2?4P%:AM2
M]!A@F^_UIF:;^B?N.Y-7I3E@YG5+(R8P9=, !TCC) 554L&YL1?324DA^THJ
M^XI"I5;)OMM=M^V&QY)V?QON2N'0 ,=!GF';LH(D2@(WR*561"W<&#8/@$[T
MV^[S#6),[OX.J %Z]L1,VY7%X899GK.15JF5?S;D@&JK2T*O5F35W,<.*Z:J
M"ZG)&JIG$UFN=*HN/ XJIFH;5&$)VI9?O:U61?K:_N_^SJP+=XIQ[F<N#FF0
MX8CDO'%C%!+?#=*$2O5LG"=E^@H WJ]D&AD) Z]-7ICUWI*]0"U)]&OW7YD[
M1"@, *.K#0XUBWH,BR8#*275I/6;'F$YTR8ER8'=DGL#?IJ]HPV;W-;FL?\*
MMZ7D"7;@5>/>W!U%MA*S 9Z*LKV X@S\2?ZH.B3U_/'T3(&A'MDI6;5Y9&?D
M4CJ!#HVWV*ES0IC^27/J,;@6?:G*6UI]H56W/Y;4H*/7#&L/HX9YW,N7JQMY
M33F6;%Y+SA *IB$]>30V!)P004D9CL=:3!%&A.@KP=@C;U/@KG=#>LVVY479
M%&E;4/^XQU9J89)[*0ZRV+==+TCCF"Q9T6Z44],!? _L?,(CD-&.;)NI>F[H
MC)%9FS85W]5<P R/L3"8HUG]?DK0S8+\G=2<&^?SGZK(W"S<NJO*S1-47!(V
M25-D!:E?>6&&FUR493^*.&GKT9 ,DS")L.MF04#CU/8=J1:MLY0,FV1.C6<9
MM 7G5>))QC&2-* Z) <:0(C0<&,U)Y N8S-*9UEC,2?NB;+/OJ"8S'541^6H
MRLJ^H?.?ZZKIU5;Y,RG*=S2O:GI/OAU?DR59A.,\H#@,T]"+,R=T0Y!B:^'*
ML!'H53'B9*&96EIPES,6BZ,),RQ2Y:-Z7"+!)CK"_P(E@E7$>-68VJ43.EV9
M7EIX6C;Q2R>,)WE@6@<_(SY.-*:"AL<MT(!+OMW6J3CSKA]E26!68BXT3D^[
MK5&!S@N,6Z[!UJ@ @V%Q9[34DCZ%-&/'$/$_]XPJ3]1D<SU2"H;GBML!)C[Q
M<!Y;B65[$8D\4*%I$TR:=ONL5JW? ''JP-V%D4G1Y-HQ##7,JNP1UEB%9@DH
MEO*]J+#X?;E=S@ 9['$YAQ9\XW'UC_7KY>]UUEQF?VM@EU #KQJV9U?_V/#6
M4 *(!NT3LR4MVYB\\_N3,T6%V9-1*35?5DT(I;13&1IOL?W*A##]7<O48PH1
M_653OBOS-1]-H9C#R.N&E>B6V1Q^Y_".EC3G$8F]+TREE,,8"/-:I4%^F&;)
MB6Z@D,.,I&KA^B-C+A>F/RW407C^S*-PU>M=/-S1M'JA]2M?3P%Y-.,C&%;
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MY00_5FW)MQ3]C?OXG/OJ_Z_N6WL;QY5$O^^O(+ 7>V> <*]DO7>!!3+I[MD
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M87=-RO(N;<;1W17?LL>G[=>=6/DN/7BM;LAZS>@O;^W8NN;!LIERZ04XIF[
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MIW7K;L!U*?-B'*>V)\:F6EX<^&D"\X;WP#!L=NXAHK)JP?*_K'^U+,M&+Z1
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MDDVYY0)_^W"%-A4>[7S!NFFPP C@/)CBH(3G1"-?8!J@!5PSHP9>31:M&SS
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MG;D>9BVFIJ8^DD),!R[O65&Y-3YDZQU?_\R%G%HXI [%-F.KD&LA-TA BF@
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M"]-TE:S\V(O=,(#430Q" AUX\RK_LPHNS"B7YE!H4QP[88J3,/8L:Q6FW*Z
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M[]F86(F/^=\<1F+?H:XGGY<\#7 AC?#<10&H!:1Y-ZX$3' $>.ULF'$$?3_
M85H+J'$%D@FMESN*R=$SN01,G)8G>3R76F*=!=.KY:DZSK@&O#=C0FU_N=M
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M7&W&12E0;0RCI(,LY"JC9\,D;BJ+;P-,][4[<"WF'A[OP!Y#5*'827GYWMD
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M-NZEXS]TGJQCK%P2"T9*]H'5__+?USM:95W5';R^<>'\F*;L/*?1(AX.+2?
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M<)$+KUUO;Y<_57T@LH!HJX!(ON"?O;8+N)[.[C;)5XHBY[1#T3&>#2'#V!1
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MK))4J!.(2\]9U%R&6+IC4O?@>6]5L;5&S_>JI6/,\^TDG"EVKH)%3@!'S)C
M009@Q0>^GQ@[[Z_RM:[@^5X5% 72&0M9+M^]OOC\YW<?+O_6PSR_]8?W7K32
MR$GY4I77=O[UW7CZ>V.;9J=D@@JGB"J((5@98W_9]SOHZ;<P15";AZPPA T#
MKK%2,OS,<_R*:?ZX>I2]8J[ -SI]EA@/&#DC=6)/&2T]<]27KFSZ.8;Y[<=
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MET_1_TG8<1;,2?CCZ?QV!LVR\\@:01#V(5!+/,:^-,:ZTCQL"^@>MM*S*7!
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M%*^RW4?/T/=W93#16(+650-U&H[U+*OK&:Q2>]:&2I^:X=GBL27<KV.I+V2
MUJ=NKQ72[-[-7$Y)\4CCF+ZR1NJ(E1>V=$CJ$$TEQ[FO/[_%N@"OD54>(Z&9
M,0*84KIT\M(1Y UKJ(IB9]\X^))*>D'&JYBYZLU U1<RUPE>+E)(7WECM2!2
M\=)>TE A\Q:A5C 668,!6<8H /6*%._3MY^B%QP2WXN=/2'QKGJITR2]@3B:
MP%*&LY&[S0_+C:A/,4I-CRI2!]B"RG*&Z?% ONP\LQBM,L@/0XN+@(PT'M%
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M,T!E:Y9P+WJK#)$-0X1R2Z;DF2 6 OC@L(VN="O0;2J&GA#<C[[WP.H$X5<
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MS!26'ML80_&QO_OH:04A_8(A=*KL*\#1^MWB0X?CM67Q?K)VU[B5>)?8<L
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MJ^EJSTW_&(YH0;7_'Y-BWQQ0=,+ GPLPZ 6NH2LK?[[N%:IX(2_,YEVH](P
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M(^PF6#B97X;7C-CVBT LL%CFB F"UPP#-80KFF.SGFN7>8PTQ:W$<60>I:7
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MD"3G%"M>'+,L4[CQ7WGZ6!X!$5$$>!-'&4,-HPF4X(KHHUQR!"$RI "7Y$'
M/+RJ;15^/>6B #0A1XBC"6DNLIP@49+##<%7:2P%CY$0GZ>J8M]TKYV4K*IU
M9D0L2$(S8WH5T0)&GE06):LFV@DB[_8&3U)82GP?FX41T4"Z[6V4A-8<PZ 3
MZ1IV+_V9%?A^R=EF#?<EUQVLI,*V3:>K8D<!UQ(/\@CU[B'GD=+:4G^"?LN9
MH*IU:F5<L[Q)M@ EO;S1W?2WEIQ>JW:IV(I8N]_NE/*(]19 >OL#I>TW0['S
MVBAF"=:>F&B:L-Y)PM1^9V79J/DG3!6\5-!,4=U49A)%@,,0#(E0"%F*5&=-
M/2I@"4D\=1\G])F>6M4G],JC4BD<"YU>\W9%,7^(Z;VA)(N(UFE<<($ER\!L
M1B3-J%M_&?@L2R-2N"S1F=&#!C$1YW@V6W I>>QB0@87JHQY)*HZCU9+:;X^
MM9E6>7*3"$?Z]<J5V=2FEO3OVIR.V>W8#YHM\VDVV^QN.T\<^3!8Q&KUGGW6
M[:[9Z_4?-6U+I[=,,;*8H31V&^W&K9WM.ND5V/6^+DE3"K]-9,GA2^YUK9$#
MW!ZZ06$G+\"N^OA2Q%4._B,\2P77>)3KZ\[$?K':J-<]G@\;G9U!IC]A'&%U
MI$CQ]SSVB5B)\9$R_@&>G]>U*IB2IR[Z0L8CYH-*W& ]>+B5^R:<A.:!N584
MK$FB0T8#/*[AT4VR"PK3\O? >Z:?/=.;)X+AX2G%T].==&_=E^\:6CV+/MF]
M=@Y67-^;_9M2\%MN]D<7)(%/!4W7JO*M>YM?SZRO1V[+SGZX_,G^WME?H+-?
MIUL]%QEY'L\3J5Y=_2\:_1L)I*4?(]WSW/'FV[Z49_H!F"MH1-19[L'W?]5S
M*.MZ"%E@I<[EW2$//A);^2S?7K;T6]-_ 5!+ 0(4 Q0    ( '. JUS9^"U%
MQHD" +):&@ 1              "  0    !B8V%X+3(P,C8P,S,Q+FAT;5!+
M 0(4 Q0    ( '2 JUP,"B6UQPT  &F*   1              "  ?6) @!B
M8V%X+3(P,C8P,S,Q+GAS9%!+ 0(4 Q0    ( '2 JUPE,MO,]!$  %O!   5
M              "  >N7 @!B8V%X+3(P,C8P,S,Q7V-A;"YX;6Q02P$"% ,4
M    " !T@*M<-+J\PH<]   =*@, %0              @ $2J@( 8F-A>"TR
M,#(V,#,S,5]D968N>&UL4$L! A0#%     @ =("K7(B;/FU@^@D ;5P, !0
M             ( !S.<" &)C87@M,C R-C S,S%?9S$N:G!G4$L! A0#%
M  @ =("K7&FY^I1=LP  \\\' !4              ( !7N(, &)C87@M,C R
M-C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( '2 JUQJ/0C2$F$  '9N!0 5
M          "  >Z5#0!B8V%X+3(P,C8P,S,Q7W!R92YX;6Q02P$"% ,4
M" !T@*M<O.Q2Q.\'  !U*   $P              @ $S]PT 97AH:6)I=#,Q
M,7$Q+3(V+FAT;5!+ 0(4 Q0    ( '2 JUS1\5<[X0<  "LH   3
M      "  5/_#0!E>&AI8FET,S$R<3$M,C8N:'1M4$L! A0#%     @ =("K
M7// ,C;2!   /!T  !,              ( !90<. &5X:&EB:70S,C%Q,2TR
;-BYH=&U02P4&      H "@"/ @  : P.

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>bcax-20260331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcax="http://www.bicara.com/20260331"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bcax-20260331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2026-05-05</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-16</startDate>
            <endDate>2024-09-16</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-16</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2024-09-16</startDate>
            <endDate>2024-09-16</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:February2026OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:February2026OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-28</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcax:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:February2026OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-28</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcax:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-28</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:February2026OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bcax:InvestmentCategorizationAxisAxis">bcax:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2023-08-16</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2025-06-02</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2025-06-02</startDate>
            <endDate>2025-06-02</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2025-06-03</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <startDate>2025-06-03</startDate>
            <endDate>2025-06-03</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
        </entity>
        <period>
            <instant>2025-10-03</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-03</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-03</startDate>
            <endDate>2025-10-03</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcax:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcax:IncentiveStockOptionsAndNonQualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2024StockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcax:A2026InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:BBLAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bcax:SyngeneAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementRefundableDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalServicesAgreementInvestigatorGrantPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementAdditionalRefundableDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-18</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalServicesAgreementInvestigatorGrantPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-18</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementDepositsForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-18</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementDepositForPassThroughCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-18</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementIncrementalReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-18</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcax:IQVIARDSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcax:MasterClinicalContractServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcax:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcax:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:ClaireMazumdanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:ClaireMazumdanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:RyanCohlheppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:RyanCohlheppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:IvanHyepMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:IvanHyepMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:LaraMeisnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:LaraMeisnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:DavidRabenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcax:DavidRabenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>bcax:segment</measure>
    </unit>
    <unit id="debtsecurity">
        <measure>bcax:debtSecurity</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0002023658</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-30">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
    <ecd:TrdArrDuration contextRef="c-131" id="f-552">P275D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-133" id="f-553">P335D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-135" id="f-554">P464D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-137" id="f-555">P459D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-139" id="f-556">P457D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-42271</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">BICARA THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">83-2903745</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">116 Huntington Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 703</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">468-4219</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">BCAX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-24">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-25">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-26" unitRef="shares">65703866</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">323462000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">96685000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">5162000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">7252000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">216291000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">318116000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">544915000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">422053000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">346000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">330000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">1428000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">1701000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">6910000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">6910000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">553599000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">430994000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-48" unitRef="usd">6188000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-49" unitRef="usd">5515000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-50" unitRef="usd">1252000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-3" id="f-51" unitRef="usd">2278000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-52" unitRef="usd">29948000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-53" unitRef="usd">18898000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-54" unitRef="usd">812000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-55" unitRef="usd">1141000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">1140000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">1117000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">39340000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">28949000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">301000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">593000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">39641000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">29542000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-64" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-65" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-66"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-67"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-68" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-69" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-70" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-71" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-72" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-73" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-76"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-77"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-78" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-79" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-80" unitRef="shares">65547037</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-81" unitRef="shares">65547037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-82" unitRef="shares">56600724</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-83" unitRef="shares">56600724</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-84" unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-86" unitRef="usd">929370000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">760168000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-88" unitRef="usd">-243000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">243000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">-415177000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">-358966000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">513958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">401452000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">553599000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">430994000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-9" decimals="-3" id="f-96" unitRef="usd">1982000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-10" decimals="-3" id="f-97" unitRef="usd">6575000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-11" decimals="-3" id="f-98" unitRef="usd">45518000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-12" decimals="-3" id="f-99" unitRef="usd">27758000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">12742000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-101" unitRef="usd">7455000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">60242000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-13" decimals="-3" id="f-103" unitRef="usd">41788000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">-60242000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-105" unitRef="usd">-41788000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">4083000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-13" decimals="-3" id="f-107" unitRef="usd">5014000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">4083000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-109" unitRef="usd">5014000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">-56159000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-111" unitRef="usd">-36774000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">52000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-113" unitRef="usd">72000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">-56211000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-115" unitRef="usd">-36846000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-116"
      unitRef="usdPerShare">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-117"
      unitRef="usdPerShare">-0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-118"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-119"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-120" unitRef="shares">60717041</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-121" unitRef="shares">60717041</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="0" id="f-122" unitRef="shares">54456515</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="0" id="f-123" unitRef="shares">54456515</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">-486000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-125" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">-486000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-127" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">-56697000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-129" unitRef="usd">-36846000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-130"
      unitRef="shares">54440013</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-131" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-132" unitRef="usd">712884000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-133" unitRef="usd">-221016000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-134" unitRef="usd">491875000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-18"
      decimals="INF"
      id="f-135"
      unitRef="shares">88962</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-19" decimals="-3" id="f-136" unitRef="usd">477000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-3" id="f-137" unitRef="usd">477000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-3" id="f-138" unitRef="usd">3451000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-139" unitRef="usd">3451000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-3" id="f-140" unitRef="usd">-36846000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-141" unitRef="usd">-36846000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-142"
      unitRef="shares">54528975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-143" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-144" unitRef="usd">716812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-145" unitRef="usd">-257862000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-146" unitRef="usd">458957000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-25"
      decimals="INF"
      id="f-147"
      unitRef="shares">56600724</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-148" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-149" unitRef="usd">760168000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-150" unitRef="usd">243000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-151" unitRef="usd">-358966000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-152" unitRef="usd">401452000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-29"
      decimals="INF"
      id="f-153"
      unitRef="shares">8581250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-29" decimals="-3" id="f-154" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-30" decimals="-3" id="f-155" unitRef="usd">161762000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">161763000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-29"
      decimals="INF"
      id="f-157"
      unitRef="shares">365063</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-30" decimals="-3" id="f-158" unitRef="usd">1582000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-159" unitRef="usd">1582000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-160" unitRef="usd">5858000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">5858000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-31" decimals="-3" id="f-162" unitRef="usd">-486000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">-486000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-32" decimals="-3" id="f-164" unitRef="usd">-56211000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">-56211000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-33"
      decimals="INF"
      id="f-166"
      unitRef="shares">65547037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-167" unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-168" unitRef="usd">929370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-169" unitRef="usd">-243000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-170" unitRef="usd">-415177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-171" unitRef="usd">513958000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">-56211000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-173" unitRef="usd">-36846000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">5858000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-3" id="f-175" unitRef="usd">3451000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">44000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-3" id="f-177" unitRef="usd">19000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">273000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-13" decimals="-3" id="f-179" unitRef="usd">138000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">-338000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-13" decimals="-3" id="f-181" unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">-2089000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-13" decimals="-3" id="f-183" unitRef="usd">-4116000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-11" decimals="-3" id="f-184" unitRef="usd">11725000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-12" decimals="-3" id="f-185" unitRef="usd">-2116000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-9" decimals="-3" id="f-186" unitRef="usd">-1354000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-10" decimals="-3" id="f-187" unitRef="usd">3279000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">-270000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-13" decimals="-3" id="f-189" unitRef="usd">-147000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">-37508000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-3" id="f-191" unitRef="usd">-28106000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">101000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-13" decimals="-3" id="f-193" unitRef="usd">0</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">60000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-3" id="f-195" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">100940000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-3" id="f-197" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">161763000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-13" decimals="-3" id="f-199" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">1582000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-13" decimals="-3" id="f-201" unitRef="usd">460000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">163345000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-3" id="f-203" unitRef="usd">460000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">226777000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-3" id="f-205" unitRef="usd">-27646000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-206" unitRef="usd">96685000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="-3" id="f-207" unitRef="usd">489711000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-208" unitRef="usd">323462000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-24" decimals="-3" id="f-209" unitRef="usd">462065000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-13" decimals="-3" id="f-211" unitRef="usd">72000</us-gaap:IncomeTaxesPaid>
    <bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">190000</bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c-13" decimals="-3" id="f-213" unitRef="usd">0</bcax:OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <bcax:VestingOfEarlyExerciseStockOptions contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">0</bcax:VestingOfEarlyExerciseStockOptions>
    <bcax:VestingOfEarlyExerciseStockOptions contextRef="c-13" decimals="-3" id="f-215" unitRef="usd">17000</bcax:VestingOfEarlyExerciseStockOptions>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-216">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"&gt;Description of Business, Organization, and Liquidity&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Bicara Therapeutics Inc. (&#x201c;Bicara&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in December 2018 and is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The Company is committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program ficerafusp alfa is a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to a human transforming growth factor beta ligand trap.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has operated in the preclinical and clinical stages and has devoted substantially all of its time and efforts to performing research and development activities, raising capital, and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, risks associated with the successful research, development and manufacturing of product candidates, competition from other companies, dependence on key personnel, protection of intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if our product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company historically has funded its operations from the issuance of common stock in connection with its initial public offering (&#x201c;IPO&#x201d;), issuance of common stock in connection with its at-the-market offering program (the &#x201c;ATM Program&#x201d;), issuance of equity securities in a public offering in February 2026, redeemable convertible preferred stock and through debt financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 16, 2024, the Company closed its IPO, through which it issued 20,125,000 shares of common stock with par value of $0.0001 per share and a purchase price of $18.00 per share. The Company raised net proceeds of $332.4&#160;million from the issuance of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2025, the Company issued 1,604,000 shares of common stock with par value of $0.0001 per share through the ATM Program and raised net proceeds of $29.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In February 2026, the Company issued and sold 8,581,250 shares of its common stock, including 1,406,250 shares pursuant to the exercise of the underwriters&#x2019; option to purchase additional shares, at a price to the public of $16.00 per share. Further, in lieu of common stock to certain investors, the Company sold pre-funded warrants to purchase 2,200,000 shares of common stock at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. As a result of the offering, the Company received approximately $161.8&#160;million in net proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. As of March&#160;31, 2026, the Company had cash, cash equivalents and marketable securities of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$539.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and an accumulated &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deficit &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$415.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects that its cash, cash equivalents and marketable securities as of March&#160;31, 2026 of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$539.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-37"
      decimals="INF"
      id="f-217"
      unitRef="shares">20125000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-38"
      decimals="INF"
      id="f-218"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-38"
      decimals="2"
      id="f-219"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-39" decimals="-5" id="f-220" unitRef="usd">332400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-40"
      decimals="INF"
      id="f-221"
      unitRef="shares">1604000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-41"
      decimals="INF"
      id="f-222"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-40" decimals="-3" id="f-223" unitRef="usd">29500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-42"
      decimals="INF"
      id="f-224"
      unitRef="shares">8581250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-43"
      decimals="INF"
      id="f-225"
      unitRef="shares">1406250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-44"
      decimals="2"
      id="f-226"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-45"
      decimals="INF"
      id="f-227"
      unitRef="shares">2200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-45"
      decimals="INF"
      id="f-228"
      unitRef="usdPerShare">15.9999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-46"
      decimals="INF"
      id="f-229"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-47" decimals="-5" id="f-230" unitRef="usd">161800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:InvestmentsAndCash contextRef="c-3" decimals="-5" id="f-231" unitRef="usd">539800000</us-gaap:InvestmentsAndCash>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-232" unitRef="usd">-415200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:InvestmentsAndCash contextRef="c-3" decimals="-5" id="f-233" unitRef="usd">539800000</us-gaap:InvestmentsAndCash>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-234">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements include the financial position, results of operations and cash flows of Bicara. The Company&#x2019;s unaudited condensed consolidated financial statements are denominated in U.S. dollars. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiary. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet as of March&#160;31, 2026, condensed consolidated statements of comprehensive loss, condensed consolidated statement of stockholders' equity for the three months ended March 31, 2026 and 2025, and condensed consolidated cash flows for the three months ended March&#160;31, 2026 and 2025 and related notes to condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#x2019;s condensed consolidated financial position, results of operations and cash flows for the periods presented. The condensed consolidated results of operations for the three months ended March&#160;31, 2026 are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December&#160;31, 2025 included herein was derived from the audited consolidated financial statements as of that date. As permitted under U.S. GAAP, certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s most recent Annual Report on Form 10-K for the year ended December 31, 2025 (the "Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bicara is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. The Company may take advantage of these exemptions until it is no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Bicara has elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, its financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that Bicara is no longer an emerging growth company. Bicara would cease to be an emerging growth company if it has more than $1.235 billion in total annual gross revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and it has been a public company for at least 12 months and has filed one annual report on Form 10-K), or it issues more than $1.0 billion of non-convertible debt securities over a three-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, and the fair values of pre-IPO common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of obligations of, and issues guaranteed by the U.S. Treasury, U.S. Agencies and U.S. Government Sponsored Enterprises.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's marketable securities are classified as available-for-sale and are carried at fair value. The Company classifies all available-for-sale securities as current assets. Marketable securities are classified as current assets because they are available to fund current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any unrealized holding gains or losses on debt securities, including their tax effect, are reported as components of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statement of comprehensive loss. Realized gains and losses, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest and other income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statement of comprehensive loss, are determined using the specific identification method for determining the cost of securities sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Declines in fair value below amortized cost related to credit losses (i.e., impairment due to credit losses) are included in the condensed consolidated statement of comprehensive loss, with a corresponding allowance established. If the estimate of expected credit losses decreases in subsequent periods, the Company will reverse the credit losses through current period earnings and adjust the allowance accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred in accordance with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 730&#x201d;). Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes salaries and benefits, stock-based compensation expense and the cost of services provided by outside contractors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes advance payments for goods or services that will be used or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed. The Company also records expenses and accruals for estimated costs of research and development activities, including third party contract services for clinical research and contract manufacturing. The Company bases its estimates on the best information available at the time. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or as accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to the Company&#x2019;s vendors. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation expense, related to the Company's executive, finance and other support functions. Other general and administrative expenses include professional fees for legal, auditing, tax, consulting services, investor relations, IT and office expenses, rent and insurance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based employee and nonemployee compensation awards in accordance with provisions of ASC 718,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 718&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. We use the Black-Scholes option-pricing model to determine the fair value of options. The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends. In applying these assumptions, we consider the following factors: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company&#x2019;s common stock is listed on the Nasdaq Global Market and its value is determined by the market price on the Nasdaq Global Market as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term:&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The expected life is applied to the stock option grant group as a whole as we do not expect substantially different exercise or post-vesting termination behavior among our employee population.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends due to absence of an active market for the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We have not paid and do not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was&#160;zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For awards that vest based solely on achievement of a service condition, the Company recognizes expense on a straight-line basis over the period during which the award holder provides such services. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with forfeited awards. In accordance with ASU 2018-07, the Company accounts for share-based compensation for awards granted to non-employees in a similar fashion to the way it accounts for share-based compensation awards to employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management assesses warrants to determine whether they should be classified as equity or liability. If the classification is determined to be equity, proceeds received for the warrants are recorded as an increase to additional paid-in capital in the condensed consolidated balance sheets. If classified as a liability, the Company records the warrant as a liability on its consolidated balance sheet and remeasures this liability to fair value at each reporting date and recognizes changes in the fair value of the warrant in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is determined by dividing the net loss applicable to common shareholders by the weighted average common shares outstanding during the period. The pre-funded warrants to purchase 2,200,000 shares of common stock issued in February 2026 and outstanding as of March 31, 2026 (see Note 9) were included in computing the weighted average common shares outstanding used in calculating basic and diluted loss per share. Outstanding common stock options are e&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;xcluded from the calculation of diluted net loss per share when their effect would be anti-dilutive. For the three months ended March 31, 2026 and 2025, the following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,874,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,271,217&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in the table above reflect the common stock equivalents of the noted instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews new accounting standards as they are issued by the FASB or other standard-setting bodies. The Company did not identify any new standards during the quarter ended March 31, 2026 that it believes will have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Issued and Not Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update 2024-03&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Income Statement Expenses (DISE)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new guidance requires all public entities to incorporate disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective prospectively for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption and retrospective application are permitted. We are currently evaluating the impact that ASU 2024-03 will have on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviewed additional recent accounting pronouncements and concluded they are either not applicable or that the Company does not expect adoption to have a material effect on the unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-235">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-236">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements include the financial position, results of operations and cash flows of Bicara. The Company&#x2019;s unaudited condensed consolidated financial statements are denominated in U.S. dollars. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiary. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-237">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates on historical experience when available and on other assumptions that management believes are reasonable under the circumstances. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to: the estimated costs of research and development activities, and the fair values of pre-IPO common stock and stock awards and associated stock-based compensation expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-238">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of obligations of, and issues guaranteed by the U.S. Treasury, U.S. Agencies and U.S. Government Sponsored Enterprises.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's marketable securities are classified as available-for-sale and are carried at fair value. The Company classifies all available-for-sale securities as current assets. Marketable securities are classified as current assets because they are available to fund current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any unrealized holding gains or losses on debt securities, including their tax effect, are reported as components of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statement of comprehensive loss. Realized gains and losses, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest and other income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated statement of comprehensive loss, are determined using the specific identification method for determining the cost of securities sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Declines in fair value below amortized cost related to credit losses (i.e., impairment due to credit losses) are included in the condensed consolidated statement of comprehensive loss, with a corresponding allowance established. If the estimate of expected credit losses decreases in subsequent periods, the Company will reverse the credit losses through current period earnings and adjust the allowance accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-239">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred in accordance with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 730&#x201d;). Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes salaries and benefits, stock-based compensation expense and the cost of services provided by outside contractors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes advance payments for goods or services that will be used or rendered for future research and development activities and recognizes expense as the related goods are delivered or services are performed. The Company also records expenses and accruals for estimated costs of research and development activities, including third party contract services for clinical research and contract manufacturing. The Company bases its estimates on the best information available at the time. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or as accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to the Company&#x2019;s vendors. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-240">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expense&lt;/span&gt;&lt;/div&gt;General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation expense, related to the Company's executive, finance and other support functions. Other general and administrative expenses include professional fees for legal, auditing, tax, consulting services, investor relations, IT and office expenses, rent and insurance.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-241">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based employee and nonemployee compensation awards in accordance with provisions of ASC 718,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 718&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires the recognition of stock-based compensation expense, using a fair-value based method, for costs related to all stock-based compensation awards. We use the Black-Scholes option-pricing model to determine the fair value of options. The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends. In applying these assumptions, we consider the following factors: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company&#x2019;s common stock is listed on the Nasdaq Global Market and its value is determined by the market price on the Nasdaq Global Market as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term:&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The expected life is applied to the stock option grant group as a whole as we do not expect substantially different exercise or post-vesting termination behavior among our employee population.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends due to absence of an active market for the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;We have not paid and do not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was&#160;zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For awards that vest based solely on achievement of a service condition, the Company recognizes expense on a straight-line basis over the period during which the award holder provides such services. The Company recognizes forfeitures as they occur and reverses any previously recognized compensation cost associated with forfeited awards. In accordance with ASU 2018-07, the Company accounts for share-based compensation for awards granted to non-employees in a similar fashion to the way it accounts for share-based compensation awards to employees.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <bcax:WarrantsPolicyPolicyTextBlock contextRef="c-1" id="f-242">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;Management assesses warrants to determine whether they should be classified as equity or liability. If the classification is determined to be equity, proceeds received for the warrants are recorded as an increase to additional paid-in capital in the condensed consolidated balance sheets. If classified as a liability, the Company records the warrant as a liability on its consolidated balance sheet and remeasures this liability to fair value at each reporting date and recognizes changes in the fair value of the warrant in earnings.</bcax:WarrantsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-243">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is determined by dividing the net loss applicable to common shareholders by the weighted average common shares outstanding during the period. The pre-funded warrants to purchase 2,200,000 shares of common stock issued in February 2026 and outstanding as of March 31, 2026 (see Note 9) were included in computing the weighted average common shares outstanding used in calculating basic and diluted loss per share. Outstanding common stock options are e&lt;/span&gt;xcluded from the calculation of diluted net loss per share when their effect would be anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-45"
      decimals="INF"
      id="f-244"
      unitRef="shares">2200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-245">For the three months ended March 31, 2026 and 2025, the following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,874,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,271,217&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-48" decimals="0" id="f-246" unitRef="shares">11874116</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-49" decimals="0" id="f-247" unitRef="shares">8271217</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-248">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-249"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-250">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews new accounting standards as they are issued by the FASB or other standard-setting bodies. The Company did not identify any new standards during the quarter ended March 31, 2026 that it believes will have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Issued and Not Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update 2024-03&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Income Statement Expenses (DISE)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new guidance requires all public entities to incorporate disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective prospectively for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption and retrospective application are permitted. We are currently evaluating the impact that ASU 2024-03 will have on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviewed additional recent accounting pronouncements and concluded they are either not applicable or that the Company does not expect adoption to have a material effect on the unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-251">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Fair Value Measurements&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets that have been measured at fair value as of March&#160;31, 2026 and December&#160;31, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Description&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;216,291&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;216,291&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;320,694&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;320,694&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;320,694&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;216,291&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;536,985&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Description&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;318,116&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;318,116&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;93,595&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;93,595&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;93,595&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;318,116&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;411,711&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of March 31, 2026 and December 31, 2025, the Company&#x2019;s cash equivalents consisted of money market funds. During the three months ended March 31, 2026 and the year ended December 31, 2025, there were no transfers between Level 1, Level 2 and Level 3.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="c-1" id="f-252">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets that have been measured at fair value as of March&#160;31, 2026 and December&#160;31, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Description&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;216,291&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;216,291&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;320,694&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;320,694&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;320,694&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;216,291&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;536,985&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Description&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;318,116&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;318,116&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;93,595&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-right:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;93,595&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;93,595&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;318,116&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;411,711&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-50" decimals="-3" id="f-253" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-51" decimals="-3" id="f-254" unitRef="usd">216291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-52" decimals="-3" id="f-255" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-53" decimals="-3" id="f-256" unitRef="usd">216291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-54" decimals="-3" id="f-257" unitRef="usd">320694000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-55" decimals="-3" id="f-258" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-56" decimals="-3" id="f-259" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-57" decimals="-3" id="f-260" unitRef="usd">320694000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-58" decimals="-3" id="f-261" unitRef="usd">320694000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-262" unitRef="usd">216291000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-263" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-264" unitRef="usd">536985000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-61" decimals="-3" id="f-265" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-62" decimals="-3" id="f-266" unitRef="usd">318116000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-267" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-268" unitRef="usd">318116000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-269" unitRef="usd">93595000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-270" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-271" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-272" unitRef="usd">93595000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-273" unitRef="usd">93595000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-274" unitRef="usd">318116000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-275" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-276" unitRef="usd">411711000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentTextBlock contextRef="c-1" id="f-277">Marketable Securities&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The fair value of available-for-sale marketable securities by type of security was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Marketable Securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;163,516&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(74)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;163,444&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities with original maturity of one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;163,516&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(74)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;163,444&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;53,018&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(171)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;52,847&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities with original maturity of one to two years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;53,018&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(171)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;52,847&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;216,534&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;216,291&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Marketable Securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;233,672&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;146&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;233,818&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities with original maturity of one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;233,672&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;146&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;233,818&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;84,201&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;97&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;84,298&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities with original maturity of one to two years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;84,201&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;97&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;84,298&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;317,873&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;243&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;318,116&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The following table summarizes the Company's available-for-sale securities in an unrealized loss position, aggregated by type and length of time in a continuous unrealized position (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;12 Months or Longer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Marketable Securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;156,241&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;156,241&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;156,241&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;156,241&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;As summarized in the tables immediately above, the Company held &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;eleven&lt;/span&gt; debt securities that were in an unrealized loss position as of March 31, 2026. The unrealized losses at March 31, 2026 were attributable to changes in interest rates and do not represent credit losses. The Company does not intend to sell these securities, and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis. The Company held no debt securities that were in an unrealized loss position as of December 31, 2025.</us-gaap:InvestmentTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-278">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The fair value of available-for-sale marketable securities by type of security was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Marketable Securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;163,516&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(74)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;163,444&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities with original maturity of one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;163,516&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(74)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;163,444&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;53,018&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(171)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;52,847&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities with original maturity of one to two years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;53,018&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(171)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;52,847&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;216,534&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;216,291&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Marketable Securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;233,672&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;146&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;233,818&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities with original maturity of one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;233,672&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;146&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;233,818&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;84,201&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;97&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;84,298&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities with original maturity of one to two years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;84,201&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;97&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;84,298&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;317,873&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;243&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;318,116&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-72" decimals="-3" id="f-279" unitRef="usd">163516000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-72" decimals="-3" id="f-280" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-72" decimals="-3" id="f-281" unitRef="usd">74000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-72" decimals="-3" id="f-282" unitRef="usd">163444000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-73" decimals="-3" id="f-283" unitRef="usd">163516000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-73" decimals="-3" id="f-284" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-73" decimals="-3" id="f-285" unitRef="usd">74000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-73" decimals="-3" id="f-286" unitRef="usd">163444000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-74" decimals="-3" id="f-287" unitRef="usd">53018000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-74" decimals="-3" id="f-288" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-74" decimals="-3" id="f-289" unitRef="usd">171000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-74" decimals="-3" id="f-290" unitRef="usd">52847000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-75" decimals="-3" id="f-291" unitRef="usd">53018000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-75" decimals="-3" id="f-292" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-75" decimals="-3" id="f-293" unitRef="usd">171000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-75" decimals="-3" id="f-294" unitRef="usd">52847000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-295" unitRef="usd">216534000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-296" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-297" unitRef="usd">245000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-298" unitRef="usd">216291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-76" decimals="-3" id="f-299" unitRef="usd">233672000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-76" decimals="-3" id="f-300" unitRef="usd">146000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-76" decimals="-3" id="f-301" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-76" decimals="-3" id="f-302" unitRef="usd">233818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-77" decimals="-3" id="f-303" unitRef="usd">233672000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-77" decimals="-3" id="f-304" unitRef="usd">146000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-77" decimals="-3" id="f-305" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-77" decimals="-3" id="f-306" unitRef="usd">233818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-78" decimals="-3" id="f-307" unitRef="usd">84201000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-78" decimals="-3" id="f-308" unitRef="usd">97000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-78" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-78" decimals="-3" id="f-310" unitRef="usd">84298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-79" decimals="-3" id="f-311" unitRef="usd">84201000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-79" decimals="-3" id="f-312" unitRef="usd">97000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-79" decimals="-3" id="f-313" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-79" decimals="-3" id="f-314" unitRef="usd">84298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-315" unitRef="usd">317873000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-316" unitRef="usd">243000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-317" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-318" unitRef="usd">318116000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-319">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The following table summarizes the Company's available-for-sale securities in an unrealized loss position, aggregated by type and length of time in a continuous unrealized position (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;12 Months or Longer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Marketable Securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;156,241&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;156,241&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;156,241&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;156,241&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-80" decimals="-3" id="f-320" unitRef="usd">156241000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-80" decimals="-3" id="f-321" unitRef="usd">245000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-80" decimals="-3" id="f-322" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-80" decimals="-3" id="f-323" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-80" decimals="-3" id="f-324" unitRef="usd">156241000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-80" decimals="-3" id="f-325" unitRef="usd">245000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-3" decimals="-3" id="f-326" unitRef="usd">156241000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-3" decimals="-3" id="f-327" unitRef="usd">245000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-3" decimals="-3" id="f-328" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-3" decimals="-3" id="f-329" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-3" decimals="-3" id="f-330" unitRef="usd">156241000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-3" decimals="-3" id="f-331" unitRef="usd">245000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <bcax:DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition
      contextRef="c-3"
      decimals="INF"
      id="f-332"
      unitRef="debtsecurity">11</bcax:DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition>
    <bcax:DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition
      contextRef="c-4"
      decimals="INF"
      id="f-333"
      unitRef="debtsecurity">0</bcax:DebtSecuritiesAvailableForSaleNumberOfSecuritiesInUnrealizedLossPosition>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-334">Leases&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 16, 2023, the Company entered into a 2.5 years lease for 4,617 square feet of office space in Boston, Massachusetts (the &#x201c;Lease Agreement&#x201d;). In October 2024, the Company amended its Lease Agreement to lease an additional 4,744 square feet of office space in order to expand the Company&#x2019;s headquarters to 9,361 square feet of office space. The lease required a security deposit totaling $0.1 million, which the Company has met with cash on deposit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 2, 2025, the Company entered into a Sublease Agreement (the &#x201c;Sublease&#x201d;) with J.W. Childs Associates, L.P., as sublandlord, effective on June 4, 2025. Under the Sublease, the Company leased approximately 9,682 square feet of additional office space as part of its corporate headquarters, through June 30, 2027. The base rent of the Sublease is approximately $0.5&#160;million per year. The Sublease required an immaterial security deposit, which the Company has satisfied with cash on deposit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 3, 2025, the Company entered into a second amendment to the Lease Agreement (the Lease Agreement, together with all amendments, the &#x201c;Amended Lease&#x201d;) to extend the term for the 9,361 square feet of office space leased under the Amended Lease through June 30, 2027. The modification of the Lease Agreement required the Company to remeasure the value of the asset and liability in accordance with ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The base rent under the Amended Lease continues to be approximately $0.6&#160;million per year. The remeasurement did not have a material impact on the Company's right-of-use-assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-81" id="f-335">P2Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <bcax:LesseeOperatingLeaseArea contextRef="c-81" decimals="0" id="f-336" unitRef="sqft">4617</bcax:LesseeOperatingLeaseArea>
    <bcax:LesseeOperatingLeaseArea contextRef="c-82" decimals="0" id="f-337" unitRef="sqft">4744</bcax:LesseeOperatingLeaseArea>
    <bcax:LesseeOperatingLeaseArea contextRef="c-3" decimals="0" id="f-338" unitRef="sqft">9361</bcax:LesseeOperatingLeaseArea>
    <us-gaap:SecurityDepositLiability contextRef="c-82" decimals="-5" id="f-339" unitRef="usd">100000</us-gaap:SecurityDepositLiability>
    <bcax:LesseeOperatingLeaseArea contextRef="c-83" decimals="0" id="f-340" unitRef="sqft">9682</bcax:LesseeOperatingLeaseArea>
    <us-gaap:OperatingLeaseExpense contextRef="c-84" decimals="-5" id="f-341" unitRef="usd">500000</us-gaap:OperatingLeaseExpense>
    <bcax:LesseeOperatingLeaseArea contextRef="c-85" decimals="0" id="f-342" unitRef="sqft">9361</bcax:LesseeOperatingLeaseArea>
    <us-gaap:OperatingLeaseExpense contextRef="c-86" decimals="-5" id="f-343" unitRef="usd">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-344">Accrued Expenses and Other Current Liabilities&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.190%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,516&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,085&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12,615&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus and payroll related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,913&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,666&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;238&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,948&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,898&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-345">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.190%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,516&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,085&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12,615&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus and payroll related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,913&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,666&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;238&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,948&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,898&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bcax:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-3" decimals="-3" id="f-346" unitRef="usd">13516000</bcax:AccruedResearchAndDevelopmentExpenseCurrent>
    <bcax:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-4" decimals="-3" id="f-347" unitRef="usd">13085000</bcax:AccruedResearchAndDevelopmentExpenseCurrent>
    <bcax:AccruedManufacturingExpensesCurrent contextRef="c-3" decimals="-3" id="f-348" unitRef="usd">12615000</bcax:AccruedManufacturingExpensesCurrent>
    <bcax:AccruedManufacturingExpensesCurrent contextRef="c-4" decimals="-3" id="f-349" unitRef="usd">0</bcax:AccruedManufacturingExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-350" unitRef="usd">1913000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-351" unitRef="usd">5041000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-3" decimals="-3" id="f-352" unitRef="usd">1666000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-353" unitRef="usd">591000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-354" unitRef="usd">238000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-355" unitRef="usd">181000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-356" unitRef="usd">29948000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-357" unitRef="usd">18898000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-358">Commitments and Contingencies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 22, 2024, a complaint was filed in federal district court in the District of Massachusetts by Y-Trap, Inc. ("Y-Trap"), naming as defendants the Company and Biocon Ltd ("Biocon"), captioned Y-Trap, Inc. v. Biocon Ltd and Bicara Therapeutics Inc., No. 24-cv-12678 (D. Mass.). On January 31, 2025, Y-Trap filed its operative amended complaint. The operative complaint alleges a claim against defendants for correction of inventorship of a number of patents, including patents alleged to be licensed to the Company relating to ficerafusp alfa. The complaint also alleges claims against defendants for unfair trade practices pursuant to Chapter 93A of the Massachusetts General Laws, unjust enrichment, and civil conspiracy. The operative complaint seeks, among other things, damages (including compensatory, enhanced, and punitive damages), an order correcting the inventorship of the patents at issue, costs and attorney&#x2019;s fees, and other equitable and injunctive relief. On February 28, 2025, Biocon and Bicara moved to dismiss all of Y-Trap&#x2019;s claims. On September 30, 2025, the court denied Bicara's motion. On October 30, 2025, Bicara answered the operative complaint. The Company will continue to vigorously defend against this litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have contingency reserves established for any litigation liabilities as of March&#160;31, 2026 and December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-359">Stockholder's Equity&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The Company has 10,000,000 shares of preferred stock authorized for issuance, par value $0.0001 per share. As of March 31, 2026 and December 31, 2025, no shares of preferred stock were issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The Company has 500,000,000 shares of Common Stock authorized for issuance, par value $0.0001 per share. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;March&#160;31, 2026 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;December&#160;31, 2025, 65,547,037&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;56,600,724&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt; shares were issued and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt; outstanding, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;February 2026 Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;In February 2026, the Company issued and sold 8,581,250 shares of its common stock, including 1,406,250 shares pursuant to the exercise of the underwriters&#x2019; option to purchase additional shares, at a price to the public of $16.00 per share, and pre-funded warrants to purchase 2,200,000 shares of common stock (the "pre-funded warrants", at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock in the offering, less the $0.0001 per share exercise price for each pre-funded warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%"&gt;Pre-funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain requirements, the pre-funded warrants, sold in the Company's February 2026 offering, can be exercised by the holder at anytime. As of March 31, 2026, there have not been any exercises of the pre-funded warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-funded warrants meet the criteria to be classified as an equity instrument under ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and funds received were recorded as an increase in additional paid-in capital in the condensed consolidated balance sheets. Funds received upon exercise of warrants will be recorded as common stock in the condensed consolidated balance sheets as the exercise price represents the par value of the underlying common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;At-The-Market Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 3, 2025, the Company filed a shelf registration statement on Form S-3 (the &#x201c;Registration Statement&#x201d;), with the SEC covering the offering of up to $400.0&#160;million of common stock, preferred stock, debt securities, warrants and/units. The Registration Statement was declared effective by the SEC on November 26, 2025. Concurrent with the filing of the Registration Statement, the Company entered into a sales agreement, dated October 3, 2025, by and between the Company and TD Securities (USA) LLC, acting as sales agent, to establish the ATM Program, pursuant to which the Company may offer and sell shares of its common stock from time to time. In connection with the ATM Program, the Company filed a prospectus with the Registration Statement for the offer and sale of up to $150.0&#160;million of shares of common stock from time to time through the sales agent. The Company will pay the agent a commission rate up to 3% of the gross proceeds of any shares sold and has agreed to provide the sales agent with customary indemnification and contributions against certain liabilities. As of March 31, 2026, the Company had remaining available capacity for share issuances of up to $120.0&#160;million under the ATM Program. During the quarter ended March 31, 2026, there were no sales under the ATM Program.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-360" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-361"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-362" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-363" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-364" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-365" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-366" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-367"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-368" unitRef="shares">65547037</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-369" unitRef="shares">65547037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-370" unitRef="shares">56600724</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-371" unitRef="shares">56600724</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-42"
      decimals="INF"
      id="f-372"
      unitRef="shares">8581250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-43"
      decimals="INF"
      id="f-373"
      unitRef="shares">1406250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-44"
      decimals="2"
      id="f-374"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-45"
      decimals="INF"
      id="f-375"
      unitRef="shares">2200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-45"
      decimals="INF"
      id="f-376"
      unitRef="usdPerShare">15.9999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bcax:ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference
      contextRef="c-45"
      decimals="INF"
      id="f-377"
      unitRef="usdPerShare">0.0001</bcax:ClassOfWarrantOrRightCommonStockExercisePriceOfWarrantsOrRightsDifference>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration contextRef="c-87" decimals="-5" id="f-378" unitRef="usd">400000000.0</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration contextRef="c-88" decimals="-5" id="f-379" unitRef="usd">150000000.0</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <bcax:SaleOfStockCommissionFeePercentage contextRef="c-89" decimals="2" id="f-380" unitRef="number">0.03</bcax:SaleOfStockCommissionFeePercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-90" decimals="-5" id="f-381" unitRef="shares">120000000.0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-382">Stock-Based Compensation&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2024 Stock Option and Grant Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2024, in connection with the Company&#x2019;s IPO, the board of directors adopted, and the Company&#x2019;s shareholders approved the 2024 Stock Option and Grant Plan (the &#x201c;2024 Plan&#x201d;) under which the Company may grant equity-based incentive awards to the Company&#x2019;s employees, officers, directors, consultants and other key persons of the Company and its affiliates upon whose judgment, initiative, and efforts the Company largely depends for the successful conduct of its business. Following the effectiveness of the 2024 Plan, no shares remained available for future issuance under the 2019 Stock Option and Grant Plan (as amended, the &#x201c;2019 Plan&#x201d;). Any other options or awards outstanding under the 2019 Plan remain outstanding and effective.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Plan, initially allowed the Company to grant awards up to 2,453,616 shares of Common Stock, plus shares of common stock subject to awards outstanding under the 2019 Plan that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated (other than by exercise). Each year starting on January 1, 2025 and on each January 1 thereafter, the number of shares of stock reserved and available for issuance under the 2024 Plan shall automatically be cumulatively increased by 5% of the outstanding shares on the immediately preceding December 31 or such lesser number of shares as approved by the Company. Through March&#160;31, 2026, the Company issued 5,239,109 of options under the 2024 Plan. The terms of equity award agreements, including vesting requirements, were &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determined by the board of directors and are subject to the provisions of the 2024 Plan. Equity awards granted to employees and non-employees generally vest over a four-year period but may be granted with different vesting terms. Certain options provide for early vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options granted to employees and non-employees expire no more than 10 years from the date of grant and are generally service based. The 2024 Plan allows for awards to contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vested period. No awards with performance-based vesting criteria have been granted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;2026 Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2026, the Company&#x2019;s board of directors adopted the Bicara Therapeutics Inc. 2026 Inducement Plan (the &#x201c;Inducement Plan&#x201d;) and reserved 1,000,000 shares of common stock for future issuance under the Inducement Plan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Inducement Plan has not been approved by the stockholders of the Company and provides for the grant of non-qualified stock options, stock appreciation rights, RSAs, RSUs, unrestricted stock awards and dividend equivalent rights to newly hired employees as a material inducement to accept employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized total stock-based compensation expense for non-employees and employees in its statements of comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,225&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,141&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,633&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,310&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,858&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation, measured at the grant date based on the fair value of the award, is typically recognized ratably over the requisite service period, using the straight-line method of expense attribution. When utilizing the Black-Scholes option-pricing model to determine the grant date fair value of stock options granted to employees or non-employees, we used the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7%-3.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0%-4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected life (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.1%-94.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6%-90.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected dividend rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Fair value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.60-$13.77&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.30-$12.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;A summary of options award activity for non-employees and employees of the Company is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average &#x2013;&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,389,555&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(366,416)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,874,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,757&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,349,637&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,004&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable and expected to vest as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,874,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10.74&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The aggregate intrinsic values is calculated as the difference between the exercise price of the underlying options and the fair value of the Company&#x2019;s common stock on March 31, 2026 for the options that were in the money.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair value of options granted during the three months ended March 31, 2026 and 2025, was $13.15 and $9.60, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options exercised for the three months ended March 31, 2026 and 2025 were $5.1&#160;million and $0.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had 8,524,479 unvested stock options outstanding as of March&#160;31, 2026. As of March&#160;31, 2026, total unrecognized compensation costs of $72.5 million related to unvested stock options are expected to be recognized as expense over a weighted average period of 3.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%"&gt;2024 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 5, 2024, the Company&#x2019;s board of directors adopted, and its stockholders approved, the 2024 Employee Stock Purchase Plan (the "ESPP"), which became effective September 5, 2024. The ESPP initially reserves and authorizes the issuance of up to 507,383 shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034, by the least of (i) 1,014,766 shares of common stock, (ii) 1% of the sum of (A) the number of shares of our common stock issued and outstanding on the immediately preceding December 31, and (B) the number of shares of common stock issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire such common stock for a nominal exercise price on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend, or other change in our capitalization. There has been no activity on this plan to date, and no stock-based compensation expense was recognized during the three months ended March 31, 2026.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-91"
      decimals="INF"
      id="f-383"
      unitRef="shares">2453616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage
      contextRef="c-92"
      decimals="INF"
      id="f-384"
      unitRef="number">0.05</bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticShareAuthorizationIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-93"
      decimals="INF"
      id="f-385"
      unitRef="shares">5239109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-92" id="f-386">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-92" id="f-387">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-94"
      decimals="INF"
      id="f-388"
      unitRef="shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-389">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized total stock-based compensation expense for non-employees and employees in its statements of comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,225&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,141&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,633&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,310&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,858&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-95" decimals="-3" id="f-390" unitRef="usd">2225000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-96" decimals="-3" id="f-391" unitRef="usd">1141000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-97" decimals="-3" id="f-392" unitRef="usd">3633000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-98" decimals="-3" id="f-393" unitRef="usd">2310000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-394" unitRef="usd">5858000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-395" unitRef="usd">3451000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-396">When utilizing the Black-Scholes option-pricing model to determine the grant date fair value of stock options granted to employees or non-employees, we used the following weighted average assumptions:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7%-3.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0%-4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected life (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.1%-94.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6%-90.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected dividend rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Fair value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.60-$13.77&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.30-$12.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-99" decimals="3" id="f-397" unitRef="number">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-100" decimals="3" id="f-398" unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-101" decimals="3" id="f-399" unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-102" decimals="3" id="f-400" unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-401">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-13" id="f-402">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-99" decimals="3" id="f-403" unitRef="number">0.941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-100" decimals="3" id="f-404" unitRef="number">0.945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-101" decimals="3" id="f-405" unitRef="number">0.906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-102" decimals="3" id="f-406" unitRef="number">0.908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-1" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-13" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice
      contextRef="c-99"
      decimals="INF"
      id="f-409"
      unitRef="usdPerShare">12.60</bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice>
    <bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice
      contextRef="c-100"
      decimals="INF"
      id="f-410"
      unitRef="usdPerShare">13.77</bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice>
    <bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice
      contextRef="c-101"
      decimals="INF"
      id="f-411"
      unitRef="usdPerShare">12.30</bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice>
    <bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice
      contextRef="c-102"
      decimals="INF"
      id="f-412"
      unitRef="usdPerShare">12.70</bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDuringPeriodExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-413">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;A summary of options award activity for non-employees and employees of the Company is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average &#x2013;&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,389,555&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(366,416)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,874,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,757&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,349,637&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,004&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable and expected to vest as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,874,116&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10.74&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The aggregate intrinsic values is calculated as the difference between the exercise price of the underlying options and the fair value of the Company&#x2019;s common stock on March 31, 2026 for the options that were in the money.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-414" unitRef="shares">9850977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-415"
      unitRef="usdPerShare">9.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-416" unitRef="shares">2389555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-417"
      unitRef="usdPerShare">16.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-418" unitRef="shares">366416</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-419"
      unitRef="usdPerShare">4.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-420" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-421"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-422" unitRef="shares">11874116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-423"
      unitRef="usdPerShare">10.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-424">P8Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-425" unitRef="usd">108757000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-426" unitRef="shares">3349637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-427"
      unitRef="usdPerShare">7.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-428">P7Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-3" id="f-429" unitRef="usd">42004000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-3" decimals="INF" id="f-430" unitRef="shares">11874116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="INF"
      id="f-431"
      unitRef="usdPerShare">10.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-432">P8Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-433"
      unitRef="usdPerShare">13.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-13"
      decimals="2"
      id="f-434"
      unitRef="usdPerShare">9.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-435" unitRef="usd">5100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-13" decimals="-5" id="f-436" unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c-3" decimals="INF" id="f-437" unitRef="shares">8524479</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-5" id="f-438" unitRef="usd">72500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-103" id="f-439">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-104"
      decimals="INF"
      id="f-440"
      unitRef="shares">507383</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="c-104"
      decimals="INF"
      id="f-441"
      unitRef="shares">1014766</bcax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="c-105" decimals="2" id="f-442" unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-443">Income TaxesDeferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#x2019;s otherwise recognizable net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-444">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#x2019;s otherwise recognizable net deferred tax assets.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-445">Significant Agreements &#x2013; Related Parties&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a master services agreement on December 15, 2020 (the &#x201c;Master Services Agreement&#x201d;) with Biocon. Pursuant to the terms of the master service agreement, Biocon provided services related to research and development, clinical trials, regulatory interactions and manufacturing. The Company incurred $0.1&#160;million and $0.0 million expenses under the Master Services Agreement during the three months ended March&#160;31, 2026 and 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;23, 2019, the Company entered into a contract manufacturing agreement with a wholly-owned subsidiary of Biocon, Biocon Biologics Limited (&#x201c;BBL&#x201d;) formerly Biocon Biologics India Limited, which was amended on November 6, 2024 to extend the term of the contract manufacturing agreement until July 23, 2026. Additionally, the Company entered into a material transfer agreement on August 17, 2023, a quality agreement on October 12, 2023, a service agreement on October 18, 2023, and a manufacturing service agreement on December 15, 2023 (collectively, the &#x201c;BBL Agreements&#x201d;). Pursuant to the terms of the BBL Agreements, BBL manufactures and supplies specified quantities of products to Bicara to be utilized in research and development and manufacturing as per purchase orders executed from time to time between the two parties. For the three months ended March&#160;31, 2026 and 2025, the Company incurred $0.1 million and $0.0 million of research and development expenses, respectively, under the BBL Agreements. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026 and December&#160;31, 2025, the Company owed $0.1&#160;million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company additionally entered into a contract manufacturing agreement with a wholly-owned subsidiary of Biocon, Syngene International Limited (&#x201c;Syngene&#x201d;), on July 17, 2019, which was amended and restated on April 1, 2020 with the amended and restated manufacturing service agreement, as amended (the &#x201c;Syngene Manufacturing Services Agreement&#x201d;), and a master contract services agreement on July 24, 2020, as amended (the &#x201c;Syngene Master Contract Services Agreement&#x201d; and together with the Syngene Manufacturing Services Agreement, the &#x201c;Syngene Agreements&#x201d;). Pursuant to the terms of the Syngene Agreements, Syngene manufactures and supplies specified quantities of products to Bicara to be used in research and development as per purchase orders executed from time to time between the two parties and performs additional contract research services under the master contract services agreement. The Syngene Manufacturing Services Agreement expires on the later of October 31, 2027 or the completion of services under all work orders under the agreement. The Syngene Master Contract Services Agreement expires on the later of November 1, 2031 or the completion of all services under the statements of work under the agreement. On December 16, 2024, the Company entered into an additional master contract services agreement with Syngene, whereby Syngene agreed to provide the Company with dedicated research laboratories and personnel (&#x201c;Dedicated Center Agreement&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Dedicated Center Agreement expires on the later of December 16, 2028 or the completion of all services under all statements of work under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2026 and 2025, the Company incurred $1.8 million and $6.4 million of manufacturing and research and development expenses, respectively, under the Syngene Agreements. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026, and December&#160;31, 2025, the Company owed Syngene $2.0 million and $3.4 million, respectively, relating to these incurred costs, of which $1.3 million and $2.3 million, respectively,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were classified in accounts payable-related party and $0.7 million and $1.1 million, respectively,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;were classified as accrued expenses-related party on the balance sheets.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-106" decimals="-5" id="f-446" unitRef="usd">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-107" decimals="-5" id="f-447" unitRef="usd">0.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-108" decimals="-5" id="f-448" unitRef="usd">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-109" decimals="-5" id="f-449" unitRef="usd">0.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-110" decimals="-5" id="f-450" unitRef="usd">100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-111" decimals="-5" id="f-451" unitRef="usd">0.0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-112" decimals="-5" id="f-452" unitRef="usd">1800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-113" decimals="-5" id="f-453" unitRef="usd">6400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LiabilitiesCurrent contextRef="c-114" decimals="-5" id="f-454" unitRef="usd">2000000.0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-115" decimals="-5" id="f-455" unitRef="usd">3400000</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-114" decimals="-5" id="f-456" unitRef="usd">1300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-115" decimals="-5" id="f-457" unitRef="usd">2300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-114" decimals="-5" id="f-458" unitRef="usd">700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-115" decimals="-5" id="f-459" unitRef="usd">1100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="c-1" id="f-460">Significant Agreements&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IQVIA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 15, 2019, the Company entered into a master clinical contract services agreement with IQVIA RDS Inc (&#x201c;IQVIA&#x201d;), which was amended in December 2023 to include global clinical trials. Pursuant to the terms of the agreement, as amended, IQVIA will provide the Company with certain global clinical-development related services and laboratory services under separately executed statements of work (&#x201c;SOWs&#x201d;). In June 2021, the Company entered into an SOW with IQVIA for lab and clinical development services, to be invoiced on a monthly basis based on work performed by IQVIA. Under this SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $1.8&#160;million, of which $1.0&#160;million was a refundable deposit and $0.8&#160;million for investigator grant payment in advance. In December 2022, Bicara entered into an authorized to proceed agreement (&#x201c;ATP&#x201d;) with IQVIA. Under the ATP, Bicara agreed to provide IQVIA with an additional refundable deposit of $0.9&#160;million, which was paid in March 2023. Both the initial deposit and the ATP deposit will be held on account and reconciled against final invoices. As of March 31, 2026 and December 31, 2025, the refundable deposit balance was $1.9&#160;million, which is included within other assets on the balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 18, 2024, the Company entered into a second SOW for lab and clinical development services with IQVIA, which was incorporated into the master clinical contract services agreement and part of the Company&#x2019;s FORTIFI-HN01 Phase 2/3 clinical trial. Services will be invoiced on a monthly basis based on work performed by IQVIA. Under this SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $12.8&#160;million, of which $7.3&#160;million was for investigator grant payments, $4.5&#160;million was a deposit for services and $1.0&#160;million was a deposit for pass through costs. The deposits will be held on account with an incremental return starting the month after 75% of the budgeted costs has been paid by the Company. IQVIA is eligible to receive potential additional payments and it is subject to potential penalties based on certain milestone targets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2026 and 2025 the Company incurred &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $14.2 million in expenses, respectively and paid &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.7 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $12.3 million, respectively, to IQVIA. As of March&#160;31, 2026 and December&#160;31, 2025, the Company had &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $0.4 million classified in accounts payable, respectively, and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $8.6 million classified in accrued expenses and other current liabilities on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Trial Collaboration and Supply Agreement with MSD&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 19, 2022, we entered into a Clinical Trial Collaboration and Supply Agreement (the "MSD Agreement") with MSD International GmbH ("MSDIG"), and MSD International Business GmbH ("MSDIB" and collectively with MSDIG, "MSD"). Pursuant to the MSD Agreement, we provide ficerafusp alfa and MSD provides pembrolizumab to be used in combination in a clinical trial sponsored by us. The clinical trial is a First-in-Human, Phase 1/1b, Open-label, Multicenter Study intended to characterize the safety, tolerability and recommended dose of single agent ficerafusp alfa and combination ficerafusp alfa plus pembrolizumab. To facilitate such collaboration activities and information exchange and pursuant to the MSD Agreement, we and MSD created a joint development committee with an equal number of representatives from each party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the MSD Agreement, all clinical data resulting from the portion of the clinical trial involving the combination of ficerafusp alfa and pembrolizumab is jointly owned by both us and MSD. We own all clinical data resulting from the part of the clinical trial involving ficerafusp alfa alone or in combination with other treatments that are not pembrolizumab, and MSD owns all clinical data resulting from the part of the clinical trial involving pembrolizumab alone or in combination with other treatments that are not ficerafusp alfa. There are no accounting considerations for this agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:OtherCommitment contextRef="c-116" decimals="-5" id="f-461" unitRef="usd">1800000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-117" decimals="-5" id="f-462" unitRef="usd">1000000.0</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-118" decimals="-5" id="f-463" unitRef="usd">800000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-119" decimals="-5" id="f-464" unitRef="usd">900000</us-gaap:OtherCommitment>
    <bcax:OtherCommitmentLiabilityRefundableDepositAmount contextRef="c-3" decimals="-5" id="f-465" unitRef="usd">1900000</bcax:OtherCommitmentLiabilityRefundableDepositAmount>
    <bcax:OtherCommitmentLiabilityRefundableDepositAmount contextRef="c-4" decimals="-5" id="f-466" unitRef="usd">1900000</bcax:OtherCommitmentLiabilityRefundableDepositAmount>
    <us-gaap:OtherCommitment contextRef="c-120" decimals="-5" id="f-467" unitRef="usd">12800000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-121" decimals="-5" id="f-468" unitRef="usd">7300000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-122" decimals="-5" id="f-469" unitRef="usd">4500000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-123" decimals="-5" id="f-470" unitRef="usd">1000000.0</us-gaap:OtherCommitment>
    <bcax:OtherCommitmentPercentage contextRef="c-124" decimals="2" id="f-471" unitRef="number">0.75</bcax:OtherCommitmentPercentage>
    <us-gaap:OperatingExpenses contextRef="c-125" decimals="-5" id="f-472" unitRef="usd">9900000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-126" decimals="-5" id="f-473" unitRef="usd">14200000</us-gaap:OperatingExpenses>
    <bcax:PaymentsForOtherCommitments contextRef="c-125" decimals="-5" id="f-474" unitRef="usd">7700000</bcax:PaymentsForOtherCommitments>
    <bcax:PaymentsForOtherCommitments contextRef="c-126" decimals="-5" id="f-475" unitRef="usd">12300000</bcax:PaymentsForOtherCommitments>
    <us-gaap:AccountsPayableCurrent contextRef="c-127" decimals="-5" id="f-476" unitRef="usd">1100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-128" decimals="-5" id="f-477" unitRef="usd">400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-127" decimals="-5" id="f-478" unitRef="usd">9800000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-128" decimals="-5" id="f-479" unitRef="usd">8600000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DefinedContributionPlanTextBlock contextRef="c-1" id="f-480">Defined Contribution Plan&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently maintains a tax-qualified 401(k) retirement savings plan for our employees. All eligible employees are able to participate in the plan beginning one month after their first day of employment. Under our defined contribution plan, employees may elect to defer a percentage of their compensation per year, subject to a maximum limit prescribed by tax law, and the Company match a portion of their eligible contributions. The Company provided matching discretionary contributions under the 401(k) plan of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.2&#160;million&lt;/span&gt; and $0.1&#160;million for the three months ended March 31, 2026 and March 31, 2025, respectively.</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-481" unitRef="usd">200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-13" decimals="-5" id="f-482" unitRef="usd">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-483">Segment Reporting&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one reportable segment relating to research and development of its product. The segment does not currently generate revenues as it is currently conducting clinical trials and has not commercialized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Chief Operating Decision Maker (the &#x201c;CODM&#x201d;), its Chief Executive Officer, manages the Company&#x2019;s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews total expenses and expenses by function and the CODM makes decisions using this information on a global basis. The CODM monitors performance at the consolidated level such that the measure of segment loss is consolidated net loss and the measure of reportable segment assets is reported on the balance sheet as total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three Months Ended March 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Manufacturing and process development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;23,208&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;18,655&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Clinical operations and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14,570&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10,026&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Research and development personnel cost and other (including stock-based compensation)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9,121&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,096&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Research&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;601&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;556&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;47,500&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;34,333&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;General and administrative personnel costs (including stock-based compensation)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,963&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,832&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,560&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,504&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Facility costs, IT, office expense and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,219&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,119&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total general and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12,742&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,455&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;60,242&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;41,788&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Operating loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(60,242)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(41,788)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,083&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,014&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,083&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,014&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Net income before losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(56,159)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(36,774)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(52)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(72)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Segment and consolidated net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(56,211)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(36,846)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included within facility costs, IT, office expense and other are depreciation expense, which is disclosed on the Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-484"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-485">&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three Months Ended March 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Manufacturing and process development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;23,208&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;18,655&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Clinical operations and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14,570&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10,026&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Research and development personnel cost and other (including stock-based compensation)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9,121&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,096&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Research&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;601&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;556&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;47,500&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;34,333&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;General and administrative personnel costs (including stock-based compensation)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,963&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,832&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,560&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,504&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Facility costs, IT, office expense and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,219&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,119&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total general and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12,742&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,455&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;60,242&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;41,788&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Operating loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(60,242)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(41,788)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,083&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,014&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,083&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,014&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Net income before losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(56,159)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(36,774)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(52)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(72)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Segment and consolidated net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(56,211)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(36,846)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <bcax:ManufacturingAndProcessDevelopmentExpense contextRef="c-129" decimals="-3" id="f-486" unitRef="usd">23208000</bcax:ManufacturingAndProcessDevelopmentExpense>
    <bcax:ManufacturingAndProcessDevelopmentExpense contextRef="c-130" decimals="-3" id="f-487" unitRef="usd">18655000</bcax:ManufacturingAndProcessDevelopmentExpense>
    <bcax:ClinicalOperationsAndDevelopmentExpense contextRef="c-129" decimals="-3" id="f-488" unitRef="usd">14570000</bcax:ClinicalOperationsAndDevelopmentExpense>
    <bcax:ClinicalOperationsAndDevelopmentExpense contextRef="c-130" decimals="-3" id="f-489" unitRef="usd">10026000</bcax:ClinicalOperationsAndDevelopmentExpense>
    <bcax:ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense contextRef="c-129" decimals="-3" id="f-490" unitRef="usd">9121000</bcax:ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense>
    <bcax:ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense contextRef="c-130" decimals="-3" id="f-491" unitRef="usd">5096000</bcax:ResearchAndDevelopmentPersonnelCostIncludingShareBasedPaymentArrangementExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-129" decimals="-3" id="f-492" unitRef="usd">601000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-130" decimals="-3" id="f-493" unitRef="usd">556000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-129" decimals="-3" id="f-494" unitRef="usd">47500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-130" decimals="-3" id="f-495" unitRef="usd">34333000</us-gaap:ResearchAndDevelopmentExpense>
    <bcax:GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation contextRef="c-129" decimals="-3" id="f-496" unitRef="usd">7963000</bcax:GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation>
    <bcax:GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation contextRef="c-130" decimals="-3" id="f-497" unitRef="usd">4832000</bcax:GeneralAndAdministrativePersonnelCostsIncludingStockBasedCompensation>
    <us-gaap:ProfessionalFees contextRef="c-129" decimals="-3" id="f-498" unitRef="usd">3560000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c-130" decimals="-3" id="f-499" unitRef="usd">1504000</us-gaap:ProfessionalFees>
    <bcax:FacilityITOfficeAndOtherExpense contextRef="c-129" decimals="-3" id="f-500" unitRef="usd">1219000</bcax:FacilityITOfficeAndOtherExpense>
    <bcax:FacilityITOfficeAndOtherExpense contextRef="c-130" decimals="-3" id="f-501" unitRef="usd">1119000</bcax:FacilityITOfficeAndOtherExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-129" decimals="-3" id="f-502" unitRef="usd">12742000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-130" decimals="-3" id="f-503" unitRef="usd">7455000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-129" decimals="-3" id="f-504" unitRef="usd">60242000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-130" decimals="-3" id="f-505" unitRef="usd">41788000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-129" decimals="-3" id="f-506" unitRef="usd">-60242000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-130" decimals="-3" id="f-507" unitRef="usd">-41788000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-129" decimals="-3" id="f-508" unitRef="usd">4083000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-130" decimals="-3" id="f-509" unitRef="usd">5014000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-129" decimals="-3" id="f-510" unitRef="usd">4083000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-130" decimals="-3" id="f-511" unitRef="usd">5014000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-129" decimals="-3" id="f-512" unitRef="usd">-56159000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-130" decimals="-3" id="f-513" unitRef="usd">-36774000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <bcax:IncomeTaxExpenseBenefitIncludingAdjustments contextRef="c-129" decimals="-3" id="f-514" unitRef="usd">52000</bcax:IncomeTaxExpenseBenefitIncludingAdjustments>
    <bcax:IncomeTaxExpenseBenefitIncludingAdjustments contextRef="c-130" decimals="-3" id="f-515" unitRef="usd">72000</bcax:IncomeTaxExpenseBenefitIncludingAdjustments>
    <us-gaap:NetIncomeLoss contextRef="c-129" decimals="-3" id="f-516" unitRef="usd">-56211000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-130" decimals="-3" id="f-517" unitRef="usd">-36846000</us-gaap:NetIncomeLoss>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-518">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-519">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-520">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-521">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:126.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:69.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:66.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:58.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:90.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%"&gt;Name (Title)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%"&gt;Action Taken (Date of Action)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%"&gt;Type of Trading Arrangements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%"&gt;Nature of Trading Arrangements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%"&gt;Duration of Trading Arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:133%"&gt;Aggregate Number of Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:132pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Claire Mazumdar, Ph.D. (Chief Executive Officer and Director)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Adoption (March&#160;31, 2026)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Until the earlier of a) December&#160;31, 2026; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Up to 150,000 shares of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:132pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Ryan Cohlhepp, Pharm.D. (President, Chief Operating Officer and Director)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Adoption (March&#160;31, 2026)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Until the earlier of a) March&#160;1, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Up to 180,000 shares of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:120pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Ivan Hyep (Chief Financial Officer and Treasurer )&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Adoption (March&#160;31, 2026)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Until the earlier of a) July&#160;8, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Up to 205,000 shares of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:126.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:69.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:66.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:58.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:90.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:120pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Lara Meisner (Chief Legal Officer, Compliance Officer and Corporate Secretary)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Adoption (March&#160;31, 2026)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Until the earlier of a) July&#160;3, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Up to 173,789 shares of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:120pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;David Raben, M.D. (former Chief Medical Officer)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Adoption (March&#160;31, 2026)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Until the earlier of a) July&#160;1, 2027; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:133%"&gt;Up to 104,000 shares of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-131" id="f-522">Claire Mazumdar</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-131" id="f-523">Chief Executive Officer and Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-131" id="f-524">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-131" id="f-525">March&#160;31, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-131" id="f-526">December&#160;31, 2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-132"
      decimals="INF"
      id="f-527"
      unitRef="shares">150000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-133" id="f-528">Ryan Cohlhepp</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-133" id="f-529">President, Chief Operating Officer and Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-133" id="f-530">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-133" id="f-531">March&#160;31, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-133" id="f-532">March&#160;1, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-134"
      decimals="INF"
      id="f-533"
      unitRef="shares">180000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-135" id="f-534">Ivan Hyep</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-135" id="f-535">Chief Financial Officer and Treasurer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-135" id="f-536">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-135" id="f-537">March&#160;31, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-135" id="f-538">July&#160;8, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-136"
      decimals="INF"
      id="f-539"
      unitRef="shares">205000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-137" id="f-540">Lara Meisner</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-137" id="f-541">Chief Legal Officer, Compliance Officer and Corporate Secretary</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-137" id="f-542">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-137" id="f-543">March&#160;31, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-137" id="f-544">July&#160;3, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-138"
      decimals="INF"
      id="f-545"
      unitRef="shares">173789</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-139" id="f-546">David Raben</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-139" id="f-547">Chief Medical Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-139" id="f-548">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-139" id="f-549">March&#160;31, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-139" id="f-550">July&#160;1, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-140"
      decimals="INF"
      id="f-551"
      unitRef="shares">104000</ecd:TrdArrSecuritiesAggAvailAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
